{"PMC4730764": [["BackgroundAlthough zebrafish (Danio rerio) and medaka (Oryzias latipes) are primitive vertebrates, they have several advantages over other model animals.", [["zebrafish", "ORGANISM", 19, 28], ["Danio rerio", "ORGANISM", 30, 41], ["medaka", "ORGANISM", 47, 53], ["Oryzias latipes", "ORGANISM", 55, 70], ["zebrafish", "SPECIES", 19, 28], ["Danio rerio", "SPECIES", 30, 41], ["Oryzias latipes", "SPECIES", 55, 70], ["Danio rerio", "SPECIES", 30, 41], ["Oryzias latipes", "SPECIES", 55, 70], ["zebrafish (Danio rerio)", "TREATMENT", 19, 42], ["medaka (Oryzias latipes)", "TREATMENT", 47, 71], ["primitive vertebrates", "PROBLEM", 76, 97], ["primitive vertebrates", "OBSERVATION", 76, 97]]], ["Microinjection of fertilized eggs is easily accessible and relatively cheap.", [["eggs", "ANATOMY", 29, 33], ["Microinjection of fertilized eggs", "TREATMENT", 0, 33]]], ["Their embryos are transparent, making it easy to monitor the dynamic gene expression in various tissues and organs in vivo without the need to sacrifice the experimental subjects.", [["embryos", "ANATOMY", 6, 13], ["tissues", "ANATOMY", 96, 103], ["organs", "ANATOMY", 108, 114], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 6, 13], ["tissues", "TISSUE", 96, 103], ["organs", "ORGAN", 108, 114], ["transparent", "OBSERVATION_MODIFIER", 18, 29]]], ["Their genome sizes are approximately 20 to 40 % of the mammalian genome, making them the only vertebrates available for large-scale mutagenesis.", [["mammalian genome", "DNA", 55, 71], ["large-scale mutagenesis", "TREATMENT", 120, 143], ["sizes", "OBSERVATION_MODIFIER", 13, 18], ["approximately", "OBSERVATION_MODIFIER", 23, 36], ["20 to 40", "OBSERVATION_MODIFIER", 37, 45], ["mammalian genome", "OBSERVATION", 55, 71]]], ["Their maturation time takes only 2 ~ 3 months, which is relatively less laborious and time-saving for generating transgenic lines.", [["transgenic lines", "CELL", 113, 129], ["transgenic lines", "CELL_LINE", 113, 129], ["generating transgenic lines", "TREATMENT", 102, 129], ["transgenic lines", "OBSERVATION", 113, 129]]], ["In addition, many routine techniques of molecular biology and genetics, including knock-in, knockdown and knockout, are well developed in the model fish.", [["fish", "ORGANISM", 148, 152]]], ["Therefore, zebrafish and medaka are new excellent animal systems for the study of vertebrate-specific biology in vivo.Germline transmission ::: ReviewThe F0 transgenic line can be established once the exogenous gene can be successfully transferred to the embryos, followed by stable germline transmission of the transgene to the F1 generation.", [["embryos", "ANATOMY", 255, 262], ["zebrafish", "ORGANISM", 11, 20], ["medaka", "ORGAN", 25, 31], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 255, 262], ["F0 transgenic line", "CELL_LINE", 154, 172], ["exogenous gene", "DNA", 201, 215], ["germline", "DNA", 283, 291], ["zebrafish", "SPECIES", 11, 20], ["zebrafish", "SPECIES", 11, 20], ["the study", "TEST", 69, 78], ["The F0 transgenic line", "TREATMENT", 150, 172]]], ["Generally, around 10\u201320 % of treated embryos have a chance to achieve germline transmission [1].", [["embryos", "ANATOMY", 37, 44], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 37, 44], ["germline", "DNA", 70, 78]]], ["It has been reported that a foreign gene flanked with inverted terminal repeats of adeno-associated virus can be used to enhance the ubiquitous expression and stable transmission of transgene in model fish [2].", [["adeno-associated virus", "ORGANISM", 83, 105], ["foreign gene", "DNA", 28, 40], ["inverted terminal repeats", "DNA", 54, 79], ["a foreign gene flanked", "TREATMENT", 26, 48], ["inverted terminal repeats of adeno-associated virus", "TREATMENT", 54, 105], ["stable", "OBSERVATION_MODIFIER", 159, 165]]], ["Meanwhile, transgenesis can be facilitated by using the Tol2 transposon derived from medaka [3].", [["Tol2", "GENE_OR_GENE_PRODUCT", 56, 60], ["Tol2 transposon", "DNA", 56, 71], ["the Tol2 transposon", "TREATMENT", 52, 71]]], ["Transposase catalyzes transposition of a transgene flanked with the Tol2 sequence [4].", [["Tol2 sequence", "DNA", 68, 81], ["Transposase catalyzes transposition", "TREATMENT", 0, 35]]], ["The efficiency of Tol-2-mediated germline transmission could range from 50 to 70 % of injected embryos [4, 5].Germline transmission ::: ReviewA cutting-edge technique has taken the study of fish gene transfer to new horizons, such as knockout zebrafish by the transcription activator-like effector nuclease (TALEN) system and the clustered regularly interspaced short palindromic repeats (CRISPR) combined with CRISPR-associated proteins 9 (Cas9) [6, 7].", [["embryos", "ANATOMY", 95, 102], ["Tol-2", "GENE_OR_GENE_PRODUCT", 18, 23], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 95, 102], ["fish", "ORGANISM", 190, 194], ["zebrafish", "ORGANISM", 243, 252], ["transcription activator-like effector nuclease", "GENE_OR_GENE_PRODUCT", 260, 306], ["TALEN", "GENE_OR_GENE_PRODUCT", 308, 313], ["CRISPR-associated proteins 9", "GENE_OR_GENE_PRODUCT", 411, 439], ["Cas9", "GENE_OR_GENE_PRODUCT", 441, 445], ["germline", "DNA", 33, 41], ["transcription activator-like effector nuclease", "PROTEIN", 260, 306], ["TALEN", "PROTEIN", 308, 313], ["clustered regularly interspaced short palindromic repeats", "DNA", 330, 387], ["CRISPR", "DNA", 389, 395], ["CRISPR-associated proteins 9", "PROTEIN", 411, 439], ["Cas9", "PROTEIN", 441, 445], ["zebrafish", "SPECIES", 243, 252], ["Tol-2-mediated germline transmission", "TREATMENT", 18, 54], ["the study", "TEST", 177, 186], ["the clustered regularly interspaced short palindromic repeats (CRISPR)", "PROBLEM", 326, 396], ["CRISPR", "TEST", 411, 417]]], ["The TALEN system involves the DNA recognition domain of transcription activator-like effectors (TALEs) and a nuclease domain for generation of nicks on DNA sequences.", [["DNA", "CELLULAR_COMPONENT", 30, 33], ["transcription activator-like effectors", "GENE_OR_GENE_PRODUCT", 56, 94], ["TALEs", "GENE_OR_GENE_PRODUCT", 96, 101], ["DNA", "CELLULAR_COMPONENT", 152, 155], ["TALEN", "PROTEIN", 4, 9], ["DNA recognition domain", "PROTEIN", 30, 52], ["transcription activator-like effectors", "PROTEIN", 56, 94], ["TALEs", "PROTEIN", 96, 101], ["nuclease domain", "PROTEIN", 109, 124], ["DNA sequences", "DNA", 152, 165], ["transcription activator", "TREATMENT", 56, 79], ["a nuclease domain", "TREATMENT", 107, 124], ["nicks on DNA sequences", "PROBLEM", 143, 165]]], ["The CRISPR/Cas9 system directed by a synthetic single guide RNA can induce targeted genetic knockout in zebrafish.", [["CRISPR/Cas9", "GENE_OR_GENE_PRODUCT", 4, 15], ["zebrafish", "ORGANISM", 104, 113], ["CRISPR", "DNA", 4, 10], ["Cas9", "DNA", 11, 15], ["synthetic single guide RNA", "RNA", 37, 63], ["zebrafish", "SPECIES", 104, 113], ["zebrafish", "SPECIES", 104, 113], ["The CRISPR/Cas9 system", "TREATMENT", 0, 22], ["a synthetic single guide RNA", "TREATMENT", 35, 63]]], ["The main difference between these two systems is based on their recognition mechanisms.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["difference", "OBSERVATION_MODIFIER", 9, 19]]], ["Unlike the TALEs applied in the TALEN system, the CRISPR/Cas9 system recognizes its target DNA fragment by the complementary non-coding RNA.", [["Cas9", "GENE_OR_GENE_PRODUCT", 57, 61], ["DNA", "CELLULAR_COMPONENT", 91, 94], ["TALEs", "DNA", 11, 16], ["TALEN", "DNA", 32, 37], ["CRISPR", "DNA", 50, 56], ["Cas9", "DNA", 57, 61], ["target DNA fragment", "DNA", 84, 103], ["complementary non-coding RNA", "RNA", 111, 139], ["the CRISPR/Cas9 system", "TREATMENT", 46, 68], ["its target DNA fragment", "PROBLEM", 80, 103], ["the complementary non-coding RNA", "PROBLEM", 107, 139], ["DNA fragment", "OBSERVATION", 91, 103], ["non-coding RNA", "OBSERVATION", 125, 139]]], ["The development of the TALEN and CRISPR/Cas9 systems provides new genomic editing approaches for establishing genetic knockout fish lines [8].Transgenic fluorescent fish ::: ReviewThe fluorescence protein gene (FPG) has been widely applied as a reporter gene in studies of the transgene expression by direct visualization under fluorescent microscopy in vivo [9].", [["TALEN", "GENE_OR_GENE_PRODUCT", 23, 28], ["Cas9", "GENE_OR_GENE_PRODUCT", 40, 44], ["FPG", "GENE_OR_GENE_PRODUCT", 211, 214], ["TALEN", "DNA", 23, 28], ["CRISPR", "DNA", 33, 39], ["Cas9", "DNA", 40, 44], ["fluorescence protein gene", "DNA", 184, 209], ["FPG", "DNA", 211, 214], ["reporter gene", "DNA", 245, 258], ["the TALEN and CRISPR/Cas9 systems", "TREATMENT", 19, 52], ["new genomic editing approaches", "TREATMENT", 62, 92], ["establishing genetic knockout fish lines", "TREATMENT", 97, 137], ["The fluorescence protein gene (FPG)", "TREATMENT", 180, 215], ["fluorescent microscopy", "TEST", 328, 350], ["fish lines", "OBSERVATION", 127, 137]]], ["Many transgenic model fish lines harbor an FPG driven by various tissue-specific promoters, including the erythroid-specific GATA promoter [10], muscle-specific \u03b1-actin promoter [11], rod-specific rhodopsin promoter [12], neuron-specific isl-1 promoter [13], pancreas-specific pdx-1 and insulin promoters [14], myocardium-specific cmlc2 promoter [15], liver-specific L-FABP promoter [16], bone-specific col10a1 promoter [17], macrophage-specific mfap4 promoter [18], and germ cell-specific vasa promoter [19].", [["fish lines", "ANATOMY", 22, 32], ["tissue", "ANATOMY", 65, 71], ["erythroid", "ANATOMY", 106, 115], ["muscle", "ANATOMY", 145, 151], ["pancreas", "ANATOMY", 259, 267], ["myocardium", "ANATOMY", 311, 321], ["liver", "ANATOMY", 352, 357], ["bone", "ANATOMY", 389, 393], ["germ cell", "ANATOMY", 471, 480], ["vasa", "ANATOMY", 490, 494], ["fish lines", "CELL", 22, 32], ["FPG", "GENE_OR_GENE_PRODUCT", 43, 46], ["tissue", "TISSUE", 65, 71], ["erythroid", "CELL", 106, 115], ["GATA promoter [10", "GENE_OR_GENE_PRODUCT", 125, 142], ["muscle", "ORGAN", 145, 151], ["\u03b1-actin", "GENE_OR_GENE_PRODUCT", 161, 168], ["rod-specific rhodopsin promoter [12]", "GENE_OR_GENE_PRODUCT", 184, 220], ["neuron-specific isl-1", "GENE_OR_GENE_PRODUCT", 222, 243], ["pancreas", "ORGAN", 259, 267], ["pdx-1", "GENE_OR_GENE_PRODUCT", 277, 282], ["insulin", "GENE_OR_GENE_PRODUCT", 287, 294], ["myocardium", "ORGAN", 311, 321], ["cmlc2", "GENE_OR_GENE_PRODUCT", 331, 336], ["liver", "ORGAN", 352, 357], ["L-FABP", "GENE_OR_GENE_PRODUCT", 367, 373], ["bone", "TISSUE", 389, 393], ["col10a1", "GENE_OR_GENE_PRODUCT", 403, 410], ["macrophage-specific mfap4 promoter [18", "GENE_OR_GENE_PRODUCT", 426, 464], ["germ cell", "CELL", 471, 480], ["vasa", "GENE_OR_GENE_PRODUCT", 490, 494], ["transgenic model fish lines", "CELL_LINE", 5, 32], ["FPG", "PROTEIN", 43, 46], ["tissue-specific promoters", "DNA", 65, 90], ["GATA promoter", "DNA", 125, 138], ["\u03b1-actin promoter", "DNA", 161, 177], ["rod-specific rhodopsin promoter [12], neuron-specific isl-1 promoter [13", "DNA", 184, 256], ["pancreas-specific pdx-1", "DNA", 259, 282], ["insulin promoters", "DNA", 287, 304], ["cmlc2 promoter", "DNA", 331, 345], ["liver-specific L-FABP promoter [16", "DNA", 352, 386], ["bone-specific col10a1 promoter [17", "DNA", 389, 423], ["mfap4 promoter [18", "DNA", 446, 464], ["vasa promoter", "DNA", 490, 503], ["Many transgenic model fish lines", "TREATMENT", 0, 32], ["the erythroid-specific GATA promoter", "TREATMENT", 102, 138], ["muscle-specific \u03b1-actin promoter", "TREATMENT", 145, 177], ["rod-specific rhodopsin promoter", "TREATMENT", 184, 215], ["pancreas-specific pdx", "TREATMENT", 259, 280], ["insulin promoters", "TREATMENT", 287, 304], ["L-FABP promoter", "TREATMENT", 367, 382], ["bone-specific col10a1 promoter", "TREATMENT", 389, 419], ["macrophage-specific mfap4 promoter", "TREATMENT", 426, 460], ["germ cell", "TEST", 471, 480], ["fish lines", "OBSERVATION", 22, 32], ["muscle", "ANATOMY", 145, 151], ["pancreas", "ANATOMY", 259, 267], ["liver", "ANATOMY", 352, 357], ["bone", "ANATOMY", 389, 393]]], ["Using medaka \u03b2-actin promoter, Tsai\u2019s lab generated a transgenic line of medaka displaying green FP ubiquitously around the whole fish from F0 through F2 generations in a Mendelian inheritance manner [20].", [["Mendelian inheritance", "DISEASE", 171, 192], ["medaka \u03b2-actin", "GENE_OR_GENE_PRODUCT", 6, 20], ["medaka", "ORGANISM", 73, 79], ["green FP", "GENE_OR_GENE_PRODUCT", 91, 99], ["medaka \u03b2-actin promoter", "DNA", 6, 29], ["medaka \u03b2-actin promoter", "TREATMENT", 6, 29]]], ["The DNA sequences of the afore-mentioned promoters ranging from 0.5 to 6.5 kb are sufficient to drive the FPG reporter to mimic the tissue-specific expression of endogenous gene.Transgenic fluorescent fish ::: ReviewHowever, some genes require a longer regulatory DNA sequence, such as more than 20 kb, to fully recapitulate the characteristic expression profiles of endogenous genes.", [["tissue", "ANATOMY", 132, 138], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["FPG", "GENE_OR_GENE_PRODUCT", 106, 109], ["tissue", "TISSUE", 132, 138], ["DNA", "CELLULAR_COMPONENT", 264, 267], ["DNA sequences", "DNA", 4, 17], ["afore-mentioned promoters", "DNA", 25, 50], ["FPG reporter", "DNA", 106, 118], ["endogenous gene", "DNA", 162, 177], ["regulatory DNA sequence", "DNA", 253, 276], ["endogenous genes", "DNA", 367, 383], ["The DNA sequences", "TEST", 0, 17], ["the FPG reporter", "TEST", 102, 118], ["a longer regulatory DNA sequence", "TREATMENT", 244, 276], ["endogenous gene", "OBSERVATION", 162, 177], ["endogenous genes", "OBSERVATION", 367, 383]]], ["In that case, bacterial artificial chromosome (BAC) and phage P1-dereived artificial chromosome (PAC) have been commonly used for this purpose [24].", [["chromosome", "ANATOMY", 35, 45], ["BAC", "ANATOMY", 47, 50], ["chromosome", "ANATOMY", 85, 95], ["chromosome", "CELLULAR_COMPONENT", 35, 45], ["BAC", "CELLULAR_COMPONENT", 47, 50], ["phage P1-dereived artificial chromosome", "CELLULAR_COMPONENT", 56, 95], ["bacterial artificial chromosome", "DNA", 14, 45], ["BAC", "DNA", 47, 50], ["phage P1", "DNA", 56, 64], ["dereived artificial chromosome", "DNA", 65, 95], ["PAC", "DNA", 97, 100], ["bacterial artificial chromosome (BAC)", "PROBLEM", 14, 51], ["phage P1", "TREATMENT", 56, 64], ["artificial chromosome (PAC", "TREATMENT", 74, 100]]], ["For example, the zebrafish rag1 gene, flanked with PAC DNA containing 80 kb at the 5\u2032 upstream and 40 kb at the 3\u2032 downstream, can be expressed specifically in lymphoid cells.", [["lymphoid cells", "ANATOMY", 160, 174], ["zebrafish", "ORGANISM", 17, 26], ["rag1", "GENE_OR_GENE_PRODUCT", 27, 31], ["PAC", "GENE_OR_GENE_PRODUCT", 51, 54], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["lymphoid cells", "CELL", 160, 174], ["zebrafish rag1 gene", "DNA", 17, 36], ["PAC DNA", "DNA", 51, 58], ["80 kb", "DNA", 70, 75], ["5\u2032 upstream", "DNA", 83, 94], ["3\u2032 downstream", "DNA", 112, 125], ["lymphoid cells", "CELL_TYPE", 160, 174], ["zebrafish", "SPECIES", 17, 26], ["PAC DNA", "TREATMENT", 51, 58], ["zebrafish", "ANATOMY", 17, 26], ["rag1 gene", "OBSERVATION", 27, 36], ["lymphoid cells", "OBSERVATION", 160, 174]]], ["Instead of using the tedious Chi-site dependent approach, Jessen et al. reported a two-step method to construct a BAC clone [25].", [["BAC clone", "DNA", 114, 123], ["the tedious Chi-site dependent approach", "TREATMENT", 17, 56], ["a BAC clone", "PROBLEM", 112, 123]]], ["Employing this protocol, Chen et al. constructed a BAC clone containing the upstream 150 kb range of zebrafish myf5 and generated a transgenic line Tg (myf5:gfp) [26].", [["BAC clone", "CELL", 51, 60], ["zebrafish", "ORGANISM", 101, 110], ["myf5", "GENE_OR_GENE_PRODUCT", 111, 115], ["gfp", "GENE_OR_GENE_PRODUCT", 157, 160], ["BAC clone", "DNA", 51, 60], ["zebrafish myf5", "DNA", 101, 115], ["this protocol", "TREATMENT", 10, 23], ["a BAC clone", "TREATMENT", 49, 60], ["zebrafish myf5", "TREATMENT", 101, 115], ["a transgenic line Tg", "TREATMENT", 130, 150]]], ["This transgenic line is able to recapitulate the somite-specific and stage-dependent expression of the endogenous myf5 at an early developmental stage.", [["somite", "ANATOMY", 49, 55], ["myf5", "GENE_OR_GENE_PRODUCT", 114, 118], ["endogenous myf5", "PROTEIN", 103, 118], ["This transgenic line", "TREATMENT", 0, 20], ["the endogenous myf5", "PROBLEM", 99, 118], ["transgenic line", "OBSERVATION", 5, 20], ["dependent expression", "OBSERVATION_MODIFIER", 75, 95], ["endogenous myf5", "OBSERVATION", 103, 118], ["early", "OBSERVATION_MODIFIER", 125, 130], ["developmental stage", "OBSERVATION_MODIFIER", 131, 150]]], ["In summary, all the above transgenic lines should be very useful materials for studying both gene regulation and cell development.Heart development ::: A) Developmental biology ::: New materials for developmental, biological and biomedical studiesZebrafish is particularly useful for studying heart development for the following reasons: (a) Zebrafish have a primitive form of the heart, which is completely developed within 48 h post-fertilization (hpf). (b) The cardiac development can be easily observed in the transgenic line possessing a FP-tagged heart. (c) The zebrafish embryos with a defective cardiovascular system can still keep on growing by acquiring oxygen diffused from water. (d) Discovery of genes involved in heart development can be facilitated by a simple haploid mutation method [27].", [["cell", "ANATOMY", 113, 117], ["Heart", "ANATOMY", 130, 135], ["heart", "ANATOMY", 293, 298], ["heart", "ANATOMY", 381, 386], ["cardiac", "ANATOMY", 464, 471], ["heart", "ANATOMY", 553, 558], ["embryos", "ANATOMY", 578, 585], ["cardiovascular system", "ANATOMY", 603, 624], ["heart", "ANATOMY", 727, 732], ["oxygen", "CHEMICAL", 664, 670], ["oxygen", "CHEMICAL", 664, 670], ["cell", "CELL", 113, 117], ["Heart", "ORGAN", 130, 135], ["Zebrafish", "ORGANISM", 247, 256], ["heart", "ORGAN", 293, 298], ["Zebrafish", "ORGANISM", 342, 351], ["heart", "ORGAN", 381, 386], ["cardiac", "ORGAN", 464, 471], ["heart", "ORGAN", 553, 558], ["zebrafish", "ORGANISM", 568, 577], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 578, 585], ["oxygen", "SIMPLE_CHEMICAL", 664, 670], ["water", "SIMPLE_CHEMICAL", 685, 690], ["heart", "ORGAN", 727, 732], ["transgenic lines", "CELL_LINE", 26, 42], ["transgenic line", "CELL_LINE", 514, 529], ["zebrafish", "SPECIES", 568, 577], ["the above transgenic lines", "TREATMENT", 16, 42], ["New materials", "TREATMENT", 181, 194], ["biomedical studiesZebrafish", "TEST", 229, 256], ["The zebrafish embryos", "TREATMENT", 564, 585], ["a defective cardiovascular system", "PROBLEM", 591, 624], ["primitive", "OBSERVATION", 359, 368], ["heart", "ANATOMY", 381, 386], ["cardiac", "ANATOMY", 464, 471], ["heart", "ANATOMY", 553, 558], ["heart", "ANATOMY", 727, 732]]], ["For example, using the zebrafish jekyll mutant, which has defective heart valves, Walsh and Stainier discovered that UDP-glucose dehydrogenase is required for zebrafish embryos to develop normal cardiac valves [28].Heart development ::: A) Developmental biology ::: New materials for developmental, biological and biomedical studiesTsai\u2019s lab is the first group to generate a transgenic zebrafish line that possesses a GFP-tagged heart [15].", [["heart valves", "ANATOMY", 68, 80], ["embryos", "ANATOMY", 169, 176], ["cardiac valves", "ANATOMY", 195, 209], ["Heart", "ANATOMY", 215, 220], ["heart", "ANATOMY", 430, 435], ["UDP", "CHEMICAL", 117, 120], ["glucose", "CHEMICAL", 121, 128], ["UDP", "CHEMICAL", 117, 120], ["glucose", "CHEMICAL", 121, 128], ["zebrafish jekyll mutant", "ORGANISM", 23, 46], ["heart valves", "MULTI-TISSUE_STRUCTURE", 68, 80], ["UDP-glucose dehydrogenase", "GENE_OR_GENE_PRODUCT", 117, 142], ["zebrafish", "ORGANISM", 159, 168], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 169, 176], ["cardiac valves", "MULTI-TISSUE_STRUCTURE", 195, 209], ["Heart", "ORGAN", 215, 220], ["zebrafish", "ORGANISM", 387, 396], ["GFP", "GENE_OR_GENE_PRODUCT", 419, 422], ["heart", "ORGAN", 430, 435], ["zebrafish jekyll mutant", "PROTEIN", 23, 46], ["UDP-glucose dehydrogenase", "PROTEIN", 117, 142], ["transgenic zebrafish line", "CELL_LINE", 376, 401], ["GFP", "PROTEIN", 419, 422], ["zebrafish", "SPECIES", 159, 168], ["the zebrafish jekyll mutant", "TREATMENT", 19, 46], ["defective heart valves", "PROBLEM", 58, 80], ["UDP", "TEST", 117, 120], ["glucose dehydrogenase", "TEST", 121, 142], ["zebrafish embryos", "PROBLEM", 159, 176], ["biomedical studies", "TEST", 314, 332], ["a transgenic zebrafish line", "TREATMENT", 374, 401], ["a GFP", "TEST", 417, 422], ["heart valves", "ANATOMY", 68, 80], ["cardiac valves", "ANATOMY", 195, 209], ["zebrafish line", "OBSERVATION", 387, 401], ["heart", "ANATOMY", 430, 435]]], ["This line was established from zebrafish embryos introduced with an expression construct, in which the GFP reporter is driven by an upstream control region of zebrafish cardiac myosin light chain 2 gene (cmlc2).", [["embryos", "ANATOMY", 41, 48], ["zebrafish", "ORGANISM", 31, 40], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 41, 48], ["GFP", "GENE_OR_GENE_PRODUCT", 103, 106], ["cardiac myosin light chain 2", "GENE_OR_GENE_PRODUCT", 169, 197], ["cmlc2", "GENE_OR_GENE_PRODUCT", 204, 209], ["GFP reporter", "DNA", 103, 115], ["upstream control region", "DNA", 132, 155], ["zebrafish cardiac myosin light chain 2 gene", "DNA", 159, 202], ["cmlc2", "DNA", 204, 209], ["zebrafish", "SPECIES", 31, 40], ["This line", "TREATMENT", 0, 9], ["zebrafish embryos", "TREATMENT", 31, 48], ["an expression construct", "TREATMENT", 65, 88], ["zebrafish embryos", "OBSERVATION", 31, 48], ["zebrafish", "ANATOMY_MODIFIER", 159, 168], ["cardiac", "ANATOMY", 169, 176], ["myosin", "ANATOMY_MODIFIER", 177, 183]]], ["Using this transgenic line, Raya et al. found that the Notch signaling pathway is activated is during the regenerative response [29].", [["Notch", "GENE_OR_GENE_PRODUCT", 55, 60], ["this transgenic line", "TREATMENT", 6, 26], ["the Notch signaling pathway", "PROBLEM", 51, 78]]], ["Shu et al. reported that Na, K-ATPase \u03b11B1 and \u03b12 isoforms have distinct roles in the patterning of zebrafish heart [30].", [["heart", "ANATOMY", 110, 115], ["Na", "CHEMICAL", 25, 27], ["Na", "CHEMICAL", 25, 27], ["Na", "GENE_OR_GENE_PRODUCT", 25, 27], ["K-ATPase \u03b11B1", "GENE_OR_GENE_PRODUCT", 29, 42], ["\u03b12", "GENE_OR_GENE_PRODUCT", 47, 49], ["zebrafish", "ORGANISM", 100, 109], ["heart", "ORGAN", 110, 115], ["Na, K-ATPase \u03b11B1", "PROTEIN", 25, 42], ["\u03b12 isoforms", "PROTEIN", 47, 58], ["zebrafish", "SPECIES", 100, 109], ["Na", "TEST", 25, 27], ["K-ATPase", "TEST", 29, 37], ["1B1", "TEST", 39, 42], ["distinct", "OBSERVATION_MODIFIER", 64, 72], ["patterning", "ANATOMY_MODIFIER", 86, 96], ["zebrafish heart", "ANATOMY", 100, 115]]], ["This transgenic line should also be useful for studying the dynamic movement and cell fate of cardiac primordial cells.", [["cell", "ANATOMY", 81, 85], ["cardiac primordial cells", "ANATOMY", 94, 118], ["cell", "CELL", 81, 85], ["cardiac primordial cells", "CELL", 94, 118], ["cardiac primordial cells", "CELL_TYPE", 94, 118], ["This transgenic line", "TREATMENT", 0, 20], ["the dynamic movement", "TEST", 56, 76], ["cardiac", "ANATOMY", 94, 101], ["primordial cells", "OBSERVATION", 102, 118]]], ["For example, Forouhar et al. proposed a hydro-impedance pump model for the embryonic heart tubes of zebrafish [31].", [["embryonic heart tubes", "ANATOMY", 75, 96], ["embryonic heart tubes", "MULTI-TISSUE_STRUCTURE", 75, 96], ["zebrafish", "ORGANISM", 100, 109], ["zebrafish", "SPECIES", 100, 109], ["a hydro-impedance pump model", "TREATMENT", 38, 66], ["the embryonic heart tubes", "TREATMENT", 71, 96], ["hydro", "OBSERVATION", 40, 45], ["heart", "ANATOMY", 85, 90], ["tubes", "OBSERVATION", 91, 96]]], ["A 4D dynamic image of cardiac development has been developed [32].", [["cardiac", "ANATOMY", 22, 29], ["cardiac", "ORGAN", 22, 29], ["A 4D dynamic image", "TEST", 0, 18], ["cardiac", "ANATOMY", 22, 29]]], ["Furthermore, Hami et al. reported that a second heart field is required during cardiac development [33].", [["heart", "ANATOMY", 48, 53], ["cardiac", "ANATOMY", 79, 86], ["heart", "ORGAN", 48, 53], ["cardiac", "ORGAN", 79, 86], ["a second heart field", "PROBLEM", 39, 59]]], ["Thus, recently, Nevis et al. stated that tbx1 plays a function for proliferation of the second heart field, and the zebrafish tbx1-null mutant resemble the heart defects in DiGeorge syndrome [34].Heart development ::: A) Developmental biology ::: New materials for developmental, biological and biomedical studiesThus, the expression pattern of heart-specific genes could be analyzed based on heart progenitor cells collected in this transgenic line.", [["heart", "ANATOMY", 95, 100], ["heart", "ANATOMY", 156, 161], ["Heart", "ANATOMY", 196, 201], ["heart", "ANATOMY", 345, 350], ["heart progenitor cells", "ANATOMY", 393, 415], ["tbx1", "CHEMICAL", 41, 45], ["heart defects", "DISEASE", 156, 169], ["DiGeorge syndrome", "DISEASE", 173, 190], ["tbx1", "GENE_OR_GENE_PRODUCT", 41, 45], ["heart", "ORGAN", 95, 100], ["zebrafish", "ORGANISM", 116, 125], ["tbx1", "GENE_OR_GENE_PRODUCT", 126, 130], ["heart", "ORGAN", 156, 161], ["Heart", "ORGAN", 196, 201], ["heart", "ORGAN", 345, 350], ["heart progenitor cells", "CELL", 393, 415], ["tbx1", "PROTEIN", 41, 45], ["tbx1", "PROTEIN", 126, 130], ["heart-specific genes", "DNA", 345, 365], ["heart progenitor cells", "CELL_TYPE", 393, 415], ["zebrafish", "SPECIES", 116, 125], ["proliferation of the second heart field", "PROBLEM", 67, 106], ["the zebrafish tbx1", "TEST", 112, 130], ["null mutant", "PROBLEM", 131, 142], ["the heart defects", "PROBLEM", 152, 169], ["DiGeorge syndrome", "PROBLEM", 173, 190], ["biomedical studies", "TEST", 295, 313], ["heart progenitor cells", "TREATMENT", 393, 415], ["this transgenic line", "TREATMENT", 429, 449], ["tbx1", "OBSERVATION", 41, 45], ["heart", "ANATOMY", 95, 100], ["heart", "ANATOMY", 156, 161], ["defects", "OBSERVATION", 162, 169], ["DiGeorge syndrome", "OBSERVATION", 173, 190], ["heart", "ANATOMY", 345, 350], ["heart", "ANATOMY", 393, 398], ["progenitor cells", "OBSERVATION", 399, 415], ["transgenic line", "OBSERVATION", 434, 449]]], ["The analysis of gene or protein expression dynamics at different developmental stages could also be conducted.", [["The analysis", "TEST", 0, 12], ["gene or protein expression dynamics", "PROBLEM", 16, 51]]], ["Furthermore, this transgenic fish is a potential platform for detecting chemicals, drugs and environmental pollutants affecting heart development, as detailed in following section.Muscle development ::: A) Developmental biology ::: New materials for developmental, biological and biomedical studiesIn vivo transient assay of the injected DNA fragments in model fish embryos is a simple yet effective way to analyze the function of regulatory cis-elements.", [["heart", "ANATOMY", 128, 133], ["Muscle", "ANATOMY", 180, 186], ["fragments", "ANATOMY", 342, 351], ["embryos", "ANATOMY", 366, 373], ["fish", "ORGANISM", 29, 33], ["heart", "ORGAN", 128, 133], ["Muscle", "ORGAN", 180, 186], ["DNA", "CELLULAR_COMPONENT", 338, 341], ["fish", "ORGANISM", 361, 365], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 366, 373], ["injected DNA fragments", "DNA", 329, 351], ["regulatory cis-elements", "DNA", 431, 454], ["drugs", "TREATMENT", 83, 88], ["environmental pollutants affecting heart development", "PROBLEM", 93, 145], ["biomedical studies", "TEST", 280, 298], ["the injected DNA fragments", "PROBLEM", 325, 351], ["heart", "ANATOMY", 128, 133], ["transient", "OBSERVATION_MODIFIER", 306, 315], ["assay", "OBSERVATION_MODIFIER", 316, 321], ["fish embryos", "OBSERVATION", 361, 373], ["regulatory cis-elements", "OBSERVATION", 431, 454]]], ["For example, Myf5, one of myogenesis regulatory factors (MRF), plays key roles in the specification and differentiation of muscle primordial cells during myogenesis.", [["muscle primordial cells", "ANATOMY", 123, 146], ["Myf5", "GENE_OR_GENE_PRODUCT", 13, 17], ["myogenesis regulatory factors", "GENE_OR_GENE_PRODUCT", 26, 55], ["MRF", "GENE_OR_GENE_PRODUCT", 57, 60], ["muscle primordial cells", "CELL", 123, 146], ["Myf5", "PROTEIN", 13, 17], ["myogenesis regulatory factors", "PROTEIN", 26, 55], ["MRF", "PROTEIN", 57, 60], ["muscle primordial cells", "CELL_TYPE", 123, 146], ["myogenesis regulatory factors", "PROBLEM", 26, 55], ["muscle primordial cells", "PROBLEM", 123, 146], ["muscle", "ANATOMY", 123, 129], ["primordial cells", "OBSERVATION", 130, 146]]], ["The expression of myf5 is somite-specific and stage-dependent, and its activation and repression are delicately orchestrated.", [["myf5", "GENE_OR_GENE_PRODUCT", 18, 22], ["myf5", "PROTEIN", 18, 22], ["stage-dependent", "PROBLEM", 46, 61], ["myf5", "ANATOMY", 18, 22], ["stage-dependent", "OBSERVATION_MODIFIER", 46, 61]]], ["Using in vivo transient assay, Chen et al. found that a novel cis-element located at \u221282/-62 is essential for somite-specific expression of myf5 [35].", [["somite", "ANATOMY", 110, 116], ["myf5", "GENE_OR_GENE_PRODUCT", 140, 144], ["cis-element", "DNA", 62, 73], ["\u221282/-62", "DNA", 85, 92], ["a novel cis-element", "PROBLEM", 54, 73]]], ["Lee et al. revealed that this \u221282/-62 cis-element is specifically bound by Forkhead box D3, and proposed that somite development is regulated by the Pax3-FoxD3-Myf5 axis [36].", [["somite", "ANATOMY", 110, 116], ["Forkhead box D3", "GENE_OR_GENE_PRODUCT", 75, 90], ["somite", "DEVELOPING_ANATOMICAL_STRUCTURE", 110, 116], ["Pax3", "GENE_OR_GENE_PRODUCT", 149, 153], ["FoxD3", "GENE_OR_GENE_PRODUCT", 154, 159], ["Myf5", "GENE_OR_GENE_PRODUCT", 160, 164], ["\u221282/-62 cis-element", "DNA", 30, 49], ["Forkhead box D3", "PROTEIN", 75, 90], ["Pax3", "PROTEIN", 149, 153], ["FoxD3", "PROTEIN", 154, 159], ["Myf5", "PROTEIN", 160, 164], ["the Pax3", "TEST", 145, 153]]], ["Besides FoxD3, FoxD5, another protein in the Forkhead box family, is necessary for maintaining the anterior-posterior polarity of somite cells in mesenchymal-epithelial transition [37].", [["somite cells", "ANATOMY", 130, 142], ["mesenchymal-epithelial", "ANATOMY", 146, 168], ["FoxD3", "GENE_OR_GENE_PRODUCT", 8, 13], ["FoxD5", "GENE_OR_GENE_PRODUCT", 15, 20], ["somite cells", "CELL", 130, 142], ["mesenchymal-epithelial", "CELL", 146, 168], ["FoxD3", "PROTEIN", 8, 13], ["FoxD5", "PROTEIN", 15, 20], ["Forkhead box family", "PROTEIN", 45, 64], ["somite cells", "CELL_TYPE", 130, 142], ["FoxD3", "TREATMENT", 8, 13], ["FoxD5", "TREATMENT", 15, 20], ["somite cells", "PROBLEM", 130, 142], ["anterior", "ANATOMY_MODIFIER", 99, 107], ["posterior", "ANATOMY_MODIFIER", 108, 117], ["somite cells", "OBSERVATION", 130, 142], ["mesenchymal", "ANATOMY", 146, 157], ["epithelial", "ANATOMY_MODIFIER", 158, 168]]], ["The expression of FoxD5 is regulated by Fgf signaling in anterior pre-somitic mesoderm (PSM), which indicates that Fgf-FoxD5-Mesp signaling takes place in somitogenesis [37].", [["anterior pre-somitic mesoderm", "ANATOMY", 57, 86], ["PSM", "ANATOMY", 88, 91], ["FoxD5", "GENE_OR_GENE_PRODUCT", 18, 23], ["Fgf", "GENE_OR_GENE_PRODUCT", 40, 43], ["anterior pre-somitic mesoderm", "TISSUE", 57, 86], ["PSM", "MULTI-TISSUE_STRUCTURE", 88, 91], ["Fgf", "GENE_OR_GENE_PRODUCT", 115, 118], ["FoxD5", "GENE_OR_GENE_PRODUCT", 119, 124], ["Mesp", "GENE_OR_GENE_PRODUCT", 125, 129], ["FoxD5", "PROTEIN", 18, 23], ["Fgf", "PROTEIN", 40, 43], ["Fgf", "PROTEIN", 115, 118], ["FoxD5", "PROTEIN", 119, 124], ["Mesp", "PROTEIN", 125, 129], ["anterior pre-somitic mesoderm", "PROBLEM", 57, 86], ["Fgf", "TEST", 115, 118], ["FoxD5", "TREATMENT", 119, 124], ["anterior", "ANATOMY_MODIFIER", 57, 65], ["pre-somitic mesoderm", "ANATOMY", 66, 86]]], ["Furthermore, analysis of the loci of adjacent mrf4 and myf5 revealed the complicated regulation mechanism of the MRF genes.", [["mrf4", "GENE_OR_GENE_PRODUCT", 46, 50], ["myf5", "GENE_OR_GENE_PRODUCT", 55, 59], ["MRF", "GENE_OR_GENE_PRODUCT", 113, 116], ["mrf4", "DNA", 46, 50], ["myf5", "DNA", 55, 59], ["MRF genes", "DNA", 113, 122], ["complicated", "OBSERVATION", 73, 84]]], ["It was also found that the biological function of Mrf4 is related to myofibril alignment, motor axon growth, and organization of axonal membrane [38].Muscle development ::: A) Developmental biology ::: New materials for developmental, biological and biomedical studiesThe molecular mechanism that underlies the repression of myf5 has also been reported.", [["myofibril", "ANATOMY", 69, 78], ["motor axon", "ANATOMY", 90, 100], ["axonal membrane", "ANATOMY", 129, 144], ["Muscle", "ANATOMY", 150, 156], ["Mrf4", "GENE_OR_GENE_PRODUCT", 50, 54], ["myofibril", "CELLULAR_COMPONENT", 69, 78], ["axon", "CELLULAR_COMPONENT", 96, 100], ["axonal membrane", "CELLULAR_COMPONENT", 129, 144], ["Muscle", "ORGAN", 150, 156], ["myf5", "GENE_OR_GENE_PRODUCT", 325, 329], ["Mrf4", "PROTEIN", 50, 54], ["myf5", "PROTEIN", 325, 329], ["myofibril alignment", "PROBLEM", 69, 88], ["biomedical studies", "TEST", 250, 268], ["related to", "UNCERTAINTY", 58, 68], ["myofibril alignment", "OBSERVATION", 69, 88], ["motor axon", "OBSERVATION", 90, 100], ["axonal membrane", "OBSERVATION", 129, 144]]], ["For example (Fig. 1a), a strong repressive element of zebrafish myf5 was found within intron I (+502/+835) [39].", [["zebrafish", "ORGANISM", 54, 63], ["myf5", "GENE_OR_GENE_PRODUCT", 64, 68], ["strong repressive element", "DNA", 25, 50], ["zebrafish myf5", "DNA", 54, 68], ["intron I", "DNA", 86, 94], ["zebrafish", "SPECIES", 54, 63], ["a strong repressive element of zebrafish myf5", "PROBLEM", 23, 68], ["zebrafish myf5", "OBSERVATION", 54, 68]]], ["This repressive element is modulated by a novel intronic microRNA, termed miR-In300 or miR-3906 [40].", [["miR-In300", "GENE_OR_GENE_PRODUCT", 74, 83], ["miR-3906", "GENE_OR_GENE_PRODUCT", 87, 95], ["repressive element", "DNA", 5, 23], ["intronic microRNA", "DNA", 48, 65], ["miR", "DNA", 74, 77], ["In300", "DNA", 78, 83], ["miR", "DNA", 87, 90], ["a novel intronic microRNA", "PROBLEM", 40, 65]]], ["When myf5 transcripts reach the highest level after specification, the accumulated miR-3906 starts to reduce the transcription of myf5 through silencing the positive factor Dickkopf-related protein 3 (Dkk3r or Dkk3a) for the myf5 promoter [41].", [["miR-3906", "CHEMICAL", 83, 91], ["myf5", "GENE_OR_GENE_PRODUCT", 5, 9], ["miR-3906", "GENE_OR_GENE_PRODUCT", 83, 91], ["myf5", "GENE_OR_GENE_PRODUCT", 130, 134], ["Dickkopf-related protein 3", "GENE_OR_GENE_PRODUCT", 173, 199], ["Dkk3r", "GENE_OR_GENE_PRODUCT", 201, 206], ["Dkk3a", "GENE_OR_GENE_PRODUCT", 210, 215], ["myf5", "GENE_OR_GENE_PRODUCT", 225, 229], ["myf5 transcripts", "RNA", 5, 21], ["miR-3906", "DNA", 83, 91], ["myf5", "PROTEIN", 130, 134], ["positive factor Dickkopf-related protein 3", "PROTEIN", 157, 199], ["Dkk3r", "PROTEIN", 201, 206], ["Dkk3a", "PROTEIN", 210, 215], ["myf5 promoter", "DNA", 225, 238]]], ["Itg\u03b16b is a receptor of secretory Dkk3a and that interaction between Itg\u03b16b and Dkk3a is required to drive the downstream signal transduction which regulates myf5 promoter activity in somite during embryogenesis of zebrafish [42].", [["somite", "ANATOMY", 184, 190], ["Itg\u03b16b", "GENE_OR_GENE_PRODUCT", 0, 6], ["Dkk3a", "GENE_OR_GENE_PRODUCT", 34, 39], ["Itg\u03b16b", "GENE_OR_GENE_PRODUCT", 69, 75], ["Dkk3a", "GENE_OR_GENE_PRODUCT", 80, 85], ["myf5", "GENE_OR_GENE_PRODUCT", 158, 162], ["somite", "DEVELOPING_ANATOMICAL_STRUCTURE", 184, 190], ["zebrafish", "ORGANISM", 215, 224], ["Itg\u03b16b", "PROTEIN", 0, 6], ["secretory Dkk3a", "PROTEIN", 24, 39], ["Itg\u03b16b", "PROTEIN", 69, 75], ["Dkk3a", "PROTEIN", 80, 85], ["myf5 promoter", "DNA", 158, 171], ["zebrafish", "SPECIES", 215, 224], ["the downstream signal transduction", "TREATMENT", 107, 141]]], ["Dkk3a regulates p38a phosphorylation to maintain Smad4 stability, which in turn enables the formation of the Smad2/3a/4 complex required for the activation of the myf5 promoter [43].", [["Dkk3a", "GENE_OR_GENE_PRODUCT", 0, 5], ["p38", "GENE_OR_GENE_PRODUCT", 16, 19], ["Smad4", "GENE_OR_GENE_PRODUCT", 49, 54], ["Smad2", "GENE_OR_GENE_PRODUCT", 109, 114], ["3a", "GENE_OR_GENE_PRODUCT", 115, 117], ["4", "GENE_OR_GENE_PRODUCT", 118, 119], ["myf5", "GENE_OR_GENE_PRODUCT", 163, 167], ["Dkk3a", "PROTEIN", 0, 5], ["p38", "PROTEIN", 16, 19], ["Smad4", "PROTEIN", 49, 54], ["Smad2/3a/4 complex", "PROTEIN", 109, 127], ["myf5 promoter", "DNA", 163, 176], ["a phosphorylation", "TREATMENT", 19, 36], ["Smad4 stability", "PROBLEM", 49, 64], ["the Smad2/3a/4 complex", "TREATMENT", 105, 127], ["the activation of the myf5 promoter", "TREATMENT", 141, 176], ["stability", "OBSERVATION_MODIFIER", 55, 64]]], ["However, when myf5 transcripts are reduced at the later differentiation stage, miR-3906 is able to be transcribed by its own promoter [40] (Fig. 1b).", [["myf5", "GENE_OR_GENE_PRODUCT", 14, 18], ["miR-3906", "GENE_OR_GENE_PRODUCT", 79, 87], ["Fig. 1b", "GENE_OR_GENE_PRODUCT", 140, 147], ["myf5 transcripts", "RNA", 14, 30], ["miR-3906", "DNA", 79, 87]]], ["Furthermore, increased expression of miR-3906 controls the intracellular concentration of Ca2+ ([Ca2+]i) in fast muscle cells through subtly reducing homer-1b expression.", [["intracellular", "ANATOMY", 59, 72], ["muscle cells", "ANATOMY", 113, 125], ["miR-3906", "CHEMICAL", 37, 45], ["Ca2", "CHEMICAL", 90, 93], ["Ca2", "CHEMICAL", 97, 100], ["Ca2+", "CHEMICAL", 90, 94], ["Ca2+]i", "CHEMICAL", 97, 103], ["miR-3906", "GENE_OR_GENE_PRODUCT", 37, 45], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 59, 72], ["Ca2+", "SIMPLE_CHEMICAL", 90, 94], ["fast muscle cells", "CELL", 108, 125], ["homer-1b", "GENE_OR_GENE_PRODUCT", 150, 158], ["miR-3906", "DNA", 37, 45], ["Ca2", "PROTEIN", 90, 93], ["fast muscle cells", "CELL_TYPE", 108, 125], ["homer", "PROTEIN", 150, 155], ["the intracellular concentration", "TEST", 55, 86], ["Ca2", "TEST", 90, 93], ["Ca2", "TEST", 97, 100], ["fast muscle cells", "PROBLEM", 108, 125], ["muscle", "ANATOMY", 113, 119]]], ["The homeostasis of [Ca2+]i is required during differentiation to help maintain normal muscle development [40].", [["muscle", "ANATOMY", 86, 92], ["Ca2", "CHEMICAL", 20, 23], ["Ca2+]", "CHEMICAL", 20, 25], ["muscle", "ORGAN", 86, 92], ["normal", "OBSERVATION", 79, 85], ["muscle", "ANATOMY", 86, 92]]], ["Nevertheless, it remains to be investigated how miR-3906 switches its target gene at different developmental stages.Muscle development ::: A) Developmental biology ::: New materials for developmental, biological and biomedical studiesApart from the regulation of somitogenesis, Myf5 is also involved in craniofacial muscle development.", [["Muscle", "ANATOMY", 116, 122], ["craniofacial muscle", "ANATOMY", 303, 322], ["miR-3906", "CHEMICAL", 48, 56], ["miR-3906", "GENE_OR_GENE_PRODUCT", 48, 56], ["Muscle", "ORGAN", 116, 122], ["Myf5", "GENE_OR_GENE_PRODUCT", 278, 282], ["craniofacial muscle", "MULTI-TISSUE_STRUCTURE", 303, 322], ["miR-3906", "DNA", 48, 56], ["target gene", "DNA", 70, 81], ["Myf5", "PROTEIN", 278, 282], ["biomedical studies", "TEST", 216, 234], ["craniofacial muscle", "ANATOMY", 303, 322]]], ["The functions of Myf5 in cranial muscles and cartilage development are independent of Myod, suggesting that Myf5 and Myod are not redundant.", [["cranial muscles", "ANATOMY", 25, 40], ["cartilage", "ANATOMY", 45, 54], ["Myf5", "GENE_OR_GENE_PRODUCT", 17, 21], ["cranial muscles", "MULTI-TISSUE_STRUCTURE", 25, 40], ["cartilage", "TISSUE", 45, 54], ["Myod", "GENE_OR_GENE_PRODUCT", 86, 90], ["Myf5", "GENE_OR_GENE_PRODUCT", 108, 112], ["Myod", "GENE_OR_GENE_PRODUCT", 117, 121], ["Myf5", "PROTEIN", 17, 21], ["Myod", "PROTEIN", 86, 90], ["Myf5", "PROTEIN", 108, 112], ["Myod", "PROTEIN", 117, 121], ["cranial muscles", "ANATOMY", 25, 40], ["cartilage", "ANATOMY", 45, 54], ["Myod", "ANATOMY", 117, 121]]], ["Thus, three possible pathways could be associated with the molecular regulation between Myf5 and Myod: (i) Myf5 alone is capable of initiating myogenesis, (ii) Myod initiates muscle primordia, which is subdivided from the myf5-positive core, and (iii) Myod alone, but not Myf5, modulates the development of muscle primordia [44].", [["muscle primordia", "ANATOMY", 175, 191], ["muscle primordia", "ANATOMY", 307, 323], ["Myf5", "GENE_OR_GENE_PRODUCT", 88, 92], ["Myod", "GENE_OR_GENE_PRODUCT", 97, 101], ["Myf5", "GENE_OR_GENE_PRODUCT", 107, 111], ["Myod", "GENE_OR_GENE_PRODUCT", 160, 164], ["muscle primordia", "MULTI-TISSUE_STRUCTURE", 175, 191], ["myf5", "GENE_OR_GENE_PRODUCT", 222, 226], ["Myod", "GENE_OR_GENE_PRODUCT", 252, 256], ["Myf5", "GENE_OR_GENE_PRODUCT", 272, 276], ["muscle", "ORGAN", 307, 313], ["Myf5", "PROTEIN", 88, 92], ["Myod", "PROTEIN", 97, 101], ["Myf5", "PROTEIN", 107, 111], ["Myod", "PROTEIN", 160, 164], ["myf5", "PROTEIN", 222, 226], ["Myod", "PROTEIN", 252, 256], ["Myf5", "PROTEIN", 272, 276], ["muscle primordia", "PROBLEM", 175, 191], ["muscle primordia", "PROBLEM", 307, 323], ["Myod", "ANATOMY", 97, 101], ["muscle", "ANATOMY", 175, 181], ["primordia", "ANATOMY_MODIFIER", 182, 191], ["muscle", "ANATOMY", 307, 313], ["primordia", "ANATOMY_MODIFIER", 314, 323]]], ["Furthermore, the six1a gene was found to play an important role in the interaction between Myf5 and Myod [45].", [["six1a", "GENE_OR_GENE_PRODUCT", 17, 22], ["Myf5", "GENE_OR_GENE_PRODUCT", 91, 95], ["six1a gene", "DNA", 17, 27], ["Myf5", "PROTEIN", 91, 95], ["Myod", "PROTEIN", 100, 104]]], ["In cartilage development, myf5 is expressed in the paraxial mesoderm at the gastrulation stage.", [["cartilage", "ANATOMY", 3, 12], ["paraxial mesoderm", "ANATOMY", 51, 68], ["cartilage", "TISSUE", 3, 12], ["myf5", "GENE_OR_GENE_PRODUCT", 26, 30], ["paraxial mesoderm", "MULTI-TISSUE_STRUCTURE", 51, 68], ["myf5", "PROTEIN", 26, 30], ["cartilage", "ANATOMY", 3, 12], ["paraxial mesoderm", "OBSERVATION", 51, 68], ["gastrulation stage", "OBSERVATION", 76, 94]]], ["Myf5 plays a role in mesoderm fate determination by maintaining the expression of fgf3/8, which in turn, promotes differentiation from neural crest cells to craniofacial cartilage [46].", [["mesoderm", "ANATOMY", 21, 29], ["neural crest cells", "ANATOMY", 135, 153], ["craniofacial cartilage", "ANATOMY", 157, 179], ["Myf5", "GENE_OR_GENE_PRODUCT", 0, 4], ["mesoderm", "DEVELOPING_ANATOMICAL_STRUCTURE", 21, 29], ["fgf3/8", "GENE_OR_GENE_PRODUCT", 82, 88], ["neural crest cells", "CELL", 135, 153], ["craniofacial cartilage", "TISSUE", 157, 179], ["Myf5", "PROTEIN", 0, 4], ["fgf3/8", "PROTEIN", 82, 88], ["neural crest cells", "CELL_TYPE", 135, 153], ["neural crest cells", "OBSERVATION", 135, 153], ["craniofacial cartilage", "ANATOMY", 157, 179]]], ["This research on myf5 not only reveals that it has different functions between craniofacial muscle development and somitogenesis, but it also opens up a new study field for understanding craniofacial muscle development.Muscle development ::: A) Developmental biology ::: New materials for developmental, biological and biomedical studiesHinits et al. reported no phenotype both in myf5-knockdown embryos and myf5-null mutant, suggesting that Myf5 is rather redundant in somitogenesis of zebrafish [47].", [["craniofacial muscle", "ANATOMY", 79, 98], ["craniofacial muscle", "ANATOMY", 187, 206], ["Muscle", "ANATOMY", 219, 225], ["embryos", "ANATOMY", 396, 403], ["craniofacial muscle", "DISEASE", 187, 206], ["myf5", "GENE_OR_GENE_PRODUCT", 17, 21], ["craniofacial muscle", "TISSUE", 79, 98], ["craniofacial muscle", "MULTI-TISSUE_STRUCTURE", 187, 206], ["Muscle", "ORGAN", 219, 225], ["myf5", "GENE_OR_GENE_PRODUCT", 381, 385], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 396, 403], ["myf5", "GENE_OR_GENE_PRODUCT", 408, 412], ["Myf5", "GENE_OR_GENE_PRODUCT", 442, 446], ["zebrafish", "ORGANISM", 487, 496], ["myf5", "DNA", 17, 21], ["myf5", "PROTEIN", 381, 385], ["myf5", "PROTEIN", 408, 412], ["Myf5", "PROTEIN", 442, 446], ["zebrafish", "SPECIES", 487, 496], ["a new study field", "TEST", 151, 168], ["biomedical studies", "TEST", 319, 337], ["phenotype", "PROBLEM", 363, 372], ["null mutant", "PROBLEM", 413, 424], ["craniofacial muscle", "ANATOMY", 79, 98], ["craniofacial muscle", "ANATOMY", 187, 206], ["no", "UNCERTAINTY", 360, 362]]], ["However, it is hard to reasonably explain why these embryos and mutant are all lethal and can\u2019t grow to adulthood.", [["embryos", "ANATOMY", 52, 59], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 52, 59], ["these embryos", "PROBLEM", 46, 59]]], ["On the other hand, Lin et al. reported an observable defective phenotype in myf5-knockdown embryos, and claimed that the concentration of myf5-MO they used can inhibit maternal myf5 mRNA translation [46].", [["embryos", "ANATOMY", 91, 98], ["myf5", "GENE_OR_GENE_PRODUCT", 76, 80], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 91, 98], ["myf5-MO", "GENE_OR_GENE_PRODUCT", 138, 145], ["myf5", "GENE_OR_GENE_PRODUCT", 177, 181], ["myf5", "PROTEIN", 76, 80], ["myf5", "PROTEIN", 138, 142], ["MO", "PROTEIN", 143, 145], ["myf5 mRNA", "RNA", 177, 186], ["an observable defective phenotype", "PROBLEM", 39, 72], ["defective phenotype", "OBSERVATION", 53, 72]]], ["This discrepancy might attribute the effectiveness of MO used or the different phenotypes between the knockdown embryos and knockout mutant in this case.Ocular and nerve development ::: New materials for developmental, biological and biomedical studiesThe retina-specific expression of the carp rhodopsin gene is controlled by two upstream regulatory DNA cis-elements [48].", [["embryos", "ANATOMY", 112, 119], ["Ocular", "ANATOMY", 153, 159], ["nerve", "ANATOMY", 164, 169], ["Ocular and nerve development", "DISEASE", 153, 181], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 112, 119], ["Ocular", "ORGAN", 153, 159], ["nerve", "MULTI-TISSUE_STRUCTURE", 164, 169], ["carp", "ORGANISM", 290, 294], ["rhodopsin", "GENE_OR_GENE_PRODUCT", 295, 304], ["DNA", "CELLULAR_COMPONENT", 351, 354], ["carp rhodopsin gene", "DNA", 290, 309], ["upstream regulatory DNA cis-elements", "DNA", 331, 367], ["the different phenotypes", "PROBLEM", 65, 89], ["the knockdown embryos", "TREATMENT", 98, 119], ["knockout mutant", "PROBLEM", 124, 139], ["biomedical studies", "TEST", 234, 252], ["the carp rhodopsin gene", "TREATMENT", 286, 309], ["knockdown embryos", "OBSERVATION", 102, 119], ["nerve", "ANATOMY", 164, 169], ["carp rhodopsin", "OBSERVATION", 290, 304], ["DNA cis-elements", "OBSERVATION", 351, 367]]], ["One is located at \u221263 to \u221275, which is the carp neural retina leucine zipper response-like element; the other is located at \u221246 to \u221252, which is a carp-specific element crucial to reporter gene expression in medaka retinae.", [["neural retina", "ANATOMY", 48, 61], ["medaka retinae", "ANATOMY", 208, 222], ["leucine", "CHEMICAL", 62, 69], ["leucine", "CHEMICAL", 62, 69], ["carp", "ORGANISM", 43, 47], ["\u221252", "GENE_OR_GENE_PRODUCT", 131, 134], ["medaka retinae", "ORGANISM", 208, 222], ["\u221263 to \u221275", "DNA", 18, 28], ["carp neural retina leucine zipper response-like element", "DNA", 43, 98], ["\u221246 to \u221252", "DNA", 124, 134], ["carp-specific element", "DNA", 147, 168], ["reporter gene", "DNA", 180, 193], ["neural", "ANATOMY_MODIFIER", 48, 54], ["retina", "ANATOMY", 55, 61], ["leucine", "OBSERVATION", 62, 69], ["zipper response", "OBSERVATION", 70, 85], ["retinae", "ANATOMY", 215, 222]]], ["Intriguingly, immediate activation of early growth response transcriptional regulator Egr1 could result in the incomplete differentiation of retina and lens, leading to microphthalmos [49].", [["retina", "ANATOMY", 141, 147], ["lens", "ANATOMY", 152, 156], ["microphthalmos", "DISEASE", 169, 183], ["Egr1", "GENE_OR_GENE_PRODUCT", 86, 90], ["retina", "MULTI-TISSUE_STRUCTURE", 141, 147], ["lens", "ORGAN", 152, 156], ["early growth response transcriptional regulator", "PROTEIN", 38, 85], ["Egr1", "PROTEIN", 86, 90], ["early growth response transcriptional regulator Egr1", "PROBLEM", 38, 90], ["microphthalmos", "PROBLEM", 169, 183], ["early", "OBSERVATION_MODIFIER", 38, 43], ["growth", "OBSERVATION_MODIFIER", 44, 50], ["retina", "ANATOMY", 141, 147], ["lens", "ANATOMY", 152, 156]]], ["Another important factor for ocular development is the ADP-ribosylation factor-like 6 interacting protein 1 (Arl6ip1).", [["ocular", "ANATOMY", 29, 35], ["ADP", "CHEMICAL", 55, 58], ["ADP", "CHEMICAL", 55, 58], ["ocular", "ORGAN", 29, 35], ["ADP-ribosylation factor-like 6 interacting protein 1", "GENE_OR_GENE_PRODUCT", 55, 107], ["Arl6ip1", "GENE_OR_GENE_PRODUCT", 109, 116], ["ADP-ribosylation factor-like 6 interacting protein 1", "PROTEIN", 55, 107], ["Arl6ip1", "PROTEIN", 109, 116], ["ocular development", "PROBLEM", 29, 47], ["the ADP-ribosylation factor", "PROBLEM", 51, 78]]], ["Loss of Arl6ip1 function leads to the absence of retinal neurons, disorganized retinal layers and smaller optic cups [50].", [["retinal neurons", "ANATOMY", 49, 64], ["retinal layers", "ANATOMY", 79, 93], ["Arl6ip1", "GENE_OR_GENE_PRODUCT", 8, 15], ["retinal neurons", "CELL", 49, 64], ["retinal layers", "TISSUE", 79, 93], ["Arl6ip1", "PROTEIN", 8, 15], ["retinal neurons", "CELL_TYPE", 49, 64], ["Loss of Arl6ip1 function", "PROBLEM", 0, 24], ["retinal neurons", "PROBLEM", 49, 64], ["disorganized retinal layers", "PROBLEM", 66, 93], ["smaller optic cups", "PROBLEM", 98, 116], ["Arl6ip1 function", "OBSERVATION", 8, 24], ["retinal neurons", "ANATOMY", 49, 64], ["disorganized", "OBSERVATION_MODIFIER", 66, 78], ["retinal", "ANATOMY", 79, 86], ["layers", "OBSERVATION_MODIFIER", 87, 93], ["smaller", "OBSERVATION_MODIFIER", 98, 105], ["optic cups", "OBSERVATION", 106, 116]]], ["Upon losing Arl6ip1, retinal progenitors continued to express cyclin D1, but not shh or p57kip2, suggesting that eye progenitor cells remained at the early progenitor stage, and could not exit the cell cycle to undergo differentiation [51].", [["retinal progenitors", "ANATOMY", 21, 40], ["eye progenitor cells", "ANATOMY", 113, 133], ["early progenitor", "ANATOMY", 150, 166], ["cell", "ANATOMY", 197, 201], ["Arl6ip1", "GENE_OR_GENE_PRODUCT", 12, 19], ["retinal progenitors", "CELL", 21, 40], ["cyclin D1", "GENE_OR_GENE_PRODUCT", 62, 71], ["shh", "GENE_OR_GENE_PRODUCT", 81, 84], ["p57kip2", "GENE_OR_GENE_PRODUCT", 88, 95], ["eye progenitor cells", "CELL", 113, 133], ["cell", "CELL", 197, 201], ["Arl6ip1", "PROTEIN", 12, 19], ["retinal progenitors", "CELL_TYPE", 21, 40], ["cyclin D1", "PROTEIN", 62, 71], ["shh", "PROTEIN", 81, 84], ["p57kip2", "PROTEIN", 88, 95], ["eye progenitor cells", "CELL_TYPE", 113, 133], ["Arl6ip1", "TREATMENT", 12, 19], ["retinal progenitors", "TREATMENT", 21, 40], ["cyclin D1", "PROBLEM", 62, 71], ["p57kip2", "TEST", 88, 95], ["eye progenitor cells", "PROBLEM", 113, 133], ["retinal", "ANATOMY", 21, 28], ["eye", "ANATOMY", 113, 116], ["progenitor cells", "OBSERVATION", 117, 133]]], ["Additionally, it has been reported that Arl6ip1 is essential for specification of neural crest derivatives, but not neural crest induction.", [["neural crest", "ANATOMY", 82, 94], ["neural crest", "ANATOMY", 116, 128], ["Arl6ip1", "GENE_OR_GENE_PRODUCT", 40, 47], ["neural crest derivatives", "CELL", 82, 106], ["neural crest", "MULTI-TISSUE_STRUCTURE", 116, 128], ["Arl6ip1", "PROTEIN", 40, 47], ["neural crest derivatives", "TREATMENT", 82, 106], ["neural crest induction", "TREATMENT", 116, 138], ["neural crest derivatives", "OBSERVATION", 82, 106], ["crest induction", "OBSERVATION", 123, 138]]], ["Tu et al. found that Arl6ip1 mutation causes abnormal neural crest derivative tissues as well as reduced expression of neural crest specifier genes, such as foxd3, snail1b and sox10, indicating that Arl6ip1 is involved in specification, but not induction, of neural crest cells [52].", [["neural crest derivative tissues", "ANATOMY", 54, 85], ["neural crest", "ANATOMY", 119, 131], ["neural crest cells", "ANATOMY", 259, 277], ["Arl6ip1", "GENE_OR_GENE_PRODUCT", 21, 28], ["neural crest derivative tissues", "TISSUE", 54, 85], ["foxd3", "GENE_OR_GENE_PRODUCT", 157, 162], ["snail1b", "GENE_OR_GENE_PRODUCT", 164, 171], ["sox10", "GENE_OR_GENE_PRODUCT", 176, 181], ["Arl6ip1", "GENE_OR_GENE_PRODUCT", 199, 206], ["neural crest cells", "CELL", 259, 277], ["Arl6ip1", "PROTEIN", 21, 28], ["neural crest specifier genes", "DNA", 119, 147], ["foxd3", "DNA", 157, 162], ["snail1b", "DNA", 164, 171], ["sox10", "DNA", 176, 181], ["Arl6ip1", "PROTEIN", 199, 206], ["neural crest cells", "CELL_TYPE", 259, 277], ["Arl6ip1 mutation", "PROBLEM", 21, 37], ["abnormal neural crest derivative tissues", "PROBLEM", 45, 85], ["abnormal", "OBSERVATION_MODIFIER", 45, 53], ["neural crest", "OBSERVATION", 54, 66], ["derivative tissues", "OBSERVATION", 67, 85], ["neural crest", "ANATOMY", 119, 131], ["neural crest", "ANATOMY", 259, 271]]], ["Furthermore, they found that Arl6ip1 could play an important role in the migration of neural crest cells because in the arl6ip1-knockdown embryos, crestin- and sox10-expressing neural crest cells failed to migrate ventrally from neural tube into trunk.", [["neural crest cells", "ANATOMY", 86, 104], ["embryos", "ANATOMY", 138, 145], ["neural crest cells", "ANATOMY", 177, 195], ["neural tube", "ANATOMY", 229, 240], ["trunk", "ANATOMY", 246, 251], ["Arl6ip1", "CHEMICAL", 29, 36], ["Arl6ip1", "GENE_OR_GENE_PRODUCT", 29, 36], ["neural crest cells", "CELL", 86, 104], ["arl6ip1", "GENE_OR_GENE_PRODUCT", 120, 127], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 138, 145], ["crestin", "GENE_OR_GENE_PRODUCT", 147, 154], ["sox10", "GENE_OR_GENE_PRODUCT", 160, 165], ["neural crest cells", "CELL", 177, 195], ["neural tube", "TISSUE", 229, 240], ["trunk", "ORGANISM_SUBDIVISION", 246, 251], ["Arl6ip1", "PROTEIN", 29, 36], ["neural crest cells", "CELL_TYPE", 86, 104], ["arl6ip1", "PROTEIN", 120, 127], ["crestin", "PROTEIN", 147, 154], ["sox10", "PROTEIN", 160, 165], ["neural crest cells", "CELL_TYPE", 177, 195], ["neural crest cells", "TREATMENT", 86, 104], ["crestin", "TEST", 147, 154], ["sox10", "TREATMENT", 160, 165], ["neural crest cells", "PROBLEM", 177, 195], ["neural crest", "ANATOMY", 86, 98], ["knockdown embryos", "OBSERVATION", 128, 145], ["neural", "ANATOMY", 177, 183], ["crest cells", "OBSERVATION", 184, 195], ["neural tube", "OBSERVATION", 229, 240], ["trunk", "ANATOMY", 246, 251]]], ["More recently, Lin et al. found that Ras-related nuclear (Ran) protein is conjugated with Arl6ip1, and proposed that Ran protein associates with Arl6ip1 to regulate the development of retinae [53].Ocular and nerve development ::: New materials for developmental, biological and biomedical studiesTo date, no in vivo model system has been established to identify cells in the CNS that can specifically respond with regeneration after stresses, and, even if identified, no method is in place to trace these responsive cells and further identify their cell fates during hypoxic regeneration.", [["nuclear", "ANATOMY", 49, 56], ["retinae", "ANATOMY", 184, 191], ["Ocular", "ANATOMY", 197, 203], ["nerve", "ANATOMY", 208, 213], ["cells", "ANATOMY", 362, 367], ["CNS", "ANATOMY", 375, 378], ["cells", "ANATOMY", 516, 521], ["cell", "ANATOMY", 549, 553], ["Ocular and nerve development", "DISEASE", 197, 225], ["Ras-related", "GENE_OR_GENE_PRODUCT", 37, 48], ["nuclear", "CELLULAR_COMPONENT", 49, 56], ["Ran", "GENE_OR_GENE_PRODUCT", 58, 61], ["Arl6ip1", "GENE_OR_GENE_PRODUCT", 90, 97], ["Ran", "GENE_OR_GENE_PRODUCT", 117, 120], ["Arl6ip1", "GENE_OR_GENE_PRODUCT", 145, 152], ["Ocular", "ORGAN", 197, 203], ["nerve", "MULTI-TISSUE_STRUCTURE", 208, 213], ["cells", "CELL", 362, 367], ["CNS", "ANATOMICAL_SYSTEM", 375, 378], ["cells", "CELL", 516, 521], ["cell", "CELL", 549, 553], ["Ras-related nuclear (Ran) protein", "PROTEIN", 37, 70], ["Arl6ip1", "PROTEIN", 90, 97], ["Ran protein", "PROTEIN", 117, 128], ["Arl6ip1", "PROTEIN", 145, 152], ["responsive cells", "CELL_TYPE", 505, 521], ["Arl6ip1", "TREATMENT", 90, 97], ["Arl6ip1", "TREATMENT", 145, 152], ["biomedical studies", "TEST", 278, 296], ["method", "TREATMENT", 471, 477], ["trace these responsive cells", "PROBLEM", 493, 521], ["hypoxic regeneration", "PROBLEM", 567, 587], ["retinae", "ANATOMY", 184, 191], ["nerve", "ANATOMY", 208, 213], ["CNS", "ANATOMY", 375, 378], ["hypoxic regeneration", "OBSERVATION", 567, 587]]], ["To address these issues, Lee et al. generated a transgenic zebrafish line huORFZ, which harbors the upstream open reading frame (uORF) from human CCAAT/enhancer-binding protein homologous protein gene (chop), fused with the GFP reporter and driven by a cytomegalovirus promoter [54].", [["zebrafish", "ORGANISM", 59, 68], ["huORFZ", "GENE_OR_GENE_PRODUCT", 74, 80], ["human", "ORGANISM", 140, 145], ["CCAAT/enhancer-binding protein homologous protein", "GENE_OR_GENE_PRODUCT", 146, 195], ["chop", "GENE_OR_GENE_PRODUCT", 202, 206], ["GFP", "GENE_OR_GENE_PRODUCT", 224, 227], ["cytomegalovirus", "ORGANISM", 253, 268], ["transgenic zebrafish line huORFZ", "DNA", 48, 80], ["upstream open reading frame", "DNA", 100, 127], ["uORF", "DNA", 129, 133], ["human CCAAT/enhancer-binding protein homologous protein gene", "DNA", 140, 200], ["chop", "DNA", 202, 206], ["GFP reporter", "DNA", 224, 236], ["cytomegalovirus promoter", "DNA", 253, 277], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["a transgenic zebrafish line huORFZ", "TREATMENT", 46, 80], ["human CCAAT/enhancer-binding protein homologous protein gene (chop", "TREATMENT", 140, 206], ["a cytomegalovirus promoter", "TREATMENT", 251, 277], ["zebrafish line", "OBSERVATION", 59, 73]]], ["After huORFZ embryos were treated with heat-shock or under hypoxia, the GFP signal was exclusively expressed in the CNS, resulting from impeding the huORFchop-mediated translation inhibition [54].", [["huORFZ embryos", "ANATOMY", 6, 20], ["CNS", "ANATOMY", 116, 119], ["shock", "DISEASE", 44, 49], ["hypoxia", "DISEASE", 59, 66], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 13, 20], ["GFP", "GENE_OR_GENE_PRODUCT", 72, 75], ["CNS", "ANATOMICAL_SYSTEM", 116, 119], ["huORFchop", "GENE_OR_GENE_PRODUCT", 149, 158], ["GFP", "PROTEIN", 72, 75], ["huORFchop", "PROTEIN", 149, 158], ["huORFZ embryos", "TREATMENT", 6, 20], ["heat-shock", "TREATMENT", 39, 49], ["hypoxia", "PROBLEM", 59, 66], ["the GFP signal", "TEST", 68, 82], ["shock", "OBSERVATION", 44, 49], ["hypoxia", "OBSERVATION", 59, 66], ["CNS", "ANATOMY", 116, 119]]], ["Interestingly, Zeng et al. found that GFP-(+) cells in spinal cord respond to stress, survive after stress and differentiate into neurons during regeneration (Chih-Wei Zeng, Yasuhiro Kamei and Huai-Jen Tsai, unpublished data).MicroRNAs and development ::: New materials for developmental, biological and biomedical studiesMicroRNAs (miRNAs) are endogenous single-stranded RNA molecules of 19\u201330 nucleotides (nt) that repress or activate the translation of their target genes through canonical seed- and non-canonical centered miRNA binding sites.", [["GFP-(+) cells", "ANATOMY", 38, 51], ["spinal cord", "ANATOMY", 55, 66], ["neurons", "ANATOMY", 130, 137], ["nucleotides", "CHEMICAL", 395, 406], ["GFP", "GENE_OR_GENE_PRODUCT", 38, 41], ["spinal cord", "ORGAN", 55, 66], ["neurons", "CELL", 130, 137], ["GFP-(+) cells", "CELL_LINE", 38, 51], ["miRNAs", "DNA", 333, 339], ["19\u201330 nucleotides", "DNA", 389, 406], ["target genes", "DNA", 462, 474], ["canonical seed- and non-canonical centered miRNA binding sites", "DNA", 483, 545], ["GFP", "TEST", 38, 41], ["cells in spinal cord", "PROBLEM", 46, 66], ["stress", "PROBLEM", 78, 84], ["stress", "PROBLEM", 100, 106], ["Chih", "TEST", 159, 163], ["Yasuhiro Kamei", "TREATMENT", 174, 188], ["Huai", "TREATMENT", 193, 197], ["biomedical studiesMicroRNAs", "TEST", 304, 331], ["nucleotides (nt)", "PROBLEM", 395, 411], ["canonical seed", "TREATMENT", 483, 497], ["non-canonical centered miRNA binding sites", "PROBLEM", 503, 545], ["spinal cord", "ANATOMY", 55, 66], ["miRNA binding", "OBSERVATION", 526, 539]]], ["The known mechanisms involved in miRNAs-mediated gene silencing are decay of mRNAs and blockage of translation [55\u201357].", [["miRNAs", "DNA", 33, 39], ["mRNAs", "RNA", 77, 82]]], ["Probably the expression of 30 ~ 50 % of human genes is regulated by miRNAs [58, 59].", [["human", "ORGANISM", 40, 45], ["human genes", "DNA", 40, 51], ["miRNAs", "DNA", 68, 74], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45]]], ["Therefore, to understand gene and function in cells or embryos, it is important to exactly know the target gene(s) of a specific miRNA at different phase of cells or at particular stages of developing embryos.MicroRNAs and development ::: New materials for developmental, biological and biomedical studiesInstead of using a bioinformatic approach, the Tsai\u2019s lab developed the Labeled miRNA Pull-down (LAMP) assay system, which is a simple but effective method to search for the candidate target gene(s) of a specific miRNA under investigation [60].", [["cells", "ANATOMY", 46, 51], ["embryos", "ANATOMY", 55, 62], ["cells", "ANATOMY", 157, 162], ["embryos", "ANATOMY", 201, 208], ["cells", "CELL", 46, 51], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 55, 62], ["cells", "CELL", 157, 162], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 201, 208], ["target gene", "DNA", 100, 111], ["candidate target gene", "DNA", 479, 500], ["a specific miRNA", "PROBLEM", 118, 134], ["developing embryos", "PROBLEM", 190, 208], ["biomedical studies", "TEST", 287, 305], ["embryos", "OBSERVATION", 201, 208]]], ["LAMP assay system yields fewer false-positive results than a bioinformatic approach.", [["LAMP assay system", "TEST", 0, 17], ["a bioinformatic approach", "TREATMENT", 59, 83]]], ["Taking advantage of LAMP, scientists discovered that miR-3906 silences different target genes at different developmental stages, e.g., at early stage, miR-3906 targets dkk3a [41], while at late stage, it targets homer-1b [40] (Fig. 1).MicroRNAs and development ::: New materials for developmental, biological and biomedical studiesIn another example (Fig. 2), miR-1 and miR-206 are two muscle-specific microRNAs sharing the same seed sequences.", [["muscle", "ANATOMY", 386, 392], ["miR-3906", "CHEMICAL", 53, 61], ["miR-3906", "GENE_OR_GENE_PRODUCT", 53, 61], ["miR-3906", "GENE_OR_GENE_PRODUCT", 151, 159], ["homer-1b", "GENE_OR_GENE_PRODUCT", 212, 220], ["miR-1", "GENE_OR_GENE_PRODUCT", 360, 365], ["miR-206", "GENE_OR_GENE_PRODUCT", 370, 377], ["muscle", "ORGAN", 386, 392], ["miR-3906", "DNA", 53, 61], ["target genes", "DNA", 81, 93], ["miR-3906", "DNA", 151, 159], ["homer", "PROTEIN", 212, 217], ["miR-1", "DNA", 360, 365], ["miR-206", "DNA", 370, 377], ["microRNAs", "DNA", 402, 411], ["seed sequences", "DNA", 429, 443], ["biomedical studies", "TEST", 313, 331], ["miR", "TEST", 360, 363], ["muscle", "ANATOMY", 386, 392]]], ["They are able to modulate the expression of vascular endothelial growth factor Aa (VegfAa) and serve as cross-tissue signaling regulators between muscle and vessels.", [["cross-tissue", "ANATOMY", 104, 116], ["muscle", "ANATOMY", 146, 152], ["vessels", "ANATOMY", 157, 164], ["vascular endothelial growth factor Aa", "GENE_OR_GENE_PRODUCT", 44, 81], ["VegfAa", "GENE_OR_GENE_PRODUCT", 83, 89], ["muscle", "ORGAN", 146, 152], ["vessels", "MULTI-TISSUE_STRUCTURE", 157, 164], ["vascular endothelial growth factor Aa", "PROTEIN", 44, 81], ["VegfAa", "PROTEIN", 83, 89], ["cross-tissue signaling regulators", "PROTEIN", 104, 137], ["vascular endothelial", "ANATOMY", 44, 64], ["muscle", "ANATOMY", 146, 152], ["vessels", "ANATOMY", 157, 164]]], ["Since miR-1 and miR-206 share identical seed sequences, Stahlhut et al. demonstrated that they can silence the same target gene, such as vegfaa, and considered them as a single cross-tissue regulator termed as miR-1/206 [61]. miR-1/206 reduces the level of VegfAa, resulting in the inhibition of the angiogenic signaling [61].", [["tissue", "ANATOMY", 183, 189], ["miR-1", "GENE_OR_GENE_PRODUCT", 6, 11], ["miR-206", "GENE_OR_GENE_PRODUCT", 16, 23], ["vegfaa", "GENE_OR_GENE_PRODUCT", 137, 143], ["tissue", "TISSUE", 183, 189], ["miR-1/206", "GENE_OR_GENE_PRODUCT", 210, 219], ["miR-1/206", "GENE_OR_GENE_PRODUCT", 226, 235], ["VegfAa", "GENE_OR_GENE_PRODUCT", 257, 263], ["miR-1", "DNA", 6, 11], ["miR-206", "DNA", 16, 23], ["seed sequences", "DNA", 40, 54], ["target gene", "DNA", 116, 127], ["vegfaa", "DNA", 137, 143], ["miR-1/206", "PROTEIN", 210, 219], ["miR-1/206", "DNA", 226, 235], ["VegfAa", "PROTEIN", 257, 263], ["the angiogenic signaling", "TEST", 296, 320]]], ["Surprisingly, using the LAMP assay system, Lin et al. reported that the target genes for miR-1 and miR-206 are different [62].", [["miR-1", "GENE_OR_GENE_PRODUCT", 89, 94], ["miR-206", "GENE_OR_GENE_PRODUCT", 99, 106], ["target genes", "DNA", 72, 84], ["miR-1", "DNA", 89, 94], ["miR-206", "DNA", 99, 106], ["the LAMP assay system", "TEST", 20, 41]]], ["While miR-206 targets vegfaa, miR-1 targets seryl-tRNA synthetase gene (sars).", [["miR-206", "CHEMICAL", 6, 13], ["seryl", "CHEMICAL", 44, 49], ["miR-206", "GENE_OR_GENE_PRODUCT", 6, 13], ["vegfaa", "GENE_OR_GENE_PRODUCT", 22, 28], ["miR-1", "GENE_OR_GENE_PRODUCT", 30, 35], ["seryl-tRNA synthetase", "GENE_OR_GENE_PRODUCT", 44, 65], ["miR-206", "DNA", 6, 13], ["vegfaa", "PROTEIN", 22, 28], ["miR-1", "DNA", 30, 35], ["seryl-tRNA synthetase gene", "DNA", 44, 70], ["sars", "DNA", 72, 76], ["vegfaa", "TEST", 22, 28], ["miR", "TEST", 30, 33], ["seryl", "TEST", 44, 49], ["tRNA synthetase gene", "TREATMENT", 50, 70]]], ["SARS is a negative regulator of VegfAa.", [["SARS", "DISEASE", 0, 4], ["VegfAa", "GENE_OR_GENE_PRODUCT", 32, 38], ["VegfAa", "PROTEIN", 32, 38]]], ["Although both miR-1 and miR-206 have identical seed sequences, the sars-3\u2032UTRs of zebrafish, human and mouse origins can be recognized only by miR-1 in zebrafish embryos and mammalian cell lines (HEK-293 T and C2C12), but not by miR-206 [62].", [["embryos", "ANATOMY", 162, 169], ["cell lines", "ANATOMY", 184, 194], ["HEK-293 T", "ANATOMY", 196, 205], ["C2C12", "ANATOMY", 210, 215], ["miR-1", "GENE_OR_GENE_PRODUCT", 14, 19], ["miR-206", "GENE_OR_GENE_PRODUCT", 24, 31], ["sars-3", "GENE_OR_GENE_PRODUCT", 67, 73], ["zebrafish", "ORGANISM", 82, 91], ["human", "ORGANISM", 93, 98], ["mouse", "ORGANISM", 103, 108], ["miR-1", "GENE_OR_GENE_PRODUCT", 143, 148], ["zebrafish", "ORGANISM", 152, 161], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 162, 169], ["mammalian cell lines", "CELL", 174, 194], ["HEK-293 T", "CELL", 196, 205], ["C2C12", "CELL", 210, 215], ["miR-206", "GENE_OR_GENE_PRODUCT", 229, 236], ["miR-1", "DNA", 14, 19], ["miR-206", "DNA", 24, 31], ["seed sequences", "DNA", 47, 61], ["sars-3\u2032UTRs", "DNA", 67, 78], ["miR-1", "DNA", 143, 148], ["mammalian cell lines", "CELL_LINE", 174, 194], ["HEK-293 T", "CELL_LINE", 196, 205], ["C2C12", "CELL_LINE", 210, 215], ["zebrafish", "SPECIES", 82, 91], ["human", "SPECIES", 93, 98], ["mouse", "SPECIES", 103, 108], ["human", "SPECIES", 93, 98], ["mouse", "SPECIES", 103, 108], ["the sars", "TEST", 63, 71], ["mammalian cell lines", "TEST", 174, 194], ["HEK", "TEST", 196, 199], ["mammalian cell lines", "OBSERVATION", 174, 194]]], ["Conversely, the vegfaa-3\u2032UTR is targeted by miR-206, but not by miR-1.", [["vegfaa-3", "GENE_OR_GENE_PRODUCT", 16, 24], ["miR-206", "GENE_OR_GENE_PRODUCT", 44, 51], ["miR-1", "GENE_OR_GENE_PRODUCT", 64, 69], ["vegfaa-3\u2032UTR", "DNA", 16, 28], ["miR-206", "DNA", 44, 51], ["miR-1", "DNA", 64, 69], ["the vegfaa", "TEST", 12, 22]]], ["Therefore, Lin et al. concluded that miR-1 and miR-206 are actually two distinct regulators and play opposing roles in zebrafish angiogenesis.", [["miR-1", "GENE_OR_GENE_PRODUCT", 37, 42], ["miR-206", "GENE_OR_GENE_PRODUCT", 47, 54], ["zebrafish", "ORGANISM", 119, 128], ["miR-1", "DNA", 37, 42], ["miR-206", "DNA", 47, 54], ["zebrafish angiogenesis", "PROBLEM", 119, 141], ["two distinct", "OBSERVATION_MODIFIER", 68, 80], ["zebrafish", "ANATOMY", 119, 128], ["angiogenesis", "OBSERVATION", 129, 141]]], ["The miR-1/SARS/VegfAa pathway promotes embryonic angiogenesis by indirectly controlling VegfAa, while miR-206/VegfAa pathway plays an anti-angiogenic role by directly reducing VegfAa.", [["embryonic", "ANATOMY", 39, 48], ["miR-1", "GENE_OR_GENE_PRODUCT", 4, 9], ["SARS", "GENE_OR_GENE_PRODUCT", 10, 14], ["VegfAa", "GENE_OR_GENE_PRODUCT", 15, 21], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 39, 48], ["VegfAa", "GENE_OR_GENE_PRODUCT", 88, 94], ["miR-206", "GENE_OR_GENE_PRODUCT", 102, 109], ["VegfAa", "GENE_OR_GENE_PRODUCT", 110, 116], ["VegfAa", "GENE_OR_GENE_PRODUCT", 176, 182], ["VegfAa", "PROTEIN", 15, 21], ["VegfAa", "PROTEIN", 88, 94], ["VegfAa", "PROTEIN", 110, 116], ["VegfAa", "PROTEIN", 176, 182], ["The miR", "TEST", 0, 7], ["SARS", "PROBLEM", 10, 14], ["/VegfAa pathway", "TREATMENT", 14, 29], ["embryonic angiogenesis", "PROBLEM", 39, 61], ["embryonic angiogenesis", "OBSERVATION", 39, 61]]], ["Interestingly, they also found that the miR-1/SARS/VegfAa pathway increasingly affects embryonic angiogenesis at late developmental stages in somitic cells [62].", [["embryonic", "ANATOMY", 87, 96], ["somitic cells", "ANATOMY", 142, 155], ["miR-1", "GENE_OR_GENE_PRODUCT", 40, 45], ["SARS", "GENE_OR_GENE_PRODUCT", 46, 50], ["VegfAa", "GENE_OR_GENE_PRODUCT", 51, 57], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 87, 96], ["somitic cells", "CELL", 142, 155], ["miR-1", "DNA", 40, 45], ["VegfAa", "PROTEIN", 51, 57], ["somitic cells", "CELL_TYPE", 142, 155], ["the miR-1/SARS/VegfAa pathway", "PROBLEM", 36, 65], ["embryonic angiogenesis", "PROBLEM", 87, 109], ["somitic cells", "PROBLEM", 142, 155], ["embryonic angiogenesis", "OBSERVATION", 87, 109], ["somitic cells", "OBSERVATION", 142, 155]]], ["It remains to be studied how miR-1 increases in abundance at late stage.miRNAs in regeneration ::: New materials for developmental, biological and biomedical studiesDifferent from mammals, zebrafish have the ability to regenerate injured parts in the CNS.", [["CNS", "ANATOMY", 251, 254], ["miR-1", "GENE_OR_GENE_PRODUCT", 29, 34], ["zebrafish", "ORGANISM", 189, 198], ["CNS", "ANATOMICAL_SYSTEM", 251, 254], ["miR-1", "DNA", 29, 34], ["miRNAs", "RNA", 72, 78], ["New materials", "TREATMENT", 99, 112], ["biomedical studies", "TEST", 147, 165], ["late stage", "OBSERVATION_MODIFIER", 61, 71], ["CNS", "ANATOMY", 251, 254]]], ["Many miRNAs have been found in the CNS.", [["CNS", "ANATOMY", 35, 38], ["CNS", "ANATOMICAL_SYSTEM", 35, 38], ["Many miRNAs", "PROBLEM", 0, 11], ["miRNAs", "OBSERVATION", 5, 11], ["CNS", "ANATOMY", 35, 38]]], ["It has been shown that several miRNAs have prominent functions in regulating the regeneration process.", [["several", "OBSERVATION_MODIFIER", 23, 30], ["miRNAs", "OBSERVATION", 31, 37], ["prominent", "OBSERVATION_MODIFIER", 43, 52], ["functions", "OBSERVATION_MODIFIER", 53, 62], ["regeneration process", "OBSERVATION", 81, 101]]], ["For example, miR-210 promotes spinal cord repair by enhancing angiogenesis [64], and the miR-15 family represses proliferation in the adult mouse heart [65].", [["spinal cord", "ANATOMY", 30, 41], ["heart", "ANATOMY", 146, 151], ["miR-210", "CHEMICAL", 13, 20], ["miR-210", "GENE_OR_GENE_PRODUCT", 13, 20], ["spinal cord", "ORGAN", 30, 41], ["miR-15", "GENE_OR_GENE_PRODUCT", 89, 95], ["mouse", "ORGANISM", 140, 145], ["heart", "ORGAN", 146, 151], ["miR-210", "PROTEIN", 13, 20], ["miR-15 family", "PROTEIN", 89, 102], ["mouse", "SPECIES", 140, 145], ["mouse", "SPECIES", 140, 145], ["miR", "TEST", 13, 16], ["spinal cord repair", "TREATMENT", 30, 48], ["enhancing angiogenesis", "PROBLEM", 52, 74], ["spinal cord", "ANATOMY", 30, 41], ["repair", "OBSERVATION", 42, 48], ["heart", "ANATOMY", 146, 151]]], ["Furthermore, miRNAs miR-29b and miR-223 are identified following optic nerve crush.", [["optic nerve", "ANATOMY", 65, 76], ["optic nerve crush", "DISEASE", 65, 82], ["miR-29b", "GENE_OR_GENE_PRODUCT", 20, 27], ["miR-223", "GENE_OR_GENE_PRODUCT", 32, 39], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 65, 76], ["miRNAs miR-29b", "DNA", 13, 27], ["miR-223", "DNA", 32, 39], ["miRNAs miR", "TEST", 13, 23], ["optic nerve crush", "TEST", 65, 82], ["optic nerve crush", "OBSERVATION", 65, 82]]], ["By gene ontology analysis, miR-29b and miR-223 are found to regulate genes, including eva1a, layna, nefmb, ina, si:ch211-51a6.2, smoc1, and sb:cb252.", [["miR-29b", "GENE_OR_GENE_PRODUCT", 27, 34], ["miR-223", "GENE_OR_GENE_PRODUCT", 39, 46], ["eva1a", "GENE_OR_GENE_PRODUCT", 86, 91], ["layna", "GENE_OR_GENE_PRODUCT", 93, 98], ["nefmb", "GENE_OR_GENE_PRODUCT", 100, 105], ["ina", "GENE_OR_GENE_PRODUCT", 107, 110], ["si:ch211-51a6.2", "GENE_OR_GENE_PRODUCT", 112, 127], ["smoc1", "GENE_OR_GENE_PRODUCT", 129, 134], ["sb:cb252", "GENE_OR_GENE_PRODUCT", 140, 148], ["miR-29b", "DNA", 27, 34], ["miR-223", "DNA", 39, 46], ["eva1a", "DNA", 86, 91], ["layna", "DNA", 93, 98], ["nefmb", "DNA", 100, 105], ["ina", "DNA", 107, 110], ["ch211", "DNA", 115, 120], ["51a6.2", "DNA", 121, 127], ["smoc1", "DNA", 129, 134], ["sb", "DNA", 140, 142], ["cb252", "DNA", 143, 148], ["miR", "TEST", 27, 30], ["miR", "TEST", 39, 42], ["layna", "TEST", 93, 98], ["smoc1", "TEST", 129, 134], ["cb", "TEST", 143, 145]]], ["These genes are involved in cell survival or apoptosis, indicating that these two miRNAs are potential regulators of optic nerve regeneration [66].Hematopoiesis ::: New materials for developmental, biological and biomedical studiesAlthough the main hematopoietic sites in zebrafish differ from those in mammals, both zebrafish and mammals share all major blood cell types that arise from common hematopoietic lineages [67].", [["cell", "ANATOMY", 28, 32], ["optic nerve", "ANATOMY", 117, 128], ["hematopoietic sites", "ANATOMY", 249, 268], ["blood cell", "ANATOMY", 355, 365], ["hematopoietic", "ANATOMY", 395, 408], ["Hematopoiesis", "DISEASE", 147, 160], ["cell", "CELL", 28, 32], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 117, 128], ["hematopoietic sites", "MULTI-TISSUE_STRUCTURE", 249, 268], ["zebrafish", "ORGANISM", 272, 281], ["zebrafish", "ORGANISM", 317, 326], ["blood cell", "CELL", 355, 365], ["major blood cell types", "CELL_TYPE", 349, 371], ["common hematopoietic lineages", "CELL_TYPE", 388, 417], ["zebrafish", "SPECIES", 272, 281], ["zebrafish", "SPECIES", 317, 326], ["cell survival", "PROBLEM", 28, 41], ["apoptosis", "PROBLEM", 45, 54], ["optic nerve regeneration", "PROBLEM", 117, 141], ["Hematopoiesis", "PROBLEM", 147, 160], ["biomedical studies", "TEST", 213, 231], ["the main hematopoietic sites", "PROBLEM", 240, 268], ["cell survival", "OBSERVATION", 28, 41], ["optic nerve regeneration", "OBSERVATION", 117, 141], ["main", "OBSERVATION_MODIFIER", 244, 248], ["hematopoietic sites", "OBSERVATION", 249, 268], ["zebrafish", "OBSERVATION_MODIFIER", 272, 281], ["cell types", "OBSERVATION", 361, 371], ["common hematopoietic", "ANATOMY", 388, 408]]], ["Moreover, many genes and signaling pathways involved in hematopoiesis are conserved among mammals and zebrafish.", [["zebrafish", "ORGANISM", 102, 111], ["zebrafish", "SPECIES", 102, 111], ["hematopoiesis", "PROBLEM", 56, 69], ["hematopoiesis", "OBSERVATION", 56, 69]]], ["For example, scl, one of the first transcription factors expressed in early hematopoietic cells, is evolutionarily conserved.", [["hematopoietic cells", "ANATOMY", 76, 95], ["scl", "GENE_OR_GENE_PRODUCT", 13, 16], ["hematopoietic cells", "CELL", 76, 95], ["scl", "PROTEIN", 13, 16], ["transcription factors", "PROTEIN", 35, 56], ["early hematopoietic cells", "CELL_TYPE", 70, 95], ["early hematopoietic cells", "PROBLEM", 70, 95], ["scl", "ANATOMY", 13, 16], ["early hematopoietic cells", "OBSERVATION", 70, 95]]], ["During definitive hematopoiesis, runx1 marks hematopoietic stem cells (HSCs) in both mouse and fish.", [["hematopoietic stem cells", "ANATOMY", 45, 69], ["HSCs", "ANATOMY", 71, 75], ["runx1", "GENE_OR_GENE_PRODUCT", 33, 38], ["hematopoietic stem cells", "CELL", 45, 69], ["HSCs", "CELL", 71, 75], ["mouse", "ORGANISM", 85, 90], ["fish", "ORGANISM", 95, 99], ["runx1", "PROTEIN", 33, 38], ["hematopoietic stem cells", "CELL_TYPE", 45, 69], ["HSCs", "CELL_TYPE", 71, 75], ["mouse", "SPECIES", 85, 90], ["mouse", "SPECIES", 85, 90], ["definitive hematopoiesis", "PROBLEM", 7, 31], ["runx1 marks hematopoietic stem cells", "PROBLEM", 33, 69], ["definitive", "UNCERTAINTY", 7, 17], ["hematopoiesis", "OBSERVATION", 18, 31], ["runx1 marks hematopoietic stem cells", "OBSERVATION", 33, 69]]], ["Additionally, in differentiated populations, gata1, the erythroid lineage regulator, pu.1 and c/ebp, the myeloid lineage regulators, and ikaros, a mark of the lymphoid population, are in accordance with the hematopoietic hierarchy in zebrafish and mammals [68].", [["erythroid lineage", "ANATOMY", 56, 73], ["myeloid lineage", "ANATOMY", 105, 120], ["lymphoid population", "ANATOMY", 159, 178], ["hematopoietic", "ANATOMY", 207, 220], ["gata1", "GENE_OR_GENE_PRODUCT", 45, 50], ["erythroid lineage", "CELL", 56, 73], ["pu.1", "GENE_OR_GENE_PRODUCT", 85, 89], ["c/ebp", "GENE_OR_GENE_PRODUCT", 94, 99], ["myeloid lineage", "CELL", 105, 120], ["ikaros", "GENE_OR_GENE_PRODUCT", 137, 143], ["lymphoid population", "CELL", 159, 178], ["zebrafish", "ORGANISM", 234, 243], ["gata1", "PROTEIN", 45, 50], ["erythroid lineage regulator", "PROTEIN", 56, 83], ["pu.1", "PROTEIN", 85, 89], ["c", "PROTEIN", 94, 95], ["ebp", "PROTEIN", 96, 99], ["myeloid lineage regulators", "PROTEIN", 105, 131], ["ikaros", "PROTEIN", 137, 143], ["zebrafish", "SPECIES", 234, 243], ["gata1", "TEST", 45, 50], ["erythroid lineage", "OBSERVATION", 56, 73], ["myeloid lineage regulators", "OBSERVATION", 105, 131], ["lymphoid population", "OBSERVATION", 159, 178], ["hematopoietic hierarchy", "OBSERVATION", 207, 230]]], ["Thus, the findings with respect to zebrafish blood development could be applied to mammalian system.Hematopoiesis ::: New materials for developmental, biological and biomedical studiesGenetic screening in zebrafish has generated many blood-related mutants that help researchers understand hematopoietic genes and their functions [69].", [["blood", "ANATOMY", 45, 50], ["blood", "ANATOMY", 234, 239], ["hematopoietic", "ANATOMY", 289, 302], ["Hematopoiesis", "DISEASE", 100, 113], ["zebrafish", "ORGANISM", 35, 44], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["zebrafish", "ORGANISM", 205, 214], ["blood", "ORGANISM_SUBSTANCE", 234, 239], ["hematopoietic", "CELL", 289, 302], ["hematopoietic genes", "DNA", 289, 308], ["zebrafish", "SPECIES", 205, 214], ["zebrafish", "SPECIES", 35, 44], ["zebrafish blood development", "TREATMENT", 35, 62], ["Hematopoiesis", "PROBLEM", 100, 113], ["biomedical studies", "TEST", 166, 184], ["Genetic screening", "TEST", 184, 201], ["many blood-related mutants", "PROBLEM", 229, 255]]], ["For example, the spadetail mutant carrying a mutated tbx16 exhibits defective mesoderm-derived tissues, including blood.", [["mesoderm", "ANATOMY", 78, 86], ["tissues", "ANATOMY", 95, 102], ["blood", "ANATOMY", 114, 119], ["spadetail mutant", "ORGANISM", 17, 33], ["tbx16", "GENE_OR_GENE_PRODUCT", 53, 58], ["tissues", "TISSUE", 95, 102], ["blood", "ORGANISM_SUBSTANCE", 114, 119], ["spadetail mutant", "PROTEIN", 17, 33], ["mutated tbx16", "PROTEIN", 45, 58], ["the spadetail mutant", "PROBLEM", 13, 33], ["defective mesoderm-derived tissues", "PROBLEM", 68, 102], ["defective mesoderm", "OBSERVATION", 68, 86]]], ["This mutant displays the decrease levels tal1, lmo2, gata2, fli1 and gata1 in the posterior lateral mesoderm, indicating the important role of tbx16 during hemangioblast regulation [70].", [["lateral mesoderm", "ANATOMY", 92, 108], ["hemangioblast", "ANATOMY", 156, 169], ["tal1", "GENE_OR_GENE_PRODUCT", 41, 45], ["lmo2", "GENE_OR_GENE_PRODUCT", 47, 51], ["gata2", "GENE_OR_GENE_PRODUCT", 53, 58], ["fli1", "GENE_OR_GENE_PRODUCT", 60, 64], ["gata1", "GENE_OR_GENE_PRODUCT", 69, 74], ["lateral mesoderm", "MULTI-TISSUE_STRUCTURE", 92, 108], ["tbx16", "GENE_OR_GENE_PRODUCT", 143, 148], ["hemangioblast", "CELL", 156, 169], ["tal1", "PROTEIN", 41, 45], ["lmo2", "PROTEIN", 47, 51], ["gata2", "PROTEIN", 53, 58], ["fli1", "PROTEIN", 60, 64], ["gata1", "PROTEIN", 69, 74], ["tbx16", "PROTEIN", 143, 148], ["the decrease levels tal1", "PROBLEM", 21, 45], ["decrease", "OBSERVATION_MODIFIER", 25, 33], ["lmo2", "ANATOMY", 47, 51], ["posterior", "ANATOMY_MODIFIER", 82, 91], ["lateral", "ANATOMY_MODIFIER", 92, 99], ["mesoderm", "ANATOMY", 100, 108]]], ["Chemical screening in zebrafish using biologically active compounds is also a powerful approach to identify factors that regulate HSCs.", [["HSCs", "ANATOMY", 130, 134], ["zebrafish", "ORGANISM", 22, 31], ["HSCs", "CELL", 130, 134], ["HSCs", "CELL_TYPE", 130, 134], ["zebrafish", "SPECIES", 22, 31], ["zebrafish", "SPECIES", 22, 31], ["Chemical screening", "TEST", 0, 18]]], ["For example, it is well known that prostaglandin (PG) E2 increases the induction of stem cells in the aorta\u2013gonad\u2013mesonephros region of zebrafish, as demonstrated by increasing expressions of runx1 and cmyb, which, in turn, increases engraftment of murine marrow in experimental transplantation [71].", [["stem cells", "ANATOMY", 84, 94], ["aorta\u2013gonad\u2013mesonephros region", "ANATOMY", 102, 132], ["marrow", "ANATOMY", 256, 262], ["prostaglandin", "CHEMICAL", 35, 48], ["PG", "CHEMICAL", 50, 52], ["E2", "CHEMICAL", 54, 56], ["prostaglandin (PG) E2", "CHEMICAL", 35, 56], ["prostaglandin (PG) E2", "GENE_OR_GENE_PRODUCT", 35, 56], ["stem cells", "CELL", 84, 94], ["aorta\u2013gonad\u2013mesonephros region", "MULTI-TISSUE_STRUCTURE", 102, 132], ["zebrafish", "ORGANISM", 136, 145], ["runx1", "GENE_OR_GENE_PRODUCT", 192, 197], ["cmyb", "GENE_OR_GENE_PRODUCT", 202, 206], ["murine", "ORGANISM", 249, 255], ["marrow", "ORGAN", 256, 262], ["stem cells", "CELL_TYPE", 84, 94], ["runx1", "PROTEIN", 192, 197], ["cmyb", "PROTEIN", 202, 206], ["murine", "SPECIES", 249, 255], ["prostaglandin (PG) E2", "TREATMENT", 35, 56], ["stem cells", "PROBLEM", 84, 94], ["increasing expressions of runx1 and cmyb", "PROBLEM", 166, 206], ["experimental transplantation", "TREATMENT", 266, 294], ["stem cells", "OBSERVATION", 84, 94], ["zebrafish", "ANATOMY", 136, 145], ["increasing", "OBSERVATION_MODIFIER", 166, 176], ["runx1", "OBSERVATION", 192, 197], ["increases", "OBSERVATION_MODIFIER", 224, 233], ["engraftment", "OBSERVATION", 234, 245], ["murine marrow", "OBSERVATION", 249, 262]]], ["In human clinical trials, the treatment of cord blood cells with dimethyl PGE2 caused an increase in long-term engraftment [72], suggesting that a compound identified in zebrafish could have clinical application in humans.Cardiovascular diseases ::: B) Zebrafish as an animal model for human diseases ::: New materials for developmental, biological and biomedical studiesModel fish are excellent materials for the study of human diseases due to some mutants display similar phenotypes of human diseases [73].", [["cord blood cells", "ANATOMY", 43, 59], ["Cardiovascular", "ANATOMY", 222, 236], ["dimethyl PGE2", "CHEMICAL", 65, 78], ["Cardiovascular diseases", "DISEASE", 222, 245], ["human diseases", "DISEASE", 488, 502], ["dimethyl PGE2", "CHEMICAL", 65, 78], ["human", "ORGANISM", 3, 8], ["cord blood cells", "CELL", 43, 59], ["dimethyl PGE2", "SIMPLE_CHEMICAL", 65, 78], ["zebrafish", "ORGANISM", 170, 179], ["humans", "ORGANISM", 215, 221], ["Zebrafish", "ORGANISM", 253, 262], ["human", "ORGANISM", 286, 291], ["fish", "ORGANISM", 377, 381], ["human", "ORGANISM", 423, 428], ["human", "ORGANISM", 488, 493], ["cord blood cells", "CELL_TYPE", 43, 59], ["human", "SPECIES", 3, 8], ["humans", "SPECIES", 215, 221], ["human", "SPECIES", 286, 291], ["human", "SPECIES", 423, 428], ["human", "SPECIES", 488, 493], ["human", "SPECIES", 3, 8], ["humans", "SPECIES", 215, 221], ["human", "SPECIES", 286, 291], ["human", "SPECIES", 423, 428], ["human", "SPECIES", 488, 493], ["the treatment of cord blood cells", "TREATMENT", 26, 59], ["dimethyl PGE2", "TREATMENT", 65, 78], ["long-term engraftment", "TREATMENT", 101, 122], ["Cardiovascular diseases", "PROBLEM", 222, 245], ["biomedical studies", "TEST", 353, 371], ["the study", "TEST", 410, 419], ["human diseases", "PROBLEM", 423, 437], ["some mutants", "PROBLEM", 445, 457], ["human diseases", "PROBLEM", 488, 502], ["increase", "OBSERVATION_MODIFIER", 89, 97], ["long-term", "OBSERVATION_MODIFIER", 101, 110], ["diseases", "OBSERVATION", 237, 245]]], ["In addition, essential genes and thereof regulation to control the development of tissues or organs are highly conserved [74].", [["tissues", "ANATOMY", 82, 89], ["organs", "ANATOMY", 93, 99], ["tissues", "TISSUE", 82, 89], ["organs", "ORGAN", 93, 99], ["essential genes", "DNA", 13, 28], ["essential genes", "OBSERVATION", 13, 28], ["tissues", "ANATOMY", 82, 89]]], ["For example, Tbx5 is a T-box transcription factor responsible for cell-type specification and morphogenesis.", [["cell", "ANATOMY", 66, 70], ["Tbx5", "GENE_OR_GENE_PRODUCT", 13, 17], ["cell", "CELL", 66, 70], ["Tbx5", "PROTEIN", 13, 17], ["T-box transcription factor", "PROTEIN", 23, 49], ["Tbx5", "PROBLEM", 13, 17], ["a T-box transcription factor", "PROBLEM", 21, 49], ["cell-type specification", "PROBLEM", 66, 89], ["Tbx5", "OBSERVATION", 13, 17]]], ["The phenotypes of tbx5 mutant are highly similar among mammals and zebrafish.", [["tbx5", "GENE_OR_GENE_PRODUCT", 18, 22], ["zebrafish", "ORGANISM", 67, 76], ["tbx5 mutant", "PROTEIN", 18, 29], ["zebrafish", "SPECIES", 67, 76], ["tbx5 mutant", "PROBLEM", 18, 29], ["tbx5 mutant", "OBSERVATION", 18, 29]]], ["Thus, transgenic fish with heart-specific fluorescence could provide a high-through screening platform for drugs for cardiovascular disease.", [["heart", "ANATOMY", 27, 32], ["cardiovascular", "ANATOMY", 117, 131], ["cardiovascular disease", "DISEASE", 117, 139], ["fish", "ORGANISM", 17, 21], ["heart", "ORGAN", 27, 32], ["cardiovascular", "ANATOMICAL_SYSTEM", 117, 131], ["drugs", "TREATMENT", 107, 112], ["cardiovascular disease", "PROBLEM", 117, 139], ["heart", "ANATOMY", 27, 32]]], ["For example, the Tsai\u2019s lab established a transgenic line which could be induced to knock down the expression level of cardiac troponin C at any developmental stage, including embryos, larva or adult fish.", [["cardiac", "ANATOMY", 119, 126], ["embryos", "ANATOMY", 176, 183], ["larva", "ANATOMY", 185, 190], ["cardiac troponin C", "GENE_OR_GENE_PRODUCT", 119, 137], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 176, 183], ["larva", "DEVELOPING_ANATOMICAL_STRUCTURE", 185, 190], ["fish", "ORGANISM_SUBDIVISION", 200, 204], ["cardiac troponin C", "PROTEIN", 119, 137], ["a transgenic line", "TREATMENT", 40, 57], ["cardiac troponin C", "PROBLEM", 119, 137], ["transgenic line", "OBSERVATION", 42, 57], ["cardiac", "ANATOMY", 119, 126]]], ["The reduction of troponin C resulted in mimicry of dilated cardiomyopathy, and the incomplete atrioventricular blocking disease in humans.", [["atrioventricular", "ANATOMY", 94, 110], ["dilated cardiomyopathy", "DISEASE", 51, 73], ["atrioventricular blocking disease", "DISEASE", 94, 127], ["troponin C", "GENE_OR_GENE_PRODUCT", 17, 27], ["humans", "ORGANISM", 131, 137], ["troponin C", "PROTEIN", 17, 27], ["humans", "SPECIES", 131, 137], ["humans", "SPECIES", 131, 137], ["troponin C", "TEST", 17, 27], ["dilated cardiomyopathy", "PROBLEM", 51, 73], ["the incomplete atrioventricular blocking disease in humans", "PROBLEM", 79, 137], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["dilated", "OBSERVATION_MODIFIER", 51, 58], ["cardiomyopathy", "OBSERVATION", 59, 73], ["incomplete", "OBSERVATION_MODIFIER", 83, 93], ["atrioventricular blocking disease", "OBSERVATION", 94, 127]]], ["Therefore, this transgenic line is expected to make a significant contribution to drug screening and the elucidation of the molecular mechanisms underlying cardiovascular diseases.", [["cardiovascular", "ANATOMY", 156, 170], ["cardiovascular diseases", "DISEASE", 156, 179], ["cardiovascular", "ANATOMICAL_SYSTEM", 156, 170], ["this transgenic line", "TREATMENT", 11, 31], ["drug screening", "TEST", 82, 96], ["cardiovascular diseases", "PROBLEM", 156, 179], ["cardiovascular diseases", "OBSERVATION", 156, 179]]], ["Next, the effect of drugs on embryonic development was also studied.Cardiovascular diseases ::: B) Zebrafish as an animal model for human diseases ::: New materials for developmental, biological and biomedical studiesAmiodarone, which is a class III antiarrhythmic agent, is being used for the treatment of tachyarrhythmia in humans.", [["embryonic", "ANATOMY", 29, 38], ["Cardiovascular", "ANATOMY", 68, 82], ["Cardiovascular diseases", "DISEASE", 68, 91], ["Amiodarone", "CHEMICAL", 217, 227], ["tachyarrhythmia", "DISEASE", 307, 322], ["Amiodarone", "CHEMICAL", 217, 227], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 29, 38], ["Zebrafish", "ORGANISM", 99, 108], ["human", "ORGANISM", 132, 137], ["Amiodarone", "SIMPLE_CHEMICAL", 217, 227], ["humans", "ORGANISM", 326, 332], ["human", "SPECIES", 132, 137], ["humans", "SPECIES", 326, 332], ["human", "SPECIES", 132, 137], ["humans", "SPECIES", 326, 332], ["drugs", "TREATMENT", 20, 25], ["embryonic development", "TREATMENT", 29, 50], ["Cardiovascular diseases", "PROBLEM", 68, 91], ["Amiodarone", "TREATMENT", 217, 227], ["a class III antiarrhythmic agent", "TREATMENT", 238, 270], ["tachyarrhythmia", "PROBLEM", 307, 322], ["diseases", "OBSERVATION", 83, 91], ["tachyarrhythmia", "OBSERVATION", 307, 322]]], ["However, Amiodarone-treated zebrafish embryos were found to exhibit backflow of blood in the heart [75].", [["embryos", "ANATOMY", 38, 45], ["blood", "ANATOMY", 80, 85], ["heart", "ANATOMY", 93, 98], ["Amiodarone", "CHEMICAL", 9, 19], ["Amiodarone", "CHEMICAL", 9, 19], ["Amiodarone", "SIMPLE_CHEMICAL", 9, 19], ["zebrafish", "ORGANISM", 28, 37], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 38, 45], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["heart", "ORGAN", 93, 98], ["zebrafish", "SPECIES", 28, 37], ["Amiodarone", "TREATMENT", 9, 19], ["zebrafish embryos", "TREATMENT", 28, 45], ["backflow of blood in the heart", "PROBLEM", 68, 98], ["backflow", "OBSERVATION", 68, 76], ["heart", "ANATOMY", 93, 98]]], ["Subsequent research showed that Amiodarone caused failure of cardiac valve formation [75].", [["cardiac valve", "ANATOMY", 61, 74], ["Amiodarone", "CHEMICAL", 32, 42], ["Amiodarone", "CHEMICAL", 32, 42], ["Amiodarone", "SIMPLE_CHEMICAL", 32, 42], ["cardiac valve", "MULTI-TISSUE_STRUCTURE", 61, 74], ["Amiodarone", "TREATMENT", 32, 42], ["failure of cardiac valve formation", "PROBLEM", 50, 84], ["cardiac valve", "ANATOMY", 61, 74]]], ["Specifically, Amiodarone induces ectopic expression of similar to versican b (s-vcanb), resulting in repression of EGFR/GSK3\u03b2/Snail signaling, which in turn, upregulates cdh5 at the heart field, and causes defective cardiac valves [76].", [["heart", "ANATOMY", 182, 187], ["cardiac valves", "ANATOMY", 216, 230], ["Amiodarone", "CHEMICAL", 14, 24], ["Amiodarone", "CHEMICAL", 14, 24], ["Amiodarone", "SIMPLE_CHEMICAL", 14, 24], ["versican b", "GENE_OR_GENE_PRODUCT", 66, 76], ["s-vcanb", "GENE_OR_GENE_PRODUCT", 78, 85], ["EGFR", "GENE_OR_GENE_PRODUCT", 115, 119], ["GSK3\u03b2", "GENE_OR_GENE_PRODUCT", 120, 125], ["Snail", "GENE_OR_GENE_PRODUCT", 126, 131], ["cdh5", "GENE_OR_GENE_PRODUCT", 170, 174], ["heart", "ORGAN", 182, 187], ["versican b", "PROTEIN", 66, 76], ["s-vcanb", "PROTEIN", 78, 85], ["EGFR", "PROTEIN", 115, 119], ["GSK3\u03b2", "PROTEIN", 120, 125], ["Snail", "PROTEIN", 126, 131], ["cdh5", "PROTEIN", 170, 174], ["Amiodarone", "TREATMENT", 14, 24], ["ectopic expression", "PROBLEM", 33, 51], ["EGFR", "TEST", 115, 119], ["GSK3", "PROBLEM", 120, 124], ["Snail signaling", "PROBLEM", 126, 141], ["defective cardiac valves", "PROBLEM", 206, 230], ["heart", "ANATOMY", 182, 187], ["defective", "OBSERVATION", 206, 215], ["cardiac valves", "ANATOMY", 216, 230]]], ["Moreover, Amiodarone was found to repress metastasis of breast cancer cells by inhibiting the EGFR/ERK/Snail pathway [77], a phenomenon analogous to the inhibitory effects of Amiodarone on EMT transition observed in the heart.Cardiovascular diseases ::: B) Zebrafish as an animal model for human diseases ::: New materials for developmental, biological and biomedical studiesLast but not least, although zebrafish has a two-chambered heart, relative to mouse, rat, and rabbit, its heart rate, action potential duration (APD) and electrocardiogram (ECG) morphology are similar to those of humans.", [["breast cancer cells", "ANATOMY", 56, 75], ["heart", "ANATOMY", 220, 225], ["Cardiovascular", "ANATOMY", 226, 240], ["heart", "ANATOMY", 434, 439], ["heart", "ANATOMY", 481, 486], ["Amiodarone", "CHEMICAL", 10, 20], ["breast cancer", "DISEASE", 56, 69], ["Amiodarone", "CHEMICAL", 175, 185], ["Cardiovascular diseases", "DISEASE", 226, 249], ["Amiodarone", "CHEMICAL", 10, 20], ["Amiodarone", "CHEMICAL", 175, 185], ["Amiodarone", "SIMPLE_CHEMICAL", 10, 20], ["breast cancer cells", "CELL", 56, 75], ["EGFR", "GENE_OR_GENE_PRODUCT", 94, 98], ["ERK", "GENE_OR_GENE_PRODUCT", 99, 102], ["Snail", "GENE_OR_GENE_PRODUCT", 103, 108], ["Amiodarone", "SIMPLE_CHEMICAL", 175, 185], ["heart", "ORGAN", 220, 225], ["human", "ORGANISM", 290, 295], ["zebrafish", "ORGANISM", 404, 413], ["heart", "ORGAN", 434, 439], ["mouse", "ORGANISM", 453, 458], ["rat", "ORGANISM", 460, 463], ["rabbit", "ORGANISM", 469, 475], ["heart", "ORGAN", 481, 486], ["humans", "ORGANISM", 588, 594], ["breast cancer cells", "CELL_TYPE", 56, 75], ["EGFR", "PROTEIN", 94, 98], ["ERK", "PROTEIN", 99, 102], ["Snail", "PROTEIN", 103, 108], ["human", "SPECIES", 290, 295], ["zebrafish", "SPECIES", 404, 413], ["mouse", "SPECIES", 453, 458], ["rat", "SPECIES", 460, 463], ["rabbit", "SPECIES", 469, 475], ["humans", "SPECIES", 588, 594], ["human", "SPECIES", 290, 295], ["zebrafish", "SPECIES", 404, 413], ["mouse", "SPECIES", 453, 458], ["rat", "SPECIES", 460, 463], ["rabbit", "SPECIES", 469, 475], ["humans", "SPECIES", 588, 594], ["Amiodarone", "TREATMENT", 10, 20], ["metastasis of breast cancer cells", "PROBLEM", 42, 75], ["the EGFR", "TEST", 90, 98], ["Snail pathway", "TEST", 103, 116], ["a phenomenon analogous", "PROBLEM", 123, 145], ["Amiodarone", "TREATMENT", 175, 185], ["Cardiovascular diseases", "PROBLEM", 226, 249], ["biomedical studies", "TEST", 357, 375], ["its heart rate", "TEST", 477, 491], ["APD", "TEST", 520, 523], ["electrocardiogram", "TEST", 529, 546], ["ECG", "TEST", 548, 551], ["metastasis", "OBSERVATION", 42, 52], ["breast", "ANATOMY", 56, 62], ["cancer", "OBSERVATION", 63, 69], ["heart", "ANATOMY", 220, 225], ["diseases", "OBSERVATION", 241, 249], ["heart", "ANATOMY", 434, 439], ["heart", "ANATOMY", 481, 486]]], ["Additionally, Tsai et al. demonstrated that the in vitro ECG recording of zebrafish heart is a simple, efficient and high throughput assay [80].", [["heart", "ANATOMY", 84, 89], ["zebrafish", "ORGANISM", 74, 83], ["heart", "ORGAN", 84, 89], ["zebrafish", "SPECIES", 74, 83], ["zebrafish", "SPECIES", 74, 83], ["the in vitro ECG", "TEST", 44, 60], ["zebrafish heart", "ANATOMY", 74, 89]]], ["Thus, zebrafish can serve as a platform for direct testing of drug effect on APD prolongation and prolonged QT interval, which is required by the FDA as a precondition for drug approval.Cancer study: melanoma ::: B) Zebrafish as an animal model for human diseases ::: New materials for developmental, biological and biomedical studiesZebrafish become a popular experimental animal for the studies of human cancer [81], in part because the fish homologs of human oncogenes and tumor suppressor genes have been identified, and in part because signaling pathways regulating cancer development are conserved [82\u201384].", [["Cancer", "ANATOMY", 186, 192], ["melanoma", "ANATOMY", 200, 208], ["cancer", "ANATOMY", 406, 412], ["tumor", "ANATOMY", 476, 481], ["cancer", "ANATOMY", 571, 577], ["Cancer", "DISEASE", 186, 192], ["melanoma", "DISEASE", 200, 208], ["cancer", "DISEASE", 406, 412], ["tumor", "DISEASE", 476, 481], ["cancer", "DISEASE", 571, 577], ["zebrafish", "ORGANISM", 6, 15], ["Cancer", "CANCER", 186, 192], ["melanoma", "CANCER", 200, 208], ["Zebrafish", "ORGANISM", 216, 225], ["human", "ORGANISM", 249, 254], ["Zebrafish", "ORGANISM", 334, 343], ["human", "ORGANISM", 400, 405], ["cancer", "CANCER", 406, 412], ["fish", "ORGANISM", 439, 443], ["human", "ORGANISM", 456, 461], ["tumor", "CANCER", 476, 481], ["cancer", "CANCER", 571, 577], ["human oncogenes and tumor suppressor genes", "DNA", 456, 498], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 400, 405], ["human", "SPECIES", 456, 461], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 400, 405], ["human", "SPECIES", 456, 461], ["direct testing", "TEST", 44, 58], ["drug effect", "PROBLEM", 62, 73], ["APD prolongation", "TREATMENT", 77, 93], ["prolonged QT interval", "PROBLEM", 98, 119], ["drug approval", "TREATMENT", 172, 185], ["melanoma", "PROBLEM", 200, 208], ["New materials", "TREATMENT", 268, 281], ["biomedical studies", "TEST", 316, 334], ["human cancer", "PROBLEM", 400, 412], ["human oncogenes", "TREATMENT", 456, 471], ["tumor suppressor genes", "PROBLEM", 476, 498], ["signaling pathways regulating cancer", "PROBLEM", 541, 577], ["melanoma", "OBSERVATION", 200, 208], ["cancer", "OBSERVATION", 571, 577]]], ["Amatruda et al. reported that many zebrafish tumors are similar to those of human cancer in the histological examination [85].", [["tumors", "ANATOMY", 45, 51], ["cancer", "ANATOMY", 82, 88], ["zebrafish tumors", "DISEASE", 35, 51], ["cancer", "DISEASE", 82, 88], ["zebrafish", "ORGANISM", 35, 44], ["tumors", "CANCER", 45, 51], ["human", "ORGANISM", 76, 81], ["cancer", "CANCER", 82, 88], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["many zebrafish tumors", "PROBLEM", 30, 51], ["human cancer", "PROBLEM", 76, 88], ["the histological examination", "TEST", 92, 120], ["many", "OBSERVATION_MODIFIER", 30, 34], ["zebrafish", "OBSERVATION_MODIFIER", 35, 44], ["tumors", "OBSERVATION", 45, 51], ["cancer", "OBSERVATION", 82, 88]]], ["The zebrafish transgenic line with skin-specific red fluorescence could be applied for skin tumor detection [86].", [["skin", "ANATOMY", 35, 39], ["skin tumor", "ANATOMY", 87, 97], ["tumor", "DISEASE", 92, 97], ["zebrafish", "ORGANISM", 4, 13], ["skin", "ORGAN", 35, 39], ["skin tumor", "CANCER", 87, 97], ["zebrafish transgenic line", "CELL_LINE", 4, 29], ["zebrafish", "SPECIES", 4, 13], ["The zebrafish transgenic line", "TREATMENT", 0, 29], ["specific red fluorescence", "TREATMENT", 40, 65], ["skin tumor detection", "TEST", 87, 107], ["zebrafish", "ANATOMY", 4, 13], ["transgenic line", "OBSERVATION", 14, 29], ["skin", "ANATOMY", 35, 39], ["skin", "ANATOMY", 87, 91], ["tumor", "OBSERVATION", 92, 97]]], ["When the embryos of this line were treated with solutions containing arsenic, the tumors induced on the skin could be easily identified by naked eye under fluorescent microscope.", [["embryos", "ANATOMY", 9, 16], ["tumors", "ANATOMY", 82, 88], ["skin", "ANATOMY", 104, 108], ["eye", "ANATOMY", 145, 148], ["arsenic", "CHEMICAL", 69, 76], ["tumors", "DISEASE", 82, 88], ["arsenic", "CHEMICAL", 69, 76], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 9, 16], ["arsenic", "SIMPLE_CHEMICAL", 69, 76], ["tumors", "CANCER", 82, 88], ["skin", "ORGAN", 104, 108], ["eye", "ORGAN", 145, 148], ["this line", "TREATMENT", 20, 29], ["solutions", "TREATMENT", 48, 57], ["the tumors", "PROBLEM", 78, 88], ["fluorescent microscope", "TEST", 155, 177], ["tumors", "OBSERVATION", 82, 88], ["skin", "ANATOMY", 104, 108], ["eye", "ANATOMY", 145, 148]]], ["Therefore, this transgenic line can be potentially used for the study of skin diseases.", [["skin", "ANATOMY", 73, 77], ["skin diseases", "DISEASE", 73, 86], ["skin", "ORGAN", 73, 77], ["this transgenic line", "TREATMENT", 11, 31], ["the study", "TEST", 60, 69], ["skin diseases", "PROBLEM", 73, 86], ["skin", "ANATOMY", 73, 77], ["diseases", "OBSERVATION", 78, 86]]], ["For example, the common skin cancer melanoma may be screened by the red fluorescence expression in this transgenic line.Cancer study: melanoma ::: B) Zebrafish as an animal model for human diseases ::: New materials for developmental, biological and biomedical studiesZebrafish transgenic line could also be applied to establish models simulating melanoma development.", [["skin cancer melanoma", "ANATOMY", 24, 44], ["Cancer", "ANATOMY", 120, 126], ["melanoma", "ANATOMY", 134, 142], ["melanoma", "ANATOMY", 347, 355], ["cancer melanoma", "DISEASE", 29, 44], ["Cancer", "DISEASE", 120, 126], ["melanoma", "DISEASE", 134, 142], ["melanoma", "DISEASE", 347, 355], ["skin cancer melanoma", "CANCER", 24, 44], ["Cancer", "CANCER", 120, 126], ["melanoma", "CANCER", 134, 142], ["Zebrafish", "ORGANISM", 150, 159], ["human", "ORGANISM", 183, 188], ["Zebrafish", "ORGANISM", 268, 277], ["melanoma", "CANCER", 347, 355], ["human", "SPECIES", 183, 188], ["human", "SPECIES", 183, 188], ["the common skin cancer melanoma", "PROBLEM", 13, 44], ["this transgenic line", "TREATMENT", 99, 119], ["melanoma", "PROBLEM", 134, 142], ["New materials", "TREATMENT", 202, 215], ["biomedical studies", "TEST", 250, 268], ["Zebrafish transgenic line", "TREATMENT", 268, 293], ["simulating melanoma development", "PROBLEM", 336, 367], ["common", "OBSERVATION_MODIFIER", 17, 23], ["skin", "ANATOMY", 24, 28], ["cancer", "OBSERVATION", 29, 35], ["transgenic line", "OBSERVATION", 104, 119], ["melanoma", "OBSERVATION", 134, 142], ["melanoma", "OBSERVATION", 347, 355]]], ["The human oncogenic BRAFV600E was expressed under the control of the zebrafish melanocyte mitfa promoter to establish a melanoma model [87].", [["melanocyte", "ANATOMY", 79, 89], ["melanoma", "ANATOMY", 120, 128], ["melanoma", "DISEASE", 120, 128], ["human", "ORGANISM", 4, 9], ["BRAFV600E", "GENE_OR_GENE_PRODUCT", 20, 29], ["zebrafish", "ORGANISM", 69, 78], ["melanocyte mitfa", "GENE_OR_GENE_PRODUCT", 79, 95], ["melanoma", "CANCER", 120, 128], ["human oncogenic BRAFV600E", "DNA", 4, 29], ["zebrafish melanocyte mitfa promoter", "DNA", 69, 104], ["human", "SPECIES", 4, 9], ["zebrafish", "SPECIES", 69, 78], ["human", "SPECIES", 4, 9], ["The human oncogenic BRAFV600E", "TREATMENT", 0, 29], ["the zebrafish melanocyte mitfa promoter", "TREATMENT", 65, 104], ["a melanoma model", "PROBLEM", 118, 134], ["oncogenic BRAFV600E", "OBSERVATION", 10, 29], ["melanoma", "OBSERVATION", 120, 128]]], ["Combining skin-specific red fluorescence with mitfa-driven oncogene expression, the melanoma could be easily traced.", [["skin", "ANATOMY", 10, 14], ["melanoma", "ANATOMY", 84, 92], ["melanoma", "DISEASE", 84, 92], ["skin", "ORGAN", 10, 14], ["mitfa", "GENE_OR_GENE_PRODUCT", 46, 51], ["melanoma", "CANCER", 84, 92], ["mitfa", "PROTEIN", 46, 51], ["oncogene", "DNA", 59, 67], ["red fluorescence", "TEST", 24, 40], ["mitfa-driven oncogene expression", "TREATMENT", 46, 78], ["the melanoma", "PROBLEM", 80, 92], ["skin", "ANATOMY", 10, 14], ["melanoma", "OBSERVATION", 84, 92]]], ["Therefore, transgenic lines and mutants of model fish could provide abundant resources for mechanistic studies and therapeutic research in human diseases.Cancer study: metastasis ::: B) Zebrafish as an animal model for human diseases ::: New materials for developmental, biological and biomedical studiesMetastasis involves processes of sequential, interlinked and selective steps, including invasion, intravasation, arrest in distant capillaries, extravasation, and colonization [88].", [["Cancer", "ANATOMY", 154, 160], ["capillaries", "ANATOMY", 435, 446], ["Cancer", "DISEASE", 154, 160], ["Metastasis", "DISEASE", 304, 314], ["transgenic lines", "CELL", 11, 27], ["fish", "ORGANISM", 49, 53], ["human", "ORGANISM", 139, 144], ["Cancer", "CANCER", 154, 160], ["Zebrafish", "ORGANISM", 186, 195], ["human", "ORGANISM", 219, 224], ["capillaries", "TISSUE", 435, 446], ["transgenic lines", "CELL_LINE", 11, 27], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 219, 224], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 219, 224], ["transgenic lines", "TREATMENT", 11, 27], ["mechanistic studies", "TEST", 91, 110], ["therapeutic research in human diseases", "PROBLEM", 115, 153], ["metastasis", "PROBLEM", 168, 178], ["New materials", "TREATMENT", 238, 251], ["developmental, biological and biomedical studiesMetastasis", "PROBLEM", 256, 314], ["invasion", "PROBLEM", 392, 400], ["intravasation", "PROBLEM", 402, 415], ["arrest", "PROBLEM", 417, 423], ["extravasation", "PROBLEM", 448, 461], ["transgenic lines", "OBSERVATION", 11, 27], ["metastasis", "OBSERVATION", 168, 178], ["Metastasis", "OBSERVATION", 304, 314], ["invasion", "OBSERVATION", 392, 400], ["intravasation", "OBSERVATION", 402, 415], ["arrest", "OBSERVATION_MODIFIER", 417, 423], ["distant", "OBSERVATION_MODIFIER", 427, 434], ["capillaries", "OBSERVATION_MODIFIER", 435, 446], ["extravasation", "OBSERVATION", 448, 461]]], ["Zebrafish is again an alternative organism for in vivo cancer biology studies.", [["cancer", "ANATOMY", 55, 61], ["cancer", "DISEASE", 55, 61], ["Zebrafish", "ORGANISM", 0, 9], ["cancer", "CANCER", 55, 61], ["Zebrafish", "SPECIES", 0, 9], ["Zebrafish", "SPECIES", 0, 9]]], ["In particular, xenotransplantation of human cancer cells into zebrafish embryos serves as an alternative approach for evaluating cancer progression and drug screening [89].", [["cancer cells", "ANATOMY", 44, 56], ["embryos", "ANATOMY", 72, 79], ["cancer", "ANATOMY", 129, 135], ["cancer", "DISEASE", 44, 50], ["cancer", "DISEASE", 129, 135], ["human", "ORGANISM", 38, 43], ["cancer cells", "CELL", 44, 56], ["zebrafish", "ORGANISM", 62, 71], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 72, 79], ["cancer", "CANCER", 129, 135], ["human cancer cells", "CELL_TYPE", 38, 56], ["human", "SPECIES", 38, 43], ["zebrafish", "SPECIES", 62, 71], ["human", "SPECIES", 38, 43], ["xenotransplantation of human cancer cells", "TREATMENT", 15, 56], ["zebrafish embryos", "TREATMENT", 62, 79], ["an alternative approach", "TREATMENT", 90, 113], ["cancer progression", "PROBLEM", 129, 147], ["drug screening", "TEST", 152, 166], ["human cancer", "OBSERVATION", 38, 50]]], ["For example, human primary tumor cells labeled with fluorescence have already been implanted in zebrafish liver, and the invasiveness and metastasis of these cells were directly observable and easily traceable [90].", [["primary tumor cells", "ANATOMY", 19, 38], ["liver", "ANATOMY", 106, 111], ["cells", "ANATOMY", 158, 163], ["tumor", "DISEASE", 27, 32], ["human", "ORGANISM", 13, 18], ["tumor cells", "CELL", 27, 38], ["zebrafish", "ORGANISM", 96, 105], ["liver", "ORGAN", 106, 111], ["cells", "CELL", 158, 163], ["human primary tumor cells", "CELL_TYPE", 13, 38], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["zebrafish", "SPECIES", 96, 105], ["human primary tumor cells", "PROBLEM", 13, 38], ["metastasis of these cells", "PROBLEM", 138, 163], ["primary", "OBSERVATION_MODIFIER", 19, 26], ["tumor", "OBSERVATION", 27, 32], ["implanted", "OBSERVATION", 83, 92], ["zebrafish", "ANATOMY_MODIFIER", 96, 105], ["liver", "ANATOMY", 106, 111], ["invasiveness", "OBSERVATION_MODIFIER", 121, 133], ["metastasis", "OBSERVATION", 138, 148]]], ["To investigate the mechanism of local cancer cell invasion, human glioblastoma cells labeled with fluorescence were infiltrated into the brain of zebrafish embryos.", [["cancer cell", "ANATOMY", 38, 49], ["glioblastoma cells", "ANATOMY", 66, 84], ["brain", "ANATOMY", 137, 142], ["embryos", "ANATOMY", 156, 163], ["cancer", "DISEASE", 38, 44], ["glioblastoma", "DISEASE", 66, 78], ["cancer cell", "CELL", 38, 49], ["human", "ORGANISM", 60, 65], ["glioblastoma cells", "CELL", 66, 84], ["brain", "ORGAN", 137, 142], ["zebrafish", "ORGANISM", 146, 155], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 156, 163], ["human glioblastoma cells", "CELL_TYPE", 60, 84], ["human", "SPECIES", 60, 65], ["zebrafish", "SPECIES", 146, 155], ["human", "SPECIES", 60, 65], ["zebrafish", "SPECIES", 146, 155], ["local cancer cell invasion", "PROBLEM", 32, 58], ["human glioblastoma cells", "PROBLEM", 60, 84], ["fluorescence", "PROBLEM", 98, 110], ["local", "OBSERVATION_MODIFIER", 32, 37], ["cancer cell invasion", "OBSERVATION", 38, 58], ["glioblastoma cells", "OBSERVATION", 66, 84], ["brain", "ANATOMY", 137, 142], ["zebrafish embryos", "OBSERVATION", 146, 163]]], ["It was observed that the injected cells aligned along the abluminal surface of brain blood vessels [91].", [["cells", "ANATOMY", 34, 39], ["abluminal surface", "ANATOMY", 58, 75], ["brain blood vessels", "ANATOMY", 79, 98], ["cells", "CELL", 34, 39], ["abluminal surface", "CELLULAR_COMPONENT", 58, 75], ["brain blood vessels", "MULTI-TISSUE_STRUCTURE", 79, 98], ["the injected cells", "PROBLEM", 21, 39], ["injected cells", "OBSERVATION", 25, 39], ["abluminal", "ANATOMY_MODIFIER", 58, 67], ["surface", "ANATOMY_MODIFIER", 68, 75], ["brain", "ANATOMY_MODIFIER", 79, 84], ["blood vessels", "ANATOMY", 85, 98]]], ["By grafting a small amount of highly metastatic human breast carcinoma cells onto the pericardial membrane of zebrafish embryos at 48 hpf, tumor cells were observed to move longitudinally along the aorta [92].", [["breast carcinoma cells", "ANATOMY", 54, 76], ["pericardial membrane", "ANATOMY", 86, 106], ["embryos", "ANATOMY", 120, 127], ["tumor cells", "ANATOMY", 139, 150], ["aorta", "ANATOMY", 198, 203], ["breast carcinoma", "DISEASE", 54, 70], ["tumor", "DISEASE", 139, 144], ["human", "ORGANISM", 48, 53], ["breast carcinoma cells", "CELL", 54, 76], ["pericardial membrane", "MULTI-TISSUE_STRUCTURE", 86, 106], ["zebrafish", "ORGANISM", 110, 119], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 120, 127], ["tumor cells", "CELL", 139, 150], ["aorta", "MULTI-TISSUE_STRUCTURE", 198, 203], ["highly metastatic human breast carcinoma cells", "CELL_TYPE", 30, 76], ["tumor cells", "CELL_TYPE", 139, 150], ["human", "SPECIES", 48, 53], ["zebrafish", "SPECIES", 110, 119], ["human", "SPECIES", 48, 53], ["highly metastatic human breast carcinoma cells", "PROBLEM", 30, 76], ["zebrafish embryos", "PROBLEM", 110, 127], ["tumor cells", "PROBLEM", 139, 150], ["grafting", "OBSERVATION", 3, 11], ["small", "OBSERVATION_MODIFIER", 14, 19], ["amount", "OBSERVATION_MODIFIER", 20, 26], ["highly", "OBSERVATION_MODIFIER", 30, 36], ["metastatic", "OBSERVATION_MODIFIER", 37, 47], ["breast", "ANATOMY", 54, 60], ["carcinoma cells", "OBSERVATION", 61, 76], ["pericardial", "ANATOMY", 86, 97], ["membrane", "ANATOMY_MODIFIER", 98, 106], ["zebrafish embryos", "OBSERVATION", 110, 127], ["tumor cells", "OBSERVATION", 139, 150], ["aorta", "ANATOMY", 198, 203]]], ["Similarly, highly metastatic human cancer cells labeled with fluorescence were injected into the pericardium of 48-hpf embryos.", [["metastatic human cancer cells", "ANATOMY", 18, 47], ["pericardium", "ANATOMY", 97, 108], ["embryos", "ANATOMY", 119, 126], ["cancer", "DISEASE", 35, 41], ["human", "ORGANISM", 29, 34], ["cancer cells", "CELL", 35, 47], ["pericardium", "ORGAN", 97, 108], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 119, 126], ["highly metastatic human cancer cells", "CELL_TYPE", 11, 47], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["highly metastatic human cancer cells", "PROBLEM", 11, 47], ["fluorescence", "TREATMENT", 61, 73], ["highly", "OBSERVATION_MODIFIER", 11, 17], ["metastatic", "OBSERVATION_MODIFIER", 18, 28], ["pericardium", "ANATOMY", 97, 108]]], ["Afterwards, it is possible to visualize how cancer cells entered the blood circulation and arrested in small vessels in head and tail [93].", [["cancer cells", "ANATOMY", 44, 56], ["blood", "ANATOMY", 69, 74], ["small vessels", "ANATOMY", 103, 116], ["head", "ANATOMY", 120, 124], ["cancer", "DISEASE", 44, 50], ["cancer cells", "CELL", 44, 56], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["small vessels", "MULTI-TISSUE_STRUCTURE", 103, 116], ["head", "ORGANISM_SUBDIVISION", 120, 124], ["cancer cells", "CELL_TYPE", 44, 56], ["cancer cells", "PROBLEM", 44, 56], ["the blood circulation", "TEST", 65, 86], ["cancer", "OBSERVATION", 44, 50], ["small", "OBSERVATION_MODIFIER", 103, 108], ["vessels", "ANATOMY", 109, 116], ["head", "ANATOMY", 120, 124], ["tail", "ANATOMY", 129, 133]]], ["In another example, zebrafish embryos were injected with tumorigenic human glioma stem cells at different stages of metastasis, including beginning, approaching, clustering, invading, migrating, and transmigrating [94].", [["embryos", "ANATOMY", 30, 37], ["glioma stem cells", "ANATOMY", 75, 92], ["zebrafish", "ORGANISM", 20, 29], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 30, 37], ["human", "ORGANISM", 69, 74], ["glioma stem cells", "CELL", 75, 92], ["tumorigenic human glioma stem cells", "CELL_TYPE", 57, 92], ["zebrafish", "SPECIES", 20, 29], ["human", "SPECIES", 69, 74], ["zebrafish", "SPECIES", 20, 29], ["human", "SPECIES", 69, 74], ["zebrafish embryos", "PROBLEM", 20, 37], ["tumorigenic human glioma stem cells", "PROBLEM", 57, 92], ["metastasis", "PROBLEM", 116, 126], ["zebrafish embryos", "OBSERVATION", 20, 37], ["glioma stem cells", "OBSERVATION", 75, 92], ["metastasis", "OBSERVATION", 116, 126]]], ["Thus, grafting a small number of labeled tumor cells into transparent zebrafish embryos allows us to dynamically monitor the cancer cells without the interference of immune suppression.Cancer study: metastasis ::: B) Zebrafish as an animal model for human diseases ::: New materials for developmental, biological and biomedical studiesApart from its utility in analyzing the mechanisms of tumor dissemination and metastasis, the zebrafish model can also be applied to screen potential anticancer compounds or drugs.", [["tumor cells", "ANATOMY", 41, 52], ["embryos", "ANATOMY", 80, 87], ["cancer cells", "ANATOMY", 125, 137], ["Cancer", "ANATOMY", 185, 191], ["tumor", "ANATOMY", 389, 394], ["anticancer", "ANATOMY", 485, 495], ["tumor", "DISEASE", 41, 46], ["cancer", "DISEASE", 125, 131], ["Cancer", "DISEASE", 185, 191], ["tumor", "DISEASE", 389, 394], ["tumor cells", "CELL", 41, 52], ["zebrafish", "ORGANISM", 70, 79], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 80, 87], ["cancer cells", "CELL", 125, 137], ["Cancer", "CANCER", 185, 191], ["Zebrafish", "ORGANISM", 217, 226], ["human", "ORGANISM", 250, 255], ["tumor", "CANCER", 389, 394], ["zebrafish", "ORGANISM", 429, 438], ["anticancer", "CANCER", 485, 495], ["labeled tumor cells", "CELL_TYPE", 33, 52], ["cancer cells", "CELL_TYPE", 125, 137], ["human", "SPECIES", 250, 255], ["human", "SPECIES", 250, 255], ["grafting", "TREATMENT", 6, 14], ["labeled tumor cells", "PROBLEM", 33, 52], ["transparent zebrafish embryos", "TREATMENT", 58, 87], ["the cancer cells", "PROBLEM", 121, 137], ["immune suppression", "PROBLEM", 166, 184], ["metastasis", "PROBLEM", 199, 209], ["biomedical studies", "TEST", 317, 335], ["tumor dissemination", "PROBLEM", 389, 408], ["metastasis", "PROBLEM", 413, 423], ["the zebrafish model", "TREATMENT", 425, 444], ["drugs", "TREATMENT", 509, 514], ["grafting", "OBSERVATION", 6, 14], ["small", "OBSERVATION_MODIFIER", 17, 22], ["number", "OBSERVATION_MODIFIER", 23, 29], ["tumor cells", "OBSERVATION", 41, 52], ["zebrafish embryos", "OBSERVATION", 70, 87], ["cancer", "OBSERVATION", 125, 131], ["metastasis", "OBSERVATION", 199, 209], ["tumor", "OBSERVATION", 389, 394], ["metastasis", "OBSERVATION", 413, 423]]], ["In addition, zebrafish feature such advantages as easy gene manipulation, short generation cycle, high reproducibility, low maintenance cost, and efficient plating of embryos [95, 96].", [["embryos", "ANATOMY", 167, 174], ["zebrafish", "ORGANISM", 13, 22], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 167, 174], ["easy gene manipulation", "TREATMENT", 50, 72], ["short generation cycle", "PROBLEM", 74, 96], ["high reproducibility", "PROBLEM", 98, 118], ["efficient plating of embryos", "TREATMENT", 146, 174]]], ["Therefore, this small fish is second only to SCID and nude mice as xenograft recipients of cancer cells.Cancer study: leukemia ::: B) Zebrafish as an animal model for human diseases ::: New materials for developmental, biological and biomedical studiesLeukemia is a cancer related to hematopoiesis.", [["xenograft", "ANATOMY", 67, 76], ["cancer cells", "ANATOMY", 91, 103], ["Cancer", "ANATOMY", 104, 110], ["leukemia", "ANATOMY", 118, 126], ["cancer", "ANATOMY", 266, 272], ["cancer", "DISEASE", 91, 97], ["Cancer", "DISEASE", 104, 110], ["leukemia", "DISEASE", 118, 126], ["studiesLeukemia", "DISEASE", 245, 260], ["cancer", "DISEASE", 266, 272], ["fish", "ORGANISM", 22, 26], ["nude mice", "ORGANISM", 54, 63], ["xenograft", "CANCER", 67, 76], ["cancer cells", "CELL", 91, 103], ["Cancer", "CANCER", 104, 110], ["leukemia", "CANCER", 118, 126], ["Zebrafish", "ORGANISM", 134, 143], ["human", "ORGANISM", 167, 172], ["cancer", "CANCER", 266, 272], ["cancer cells", "CELL_TYPE", 91, 103], ["mice", "SPECIES", 59, 63], ["human", "SPECIES", 167, 172], ["mice", "SPECIES", 59, 63], ["human", "SPECIES", 167, 172], ["cancer cells", "PROBLEM", 91, 103], ["leukemia", "PROBLEM", 118, 126], ["New materials", "TREATMENT", 186, 199], ["a cancer", "PROBLEM", 264, 272], ["hematopoiesis", "PROBLEM", 284, 297], ["small", "OBSERVATION_MODIFIER", 16, 21], ["fish", "OBSERVATION", 22, 26], ["cancer cells", "OBSERVATION", 91, 103], ["leukemia", "OBSERVATION", 118, 126], ["cancer", "OBSERVATION", 266, 272], ["hematopoiesis", "OBSERVATION", 284, 297]]], ["Most often, leukemia results from the abnormal increase of white blood cells.", [["leukemia", "ANATOMY", 12, 20], ["white blood cells", "ANATOMY", 59, 76], ["leukemia", "DISEASE", 12, 20], ["leukemia", "CANCER", 12, 20], ["white blood cells", "CELL", 59, 76], ["white blood cells", "CELL_TYPE", 59, 76], ["leukemia", "PROBLEM", 12, 20], ["the abnormal increase of white blood cells", "PROBLEM", 34, 76], ["leukemia", "OBSERVATION", 12, 20], ["abnormal", "OBSERVATION_MODIFIER", 38, 46], ["increase", "OBSERVATION_MODIFIER", 47, 55]]], ["However, some human cancers of bone marrow and blood origins have their parental cells from other blood cell types.", [["cancers", "ANATOMY", 20, 27], ["bone marrow", "ANATOMY", 31, 42], ["blood", "ANATOMY", 47, 52], ["cells", "ANATOMY", 81, 86], ["blood cell", "ANATOMY", 98, 108], ["cancers", "DISEASE", 20, 27], ["human", "ORGANISM", 14, 19], ["cancers", "CANCER", 20, 27], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 31, 42], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["cells", "CELL", 81, 86], ["blood cell", "CELL", 98, 108], ["parental cells", "CELL_TYPE", 72, 86], ["blood cell types", "CELL_TYPE", 98, 114], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["some human cancers of bone marrow", "PROBLEM", 9, 42], ["cancers", "OBSERVATION", 20, 27], ["bone marrow", "ANATOMY", 31, 42], ["parental cells", "OBSERVATION", 72, 86], ["blood cell types", "OBSERVATION", 98, 114]]], ["The search for efficacious therapies for leukemia is ongoing.", [["leukemia", "ANATOMY", 41, 49], ["leukemia", "DISEASE", 41, 49], ["leukemia", "CANCER", 41, 49], ["efficacious therapies", "TREATMENT", 15, 36], ["leukemia", "PROBLEM", 41, 49], ["leukemia", "OBSERVATION", 41, 49]]], ["Interestingly, the developmental processes and genes related to hematopoiesis are similar between zebrafish and humans, making zebrafish a feasible model for the study of leukemia.", [["leukemia", "ANATOMY", 171, 179], ["leukemia", "DISEASE", 171, 179], ["zebrafish", "ORGANISM", 98, 107], ["humans", "ORGANISM", 112, 118], ["zebrafish", "ORGANISM", 127, 136], ["leukemia", "CANCER", 171, 179], ["zebrafish", "SPECIES", 98, 107], ["humans", "SPECIES", 112, 118], ["humans", "SPECIES", 112, 118], ["the developmental processes", "PROBLEM", 15, 42], ["hematopoiesis", "PROBLEM", 64, 77], ["the study", "TEST", 158, 167], ["leukemia", "PROBLEM", 171, 179], ["hematopoiesis", "OBSERVATION", 64, 77], ["leukemia", "OBSERVATION", 171, 179]]], ["In addition, gene expression in zebrafish could be conveniently modified by several approaches, e.g., MO-induced gene knockdown, TALENs and CRISPR/Cas9 gene knockout, and DNA/RNA introduced overexpression [6, 7].", [["zebrafish", "ORGANISM", 32, 41], ["MO", "GENE_OR_GENE_PRODUCT", 102, 104], ["CRISPR/Cas9", "GENE_OR_GENE_PRODUCT", 140, 151], ["DNA", "CELLULAR_COMPONENT", 171, 174], ["TALENs", "DNA", 129, 135], ["CRISPR", "DNA", 140, 146], ["CRISPR/Cas9 gene knockout", "TREATMENT", 140, 165]]], ["In the study of Yeh et al. [97], the zebrafish model was applied to screen for chemical modifiers of AML1-ETO, an oncogenic fusion protein prevalent in acute myeloid leukemia (AML).", [["acute myeloid leukemia", "ANATOMY", 152, 174], ["AML", "ANATOMY", 176, 179], ["acute myeloid leukemia", "DISEASE", 152, 174], ["AML", "DISEASE", 176, 179], ["zebrafish", "ORGANISM", 37, 46], ["AML1", "GENE_OR_GENE_PRODUCT", 101, 105], ["ETO", "GENE_OR_GENE_PRODUCT", 106, 109], ["acute myeloid leukemia", "CANCER", 152, 174], ["AML", "CANCER", 176, 179], ["AML1", "PROTEIN", 101, 105], ["ETO", "PROTEIN", 106, 109], ["oncogenic fusion protein", "PROTEIN", 114, 138], ["the study", "TEST", 3, 12], ["the zebrafish model", "TREATMENT", 33, 52], ["chemical modifiers", "TREATMENT", 79, 97], ["AML1", "PROBLEM", 101, 105], ["ETO", "TREATMENT", 106, 109], ["an oncogenic fusion protein", "TREATMENT", 111, 138], ["acute myeloid leukemia", "PROBLEM", 152, 174], ["acute myeloid leukemia", "OBSERVATION", 152, 174]]], ["Treatment of zebrafish with chemical modifiers of AML1-ETO resulted in hematopoietic dysregulation and elicited a malignant phenotype similar to human AML.", [["hematopoietic", "ANATOMY", 71, 84], ["AML", "ANATOMY", 151, 154], ["ETO", "CHEMICAL", 55, 58], ["AML", "DISEASE", 151, 154], ["zebrafish", "ORGANISM", 13, 22], ["AML1", "GENE_OR_GENE_PRODUCT", 50, 54], ["ETO", "GENE_OR_GENE_PRODUCT", 55, 58], ["hematopoietic", "CELL", 71, 84], ["human", "ORGANISM", 145, 150], ["AML", "CANCER", 151, 154], ["AML1", "PROTEIN", 50, 54], ["ETO", "PROTEIN", 55, 58], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 145, 150], ["chemical modifiers of AML1", "TREATMENT", 28, 54], ["ETO", "TREATMENT", 55, 58], ["hematopoietic dysregulation", "PROBLEM", 71, 98], ["a malignant phenotype", "PROBLEM", 112, 133], ["human AML", "PROBLEM", 145, 154], ["hematopoietic dysregulation", "OBSERVATION", 71, 98], ["malignant", "OBSERVATION_MODIFIER", 114, 123], ["human AML", "OBSERVATION", 145, 154]]], ["Cyclooxygenase-2 (COX2) is an enzyme causing inflammation and pain.", [["inflammation", "DISEASE", 45, 57], ["pain", "DISEASE", 62, 66], ["Cyclooxygenase-2", "GENE_OR_GENE_PRODUCT", 0, 16], ["COX2", "GENE_OR_GENE_PRODUCT", 18, 22], ["Cyclooxygenase-2", "PROTEIN", 0, 16], ["COX2", "PROTEIN", 18, 22], ["Cyclooxygenase-2 (COX2", "TREATMENT", 0, 22], ["an enzyme", "TEST", 27, 36], ["inflammation", "PROBLEM", 45, 57], ["pain", "PROBLEM", 62, 66], ["inflammation", "OBSERVATION", 45, 57]]], ["Nimesulide is an inhibitor of COX2 and an antagonist to AML1-ETO in hematopoietic differentiation.Cancer study: leukemia ::: B) Zebrafish as an animal model for human diseases ::: New materials for developmental, biological and biomedical studiesFMS-like tyrosine kinase 3 (FLT3) is a class III receptor tyrosine kinase which is normally expressed in human hematopoietic stem and progenitor cells (HSPCs) [98].", [["hematopoietic", "ANATOMY", 68, 81], ["Cancer", "ANATOMY", 98, 104], ["leukemia", "ANATOMY", 112, 120], ["hematopoietic stem and progenitor cells", "ANATOMY", 357, 396], ["HSPCs", "ANATOMY", 398, 403], ["Nimesulide", "CHEMICAL", 0, 10], ["Cancer", "DISEASE", 98, 104], ["leukemia", "DISEASE", 112, 120], ["tyrosine", "CHEMICAL", 255, 263], ["tyrosine", "CHEMICAL", 304, 312], ["Nimesulide", "CHEMICAL", 0, 10], ["tyrosine", "CHEMICAL", 255, 263], ["tyrosine", "CHEMICAL", 304, 312], ["Nimesulide", "SIMPLE_CHEMICAL", 0, 10], ["COX2", "GENE_OR_GENE_PRODUCT", 30, 34], ["AML1", "GENE_OR_GENE_PRODUCT", 56, 60], ["ETO", "GENE_OR_GENE_PRODUCT", 61, 64], ["hematopoietic", "CELL", 68, 81], ["Cancer", "CANCER", 98, 104], ["leukemia", "CANCER", 112, 120], ["Zebrafish", "ORGANISM", 128, 137], ["human", "ORGANISM", 161, 166], ["studiesFMS-like tyrosine kinase 3", "GENE_OR_GENE_PRODUCT", 239, 272], ["FLT3", "GENE_OR_GENE_PRODUCT", 274, 278], ["human", "ORGANISM", 351, 356], ["hematopoietic stem and progenitor cells", "CELL", 357, 396], ["HSPCs", "CELL", 398, 403], ["COX2", "PROTEIN", 30, 34], ["AML1", "PROTEIN", 56, 60], ["ETO", "PROTEIN", 61, 64], ["studiesFMS-like tyrosine kinase 3", "PROTEIN", 239, 272], ["FLT3", "PROTEIN", 274, 278], ["class III receptor tyrosine kinase", "PROTEIN", 285, 319], ["human hematopoietic stem and progenitor cells", "CELL_TYPE", 351, 396], ["HSPCs", "CELL_TYPE", 398, 403], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 351, 356], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 351, 356], ["Nimesulide", "TREATMENT", 0, 10], ["an inhibitor of COX2", "TREATMENT", 14, 34], ["an antagonist to AML1", "TREATMENT", 39, 60], ["leukemia", "PROBLEM", 112, 120], ["biomedical studiesFMS", "TEST", 228, 249], ["tyrosine kinase", "TREATMENT", 255, 270], ["a class III receptor tyrosine kinase", "TREATMENT", 283, 319], ["hematopoietic differentiation", "OBSERVATION", 68, 97], ["leukemia", "OBSERVATION", 112, 120], ["human hematopoietic stem", "OBSERVATION", 351, 375]]], ["Internal tandem duplication (ITD), which may occur at either the juxtamembrane domain (JMD) or the tyrosine kinase domain (TKDs) of FLT3, is observed in one-third of human AML.", [["AML", "ANATOMY", 172, 175], ["tyrosine", "CHEMICAL", 99, 107], ["AML", "DISEASE", 172, 175], ["tyrosine", "CHEMICAL", 99, 107], ["FLT3", "GENE_OR_GENE_PRODUCT", 132, 136], ["human", "ORGANISM", 166, 171], ["AML", "CANCER", 172, 175], ["ITD", "DNA", 29, 32], ["juxtamembrane domain", "PROTEIN", 65, 85], ["JMD", "PROTEIN", 87, 90], ["tyrosine kinase domain", "PROTEIN", 99, 121], ["TKDs", "PROTEIN", 123, 127], ["FLT3", "PROTEIN", 132, 136], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 166, 171], ["Internal tandem duplication (ITD)", "TREATMENT", 0, 33], ["the tyrosine kinase domain (TKDs) of FLT3", "PROBLEM", 95, 136], ["human AML", "PROBLEM", 166, 175], ["tandem duplication", "OBSERVATION", 9, 27], ["tyrosine kinase", "OBSERVATION", 99, 114], ["FLT3", "OBSERVATION", 132, 136], ["human AML", "OBSERVATION", 166, 175]]], ["Zebrafish Flt3 shares an overall 32, 35, and 34% sequence identity with that of human, mouse, and rat, respectively.", [["Zebrafish", "ORGANISM", 0, 9], ["Flt3", "GENE_OR_GENE_PRODUCT", 10, 14], ["human", "ORGANISM", 80, 85], ["mouse", "ORGANISM", 87, 92], ["rat", "ORGANISM", 98, 101], ["Flt3", "PROTEIN", 10, 14], ["Zebrafish", "SPECIES", 0, 9], ["human", "SPECIES", 80, 85], ["mouse", "SPECIES", 87, 92], ["rat", "SPECIES", 98, 101], ["Zebrafish", "SPECIES", 0, 9], ["human", "SPECIES", 80, 85], ["mouse", "SPECIES", 87, 92], ["rat", "SPECIES", 98, 101]]], ["However, the JMD and the activation loops of TKD are highly conserved, implicating that the functions of FLT3 signaling are evolutionally conserved.", [["JMD", "GENE_OR_GENE_PRODUCT", 13, 16], ["TKD", "GENE_OR_GENE_PRODUCT", 45, 48], ["FLT3", "GENE_OR_GENE_PRODUCT", 105, 109], ["JMD", "PROTEIN", 13, 16], ["TKD", "PROTEIN", 45, 48], ["FLT3", "PROTEIN", 105, 109], ["the JMD", "PROBLEM", 9, 16], ["the activation loops of TKD", "PROBLEM", 21, 48], ["FLT3 signaling", "PROBLEM", 105, 119], ["activation loops", "OBSERVATION", 25, 41]]], ["Overexpression of human FLT3-ITD in zebrafish embryos induces the ectopic expansion of FLT3-ITD positive myeloid cells.", [["embryos", "ANATOMY", 46, 53], ["FLT3-ITD positive myeloid cells", "ANATOMY", 87, 118], ["human", "ORGANISM", 18, 23], ["FLT3-ITD", "GENE_OR_GENE_PRODUCT", 24, 32], ["zebrafish", "ORGANISM", 36, 45], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 46, 53], ["FLT3-ITD", "GENE_OR_GENE_PRODUCT", 87, 95], ["human FLT3-ITD", "DNA", 18, 32], ["FLT3-ITD positive myeloid cells", "CELL_LINE", 87, 118], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["human FLT3", "TREATMENT", 18, 28], ["ITD in zebrafish embryos", "TREATMENT", 29, 53], ["the ectopic expansion of FLT3", "PROBLEM", 62, 91], ["ITD positive myeloid cells", "PROBLEM", 92, 118], ["human FLT3", "OBSERVATION", 18, 28], ["zebrafish embryos", "OBSERVATION", 36, 53], ["FLT3", "ANATOMY", 87, 91], ["positive myeloid cells", "OBSERVATION", 96, 118]]], ["If those embryos are treated with AC220, a potent and relatively selective inhibitor of FLT3, FLT3-ITD myeloid expansion is effectively ameliorated [99].", [["embryos", "ANATOMY", 9, 16], ["myeloid", "ANATOMY", 103, 110], ["AC220", "CHEMICAL", 34, 39], ["AC220", "CHEMICAL", 34, 39], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 9, 16], ["AC220", "SIMPLE_CHEMICAL", 34, 39], ["FLT3", "GENE_OR_GENE_PRODUCT", 88, 92], ["FLT3", "GENE_OR_GENE_PRODUCT", 94, 98], ["FLT3", "PROTEIN", 88, 92], ["FLT3", "PROTEIN", 94, 98], ["AC220", "TREATMENT", 34, 39], ["a potent and relatively selective inhibitor of FLT3", "TREATMENT", 41, 92], ["ITD myeloid expansion", "TREATMENT", 99, 120], ["myeloid expansion", "OBSERVATION", 103, 120]]], ["In another example, isocitrate dehydrogenase (IDH) 1 and 2 are involved in citric acid cycle in intermediary metabolism.", [["isocitrate", "CHEMICAL", 20, 30], ["citric acid", "CHEMICAL", 75, 86], ["isocitrate", "CHEMICAL", 20, 30], ["citric acid", "CHEMICAL", 75, 86], ["isocitrate dehydrogenase", "GENE_OR_GENE_PRODUCT", 20, 44], ["IDH) 1", "GENE_OR_GENE_PRODUCT", 46, 52], ["2", "GENE_OR_GENE_PRODUCT", 57, 58], ["citric acid", "SIMPLE_CHEMICAL", 75, 86], ["isocitrate dehydrogenase (IDH) 1 and 2", "PROTEIN", 20, 58], ["isocitrate dehydrogenase (IDH)", "PROBLEM", 20, 50], ["citric acid cycle", "TEST", 75, 92], ["intermediary metabolism", "OBSERVATION", 96, 119]]], ["IDH mutations are found in approximately 30 % of cytogenetically abnormal AML, suggesting a pathogenetic link in leukemia initiation [100, 101].", [["AML", "ANATOMY", 74, 77], ["leukemia", "ANATOMY", 113, 121], ["abnormal AML", "DISEASE", 65, 77], ["leukemia", "DISEASE", 113, 121], ["IDH", "GENE_OR_GENE_PRODUCT", 0, 3], ["AML", "CANCER", 74, 77], ["leukemia", "CANCER", 113, 121], ["IDH", "PROTEIN", 0, 3], ["IDH mutations", "PROBLEM", 0, 13], ["cytogenetically abnormal AML", "PROBLEM", 49, 77], ["a pathogenetic link in leukemia initiation", "PROBLEM", 90, 132], ["abnormal AML", "OBSERVATION", 65, 77], ["leukemia", "OBSERVATION", 113, 121]]], ["Injection of either human IDH1-R132H or zebrafish idh1-R146H, a mutant corresponding to human IDH1-R132H, resulted in increased 2-hydroxyglutarate, which in turn induced the expansion of primitive myelopoiesis [102].", [["2-hydroxyglutarate", "CHEMICAL", 128, 146], ["2-hydroxyglutarate", "CHEMICAL", 128, 146], ["human", "ORGANISM", 20, 25], ["IDH1-R132H", "GENE_OR_GENE_PRODUCT", 26, 36], ["zebrafish idh1-R146H", "GENE_OR_GENE_PRODUCT", 40, 60], ["human", "ORGANISM", 88, 93], ["IDH1-R132H", "GENE_OR_GENE_PRODUCT", 94, 104], ["2-hydroxyglutarate", "SIMPLE_CHEMICAL", 128, 146], ["human IDH1-R132H or zebrafish idh1-R146H", "DNA", 20, 60], ["human IDH1-R132H", "DNA", 88, 104], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 88, 93], ["either human IDH1", "TEST", 13, 30], ["zebrafish idh1", "TEST", 40, 54], ["human IDH1", "TEST", 88, 98], ["primitive myelopoiesis", "PROBLEM", 187, 209], ["expansion", "OBSERVATION_MODIFIER", 174, 183], ["primitive myelopoiesis", "OBSERVATION", 187, 209]]], ["Taken together, these reports suggest that the molecular pathways involved in leukemia are conserved between humans and zebrafish.", [["leukemia", "ANATOMY", 78, 86], ["leukemia", "DISEASE", 78, 86], ["leukemia", "CANCER", 78, 86], ["humans", "ORGANISM", 109, 115], ["zebrafish", "ORGANISM", 120, 129], ["humans", "SPECIES", 109, 115], ["zebrafish", "SPECIES", 120, 129], ["humans", "SPECIES", 109, 115], ["leukemia", "PROBLEM", 78, 86], ["leukemia", "OBSERVATION", 78, 86]]], ["Based on the aforementioned experimental evidence, zebrafish can be an exceptional platform for mimicking human myelodysplastic syndromes and establishing an in vivo vertebrate model for drug screening.Cancer study: hepatoma ::: B) Zebrafish as an animal model for human diseases ::: New materials for developmental, biological and biomedical studiesSeveral liver tumor models have been reported by liver-specific expression of transgenic oncogenes such as kras, xmrk and myc.", [["Cancer", "ANATOMY", 202, 208], ["hepatoma", "ANATOMY", 216, 224], ["liver tumor", "ANATOMY", 358, 369], ["liver", "ANATOMY", 399, 404], ["myelodysplastic syndromes", "DISEASE", 112, 137], ["Cancer", "DISEASE", 202, 208], ["hepatoma", "DISEASE", 216, 224], ["liver tumor", "DISEASE", 358, 369], ["zebrafish", "ORGANISM", 51, 60], ["human", "ORGANISM", 106, 111], ["Cancer", "CANCER", 202, 208], ["hepatoma", "CANCER", 216, 224], ["Zebrafish", "ORGANISM", 232, 241], ["human", "ORGANISM", 265, 270], ["liver tumor", "CANCER", 358, 369], ["liver", "ORGAN", 399, 404], ["kras", "GENE_OR_GENE_PRODUCT", 457, 461], ["xmrk", "GENE_OR_GENE_PRODUCT", 463, 467], ["myc", "GENE_OR_GENE_PRODUCT", 472, 475], ["transgenic oncogenes", "DNA", 428, 448], ["kras", "PROTEIN", 457, 461], ["xmrk", "DNA", 463, 467], ["myc", "DNA", 472, 475], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 265, 270], ["zebrafish", "SPECIES", 51, 60], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 265, 270], ["mimicking human myelodysplastic syndromes", "PROBLEM", 96, 137], ["drug screening", "TEST", 187, 201], ["biomedical studies", "TEST", 332, 350], ["Several liver tumor models", "PROBLEM", 350, 376], ["transgenic oncogenes", "TREATMENT", 428, 448], ["kras", "TEST", 457, 461], ["myelodysplastic syndromes", "OBSERVATION", 112, 137], ["hepatoma", "ANATOMY", 216, 224], ["liver", "ANATOMY", 358, 363], ["tumor", "OBSERVATION", 364, 369], ["liver", "ANATOMY", 399, 404]]], ["These transgenic lines of zebrafish usually generate liver tumors with various severity from hepatocellular adenoma (HCA) to hepatocellular carcinoma (HCC) [103\u2013105].", [["liver tumors", "ANATOMY", 53, 65], ["hepatocellular adenoma", "ANATOMY", 93, 115], ["HCA", "ANATOMY", 117, 120], ["hepatocellular carcinoma", "ANATOMY", 125, 149], ["HCC", "ANATOMY", 151, 154], ["liver tumors", "DISEASE", 53, 65], ["hepatocellular adenoma", "DISEASE", 93, 115], ["HCA", "DISEASE", 117, 120], ["hepatocellular carcinoma", "DISEASE", 125, 149], ["HCC", "DISEASE", 151, 154], ["zebrafish", "ORGANISM", 26, 35], ["liver tumors", "CANCER", 53, 65], ["hepatocellular adenoma", "CANCER", 93, 115], ["HCA", "CANCER", 117, 120], ["hepatocellular carcinoma", "CANCER", 125, 149], ["HCC", "CANCER", 151, 154], ["transgenic lines", "CELL_LINE", 6, 22], ["zebrafish", "SPECIES", 26, 35], ["liver tumors", "PROBLEM", 53, 65], ["various severity", "PROBLEM", 71, 87], ["hepatocellular adenoma", "PROBLEM", 93, 115], ["hepatocellular carcinoma", "PROBLEM", 125, 149], ["transgenic lines", "OBSERVATION", 6, 22], ["liver", "ANATOMY", 53, 58], ["tumors", "OBSERVATION", 59, 65], ["various severity", "OBSERVATION_MODIFIER", 71, 87], ["hepatocellular", "ANATOMY", 93, 107], ["adenoma", "OBSERVATION", 108, 115], ["hepatocellular", "ANATOMY", 125, 139], ["carcinoma", "OBSERVATION", 140, 149]]], ["These three transgenic liver cancer models have been used to identify differentially expressed genes through RNA-SAGE sequencing.", [["liver cancer", "ANATOMY", 23, 35], ["liver cancer", "DISEASE", 23, 35], ["liver cancer", "CANCER", 23, 35], ["These three transgenic liver cancer", "PROBLEM", 0, 35], ["transgenic", "OBSERVATION_MODIFIER", 12, 22], ["liver", "ANATOMY", 23, 28], ["cancer", "OBSERVATION", 29, 35]]], ["For example, researchers have searched genes either up- or downregulated among the three tumor models and analyzed the possible signaling pathways.", [["tumor", "ANATOMY", 89, 94], ["tumor", "DISEASE", 89, 94], ["tumor", "CANCER", 89, 94], ["tumor", "OBSERVATION", 89, 94], ["possible", "UNCERTAINTY", 119, 127]]], ["Then, correlation between zebrafish liver tumor signatures and the different stages of human hepatocarcinogenesis was determined [106].", [["liver tumor", "ANATOMY", 36, 47], ["liver tumor", "DISEASE", 36, 47], ["hepatocarcinogenesis", "DISEASE", 93, 113], ["zebrafish", "ORGANISM", 26, 35], ["liver tumor", "CANCER", 36, 47], ["human", "ORGANISM", 87, 92], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["zebrafish liver tumor signatures", "TEST", 26, 58], ["human hepatocarcinogenesis", "PROBLEM", 87, 113], ["liver", "ANATOMY", 36, 41], ["tumor", "OBSERVATION", 42, 47]]], ["High tumor incidence and convenient chemical treatment make this inducible transgenic zebrafish a plausible platform for studying on liver tumor progression, regression, and anticancer drug screening.Behavioral studies ::: New materials for developmental, biological and biomedical studiesInterestingly, zebrafish become a modern organism for studying on depressive disorders [107\u2013109].", [["tumor", "ANATOMY", 5, 10], ["liver tumor", "ANATOMY", 133, 144], ["anticancer", "ANATOMY", 174, 184], ["tumor", "DISEASE", 5, 10], ["liver tumor", "DISEASE", 133, 144], ["depressive disorders", "DISEASE", 355, 375], ["tumor", "CANCER", 5, 10], ["zebrafish", "ORGANISM", 86, 95], ["liver tumor", "CANCER", 133, 144], ["anticancer", "CANCER", 174, 184], ["zebrafish", "ORGANISM", 304, 313], ["High tumor incidence", "PROBLEM", 0, 20], ["convenient chemical treatment", "TREATMENT", 25, 54], ["liver tumor progression", "PROBLEM", 133, 156], ["anticancer drug screening", "TEST", 174, 199], ["Behavioral studies", "TEST", 200, 218], ["biomedical studies", "TEST", 271, 289], ["depressive disorders", "PROBLEM", 355, 375], ["tumor", "OBSERVATION", 5, 10], ["liver", "ANATOMY", 133, 138], ["tumor", "OBSERVATION", 139, 144]]], ["Because the physiological (neuroanatomical, neuroendocrine, neurochemical) and genetic characteristics of zebrafish are similar to mammals, zebrafish are ideal for high-throughput genetic and chemical genetic screening.", [["neuroendocrine", "ANATOMY", 44, 58], ["neuroendocrine", "ANATOMICAL_SYSTEM", 44, 58], ["zebrafish", "ORGANISM", 106, 115], ["zebrafish", "ORGANISM", 140, 149], ["zebrafish", "SPECIES", 106, 115], ["zebrafish", "SPECIES", 140, 149], ["chemical genetic screening", "TEST", 192, 218]]], ["Furthermore, since behavioral test of zebrafish for cognitive, approach-avoidance, and social paradigms are available, the identification of depression-like indices in response to physiological, genetic, environmental, and/or psychopharmacological alterations is feasible [110].", [["depression", "DISEASE", 141, 151], ["zebrafish", "ORGANISM", 38, 47], ["behavioral test", "TEST", 19, 34], ["depression", "PROBLEM", 141, 151], ["psychopharmacological alterations", "PROBLEM", 226, 259]]], ["Actually, zebrafish display highly robust phenotypes of neurobehavioral disorders such as anxiety-like and approach\u2013avoidance behaviors.", [["neurobehavioral disorders", "DISEASE", 56, 81], ["anxiety-like and approach\u2013avoidance behaviors", "DISEASE", 90, 135], ["zebrafish", "ORGANISM", 10, 19], ["zebrafish", "SPECIES", 10, 19], ["neurobehavioral disorders", "PROBLEM", 56, 81], ["anxiety", "PROBLEM", 90, 97]]], ["Furthermore, novel information of behavioral indices can be exposed, including geotaxis via top-bottom vertical movement [111].", [["behavioral indices", "TEST", 34, 52], ["geotaxis", "TEST", 79, 87]]], ["Zebrafish behavior can also be monitored using automated behavioral tracking software, which enhances efficiency and reduces interrater variance [112].", [["Zebrafish", "ORGANISM", 0, 9], ["Zebrafish", "SPECIES", 0, 9], ["Zebrafish", "SPECIES", 0, 9], ["automated behavioral tracking software", "TEST", 47, 85], ["interrater variance", "TEST", 125, 144]]], ["Additionally, zebrafish offer a potential insight into the social aspects of depression [113] and may be suitable for studying the cognitive deficits of depression [114] and its putative etiological pathways [115].", [["depression", "DISEASE", 77, 87], ["cognitive deficits", "DISEASE", 131, 149], ["depression", "DISEASE", 153, 163], ["zebrafish", "ORGANISM", 14, 23], ["depression", "PROBLEM", 77, 87], ["depression", "PROBLEM", 153, 163]]], ["Last but not least, zebrafish are highly sensitive to psychotropic drugs, such as antidepressants, anxiolytics, mood stabilizers, and antipsychotics [116\u2013118], serving as an important tool for drug discovery.C) Biosensor for environmental toxicants ::: New materials for developmental, biological and biomedical studiesAromatic hydrocarbons, heavy metals and environmental estrogens are currently being used to test the impact of environmental pollutants on animals [119].", [["antidepressants", "CHEMICAL", 82, 97], ["Aromatic hydrocarbons", "CHEMICAL", 319, 340], ["estrogens", "CHEMICAL", 373, 382], ["Aromatic hydrocarbons", "CHEMICAL", 319, 340], ["estrogens", "CHEMICAL", 373, 382], ["zebrafish", "ORGANISM", 20, 29], ["Aromatic hydrocarbons", "SIMPLE_CHEMICAL", 319, 340], ["heavy metals", "SIMPLE_CHEMICAL", 342, 354], ["estrogens", "SIMPLE_CHEMICAL", 373, 382], ["zebrafish", "SPECIES", 20, 29], ["zebrafish", "SPECIES", 20, 29], ["psychotropic drugs", "TREATMENT", 54, 72], ["antidepressants", "TREATMENT", 82, 97], ["anxiolytics", "TREATMENT", 99, 110], ["mood stabilizers", "TREATMENT", 112, 128], ["antipsychotics", "TREATMENT", 134, 148], ["New materials", "TREATMENT", 253, 266], ["biomedical studies", "TEST", 301, 319], ["heavy metals", "TREATMENT", 342, 354], ["environmental estrogens", "TREATMENT", 359, 382]]], ["These studies mainly focused on mortality and abnormality rates.", [["These studies", "TEST", 0, 13], ["abnormality rates", "PROBLEM", 46, 63]]], ["However, the developing embryos may have already been damaged in a subtle way that would have precluded direct observation of morphology and detection of mortality.", [["embryos", "ANATOMY", 24, 31], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 24, 31], ["the developing embryos", "PROBLEM", 9, 31], ["mortality", "PROBLEM", 154, 163], ["embryos", "OBSERVATION", 24, 31]]], ["To overcome this drawback, transgenic fish can be used because they are designed to study (a) whether toxicants cause defective genes during embryogenesis; (b) whether pollutants affect the expression of tissue-specific gene; and (c) whether the impact of pollutants on embryonic development is dosage dependent.", [["tissue", "ANATOMY", 204, 210], ["embryonic", "ANATOMY", 270, 279], ["fish", "ORGANISM", 38, 42], ["tissue", "TISSUE", 204, 210], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 270, 279], ["this drawback", "TREATMENT", 12, 25], ["transgenic fish", "TREATMENT", 27, 42], ["defective genes during embryogenesis", "PROBLEM", 118, 154], ["embryonic development", "TREATMENT", 270, 291]]], ["Pollutants can be directly detected by simply observing the coloration change of cells before or after the pollutants can cause morphological damage.", [["cells", "ANATOMY", 81, 86], ["cells", "CELL", 81, 86], ["morphological damage", "PROBLEM", 128, 148], ["damage", "OBSERVATION", 142, 148]]], ["Therefore, transgenic model fish are promising organisms for use as bioindicators to environmental toxicants and mutagens [120, 121].", [["fish", "ORGANISM", 28, 32]]], ["In addition, Chen and Lu reported that the environmental xenobiotics can be detected by a transgenic line of medaka carrying a GFP reporter driven by cytochrome P450 1a promoter (CYP1A-GFP) [122].", [["medaka", "ORGANISM", 109, 115], ["GFP", "GENE_OR_GENE_PRODUCT", 127, 130], ["cytochrome P450 1a", "GENE_OR_GENE_PRODUCT", 150, 168], ["CYP1A-GFP", "GENE_OR_GENE_PRODUCT", 179, 188], ["GFP reporter", "DNA", 127, 139], ["cytochrome P450 1a promoter", "DNA", 150, 177], ["CYP1A", "DNA", 179, 184], ["GFP", "DNA", 185, 188]]], ["Furthermore, the environmental xenoestrogenic compounds can be specifically detected by a hybrid transgenic line derived from crossing between line CYP1A-GFP and line VG-Lux whose Lux reporter activity is driven by a vitellogenin promoter [123].", [["CYP1A", "GENE_OR_GENE_PRODUCT", 148, 153], ["GFP", "GENE_OR_GENE_PRODUCT", 154, 157], ["VG-Lux", "GENE_OR_GENE_PRODUCT", 167, 173], ["Lux", "GENE_OR_GENE_PRODUCT", 180, 183], ["vitellogenin", "GENE_OR_GENE_PRODUCT", 217, 229], ["hybrid transgenic line", "CELL_LINE", 90, 112], ["CYP1A-GFP and line VG-Lux whose Lux reporter", "DNA", 148, 192], ["vitellogenin promoter", "DNA", 217, 238], ["the environmental xenoestrogenic compounds", "PROBLEM", 13, 55], ["a hybrid transgenic line", "TREATMENT", 88, 112], ["line CYP1A", "TEST", 143, 153], ["line VG", "TREATMENT", 162, 169], ["Lux reporter activity", "TEST", 180, 201]]], ["Lee et al. reported another zebrafish transgenic line, termed huORFZ [54], as it has been described in pervious section .", [["zebrafish", "ORGANISM", 28, 37], ["huORFZ [54]", "CELL", 62, 73], ["zebrafish transgenic line", "CELL_LINE", 28, 53], ["zebrafish", "SPECIES", 28, 37], ["another zebrafish transgenic line", "TREATMENT", 20, 53], ["transgenic line", "OBSERVATION", 38, 53]]], ["At normal condition, the translation of the transferred huORFchop-gfp mRNA in huORFZ embryos is completely suppressed by an inhibitory uORF of human chop mRNA (huORFchop).", [["huORFZ embryos", "ANATOMY", 78, 92], ["huORFchop", "GENE_OR_GENE_PRODUCT", 56, 65], ["gfp", "GENE_OR_GENE_PRODUCT", 66, 69], ["huORFZ embryos", "ORGAN", 78, 92], ["human", "ORGANISM", 143, 148], ["chop", "GENE_OR_GENE_PRODUCT", 149, 153], ["huORFchop", "GENE_OR_GENE_PRODUCT", 160, 169], ["huORFchop-gfp mRNA", "RNA", 56, 74], ["uORF", "DNA", 135, 139], ["human chop mRNA", "RNA", 143, 158], ["huORFchop", "PROTEIN", 160, 169], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 143, 148], ["the transferred huORFchop", "TREATMENT", 40, 65], ["human chop mRNA", "TREATMENT", 143, 158]]], ["However, when the huORFZ embryos were under ER stress, such as heat shock, cold shock, hypoxia, metals, alcohol, toxicants or drugs, the downstream GFP became apparent due to the blockage of huORFchop-mediated translation inhibition.", [["huORFZ embryos", "ANATOMY", 18, 32], ["shock", "DISEASE", 68, 73], ["shock", "DISEASE", 80, 85], ["hypoxia", "DISEASE", 87, 94], ["metals", "CHEMICAL", 96, 102], ["alcohol", "CHEMICAL", 104, 111], ["alcohol", "CHEMICAL", 104, 111], ["huORFZ", "ORGANISM", 18, 24], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 25, 32], ["ER", "GENE_OR_GENE_PRODUCT", 44, 46], ["alcohol", "SIMPLE_CHEMICAL", 104, 111], ["GFP", "GENE_OR_GENE_PRODUCT", 148, 151], ["huORFchop", "GENE_OR_GENE_PRODUCT", 191, 200], ["ER", "PROTEIN", 44, 46], ["GFP", "PROTEIN", 148, 151], ["huORFchop", "PROTEIN", 191, 200], ["the huORFZ embryos", "PROBLEM", 14, 32], ["heat shock", "PROBLEM", 63, 73], ["cold shock", "PROBLEM", 75, 85], ["hypoxia", "PROBLEM", 87, 94], ["drugs", "TREATMENT", 126, 131], ["the downstream GFP", "PROBLEM", 133, 151], ["the blockage of huORFchop", "PROBLEM", 175, 200], ["blockage", "OBSERVATION", 179, 187]]], ["Therefore, huORFZ embryos can be used to study the mechanism of translational inhibition.", [["huORFZ embryos", "ANATOMY", 11, 25], ["huORFZ embryos", "CELL", 11, 25], ["huORFZ embryos", "TREATMENT", 11, 25], ["translational inhibition", "TREATMENT", 64, 88]]], ["Additionally, huORFZ embryos can serve a living material to monitor the contamination of hazardous pollutants [124].", [["huORFZ embryos", "ANATOMY", 14, 28], ["huORFZ embryos", "CELL", 14, 28], ["huORFZ embryos", "PROBLEM", 14, 28]]], ["Besides the universal huORFZ system, zebrafish could also be indicators for specific pollutants.", [["zebrafish", "ORGANISM", 37, 46], ["huORFZ", "PROTEIN", 22, 28], ["specific pollutants", "PROBLEM", 76, 95]]], ["For example, Xu et al. reported a transgenic zebrafish Tg (cyp1a:gfp) which can serve as an in vivo assay for screening xenobiotic compounds, since Cyp1a is involved in the aryl hydrocarbon receptor pathway, and can be induced in the presence of Dioxins/Dioxin-like compounds and polycyclic aromatic hydrocarbons [125].", [["Cyp1a", "CHEMICAL", 148, 153], ["Dioxins", "CHEMICAL", 246, 253], ["Dioxin", "CHEMICAL", 254, 260], ["polycyclic aromatic hydrocarbons", "CHEMICAL", 280, 312], ["aryl hydrocarbon", "CHEMICAL", 173, 189], ["Dioxins", "CHEMICAL", 246, 253], ["Dioxin", "CHEMICAL", 254, 260], ["polycyclic aromatic hydrocarbons", "CHEMICAL", 280, 312], ["zebrafish", "ORGANISM", 45, 54], ["Tg", "ORGANISM", 55, 57], ["cyp1a", "GENE_OR_GENE_PRODUCT", 59, 64], ["gfp", "GENE_OR_GENE_PRODUCT", 65, 68], ["Cyp1a", "GENE_OR_GENE_PRODUCT", 148, 153], ["aryl hydrocarbon receptor", "GENE_OR_GENE_PRODUCT", 173, 198], ["Dioxins", "SIMPLE_CHEMICAL", 246, 253], ["Dioxin-like compounds", "SIMPLE_CHEMICAL", 254, 275], ["polycyclic aromatic hydrocarbons", "SIMPLE_CHEMICAL", 280, 312], ["transgenic zebrafish Tg (cyp1a:gfp", "DNA", 34, 68], ["Cyp1a", "PROTEIN", 148, 153], ["aryl hydrocarbon receptor", "PROTEIN", 173, 198], ["zebrafish", "SPECIES", 45, 54], ["screening xenobiotic compounds", "TEST", 110, 140], ["Dioxins", "TREATMENT", 246, 253], ["Dioxin", "TREATMENT", 254, 260], ["polycyclic aromatic hydrocarbons", "PROBLEM", 280, 312]]], ["Additional advantages of zebrafish include the small size, abundant number, rapid development and transparent eggs.", [["eggs", "ANATOMY", 110, 114], ["zebrafish", "ORGANISM", 25, 34], ["zebrafish", "TREATMENT", 25, 34], ["small", "OBSERVATION_MODIFIER", 47, 52], ["size", "OBSERVATION_MODIFIER", 53, 57], ["abundant", "OBSERVATION_MODIFIER", 59, 67], ["number", "OBSERVATION_MODIFIER", 68, 74], ["rapid", "OBSERVATION_MODIFIER", 76, 81], ["transparent eggs", "OBSERVATION", 98, 114]]], ["These features make this model fish more accessible for the studies of molecular toxicology.ConclusionIt is increasingly clear that the transgenic fish model is a powerful biomaterial for the studies of multiple disciplines, including molecular biology, developmental biology, neurobiology, cancer biology and regenerative medicine.", [["cancer", "ANATOMY", 291, 297], ["cancer", "DISEASE", 291, 297], ["cancer", "CANCER", 291, 297], ["the studies", "TEST", 56, 67], ["the studies", "TEST", 188, 199], ["regenerative medicine", "TREATMENT", 310, 331], ["increasingly", "OBSERVATION_MODIFIER", 108, 120], ["clear", "OBSERVATION", 121, 126]]], ["It provides a simple, yet effective, in vivo approach to identify regulatory DNA sequences, as well as determine gene function and molecular pathways.", [["DNA", "CELLULAR_COMPONENT", 77, 80], ["regulatory DNA sequences", "DNA", 66, 90], ["regulatory DNA sequences", "TEST", 66, 90]]], ["More importantly, an increasing number of papers have reported that (a) the defective phenotype of mutants of model fish can photocopy with known human disorders; and (b) drugs have similar effects on zebrafish and mammalian systems.", [["human disorders", "DISEASE", 146, 161], ["fish", "ORGANISM", 116, 120], ["human", "ORGANISM", 146, 151], ["zebrafish", "ORGANISM", 201, 210], ["human", "SPECIES", 146, 151], ["zebrafish", "SPECIES", 201, 210], ["human", "SPECIES", 146, 151], ["known human disorders", "PROBLEM", 140, 161], ["drugs", "TREATMENT", 171, 176], ["mammalian systems", "TREATMENT", 215, 232], ["increasing", "OBSERVATION_MODIFIER", 21, 31]]], ["Additionally, it can serve as an environmental indicator for detecting pollutants in our daily lives.ConclusionNevertheless, there are several limitations and caveats of this fish model.", [["fish", "ORGANISM", 175, 179]]], ["First, unlike mammals, fish lack the heart septation, lung, mammary gland, prostate gland and limbs, which make the fish model impossible for studies of these tissues and organs.", [["heart", "ANATOMY", 37, 42], ["lung", "ANATOMY", 54, 58], ["mammary gland", "ANATOMY", 60, 73], ["prostate gland", "ANATOMY", 75, 89], ["limbs", "ANATOMY", 94, 99], ["tissues", "ANATOMY", 159, 166], ["organs", "ANATOMY", 171, 177], ["fish", "ORGANISM", 23, 27], ["heart", "ORGAN", 37, 42], ["lung", "ORGAN", 54, 58], ["mammary gland", "ORGAN", 60, 73], ["prostate gland", "MULTI-TISSUE_STRUCTURE", 75, 89], ["limbs", "ORGAN", 94, 99], ["tissues", "TISSUE", 159, 166], ["organs", "ORGAN", 171, 177], ["fish lack the heart septation, lung, mammary gland, prostate gland and limbs", "PROBLEM", 23, 99], ["heart", "ANATOMY", 37, 42], ["septation", "OBSERVATION", 43, 52], ["lung", "ANATOMY", 54, 58], ["mammary gland", "ANATOMY", 60, 73], ["prostate gland", "ANATOMY", 75, 89], ["limbs", "ANATOMY", 94, 99], ["organs", "ANATOMY", 171, 177]]], ["Additionally, fish are absent of placenta so that fish embryos are directly exposed to the environment (e.g., drugs or pollutants) without involving the placenta.", [["placenta", "ANATOMY", 33, 41], ["embryos", "ANATOMY", 55, 62], ["placenta", "ANATOMY", 153, 161], ["fish", "ORGANISM", 14, 18], ["placenta", "ORGAN", 33, 41], ["fish", "ORGANISM", 50, 54], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 55, 62], ["placenta", "ORGAN", 153, 161], ["fish embryos", "PROBLEM", 50, 62], ["drugs", "TREATMENT", 110, 115], ["absent", "OBSERVATION", 23, 29], ["placenta", "ANATOMY", 33, 41], ["placenta", "ANATOMY", 153, 161]]], ["Second, fish are poikilothermic and usually maintained below 30 \u00b0C, which may not be optimal for those mammalian agents adapted for 37 \u00b0C in evolution.", [["fish", "ORGANISM", 8, 12], ["poikilothermic", "PROBLEM", 17, 31], ["those mammalian agents", "TREATMENT", 97, 119], ["poikilothermic", "OBSERVATION", 17, 31]]], ["Last, since the zebrafish genome is tetraploid, it is less straight forward to conduct loss-of-function studies for certain genes.", [["zebrafish", "ORGANISM", 16, 25], ["zebrafish genome", "DNA", 16, 32], ["zebrafish", "SPECIES", 16, 25], ["function studies", "TEST", 95, 111], ["tetraploid", "OBSERVATION", 36, 46]]]], "71190b206d2f4815109c1b1b04aa8abc6495891a": [["IntroductionMetabolic syndrome (MetS) refers to a cluster of risk factors related to the development of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) (Alberti et al., 2009 ).", [["cardiovascular", "ANATOMY", 104, 118], ["IntroductionMetabolic syndrome", "DISEASE", 0, 30], ["MetS", "DISEASE", 32, 36], ["cardiovascular disease", "DISEASE", 104, 126], ["CVD", "DISEASE", 128, 131], ["type 2 diabetes mellitus", "DISEASE", 137, 161], ["T2DM", "DISEASE", 163, 167], ["cardiovascular", "ANATOMICAL_SYSTEM", 104, 118], ["IntroductionMetabolic syndrome", "PROBLEM", 0, 30], ["MetS", "PROBLEM", 32, 36], ["cardiovascular disease", "PROBLEM", 104, 126], ["CVD", "PROBLEM", 128, 131], ["type 2 diabetes mellitus", "PROBLEM", 137, 161], ["T2DM)", "PROBLEM", 163, 168], ["cardiovascular", "ANATOMY", 104, 118], ["disease", "OBSERVATION", 119, 126], ["diabetes", "OBSERVATION", 144, 152]]], ["This pathological condition represents a public health concern in most nations due to its association with mortality caused by the cardiovascular and metabolic complications (Ju et al., 2017) .", [["cardiovascular", "ANATOMY", 131, 145], ["cardiovascular and metabolic complications", "DISEASE", 131, 173], ["cardiovascular", "ANATOMICAL_SYSTEM", 131, 145], ["This pathological condition", "PROBLEM", 0, 27], ["the cardiovascular and metabolic complications", "PROBLEM", 127, 173], ["cardiovascular", "ANATOMY", 131, 145], ["metabolic complications", "OBSERVATION", 150, 173]]], ["Indeed, MetS is recognized as a risk factor that influences progression and prognosis of coronavirus disease 2019, the infectious disease caused by the most recently discovered coronavirus SARS-CoV-2 (Costa et al., 2020) .", [["MetS", "DISEASE", 8, 12], ["coronavirus disease", "DISEASE", 89, 108], ["infectious disease", "DISEASE", 119, 137], ["SARS", "DISEASE", 189, 193], ["coronavirus", "ORGANISM", 89, 100], ["coronavirus SARS-CoV-2", "ORGANISM", 177, 199], ["coronavirus", "SPECIES", 177, 188], ["MetS", "PROBLEM", 8, 12], ["a risk factor", "PROBLEM", 30, 43], ["coronavirus disease", "PROBLEM", 89, 108], ["the infectious disease", "PROBLEM", 115, 137], ["coronavirus SARS", "PROBLEM", 177, 193], ["MetS", "OBSERVATION", 8, 12], ["coronavirus disease", "OBSERVATION", 89, 108]]], ["Lifestyle modifications remain the primary component of MetSs risk factors reduction and pharmacological therapies are indicated in special situations to improving more than one factor (Larsen et al., 2018) .", [["Lifestyle modifications", "TREATMENT", 0, 23], ["MetSs risk factors reduction", "TREATMENT", 56, 84], ["pharmacological therapies", "TREATMENT", 89, 114]]], ["In latter years, secondary plant metabolites have become of special interest in the scientific community because of their potential role in preventing and managing MetS (Cicero and Colletti, 2016; Francini-Pesenti et al., 2019) .", [["MetS", "DISEASE", 164, 168], ["secondary plant metabolites", "PROBLEM", 17, 44], ["managing MetS", "PROBLEM", 155, 168]]], ["Many compounds, such as sesquiterpene lactones (SLns), have been isolated from medicinal plants and their hypoglycemic, anti-inflammatory, and antioxidative properties coupled with their capacity to modulate key cellular functions have been confirmed by in vitro and in vivo methods (Chadwick et al., 2013; Chaturvedi et al., 2016; Alonso et al., 2018) .", [["cellular", "ANATOMY", 212, 220], ["sesquiterpene lactones", "CHEMICAL", 24, 46], ["SLns", "CHEMICAL", 48, 52], ["sesquiterpene lactones", "CHEMICAL", 24, 46], ["SLns", "CHEMICAL", 48, 52], ["sesquiterpene lactones", "SIMPLE_CHEMICAL", 24, 46], ["SLns", "SIMPLE_CHEMICAL", 48, 52], ["cellular", "CELL", 212, 220], ["Many compounds", "PROBLEM", 0, 14], ["sesquiterpene lactones", "TREATMENT", 24, 46], ["medicinal plants", "TREATMENT", 79, 95], ["anti-inflammatory", "TREATMENT", 120, 137], ["antioxidative properties", "TREATMENT", 143, 167]]], ["Despite these effects are linked to the pathogenesis of MetS, the role of these compounds to avoid its progression is not well documented compared to many other compounds such as polyphenols into which a great deal of research has been conducted.", [["MetS", "DISEASE", 56, 60], ["polyphenols", "CHEMICAL", 179, 190], ["polyphenols", "SIMPLE_CHEMICAL", 179, 190], ["MetS", "PROBLEM", 56, 60], ["polyphenols", "TREATMENT", 179, 190], ["MetS", "OBSERVATION", 56, 60]]], ["Therefore, in order to provide relevant information regarding the potential benefits of SLns in preventing Abbreviations: ACE, angiotensin I-converting enzyme; AMPK, activated protein kinase; APOC3, apolipoprotein C3; AT, adipose tissue; CAT, catalase; COX-2, cyclooxygenase 2; CVD, cardiovascular disease; FFA, free fatty acids; FN, fibronectin; G6Pase, glucose-6-phosphatase; GK, glucokinase; GPx, glutathione peroxidase; GSH, reduced glutathione; HDL-C, high-density lipoproteins-cholesterol; IFN-g, interferon gamma; IL-1b, interleukin 1 beta; IL-6, interleukin 6; iNOS, inducible nitric oxide synthase; IR, insulin resistance; JNK, c-Jun N-terminal kinases; LDL-C, low-density lipoprotein-cholesterol; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinases; MCP-1, monocyte chemoattractant protein 1; MetS, metabolic syndrome; NF-kB, nuclear factor kappa B; NO, nitric oxide; ROS, reactive oxygen species; SLns, sesquiterpene lactones; SOD, superoxide dismutase; STAT1, signal transducer and activator of transcription 1; STZ, streptozotocin; T2DM, type 2 diabetes mellitus; TBARS, thiobarbituric acid reactive substances; TC, total cholesterol; TG, triglycerides; TGF-b1, transforming growth factor beta; TLRs, Toll-like receptor; TNF-a, tumor necrosis factor alpha; VLDL, very-low-density lipoprotein and managing MetS, this review addresses plant-derived SLns that are potentially responsible for the positive effect in improving risk factors associated with MetS.Search strategyAn electronic literature search was conducted on SLns with hypoglycemic and/or hypolipidemic effects and isolated from plants used in traditional medicine for the same purposes.", [["adipose tissue", "ANATOMY", 222, 236], ["cardiovascular", "ANATOMY", 283, 297], ["SLns", "CHEMICAL", 88, 92], ["angiotensin", "CHEMICAL", 127, 138], ["CVD", "DISEASE", 278, 281], ["cardiovascular disease", "DISEASE", 283, 305], ["FFA", "CHEMICAL", 307, 310], ["fatty acids", "CHEMICAL", 317, 328], ["glutathione", "CHEMICAL", 400, 411], ["GSH", "CHEMICAL", 424, 427], ["glutathione", "CHEMICAL", 437, 448], ["cholesterol", "CHEMICAL", 483, 494], ["nitric oxide", "CHEMICAL", 585, 597], ["cholesterol", "CHEMICAL", 694, 705], ["LPS", "CHEMICAL", 707, 710], ["lipopolysaccharide", "CHEMICAL", 712, 730], ["metabolic syndrome", "DISEASE", 822, 840], ["NO", "CHEMICAL", 873, 875], ["nitric oxide", "CHEMICAL", 877, 889], ["ROS", "CHEMICAL", 891, 894], ["oxygen", "CHEMICAL", 905, 911], ["superoxide", "CHEMICAL", 956, 966], ["streptozotocin", "CHEMICAL", 1042, 1056], ["T2DM", "DISEASE", 1058, 1062], ["type 2 diabetes mellitus", "DISEASE", 1064, 1088], ["TBARS", "CHEMICAL", 1090, 1095], ["thiobarbituric acid", "CHEMICAL", 1097, 1116], ["cholesterol", "CHEMICAL", 1148, 1159], ["tumor necrosis", "DISEASE", 1254, 1268], ["MetS", "DISEASE", 1331, 1335], ["MetS", "DISEASE", 1477, 1481], ["SLns", "CHEMICAL", 1546, 1550], ["hypoglycemic", "DISEASE", 1556, 1568], ["fatty acids", "CHEMICAL", 317, 328], ["glucose", "CHEMICAL", 355, 362], ["glutathione", "CHEMICAL", 400, 411], ["GSH", "CHEMICAL", 424, 427], ["reduced glutathione", "CHEMICAL", 429, 448], ["cholesterol", "CHEMICAL", 483, 494], ["nitric oxide", "CHEMICAL", 585, 597], ["N", "CHEMICAL", 643, 644], ["cholesterol", "CHEMICAL", 694, 705], ["NO", "CHEMICAL", 873, 875], ["nitric oxide", "CHEMICAL", 877, 889], ["oxygen", "CHEMICAL", 905, 911], ["SLns", "CHEMICAL", 921, 925], ["sesquiterpene lactones", "CHEMICAL", 927, 949], ["superoxide", "CHEMICAL", 956, 966], ["STZ", "CHEMICAL", 1037, 1040], ["streptozotocin", "CHEMICAL", 1042, 1056], ["thiobarbituric acid", "CHEMICAL", 1097, 1116], ["cholesterol", "CHEMICAL", 1148, 1159], ["triglycerides", "CHEMICAL", 1165, 1178], ["SLns", "SIMPLE_CHEMICAL", 88, 92], ["ACE", "GENE_OR_GENE_PRODUCT", 122, 125], ["angiotensin I-converting enzyme", "GENE_OR_GENE_PRODUCT", 127, 158], ["AMPK", "GENE_OR_GENE_PRODUCT", 160, 164], ["APOC3", "GENE_OR_GENE_PRODUCT", 192, 197], ["apolipoprotein C3", "GENE_OR_GENE_PRODUCT", 199, 216], ["AT", "GENE_OR_GENE_PRODUCT", 218, 220], ["adipose tissue", "TISSUE", 222, 236], ["CAT", "GENE_OR_GENE_PRODUCT", 238, 241], ["catalase", "GENE_OR_GENE_PRODUCT", 243, 251], ["COX-2", "GENE_OR_GENE_PRODUCT", 253, 258], ["cyclooxygenase 2", "GENE_OR_GENE_PRODUCT", 260, 276], ["cardiovascular", "ANATOMICAL_SYSTEM", 283, 297], ["FFA", "SIMPLE_CHEMICAL", 307, 310], ["free fatty acids", "SIMPLE_CHEMICAL", 312, 328], ["FN", "GENE_OR_GENE_PRODUCT", 330, 332], ["fibronectin", "GENE_OR_GENE_PRODUCT", 334, 345], ["G6Pase", "GENE_OR_GENE_PRODUCT", 347, 353], ["glucose-6-phosphatase", "GENE_OR_GENE_PRODUCT", 355, 376], ["GK", "GENE_OR_GENE_PRODUCT", 378, 380], ["glucokinase", "GENE_OR_GENE_PRODUCT", 382, 393], ["GPx", "SIMPLE_CHEMICAL", 395, 398], ["glutathione", "SIMPLE_CHEMICAL", 400, 411], ["peroxidase", "SIMPLE_CHEMICAL", 412, 422], ["GSH", "SIMPLE_CHEMICAL", 424, 427], ["glutathione", "SIMPLE_CHEMICAL", 437, 448], ["HDL-C", "SIMPLE_CHEMICAL", 450, 455], ["high-density lipoproteins-cholesterol", "SIMPLE_CHEMICAL", 457, 494], ["IFN-g", "GENE_OR_GENE_PRODUCT", 496, 501], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 503, 519], ["IL-1b", "GENE_OR_GENE_PRODUCT", 521, 526], ["interleukin 1 beta", "GENE_OR_GENE_PRODUCT", 528, 546], ["IL-6", "GENE_OR_GENE_PRODUCT", 548, 552], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 554, 567], ["iNOS", "GENE_OR_GENE_PRODUCT", 569, 573], ["inducible nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 575, 606], ["insulin", "GENE_OR_GENE_PRODUCT", 612, 619], ["JNK", "GENE_OR_GENE_PRODUCT", 632, 635], ["c-Jun N-terminal kinases", "GENE_OR_GENE_PRODUCT", 637, 661], ["LDL-C", "SIMPLE_CHEMICAL", 663, 668], ["low-density lipoprotein-cholesterol", "SIMPLE_CHEMICAL", 670, 705], ["LPS", "SIMPLE_CHEMICAL", 707, 710], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 712, 730], ["MAPK", "GENE_OR_GENE_PRODUCT", 732, 736], ["mitogen-activated protein kinases", "GENE_OR_GENE_PRODUCT", 738, 771], ["MCP-1", "GENE_OR_GENE_PRODUCT", 773, 778], ["monocyte chemoattractant protein 1", "GENE_OR_GENE_PRODUCT", 780, 814], ["NF-kB", "GENE_OR_GENE_PRODUCT", 842, 847], ["nuclear factor kappa B", "GENE_OR_GENE_PRODUCT", 849, 871], ["NO", "SIMPLE_CHEMICAL", 873, 875], ["nitric oxide", "SIMPLE_CHEMICAL", 877, 889], ["ROS", "SIMPLE_CHEMICAL", 891, 894], ["reactive oxygen species", "SIMPLE_CHEMICAL", 896, 919], ["SLns", "SIMPLE_CHEMICAL", 921, 925], ["sesquiterpene lactones", "SIMPLE_CHEMICAL", 927, 949], ["SOD", "SIMPLE_CHEMICAL", 951, 954], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 956, 976], ["STAT1", "GENE_OR_GENE_PRODUCT", 978, 983], ["signal transducer and activator of transcription 1", "GENE_OR_GENE_PRODUCT", 985, 1035], ["STZ", "SIMPLE_CHEMICAL", 1037, 1040], ["streptozotocin", "SIMPLE_CHEMICAL", 1042, 1056], ["TBARS", "SIMPLE_CHEMICAL", 1090, 1095], ["thiobarbituric acid reactive substances", "SIMPLE_CHEMICAL", 1097, 1136], ["TC", "SIMPLE_CHEMICAL", 1138, 1140], ["cholesterol", "SIMPLE_CHEMICAL", 1148, 1159], ["TG", "SIMPLE_CHEMICAL", 1161, 1163], ["triglycerides", "SIMPLE_CHEMICAL", 1165, 1178], ["TGF-b1", "GENE_OR_GENE_PRODUCT", 1180, 1186], ["transforming growth factor beta", "GENE_OR_GENE_PRODUCT", 1188, 1219], ["TLRs", "GENE_OR_GENE_PRODUCT", 1221, 1225], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 1227, 1245], ["TNF-a", "GENE_OR_GENE_PRODUCT", 1247, 1252], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 1254, 1281], ["VLDL", "SIMPLE_CHEMICAL", 1283, 1287], ["low-density lipoprotein", "SIMPLE_CHEMICAL", 1294, 1317], ["SLns", "GENE_OR_GENE_PRODUCT", 1373, 1377], ["SLns", "SIMPLE_CHEMICAL", 1546, 1550], ["ACE", "PROTEIN", 122, 125], ["angiotensin I-converting enzyme", "PROTEIN", 127, 158], ["AMPK", "PROTEIN", 160, 164], ["activated protein kinase", "PROTEIN", 166, 190], ["APOC3", "PROTEIN", 192, 197], ["apolipoprotein C3", "PROTEIN", 199, 216], ["CAT", "PROTEIN", 238, 241], ["catalase", "PROTEIN", 243, 251], ["COX", "PROTEIN", 253, 256], ["cyclooxygenase 2", "PROTEIN", 260, 276], ["FN", "PROTEIN", 330, 332], ["fibronectin", "PROTEIN", 334, 345], ["G6Pase", "PROTEIN", 347, 353], ["glucose-6-phosphatase", "PROTEIN", 355, 376], ["GK", "PROTEIN", 378, 380], ["glucokinase", "PROTEIN", 382, 393], ["GPx", "PROTEIN", 395, 398], ["glutathione peroxidase", "PROTEIN", 400, 422], ["HDL", "PROTEIN", 450, 453], ["high-density lipoproteins", "PROTEIN", 457, 482], ["IFN", "PROTEIN", 496, 499], ["interferon gamma; IL-1b", "PROTEIN", 503, 526], ["interleukin 1 beta", "PROTEIN", 528, 546], ["IL-6", "PROTEIN", 548, 552], ["interleukin 6", "PROTEIN", 554, 567], ["iNOS", "PROTEIN", 569, 573], ["nitric oxide synthase", "PROTEIN", 585, 606], ["JNK", "PROTEIN", 632, 635], ["c-Jun N-terminal kinases", "PROTEIN", 637, 661], ["LDL-C", "PROTEIN", 663, 668], ["low-density lipoprotein", "PROTEIN", 670, 693], ["MAPK", "PROTEIN", 732, 736], ["mitogen-activated protein kinases", "PROTEIN", 738, 771], ["MCP-1", "PROTEIN", 773, 778], ["monocyte chemoattractant protein 1", "PROTEIN", 780, 814], ["NF-kB", "PROTEIN", 842, 847], ["nuclear factor kappa B", "PROTEIN", 849, 871], ["SOD", "PROTEIN", 951, 954], ["superoxide dismutase", "PROTEIN", 956, 976], ["STAT1", "PROTEIN", 978, 983], ["signal transducer and activator of transcription 1", "PROTEIN", 985, 1035], ["TG", "PROTEIN", 1161, 1163], ["TGF-b1", "PROTEIN", 1180, 1186], ["transforming growth factor beta", "PROTEIN", 1188, 1219], ["TLRs", "PROTEIN", 1221, 1225], ["Toll-like receptor", "PROTEIN", 1227, 1245], ["TNF", "PROTEIN", 1247, 1250], ["tumor necrosis factor alpha", "PROTEIN", 1254, 1281], ["VLDL", "PROTEIN", 1283, 1287], ["low-density lipoprotein", "PROTEIN", 1294, 1317], ["SLns", "TREATMENT", 88, 92], ["ACE", "TREATMENT", 122, 125], ["enzyme", "TEST", 152, 158], ["AMPK", "TEST", 160, 164], ["activated protein kinase", "TEST", 166, 190], ["APOC3", "TEST", 192, 197], ["apolipoprotein C3", "TEST", 199, 216], ["CAT", "TEST", 238, 241], ["COX", "TEST", 253, 256], ["cyclooxygenase", "TREATMENT", 260, 274], ["CVD", "PROBLEM", 278, 281], ["cardiovascular disease", "PROBLEM", 283, 305], ["FFA", "TEST", 307, 310], ["free fatty acids", "TEST", 312, 328], ["FN", "TEST", 330, 332], ["fibronectin", "TEST", 334, 345], ["G6Pase", "TEST", 347, 353], ["glucose", "TEST", 355, 362], ["phosphatase", "TEST", 365, 376], ["GK", "TEST", 378, 380], ["glucokinase", "TEST", 382, 393], ["GPx", "TEST", 395, 398], ["glutathione peroxidase", "TEST", 400, 422], ["GSH", "TEST", 424, 427], ["reduced glutathione", "PROBLEM", 429, 448], ["HDL", "TEST", 450, 453], ["C", "TEST", 454, 455], ["high-density lipoproteins", "TREATMENT", 457, 482], ["cholesterol", "TEST", 483, 494], ["IFN", "TEST", 496, 499], ["interferon gamma", "TREATMENT", 503, 519], ["IL", "TEST", 521, 523], ["interleukin", "TEST", 528, 539], ["IL", "TEST", 548, 550], ["interleukin", "TREATMENT", 554, 565], ["iNOS", "PROBLEM", 569, 573], ["inducible nitric oxide synthase", "TREATMENT", 575, 606], ["IR", "TEST", 608, 610], ["insulin resistance", "TEST", 612, 630], ["JNK", "TEST", 632, 635], ["c", "TEST", 637, 638], ["Jun N", "TEST", 639, 644], ["terminal kinases", "TEST", 645, 661], ["LDL", "TEST", 663, 666], ["C", "TEST", 667, 668], ["lipoprotein", "TEST", 682, 693], ["cholesterol", "TEST", 694, 705], ["LPS", "TEST", 707, 710], ["lipopolysaccharide", "TEST", 712, 730], ["MAPK", "TEST", 732, 736], ["mitogen", "TEST", 738, 745], ["activated protein kinases", "TEST", 746, 771], ["MCP", "TEST", 773, 776], ["monocyte chemoattractant protein", "TEST", 780, 812], ["MetS", "PROBLEM", 816, 820], ["metabolic syndrome", "PROBLEM", 822, 840], ["NF", "PROBLEM", 842, 844], ["nitric oxide", "TREATMENT", 877, 889], ["reactive oxygen species", "PROBLEM", 896, 919], ["SLns", "TREATMENT", 921, 925], ["sesquiterpene lactones", "TREATMENT", 927, 949], ["SOD", "TREATMENT", 951, 954], ["superoxide dismutase", "TREATMENT", 956, 976], ["STAT1, signal transducer and activator of transcription", "TREATMENT", 978, 1033], ["STZ", "TREATMENT", 1037, 1040], ["streptozotocin", "TREATMENT", 1042, 1056], ["T2DM", "PROBLEM", 1058, 1062], ["type 2 diabetes mellitus", "PROBLEM", 1064, 1088], ["TBARS", "TEST", 1090, 1095], ["thiobarbituric acid reactive substances", "PROBLEM", 1097, 1136], ["TC", "TEST", 1138, 1140], ["total cholesterol", "TEST", 1142, 1159], ["TG", "TEST", 1161, 1163], ["triglycerides", "TEST", 1165, 1178], ["TGF", "TEST", 1180, 1183], ["transforming growth factor beta", "PROBLEM", 1188, 1219], ["TNF", "TEST", 1247, 1250], ["tumor necrosis factor alpha", "PROBLEM", 1254, 1281], ["VLDL", "TEST", 1283, 1287], ["very-low-density lipoprotein", "PROBLEM", 1289, 1317], ["managing MetS", "PROBLEM", 1322, 1335], ["derived SLns", "PROBLEM", 1365, 1377], ["the positive effect", "PROBLEM", 1415, 1434], ["MetS", "PROBLEM", 1477, 1481], ["SLns", "TREATMENT", 1546, 1550], ["hypoglycemic", "PROBLEM", 1556, 1568], ["hypolipidemic effects", "PROBLEM", 1576, 1597], ["traditional medicine", "TREATMENT", 1631, 1651], ["adipose tissue", "ANATOMY", 222, 236], ["cardiovascular", "ANATOMY", 283, 297], ["disease", "OBSERVATION", 298, 305], ["LDL", "ANATOMY", 663, 666], ["metabolic syndrome", "OBSERVATION", 822, 840], ["reactive", "OBSERVATION", 896, 904], ["oxygen species", "OBSERVATION", 905, 919], ["tumor", "OBSERVATION_MODIFIER", 1254, 1259], ["necrosis", "OBSERVATION", 1260, 1268], ["VLDL", "ANATOMY", 1283, 1287], ["low-density lipoprotein", "OBSERVATION_MODIFIER", 1294, 1317]]], ["The search was done in databases of Google Scholar, Science Direct, and SciFinder until June 2020 using the keyword sesquiterpene lactones and following terms: metabolic syndrome, hypoglycemic, hypolipidemic, antidiabetic, antihypertensive, and medicinal plants.", [["sesquiterpene lactones", "CHEMICAL", 116, 138], ["metabolic syndrome", "DISEASE", 160, 178], ["hypoglycemic", "DISEASE", 180, 192], ["sesquiterpene lactones", "CHEMICAL", 116, 138], ["sesquiterpene lactones", "SIMPLE_CHEMICAL", 116, 138], ["the keyword sesquiterpene lactones", "TREATMENT", 104, 138], ["metabolic syndrome", "PROBLEM", 160, 178], ["hypoglycemic", "PROBLEM", 180, 192], ["hypolipidemic", "TREATMENT", 194, 207], ["antidiabetic", "TREATMENT", 209, 221], ["antihypertensive", "TREATMENT", 223, 239], ["medicinal plants", "TREATMENT", 245, 261], ["metabolic syndrome", "OBSERVATION", 160, 178], ["medicinal plants", "OBSERVATION", 245, 261]]], ["Although many SLns were screened in some of the studies, only those considered active by the authors are included in this review.", [["SLns", "GENE_OR_GENE_PRODUCT", 14, 18], ["the studies", "TEST", 44, 55], ["SLns", "OBSERVATION", 14, 18]]], ["Compound class, plant source, biological activity and important aspects related with MetS are summarized in the Table 1 .Metabolic syndromeMetS is defined as a cluster of risk factors such as raised blood pressure, atherogenic dyslipidemia, raised fasting glucose, and central obesity, related to the development of CVD and T2DM (Alberti et al., 2009) .", [["blood", "ANATOMY", 199, 204], ["MetS", "DISEASE", 85, 89], ["Metabolic syndromeMetS", "DISEASE", 121, 143], ["atherogenic dyslipidemia", "DISEASE", 215, 239], ["obesity", "DISEASE", 277, 284], ["CVD", "DISEASE", 316, 319], ["T2DM", "DISEASE", 324, 328], ["glucose", "CHEMICAL", 256, 263], ["blood", "ORGANISM_SUBSTANCE", 199, 204], ["glucose", "SIMPLE_CHEMICAL", 256, 263], ["MetS", "PROBLEM", 85, 89], ["Metabolic syndromeMetS", "PROBLEM", 121, 143], ["raised blood pressure", "PROBLEM", 192, 213], ["atherogenic dyslipidemia", "PROBLEM", 215, 239], ["raised fasting glucose", "PROBLEM", 241, 263], ["central obesity", "PROBLEM", 269, 284], ["CVD", "PROBLEM", 316, 319], ["T2DM", "PROBLEM", 324, 328], ["atherogenic", "OBSERVATION_MODIFIER", 215, 226], ["dyslipidemia", "OBSERVATION", 227, 239], ["central obesity", "OBSERVATION", 269, 284], ["CVD", "OBSERVATION", 316, 319], ["T2DM", "OBSERVATION", 324, 328]]], ["Since the World Health Organization (WHO) reported the first formalized definition of the MetS, the diagnostic criteria have been sequentially developed by several public health organizations (Engin, 2017) .", [["MetS", "DISEASE", 90, 94], ["the MetS", "PROBLEM", 86, 94], ["MetS", "OBSERVATION", 90, 94], ["several", "OBSERVATION_MODIFIER", 156, 163]]], ["Nowadays, the most recognized criterion for the clinical diagnosis of MetS (Alberti et al., 2009 ) is based on identifying at least three of the following risk factors: (1) elevated waist circumference (population and country-specific definitions determined by local organizations); (2) triglycerides (TG) 150 mg/ Dl (<1.0 mmol/L) or on drug treatment for elevated triglycerides; (3) high-density lipoproteins-cholesterol (HDL-C) <40 mg/dL (<1.0 mmol/L) in men or <50 mg/dL (<1.3 mmol/L) in women or on drug treatment for reduced HDL-C; (4) blood pressure 130/ 85 mmHg or on antihypertensive medication treatment, and/or a history of hypertension; and (5) fasting glucose >100 mg/dL (>5.6 mmol/L) or on drug treatment for elevated glucose.Pathogenesis of MetSThe mechanisms underlying pathogenesis of MetS have not been completely explored, but obesity-induced adipocyte dysfunction and inflammation is associated with the progression of insulin resistance and metabolic disorders (Kl\u20ac oting and Bl\u20ac uher, 2014) .", [["waist", "ANATOMY", 182, 187], ["blood", "ANATOMY", 541, 546], ["adipocyte", "ANATOMY", 861, 870], ["MetS", "DISEASE", 70, 74], ["TG", "DISEASE", 302, 304], ["cholesterol", "CHEMICAL", 410, 421], ["HDL-C", "CHEMICAL", 423, 428], ["hypertension", "DISEASE", 634, 646], ["glucose", "CHEMICAL", 664, 671], ["glucose", "CHEMICAL", 731, 738], ["MetS", "DISEASE", 801, 805], ["obesity", "DISEASE", 845, 852], ["adipocyte dysfunction", "DISEASE", 861, 882], ["inflammation", "DISEASE", 887, 899], ["metabolic disorders", "DISEASE", 961, 980], ["triglycerides", "CHEMICAL", 287, 300], ["triglycerides", "CHEMICAL", 365, 378], ["cholesterol", "CHEMICAL", 410, 421], ["glucose", "CHEMICAL", 664, 671], ["glucose", "CHEMICAL", 731, 738], ["waist", "ORGANISM_SUBDIVISION", 182, 187], ["triglycerides", "SIMPLE_CHEMICAL", 287, 300], ["TG", "SIMPLE_CHEMICAL", 302, 304], ["triglycerides", "SIMPLE_CHEMICAL", 365, 378], ["high-density lipoproteins-cholesterol", "SIMPLE_CHEMICAL", 384, 421], ["HDL-C", "SIMPLE_CHEMICAL", 423, 428], ["men", "ORGANISM", 457, 460], ["women", "ORGANISM", 491, 496], ["HDL-C", "SIMPLE_CHEMICAL", 530, 535], ["blood", "ORGANISM_SUBSTANCE", 541, 546], ["glucose", "SIMPLE_CHEMICAL", 664, 671], ["glucose", "SIMPLE_CHEMICAL", 731, 738], ["adipocyte", "CELL", 861, 870], ["insulin", "GENE_OR_GENE_PRODUCT", 938, 945], ["high-density lipoproteins", "PROTEIN", 384, 409], ["HDL", "PROTEIN", 423, 426], ["men", "SPECIES", 457, 460], ["women", "SPECIES", 491, 496], ["MetS", "PROBLEM", 70, 74], ["elevated waist circumference", "PROBLEM", 173, 201], ["triglycerides", "TEST", 287, 300], ["TG", "TEST", 302, 304], ["drug treatment", "TREATMENT", 337, 351], ["elevated triglycerides", "PROBLEM", 356, 378], ["high-density lipoproteins", "TEST", 384, 409], ["cholesterol", "TEST", 410, 421], ["HDL", "TEST", 423, 426], ["drug treatment", "TREATMENT", 503, 517], ["blood pressure", "TEST", 541, 555], ["antihypertensive medication treatment", "TREATMENT", 575, 612], ["hypertension", "PROBLEM", 634, 646], ["fasting glucose", "TEST", 656, 671], ["drug treatment", "TREATMENT", 703, 717], ["elevated glucose", "PROBLEM", 722, 738], ["MetS", "PROBLEM", 801, 805], ["obesity", "PROBLEM", 845, 852], ["adipocyte dysfunction", "PROBLEM", 861, 882], ["inflammation", "PROBLEM", 887, 899], ["insulin resistance", "PROBLEM", 938, 956], ["metabolic disorders", "PROBLEM", 961, 980], ["hypertension", "OBSERVATION", 634, 646], ["MetS", "OBSERVATION", 801, 805], ["obesity", "OBSERVATION", 845, 852], ["adipocyte", "ANATOMY", 861, 870], ["dysfunction", "OBSERVATION", 871, 882], ["inflammation", "OBSERVATION", 887, 899], ["insulin resistance", "OBSERVATION", 938, 956], ["metabolic disorders", "OBSERVATION", 961, 980]]], ["Body fat mass accumulation in obesity depends on different factors including the relationship of energy intake to energy expenditure and body energy storage (Gomez-Hernandez et al., 2016) .", [["Body fat", "ANATOMY", 0, 8], ["body", "ANATOMY", 137, 141], ["obesity", "DISEASE", 30, 37], ["Body fat", "TISSUE", 0, 8], ["body", "ORGANISM_SUBDIVISION", 137, 141], ["Body fat mass accumulation", "PROBLEM", 0, 26], ["obesity", "PROBLEM", 30, 37], ["mass", "OBSERVATION", 9, 13], ["obesity", "OBSERVATION", 30, 37]]], ["Adipose tissue (AT) plays an important role as an energy storage organ, as well as an endocrine organ produces adipokines such as leptin, adiponectin, monocyte chemoattractant protein 1 (MCP1), tumor necrosis factor alpha (TNFa) and interleukin 6 (IL-6), which circulate and regulate systemic metabolism and inflammation.", [["Adipose tissue", "ANATOMY", 0, 14], ["organ", "ANATOMY", 65, 70], ["endocrine organ", "ANATOMY", 86, 101], ["necrosis", "DISEASE", 200, 208], ["inflammation", "DISEASE", 308, 320], ["Adipose tissue", "TISSUE", 0, 14], ["organ", "ORGAN", 65, 70], ["endocrine organ", "TISSUE", 86, 101], ["adipokines", "GENE_OR_GENE_PRODUCT", 111, 121], ["leptin", "GENE_OR_GENE_PRODUCT", 130, 136], ["adiponectin", "GENE_OR_GENE_PRODUCT", 138, 149], ["monocyte chemoattractant protein 1", "GENE_OR_GENE_PRODUCT", 151, 185], ["MCP1", "GENE_OR_GENE_PRODUCT", 187, 191], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 194, 221], ["TNFa", "GENE_OR_GENE_PRODUCT", 223, 227], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 233, 246], ["IL-6", "GENE_OR_GENE_PRODUCT", 248, 252], ["leptin", "PROTEIN", 130, 136], ["adiponectin", "PROTEIN", 138, 149], ["monocyte chemoattractant protein 1", "PROTEIN", 151, 185], ["MCP1", "PROTEIN", 187, 191], ["tumor necrosis factor alpha", "PROTEIN", 194, 221], ["TNFa", "PROTEIN", 223, 227], ["interleukin 6 (IL-6", "PROTEIN", 233, 252], ["Adipose tissue", "PROBLEM", 0, 14], ["leptin, adiponectin", "TREATMENT", 130, 149], ["monocyte chemoattractant protein", "TREATMENT", 151, 183], ["tumor necrosis factor", "PROBLEM", 194, 215], ["alpha (TNFa", "TEST", 216, 227], ["interleukin", "TEST", 233, 244], ["IL", "TEST", 248, 250], ["inflammation", "PROBLEM", 308, 320], ["tumor", "OBSERVATION_MODIFIER", 194, 199], ["necrosis", "OBSERVATION", 200, 208], ["systemic metabolism", "OBSERVATION", 284, 303], ["inflammation", "OBSERVATION", 308, 320]]], ["The cell type composition of AT includes adipocytes, fibroblasts, macrophages, stromal cells, monocytes and preadipocytes (R afols, 2014) .", [["cell", "ANATOMY", 4, 8], ["adipocytes", "ANATOMY", 41, 51], ["fibroblasts", "ANATOMY", 53, 64], ["macrophages", "ANATOMY", 66, 77], ["stromal cells", "ANATOMY", 79, 92], ["monocytes", "ANATOMY", 94, 103], ["preadipocytes", "ANATOMY", 108, 121], ["cell", "CELL", 4, 8], ["adipocytes", "CELL", 41, 51], ["fibroblasts", "CELL", 53, 64], ["macrophages", "CELL", 66, 77], ["stromal cells", "CELL", 79, 92], ["monocytes", "CELL", 94, 103], ["preadipocytes", "CELL", 108, 121], ["R afols", "CELL", 123, 130], ["adipocytes", "CELL_TYPE", 41, 51], ["fibroblasts", "CELL_TYPE", 53, 64], ["macrophages", "CELL_TYPE", 66, 77], ["stromal cells", "CELL_TYPE", 79, 92], ["monocytes", "CELL_TYPE", 94, 103], ["preadipocytes", "CELL_TYPE", 108, 121], ["stromal cells", "PROBLEM", 79, 92], ["monocytes", "TEST", 94, 103], ["preadipocytes", "TEST", 108, 121], ["cell type", "OBSERVATION", 4, 13], ["adipocytes", "ANATOMY", 41, 51], ["fibroblasts", "ANATOMY", 53, 64], ["macrophages", "ANATOMY", 66, 77], ["stromal cells", "OBSERVATION", 79, 92]]], ["On further AT expansion, hypertrophy of adipocytes and increased secretion of macrophage chemoattractants occurs, including the secretion of MCP-1, which recruits additional macrophages.", [["adipocytes", "ANATOMY", 40, 50], ["macrophage", "ANATOMY", 78, 88], ["macrophages", "ANATOMY", 174, 185], ["hypertrophy", "DISEASE", 25, 36], ["adipocytes", "CELL", 40, 50], ["macrophage", "CELL", 78, 88], ["MCP-1", "GENE_OR_GENE_PRODUCT", 141, 146], ["macrophages", "CELL", 174, 185], ["adipocytes", "CELL_TYPE", 40, 50], ["macrophage chemoattractants", "PROTEIN", 78, 105], ["MCP-1", "PROTEIN", 141, 146], ["macrophages", "CELL_TYPE", 174, 185], ["further AT expansion", "TEST", 3, 23], ["hypertrophy of adipocytes", "PROBLEM", 25, 50], ["increased secretion of macrophage chemoattractants", "PROBLEM", 55, 105], ["the secretion of MCP", "TEST", 124, 144], ["hypertrophy", "OBSERVATION", 25, 36], ["adipocytes", "ANATOMY", 40, 50], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["secretion", "OBSERVATION_MODIFIER", 65, 74], ["macrophage chemoattractants", "OBSERVATION", 78, 105], ["macrophages", "OBSERVATION", 174, 185]]], ["These actions in turn result in local inflammatory state, enhanced basal lipolysis, increasing the leakage of free fatty acids (FFA) and a dysregulated secretion of several proinflammatory adipokines (Longo et al., 2019; Xu et al., 2019) .Pathogenesis of MetSSubsequently, these adverse signals reach metabolic tissues (e.g. liver, pancreatic islets, and skeletal muscle) and modify inflammatory responses as well as glucose and lipid metabolism, thereby contributing to a global metabolic effect of insulin resistance.Pathogenesis of MetSChronic low-grade inflammation in obesity results from the activation of various inflammatory mechanisms through nuclear factor kappa B (NF-kB) and c-Jun N-terminal kinases (JNK) pathways.", [["metabolic tissues", "ANATOMY", 301, 318], ["liver", "ANATOMY", 325, 330], ["pancreatic islets", "ANATOMY", 332, 349], ["skeletal muscle", "ANATOMY", 355, 370], ["fatty acids", "CHEMICAL", 115, 126], ["FFA", "CHEMICAL", 128, 131], ["glucose", "CHEMICAL", 417, 424], ["inflammation", "DISEASE", 557, 569], ["obesity", "DISEASE", 573, 580], ["fatty acids", "CHEMICAL", 115, 126], ["glucose", "CHEMICAL", 417, 424], ["N", "CHEMICAL", 693, 694], ["free fatty acids", "SIMPLE_CHEMICAL", 110, 126], ["FFA", "SIMPLE_CHEMICAL", 128, 131], ["metabolic tissues", "TISSUE", 301, 318], ["liver", "ORGAN", 325, 330], ["pancreatic islets", "MULTI-TISSUE_STRUCTURE", 332, 349], ["skeletal muscle", "TISSUE", 355, 370], ["glucose", "SIMPLE_CHEMICAL", 417, 424], ["lipid", "SIMPLE_CHEMICAL", 429, 434], ["insulin", "GENE_OR_GENE_PRODUCT", 500, 507], ["MetSChronic low-grade", "PATHOLOGICAL_FORMATION", 535, 556], ["nuclear factor kappa B", "GENE_OR_GENE_PRODUCT", 652, 674], ["NF-kB", "GENE_OR_GENE_PRODUCT", 676, 681], ["c-Jun N-terminal kinases", "GENE_OR_GENE_PRODUCT", 687, 711], ["JNK", "GENE_OR_GENE_PRODUCT", 713, 716], ["proinflammatory adipokines", "PROTEIN", 173, 199], ["NF-kB", "PROTEIN", 676, 681], ["Jun N-terminal kinases", "PROTEIN", 689, 711], ["JNK", "PROTEIN", 713, 716], ["local inflammatory state", "PROBLEM", 32, 56], ["enhanced basal lipolysis", "PROBLEM", 58, 82], ["increasing the leakage of free fatty acids", "PROBLEM", 84, 126], ["a dysregulated secretion", "PROBLEM", 137, 161], ["inflammatory responses", "PROBLEM", 383, 405], ["glucose", "TEST", 417, 424], ["lipid metabolism", "PROBLEM", 429, 445], ["insulin resistance", "PROBLEM", 500, 518], ["MetSChronic low-grade inflammation in obesity", "PROBLEM", 535, 580], ["various inflammatory mechanisms", "PROBLEM", 612, 643], ["nuclear factor kappa", "TEST", 652, 672], ["local", "OBSERVATION_MODIFIER", 32, 37], ["inflammatory", "OBSERVATION", 38, 50], ["basal lipolysis", "OBSERVATION", 67, 82], ["leakage", "OBSERVATION_MODIFIER", 99, 106], ["free fatty acids", "OBSERVATION", 110, 126], ["several", "OBSERVATION_MODIFIER", 165, 172], ["proinflammatory", "OBSERVATION_MODIFIER", 173, 188], ["metabolic tissues", "OBSERVATION", 301, 318], ["liver", "ANATOMY", 325, 330], ["pancreatic islets", "ANATOMY", 332, 349], ["skeletal muscle", "ANATOMY", 355, 370], ["inflammatory", "OBSERVATION", 383, 395], ["metabolic effect", "OBSERVATION", 480, 496], ["insulin resistance", "OBSERVATION", 500, 518], ["low-grade", "OBSERVATION_MODIFIER", 547, 556], ["inflammation", "OBSERVATION", 557, 569], ["obesity", "OBSERVATION", 573, 580], ["inflammatory", "OBSERVATION_MODIFIER", 620, 632]]], ["These pathways represent important modulators of cytokine gene expression downstream of Toll-like receptors (TLRs) in insulin target cells (Catrysse and van Loo, 2017; Rogero and Calder, 2018) .", [["cells", "ANATOMY", 133, 138], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 88, 107], ["TLRs", "GENE_OR_GENE_PRODUCT", 109, 113], ["insulin", "GENE_OR_GENE_PRODUCT", 118, 125], ["cells", "CELL", 133, 138], ["cytokine gene", "DNA", 49, 62], ["Toll-like receptors", "PROTEIN", 88, 107], ["TLRs", "PROTEIN", 109, 113], ["insulin target cells", "CELL_TYPE", 118, 138], ["cytokine gene expression", "TREATMENT", 49, 73]]], ["NF-kB is an important transcription factor involved in different processes of the immune and inflammatory responses.", [["NF-kB", "GENE_OR_GENE_PRODUCT", 0, 5], ["NF-kB", "PROTEIN", 0, 5], ["transcription factor", "PROTEIN", 22, 42], ["-kB", "OBSERVATION_MODIFIER", 2, 5], ["inflammatory", "OBSERVATION_MODIFIER", 93, 105]]], ["It is composed of p50 and p65 subunits and is found in the cytoplasm in complex with inhibitory proteins of the IkB family.", [["cytoplasm", "ANATOMY", 59, 68], ["p50", "GENE_OR_GENE_PRODUCT", 18, 21], ["p65", "GENE_OR_GENE_PRODUCT", 26, 29], ["cytoplasm", "ORGANISM_SUBSTANCE", 59, 68], ["IkB", "GENE_OR_GENE_PRODUCT", 112, 115], ["p50", "PROTEIN", 18, 21], ["p65 subunits", "PROTEIN", 26, 38], ["inhibitory proteins", "PROTEIN", 85, 104], ["IkB family", "PROTEIN", 112, 122], ["p50 and p65 subunits", "TREATMENT", 18, 38]]], ["Cytokines and lipopolysaccharide (LPS) can stimulate cell surface receptors including Toll-like receptor (TLR4) to initiate a signaling cascade that converge on the activation of the inhibitor of kB kinase (IKK) complex (Baker et al., 2011) .", [["cell surface", "ANATOMY", 53, 65], ["lipopolysaccharide", "CHEMICAL", 14, 32], ["LPS", "CHEMICAL", 34, 37], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 14, 32], ["LPS", "SIMPLE_CHEMICAL", 34, 37], ["cell", "CELL", 53, 57], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 86, 104], ["TLR4", "GENE_OR_GENE_PRODUCT", 106, 110], ["kB kinase", "GENE_OR_GENE_PRODUCT", 196, 205], ["IKK", "GENE_OR_GENE_PRODUCT", 207, 210], ["Cytokines", "PROTEIN", 0, 9], ["cell surface receptors", "PROTEIN", 53, 75], ["Toll-like receptor", "PROTEIN", 86, 104], ["TLR4", "PROTEIN", 106, 110], ["kB kinase (IKK) complex", "PROTEIN", 196, 219], ["Cytokines", "TREATMENT", 0, 9], ["lipopolysaccharide (LPS)", "TREATMENT", 14, 38], ["cell surface receptors", "TREATMENT", 53, 75], ["Toll-like receptor (TLR4)", "TREATMENT", 86, 111], ["a signaling cascade", "TREATMENT", 124, 143]]], ["The IKK complex phosphorylates IkBa and induces its degradation, leading to the release and nuclear translocation of NF-kB to promote transcription of target genes such as TNF-a, interleukin-1beta (IL-1b), IL-6, IL-8, cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) (Knab et al., 2014; Ruan et al., 2011) .Pathogenesis of MetSOn the other hand, JNK are members of the mitogen-activated protein kinases (MAPK) that mediate cellular responses to a variety of intra-and extracellular stresses (Zeke et al., 2016) .", [["nuclear", "ANATOMY", 92, 99], ["cellular", "ANATOMY", 442, 450], ["extracellular", "ANATOMY", 487, 500], ["nitric oxide", "CHEMICAL", 257, 269], ["nitric oxide", "CHEMICAL", 257, 269], ["IKK", "GENE_OR_GENE_PRODUCT", 4, 7], ["IkBa", "GENE_OR_GENE_PRODUCT", 31, 35], ["nuclear", "CELLULAR_COMPONENT", 92, 99], ["NF-kB", "GENE_OR_GENE_PRODUCT", 117, 122], ["TNF-a", "GENE_OR_GENE_PRODUCT", 172, 177], ["interleukin-1beta", "GENE_OR_GENE_PRODUCT", 179, 196], ["IL-1b", "GENE_OR_GENE_PRODUCT", 198, 203], ["IL-6", "GENE_OR_GENE_PRODUCT", 206, 210], ["IL-8", "GENE_OR_GENE_PRODUCT", 212, 216], ["cyclooxygenase 2", "GENE_OR_GENE_PRODUCT", 218, 234], ["COX-2", "GENE_OR_GENE_PRODUCT", 236, 241], ["inducible nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 247, 278], ["iNOS", "GENE_OR_GENE_PRODUCT", 280, 284], ["JNK", "GENE_OR_GENE_PRODUCT", 365, 368], ["mitogen-activated protein kinases", "GENE_OR_GENE_PRODUCT", 388, 421], ["MAPK", "GENE_OR_GENE_PRODUCT", 423, 427], ["cellular", "CELL", 442, 450], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 487, 500], ["IKK complex", "PROTEIN", 4, 15], ["IkBa", "PROTEIN", 31, 35], ["NF-kB", "PROTEIN", 117, 122], ["target genes", "DNA", 151, 163], ["TNF", "PROTEIN", 172, 175], ["interleukin-1beta (IL-1b", "DNA", 179, 203], ["cyclooxygenase 2", "PROTEIN", 218, 234], ["COX", "PROTEIN", 236, 239], ["nitric oxide synthase", "PROTEIN", 257, 278], ["iNOS", "PROTEIN", 280, 284], ["JNK", "PROTEIN", 365, 368], ["mitogen-activated protein kinases", "PROTEIN", 388, 421], ["MAPK", "PROTEIN", 423, 427], ["its degradation", "PROBLEM", 48, 63], ["TNF", "TEST", 172, 175], ["a, interleukin-1beta (IL", "TREATMENT", 176, 200], ["IL", "TEST", 206, 208], ["IL", "TREATMENT", 212, 214], ["cyclooxygenase", "TREATMENT", 218, 232], ["COX", "TEST", 236, 239], ["inducible nitric oxide synthase", "TREATMENT", 247, 278], ["the mitogen", "TEST", 384, 395], ["intra-and extracellular stresses", "PROBLEM", 477, 509]]], ["In the context of obesity, JNK pathways can be activated by proinflammatory cytokines, FFA and reactive oxygen species (ROS), and regulate several nuclear and extra-nuclear substrates, specially the transcription factor activator protein 1 (AP1) which controls the expression of proinflammatory genes and protein synthesis (e.g. TNF-a, IL-1b, IL-6 and IL-8) (Pal et al., 2016; Feng et al., 2020) .", [["nuclear", "ANATOMY", 147, 154], ["obesity", "DISEASE", 18, 25], ["FFA", "CHEMICAL", 87, 90], ["oxygen", "CHEMICAL", 104, 110], ["ROS", "CHEMICAL", 120, 123], ["oxygen", "CHEMICAL", 104, 110], ["JNK", "GENE_OR_GENE_PRODUCT", 27, 30], ["FFA", "SIMPLE_CHEMICAL", 87, 90], ["reactive oxygen species", "SIMPLE_CHEMICAL", 95, 118], ["ROS", "SIMPLE_CHEMICAL", 120, 123], ["nuclear", "CELLULAR_COMPONENT", 147, 154], ["activator protein 1", "GENE_OR_GENE_PRODUCT", 220, 239], ["AP1", "GENE_OR_GENE_PRODUCT", 241, 244], ["TNF-a", "GENE_OR_GENE_PRODUCT", 329, 334], ["IL-1b", "GENE_OR_GENE_PRODUCT", 336, 341], ["IL-6", "GENE_OR_GENE_PRODUCT", 343, 347], ["IL-8", "GENE_OR_GENE_PRODUCT", 352, 356], ["JNK", "PROTEIN", 27, 30], ["proinflammatory cytokines", "PROTEIN", 60, 85], ["nuclear and extra-nuclear substrates", "PROTEIN", 147, 183], ["transcription factor activator protein 1", "PROTEIN", 199, 239], ["AP1", "PROTEIN", 241, 244], ["proinflammatory genes", "DNA", 279, 300], ["TNF", "PROTEIN", 329, 332], ["obesity", "PROBLEM", 18, 25], ["JNK pathways", "PROBLEM", 27, 39], ["proinflammatory cytokines", "TEST", 60, 85], ["FFA", "TEST", 87, 90], ["reactive oxygen species", "PROBLEM", 95, 118], ["several nuclear and extra-nuclear substrates", "PROBLEM", 139, 183], ["the transcription factor activator protein", "TREATMENT", 195, 237], ["proinflammatory genes", "PROBLEM", 279, 300], ["protein synthesis", "TEST", 305, 322], ["TNF", "TEST", 329, 332], ["IL", "TEST", 336, 338], ["IL", "TEST", 343, 345], ["IL", "TEST", 352, 354], ["obesity", "OBSERVATION", 18, 25], ["reactive", "OBSERVATION_MODIFIER", 95, 103], ["oxygen species", "OBSERVATION", 104, 118], ["proinflammatory genes", "OBSERVATION", 279, 300]]], ["Deregulated activation of NF-kB and JNK pathways results in increased transcription of IL-6 and TNF-a, which reduce the sensitivity of insulin target cells towards insulin.", [["cells", "ANATOMY", 150, 155], ["NF-kB", "GENE_OR_GENE_PRODUCT", 26, 31], ["JNK", "GENE_OR_GENE_PRODUCT", 36, 39], ["IL-6", "GENE_OR_GENE_PRODUCT", 87, 91], ["TNF-a", "GENE_OR_GENE_PRODUCT", 96, 101], ["insulin", "GENE_OR_GENE_PRODUCT", 135, 142], ["cells", "CELL", 150, 155], ["insulin", "GENE_OR_GENE_PRODUCT", 164, 171], ["NF-kB", "PROTEIN", 26, 31], ["JNK", "PROTEIN", 36, 39], ["IL-6", "PROTEIN", 87, 91], ["TNF", "PROTEIN", 96, 99], ["insulin target cells", "CELL_TYPE", 135, 155], ["insulin", "PROTEIN", 164, 171], ["JNK pathways", "TEST", 36, 48], ["IL", "TEST", 87, 89], ["TNF", "TEST", 96, 99], ["insulin target cells", "TREATMENT", 135, 155], ["insulin", "TREATMENT", 164, 171]]], ["Thus, chronically activated NF-kB and JNK pathways leads to the promotion of insulin resistance (Yung and Giacca, 2020) .Pathogenesis of MetSAdditionally, increased flux of FFA to the liver in the insulin resistant state stimulates production TG and secretion in the form of verylow-density lipoprotein (VLDL).", [["liver", "ANATOMY", 184, 189], ["FFA", "CHEMICAL", 173, 176], ["NF-kB", "GENE_OR_GENE_PRODUCT", 28, 33], ["JNK", "GENE_OR_GENE_PRODUCT", 38, 41], ["insulin", "GENE_OR_GENE_PRODUCT", 77, 84], ["FFA", "SIMPLE_CHEMICAL", 173, 176], ["liver", "ORGAN", 184, 189], ["insulin", "GENE_OR_GENE_PRODUCT", 197, 204], ["TG", "SIMPLE_CHEMICAL", 243, 245], ["verylow-density lipoprotein", "SIMPLE_CHEMICAL", 275, 302], ["VLDL", "SIMPLE_CHEMICAL", 304, 308], ["NF-kB", "PROTEIN", 28, 33], ["JNK", "PROTEIN", 38, 41], ["verylow-density lipoprotein", "PROTEIN", 275, 302], ["VLDL", "PROTEIN", 304, 308], ["chronically activated NF", "PROBLEM", 6, 30], ["JNK pathways", "PROBLEM", 38, 50], ["insulin resistance", "TREATMENT", 77, 95], ["Pathogenesis of MetSAdditionally", "PROBLEM", 121, 153], ["increased flux of FFA", "PROBLEM", 155, 176], ["insulin resistance", "OBSERVATION", 77, 95], ["increased", "OBSERVATION_MODIFIER", 155, 164], ["flux", "OBSERVATION_MODIFIER", 165, 169], ["liver", "ANATOMY", 184, 189], ["insulin resistant", "OBSERVATION_MODIFIER", 197, 214]]], ["The resulting hypertriglyceridemia leads to lower HDL\u00c0C levels and normal or slightly elevated lowdensity lipoprotein-cholesterol (LDL-C) levels (Iqbal et al., 2018) .", [["hypertriglyceridemia", "DISEASE", 14, 34], ["cholesterol", "CHEMICAL", 118, 129], ["cholesterol", "CHEMICAL", 118, 129], ["HDL\u00c0C", "GENE_OR_GENE_PRODUCT", 50, 55], ["lowdensity lipoprotein-cholesterol", "SIMPLE_CHEMICAL", 95, 129], ["LDL-C", "SIMPLE_CHEMICAL", 131, 136], ["HDL\u00c0C", "PROTEIN", 50, 55], ["LDL", "PROTEIN", 131, 134], ["The resulting hypertriglyceridemia", "PROBLEM", 0, 34], ["lower HDL\u00c0C levels", "PROBLEM", 44, 62], ["slightly elevated lowdensity lipoprotein", "PROBLEM", 77, 117], ["LDL", "TEST", 131, 134], ["hypertriglyceridemia", "OBSERVATION", 14, 34], ["lower", "ANATOMY_MODIFIER", 44, 49], ["normal", "OBSERVATION", 67, 73], ["slightly", "OBSERVATION_MODIFIER", 77, 85], ["elevated", "OBSERVATION_MODIFIER", 86, 94]]], ["This is related to the typical dyslipidemic profile in MetS.Pathogenesis of MetSConsistent with a potential role in the pathogenesis of MetS, SLns interfering with these processes described above could be useful to prevent the onset of insulin resistance and the risk of T2DM and CVD in obese individuals.Sesquiterpene lactonesSLns represent a diverse group of terpenoids with more than 5000 different elucidated structures.", [["dyslipidemic", "DISEASE", 31, 43], ["MetS", "DISEASE", 55, 59], ["MetS", "DISEASE", 136, 140], ["T2DM", "DISEASE", 271, 275], ["CVD", "DISEASE", 280, 283], ["Sesquiterpene", "CHEMICAL", 305, 318], ["Sesquiterpene lactonesSLns", "CHEMICAL", 305, 331], ["terpenoids", "CHEMICAL", 361, 371], ["SLns", "GENE_OR_GENE_PRODUCT", 142, 146], ["insulin", "GENE_OR_GENE_PRODUCT", 236, 243], ["Sesquiterpene lactonesSLns", "SIMPLE_CHEMICAL", 305, 331], ["the typical dyslipidemic profile in MetS", "PROBLEM", 19, 59], ["Pathogenesis of MetSConsistent", "PROBLEM", 60, 90], ["MetS", "PROBLEM", 136, 140], ["SLns", "TREATMENT", 142, 146], ["insulin resistance", "PROBLEM", 236, 254], ["T2DM", "PROBLEM", 271, 275], ["CVD in obese individuals", "PROBLEM", 280, 304], ["Sesquiterpene lactonesSLns", "TREATMENT", 305, 331], ["related to", "UNCERTAINTY", 8, 18], ["typical", "OBSERVATION_MODIFIER", 23, 30], ["dyslipidemic", "OBSERVATION", 31, 43], ["MetS", "OBSERVATION", 55, 59], ["MetS", "OBSERVATION", 136, 140], ["insulin resistance", "OBSERVATION", 236, 254], ["T2DM", "OBSERVATION", 271, 275], ["diverse", "OBSERVATION_MODIFIER", 344, 351]]], ["They are particularly diversified in the Compositae (Asteraceae) family, but also occurring in Apiaceae, Illiciaceae, Magnoliaceae, Solanaceae, and Euphorbiaceae families (Padilla-Gonzalez et al., 2016) .", [["Magnoliaceae", "GENE_OR_GENE_PRODUCT", 118, 130], ["Euphorbiaceae", "ORGANISM", 148, 161], ["Magnoliaceae", "TREATMENT", 118, 130], ["Solanaceae", "TREATMENT", 132, 142], ["diversified", "OBSERVATION_MODIFIER", 22, 33]]], ["Numerous species of these families are used in traditional medicine and SLns have been described as their primary active constituents.", [["SLns", "SIMPLE_CHEMICAL", 72, 76], ["SLns", "TREATMENT", 72, 76]]], ["These compounds possess several biological activities such as anti-inflammatory, antidiabetic, antimalarial, anti-proliferative, anti-parasitic and antimicrobial (Merfort, 2011; Chadwick et al., 2013; Chaturvedi et al., 2011).", [["anti-inflammatory, antidiabetic", "TREATMENT", 62, 93], ["antimalarial", "TREATMENT", 95, 107]]], ["SLns are characterized by the presence of a g-lactone ring.", [["g-lactone", "CHEMICAL", 44, 53], ["SLns", "GENE_OR_GENE_PRODUCT", 0, 4], ["SLns", "PROTEIN", 0, 4], ["SLns", "TREATMENT", 0, 4], ["a g-lactone ring", "TREATMENT", 42, 58], ["g-lactone ring", "OBSERVATION", 44, 58]]], ["The lactone ring can be fused to the remaining skeleton in either a cis or trans configuration, being most common the trans configuration (Fischer et al., 1979; Fischer, 1990; .", [["lactone", "CHEMICAL", 4, 11], ["lactone", "CHEMICAL", 4, 11], ["lactone ring", "SIMPLE_CHEMICAL", 4, 16], ["The lactone ring", "TREATMENT", 0, 16], ["lactone ring", "OBSERVATION", 4, 16], ["remaining", "ANATOMY_MODIFIER", 37, 46], ["skeleton", "ANATOMY", 47, 55]]], ["Based on their carbocyclic skeleton, SLns are mainly classified in four major groups: germacranolides (10-membered ring), eudesmanolides (6\u00c06 bicyclic compounds), guaianolides and pseudoguaianolides (5\u00c07 Blood glucose levels (#), HbA1c (#), plasma insulin (\"), tissue glycogen (\") TC, TG and LDL-C (#); HDL-C (\") TBARS levels (#), GSH (\"), SOD, CAT and GPx (\") in brain, liver, heart, kidney, and pancreas Eliza et al., 2009a Eliza et al., , 2009b Eliza et al., , 2010 5 Costunolide Germacrolide Costus speciosus 6Sesquiterpene lactonesAlantolactone Eudesmanolide Inula helenium Antiinflammatory-associated to glucose intolerance and IR (in vitro) Antiinflamatory-obesity-induced IR (in vitro) Attenuates lipid accumulation (in vitro) Antiinflamatory-associated to diabetic nephropathy (in vivo)Sesquiterpene lactonesSTAT3 inhibitor.", [["plasma", "ANATOMY", 241, 247], ["tissue", "ANATOMY", 261, 267], ["brain", "ANATOMY", 364, 369], ["liver", "ANATOMY", 371, 376], ["heart", "ANATOMY", 378, 383], ["kidney", "ANATOMY", 385, 391], ["pancreas", "ANATOMY", 397, 405], ["germacranolides", "CHEMICAL", 86, 101], ["eudesmanolides", "CHEMICAL", 122, 136], ["6\u00c06 bicyclic compounds", "CHEMICAL", 138, 160], ["guaianolides", "CHEMICAL", 163, 175], ["pseudoguaianolides", "CHEMICAL", 180, 198], ["glucose", "CHEMICAL", 210, 217], ["TG", "DISEASE", 285, 287], ["TBARS", "CHEMICAL", 313, 318], ["GSH", "CHEMICAL", 331, 334], ["Costunolide Germacrolide Costus speciosus 6Sesquiterpene lactones", "CHEMICAL", 471, 536], ["glucose intolerance", "DISEASE", 610, 629], ["IR", "CHEMICAL", 634, 636], ["obesity", "DISEASE", 664, 671], ["diabetic nephropathy", "DISEASE", 765, 785], ["Sesquiterpene", "CHEMICAL", 795, 808], ["germacranolides", "CHEMICAL", 86, 101], ["eudesmanolides", "CHEMICAL", 122, 136], ["guaianolides", "CHEMICAL", 163, 175], ["pseudoguaianolides", "CHEMICAL", 180, 198], ["glucose", "CHEMICAL", 210, 217], ["GSH", "CHEMICAL", 331, 334], ["lactones", "CHEMICAL", 528, 536], ["glucose", "CHEMICAL", 610, 617], ["Sesquiterpene", "CHEMICAL", 795, 808], ["SLns", "SIMPLE_CHEMICAL", 37, 41], ["germacranolides", "SIMPLE_CHEMICAL", 86, 101], ["10-membered ring", "SIMPLE_CHEMICAL", 103, 119], ["eudesmanolides", "SIMPLE_CHEMICAL", 122, 136], ["6\u00c06 bicyclic compounds", "SIMPLE_CHEMICAL", 138, 160], ["guaianolides", "SIMPLE_CHEMICAL", 163, 175], ["pseudoguaianolides", "SIMPLE_CHEMICAL", 180, 198], ["Blood", "ORGANISM_SUBSTANCE", 204, 209], ["glucose", "SIMPLE_CHEMICAL", 210, 217], ["HbA1c", "SIMPLE_CHEMICAL", 230, 235], ["plasma", "ORGANISM_SUBSTANCE", 241, 247], ["insulin", "GENE_OR_GENE_PRODUCT", 248, 255], ["tissue", "TISSUE", 261, 267], ["glycogen", "SIMPLE_CHEMICAL", 268, 276], ["TC", "SIMPLE_CHEMICAL", 281, 283], ["TG", "SIMPLE_CHEMICAL", 285, 287], ["LDL-C", "SIMPLE_CHEMICAL", 292, 297], ["HDL-C", "SIMPLE_CHEMICAL", 303, 308], ["TBARS", "SIMPLE_CHEMICAL", 313, 318], ["GSH", "SIMPLE_CHEMICAL", 331, 334], ["SOD", "SIMPLE_CHEMICAL", 340, 343], ["CAT", "SIMPLE_CHEMICAL", 345, 348], ["GPx", "SIMPLE_CHEMICAL", 353, 356], ["brain", "ORGAN", 364, 369], ["liver", "ORGAN", 371, 376], ["heart", "ORGAN", 378, 383], ["kidney", "ORGAN", 385, 391], ["pancreas", "ORGAN", 397, 405], ["glucose", "SIMPLE_CHEMICAL", 610, 617], ["lipid", "SIMPLE_CHEMICAL", 705, 710], ["Sesquiterpene lactonesSTAT3", "SIMPLE_CHEMICAL", 795, 822], ["LDL", "PROTEIN", 292, 295], ["SOD", "PROTEIN", 340, 343], ["CAT", "PROTEIN", 345, 348], ["GPx", "PROTEIN", 353, 356], ["Costus speciosus", "SPECIES", 496, 512], ["SLns", "TREATMENT", 37, 41], ["germacranolides", "TREATMENT", 86, 101], ["eudesmanolides (6\u00c06 bicyclic compounds", "TREATMENT", 122, 160], ["guaianolides", "TREATMENT", 163, 175], ["pseudoguaianolides", "TEST", 180, 198], ["Blood glucose levels", "TEST", 204, 224], ["HbA1c", "TEST", 230, 235], ["plasma insulin", "TREATMENT", 241, 255], ["tissue glycogen", "TEST", 261, 276], ["TG", "TEST", 285, 287], ["LDL", "TEST", 292, 295], ["HDL", "TEST", 303, 306], ["TBARS levels", "TEST", 313, 325], ["Costunolide", "TEST", 471, 482], ["Germacrolide", "TEST", 483, 495], ["Costus", "TEST", 496, 502], ["6Sesquiterpene lactones", "TREATMENT", 513, 536], ["Alantolactone", "TREATMENT", 536, 549], ["Inula helenium", "TREATMENT", 564, 578], ["Antiinflammatory", "TREATMENT", 579, 595], ["glucose intolerance", "PROBLEM", 610, 629], ["IR (in vitro)", "TREATMENT", 634, 647], ["obesity", "PROBLEM", 664, 671], ["lipid accumulation", "PROBLEM", 705, 723], ["Antiinflamatory", "TREATMENT", 735, 750], ["diabetic nephropathy", "PROBLEM", 765, 785], ["Sesquiterpene lactonesSTAT3 inhibitor", "TREATMENT", 795, 832], ["brain", "ANATOMY", 364, 369], ["liver", "ANATOMY", 371, 376], ["heart", "ANATOMY", 378, 383], ["kidney", "ANATOMY", 385, 391], ["pancreas", "ANATOMY", 397, 405], ["obesity", "OBSERVATION", 664, 671], ["lipid accumulation", "OBSERVATION", 705, 723], ["diabetic nephropathy", "OBSERVATION", 765, 785]]], ["Inhibition of the TLR4 gene expression.", [["TLR4", "GENE_OR_GENE_PRODUCT", 18, 22], ["TLR4 gene", "DNA", 18, 27], ["the TLR4 gene expression", "TREATMENT", 14, 38], ["TLR4 gene expression", "OBSERVATION", 18, 38]]], ["Inhibition of TLR4-JNK signaling.", [["TLR4", "GENE_OR_GENE_PRODUCT", 14, 18], ["JNK", "GENE_OR_GENE_PRODUCT", 19, 22], ["TLR4", "PROTEIN", 14, 18], ["JNK", "PROTEIN", 19, 22], ["TLR4", "OBSERVATION", 14, 18], ["JNK signaling", "OBSERVATION", 19, 32]]], ["IL-6 and MCP-1 (#).", [["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["MCP-1", "GENE_OR_GENE_PRODUCT", 9, 14], ["#", "GENE_OR_GENE_PRODUCT", 16, 17], ["IL-6", "PROTEIN", 0, 4], ["MCP", "PROTEIN", 9, 12], ["IL", "TEST", 0, 2]]], ["APOC3 expression at both mRNA and protein levels (#) TNF-a and IL-6 (#) in diabetic kidney.", [["kidney", "ANATOMY", 84, 90], ["diabetic", "DISEASE", 75, 83], ["APOC3", "GENE_OR_GENE_PRODUCT", 0, 5], ["TNF-a", "GENE_OR_GENE_PRODUCT", 53, 58], ["IL-6", "GENE_OR_GENE_PRODUCT", 63, 67], ["#", "GENE_OR_GENE_PRODUCT", 69, 70], ["kidney", "ORGAN", 84, 90], ["APOC3", "PROTEIN", 0, 5], ["TNF", "PROTEIN", 53, 56], ["IL-6 (#)", "PROTEIN", 63, 71], ["APOC3 expression", "PROBLEM", 0, 16], ["protein levels", "TEST", 34, 48], ["TNF", "TEST", 53, 56], ["diabetic kidney", "PROBLEM", 75, 90], ["diabetic", "OBSERVATION", 75, 83], ["kidney", "ANATOMY", 84, 90]]], ["Serum creatinine and urea nitrogen levels (#).", [["Serum", "ANATOMY", 0, 5], ["creatinine", "CHEMICAL", 6, 16], ["urea nitrogen", "CHEMICAL", 21, 34], ["creatinine", "CHEMICAL", 6, 16], ["urea", "CHEMICAL", 21, 25], ["nitrogen", "CHEMICAL", 26, 34], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["creatinine", "SIMPLE_CHEMICAL", 6, 16], ["urea", "SIMPLE_CHEMICAL", 21, 25], ["Serum creatinine", "TEST", 0, 16], ["urea nitrogen levels", "TEST", 21, 41]]], ["Kim et al., 2017a Kim et al., , 2017b Yang et al., 2018; Zhu et al., 2020 7 Tirotundin 3,10epoxygermacranolideTithonia diversifoliaAntidiabetic (in vitro) Dual PPARa/g agonists Lin, 2012 8 Tagitinin A 9Tithonia diversifoliaTagitinin G Anti-hyperglycemic (in vitro) Glucose uptake in 3T3-L1 adipocytes (\").", [["3T3-L1 adipocytes", "ANATOMY", 283, 300], ["Tirotundin 3,10epoxygermacranolideTithonia diversifoliaAntidiabetic", "CHEMICAL", 76, 143], ["Glucose", "CHEMICAL", 265, 272], ["diversifoliaTagitinin G", "CHEMICAL", 211, 234], ["Glucose", "CHEMICAL", 265, 272], ["diversifoliaTagitinin G Anti-hyperglycemic", "SIMPLE_CHEMICAL", 211, 253], ["Glucose", "SIMPLE_CHEMICAL", 265, 272], ["3T3-L1 adipocytes", "CELL", 283, 300], ["3T3-L1 adipocytes", "CELL_LINE", 283, 300], ["Tirotundin", "TREATMENT", 76, 86], ["diversifoliaAntidiabetic (in vitro)", "TREATMENT", 119, 154], ["Dual PPARa/g agonists Lin", "TREATMENT", 155, 180], ["Tagitinin", "TREATMENT", 189, 198], ["diversifoliaTagitinin G Anti-hyperglycemic", "TREATMENT", 211, 253], ["Glucose uptake", "TEST", 265, 279], ["L1 adipocytes", "ANATOMY", 287, 300]]], ["Blood glucose levels (#), serum insulin and pancreatic insulin levels (\") G6Pase activity (#) and GK activity (\") TC, TG, LDL-C and VLDL (#); HDL-C (\") TBARS levels (#), SOD, CAT and GPx (\") in liver, kidneys, and pancreas TNF-a levels (#).", [["Blood", "ANATOMY", 0, 5], ["serum", "ANATOMY", 26, 31], ["pancreatic", "ANATOMY", 44, 54], ["liver", "ANATOMY", 194, 199], ["kidneys", "ANATOMY", 201, 208], ["pancreas", "ANATOMY", 214, 222], ["glucose", "CHEMICAL", 6, 13], ["TG", "DISEASE", 118, 120], ["TBARS", "CHEMICAL", 152, 157], ["glucose", "CHEMICAL", 6, 13], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["glucose", "SIMPLE_CHEMICAL", 6, 13], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["insulin", "GENE_OR_GENE_PRODUCT", 32, 39], ["pancreatic", "ORGAN", 44, 54], ["insulin", "GENE_OR_GENE_PRODUCT", 55, 62], ["G6Pase", "GENE_OR_GENE_PRODUCT", 74, 80], ["GK", "GENE_OR_GENE_PRODUCT", 98, 100], ["TC", "SIMPLE_CHEMICAL", 114, 116], ["TG", "SIMPLE_CHEMICAL", 118, 120], ["LDL-C", "SIMPLE_CHEMICAL", 122, 127], ["VLDL", "SIMPLE_CHEMICAL", 132, 136], ["HDL-C", "SIMPLE_CHEMICAL", 142, 147], ["TBARS", "SIMPLE_CHEMICAL", 152, 157], ["SOD", "SIMPLE_CHEMICAL", 170, 173], ["CAT", "SIMPLE_CHEMICAL", 175, 178], ["GPx", "SIMPLE_CHEMICAL", 183, 186], ["liver", "ORGAN", 194, 199], ["kidneys", "ORGAN", 201, 208], ["pancreas", "ORGAN", 214, 222], ["TNF-a", "GENE_OR_GENE_PRODUCT", 223, 228], ["serum insulin", "PROTEIN", 26, 39], ["G6Pase", "PROTEIN", 74, 80], ["LDL", "PROTEIN", 122, 125], ["SOD", "PROTEIN", 170, 173], ["CAT", "PROTEIN", 175, 178], ["GPx", "PROTEIN", 183, 186], ["TNF", "PROTEIN", 223, 226], ["Blood glucose levels", "TEST", 0, 20], ["serum insulin", "TREATMENT", 26, 39], ["pancreatic insulin levels", "TEST", 44, 69], ["G6Pase activity", "TEST", 74, 89], ["GK activity", "TEST", 98, 109], ["TC", "TEST", 114, 116], ["TG", "TEST", 118, 120], ["LDL", "TEST", 122, 125], ["VLDL", "TEST", 132, 136], ["HDL", "TEST", 142, 145], ["TBARS levels", "TEST", 152, 164], ["SOD", "PROBLEM", 170, 173], ["pancreas TNF", "TEST", 214, 226], ["pancreatic", "ANATOMY", 44, 54], ["liver", "ANATOMY", 194, 199], ["kidneys", "ANATOMY", 201, 208], ["pancreas", "ANATOMY", 214, 222]]], ["Normalization of blood pressure Hong et al., 1999 Hong et al., , 2005 Reduction (#); increment (\"); thiobarbituric acid reactive substances (TBARS); reduced glutathione (GSH); superoxide dismutase (SOD); catalase (CAT); glutathione peroxidase (GPx); insulin resistance (IR); Toll-like receptor 4 (TLR4); c-Jun N-terminal kinases (JNK); interleukin 6 (IL-6); monocyte chemoattractant protein 1 (MCP-1); Apolipoprotein C3 (APOC3); AMP-activated protein kinase (AMPK); peroxisome proliferator-activated receptors a and g (PPARa/g); nuclear factor kappa B (NF-kB); transforming growth factor beta (TGF-b1); fibronectin (FN); glucose-6-phosphatase (G6Pase); glucokinase (GK); cyclooxygenase 2 (COX-2); interferon-gamma (IFN-g); tumor necrosis factor a (TNF-a);Tithonia diversifoliaangiotensin I-converting enzyme (ACE).Tithonia diversifoliaA.", [["blood", "ANATOMY", 17, 22], ["thiobarbituric acid", "CHEMICAL", 100, 119], ["TBARS", "CHEMICAL", 141, 146], ["glutathione", "CHEMICAL", 157, 168], ["GSH", "CHEMICAL", 170, 173], ["superoxide", "CHEMICAL", 176, 186], ["glutathione", "CHEMICAL", 220, 231], ["tumor necrosis", "DISEASE", 723, 737], ["thiobarbituric acid", "CHEMICAL", 100, 119], ["reduced glutathione", "CHEMICAL", 149, 168], ["GSH", "CHEMICAL", 170, 173], ["superoxide", "CHEMICAL", 176, 186], ["glutathione", "CHEMICAL", 220, 231], ["N", "CHEMICAL", 310, 311], ["AMP", "CHEMICAL", 429, 432], ["glucose", "CHEMICAL", 621, 628], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["thiobarbituric acid reactive substances", "SIMPLE_CHEMICAL", 100, 139], ["TBARS", "SIMPLE_CHEMICAL", 141, 146], ["glutathione", "SIMPLE_CHEMICAL", 157, 168], ["GSH", "SIMPLE_CHEMICAL", 170, 173], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 176, 196], ["SOD", "SIMPLE_CHEMICAL", 198, 201], ["catalase", "SIMPLE_CHEMICAL", 204, 212], ["CAT", "SIMPLE_CHEMICAL", 214, 217], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 220, 242], ["GPx", "SIMPLE_CHEMICAL", 244, 247], ["insulin", "GENE_OR_GENE_PRODUCT", 250, 257], ["Toll-like receptor 4", "GENE_OR_GENE_PRODUCT", 275, 295], ["TLR4", "GENE_OR_GENE_PRODUCT", 297, 301], ["c-Jun N-terminal kinases", "GENE_OR_GENE_PRODUCT", 304, 328], ["JNK", "GENE_OR_GENE_PRODUCT", 330, 333], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 336, 349], ["IL-6", "GENE_OR_GENE_PRODUCT", 351, 355], ["monocyte chemoattractant protein 1", "GENE_OR_GENE_PRODUCT", 358, 392], ["MCP-1", "GENE_OR_GENE_PRODUCT", 394, 399], ["Apolipoprotein C3", "GENE_OR_GENE_PRODUCT", 402, 419], ["APOC3", "GENE_OR_GENE_PRODUCT", 421, 426], ["AMP-activated protein kinase", "GENE_OR_GENE_PRODUCT", 429, 457], ["AMPK", "GENE_OR_GENE_PRODUCT", 459, 463], ["peroxisome proliferator-activated receptors a", "GENE_OR_GENE_PRODUCT", 466, 511], ["PPARa", "GENE_OR_GENE_PRODUCT", 519, 524], ["nuclear factor kappa B", "GENE_OR_GENE_PRODUCT", 529, 551], ["NF-kB", "GENE_OR_GENE_PRODUCT", 553, 558], ["transforming growth factor beta", "GENE_OR_GENE_PRODUCT", 561, 592], ["TGF-b1", "GENE_OR_GENE_PRODUCT", 594, 600], ["fibronectin", "GENE_OR_GENE_PRODUCT", 603, 614], ["FN", "GENE_OR_GENE_PRODUCT", 616, 618], ["glucose-6-phosphatase", "GENE_OR_GENE_PRODUCT", 621, 642], ["G6Pase", "GENE_OR_GENE_PRODUCT", 644, 650], ["glucokinase", "GENE_OR_GENE_PRODUCT", 653, 664], ["GK", "GENE_OR_GENE_PRODUCT", 666, 668], ["cyclooxygenase 2", "GENE_OR_GENE_PRODUCT", 671, 687], ["COX-2", "GENE_OR_GENE_PRODUCT", 689, 694], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 697, 713], ["IFN-g", "GENE_OR_GENE_PRODUCT", 715, 720], ["tumor necrosis factor a", "GENE_OR_GENE_PRODUCT", 723, 746], ["TNF-a", "GENE_OR_GENE_PRODUCT", 748, 753], ["Tithonia diversifoliaangiotensin I-converting enzyme", "GENE_OR_GENE_PRODUCT", 755, 807], ["ACE", "GENE_OR_GENE_PRODUCT", 809, 812], ["Tithonia diversifoliaA", "ORGANISM", 814, 836], ["superoxide dismutase", "PROTEIN", 176, 196], ["SOD", "PROTEIN", 198, 201], ["catalase", "PROTEIN", 204, 212], ["CAT", "PROTEIN", 214, 217], ["glutathione peroxidase", "PROTEIN", 220, 242], ["GPx", "PROTEIN", 244, 247], ["Toll-like receptor 4", "PROTEIN", 275, 295], ["TLR4", "PROTEIN", 297, 301], ["Jun N-terminal kinases", "PROTEIN", 306, 328], ["JNK", "PROTEIN", 330, 333], ["interleukin 6 (IL-6", "PROTEIN", 336, 355], ["monocyte chemoattractant protein 1 (MCP-1", "PROTEIN", 358, 399], ["Apolipoprotein C3", "PROTEIN", 402, 419], ["APOC3", "PROTEIN", 421, 426], ["AMP-activated protein kinase", "PROTEIN", 429, 457], ["AMPK", "PROTEIN", 459, 463], ["peroxisome proliferator-activated receptors", "PROTEIN", 466, 509], ["g (PPARa/g", "PROTEIN", 516, 526], ["nuclear factor kappa B (NF-kB", "PROTEIN", 529, 558], ["transforming growth factor beta", "PROTEIN", 561, 592], ["TGF-b1", "PROTEIN", 594, 600], ["fibronectin", "PROTEIN", 603, 614], ["FN", "PROTEIN", 616, 618], ["glucose-6-phosphatase", "PROTEIN", 621, 642], ["G6Pase", "PROTEIN", 644, 650], ["glucokinase", "PROTEIN", 653, 664], ["GK", "PROTEIN", 666, 668], ["cyclooxygenase 2 (COX-2", "PROTEIN", 671, 694], ["interferon-gamma", "PROTEIN", 697, 713], ["IFN", "PROTEIN", 715, 718], ["tumor necrosis factor", "PROTEIN", 723, 744], ["TNF", "PROTEIN", 748, 751], ["Tithonia diversifoliaangiotensin I-converting enzyme", "PROTEIN", 755, 807], ["ACE", "PROTEIN", 809, 812], ["Tithonia diversifoliaA", "SPECIES", 814, 836], ["Tithonia diversifoliaA", "SPECIES", 814, 836], ["blood pressure", "TEST", 17, 31], ["thiobarbituric acid reactive substances (TBARS)", "PROBLEM", 100, 147], ["reduced glutathione (GSH)", "PROBLEM", 149, 174], ["superoxide dismutase (SOD)", "TREATMENT", 176, 202], ["catalase (CAT)", "TREATMENT", 204, 218], ["glutathione peroxidase (GPx)", "TREATMENT", 220, 248], ["insulin resistance (IR", "TREATMENT", 250, 272], ["c-Jun N-terminal kinases (JNK)", "TEST", 304, 334], ["interleukin", "TEST", 336, 347], ["IL", "TEST", 351, 353], ["monocyte chemoattractant protein", "TEST", 358, 390], ["MCP", "TEST", 394, 397], ["Apolipoprotein C3 (APOC3", "TEST", 402, 426], ["AMP-activated protein kinase", "TEST", 429, 457], ["AMPK", "TEST", 459, 463], ["peroxisome proliferator", "TEST", 466, 489], ["activated receptors a and g (PPARa/g", "TREATMENT", 490, 526], ["nuclear factor kappa B", "TEST", 529, 551], ["transforming growth factor beta (TGF", "TEST", 561, 597], ["fibronectin (FN)", "TEST", 603, 619], ["glucose", "TEST", 621, 628], ["phosphatase (G6Pase)", "TEST", 631, 651], ["glucokinase (GK)", "TEST", 653, 669], ["cyclooxygenase", "TEST", 671, 685], ["COX", "TEST", 689, 692], ["interferon-gamma (IFN-g", "TREATMENT", 697, 720], ["tumor necrosis factor", "PROBLEM", 723, 744], ["Tithonia diversifoliaangiotensin I-converting enzyme (ACE)", "TREATMENT", 755, 813], ["Tithonia diversifoliaA", "PROBLEM", 814, 836], ["gamma", "ANATOMY", 708, 713], ["tumor", "ANATOMY", 723, 728], ["necrosis", "OBSERVATION", 729, 737]]], ["Salazar-G omez et al. / South African Journal of Botany 135 (2020) 1\u00c012Tithonia diversifoliabicyclic compounds) and many subtypes of SLns according to their skeletal arrangement (Adekenov, 2017; Padilla-Gonzalez et al., 2016) .", [["skeletal", "ANATOMY", 157, 165], ["SLns", "CANCER", 133, 137], ["skeletal", "ORGAN", 157, 165], ["Salazar", "TREATMENT", 0, 7], ["SLns", "TREATMENT", 133, 137], ["SLns", "OBSERVATION", 133, 137], ["skeletal", "ANATOMY", 157, 165]]], ["In many cases, the g-lactone ring contains an exocyclic double bond conjugated to the carbonyl group (a-methylene-g-lactone) but in some cases the exocyclic methylene is reduced or the double bond can be endocyclic (Mart\u00ednez et al., 2012; Padilla-Gonzalez et al., 2016; .", [["g-lactone", "CHEMICAL", 19, 28], ["carbonyl", "CHEMICAL", 86, 94], ["a-methylene-g-lactone", "CHEMICAL", 102, 123], ["methylene", "CHEMICAL", 157, 166], ["g-lactone", "CHEMICAL", 19, 28], ["carbonyl", "CHEMICAL", 86, 94], ["a-methylene-g-lactone", "CHEMICAL", 102, 123], ["exocyclic methylene", "CHEMICAL", 147, 166], ["g-lactone ring", "SIMPLE_CHEMICAL", 19, 33], ["carbonyl", "SIMPLE_CHEMICAL", 86, 94], ["a-methylene-g-lactone", "SIMPLE_CHEMICAL", 102, 123], ["methylene", "SIMPLE_CHEMICAL", 157, 166], ["the g-lactone ring", "TREATMENT", 15, 33], ["an exocyclic double bond", "TREATMENT", 43, 67], ["the carbonyl group", "TREATMENT", 82, 100], ["a-methylene-g-lactone", "TREATMENT", 102, 123], ["the exocyclic methylene", "TREATMENT", 143, 166]]], ["It has been well documented that biological activity of the most common types of SLns is mainly attributed to formation of covalent union between the a,b-unsaturated group in the exo-methylene-g-lactone and nucleophilic biological targets (e.g. free cysteine sulfhydryl) resulting in alkylation through Michael-type addition (Schmidt, 2006) .", [["SLns", "CHEMICAL", 81, 85], ["exo-methylene-g-lactone", "CHEMICAL", 179, 202], ["cysteine sulfhydryl", "CHEMICAL", 250, 269], ["exo-methylene-g-lactone", "CHEMICAL", 179, 202], ["cysteine sulfhydryl", "CHEMICAL", 250, 269], ["SLns", "GENE_OR_GENE_PRODUCT", 81, 85], ["b-unsaturated", "SIMPLE_CHEMICAL", 152, 165], ["exo-methylene-g-lactone", "SIMPLE_CHEMICAL", 179, 202], ["free cysteine sulfhydryl", "SIMPLE_CHEMICAL", 245, 269], ["SLns", "TREATMENT", 81, 85], ["the exo-methylene-g-lactone", "TREATMENT", 175, 202], ["nucleophilic biological targets", "TREATMENT", 207, 238], ["free cysteine sulfhydryl", "TREATMENT", 245, 269], ["activity", "OBSERVATION_MODIFIER", 44, 52], ["SLns", "OBSERVATION", 81, 85], ["covalent union", "OBSERVATION", 123, 137]]], ["This chemical reaction induces steric and chemical changes in enzymes, receptors or transcriptional factors leading to a series of cellular events that culminate in diverse biologic responses.", [["cellular", "ANATOMY", 131, 139], ["cellular", "CELL", 131, 139], ["enzymes", "PROTEIN", 62, 69], ["transcriptional factors", "PROTEIN", 84, 107], ["This chemical reaction", "PROBLEM", 0, 22], ["steric and chemical changes in enzymes", "PROBLEM", 31, 69], ["transcriptional factors", "PROBLEM", 84, 107], ["cellular events", "PROBLEM", 131, 146], ["steric", "OBSERVATION_MODIFIER", 31, 37]]], ["The number of alkylating structural elements present on the molecule define differences between the activity of each SLn.", [["alkylating", "CHEMICAL", 14, 24], ["SLn", "CHEMICAL", 117, 120], ["SLn", "GENE_OR_GENE_PRODUCT", 117, 120], ["SLn", "PROTEIN", 117, 120], ["alkylating structural elements", "PROBLEM", 14, 44], ["alkylating structural elements", "OBSERVATION", 14, 44]]], ["Another structural influences on the biological effects are the molecular size, hydrophobicity, chemical environment and the presence of other functional groups (e.g., epoxy groups, hydroxyls or hydroxyls esterified with acetate, propionate, isobutyrate, angelate, epoxyangelate, and benzoate) (Chaturvedi, 2011; Ivanescu et al., 2015; Padilla-Gonzalez et al., 2016; .", [["hydroxyls esterified", "CHEMICAL", 195, 215], ["acetate, propionate, isobutyrate, angelate, epoxyangelate, and benzoate", "CHEMICAL", 221, 292], ["epoxy", "CHEMICAL", 168, 173], ["hydroxyls", "CHEMICAL", 182, 191], ["hydroxyls", "CHEMICAL", 195, 204], ["acetate", "CHEMICAL", 221, 228], ["propionate", "CHEMICAL", 230, 240], ["isobutyrate", "CHEMICAL", 242, 253], ["angelate", "CHEMICAL", 255, 263], ["epoxyangelate", "CHEMICAL", 265, 278], ["benzoate", "CHEMICAL", 284, 292], ["hydroxyls", "SIMPLE_CHEMICAL", 182, 191], ["hydroxyls esterified", "SIMPLE_CHEMICAL", 195, 215], ["acetate", "SIMPLE_CHEMICAL", 221, 228], ["propionate", "SIMPLE_CHEMICAL", 230, 240], ["isobutyrate", "SIMPLE_CHEMICAL", 242, 253], ["angelate", "SIMPLE_CHEMICAL", 255, 263], ["epoxyangelate", "SIMPLE_CHEMICAL", 265, 278], ["benzoate", "SIMPLE_CHEMICAL", 284, 292], ["e.g., epoxy groups", "TREATMENT", 162, 180], ["hydroxyls", "TREATMENT", 182, 191], ["hydroxyls esterified", "TREATMENT", 195, 215], ["acetate", "TREATMENT", 221, 228], ["propionate", "TREATMENT", 230, 240], ["isobutyrate", "TREATMENT", 242, 253], ["epoxyangelate", "TREATMENT", 265, 278], ["size", "OBSERVATION_MODIFIER", 74, 78], ["hydrophobicity", "OBSERVATION_MODIFIER", 80, 94], ["chemical environment", "OBSERVATION", 96, 116]]], ["The structural diversity and the broad spectrum of biological activities drew significant interests in the pharmacological applications of SLns (Moujir et al., 2020) .", [["SLns", "SIMPLE_CHEMICAL", 139, 143], ["structural", "OBSERVATION_MODIFIER", 4, 14], ["diversity", "OBSERVATION_MODIFIER", 15, 24], ["broad", "OBSERVATION_MODIFIER", 33, 38]]], ["Many SLns have proved to have a significant anti-inflammatory, hypoglycemic and hypolipidemic activity therefore making them attractive for MetS therapy (Chaturvedi, 2011; Chaturvedi et al., 2016) .SLns isolated from medicinal plants and their potential role for MetS treatment6.1.", [["SLns", "CHEMICAL", 5, 9], ["hypoglycemic", "DISEASE", 63, 75], ["MetS", "DISEASE", 140, 144], ["SLns", "CHEMICAL", 198, 202], ["MetS", "DISEASE", 263, 267], ["SLns", "GENE_OR_GENE_PRODUCT", 5, 9], ["SLns", "GENE_OR_GENE_PRODUCT", 198, 202], ["SLns", "PROTEIN", 198, 202], ["a significant anti-inflammatory, hypoglycemic and hypolipidemic activity", "PROBLEM", 30, 102], ["MetS therapy", "TREATMENT", 140, 152], ["SLns", "TREATMENT", 198, 202], ["medicinal plants", "TREATMENT", 217, 233], ["MetS treatment6", "TREATMENT", 263, 278], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["anti-inflammatory", "OBSERVATION_MODIFIER", 44, 61], ["medicinal plants", "OBSERVATION", 217, 233]]], ["Enhydrin from Smallanthus sonchifolius (Poepp.)", [["Enhydrin", "CHEMICAL", 0, 8], ["Enhydrin", "CHEMICAL", 0, 8], ["Enhydrin", "SIMPLE_CHEMICAL", 0, 8], ["Smallanthus sonchifolius", "ORGANISM", 14, 38], ["Smallanthus sonchifolius", "SPECIES", 14, 38], ["Smallanthus sonchifolius", "SPECIES", 14, 38], ["Enhydrin", "TREATMENT", 0, 8]]], ["H.Rob Smallanthus sonchifolius (Poepp.)", [["H.Rob Smallanthus sonchifolius", "ORGANISM", 0, 30], ["Smallanthus sonchifolius", "SPECIES", 6, 30], ["Smallanthus sonchifolius", "SPECIES", 6, 30]]], ["H.Rob., commonly known as yacon, is a perennial herbaceous plant native to the Andean regions of South America (Caetano et al., 2016) .", [["Andean", "ANATOMY_MODIFIER", 79, 85], ["regions", "ANATOMY_MODIFIER", 86, 93]]], ["Yacon is consumed as a safety dietary supplement and because of its low glucose content and high fructooligosaccharide levels putative antidiabetic effects were suggested (Delgado et al., 2013) .", [["Yacon", "CHEMICAL", 0, 5], ["glucose", "CHEMICAL", 72, 79], ["fructooligosaccharide", "CHEMICAL", 97, 118], ["glucose", "CHEMICAL", 72, 79], ["fructooligosaccharide", "CHEMICAL", 97, 118], ["Yacon", "SIMPLE_CHEMICAL", 0, 5], ["glucose", "SIMPLE_CHEMICAL", 72, 79], ["fructooligosaccharide", "SIMPLE_CHEMICAL", 97, 118], ["a safety dietary supplement", "TREATMENT", 21, 48], ["its low glucose content", "PROBLEM", 64, 87], ["high fructooligosaccharide levels putative antidiabetic effects", "PROBLEM", 92, 155]]], ["Indeed, this suggestion is supported by the hypoglycemic (Aybar et al., 2001; Baroni et al., 2008) and hypolipidemic (Miura et al., 2004; Habib et al., 2011) reported activities.", [["hypoglycemic", "DISEASE", 44, 56], ["the hypoglycemic", "PROBLEM", 40, 56], ["hypolipidemic", "PROBLEM", 103, 116]]], ["Also, a potential use in metabolic disorders could be proposed based on the anti-inflammatory and antioxidant properties (Feltenstein et al., 2004; Sousa et al., 2015) .", [["metabolic disorders", "DISEASE", 25, 44], ["metabolic disorders", "PROBLEM", 25, 44], ["the anti-inflammatory and antioxidant properties", "TREATMENT", 72, 120]]], ["Besides the above mentioned evidences, enhydrin (1), a melampolide (cis,trans-germacranolide) and the major sesquiterpene lactone component in leaves of S. sonchifolius, has proven to be effective reducing post-prandial glucose levels and a useful compound for blood glucose control by the induction of a late increase in plasma insulin in streptozotocin (STZ)- induced diabetic rats (Genta et al., 2010) .", [["leaves", "ANATOMY", 143, 149], ["blood", "ANATOMY", 261, 266], ["plasma", "ANATOMY", 322, 328], ["enhydrin", "CHEMICAL", 39, 47], ["melampolide", "CHEMICAL", 55, 66], ["cis,trans-germacranolide", "CHEMICAL", 68, 92], ["sesquiterpene lactone", "CHEMICAL", 108, 129], ["glucose", "CHEMICAL", 220, 227], ["streptozotocin", "CHEMICAL", 340, 354], ["STZ", "CHEMICAL", 356, 359], ["diabetic", "DISEASE", 370, 378], ["enhydrin", "CHEMICAL", 39, 47], ["melampolide", "CHEMICAL", 55, 66], ["cis,trans-germacranolide", "CHEMICAL", 68, 92], ["sesquiterpene lactone", "CHEMICAL", 108, 129], ["glucose", "CHEMICAL", 220, 227], ["glucose", "CHEMICAL", 267, 274], ["streptozotocin", "CHEMICAL", 340, 354], ["STZ", "CHEMICAL", 356, 359], ["enhydrin (1)", "SIMPLE_CHEMICAL", 39, 51], ["melampolide", "SIMPLE_CHEMICAL", 55, 66], ["cis,trans-germacranolide", "SIMPLE_CHEMICAL", 68, 92], ["sesquiterpene lactone", "SIMPLE_CHEMICAL", 108, 129], ["leaves", "ORGANISM_SUBDIVISION", 143, 149], ["S. sonchifolius", "ORGANISM", 153, 168], ["post-prandial", "ORGANISM_SUBDIVISION", 206, 219], ["glucose", "SIMPLE_CHEMICAL", 220, 227], ["blood", "ORGANISM_SUBSTANCE", 261, 266], ["glucose", "SIMPLE_CHEMICAL", 267, 274], ["plasma", "ORGANISM_SUBSTANCE", 322, 328], ["insulin", "GENE_OR_GENE_PRODUCT", 329, 336], ["streptozotocin", "SIMPLE_CHEMICAL", 340, 354], ["STZ", "SIMPLE_CHEMICAL", 356, 359], ["rats", "ORGANISM", 379, 383], ["S. sonchifolius", "SPECIES", 153, 168], ["rats", "SPECIES", 379, 383], ["S. sonchifolius", "SPECIES", 153, 168], ["enhydrin", "TREATMENT", 39, 47], ["a melampolide (cis,trans-germacranolide", "TREATMENT", 53, 92], ["the major sesquiterpene lactone component", "TREATMENT", 98, 139], ["S. sonchifolius", "PROBLEM", 153, 168], ["post-prandial glucose levels", "PROBLEM", 206, 234], ["blood glucose control", "TREATMENT", 261, 282], ["a late increase in plasma insulin", "TREATMENT", 303, 336], ["streptozotocin (STZ", "TREATMENT", 340, 359], ["sesquiterpene lactone", "OBSERVATION", 108, 129]]], ["More recently, in vivo and in vitro experiments showed that enhydrin (1) is effective in the management of post-prandial hyperglycemia through inhibition of a-glucosidase in the small intestine (Serra-Barcellona et al., 2017) .", [["small intestine", "ANATOMY", 178, 193], ["enhydrin", "CHEMICAL", 60, 68], ["hyperglycemia", "DISEASE", 121, 134], ["enhydrin", "CHEMICAL", 60, 68], ["enhydrin (1)", "GENE_OR_GENE_PRODUCT", 60, 72], ["post-prandial", "ORGANISM_SUBDIVISION", 107, 120], ["a-glucosidase", "GENE_OR_GENE_PRODUCT", 157, 170], ["small intestine", "ORGAN", 178, 193], ["a-glucosidase", "PROTEIN", 157, 170], ["post-prandial hyperglycemia", "PROBLEM", 107, 134], ["a-glucosidase in the small intestine", "PROBLEM", 157, 193], ["post-prandial hyperglycemia", "OBSERVATION", 107, 134], ["small intestine", "ANATOMY", 178, 193]]], ["The inhibition of this enzyme has been linked to the presence of the a,b-unsaturatedg-lactone ring system (Yin et al., 2014) , similar to the intact exo-methylene-g-lactone group in 1 (Fig. 1) .", [["b-unsaturatedg-lactone", "CHEMICAL", 71, 93], ["exo-methylene-g-lactone", "CHEMICAL", 149, 172], ["b-unsaturatedg-lactone", "CHEMICAL", 71, 93], ["exo-methylene-g-lactone", "CHEMICAL", 149, 172], ["b-unsaturatedg-lactone", "SIMPLE_CHEMICAL", 71, 93], ["exo-methylene-g-lactone", "SIMPLE_CHEMICAL", 149, 172], ["this enzyme", "TEST", 18, 29], ["unsaturatedg-lactone ring system", "TREATMENT", 73, 105], ["the intact exo-methylene-g-lactone group", "TREATMENT", 138, 178]]], ["Thus, the antia-glucosidase activity of enhydrin could be derived from this interaction.", [["enhydrin", "CHEMICAL", 40, 48], ["enhydrin", "CHEMICAL", 40, 48], ["antia-glucosidase", "GENE_OR_GENE_PRODUCT", 10, 27], ["enhydrin", "SIMPLE_CHEMICAL", 40, 48], ["enhydrin", "PROTEIN", 40, 48], ["enhydrin", "TREATMENT", 40, 48]]], ["In addition, the alkylation of nucleophilic sites of factors involved in early stages of the inflammatory cascade described above allows to relate the anti-inflammatory properties reported for 1 with the presence of the exo-methylene-g-lactone ring system (Feltenstein et al., 2004; Ma et al., 2007) .SLns isolated from medicinal plants and their potential role for MetS treatmentRegarding toxicological studies, it has been reported that a single oral administration of enhydrin (1) at doses of 1.6, 4 and 8 mg/kg body weight (b.w.) did not caused deaths or acute toxic effects within 7 days in male and female rats (Genta et al., 2010) .", [["oral", "ANATOMY", 448, 452], ["body", "ANATOMY", 515, 519], ["exo-methylene-g-lactone", "CHEMICAL", 220, 243], ["SLns", "CHEMICAL", 301, 305], ["MetS", "DISEASE", 366, 370], ["enhydrin", "CHEMICAL", 471, 479], ["deaths", "DISEASE", 549, 555], ["exo-methylene-g-lactone", "CHEMICAL", 220, 243], ["enhydrin", "CHEMICAL", 471, 479], ["exo-methylene-g-lactone", "SIMPLE_CHEMICAL", 220, 243], ["SLns", "GENE_OR_GENE_PRODUCT", 301, 305], ["oral", "ORGANISM_SUBDIVISION", 448, 452], ["enhydrin", "SIMPLE_CHEMICAL", 471, 479], ["body", "ORGANISM_SUBDIVISION", 515, 519], ["rats", "ORGANISM", 612, 616], ["SLns", "PROTEIN", 301, 305], ["rats", "SPECIES", 612, 616], ["the alkylation of nucleophilic sites", "TREATMENT", 13, 49], ["the inflammatory cascade", "PROBLEM", 89, 113], ["the exo-methylene-g-lactone ring system", "TREATMENT", 216, 255], ["SLns", "TREATMENT", 301, 305], ["medicinal plants", "TREATMENT", 320, 336], ["MetS treatment", "TREATMENT", 366, 380], ["toxicological studies", "TEST", 390, 411], ["a single oral administration of enhydrin", "TREATMENT", 439, 479], ["acute toxic effects", "PROBLEM", 559, 578], ["nucleophilic sites", "OBSERVATION", 31, 49], ["early stages", "OBSERVATION_MODIFIER", 73, 85], ["inflammatory", "OBSERVATION", 93, 105], ["medicinal plants", "OBSERVATION", 320, 336], ["acute", "OBSERVATION_MODIFIER", 559, 564], ["toxic", "OBSERVATION_MODIFIER", 565, 570]]], ["In acute study in rats, there were no deaths or signs of toxicity observed after single oral administration of 1 at any dose level up to the highest dose tested (0.32 g/kg b.w.) within 14 days.", [["oral", "ANATOMY", 88, 92], ["deaths", "DISEASE", 38, 44], ["toxicity", "DISEASE", 57, 65], ["rats", "ORGANISM", 18, 22], ["oral", "ORGANISM_SUBDIVISION", 88, 92], ["rats", "SPECIES", 18, 22], ["acute study", "TEST", 3, 14], ["deaths", "PROBLEM", 38, 44], ["toxicity", "PROBLEM", 57, 65], ["single oral administration", "TREATMENT", 81, 107], ["acute", "OBSERVATION_MODIFIER", 3, 8], ["no", "UNCERTAINTY", 35, 37]]], ["In subchronic studies, after oral administration for 90 days at daily doses of 0.4, 0.8 and 8.0 mg/ kg b.w., did not caused hematological, biochemical and histological alterations in rats (Serra et al., 2012) .Polymatin A from Smallanthus macroscyphus (Baker ex Baker) A. GrauSmallanthus macroscyphus (Heliantheae, Asteraceae), is a perennial herb commonly known as ''wild yacon'' native from the South American region comprising from southern Bolivia to northwestern Argentina.", [["oral", "ANATOMY", 29, 33], ["Polymatin A", "CHEMICAL", 210, 221], ["oral", "ORGANISM_SUBDIVISION", 29, 33], ["rats", "ORGANISM", 183, 187], ["Polymatin A", "SIMPLE_CHEMICAL", 210, 221], ["Smallanthus macroscyphus", "ORGANISM", 227, 251], ["Baker ex Baker)", "ORGANISM", 253, 268], ["A. GrauSmallanthus macroscyphus", "ORGANISM", 269, 300], ["Heliantheae, Asteraceae", "ORGANISM", 302, 325], ["rats", "SPECIES", 183, 187], ["Smallanthus macroscyphus", "SPECIES", 227, 251], ["A.", "SPECIES", 269, 271], ["GrauSmallanthus macroscyphus", "SPECIES", 272, 300], ["Smallanthus macroscyphus (Baker ex Baker)", "SPECIES", 227, 268], ["GrauSmallanthus macroscyphus", "SPECIES", 272, 300], ["subchronic studies", "TEST", 3, 21], ["oral administration", "TREATMENT", 29, 48], ["hematological, biochemical and histological alterations in rats", "PROBLEM", 124, 187]]], ["This species is closely related to S. sonchifolius and possibly with similar antidiabetic properties.", [["S. sonchifolius", "ORGANISM", 35, 50], ["S. sonchifolius", "SPECIES", 35, 50], ["S. sonchifolius", "SPECIES", 35, 50], ["This species", "PROBLEM", 0, 12], ["S. sonchifolius", "PROBLEM", 35, 50]]], ["Polymatin A (2) is the main sesquiterpene lactone isolated from S. macroscyphus (De Pedro et al., 2003) .", [["Polymatin A (2) is the main sesquiterpene lactone", "CHEMICAL", 0, 49], ["Polymatin A", "CHEMICAL", 0, 11], ["sesquiterpene lactone", "CHEMICAL", 28, 49], ["Polymatin A (2)", "SIMPLE_CHEMICAL", 0, 15], ["sesquiterpene lactone", "SIMPLE_CHEMICAL", 28, 49], ["S. macroscyphus", "ORGANISM", 64, 79], ["S. macroscyphus", "SPECIES", 64, 79], ["S. macroscyphus", "SPECIES", 64, 79], ["the main sesquiterpene lactone", "TEST", 19, 49]]], ["This melampolide exerts an effective inhibition of post-prandial blood glucose peak and hypoglycemic activity in STZ-diabetic rats probably by the stimulation of insulin release or due to an insulin-like effect (Serra-Barcellona et al., 2014) .", [["blood", "ANATOMY", 65, 70], ["melampolide", "CHEMICAL", 5, 16], ["glucose", "CHEMICAL", 71, 78], ["hypoglycemic", "DISEASE", 88, 100], ["STZ", "CHEMICAL", 113, 116], ["diabetic", "DISEASE", 117, 125], ["melampolide", "CHEMICAL", 5, 16], ["glucose", "CHEMICAL", 71, 78], ["STZ", "CHEMICAL", 113, 116], ["melampolide", "SIMPLE_CHEMICAL", 5, 16], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["glucose", "SIMPLE_CHEMICAL", 71, 78], ["STZ", "SIMPLE_CHEMICAL", 113, 116], ["rats", "ORGANISM", 126, 130], ["insulin", "GENE_OR_GENE_PRODUCT", 162, 169], ["insulin", "GENE_OR_GENE_PRODUCT", 191, 198], ["rats", "SPECIES", 126, 130], ["post-prandial blood glucose peak", "PROBLEM", 51, 83], ["hypoglycemic activity", "PROBLEM", 88, 109], ["diabetic rats", "PROBLEM", 117, 130], ["insulin release", "TREATMENT", 162, 177], ["an insulin", "TREATMENT", 188, 198], ["effective", "OBSERVATION_MODIFIER", 27, 36], ["hypoglycemic activity", "OBSERVATION", 88, 109]]], ["Due to the close relationship in the polymatin A (2) and enhydrin (1) structures, the melampolide 2 could be effective in the management of postprandial hyperglycemia through inhibition of a-glucosidase.", [["melampolide 2", "CHEMICAL", 86, 99], ["hyperglycemia", "DISEASE", 153, 166], ["polymatin A (2)", "CHEMICAL", 37, 52], ["enhydrin", "CHEMICAL", 57, 65], ["melampolide 2", "CHEMICAL", 86, 99], ["polymatin A (2)", "SIMPLE_CHEMICAL", 37, 52], ["enhydrin (1) structures", "SIMPLE_CHEMICAL", 57, 80], ["melampolide 2", "SIMPLE_CHEMICAL", 86, 99], ["a-glucosidase", "GENE_OR_GENE_PRODUCT", 189, 202], ["a-glucosidase", "PROTEIN", 189, 202], ["enhydrin (1) structures", "TREATMENT", 57, 80], ["the melampolide 2", "TREATMENT", 82, 99], ["postprandial hyperglycemia", "PROBLEM", 140, 166], ["inhibition of a-glucosidase", "TREATMENT", 175, 202], ["postprandial hyperglycemia", "OBSERVATION", 140, 166]]], ["However, no studies of these effects were found.Polymatin A from Smallanthus macroscyphus (Baker ex Baker) A. GrauIn contrast to the C4\u00c0C5 epoxy group in enhydrin (1), polymatin A (2) presents a double bond (Fig. 1 ).", [["Polymatin A", "CHEMICAL", 48, 59], ["enhydrin", "CHEMICAL", 154, 162], ["polymatin A", "CHEMICAL", 168, 179], ["Polymatin A", "CHEMICAL", 48, 59], ["C4\u00c0C5", "CHEMICAL", 133, 138], ["epoxy", "CHEMICAL", 139, 144], ["enhydrin", "CHEMICAL", 154, 162], ["polymatin A", "CHEMICAL", 168, 179], ["Polymatin A", "SIMPLE_CHEMICAL", 48, 59], ["Smallanthus macroscyphus", "ORGANISM", 65, 89], ["enhydrin (1)", "SIMPLE_CHEMICAL", 154, 166], ["polymatin A (2)", "SIMPLE_CHEMICAL", 168, 183], ["Smallanthus macroscyphus", "SPECIES", 65, 89], ["Smallanthus macroscyphus (Baker ex Baker)", "SPECIES", 65, 106], ["a double bond (Fig.", "TREATMENT", 193, 212]]], ["C4\u00c0C5 epoxy groups in melampolides such as enhydrin have been reported to hinder the ability of these compounds to inhibit NF-kB DNA binding responsible to cytokines expression (Schorr et al., 2007) commonly observed in inflammatory response.", [["C4\u00c0C5 epoxy", "CHEMICAL", 0, 11], ["melampolides", "CHEMICAL", 22, 34], ["enhydrin", "CHEMICAL", 43, 51], ["epoxy", "CHEMICAL", 6, 11], ["melampolides", "CHEMICAL", 22, 34], ["enhydrin", "CHEMICAL", 43, 51], ["C4\u00c0C5", "SIMPLE_CHEMICAL", 0, 5], ["melampolides", "SIMPLE_CHEMICAL", 22, 34], ["enhydrin", "SIMPLE_CHEMICAL", 43, 51], ["NF-kB", "GENE_OR_GENE_PRODUCT", 123, 128], ["DNA", "CELLULAR_COMPONENT", 129, 132], ["NF-kB", "PROTEIN", 123, 128], ["cytokines", "PROTEIN", 156, 165], ["enhydrin", "TREATMENT", 43, 51], ["kB DNA binding", "PROBLEM", 126, 140], ["inflammatory response", "PROBLEM", 220, 241], ["inflammatory response", "OBSERVATION", 220, 241]]], ["Conversely, the effect is favored by the presence of a double bond between C-4\u00c0C-5 in other melampolides (Schorr et al., 2007) .", [["C-4\u00c0C-5", "CHEMICAL", 75, 82], ["melampolides", "CHEMICAL", 92, 104], ["C-4\u00c0C-5", "SIMPLE_CHEMICAL", 75, 82], ["melampolides", "SIMPLE_CHEMICAL", 92, 104], ["a double bond between C", "TEST", 53, 76]]], ["Hence, hopeful results could be expected in future studies to explore anti-inflammatory activity in polymatin A.Polymatin A from Smallanthus macroscyphus (Baker ex Baker) A. GrauAcute oral toxicity of polymatin A (2) in normal healthy rats at doses assayed (0.7, 1.4 and 2.8 g dried powder/kg b.w.) do not produced deaths or acute toxic effect (changes in behavior or posture, presence of convulsions or occurrence of secretions) within 14 days.", [["oral", "ANATOMY", 184, 188], ["secretions", "ANATOMY", 418, 428], ["polymatin A.Polymatin A", "CHEMICAL", 100, 123], ["toxicity", "DISEASE", 189, 197], ["polymatin A (2)", "CHEMICAL", 201, 216], ["deaths", "DISEASE", 315, 321], ["convulsions", "DISEASE", 389, 400], ["polymatin A.Polymatin A", "CHEMICAL", 100, 123], ["polymatin A (2)", "CHEMICAL", 201, 216], ["polymatin A.Polymatin A", "SIMPLE_CHEMICAL", 100, 123], ["Smallanthus macroscyphus", "ORGANISM", 129, 153], ["Baker ex Baker", "ORGANISM", 155, 169], ["oral", "ORGANISM_SUBDIVISION", 184, 188], ["polymatin A", "SIMPLE_CHEMICAL", 201, 212], ["rats", "ORGANISM", 235, 239], ["Smallanthus macroscyphus", "SPECIES", 129, 153], ["rats", "SPECIES", 235, 239], ["Smallanthus macroscyphus", "SPECIES", 129, 153], ["future studies", "TEST", 44, 58], ["anti-inflammatory activity", "PROBLEM", 70, 96], ["acute toxic effect", "PROBLEM", 325, 343], ["convulsions", "PROBLEM", 389, 400], ["secretions", "PROBLEM", 418, 428], ["acute", "OBSERVATION_MODIFIER", 325, 330], ["toxic", "OBSERVATION_MODIFIER", 331, 336]]], ["The doses were well tolerated and did not produce adverse nutritional effect.", [["adverse nutritional effect", "PROBLEM", 50, 76]]], ["No gastrointestinal symptom such as diarrhea or constipation were observed at the doses assayed.", [["gastrointestinal", "ANATOMY", 3, 19], ["diarrhea", "DISEASE", 36, 44], ["constipation", "DISEASE", 48, 60], ["gastrointestinal", "ORGAN", 3, 19], ["gastrointestinal symptom", "PROBLEM", 3, 27], ["diarrhea", "PROBLEM", 36, 44], ["constipation", "PROBLEM", 48, 60], ["gastrointestinal", "ANATOMY", 3, 19], ["symptom", "OBSERVATION", 20, 27]]], ["Volume, pH and urine specific gravity were within normal ranges.", [["urine", "ANATOMY", 15, 20], ["urine", "ORGANISM_SUBSTANCE", 15, 20], ["Volume", "TEST", 0, 6], ["pH", "TEST", 8, 10], ["urine specific gravity", "TEST", 15, 37], ["normal ranges", "OBSERVATION", 50, 63]]], ["No nitrites, protein or blood were detected in the urine samples of the animal groups treated (Serra-Barcellona et al., 2014) .Polymatin A from Smallanthus macroscyphus (Baker ex Baker) A. GrauIn subchronic studies, polymatin A (2) was orally administered to Wistar rats for 90 days at daily doses of 7, 14 and 28 mg/kg b.w.", [["blood", "ANATOMY", 24, 29], ["urine samples", "ANATOMY", 51, 64], ["nitrites", "CHEMICAL", 3, 11], ["Polymatin A", "CHEMICAL", 127, 138], ["polymatin A (2)", "CHEMICAL", 216, 231], ["nitrites", "CHEMICAL", 3, 11], ["Polymatin A", "CHEMICAL", 127, 138], ["polymatin A", "CHEMICAL", 216, 227], ["nitrites", "SIMPLE_CHEMICAL", 3, 11], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["urine samples", "ORGANISM_SUBSTANCE", 51, 64], ["Polymatin A", "SIMPLE_CHEMICAL", 127, 138], ["Smallanthus macroscyphus", "ORGANISM", 144, 168], ["Baker ex Baker", "ORGANISM", 170, 184], ["polymatin A (2)", "SIMPLE_CHEMICAL", 216, 231], ["Wistar rats", "ORGANISM", 259, 270], ["Smallanthus macroscyphus", "SPECIES", 144, 168], ["rats", "SPECIES", 266, 270], ["Smallanthus macroscyphus", "SPECIES", 144, 168], ["nitrites", "PROBLEM", 3, 11], ["blood", "PROBLEM", 24, 29], ["the urine samples", "TEST", 47, 64], ["nitrites", "OBSERVATION", 3, 11], ["blood", "ANATOMY", 24, 29]]], ["No toxicity signs or deaths were observed.", [["toxicity", "DISEASE", 3, 11], ["deaths", "DISEASE", 21, 27], ["toxicity signs", "PROBLEM", 3, 17], ["deaths", "PROBLEM", 21, 27], ["toxicity", "OBSERVATION", 3, 11]]], ["There were no changes in the behavior, body or organ weights, hematological, biochemical or urine parameters of the rats.", [["body", "ANATOMY", 39, 43], ["organ", "ANATOMY", 47, 52], ["urine", "ANATOMY", 92, 97], ["body", "ORGANISM_SUBDIVISION", 39, 43], ["organ", "ORGAN", 47, 52], ["urine", "ORGANISM_SUBSTANCE", 92, 97], ["rats", "ORGANISM", 116, 120], ["rats", "SPECIES", 116, 120], ["changes in the behavior", "PROBLEM", 14, 37], ["organ weights", "TEST", 47, 60], ["urine parameters", "TEST", 92, 108], ["no", "UNCERTAINTY", 11, 13], ["changes", "OBSERVATION_MODIFIER", 14, 21]]], ["No histopathological lesions were observed in the examined organs.", [["lesions", "ANATOMY", 21, 28], ["organs", "ANATOMY", 59, 65], ["lesions", "PATHOLOGICAL_FORMATION", 21, 28], ["organs", "ORGAN", 59, 65], ["histopathological lesions", "PROBLEM", 3, 28], ["histopathological", "OBSERVATION_MODIFIER", 3, 20], ["lesions", "OBSERVATION", 21, 28], ["organs", "ANATOMY", 59, 65]]], ["The results indicate that polymatin A (2) from S. macroscyphus leaves may be considered as nontoxic substance at a wide range of doses (Serra-Barcellona., 2016) .20-dehydroeucannabinolide from Helianthus annuus LinnThe common sunflower, Helianthus annuus Linn (Asteraceae), is a well-known plant with edible seeds, flower petals and tender leaf petioles.", [["leaves", "ANATOMY", 63, 69], ["seeds", "ANATOMY", 308, 313], ["petals", "ANATOMY", 322, 328], ["leaf petioles", "ANATOMY", 340, 353], ["polymatin A (2)", "CHEMICAL", 26, 41], [".20-dehydroeucannabinolide", "CHEMICAL", 161, 187], ["polymatin A", "CHEMICAL", 26, 37], [".20-dehydroeucannabinolide", "CHEMICAL", 161, 187], ["polymatin A (2)", "SIMPLE_CHEMICAL", 26, 41], ["S. macroscyphus leaves", "ORGANISM", 47, 69], [".20-dehydroeucannabinolide", "SIMPLE_CHEMICAL", 161, 187], ["Helianthus annuus", "ORGANISM", 193, 210], ["LinnThe", "ORGANISM", 211, 218], ["sunflower", "ORGANISM_SUBDIVISION", 226, 235], ["Helianthus annuus Linn", "ORGANISM", 237, 259], ["seeds", "ORGANISM_SUBDIVISION", 308, 313], ["flower petals", "MULTI-TISSUE_STRUCTURE", 315, 328], ["leaf petioles", "MULTI-TISSUE_STRUCTURE", 340, 353], ["S. macroscyphus", "SPECIES", 47, 62], ["Helianthus annuus", "SPECIES", 193, 210], ["sunflower", "SPECIES", 226, 235], ["Helianthus annuus", "SPECIES", 237, 254], ["S. macroscyphus", "SPECIES", 47, 62], ["Helianthus annuus", "SPECIES", 193, 210], ["Helianthus annuus", "SPECIES", 237, 254], ["polymatin A", "PROBLEM", 26, 37], ["S. macroscyphus leaves", "PROBLEM", 47, 69], ["nontoxic substance", "PROBLEM", 91, 109], ["edible seeds", "TREATMENT", 301, 313], ["edible seeds", "OBSERVATION", 301, 313], ["flower petals", "OBSERVATION", 315, 328], ["tender", "OBSERVATION_MODIFIER", 333, 339], ["leaf petioles", "OBSERVATION", 340, 353]]], ["To provide a scientific explanation for its use in Nigerian traditional medicine, Onoja and Anaga (2014) reported a hypoglycemic effect on the fasting blood glucose level in alloxan-induced diabetic rats after a single dose of the methanolic extract of H. annuus leaves.", [["blood", "ANATOMY", 151, 156], ["leaves", "ANATOMY", 263, 269], ["hypoglycemic", "DISEASE", 116, 128], ["glucose", "CHEMICAL", 157, 164], ["alloxan", "CHEMICAL", 174, 181], ["diabetic", "DISEASE", 190, 198], ["glucose", "CHEMICAL", 157, 164], ["alloxan", "CHEMICAL", 174, 181], ["blood", "ORGANISM_SUBSTANCE", 151, 156], ["glucose", "SIMPLE_CHEMICAL", 157, 164], ["alloxan", "SIMPLE_CHEMICAL", 174, 181], ["rats", "ORGANISM", 199, 203], ["H. annuus", "ORGANISM", 253, 262], ["leaves", "ORGANISM", 263, 269], ["rats", "SPECIES", 199, 203], ["H. annuus", "SPECIES", 253, 262], ["H. annuus", "SPECIES", 253, 262], ["a hypoglycemic effect", "PROBLEM", 114, 135], ["the fasting blood glucose level", "TEST", 139, 170], ["alloxan-induced diabetic rats", "TREATMENT", 174, 203], ["the methanolic extract", "TREATMENT", 227, 249]]], ["This study led to the recent isolation of the heliangolide 20-dehydroeucannabinolide (3) (Fig. 1) .", [["heliangolide 20-dehydroeucannabinolide", "CHEMICAL", 46, 84], ["heliangolide 20-dehydroeucannabinolide", "CHEMICAL", 46, 84], ["heliangolide 20-dehydroeucannabinolide (3)", "SIMPLE_CHEMICAL", 46, 88], ["This study", "TEST", 0, 10], ["the heliangolide", "TREATMENT", 42, 58]]], ["Heliangolide SLns represent an isomeric form of germacranolides with a cyclodecadiene skeleton and double bonds at C1=C10 and C4=C5, which stereochemical configurations are trans, cis respectively (S\u20ac ulsen and Martino, 2018).", [["Heliangolide", "CHEMICAL", 0, 12], ["germacranolides", "CHEMICAL", 48, 63], ["cyclodecadiene", "CHEMICAL", 71, 85], ["Heliangolide SLns", "CHEMICAL", 0, 17], ["germacranolides", "CHEMICAL", 48, 63], ["cyclodecadiene", "CHEMICAL", 71, 85], ["C4=C5", "CHEMICAL", 126, 131], ["Heliangolide SLns", "SIMPLE_CHEMICAL", 0, 17], ["germacranolides", "SIMPLE_CHEMICAL", 48, 63], ["cyclodecadiene", "SIMPLE_CHEMICAL", 71, 85], ["C1=C10", "SIMPLE_CHEMICAL", 115, 121], ["C4=C5", "SIMPLE_CHEMICAL", 126, 131], ["Heliangolide SLns", "TREATMENT", 0, 17], ["a cyclodecadiene skeleton", "TEST", 69, 94], ["skeleton", "ANATOMY", 86, 94], ["double bonds", "OBSERVATION", 99, 111], ["C1", "ANATOMY_MODIFIER", 115, 117], ["C10", "ANATOMY_MODIFIER", 118, 121], ["C4", "ANATOMY_MODIFIER", 126, 128], ["C5", "ANATOMY_MODIFIER", 129, 131], ["stereochemical configurations", "OBSERVATION", 139, 168]]], ["The heliangolide 3 reduced the fasting blood glucose level at dose of 0.2 mmol/kg in alloxaninduced diabetic rats (Onoja et al., 2020) .", [["blood", "ANATOMY", 39, 44], ["heliangolide", "CHEMICAL", 4, 16], ["glucose", "CHEMICAL", 45, 52], ["diabetic", "DISEASE", 100, 108], ["heliangolide 3", "CHEMICAL", 4, 18], ["glucose", "CHEMICAL", 45, 52], ["heliangolide 3", "GENE_OR_GENE_PRODUCT", 4, 18], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["glucose", "SIMPLE_CHEMICAL", 45, 52], ["rats", "ORGANISM", 109, 113], ["rats", "SPECIES", 109, 113], ["The heliangolide", "TREATMENT", 0, 16], ["the fasting blood glucose level", "TEST", 27, 58]]], ["The authors suggested that this sesquiterpene lactone might have reducing effects in glucose absorption based on the heliangolide derivative structure, which presents an intact exo-methylene-g-lactone group.", [["sesquiterpene lactone", "CHEMICAL", 32, 53], ["glucose", "CHEMICAL", 85, 92], ["heliangolide", "CHEMICAL", 117, 129], ["exo-methylene-g-lactone", "CHEMICAL", 177, 200], ["sesquiterpene lactone", "CHEMICAL", 32, 53], ["glucose", "CHEMICAL", 85, 92], ["heliangolide", "CHEMICAL", 117, 129], ["exo-methylene-g-lactone", "CHEMICAL", 177, 200], ["sesquiterpene lactone", "SIMPLE_CHEMICAL", 32, 53], ["glucose", "SIMPLE_CHEMICAL", 85, 92], ["heliangolide", "SIMPLE_CHEMICAL", 117, 129], ["exo-methylene-g-lactone", "SIMPLE_CHEMICAL", 177, 200], ["this sesquiterpene lactone", "TREATMENT", 27, 53], ["glucose absorption", "PROBLEM", 85, 103], ["the heliangolide derivative structure", "PROBLEM", 113, 150], ["intact", "OBSERVATION", 170, 176]]], ["As mentioned above, a,b-unsaturated g-lactone ring system has an important relation in the inhibition of a-glucosidase activity, thus the heliangolide 3 may be inhibiting this enzyme similar to enhydrin (1).20-dehydroeucannabinolide from Helianthus annuus LinnIn addition to blood glucose regulation, it has also been demonstrated the positive effects of hydromethanolic leaf extract of H. annuus L. on other components of MetS, including reduced LDL-C and TG levels as well as hepatoprotective and antilipid peroxidation activities of alloxan-induced diabetic rats (Onoja et al., 2018) .", [["blood", "ANATOMY", 275, 280], ["unsaturated g-lactone", "CHEMICAL", 24, 45], ["heliangolide", "CHEMICAL", 138, 150], ["enhydrin", "CHEMICAL", 194, 202], ["20-dehydroeucannabinolide", "CHEMICAL", 207, 232], ["glucose", "CHEMICAL", 281, 288], ["hydromethanolic leaf extract", "CHEMICAL", 355, 383], ["MetS", "DISEASE", 423, 427], ["alloxan", "CHEMICAL", 536, 543], ["diabetic", "DISEASE", 552, 560], [",b-unsaturated g-lactone", "CHEMICAL", 21, 45], ["heliangolide 3", "CHEMICAL", 138, 152], ["enhydrin", "CHEMICAL", 194, 202], ["20-dehydroeucannabinolide", "CHEMICAL", 207, 232], ["glucose", "CHEMICAL", 281, 288], ["alloxan", "CHEMICAL", 536, 543], [",b-unsaturated g-lactone", "SIMPLE_CHEMICAL", 21, 45], ["a-glucosidase", "GENE_OR_GENE_PRODUCT", 105, 118], ["heliangolide 3", "GENE_OR_GENE_PRODUCT", 138, 152], ["enhydrin (1)", "GENE_OR_GENE_PRODUCT", 194, 206], ["20-dehydroeucannabinolide", "SIMPLE_CHEMICAL", 207, 232], ["Helianthus annuus", "ORGANISM", 238, 255], ["LinnIn", "ORGANISM", 256, 262], ["blood", "ORGANISM_SUBSTANCE", 275, 280], ["glucose", "SIMPLE_CHEMICAL", 281, 288], ["hydromethanolic leaf extract", "ORGANISM_SUBSTANCE", 355, 383], ["H. annuus L.", "ORGANISM", 387, 399], ["LDL-C", "SIMPLE_CHEMICAL", 447, 452], ["TG", "SIMPLE_CHEMICAL", 457, 459], ["antilipid", "SIMPLE_CHEMICAL", 499, 508], ["alloxan", "SIMPLE_CHEMICAL", 536, 543], ["rats", "ORGANISM", 561, 565], ["a-glucosidase", "PROTEIN", 105, 118], ["LDL", "PROTEIN", 447, 450], ["Helianthus annuus", "SPECIES", 238, 255], ["H. annuus", "SPECIES", 387, 396], ["rats", "SPECIES", 561, 565], ["Helianthus annuus", "SPECIES", 238, 255], ["H. annuus L.", "SPECIES", 387, 399], ["a,b-unsaturated g-lactone ring system", "TREATMENT", 20, 57], ["a-glucosidase activity", "TREATMENT", 105, 127], ["the heliangolide", "TREATMENT", 134, 150], ["this enzyme", "TEST", 171, 182], ["blood glucose regulation", "TEST", 275, 299], ["hydromethanolic leaf extract", "TREATMENT", 355, 383], ["H. annuus L.", "PROBLEM", 387, 399], ["MetS", "PROBLEM", 423, 427], ["LDL", "TEST", 447, 450], ["TG levels", "TEST", 457, 466], ["hepatoprotective and antilipid peroxidation activities", "TREATMENT", 478, 532], ["alloxan", "TREATMENT", 536, 543], ["positive effects", "OBSERVATION_MODIFIER", 335, 351], ["H. annuus", "OBSERVATION", 387, 396], ["MetS", "OBSERVATION", 423, 427]]], ["Since 20-dehydroeucannabinolide (3) is one of the major components of the extract, potential activity of this molecule in managing dyslipidemia may be proposed.", [["extract", "ANATOMY", 74, 81], ["20-dehydroeucannabinolide", "CHEMICAL", 6, 31], ["dyslipidemia", "DISEASE", 131, 143], ["20-dehydroeucannabinolide", "CHEMICAL", 6, 31], ["20-dehydroeucannabinolide (3)", "SIMPLE_CHEMICAL", 6, 35], ["this molecule", "PROBLEM", 105, 118], ["managing dyslipidemia", "PROBLEM", 122, 143], ["activity", "OBSERVATION_MODIFIER", 93, 101]]], ["However, additional studies are needed to ascertain the hypolipidemic property of this compound.20-dehydroeucannabinolide from Helianthus annuus LinnNo in vivo toxicity studies on 20-dehydroeucannabinolide (3) have been reported to date.Costunolide and eremanthin from Costus speciosus (J. Koenig) SmCostus speciosus (J. Koenig) Sm is a plant used in traditional medicine in South Asia to treat diabetic patients by eating one leaf of this species per day to regulate blood glucose levels (Waisundara et al., 2015) .", [["leaf", "ANATOMY", 427, 431], ["blood", "ANATOMY", 468, 473], ["20-dehydroeucannabinolide", "CHEMICAL", 96, 121], ["toxicity", "DISEASE", 160, 168], ["20-dehydroeucannabinolide", "CHEMICAL", 180, 205], ["Costunolide", "CHEMICAL", 237, 248], ["eremanthin", "CHEMICAL", 253, 263], ["diabetic", "DISEASE", 395, 403], ["glucose", "CHEMICAL", 474, 481], ["20-dehydroeucannabinolide", "CHEMICAL", 96, 121], ["20-dehydroeucannabinolide", "CHEMICAL", 180, 205], ["Costunolide", "CHEMICAL", 237, 248], ["eremanthin", "CHEMICAL", 253, 263], ["glucose", "CHEMICAL", 474, 481], ["20-dehydroeucannabinolide", "SIMPLE_CHEMICAL", 96, 121], ["Helianthus annuus", "ORGANISM", 127, 144], ["LinnNo", "ORGANISM", 145, 151], ["20-dehydroeucannabinolide", "SIMPLE_CHEMICAL", 180, 205], ["Costunolide", "SIMPLE_CHEMICAL", 237, 248], ["eremanthin", "SIMPLE_CHEMICAL", 253, 263], ["Costus speciosus", "ORGANISM", 269, 285], ["J. Koenig", "ORGANISM", 287, 296], ["SmCostus speciosus", "ORGANISM", 298, 316], ["Sm", "GENE_OR_GENE_PRODUCT", 329, 331], ["patients", "ORGANISM", 404, 412], ["leaf", "ORGAN", 427, 431], ["blood", "ORGANISM_SUBSTANCE", 468, 473], ["glucose", "SIMPLE_CHEMICAL", 474, 481], ["Sm", "PROTEIN", 329, 331], ["Helianthus annuus", "SPECIES", 127, 144], ["Costus speciosus", "SPECIES", 269, 285], ["SmCostus speciosus", "SPECIES", 298, 316], ["patients", "SPECIES", 404, 412], ["Helianthus annuus", "SPECIES", 127, 144], ["Costus speciosus", "SPECIES", 269, 285], ["SmCostus speciosus", "SPECIES", 298, 316], ["additional studies", "TEST", 9, 27], ["dehydroeucannabinolide", "TREATMENT", 99, 121], ["Helianthus annuus LinnNo", "TREATMENT", 127, 151], ["vivo toxicity studies", "TEST", 155, 176], ["Costunolide", "TREATMENT", 237, 248], ["traditional medicine", "TREATMENT", 351, 371], ["diabetic patients", "PROBLEM", 395, 412], ["blood glucose levels", "TEST", 468, 488]]], ["Also, the hypoglycemic effect of C. speciosus root crude extracts have been reported (Daisy et al., 2008) .", [["extracts", "ANATOMY", 57, 65], ["hypoglycemic", "DISEASE", 10, 22], ["C. speciosus root", "ORGANISM", 33, 50], ["extracts", "ORGANISM_SUBSTANCE", 57, 65], ["C. speciosus", "SPECIES", 33, 45], ["C. speciosus", "SPECIES", 33, 45], ["the hypoglycemic effect", "PROBLEM", 6, 29], ["C. speciosus root crude extracts", "PROBLEM", 33, 65], ["hypoglycemic effect", "OBSERVATION", 10, 29]]], ["Eremanthin (4) (Fig. 1) is a guaianolide sesquiterpene lactone present in C. speciosus and other plants such as Pterodon pubescens (Benth.)", [["Eremanthin", "CHEMICAL", 0, 10], ["guaianolide sesquiterpene lactone", "CHEMICAL", 29, 62], ["Eremanthin", "CHEMICAL", 0, 10], ["guaianolide sesquiterpene lactone", "CHEMICAL", 29, 62], ["Eremanthin (4)", "SIMPLE_CHEMICAL", 0, 14], ["Fig. 1)", "SIMPLE_CHEMICAL", 16, 23], ["guaianolide sesquiterpene lactone", "SIMPLE_CHEMICAL", 29, 62], ["C. speciosus", "ORGANISM", 74, 86], ["Pterodon pubescens", "ORGANISM", 112, 130], ["C. speciosus", "SPECIES", 74, 86], ["Pterodon pubescens", "SPECIES", 112, 130], ["C. speciosus", "SPECIES", 74, 86], ["Pterodon pubescens", "SPECIES", 112, 130], ["a guaianolide sesquiterpene lactone", "TREATMENT", 27, 62], ["C. speciosus", "PROBLEM", 74, 86]]], ["Benth., Eremanthus elaeagnus (Mart. ex DC.)", [["Eremanthus elaeagnus", "ORGANISM", 8, 28], ["Eremanthus elaeagnus", "SPECIES", 8, 28], ["Eremanthus elaeagnus", "SPECIES", 8, 28]]], ["Sch.Bip. and Laurus nobilis L. (Eliza et al., 2009a; Waisundara et al., 2015) .", [["Sch", "CHEMICAL", 0, 3], ["Laurus nobilis", "ORGANISM", 13, 27], ["L.", "ORGANISM", 28, 30], ["Laurus nobilis L.", "SPECIES", 13, 30], ["Laurus nobilis L.", "SPECIES", 13, 30], ["Sch", "TREATMENT", 0, 3], ["Laurus nobilis", "ANATOMY", 13, 27]]], ["Another sesquiterpene lactone reported to be present in C. speciosus is the germacrolide (a trans, trans-germacranolide) costunolide (5) (Fig. 1) (Eliza et al., 2009b) , which has been also isolated from Magnolia spp, Laurus nobilis and Saussurea costus (Falc.)", [["sesquiterpene lactone", "CHEMICAL", 8, 29], ["germacrolide", "CHEMICAL", 76, 88], ["trans, trans-germacranolide", "CHEMICAL", 92, 119], ["costunolide", "CHEMICAL", 121, 132], ["sesquiterpene lactone", "CHEMICAL", 8, 29], ["germacrolide", "CHEMICAL", 76, 88], ["trans, trans-germacranolide", "CHEMICAL", 92, 119], ["costunolide", "CHEMICAL", 121, 132], ["sesquiterpene lactone", "SIMPLE_CHEMICAL", 8, 29], ["C. speciosus", "ORGANISM", 56, 68], ["germacrolide", "SIMPLE_CHEMICAL", 76, 88], ["trans-germacranolide", "SIMPLE_CHEMICAL", 99, 119], ["costunolide", "SIMPLE_CHEMICAL", 121, 132], ["Magnolia spp", "ORGANISM", 204, 216], ["Laurus nobilis", "ORGANISM", 218, 232], ["Saussurea costus", "ORGANISM", 237, 253], ["C. speciosus", "SPECIES", 56, 68], ["Magnolia spp", "SPECIES", 204, 216], ["Laurus nobilis", "SPECIES", 218, 232], ["Saussurea costus", "SPECIES", 237, 253], ["C. speciosus", "SPECIES", 56, 68], ["Magnolia spp", "SPECIES", 204, 216], ["Laurus nobilis", "SPECIES", 218, 232], ["Saussurea costus", "SPECIES", 237, 253], ["Another sesquiterpene lactone", "TEST", 0, 29], ["the germacrolide (a trans, trans-germacranolide) costunolide", "TREATMENT", 72, 132], ["Magnolia spp", "TEST", 204, 216], ["Laurus nobilis", "PROBLEM", 218, 232], ["nobilis", "ANATOMY", 225, 232]]], ["Lipsch (Koo et al., 2001) .Costunolide and eremanthin from Costus speciosus (J. Koenig) SmStudies in STZ-induced diabetic rats showed that oral administration of 4 and 5 decreased plasma glucose level, glycosylated hemoglobin (HbA1c), total cholesterol (TC), TG, LDL-C and at the same time markedly increased plasma insulin, tissue glycogen and HDL-C (Eliza et al., 2009a (Eliza et al., , 2009b .", [["oral", "ANATOMY", 139, 143], ["plasma", "ANATOMY", 180, 186], ["plasma", "ANATOMY", 309, 315], ["tissue", "ANATOMY", 325, 331], ["Costunolide", "CHEMICAL", 27, 38], ["eremanthin", "CHEMICAL", 43, 53], ["STZ", "CHEMICAL", 101, 104], ["diabetic", "DISEASE", 113, 121], ["glucose", "CHEMICAL", 187, 194], ["cholesterol", "CHEMICAL", 241, 252], ["Costunolide", "CHEMICAL", 27, 38], ["eremanthin", "CHEMICAL", 43, 53], ["STZ", "CHEMICAL", 101, 104], ["glucose", "CHEMICAL", 187, 194], ["cholesterol", "CHEMICAL", 241, 252], ["Costunolide", "SIMPLE_CHEMICAL", 27, 38], ["eremanthin", "SIMPLE_CHEMICAL", 43, 53], ["Costus speciosus", "ORGANISM", 59, 75], ["STZ", "SIMPLE_CHEMICAL", 101, 104], ["rats", "ORGANISM", 122, 126], ["oral", "ORGANISM_SUBDIVISION", 139, 143], ["plasma", "ORGANISM_SUBSTANCE", 180, 186], ["glucose", "SIMPLE_CHEMICAL", 187, 194], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 215, 225], ["HbA1c", "SIMPLE_CHEMICAL", 227, 232], ["cholesterol", "SIMPLE_CHEMICAL", 241, 252], ["TC", "SIMPLE_CHEMICAL", 254, 256], ["TG", "SIMPLE_CHEMICAL", 259, 261], ["LDL-C", "SIMPLE_CHEMICAL", 263, 268], ["plasma", "ORGANISM_SUBSTANCE", 309, 315], ["insulin", "GENE_OR_GENE_PRODUCT", 316, 323], ["tissue", "TISSUE", 325, 331], ["glycogen", "SIMPLE_CHEMICAL", 332, 340], ["HDL-C", "SIMPLE_CHEMICAL", 345, 350], ["glycosylated hemoglobin", "PROTEIN", 202, 225], ["HbA1c", "PROTEIN", 227, 232], ["LDL", "PROTEIN", 263, 266], ["plasma insulin", "PROTEIN", 309, 323], ["Costus speciosus", "SPECIES", 59, 75], ["rats", "SPECIES", 122, 126], ["Costus speciosus", "SPECIES", 59, 75], ["Costunolide", "TREATMENT", 27, 38], ["STZ", "TEST", 101, 104], ["diabetic rats", "PROBLEM", 113, 126], ["oral administration", "TREATMENT", 139, 158], ["plasma glucose level", "TEST", 180, 200], ["glycosylated", "TEST", 202, 214], ["hemoglobin", "TEST", 215, 225], ["HbA1c", "TEST", 227, 232], ["total cholesterol", "TEST", 235, 252], ["TC", "TEST", 254, 256], ["TG", "TEST", 259, 261], ["LDL", "TEST", 263, 266], ["C", "TEST", 267, 268], ["plasma insulin", "TREATMENT", 309, 323], ["tissue glycogen", "TEST", 325, 340], ["HDL", "TEST", 345, 348], ["increased", "OBSERVATION", 299, 308], ["plasma insulin", "OBSERVATION", 309, 323]]], ["The specific mechanism of eremanthin (4) bioactivity is not completely characterized, but the experimental model used in both works allowed the authors to suggest that this molecule might exert an insulin-like effect on peripheral tissues by either promoting glucose uptake metabolism, by inhibiting hepatic gluconeogenesis or by absorption of glucose into the muscle and adipose tissues through the stimulation of a regeneration process and revitalization of the remaining b cells (Eliza et al., 2009a (Eliza et al., , 2009b ).Costunolide and eremanthin from Costus speciosus (J. Koenig) SmIn addition, costunolide (5) has shown to suppress LPS-induced NF-kB activation that leads to the suppression of iNOS and a consequent nonproduction of NO.", [["peripheral tissues", "ANATOMY", 220, 238], ["hepatic", "ANATOMY", 300, 307], ["muscle", "ANATOMY", 361, 367], ["adipose tissues", "ANATOMY", 372, 387], ["b cells", "ANATOMY", 474, 481], ["eremanthin", "CHEMICAL", 26, 36], ["glucose", "CHEMICAL", 259, 266], ["glucose", "CHEMICAL", 344, 351], ["Costunolide", "CHEMICAL", 528, 539], ["eremanthin", "CHEMICAL", 544, 554], ["costunolide", "CHEMICAL", 604, 615], ["LPS", "CHEMICAL", 642, 645], ["NO", "CHEMICAL", 743, 745], ["eremanthin (4)", "CHEMICAL", 26, 40], ["glucose", "CHEMICAL", 259, 266], ["glucose", "CHEMICAL", 344, 351], ["Costunolide", "CHEMICAL", 528, 539], ["eremanthin", "CHEMICAL", 544, 554], ["costunolide", "CHEMICAL", 604, 615], ["NO", "CHEMICAL", 743, 745], ["eremanthin (4)", "SIMPLE_CHEMICAL", 26, 40], ["insulin", "GENE_OR_GENE_PRODUCT", 197, 204], ["peripheral tissues", "TISSUE", 220, 238], ["glucose", "SIMPLE_CHEMICAL", 259, 266], ["hepatic", "MULTI-TISSUE_STRUCTURE", 300, 307], ["glucose", "SIMPLE_CHEMICAL", 344, 351], ["muscle", "TISSUE", 361, 367], ["adipose tissues", "TISSUE", 372, 387], ["b cells", "CELL", 474, 481], ["Costunolide", "SIMPLE_CHEMICAL", 528, 539], ["eremanthin", "SIMPLE_CHEMICAL", 544, 554], ["Costus speciosus", "ORGANISM", 560, 576], ["costunolide (5)", "SIMPLE_CHEMICAL", 604, 619], ["LPS", "SIMPLE_CHEMICAL", 642, 645], ["NF-kB", "GENE_OR_GENE_PRODUCT", 654, 659], ["iNOS", "GENE_OR_GENE_PRODUCT", 704, 708], ["NO", "SIMPLE_CHEMICAL", 743, 745], ["b cells", "CELL_TYPE", 474, 481], ["NF-kB", "PROTEIN", 654, 659], ["iNOS", "PROTEIN", 704, 708], ["Costus speciosus", "SPECIES", 560, 576], ["Costus speciosus", "SPECIES", 560, 576], ["eremanthin (4) bioactivity", "PROBLEM", 26, 52], ["an insulin", "TREATMENT", 194, 204], ["peripheral tissues", "PROBLEM", 220, 238], ["promoting glucose uptake metabolism", "PROBLEM", 249, 284], ["hepatic gluconeogenesis", "PROBLEM", 300, 323], ["a regeneration process", "TREATMENT", 415, 437], ["Costunolide", "TREATMENT", 528, 539], ["LPS", "TEST", 642, 645], ["kB activation", "PROBLEM", 657, 670], ["iNOS", "PROBLEM", 704, 708], ["not completely characterized", "OBSERVATION_MODIFIER", 56, 84], ["hepatic", "ANATOMY", 300, 307], ["muscle", "ANATOMY", 361, 367], ["adipose tissues", "ANATOMY", 372, 387]]], ["This activity was stronger than the observed for parthenolide, a germacranolide sesquiterpene lactone (Koo et al., 2001) .", [["parthenolide", "CHEMICAL", 49, 61], ["germacranolide sesquiterpene lactone", "CHEMICAL", 65, 101], ["parthenolide", "CHEMICAL", 49, 61], ["germacranolide sesquiterpene lactone", "CHEMICAL", 65, 101], ["parthenolide", "SIMPLE_CHEMICAL", 49, 61], ["germacranolide sesquiterpene lactone", "SIMPLE_CHEMICAL", 65, 101], ["parthenolide", "TREATMENT", 49, 61], ["a germacranolide sesquiterpene lactone", "TREATMENT", 63, 101]]], ["Thus, the anti-inflammatory activity exhibited by 5 serve as a promising and expanding strategy for treatment of metabolic disease-associated inflammation.Costunolide and eremanthin from Costus speciosus (J. Koenig) SmOn the other hand, the possible inhibition of inflammatory processes has not been studied in eremanthin (4).", [["metabolic disease", "DISEASE", 113, 130], ["inflammation", "DISEASE", 142, 154], ["Costunolide", "CHEMICAL", 155, 166], ["eremanthin", "CHEMICAL", 171, 181], ["eremanthin", "CHEMICAL", 311, 321], ["Costunolide", "CHEMICAL", 155, 166], ["eremanthin", "CHEMICAL", 171, 181], ["eremanthin", "CHEMICAL", 311, 321], ["Costunolide", "SIMPLE_CHEMICAL", 155, 166], ["eremanthin", "SIMPLE_CHEMICAL", 171, 181], ["Costus speciosus", "ORGANISM", 187, 203], ["hand", "ORGANISM_SUBDIVISION", 231, 235], ["Costus speciosus", "SPECIES", 187, 203], ["Costus speciosus", "SPECIES", 187, 203], ["expanding strategy", "TREATMENT", 77, 95], ["metabolic disease", "PROBLEM", 113, 130], ["associated inflammation", "PROBLEM", 131, 154], ["Costunolide", "TREATMENT", 155, 166], ["inflammatory processes", "PROBLEM", 264, 286], ["anti-inflammatory activity", "OBSERVATION", 10, 36], ["metabolic disease", "OBSERVATION", 113, 130], ["inflammation", "OBSERVATION", 142, 154], ["inflammatory", "OBSERVATION", 264, 276]]], ["However, this compound has a rigid skeleton and an intact exo-methylene-g-lactone group, previously related to anti-inflammatory properties (Simonsen et al., 2013) .", [["exo-methylene-g-lactone", "CHEMICAL", 58, 81], ["exo-methylene-g-lactone", "CHEMICAL", 58, 81], ["exo-methylene-g-lactone", "SIMPLE_CHEMICAL", 58, 81], ["a rigid skeleton", "PROBLEM", 27, 43], ["an intact exo-methylene-g-lactone group", "TREATMENT", 48, 87], ["rigid skeleton", "OBSERVATION", 29, 43], ["intact", "OBSERVATION", 51, 57]]], ["Additionally, the absence of free hydroxyl groups in 4 could help to improve anti-inflammatory properties since an increasing number of free hydroxyl groups are reported to diminish NF-kB inhibition activity (Simonsen et al., 2013) .", [["hydroxyl", "CHEMICAL", 34, 42], ["hydroxyl", "CHEMICAL", 141, 149], ["hydroxyl", "CHEMICAL", 34, 42], ["hydroxyl", "CHEMICAL", 141, 149], ["NF-kB", "GENE_OR_GENE_PRODUCT", 182, 187], ["NF-kB", "PROTEIN", 182, 187], ["free hydroxyl groups", "TREATMENT", 29, 49], ["anti-inflammatory properties", "TREATMENT", 77, 105], ["free hydroxyl groups", "TREATMENT", 136, 156], ["increasing", "OBSERVATION_MODIFIER", 115, 125], ["number", "OBSERVATION_MODIFIER", 126, 132], ["free hydroxyl", "OBSERVATION", 136, 149]]], ["Taking together these structural characteristics, we suggest that eremathin (4) is a candidate to be tested for inhibition of inflammatory processes related to metabolic diseases.Costunolide and eremanthin from Costus speciosus (J. Koenig) SmAcute oral toxicity of eremanthin (4) and costunolide (5) in normal healthy male Wistar rats at doses assayed (10, 20, 40, 80 and 160 mg/kg b.w.) do not produced behavioral changes on the rats and mortality was not observed during acute toxicity test (10 days) (Eliza et al., 2010) .Costunolide and eremanthin from Costus speciosus (J. Koenig) SmFinally, the antioxidant activity of eremanthin (4) and costunolide (5) has been demonstrated by significantly decreasing of the thiobarbituric acid reactive substances (TBARS) and lipid peroxidation markers levels as well as by increasing reduced glutathione (GSH) levels and enzymatic antioxidants (Eliza et al., 2010) .", [["oral", "ANATOMY", 248, 252], ["eremathin", "CHEMICAL", 66, 75], ["metabolic diseases", "DISEASE", 160, 178], ["Costunolide", "CHEMICAL", 179, 190], ["eremanthin", "CHEMICAL", 195, 205], ["toxicity", "DISEASE", 253, 261], ["eremanthin", "CHEMICAL", 265, 275], ["costunolide", "CHEMICAL", 284, 295], ["toxicity", "DISEASE", 479, 487], ["Costunolide", "CHEMICAL", 525, 536], ["eremanthin", "CHEMICAL", 541, 551], ["eremanthin", "CHEMICAL", 625, 635], ["costunolide", "CHEMICAL", 644, 655], ["thiobarbituric acid", "CHEMICAL", 717, 736], ["TBARS", "CHEMICAL", 758, 763], ["glutathione", "CHEMICAL", 836, 847], ["GSH", "CHEMICAL", 849, 852], ["eremathin", "CHEMICAL", 66, 75], ["Costunolide", "CHEMICAL", 179, 190], ["eremanthin", "CHEMICAL", 195, 205], ["eremanthin", "CHEMICAL", 265, 275], ["costunolide", "CHEMICAL", 284, 295], ["Costunolide", "CHEMICAL", 525, 536], ["eremanthin", "CHEMICAL", 541, 551], ["eremanthin", "CHEMICAL", 625, 635], ["costunolide", "CHEMICAL", 644, 655], ["thiobarbituric acid", "CHEMICAL", 717, 736], ["reduced glutathione", "CHEMICAL", 828, 847], ["GSH", "CHEMICAL", 849, 852], ["eremathin (4)", "SIMPLE_CHEMICAL", 66, 79], ["Costunolide", "SIMPLE_CHEMICAL", 179, 190], ["eremanthin", "SIMPLE_CHEMICAL", 195, 205], ["Costus speciosus", "ORGANISM", 211, 227], ["oral", "ORGANISM_SUBDIVISION", 248, 252], ["eremanthin (4)", "SIMPLE_CHEMICAL", 265, 279], ["costunolide", "SIMPLE_CHEMICAL", 284, 295], ["Wistar rats", "ORGANISM", 323, 334], ["rats", "ORGANISM", 430, 434], ["Costunolide", "SIMPLE_CHEMICAL", 525, 536], ["eremanthin", "SIMPLE_CHEMICAL", 541, 551], ["Costus speciosus", "ORGANISM", 557, 573], ["eremanthin (4)", "SIMPLE_CHEMICAL", 625, 639], ["costunolide (5", "SIMPLE_CHEMICAL", 644, 658], ["thiobarbituric acid", "SIMPLE_CHEMICAL", 717, 736], ["TBARS", "SIMPLE_CHEMICAL", 758, 763], ["lipid", "SIMPLE_CHEMICAL", 769, 774], ["glutathione", "SIMPLE_CHEMICAL", 836, 847], ["GSH", "SIMPLE_CHEMICAL", 849, 852], ["Costus speciosus", "SPECIES", 211, 227], ["rats", "SPECIES", 330, 334], ["rats", "SPECIES", 430, 434], ["Costus speciosus", "SPECIES", 557, 573], ["Costus speciosus", "SPECIES", 211, 227], ["Costus speciosus", "SPECIES", 557, 573], ["inflammatory processes", "PROBLEM", 126, 148], ["metabolic diseases", "PROBLEM", 160, 178], ["Costunolide", "TREATMENT", 179, 190], ["behavioral changes", "PROBLEM", 404, 422], ["acute toxicity test", "PROBLEM", 473, 492], ["Costunolide", "TREATMENT", 525, 536], ["the thiobarbituric acid reactive substances", "PROBLEM", 713, 756], ["TBARS)", "TEST", 758, 764], ["lipid peroxidation markers levels", "TEST", 769, 802], ["increasing reduced glutathione (GSH) levels", "PROBLEM", 817, 860], ["inflammatory", "OBSERVATION", 126, 138], ["metabolic diseases", "OBSERVATION", 160, 178], ["significantly", "OBSERVATION_MODIFIER", 685, 698], ["decreasing", "OBSERVATION_MODIFIER", 699, 709], ["reactive substances", "OBSERVATION", 737, 756]]], ["This activity could indicate a protective effect of both on oxidative stress in diabetes.Alantolactone from Inula sppInula (Asteraceae) is one of the most popular herbs in Traditional Chinese Medicine.", [["diabetes", "DISEASE", 80, 88], ["Alantolactone", "CHEMICAL", 89, 102], ["Inula sppInula", "CHEMICAL", 108, 122], ["Alantolactone", "CHEMICAL", 89, 102], ["Alantolactone", "SIMPLE_CHEMICAL", 89, 102], ["Inula sppInula", "ORGANISM", 108, 122], ["Asteraceae", "ORGANISM", 124, 134], ["oxidative stress in diabetes", "PROBLEM", 60, 88], ["Alantolactone", "TREATMENT", 89, 102], ["Traditional Chinese Medicine", "TREATMENT", 172, 200], ["diabetes", "OBSERVATION", 80, 88], ["Inula sppInula", "OBSERVATION", 108, 122]]], ["This genus comprises more than one hundred species widely distributed throughout Asia, Africa, and Europe, and many of these have been used to treat a wide range of diseases such as bronchitis, diabetes, obesity, hypertension, and inflammation (Seca et al., 2014) .", [["bronchitis", "DISEASE", 182, 192], ["diabetes", "DISEASE", 194, 202], ["obesity", "DISEASE", 204, 211], ["hypertension", "DISEASE", 213, 225], ["inflammation", "DISEASE", 231, 243], ["a wide range of diseases", "PROBLEM", 149, 173], ["bronchitis", "PROBLEM", 182, 192], ["diabetes", "PROBLEM", 194, 202], ["obesity", "PROBLEM", 204, 211], ["hypertension", "PROBLEM", 213, 225], ["inflammation", "PROBLEM", 231, 243], ["widely", "OBSERVATION_MODIFIER", 51, 57], ["distributed", "OBSERVATION_MODIFIER", 58, 69], ["wide", "OBSERVATION_MODIFIER", 151, 155], ["diseases", "OBSERVATION", 165, 173], ["bronchitis", "OBSERVATION", 182, 192], ["diabetes", "OBSERVATION", 194, 202], ["obesity", "OBSERVATION", 204, 211], ["hypertension", "OBSERVATION", 213, 225], ["inflammation", "OBSERVATION", 231, 243]]], ["Extracts of Inula spp. such as Inula britannica L., Inula viscosa [the accepted name is Dittrichia viscosa (L.)", [["Extracts", "ANATOMY", 0, 8], ["Inula spp", "ORGANISM", 12, 21], ["Inula britannica L.", "ORGANISM", 31, 50], ["Inula viscosa", "ORGANISM", 52, 65], ["Dittrichia viscosa", "ORGANISM", 88, 106], ["Inula britannica L.", "SPECIES", 31, 50], ["Inula viscosa", "SPECIES", 52, 65], ["Dittrichia viscosa", "SPECIES", 88, 106], ["Inula britannica L.", "SPECIES", 31, 50], ["Inula viscosa", "SPECIES", 52, 65], ["Dittrichia viscosa", "SPECIES", 88, 106], ["Inula spp", "OBSERVATION", 12, 21], ["Inula viscosa", "OBSERVATION", 52, 65]]], ["Greuter.], Inula racemosa Hook.f., Inula helenium L., etc., have been documented for their potential effects on some components of MetS, especially hypoglycemic, hypolipidemic and antioxidant activities (Kobayashi et al., 2002; Zeggwagh et al., 2006; Shan et al., 2006; Ajani et al., 2009 ) as well as inhibition of a-glucosidase enzyme (Orhan et al., 2017) .", [["MetS", "DISEASE", 131, 135], ["hypoglycemic", "DISEASE", 148, 160], ["Inula racemosa", "ORGANISM", 11, 25], ["Hook.f.", "ORGANISM", 26, 33], ["Inula helenium L.", "ORGANISM", 35, 52], ["a-glucosidase", "GENE_OR_GENE_PRODUCT", 316, 329], ["a-glucosidase enzyme", "PROTEIN", 316, 336], ["Inula racemosa", "SPECIES", 11, 25], ["helenium L.", "SPECIES", 41, 52], ["Inula racemosa", "SPECIES", 11, 25], ["Inula helenium L.", "SPECIES", 35, 52], ["Greuter", "TEST", 0, 7], ["MetS", "PROBLEM", 131, 135], ["hypoglycemic", "PROBLEM", 148, 160], ["Inula racemosa", "ANATOMY", 11, 25], ["Inula helenium", "ANATOMY", 35, 49], ["MetS", "OBSERVATION", 131, 135]]], ["Regarding bioactive secondary metabolites, SLns represent the largest group of compounds occurring in Inula spp.", [["SLns", "SIMPLE_CHEMICAL", 43, 47], ["Inula spp", "ORGANISM", 102, 111], ["bioactive secondary metabolites", "PROBLEM", 10, 41], ["SLns", "TREATMENT", 43, 47], ["secondary metabolites", "OBSERVATION", 20, 41], ["largest", "OBSERVATION_MODIFIER", 62, 69], ["compounds", "OBSERVATION_MODIFIER", 79, 88], ["Inula spp", "OBSERVATION", 102, 111]]], ["The anti-inflammatory mechanisms of some SLns have been related to their influence on directly inhibit the MAPK and block the activation of NF-kB, thus achieving the prevention of pro-inflammatory signaling (Han et al., 2001; Park et al., 2013) .", [["SLns", "CHEMICAL", 41, 45], ["SLns", "GENE_OR_GENE_PRODUCT", 41, 45], ["MAPK", "GENE_OR_GENE_PRODUCT", 107, 111], ["NF-kB", "GENE_OR_GENE_PRODUCT", 140, 145], ["SLns", "PROTEIN", 41, 45], ["MAPK", "PROTEIN", 107, 111], ["NF-kB", "PROTEIN", 140, 145], ["some SLns", "PROBLEM", 36, 45], ["pro-inflammatory signaling", "PROBLEM", 180, 206], ["anti-inflammatory", "OBSERVATION_MODIFIER", 4, 21]]], ["Alantolactone (6) (Fig. 1) is the most known eudesmanolide present in several Inula species, including Inula helenium L. used for hypoglycemic and antiobesity purposes (Seca et al., 2014; Wang et al., 2014) .", [["Alantolactone", "CHEMICAL", 0, 13], ["eudesmanolide", "CHEMICAL", 45, 58], ["Inula helenium L.", "CHEMICAL", 103, 120], ["hypoglycemic", "DISEASE", 130, 142], ["Alantolactone", "CHEMICAL", 0, 13], ["eudesmanolide", "CHEMICAL", 45, 58], ["Alantolactone (6)", "SIMPLE_CHEMICAL", 0, 17], ["Fig. 1)", "SIMPLE_CHEMICAL", 19, 26], ["eudesmanolide", "SIMPLE_CHEMICAL", 45, 58], ["Inula helenium L.", "ORGANISM", 103, 120], ["Inula helenium L.", "SPECIES", 103, 120], ["Inula helenium L.", "SPECIES", 103, 120], ["Alantolactone", "TREATMENT", 0, 13], ["several Inula species", "PROBLEM", 70, 91], ["Inula helenium L.", "TREATMENT", 103, 120], ["hypoglycemic", "PROBLEM", 130, 142], ["Inula species", "OBSERVATION", 78, 91]]], ["This compound has been extensively studied for its antitumor, antioxidant and anti-inflammatory effects (Moujir et al., 2020) .", [["antitumor", "ANATOMY", 51, 60], ["antitumor", "CANCER", 51, 60], ["antioxidant and anti-inflammatory effects", "TREATMENT", 62, 103]]], ["Regarding anti-inflammatory activity, the eudesmanolide 6 suppresses NO, PGE 2 and TNF-a production in LPS-stimulated RAW 264.7 cells by modulating the activity of the NF-kB and MAPK signaling pathways (Chun et al., 2012) , and it also suppresses TNF-a and interferon gamma (IFN-g)-induced production of chemokines by blocking the Signal Transducer and Activator of Transcription 1 (STAT1) phosphorylation in HaCaT cells (Lim et al., 2015) .Alantolactone from Inula sppAs previously mentioned, it is recognized the fact that TLRs are responsible for the activation of inflammatory pathways in obesity state.", [["RAW 264.7 cells", "ANATOMY", 118, 133], ["HaCaT cells", "ANATOMY", 409, 420], ["eudesmanolide 6", "CHEMICAL", 42, 57], ["NO", "CHEMICAL", 69, 71], ["LPS", "CHEMICAL", 103, 106], ["Alantolactone", "CHEMICAL", 441, 454], ["obesity", "DISEASE", 593, 600], ["eudesmanolide 6", "CHEMICAL", 42, 57], ["NO", "CHEMICAL", 69, 71], ["PGE 2", "CHEMICAL", 73, 78], ["Alantolactone", "CHEMICAL", 441, 454], ["eudesmanolide 6", "SIMPLE_CHEMICAL", 42, 57], ["NO", "SIMPLE_CHEMICAL", 69, 71], ["PGE 2", "GENE_OR_GENE_PRODUCT", 73, 78], ["TNF-a", "GENE_OR_GENE_PRODUCT", 83, 88], ["LPS", "SIMPLE_CHEMICAL", 103, 106], ["RAW 264.7 cells", "CELL", 118, 133], ["NF-kB", "GENE_OR_GENE_PRODUCT", 168, 173], ["MAPK", "GENE_OR_GENE_PRODUCT", 178, 182], ["TNF-a", "GENE_OR_GENE_PRODUCT", 247, 252], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 257, 273], ["IFN-g", "GENE_OR_GENE_PRODUCT", 275, 280], ["Signal Transducer and Activator of Transcription 1", "GENE_OR_GENE_PRODUCT", 331, 381], ["STAT1", "GENE_OR_GENE_PRODUCT", 383, 388], ["HaCaT cells", "CELL", 409, 420], ["Alantolactone", "SIMPLE_CHEMICAL", 441, 454], ["Inula sppAs", "ORGANISM", 460, 471], ["TLRs", "GENE_OR_GENE_PRODUCT", 525, 529], ["TNF", "PROTEIN", 83, 86], ["RAW 264.7 cells", "CELL_LINE", 118, 133], ["NF-kB", "PROTEIN", 168, 173], ["MAPK", "PROTEIN", 178, 182], ["TNF", "PROTEIN", 247, 250], ["interferon gamma", "PROTEIN", 257, 273], ["chemokines", "PROTEIN", 304, 314], ["Signal Transducer and Activator of Transcription 1", "PROTEIN", 331, 381], ["STAT1", "PROTEIN", 383, 388], ["HaCaT cells", "CELL_LINE", 409, 420], ["TLRs", "PROTEIN", 525, 529], ["anti-inflammatory activity", "TREATMENT", 10, 36], ["the eudesmanolide", "TREATMENT", 38, 55], ["PGE", "TEST", 73, 76], ["TNF", "TEST", 83, 86], ["LPS", "TEST", 103, 106], ["MAPK signaling pathways", "TEST", 178, 201], ["TNF", "TEST", 247, 250], ["a and interferon gamma (IFN-g)", "TREATMENT", 251, 281], ["chemokines", "TREATMENT", 304, 314], ["blocking the Signal Transducer", "TREATMENT", 318, 348], ["Activator of Transcription", "TREATMENT", 353, 379], ["STAT1) phosphorylation in HaCaT cells", "TREATMENT", 383, 420], ["Alantolactone", "TREATMENT", 441, 454], ["Inula sppAs", "TREATMENT", 460, 471], ["inflammatory pathways", "PROBLEM", 568, 589], ["obesity state", "PROBLEM", 593, 606], ["anti-inflammatory activity", "OBSERVATION", 10, 36], ["HaCaT cells", "ANATOMY", 409, 420], ["inflammatory", "OBSERVATION_MODIFIER", 568, 580], ["obesity", "OBSERVATION", 593, 600]]], ["In vitro trials confirmed that alantolactone (6) prevents the increase of IL-6 levels and regulates macrophage infiltration by reduction of MCP-1 concentrations via inhibition of the TLR4-JNK pathway in both, lean (adipocytes) and obese (adipocyte-macrophage) states (Kim et al., 2017a (Kim et al., , 2017b .Alantolactone from Inula sppBesides the effect on adipocytes, alantolactone (6) can also act in skeletal muscle and liver cells.", [["macrophage", "ANATOMY", 100, 110], ["adipocytes", "ANATOMY", 215, 225], ["adipocyte-macrophage", "ANATOMY", 238, 258], ["adipocytes", "ANATOMY", 358, 368], ["skeletal muscle", "ANATOMY", 404, 419], ["liver cells", "ANATOMY", 424, 435], ["alantolactone", "CHEMICAL", 31, 44], ["Alantolactone", "CHEMICAL", 308, 321], ["alantolactone", "CHEMICAL", 370, 383], ["alantolactone (6)", "CHEMICAL", 31, 48], ["Alantolactone", "CHEMICAL", 308, 321], ["alantolactone", "CHEMICAL", 370, 383], ["alantolactone (6)", "SIMPLE_CHEMICAL", 31, 48], ["IL-6", "GENE_OR_GENE_PRODUCT", 74, 78], ["macrophage", "CELL", 100, 110], ["MCP-1", "GENE_OR_GENE_PRODUCT", 140, 145], ["TLR4", "GENE_OR_GENE_PRODUCT", 183, 187], ["JNK", "GENE_OR_GENE_PRODUCT", 188, 191], ["adipocytes", "CELL", 215, 225], ["adipocyte-macrophage", "CELL", 238, 258], ["Alantolactone", "SIMPLE_CHEMICAL", 308, 321], ["Inula sppBesides", "SIMPLE_CHEMICAL", 327, 343], ["adipocytes", "CELL", 358, 368], ["alantolactone (6)", "SIMPLE_CHEMICAL", 370, 387], ["skeletal muscle", "TISSUE", 404, 419], ["liver cells", "CELL", 424, 435], ["IL-6", "PROTEIN", 74, 78], ["MCP", "PROTEIN", 140, 143], ["TLR4", "PROTEIN", 183, 187], ["JNK", "PROTEIN", 188, 191], ["adipocytes", "CELL_TYPE", 215, 225], ["adipocytes", "CELL_TYPE", 358, 368], ["liver cells", "CELL_TYPE", 424, 435], ["alantolactone", "TREATMENT", 31, 44], ["the increase of IL", "TREATMENT", 58, 76], ["macrophage infiltration", "PROBLEM", 100, 123], ["MCP", "TEST", 140, 143], ["the TLR4-JNK pathway", "TEST", 179, 199], ["obese", "PROBLEM", 231, 236], ["Alantolactone", "TREATMENT", 308, 321], ["Inula", "TREATMENT", 327, 332], ["adipocytes", "TREATMENT", 358, 368], ["alantolactone", "TREATMENT", 370, 383], ["increase", "OBSERVATION_MODIFIER", 62, 70], ["macrophage infiltration", "OBSERVATION", 100, 123], ["adipocytes", "ANATOMY", 215, 225], ["obese", "OBSERVATION", 231, 236], ["adipocyte", "ANATOMY", 238, 247], ["adipocytes", "ANATOMY", 358, 368], ["skeletal muscle", "ANATOMY", 404, 419], ["liver", "ANATOMY", 424, 429]]], ["In this context, the compound 6 inhibits IL-6-induced insulin-stimulated glucose intolerance and insulin resistance in the skeletal muscle through blockade the activation of STAT3 and the abnormal expression of TLR4 (Kim et al., 2017a (Kim et al., , 2017b .", [["skeletal muscle", "ANATOMY", 123, 138], ["glucose intolerance", "DISEASE", 73, 92], ["glucose", "CHEMICAL", 73, 80], ["IL-6", "GENE_OR_GENE_PRODUCT", 41, 45], ["insulin", "GENE_OR_GENE_PRODUCT", 54, 61], ["glucose", "SIMPLE_CHEMICAL", 73, 80], ["insulin", "GENE_OR_GENE_PRODUCT", 97, 104], ["skeletal muscle", "ORGAN", 123, 138], ["STAT3", "GENE_OR_GENE_PRODUCT", 174, 179], ["TLR4", "GENE_OR_GENE_PRODUCT", 211, 215], ["IL-6", "PROTEIN", 41, 45], ["STAT3", "PROTEIN", 174, 179], ["TLR4", "PROTEIN", 211, 215], ["IL", "TEST", 41, 43], ["insulin", "TREATMENT", 54, 61], ["stimulated glucose intolerance", "PROBLEM", 62, 92], ["insulin resistance", "TREATMENT", 97, 115], ["glucose intolerance", "OBSERVATION", 73, 92], ["insulin resistance", "OBSERVATION", 97, 115], ["skeletal muscle", "ANATOMY", 123, 138]]], ["In L02 cells, alantolactone (6) also inhibits oxLDL-induced lipid accumulation trough regulating the apolipoprotein C3 (APOC3) expression partly by decreasing the activation of STAT3 .", [["L02 cells", "ANATOMY", 3, 12], ["alantolactone", "CHEMICAL", 14, 27], ["oxLDL", "CHEMICAL", 46, 51], ["alantolactone", "CHEMICAL", 14, 27], ["L02 cells", "CELL", 3, 12], ["alantolactone (6)", "SIMPLE_CHEMICAL", 14, 31], ["oxLDL", "SIMPLE_CHEMICAL", 46, 51], ["lipid", "SIMPLE_CHEMICAL", 60, 65], ["apolipoprotein C3", "GENE_OR_GENE_PRODUCT", 101, 118], ["APOC3", "GENE_OR_GENE_PRODUCT", 120, 125], ["STAT3", "GENE_OR_GENE_PRODUCT", 177, 182], ["L02 cells", "CELL_LINE", 3, 12], ["oxLDL", "PROTEIN", 46, 51], ["apolipoprotein C3", "PROTEIN", 101, 118], ["APOC3", "PROTEIN", 120, 125], ["STAT3", "PROTEIN", 177, 182], ["L02 cells", "TREATMENT", 3, 12], ["alantolactone", "TREATMENT", 14, 27], ["oxLDL", "TREATMENT", 46, 51], ["lipid accumulation trough", "TEST", 60, 85], ["the apolipoprotein C3 (APOC3) expression", "TREATMENT", 97, 137], ["L02 cells", "OBSERVATION", 3, 12]]], ["Thus, may be relevant to explore further its role in managing metabolic complications on e.g. modulating hepatic IL-6/STAT3 signaling in high-fat diet-induced metabolic disorder in animal models, since the physiological metabolic response to IL-6 depends on the specific source of IL-6 in vivo (Han et al., 2020) Concerning to in vivo experiments, no hypoglycemic effect was observed on STZ-induced diabetic mice after oral administration of alantolactone.", [["hepatic", "ANATOMY", 105, 112], ["oral", "ANATOMY", 419, 423], ["metabolic disorder", "DISEASE", 159, 177], ["hypoglycemic", "DISEASE", 351, 363], ["STZ", "CHEMICAL", 387, 390], ["diabetic", "DISEASE", 399, 407], ["alantolactone", "CHEMICAL", 442, 455], ["STZ", "CHEMICAL", 387, 390], ["alantolactone", "CHEMICAL", 442, 455], ["IL-6", "GENE_OR_GENE_PRODUCT", 113, 117], ["STAT3", "GENE_OR_GENE_PRODUCT", 118, 123], ["IL-6", "GENE_OR_GENE_PRODUCT", 242, 246], ["IL-6", "GENE_OR_GENE_PRODUCT", 281, 285], ["STZ", "SIMPLE_CHEMICAL", 387, 390], ["mice", "ORGANISM", 408, 412], ["oral", "ORGANISM_SUBDIVISION", 419, 423], ["alantolactone", "SIMPLE_CHEMICAL", 442, 455], ["hepatic IL-6", "PROTEIN", 105, 117], ["STAT3", "PROTEIN", 118, 123], ["IL-6", "PROTEIN", 242, 246], ["IL-6", "PROTEIN", 281, 285], ["mice", "SPECIES", 408, 412], ["mice", "SPECIES", 408, 412], ["managing metabolic complications", "PROBLEM", 53, 85], ["modulating hepatic IL", "TREATMENT", 94, 115], ["STAT3 signaling", "PROBLEM", 118, 133], ["high-fat diet", "TREATMENT", 137, 150], ["metabolic disorder", "PROBLEM", 159, 177], ["IL", "TEST", 242, 244], ["hypoglycemic effect", "PROBLEM", 351, 370], ["STZ", "TREATMENT", 387, 390], ["oral administration of alantolactone", "TREATMENT", 419, 455], ["hepatic", "ANATOMY", 105, 112], ["metabolic disorder", "OBSERVATION", 159, 177], ["metabolic response", "OBSERVATION", 220, 238]]], ["However, inflammation and renal abnormalities were suppressed via inhibition of NF-kB gene expression and the high glucose-induced overexpression of pro-inflammatory cytokines and macrophage adhesion in renal NRK-52E cells were inhibited.", [["renal", "ANATOMY", 26, 31], ["macrophage", "ANATOMY", 180, 190], ["renal NRK-52E cells", "ANATOMY", 203, 222], ["inflammation", "DISEASE", 9, 21], ["renal abnormalities", "DISEASE", 26, 45], ["glucose", "CHEMICAL", 115, 122], ["glucose", "CHEMICAL", 115, 122], ["renal", "ORGAN", 26, 31], ["NF-kB", "GENE_OR_GENE_PRODUCT", 80, 85], ["glucose", "SIMPLE_CHEMICAL", 115, 122], ["macrophage", "CELL", 180, 190], ["renal NRK-52E cells", "CELL", 203, 222], ["NF-kB gene", "DNA", 80, 90], ["pro-inflammatory cytokines", "PROTEIN", 149, 175], ["renal NRK-52E cells", "CELL_LINE", 203, 222], ["NRK-52E", "SPECIES", 209, 216], ["inflammation", "PROBLEM", 9, 21], ["renal abnormalities", "PROBLEM", 26, 45], ["NF-kB gene expression", "TREATMENT", 80, 101], ["the high glucose", "PROBLEM", 106, 122], ["pro-inflammatory cytokines", "PROBLEM", 149, 175], ["macrophage adhesion", "PROBLEM", 180, 199], ["renal NRK", "TEST", 203, 212], ["inflammation", "OBSERVATION", 9, 21], ["renal", "ANATOMY", 26, 31], ["abnormalities", "OBSERVATION", 32, 45], ["pro-inflammatory cytokines", "OBSERVATION", 149, 175], ["macrophage adhesion", "OBSERVATION", 180, 199], ["renal NRK", "ANATOMY", 203, 212]]], ["These results led the authors to propose a beneficial use for the treatment of diabetic neuropathy.", [["diabetic neuropathy", "DISEASE", 79, 98], ["diabetic neuropathy", "PROBLEM", 79, 98], ["diabetic neuropathy", "OBSERVATION", 79, 98]]], ["Taking together all evidences mentioned for alantolactone (6) activity, it is probably that this compound could reduce some components of MetS by the regulation of inflammatory processes.Alantolactone from Inula sppAlantolactone (6) did not induced significant hepatotoxicity and nephrotoxicity after daily administration (100 mg/kg b.w.) for 5 weeks in mice .", [["alantolactone", "CHEMICAL", 44, 57], ["MetS", "DISEASE", 138, 142], ["Alantolactone", "CHEMICAL", 187, 200], ["Inula sppAlantolactone", "CHEMICAL", 206, 228], ["hepatotoxicity", "DISEASE", 261, 275], ["nephrotoxicity", "DISEASE", 280, 294], ["alantolactone", "CHEMICAL", 44, 57], ["Alantolactone", "CHEMICAL", 187, 200], ["Inula sppAlantolactone", "CHEMICAL", 206, 228], ["alantolactone (6)", "SIMPLE_CHEMICAL", 44, 61], ["Alantolactone", "SIMPLE_CHEMICAL", 187, 200], ["mice", "ORGANISM", 354, 358], ["mice", "SPECIES", 354, 358], ["mice", "SPECIES", 354, 358], ["alantolactone", "TREATMENT", 44, 57], ["this compound", "PROBLEM", 92, 105], ["MetS", "PROBLEM", 138, 142], ["inflammatory processes", "PROBLEM", 164, 186], ["Alantolactone", "TREATMENT", 187, 200], ["Inula sppAlantolactone", "TREATMENT", 206, 228], ["significant hepatotoxicity", "PROBLEM", 249, 275], ["nephrotoxicity", "PROBLEM", 280, 294], ["MetS", "OBSERVATION", 138, 142], ["inflammatory", "OBSERVATION", 164, 176], ["significant", "OBSERVATION_MODIFIER", 249, 260], ["hepatotoxicity", "OBSERVATION", 261, 275]]], ["This compound also is a contact allergen, and in vitro is cytotoxic in cancer cells and induces apoptosis (Tisserand and Young, 2014) .", [["cancer cells", "ANATOMY", 71, 83], ["cancer", "DISEASE", 71, 77], ["cancer cells", "CELL", 71, 83], ["cancer cells", "CELL_TYPE", 71, 83], ["a contact allergen", "PROBLEM", 22, 40], ["cytotoxic in cancer cells", "PROBLEM", 58, 83], ["apoptosis", "PROBLEM", 96, 105], ["contact allergen", "OBSERVATION", 24, 40], ["cytotoxic", "OBSERVATION_MODIFIER", 58, 67], ["cancer cells", "OBSERVATION", 71, 83]]], ["3,10-Epoxygermacranolides from Tithonia diversifolia (Hemsl.)", [["3,10-Epoxygermacranolides", "CHEMICAL", 0, 25], ["3,10-Epoxygermacranolides", "CHEMICAL", 0, 25], ["3,10-Epoxygermacranolides", "SIMPLE_CHEMICAL", 0, 25], ["Tithonia diversifolia", "ORGANISM", 31, 52], ["Tithonia diversifolia", "SPECIES", 31, 52], ["Tithonia diversifolia", "SPECIES", 31, 52]]], ["A. Gray Tithonia diversifolia (Hemsl) A. Gray, commonly known as tree marigold or Mexican sunflower (Asteraceae: Heliantheae), is a shrublike perennial or annual invasive plant, native from North and Central America.", [["A. Gray Tithonia diversifolia", "ORGANISM", 0, 29], ["Hemsl) A. Gray", "ORGANISM", 31, 45], ["sunflower", "ORGANISM_SUBDIVISION", 90, 99], ["Tithonia diversifolia", "SPECIES", 8, 29], ["sunflower", "SPECIES", 90, 99], ["Tithonia diversifolia", "SPECIES", 8, 29], ["Mexican sunflower", "SPECIES", 82, 99], ["annual", "OBSERVATION_MODIFIER", 155, 161], ["invasive", "OBSERVATION", 162, 170], ["Central", "ANATOMY_MODIFIER", 200, 207]]], ["Traditionally, its leaves are widely used by indigenous people for treating a wide spectrum of diseases, including diabetes mellitus.", [["leaves", "ANATOMY", 19, 25], ["diabetes mellitus", "DISEASE", 115, 132], ["people", "ORGANISM", 56, 62], ["people", "SPECIES", 56, 62], ["a wide spectrum of diseases", "PROBLEM", 76, 103], ["diabetes mellitus", "PROBLEM", 115, 132], ["diseases", "OBSERVATION", 95, 103], ["diabetes mellitus", "OBSERVATION", 115, 132]]], ["Several in vitro and in vivo studies have stated the antioxidant antidiabetic, hypolipidemic and antiobesity effects of T. diversifolia (Ajao and Moteetee, 2017; Tagne et al., 2018) .", [["T. diversifolia", "ORGANISM", 120, 135], ["T. diversifolia", "SPECIES", 120, 135], ["T. diversifolia", "SPECIES", 120, 135], ["vivo studies", "TEST", 24, 36], ["the antioxidant antidiabetic", "TREATMENT", 49, 77], ["hypolipidemic", "TREATMENT", 79, 92]]], ["Germacranolides, eudesmanolides and guaianolides are some of the major components occurring in this plant (Ajao and Moteetee, 2017; Tagne et al., 2018) and because of their previously described activity, they apparently are involved in the important spectrum of bioactivity reported for T. diversifolia.", [["Germacranolides", "CHEMICAL", 0, 15], ["eudesmanolides", "CHEMICAL", 17, 31], ["guaianolides", "CHEMICAL", 36, 48], ["Germacranolides", "CHEMICAL", 0, 15], ["eudesmanolides", "CHEMICAL", 17, 31], ["guaianolides", "CHEMICAL", 36, 48], ["Germacranolides", "SIMPLE_CHEMICAL", 0, 15], ["eudesmanolides", "SIMPLE_CHEMICAL", 17, 31], ["guaianolides", "SIMPLE_CHEMICAL", 36, 48], ["T. diversifolia", "ORGANISM", 287, 302], ["T. diversifolia", "SPECIES", 287, 302], ["T. diversifolia", "SPECIES", 287, 302], ["Germacranolides", "TREATMENT", 0, 15], ["eudesmanolides", "TREATMENT", 17, 31], ["guaianolides", "TREATMENT", 36, 48], ["T. diversifolia", "PROBLEM", 287, 302], ["major", "OBSERVATION_MODIFIER", 65, 70], ["components", "OBSERVATION_MODIFIER", 71, 81]]], ["Tirotundin (7) and tagitinin A (8) (Fig. 1) isolated from the ethyl acetate soluble fraction of T. diversifolia are related to the activation of peroxisome proliferator-activated receptors (PPARs) (Lin, 2012) .", [["Tirotundin", "CHEMICAL", 0, 10], ["tagitinin A", "CHEMICAL", 19, 30], ["ethyl acetate", "CHEMICAL", 62, 75], ["Tirotundin", "CHEMICAL", 0, 10], ["tagitinin A", "CHEMICAL", 19, 30], ["ethyl acetate", "CHEMICAL", 62, 75], ["Tirotundin (7)", "SIMPLE_CHEMICAL", 0, 14], ["tagitinin A (8)", "SIMPLE_CHEMICAL", 19, 34], ["Fig. 1", "SIMPLE_CHEMICAL", 36, 42], ["ethyl acetate", "SIMPLE_CHEMICAL", 62, 75], ["T. diversifolia", "ORGANISM", 96, 111], ["peroxisome proliferator-activated receptors", "GENE_OR_GENE_PRODUCT", 145, 188], ["PPARs", "GENE_OR_GENE_PRODUCT", 190, 195], ["peroxisome proliferator-activated receptors", "PROTEIN", 145, 188], ["PPARs", "PROTEIN", 190, 195], ["T. diversifolia", "SPECIES", 96, 111], ["T. diversifolia", "SPECIES", 96, 111], ["Tirotundin", "TREATMENT", 0, 10], ["tagitinin A (8) (Fig. 1)", "TREATMENT", 19, 43], ["the ethyl acetate soluble fraction", "TREATMENT", 58, 92], ["T. diversifolia", "PROBLEM", 96, 111], ["T. diversifolia", "OBSERVATION", 96, 111]]], ["PPARs are members of nuclear hormone receptors superfamily involved in the metabolic regulation of lipid and lipoprotein levels, blood glucose, and abdominal adiposity.", [["nuclear", "ANATOMY", 21, 28], ["blood", "ANATOMY", 129, 134], ["abdominal", "ANATOMY", 148, 157], ["glucose", "CHEMICAL", 135, 142], ["glucose", "CHEMICAL", 135, 142], ["PPARs", "GENE_OR_GENE_PRODUCT", 0, 5], ["nuclear hormone receptors", "GENE_OR_GENE_PRODUCT", 21, 46], ["lipid", "SIMPLE_CHEMICAL", 99, 104], ["lipoprotein", "SIMPLE_CHEMICAL", 109, 120], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["glucose", "SIMPLE_CHEMICAL", 135, 142], ["abdominal", "ORGANISM_SUBDIVISION", 148, 157], ["PPARs", "PROTEIN", 0, 5], ["nuclear hormone receptors superfamily", "PROTEIN", 21, 58], ["nuclear hormone receptors", "TEST", 21, 46], ["lipoprotein levels", "TEST", 109, 127], ["blood glucose", "TEST", 129, 142], ["abdominal adiposity", "PROBLEM", 148, 167], ["abdominal", "ANATOMY", 148, 157]]], ["In mammals, three isoforms of PPARs have been recognized namely PPAR-a, PPAR-b/d and PPAR-g.", [["PPARs", "GENE_OR_GENE_PRODUCT", 30, 35], ["PPAR-a", "GENE_OR_GENE_PRODUCT", 64, 70], ["PPAR-b", "GENE_OR_GENE_PRODUCT", 72, 78], ["PPAR", "GENE_OR_GENE_PRODUCT", 85, 89], ["PPARs", "PROTEIN", 30, 35], ["PPAR", "PROTEIN", 64, 68], ["PPAR", "PROTEIN", 72, 76], ["PPAR", "PROTEIN", 85, 89], ["PPAR", "TEST", 64, 68], ["PPAR", "TEST", 72, 76], ["PPAR", "ANATOMY", 85, 89]]], ["Activation of PPAR-a by hypolipidemic fibrate class of drugs decreases TG levels and raises HDL-C in dyslipidemic individuals, whereas activation of PPAR-g by antidiabetic thiazolidinedione agents causes insulin sensitization to enhance glucose metabolism (Botta et al., 2018) .", [["TG", "DISEASE", 71, 73], ["HDL-C", "CHEMICAL", 92, 97], ["dyslipidemic", "DISEASE", 101, 113], ["antidiabetic thiazolidinedione", "CHEMICAL", 159, 189], ["glucose", "CHEMICAL", 237, 244], ["thiazolidinedione", "CHEMICAL", 172, 189], ["glucose", "CHEMICAL", 237, 244], ["PPAR-a", "GENE_OR_GENE_PRODUCT", 14, 20], ["TG", "SIMPLE_CHEMICAL", 71, 73], ["HDL-C", "SIMPLE_CHEMICAL", 92, 97], ["PPAR-g", "GENE_OR_GENE_PRODUCT", 149, 155], ["antidiabetic thiazolidinedione agents", "SIMPLE_CHEMICAL", 159, 196], ["insulin", "GENE_OR_GENE_PRODUCT", 204, 211], ["glucose", "SIMPLE_CHEMICAL", 237, 244], ["PPAR", "PROTEIN", 14, 18], ["PPAR", "PROTEIN", 149, 153], ["Activation of PPAR", "TREATMENT", 0, 18], ["drugs", "TREATMENT", 55, 60], ["TG levels", "TEST", 71, 80], ["HDL", "TEST", 92, 95], ["dyslipidemic individuals", "PROBLEM", 101, 125], ["PPAR", "TREATMENT", 149, 153], ["antidiabetic thiazolidinedione agents", "TREATMENT", 159, 196], ["insulin sensitization", "TREATMENT", 204, 225]]], ["Currently, dual PPARa/g agonists, which stimulate both PPARa and PPAR-g isoforms to similar extents, are gaining popularity since it is believed that they are able to ameliorate the unwanted side effects of selective PPAR-a and PPAR-g agonists; and may also be used to treat dyslipidemia and T2DM simultaneously (Balakumar et al., 2019) .", [["dyslipidemia", "DISEASE", 275, 287], ["T2DM", "DISEASE", 292, 296], ["PPARa", "GENE_OR_GENE_PRODUCT", 16, 21], ["PPARa", "GENE_OR_GENE_PRODUCT", 55, 60], ["PPAR-g", "GENE_OR_GENE_PRODUCT", 65, 71], ["PPAR-a", "GENE_OR_GENE_PRODUCT", 217, 223], ["PPAR-g", "GENE_OR_GENE_PRODUCT", 228, 234], ["PPARa", "PROTEIN", 16, 21], ["PPARa", "PROTEIN", 55, 60], ["PPAR", "PROTEIN", 65, 69], ["PPAR", "PROTEIN", 217, 221], ["dual PPARa/g agonists", "TREATMENT", 11, 32], ["selective PPAR", "TREATMENT", 207, 221], ["a and PPAR-g agonists", "TREATMENT", 222, 243], ["dyslipidemia", "PROBLEM", 275, 287], ["T2DM", "PROBLEM", 292, 296]]], ["Tirotundin (7) and tagitinin A (8) have been suggested being dual PPARa/g agonists after the evaluation of their agonistic activity against PPARs employing a transient transfection reporter assay in HepG2 cells .Alantolactone from Inula sppOn the other hand, the germacranolides tagitinin G (9), tagitinin I (10), 1b-hydroxydiversifolin-3-O-methyl ether (11) and 1b-hydroxytirotundin-3-O-methyl ether (12) (Fig. 1) isolated from the aerial parts of T. diversifolia were found to significantly elevate glucose uptake in 3T3-L1 adipocytes without any toxicity (Zhao et al., 2012) .", [["HepG2 cells", "ANATOMY", 199, 210], ["aerial parts", "ANATOMY", 433, 445], ["3T3-L1 adipocytes", "ANATOMY", 519, 536], ["Tirotundin", "CHEMICAL", 0, 10], ["tagitinin A", "CHEMICAL", 19, 30], ["Alantolactone", "CHEMICAL", 212, 225], ["germacranolides tagitinin G (9), tagitinin I (10), 1b-hydroxydiversifolin-3-O-methyl ether", "CHEMICAL", 263, 353], ["1b-hydroxytirotundin-3-O-methyl ether", "CHEMICAL", 363, 400], ["glucose", "CHEMICAL", 501, 508], ["toxicity", "DISEASE", 549, 557], ["Tirotundin", "CHEMICAL", 0, 10], ["tagitinin A", "CHEMICAL", 19, 30], ["Alantolactone", "CHEMICAL", 212, 225], ["tagitinin G", "CHEMICAL", 279, 290], ["tagitinin I", "CHEMICAL", 296, 307], ["1b-hydroxydiversifolin-3-O-methyl ether", "CHEMICAL", 314, 353], ["1b-hydroxytirotundin-3-O-methyl ether", "CHEMICAL", 363, 400], ["glucose", "CHEMICAL", 501, 508], ["Tirotundin (7)", "SIMPLE_CHEMICAL", 0, 14], ["tagitinin A (8)", "SIMPLE_CHEMICAL", 19, 34], ["PPARa", "GENE_OR_GENE_PRODUCT", 66, 71], ["PPARs", "GENE_OR_GENE_PRODUCT", 140, 145], ["HepG2 cells", "CELL", 199, 210], ["Alantolactone", "SIMPLE_CHEMICAL", 212, 225], ["hand", "ORGANISM_SUBDIVISION", 253, 257], ["germacranolides tagitinin G (9)", "SIMPLE_CHEMICAL", 263, 294], ["tagitinin I (10)", "SIMPLE_CHEMICAL", 296, 312], ["1b-hydroxydiversifolin-3-O-methyl ether (11)", "SIMPLE_CHEMICAL", 314, 358], ["1b-hydroxytirotundin-3-O-methyl ether (12)", "SIMPLE_CHEMICAL", 363, 405], ["Fig. 1)", "SIMPLE_CHEMICAL", 407, 414], ["T. diversifolia", "ORGANISM", 449, 464], ["glucose", "SIMPLE_CHEMICAL", 501, 508], ["3T3-L1 adipocytes", "CELL", 519, 536], ["PPARs", "PROTEIN", 140, 145], ["HepG2 cells", "CELL_LINE", 199, 210], ["3T3-L1 adipocytes", "CELL_LINE", 519, 536], ["T. diversifolia", "SPECIES", 449, 464], ["T. diversifolia", "SPECIES", 449, 464], ["Tirotundin", "TREATMENT", 0, 10], ["dual PPARa/g agonists", "TREATMENT", 61, 82], ["the evaluation", "TEST", 89, 103], ["a transient transfection reporter assay in HepG2 cells", "PROBLEM", 156, 210], ["Alantolactone", "TREATMENT", 212, 225], ["the germacranolides tagitinin G", "TREATMENT", 259, 290], ["tagitinin I", "TREATMENT", 296, 307], ["hydroxydiversifolin", "TREATMENT", 317, 336], ["methyl ether", "TREATMENT", 341, 353], ["hydroxytirotundin", "TREATMENT", 366, 383], ["methyl ether", "TREATMENT", 388, 400], ["T. diversifolia", "PROBLEM", 449, 464], ["glucose uptake in 3T3-L1 adipocytes", "PROBLEM", 501, 536], ["any toxicity", "PROBLEM", 545, 557], ["L1 adipocytes", "ANATOMY", 523, 536], ["without", "UNCERTAINTY", 537, 544]]], ["The authors suggested that these compounds had PPARg agonist activity on glucose uptake, similar to pioglitazone, a PPAR-g agonist used as a control compound in the study.", [["glucose", "CHEMICAL", 73, 80], ["pioglitazone", "CHEMICAL", 100, 112], ["glucose", "CHEMICAL", 73, 80], ["pioglitazone", "CHEMICAL", 100, 112], ["PPARg", "SIMPLE_CHEMICAL", 47, 52], ["glucose", "SIMPLE_CHEMICAL", 73, 80], ["pioglitazone", "SIMPLE_CHEMICAL", 100, 112], ["PPAR-g", "GENE_OR_GENE_PRODUCT", 116, 122], ["glucose uptake", "TEST", 73, 87], ["pioglitazone", "TREATMENT", 100, 112], ["a PPAR-g agonist", "TREATMENT", 114, 130], ["the study", "TEST", 161, 170]]], ["No in vivo acute, subchronic or chronic toxicity studies on 3,10-epoxygermacranolides described above have been reported to date.Alantolactone from Inula sppThe increasing abundance of Tithonia diversifolia in conservation and agricultural areas over the past ten years in South Africa has been of concern.", [["toxicity", "DISEASE", 40, 48], ["3,10-epoxygermacranolides", "CHEMICAL", 60, 85], ["Alantolactone", "CHEMICAL", 129, 142], ["Tithonia diversifolia", "CHEMICAL", 185, 206], ["3,10-epoxygermacranolides", "CHEMICAL", 60, 85], ["Alantolactone", "CHEMICAL", 129, 142], ["3,10-epoxygermacranolides", "SIMPLE_CHEMICAL", 60, 85], ["Alantolactone", "SIMPLE_CHEMICAL", 129, 142], ["Inula spp", "ORGANISM", 148, 157], ["Tithonia diversifolia", "ORGANISM", 185, 206], ["Tithonia diversifolia", "SPECIES", 185, 206], ["Tithonia diversifolia", "SPECIES", 185, 206], ["chronic toxicity studies", "PROBLEM", 32, 56], ["epoxygermacranolides", "TREATMENT", 65, 85], ["Alantolactone", "TREATMENT", 129, 142], ["Tithonia diversifolia", "PROBLEM", 185, 206], ["vivo", "OBSERVATION_MODIFIER", 6, 10], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["subchronic", "OBSERVATION_MODIFIER", 18, 28], ["chronic", "OBSERVATION_MODIFIER", 32, 39], ["toxicity", "OBSERVATION", 40, 48], ["Inula spp", "OBSERVATION_MODIFIER", 148, 157], ["increasing", "OBSERVATION_MODIFIER", 161, 171], ["abundance", "OBSERVATION_MODIFIER", 172, 181], ["Tithonia diversifolia", "OBSERVATION", 185, 206], ["agricultural", "OBSERVATION_MODIFIER", 227, 239], ["areas", "OBSERVATION_MODIFIER", 240, 245]]], ["This plant is considered as a scrub resulting in the initiation of a biological control program against its propagation (Simelane et al., 2011) .", [["a scrub", "TREATMENT", 28, 35], ["a biological control program", "TREATMENT", 67, 95]]], ["Therefore, utilization for medicinal purposes of this invasive plant could be important before major eradication takes place.Micheliolide from Magnolia compressa (Maxim.)", [["Micheliolide", "CHEMICAL", 125, 137], ["Micheliolide", "CHEMICAL", 125, 137], ["Micheliolide", "SIMPLE_CHEMICAL", 125, 137], ["Magnolia compressa", "ORGANISM", 143, 161], ["Magnolia compressa", "SPECIES", 143, 161], ["Magnolia compressa", "SPECIES", 143, 161], ["medicinal purposes", "TREATMENT", 27, 45], ["this invasive plant", "TREATMENT", 49, 68], ["Micheliolide", "TREATMENT", 125, 137], ["Magnolia compressa", "OBSERVATION", 143, 161]]], ["SargThe genus Magnolia, previously known as Michellia, reported to exert various biological effects, including anti-cancer, anti-anxiety, antidepressant, antioxidant and anti-inflammatory (Lee et al., 2011) .", [["Sarg", "CHEMICAL", 0, 4], ["Michellia", "CHEMICAL", 44, 53], ["antidepressant", "CHEMICAL", 138, 152], ["The genus Magnolia", "PROBLEM", 4, 22], ["anti-cancer", "TREATMENT", 111, 122], ["anti-anxiety", "TREATMENT", 124, 136], ["antidepressant", "TREATMENT", 138, 152], ["antioxidant", "TREATMENT", 154, 165], ["genus Magnolia", "OBSERVATION", 8, 22]]], ["In later years, Magnolia species and their components have been related to ameliorate characters of obesity and diabetes, such as hyperglycemia, hyperlipidemia, and other complications .", [["obesity", "DISEASE", 100, 107], ["diabetes", "DISEASE", 112, 120], ["hyperglycemia", "DISEASE", 130, 143], ["hyperlipidemia", "DISEASE", 145, 159], ["Magnolia species", "ORGANISM", 16, 32], ["Magnolia species", "PROBLEM", 16, 32], ["obesity", "PROBLEM", 100, 107], ["diabetes", "PROBLEM", 112, 120], ["hyperglycemia", "PROBLEM", 130, 143], ["hyperlipidemia", "PROBLEM", 145, 159], ["other complications", "PROBLEM", 165, 184], ["Magnolia species", "OBSERVATION", 16, 32], ["obesity", "OBSERVATION", 100, 107], ["diabetes", "OBSERVATION", 112, 120], ["hyperlipidemia", "OBSERVATION", 145, 159]]], ["Since terpenoids are one of the principal substantial compounds in Magnolia species, SLns may be related with its medicinal properties (Sun et al., 2015) .", [["SLns", "CHEMICAL", 85, 89], ["terpenoids", "CHEMICAL", 6, 16], ["terpenoids", "SIMPLE_CHEMICAL", 6, 16], ["Magnolia species", "ORGANISM", 67, 83], ["SLns", "SIMPLE_CHEMICAL", 85, 89], ["terpenoids", "TREATMENT", 6, 16], ["Magnolia species", "PROBLEM", 67, 83], ["SLns", "TREATMENT", 85, 89], ["terpenoids", "OBSERVATION_MODIFIER", 6, 16], ["principal", "OBSERVATION_MODIFIER", 32, 41], ["substantial", "OBSERVATION_MODIFIER", 42, 53], ["compounds", "OBSERVATION_MODIFIER", 54, 63], ["Magnolia species", "OBSERVATION", 67, 83], ["may be related with", "UNCERTAINTY", 90, 109]]], ["Anticancer activity investigation lead to the isolation of the guaianolide micheliolide (13) (Fig. 1) from M. compressa (Maxim.)", [["micheliolide", "CHEMICAL", 75, 87], ["guaianolide micheliolide", "CHEMICAL", 63, 87], ["guaianolide micheliolide (13)", "SIMPLE_CHEMICAL", 63, 92], ["M. compressa", "ORGANISM", 107, 119], ["M. compressa", "SPECIES", 107, 119], ["M. compressa", "SPECIES", 107, 119], ["Anticancer activity investigation", "TREATMENT", 0, 33], ["the guaianolide micheliolide", "TREATMENT", 59, 87]]], ["Sarg.", [["Sarg", "GENE_OR_GENE_PRODUCT", 0, 4], ["Sarg", "PROTEIN", 0, 4]]], ["This compound has also been obtained in a semi-synthetic way from a BF 3 -mediated rearrangement of parthenolide (Casta\u00f1eda-Acosta et al., 1993; Zhai et al., 2012) , presenting enhanced stability and remarkable antiinflammatory effect by suppressing activation of the NF-kB through inhibition of IkBa degradation as well as for the inhibition of p65 translocation to the nucleus (Viennois et al., 2014) .", [["nucleus", "ANATOMY", 371, 378], ["parthenolide", "CHEMICAL", 100, 112], ["parthenolide", "CHEMICAL", 100, 112], ["BF 3", "GENE_OR_GENE_PRODUCT", 68, 72], ["parthenolide", "SIMPLE_CHEMICAL", 100, 112], ["NF-kB", "GENE_OR_GENE_PRODUCT", 268, 273], ["IkBa", "GENE_OR_GENE_PRODUCT", 296, 300], ["p65", "GENE_OR_GENE_PRODUCT", 346, 349], ["nucleus", "CELLULAR_COMPONENT", 371, 378], ["NF-kB", "PROTEIN", 268, 273], ["IkBa", "PROTEIN", 296, 300], ["p65", "PROTEIN", 346, 349], ["parthenolide", "TREATMENT", 100, 112], ["the NF", "TREATMENT", 264, 270], ["IkBa degradation", "TREATMENT", 296, 312], ["antiinflammatory effect", "OBSERVATION", 211, 234], ["nucleus", "ANATOMY", 371, 378]]], ["The compound also influenced the MAPK and PI3K/Akt signaling pathways in LPSstimulated BV-2 cells (Sun et al., 2017) .", [["BV-2 cells", "ANATOMY", 87, 97], ["MAPK", "GENE_OR_GENE_PRODUCT", 33, 37], ["PI3K", "GENE_OR_GENE_PRODUCT", 42, 46], ["Akt", "GENE_OR_GENE_PRODUCT", 47, 50], ["LPSstimulated BV-2 cells", "CELL", 73, 97], ["MAPK", "PROTEIN", 33, 37], ["PI3K", "PROTEIN", 42, 46], ["Akt", "PROTEIN", 47, 50], ["LPSstimulated BV-2 cells", "CELL_LINE", 73, 97], ["the MAPK", "TEST", 29, 37], ["PI3K", "TEST", 42, 46], ["Akt signaling pathways", "TEST", 47, 69], ["LPSstimulated BV", "TEST", 73, 89]]], ["Further, an in vitro assay has revealed that 13 attenuate the high glucose-stimulated activation of NF-kB, the degradation of IkBa, and the expression of MCP-1 in rat mesangial cells (Jia et al., 2013) .Micheliolide from Magnolia compressa (Maxim.)", [["mesangial cells", "ANATOMY", 167, 182], ["glucose", "CHEMICAL", 67, 74], ["Micheliolide", "CHEMICAL", 203, 215], ["glucose", "CHEMICAL", 67, 74], ["Micheliolide", "CHEMICAL", 203, 215], ["glucose", "SIMPLE_CHEMICAL", 67, 74], ["NF-kB", "GENE_OR_GENE_PRODUCT", 100, 105], ["IkBa", "GENE_OR_GENE_PRODUCT", 126, 130], ["MCP-1", "GENE_OR_GENE_PRODUCT", 154, 159], ["rat", "ORGANISM", 163, 166], ["mesangial cells", "CELL", 167, 182], ["Micheliolide", "SIMPLE_CHEMICAL", 203, 215], ["Magnolia compressa", "ORGANISM", 221, 239], ["NF-kB", "PROTEIN", 100, 105], ["IkBa", "PROTEIN", 126, 130], ["MCP-1", "PROTEIN", 154, 159], ["rat mesangial cells", "CELL_TYPE", 163, 182], ["rat", "SPECIES", 163, 166], ["Magnolia compressa", "SPECIES", 221, 239], ["Magnolia compressa", "SPECIES", 221, 239], ["an in vitro assay", "TEST", 9, 26], ["IkBa", "TREATMENT", 126, 130], ["MCP", "TEST", 154, 157], ["Micheliolide", "TREATMENT", 203, 215], ["mesangial cells", "ANATOMY", 167, 182], ["Magnolia compressa", "OBSERVATION", 221, 239]]], ["SargIn addition, the dimethylamino Michael adduct of 13 known as dimethylaminomicheliolide is a pro-drug of this sesquiterpene lactone approved for clinical trials for glioblastoma treatment .", [["glioblastoma", "ANATOMY", 168, 180], ["SargIn", "CHEMICAL", 0, 6], ["dimethylaminomicheliolide", "CHEMICAL", 65, 90], ["sesquiterpene lactone", "CHEMICAL", 113, 134], ["glioblastoma", "DISEASE", 168, 180], ["SargIn", "CHEMICAL", 0, 6], ["dimethylamino", "CHEMICAL", 21, 34], ["dimethylaminomicheliolide", "CHEMICAL", 65, 90], ["sesquiterpene lactone", "CHEMICAL", 113, 134], ["SargIn", "SIMPLE_CHEMICAL", 0, 6], ["dimethylamino Michael adduct", "SIMPLE_CHEMICAL", 21, 49], ["dimethylaminomicheliolide", "SIMPLE_CHEMICAL", 65, 90], ["sesquiterpene lactone", "SIMPLE_CHEMICAL", 113, 134], ["glioblastoma", "CANCER", 168, 180], ["the dimethylamino Michael adduct", "TREATMENT", 17, 49], ["this sesquiterpene lactone", "TREATMENT", 108, 134], ["clinical trials", "TREATMENT", 148, 163], ["glioblastoma treatment", "TREATMENT", 168, 190], ["glioblastoma", "OBSERVATION", 168, 180]]], ["This compound protects the kidneys against proteinuria, renal failure, histopathological injury, and inflammation by suppressing activation of the NF-kB signaling pathway in db/db mice .", [["kidneys", "ANATOMY", 27, 34], ["renal", "ANATOMY", 56, 61], ["proteinuria", "DISEASE", 43, 54], ["renal failure", "DISEASE", 56, 69], ["inflammation", "DISEASE", 101, 113], ["kidneys", "ORGAN", 27, 34], ["renal", "ORGAN", 56, 61], ["NF-kB", "GENE_OR_GENE_PRODUCT", 147, 152], ["db/db mice", "ORGANISM", 174, 184], ["NF-kB", "PROTEIN", 147, 152], ["mice", "SPECIES", 180, 184], ["proteinuria", "PROBLEM", 43, 54], ["renal failure", "PROBLEM", 56, 69], ["histopathological injury", "PROBLEM", 71, 95], ["inflammation", "PROBLEM", 101, 113], ["kidneys", "ANATOMY", 27, 34], ["proteinuria", "OBSERVATION", 43, 54], ["renal", "ANATOMY", 56, 61], ["failure", "OBSERVATION", 62, 69], ["histopathological", "OBSERVATION_MODIFIER", 71, 88], ["injury", "OBSERVATION", 89, 95], ["inflammation", "OBSERVATION", 101, 113]]], ["These results showed that dimethylaminomicheliolide intervention mitigated diabetic kidney disease in db/db mice without directly affecting hyperglycemia.Micheliolide from Magnolia compressa (Maxim.)", [["kidney", "ANATOMY", 84, 90], ["dimethylaminomicheliolide", "CHEMICAL", 26, 51], ["diabetic kidney disease", "DISEASE", 75, 98], ["hyperglycemia", "DISEASE", 140, 153], ["Micheliolide", "CHEMICAL", 154, 166], ["dimethylaminomicheliolide", "CHEMICAL", 26, 51], ["Micheliolide", "CHEMICAL", 154, 166], ["dimethylaminomicheliolide", "SIMPLE_CHEMICAL", 26, 51], ["kidney", "ORGAN", 84, 90], ["Micheliolide", "SIMPLE_CHEMICAL", 154, 166], ["Magnolia compressa", "ORGANISM", 172, 190], ["mice", "SPECIES", 108, 112], ["Magnolia compressa", "SPECIES", 172, 190], ["db/db mice", "SPECIES", 102, 112], ["Magnolia compressa", "SPECIES", 172, 190], ["dimethylaminomicheliolide intervention", "TREATMENT", 26, 64], ["diabetic kidney disease in db/db mice", "PROBLEM", 75, 112], ["hyperglycemia", "PROBLEM", 140, 153], ["Micheliolide", "TREATMENT", 154, 166], ["diabetic", "OBSERVATION_MODIFIER", 75, 83], ["kidney", "ANATOMY", 84, 90], ["disease", "OBSERVATION", 91, 98], ["hyperglycemia", "OBSERVATION", 140, 153], ["Magnolia compressa", "OBSERVATION", 172, 190]]], ["SargFurthermore, it has been demonstrated that micheliolide (13) alleviates hepatic steatosis in obese db/db mice, and the molecular mechanisms driving the therapeutic effects of this compound might involve PPAR-g upregulation to consequently inhibit NF-kB mediated inflammation and activate AMPK/mTOR-dependent autophagy (Zhong et al., 2018) .", [["hepatic", "ANATOMY", 76, 83], ["micheliolide", "CHEMICAL", 47, 59], ["hepatic steatosis", "DISEASE", 76, 93], ["inflammation", "DISEASE", 266, 278], ["micheliolide", "CHEMICAL", 47, 59], ["micheliolide (13)", "SIMPLE_CHEMICAL", 47, 64], ["hepatic", "ORGAN", 76, 83], ["db/db mice", "ORGANISM", 103, 113], ["PPAR-g", "GENE_OR_GENE_PRODUCT", 207, 213], ["NF-kB", "GENE_OR_GENE_PRODUCT", 251, 256], ["AMPK", "GENE_OR_GENE_PRODUCT", 292, 296], ["mTOR", "GENE_OR_GENE_PRODUCT", 297, 301], ["PPAR", "PROTEIN", 207, 211], ["NF-kB", "PROTEIN", 251, 256], ["AMPK", "PROTEIN", 292, 296], ["mTOR", "PROTEIN", 297, 301], ["mice", "SPECIES", 109, 113], ["hepatic steatosis in obese db/db mice", "PROBLEM", 76, 113], ["the molecular mechanisms", "PROBLEM", 119, 143], ["this compound", "PROBLEM", 179, 192], ["PPAR", "TEST", 207, 211], ["NF", "PROBLEM", 251, 253], ["kB mediated inflammation", "PROBLEM", 254, 278], ["AMPK/mTOR", "TEST", 292, 301], ["dependent autophagy", "PROBLEM", 302, 321], ["hepatic", "ANATOMY", 76, 83], ["steatosis", "OBSERVATION", 84, 93], ["obese", "OBSERVATION", 97, 102], ["inflammation", "OBSERVATION", 266, 278]]], ["Thus, it will be interesting to future work evaluate if this effect in hepatic steatosis impacts glucose metabolism.", [["hepatic", "ANATOMY", 71, 78], ["steatosis", "DISEASE", 79, 88], ["glucose", "CHEMICAL", 97, 104], ["glucose", "CHEMICAL", 97, 104], ["hepatic", "ORGAN", 71, 78], ["glucose", "SIMPLE_CHEMICAL", 97, 104], ["hepatic steatosis impacts glucose metabolism", "PROBLEM", 71, 115], ["hepatic", "ANATOMY", 71, 78], ["steatosis", "OBSERVATION", 79, 88]]], ["No in vivo toxicity studies on micheliolide (13) have been reported to date.Byrsonines A and B from Byrsonima crassifolia (L.)", [["toxicity", "DISEASE", 11, 19], ["micheliolide", "CHEMICAL", 31, 43], ["Byrsonines A and B", "CHEMICAL", 76, 94], ["micheliolide", "CHEMICAL", 31, 43], ["Byrsonines A and B", "CHEMICAL", 76, 94], ["micheliolide", "SIMPLE_CHEMICAL", 31, 43], ["Byrsonines A", "SIMPLE_CHEMICAL", 76, 88], ["B", "GENE_OR_GENE_PRODUCT", 93, 94], ["Byrsonima crassifolia", "ORGANISM", 100, 121], ["L.)", "ORGANISM", 123, 126], ["Byrsonima crassifolia", "SPECIES", 100, 121], ["Byrsonima crassifolia", "SPECIES", 100, 121], ["micheliolide", "TREATMENT", 31, 43]]], ["KunthByrsonima crassifolia (Malpighiaceae), commonly known as \"nanche\", is a tropical tree widely distributed in Mexico, Central and South America.", [["KunthByrsonima", "CHEMICAL", 0, 14], ["KunthByrsonima crassifolia", "ORGANISM", 0, 26], ["Malpighiaceae", "ORGANISM", 28, 41], ["KunthByrsonima crassifolia", "SPECIES", 0, 26], ["KunthByrsonima crassifolia", "SPECIES", 0, 26], ["tropical tree", "OBSERVATION", 77, 90], ["Central", "ANATOMY_MODIFIER", 121, 128]]], ["This tree is commonly harvested, both for its edible fruit and for its health benefits (B ejar and Malone, 1993; Duarte, 2011) .", [["fruit", "ANATOMY", 53, 58], ["commonly", "OBSERVATION_MODIFIER", 13, 21], ["harvested", "OBSERVATION", 22, 31]]], ["In folk medicine, the fruit or bark infusion have been used as hypoglycemic remedy (Andrade-Cetto and Heinrich, 2005) and according to ethnomedicinal reports, the antihyperglycemic activity of hexane and chloroform extracts from fruits and seeds of B. crassifolia in STZinduced diabetic rats was reported (Perez-Gutierrez et al., 2010) .", [["fruit", "ANATOMY", 22, 27], ["bark", "ANATOMY", 31, 35], ["extracts", "ANATOMY", 215, 223], ["fruits", "ANATOMY", 229, 235], ["seeds", "ANATOMY", 240, 245], ["hexane and chloroform extracts from fruits and seeds of B. crassifolia", "CHEMICAL", 193, 263], ["diabetic", "DISEASE", 278, 286], ["hexane", "CHEMICAL", 193, 199], ["chloroform", "CHEMICAL", 204, 214], ["bark", "ORGANISM_SUBDIVISION", 31, 35], ["hexane", "SIMPLE_CHEMICAL", 193, 199], ["chloroform extracts", "ORGANISM_SUBSTANCE", 204, 223], ["fruits", "ORGANISM_SUBDIVISION", 229, 235], ["seeds", "ORGANISM_SUBDIVISION", 240, 245], ["B. crassifolia", "ORGANISM", 249, 263], ["STZinduced diabetic rats", "ORGANISM", 267, 291], ["B. crassifolia", "SPECIES", 249, 263], ["rats", "SPECIES", 287, 291], ["B. crassifolia", "SPECIES", 249, 263], ["folk medicine", "TREATMENT", 3, 16], ["bark infusion", "TREATMENT", 31, 44], ["hypoglycemic remedy", "PROBLEM", 63, 82], ["the antihyperglycemic activity of hexane", "TREATMENT", 159, 199], ["chloroform extracts", "TREATMENT", 204, 223], ["B. crassifolia in STZinduced diabetic rats", "PROBLEM", 249, 291]]], ["The phytochemical analysis of antihyperglycemic extract from the seed of B. crassifolia revealed that byrsonines A (14) and B (15) (Fig. 2) , two dimeric guaianolides, are responsible for the antioxidant, hypoglycemic and hypolipidemic activities (Guti errez and Ramirez, 2016) .", [["seed", "ANATOMY", 65, 69], ["antihyperglycemic extract", "CHEMICAL", 30, 55], ["byrsonines A (14) and B", "CHEMICAL", 102, 125], ["guaianolides", "CHEMICAL", 154, 166], ["hypoglycemic", "DISEASE", 205, 217], ["byrsonines A (14) and B", "CHEMICAL", 102, 125], ["guaianolides", "CHEMICAL", 154, 166], ["seed", "ORGANISM_SUBDIVISION", 65, 69], ["B. crassifolia", "ORGANISM", 73, 87], ["byrsonines A (14)", "SIMPLE_CHEMICAL", 102, 119], ["B (15)", "SIMPLE_CHEMICAL", 124, 130], ["Fig. 2", "SIMPLE_CHEMICAL", 132, 138], ["guaianolides", "SIMPLE_CHEMICAL", 154, 166], ["B. crassifolia", "SPECIES", 73, 87], ["B. crassifolia", "SPECIES", 73, 87], ["The phytochemical analysis", "TEST", 0, 26], ["antihyperglycemic extract", "TREATMENT", 30, 55], ["B. crassifolia", "TEST", 73, 87], ["byrsonines A", "TEST", 102, 114], ["the antioxidant", "PROBLEM", 188, 203], ["hypoglycemic", "PROBLEM", 205, 217], ["hypolipidemic activities", "PROBLEM", 222, 246]]], ["In particular, it has been proposed that the antihyperglycemic activity of these compounds may involve both pancreatic and extra pancreatic mechanisms, based on the observed increase in serum insulin level and the reduction of hepatic glucose output via decreasing glucose-6phosphatase (G6Pase) activity and increasing glucokinase activity (Guti errez and Ramirez, 2016) .", [["pancreatic", "ANATOMY", 108, 118], ["pancreatic", "ANATOMY", 129, 139], ["serum", "ANATOMY", 186, 191], ["hepatic", "ANATOMY", 227, 234], ["glucose", "CHEMICAL", 235, 242], ["glucose", "CHEMICAL", 265, 272], ["glucose", "CHEMICAL", 235, 242], ["glucose", "CHEMICAL", 265, 272], ["pancreatic", "MULTI-TISSUE_STRUCTURE", 108, 118], ["pancreatic", "ORGAN", 129, 139], ["serum", "ORGANISM_SUBSTANCE", 186, 191], ["insulin", "GENE_OR_GENE_PRODUCT", 192, 199], ["hepatic", "ORGAN", 227, 234], ["glucose", "SIMPLE_CHEMICAL", 235, 242], ["glucose-6phosphatase", "GENE_OR_GENE_PRODUCT", 265, 285], ["G6Pase", "GENE_OR_GENE_PRODUCT", 287, 293], ["glucokinase", "GENE_OR_GENE_PRODUCT", 319, 330], ["serum insulin", "PROTEIN", 186, 199], ["glucose-6phosphatase", "PROTEIN", 265, 285], ["G6Pase", "PROTEIN", 287, 293], ["glucokinase", "PROTEIN", 319, 330], ["these compounds", "TREATMENT", 75, 90], ["both pancreatic and extra pancreatic mechanisms", "PROBLEM", 103, 150], ["serum insulin level", "TEST", 186, 205], ["hepatic glucose output", "TEST", 227, 249], ["decreasing glucose", "PROBLEM", 254, 272], ["increasing glucokinase activity", "PROBLEM", 308, 339], ["pancreatic", "ANATOMY", 108, 118], ["pancreatic", "ANATOMY", 129, 139], ["increase", "OBSERVATION_MODIFIER", 174, 182], ["hepatic", "ANATOMY", 227, 234], ["glucose output", "OBSERVATION", 235, 249], ["increasing", "OBSERVATION_MODIFIER", 308, 318], ["glucokinase activity", "OBSERVATION", 319, 339]]], ["Although the mechanisms underlying the antihyperglycemic activity of 14 and 15 have not been completely explored, this effect could likely be ascribed to the activation AMPactivated protein kinase (AMPK).", [["AMPactivated protein kinase", "GENE_OR_GENE_PRODUCT", 169, 196], ["AMPK", "GENE_OR_GENE_PRODUCT", 198, 202], ["activation AMPactivated protein kinase", "PROTEIN", 158, 196], ["AMPK", "PROTEIN", 198, 202], ["the antihyperglycemic activity", "TEST", 35, 65], ["antihyperglycemic", "OBSERVATION_MODIFIER", 39, 56]]], ["Activation of the AMPK pathway in the liver regulates glucose homeostasis by inhibiting hepatic glucose production and downregulating the expression of gluconeogenic genes, including G6Pase gene expression.", [["liver", "ANATOMY", 38, 43], ["hepatic", "ANATOMY", 88, 95], ["glucose", "CHEMICAL", 54, 61], ["glucose", "CHEMICAL", 96, 103], ["glucose", "CHEMICAL", 54, 61], ["glucose", "CHEMICAL", 96, 103], ["AMPK", "GENE_OR_GENE_PRODUCT", 18, 22], ["liver", "ORGAN", 38, 43], ["glucose", "SIMPLE_CHEMICAL", 54, 61], ["hepatic", "MULTI-TISSUE_STRUCTURE", 88, 95], ["glucose", "SIMPLE_CHEMICAL", 96, 103], ["G6Pase", "GENE_OR_GENE_PRODUCT", 183, 189], ["AMPK", "PROTEIN", 18, 22], ["gluconeogenic genes", "DNA", 152, 171], ["G6Pase gene", "DNA", 183, 194], ["the AMPK pathway", "TREATMENT", 14, 30], ["hepatic glucose production", "TREATMENT", 88, 114], ["gluconeogenic genes", "TREATMENT", 152, 171], ["G6Pase gene expression", "TREATMENT", 183, 205], ["liver", "ANATOMY", 38, 43], ["glucose homeostasis", "OBSERVATION", 54, 73], ["hepatic", "ANATOMY", 88, 95], ["glucose production", "OBSERVATION", 96, 114], ["gluconeogenic genes", "OBSERVATION", 152, 171]]], ["Targeting AMPK by natural products demonstrated considerable success in lowering blood glucose levels (Joshi et al., 2019) .", [["blood", "ANATOMY", 81, 86], ["glucose", "CHEMICAL", 87, 94], ["glucose", "CHEMICAL", 87, 94], ["AMPK", "GENE_OR_GENE_PRODUCT", 10, 14], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["glucose", "SIMPLE_CHEMICAL", 87, 94], ["AMPK", "PROTEIN", 10, 14], ["lowering blood glucose levels", "TEST", 72, 101], ["considerable", "OBSERVATION_MODIFIER", 48, 60], ["success", "OBSERVATION_MODIFIER", 61, 68]]], ["Nevertheless, more experimental research is needed to substantiate this claim.Byrsonines A and B from Byrsonima crassifolia (L.)", [["Byrsonines A and B", "CHEMICAL", 78, 96], ["Byrsonines A and B", "CHEMICAL", 78, 96], ["Byrsonines A", "SIMPLE_CHEMICAL", 78, 90], ["B", "GENE_OR_GENE_PRODUCT", 95, 96], ["Byrsonima crassifolia", "ORGANISM", 102, 123], ["L.)", "ORGANISM", 125, 128], ["Byrsonima crassifolia", "SPECIES", 102, 123], ["Byrsonima crassifolia", "SPECIES", 102, 123]]], ["KunthOn the other hand, the induction of antioxidant enzymes in hepatic, renal, and pancreas tissues after the administration of 14 and 15, indicates a positive effect of these molecules in improving glycemic control in STZ-induced diabetic rats (Guti errez and Ramirez, 2016), since oxidative stress takes an important role in the pathogenesis and progression of diabetic tissue injury.", [["hepatic", "ANATOMY", 64, 71], ["renal", "ANATOMY", 73, 78], ["pancreas tissues", "ANATOMY", 84, 100], ["tissue", "ANATOMY", 373, 379], ["STZ", "CHEMICAL", 220, 223], ["diabetic", "DISEASE", 232, 240], ["diabetic tissue injury", "DISEASE", 364, 386], ["STZ", "CHEMICAL", 220, 223], ["hepatic", "MULTI-TISSUE_STRUCTURE", 64, 71], ["renal", "ORGAN", 73, 78], ["pancreas tissues", "TISSUE", 84, 100], ["STZ", "SIMPLE_CHEMICAL", 220, 223], ["rats", "ORGANISM", 241, 245], ["tissue", "TISSUE", 373, 379], ["antioxidant enzymes", "PROTEIN", 41, 60], ["rats", "SPECIES", 241, 245], ["antioxidant enzymes", "TEST", 41, 60], ["these molecules", "PROBLEM", 171, 186], ["diabetic rats", "PROBLEM", 232, 245], ["oxidative stress", "PROBLEM", 284, 300], ["diabetic tissue injury", "PROBLEM", 364, 386], ["hepatic", "ANATOMY", 64, 71], ["renal", "ANATOMY", 73, 78], ["pancreas", "ANATOMY", 84, 92], ["positive effect", "OBSERVATION_MODIFIER", 152, 167], ["improving", "OBSERVATION_MODIFIER", 190, 199], ["glycemic control", "OBSERVATION", 200, 216], ["progression", "OBSERVATION_MODIFIER", 349, 360], ["diabetic tissue injury", "OBSERVATION", 364, 386]]], ["In this sense, the reported improvement in insulin resistance by byrsonines A and B can be related to the observed increase in the HDL-C levels and the decrease in TC, TG, LDL-C, and VLDL (Guti errez and Ramirez, 2016).", [["byrsonines A and B", "CHEMICAL", 65, 83], ["byrsonines A and B", "CHEMICAL", 65, 83], ["insulin", "GENE_OR_GENE_PRODUCT", 43, 50], ["byrsonines A", "SIMPLE_CHEMICAL", 65, 77], ["B", "SIMPLE_CHEMICAL", 82, 83], ["HDL-C", "SIMPLE_CHEMICAL", 131, 136], ["TC", "SIMPLE_CHEMICAL", 164, 166], ["TG", "SIMPLE_CHEMICAL", 168, 170], ["LDL-C", "SIMPLE_CHEMICAL", 172, 177], ["VLDL", "SIMPLE_CHEMICAL", 183, 187], ["HDL", "PROTEIN", 131, 134], ["LDL", "PROTEIN", 172, 175], ["insulin resistance", "PROBLEM", 43, 61], ["the HDL", "TEST", 127, 134], ["the decrease in TC", "PROBLEM", 148, 166], ["TG", "TEST", 168, 170], ["LDL", "TEST", 172, 175], ["C", "TEST", 176, 177], ["VLDL", "TEST", 183, 187], ["improvement", "OBSERVATION_MODIFIER", 28, 39], ["insulin resistance", "OBSERVATION", 43, 61], ["increase", "OBSERVATION_MODIFIER", 115, 123], ["decrease", "OBSERVATION_MODIFIER", 152, 160]]], ["Additionally, TNF-a levels were also decreased after treatment of byrsonines A and B in STZ-induced diabetic rats.Byrsonines A and B from Byrsonima crassifolia (L.)", [["byrsonines A and B", "CHEMICAL", 66, 84], ["STZ", "CHEMICAL", 88, 91], ["diabetic", "DISEASE", 100, 108], ["Byrsonines A and B", "CHEMICAL", 114, 132], ["byrsonines A and B", "CHEMICAL", 66, 84], ["STZ", "CHEMICAL", 88, 91], ["Byrsonines A and B", "CHEMICAL", 114, 132], ["TNF-a", "GENE_OR_GENE_PRODUCT", 14, 19], ["byrsonines A", "SIMPLE_CHEMICAL", 66, 78], ["B", "SIMPLE_CHEMICAL", 83, 84], ["STZ", "SIMPLE_CHEMICAL", 88, 91], ["rats", "ORGANISM", 109, 113], ["Byrsonines A", "SIMPLE_CHEMICAL", 114, 126], ["B", "GENE_OR_GENE_PRODUCT", 131, 132], ["Byrsonima crassifolia", "ORGANISM", 138, 159], ["L.)", "ORGANISM", 161, 164], ["TNF", "PROTEIN", 14, 17], ["rats", "SPECIES", 109, 113], ["Byrsonima crassifolia", "SPECIES", 138, 159], ["Byrsonima crassifolia", "SPECIES", 138, 159], ["TNF", "TEST", 14, 17], ["a levels", "TEST", 18, 26], ["byrsonines", "TREATMENT", 66, 76], ["induced diabetic rats", "PROBLEM", 92, 113], ["decreased", "OBSERVATION_MODIFIER", 37, 46], ["diabetic", "OBSERVATION", 100, 108]]], ["KunthThe bioactivity described for 14 and 15 makes them one of the most active guaianolides on different components of MetS reported at this time.", [["guaianolides", "CHEMICAL", 79, 91], ["MetS", "DISEASE", 119, 123], ["guaianolides", "CHEMICAL", 79, 91], ["guaianolides", "SIMPLE_CHEMICAL", 79, 91], ["Kunth", "SPECIES", 0, 5], ["MetS", "PROBLEM", 119, 123], ["bioactivity", "OBSERVATION", 9, 20], ["MetS", "OBSERVATION", 119, 123]]], ["As described above, another molecule of this family with activity on different components of MetS is eremathin.", [["MetS", "DISEASE", 93, 97], ["eremathin", "CHEMICAL", 101, 110], ["eremathin", "SIMPLE_CHEMICAL", 101, 110], ["MetS", "PROBLEM", 93, 97], ["eremathin", "PROBLEM", 101, 110], ["MetS", "OBSERVATION", 93, 97]]], ["However, byrsonines A and B (14, 15) seems to be more effective, which could be due to their dimeric structure that provides two possible Michaels acceptors.", [["byrsonines A and B", "CHEMICAL", 9, 27], ["byrsonines A and B", "CHEMICAL", 9, 27], ["byrsonines A", "SIMPLE_CHEMICAL", 9, 21], ["B", "SIMPLE_CHEMICAL", 26, 27], ["Michaels acceptors", "SIMPLE_CHEMICAL", 138, 156], ["Michaels acceptors", "TREATMENT", 138, 156], ["more effective", "OBSERVATION_MODIFIER", 49, 63]]], ["Dimeric SLns have been found to be more potently cytotoxic than their monomers toward human cancer cells, indicating that the antitumor potential of SLns are improved by the presence of additional a-methylene-g-lactone ring (Singh et al., 2011; Ren et al., 2016) .", [["cancer cells", "ANATOMY", 92, 104], ["antitumor", "ANATOMY", 126, 135], ["cancer", "DISEASE", 92, 98], ["SLns", "CHEMICAL", 149, 153], ["a-methylene-g-lactone", "CHEMICAL", 197, 218], ["a-methylene-g-lactone", "CHEMICAL", 197, 218], ["SLns", "SIMPLE_CHEMICAL", 8, 12], ["human", "ORGANISM", 86, 91], ["cancer cells", "CELL", 92, 104], ["antitumor", "CANCER", 126, 135], ["SLns", "SIMPLE_CHEMICAL", 149, 153], ["a-methylene-g-lactone ring", "SIMPLE_CHEMICAL", 197, 223], ["SLns", "PROTEIN", 8, 12], ["human cancer cells", "CELL_TYPE", 86, 104], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["Dimeric SLns", "TREATMENT", 0, 12], ["human cancer cells", "PROBLEM", 86, 104], ["SLns", "PROBLEM", 149, 153], ["additional a-methylene-g-lactone ring", "TREATMENT", 186, 223], ["SLns", "OBSERVATION", 8, 12], ["more potently", "OBSERVATION_MODIFIER", 35, 48], ["cytotoxic", "OBSERVATION_MODIFIER", 49, 58], ["cancer cells", "OBSERVATION", 92, 104], ["SLns", "OBSERVATION", 149, 153]]], ["This phenomenon could be studied in 14 and 15 for MetS treatment due to their extended activity reviewed here.", [["MetS", "DISEASE", 50, 54], ["MetS treatment", "TREATMENT", 50, 64]]], ["Moreover, pharmacokinetics studies are needed to understand either byrsonines suffer biotransformation reactions and act as monomeric molecules or if they can show biological activity in their original dimeric forms.", [["byrsonines", "CHEMICAL", 67, 77], ["byrsonines", "CHEMICAL", 67, 77], ["byrsonines", "SIMPLE_CHEMICAL", 67, 77], ["pharmacokinetics studies", "TEST", 10, 34], ["biotransformation reactions", "PROBLEM", 85, 112]]], ["No in vivo toxicity studies on byrsonines A (14) and B (15) have been reported to date.Lactucain from Lactuca indica LinnVarious species of the genus Lactuca are globally important edible plants containing valuable nutrients such as polyphenols, sterols, vitamins, minerals, and dietary fiber.", [["toxicity", "DISEASE", 11, 19], ["byrsonines", "CHEMICAL", 31, 41], ["Lactucain", "CHEMICAL", 87, 96], ["sterols", "CHEMICAL", 246, 253], ["vitamins, minerals", "CHEMICAL", 255, 273], ["byrsonines A (14) and B", "CHEMICAL", 31, 54], ["Lactucain", "CHEMICAL", 87, 96], ["polyphenols", "CHEMICAL", 233, 244], ["sterols", "CHEMICAL", 246, 253], ["vitamins", "CHEMICAL", 255, 263], ["byrsonines A (14)", "SIMPLE_CHEMICAL", 31, 48], ["B (15)", "SIMPLE_CHEMICAL", 53, 59], ["Lactucain", "SIMPLE_CHEMICAL", 87, 96], ["Lactuca indica", "ORGANISM", 102, 116], ["LinnVarious species", "ORGANISM", 117, 136], ["genus Lactuca", "ORGANISM", 144, 157], ["polyphenols", "SIMPLE_CHEMICAL", 233, 244], ["sterols", "SIMPLE_CHEMICAL", 246, 253], ["vitamins", "SIMPLE_CHEMICAL", 255, 263], ["minerals", "SIMPLE_CHEMICAL", 265, 273], ["Lactuca indica", "SPECIES", 102, 116], ["Lactuca", "SPECIES", 150, 157], ["Lactuca indica", "SPECIES", 102, 116], ["Lactucain", "TREATMENT", 87, 96], ["valuable nutrients", "TREATMENT", 206, 224], ["polyphenols", "TREATMENT", 233, 244], ["sterols", "TREATMENT", 246, 253], ["vitamins", "TREATMENT", 255, 263], ["minerals", "TREATMENT", 265, 273], ["dietary fiber", "TREATMENT", 279, 292], ["LinnVarious species", "OBSERVATION", 117, 136], ["genus Lactuca", "OBSERVATION", 144, 157]]], ["L. sativa L., Lactuca indica L. and L. serriola L. (syn.", [["L. sativa", "ORGANISM", 0, 9], ["L.", "ORGANISM", 10, 12], ["Lactuca indica", "ORGANISM", 14, 28], ["L.", "ORGANISM", 29, 31], ["L. serriola L.", "ORGANISM", 36, 50], ["L. sativa", "SPECIES", 0, 9], ["L.", "SPECIES", 10, 12], ["Lactuca indica", "SPECIES", 14, 28], ["L.", "SPECIES", 29, 31], ["L. serriola", "SPECIES", 36, 47], ["L.", "SPECIES", 48, 50], ["L. sativa L.", "SPECIES", 0, 12], ["Lactuca indica L.", "SPECIES", 14, 31], ["L. serriola L.", "SPECIES", 36, 50], ["sativa", "OBSERVATION_MODIFIER", 3, 9], ["L.", "OBSERVATION_MODIFIER", 10, 12], ["L.", "OBSERVATION_MODIFIER", 36, 38], ["serriola", "OBSERVATION_MODIFIER", 39, 47], ["syn", "ANATOMY", 52, 55]]], ["L. scariola L.) have been used in the treatment of diabetes mellitus, hypertension, and cardiac diseases (Eddouks et al., 2002; Subramoniam, 2016) .", [["cardiac", "ANATOMY", 88, 95], ["diabetes mellitus", "DISEASE", 51, 68], ["hypertension", "DISEASE", 70, 82], ["cardiac diseases", "DISEASE", 88, 104], ["L. scariola L.", "ORGANISM", 0, 14], ["cardiac", "ORGAN", 88, 95], ["L. scariola L.", "SPECIES", 0, 14], ["L. scariola L.", "SPECIES", 0, 14], ["diabetes mellitus", "PROBLEM", 51, 68], ["hypertension", "PROBLEM", 70, 82], ["cardiac diseases", "PROBLEM", 88, 104], ["diabetes", "OBSERVATION", 51, 59], ["hypertension", "OBSERVATION", 70, 82], ["cardiac", "ANATOMY", 88, 95], ["diseases", "OBSERVATION", 96, 104]]], ["In vivo experiments of some Lactuca species shown the ability to reduce several metabolic risk factors, especially hyperglycemia, TG and TC (Nicolle et al., 2004; Salih, 2019) .", [["hyperglycemia", "DISEASE", 115, 128], ["TG", "DISEASE", 130, 132], ["Lactuca species", "ORGANISM", 28, 43], ["TG", "SIMPLE_CHEMICAL", 130, 132], ["some Lactuca species", "PROBLEM", 23, 43], ["several metabolic risk factors", "PROBLEM", 72, 102], ["hyperglycemia", "PROBLEM", 115, 128], ["TG", "TEST", 130, 132], ["Lactuca species", "OBSERVATION", 28, 43]]], ["SLns are commonly found in Lactuca species and are represented as subgroups such as lactucin-type guaianolides and the eudesmanolide-type.", [["lactucin-type guaianolides", "CHEMICAL", 84, 110], ["eudesmanolide", "CHEMICAL", 119, 132], ["lactucin", "CHEMICAL", 84, 92], ["guaianolides", "CHEMICAL", 98, 110], ["eudesmanolide", "CHEMICAL", 119, 132], ["SLns", "GENE_OR_GENE_PRODUCT", 0, 4], ["Lactuca species", "ORGANISM", 27, 42], ["lactucin-type guaianolides", "SIMPLE_CHEMICAL", 84, 110], ["eudesmanolide", "SIMPLE_CHEMICAL", 119, 132], ["SLns", "PROTEIN", 0, 4], ["SLns", "TREATMENT", 0, 4], ["Lactuca species", "PROBLEM", 27, 42], ["Lactuca species", "OBSERVATION", 27, 42]]], ["The latter is commonly found in some species of Lactuca such as L. sativa L. var. anagustata, L. saligna L. and L. canadensis L. (Han et al., 2010; Kisiel and Gromek, 1993; Michalska et al., 2013) .Lactucain from Lactuca indica LinnThe dimeric guaianolide lactucain C (16) (Fig. 2) , isolated from L. indica Linn. showed moderate lowering of plasma glucose in STZ-diabetic rats (Hou et al., 2003) .", [["plasma", "ANATOMY", 342, 348], ["Lactucain", "CHEMICAL", 198, 207], ["guaianolide lactucain C", "CHEMICAL", 244, 267], ["glucose", "CHEMICAL", 349, 356], ["STZ", "CHEMICAL", 360, 363], ["diabetic", "DISEASE", 364, 372], ["Lactucain", "CHEMICAL", 198, 207], ["lactucain C", "CHEMICAL", 256, 267], ["glucose", "CHEMICAL", 349, 356], ["STZ", "CHEMICAL", 360, 363], ["Lactuca", "ORGANISM_SUBDIVISION", 48, 55], ["L. sativa", "ORGANISM", 64, 73], ["L.", "ORGANISM", 74, 76], ["var", "ORGANISM", 77, 80], ["anagustata", "ORGANISM", 82, 92], ["L. saligna L.", "ORGANISM", 94, 107], ["L. canadensis", "ORGANISM", 112, 125], ["L.", "ORGANISM", 126, 128], ["Lactucain", "SIMPLE_CHEMICAL", 198, 207], ["Lactuca indica", "ORGANISM", 213, 227], ["guaianolide lactucain C (16)", "SIMPLE_CHEMICAL", 244, 272], ["Fig. 2)", "SIMPLE_CHEMICAL", 274, 281], ["L. indica", "ORGANISM", 298, 307], ["Linn", "ORGANISM", 308, 312], ["plasma", "ORGANISM_SUBSTANCE", 342, 348], ["glucose", "SIMPLE_CHEMICAL", 349, 356], ["STZ", "SIMPLE_CHEMICAL", 360, 363], ["rats", "ORGANISM", 373, 377], ["L. sativa", "SPECIES", 64, 73], ["L. var", "SPECIES", 74, 80], ["anagustata", "SPECIES", 82, 92], ["L. saligna", "SPECIES", 94, 104], ["L. canadensis", "SPECIES", 112, 125], ["L.", "SPECIES", 126, 128], ["Lactuca indica", "SPECIES", 213, 227], ["L. indica", "SPECIES", 298, 307], ["rats", "SPECIES", 373, 377], ["L. sativa", "SPECIES", 64, 73], ["anagustata", "SPECIES", 82, 92], ["L. saligna L.", "SPECIES", 94, 107], ["L. canadensis L.", "SPECIES", 112, 128], ["Lactuca indica", "SPECIES", 213, 227], ["L. indica", "SPECIES", 298, 307], ["Lactucain", "TREATMENT", 198, 207], ["Lactuca indica LinnThe dimeric guaianolide lactucain C", "TREATMENT", 213, 267], ["moderate lowering of plasma glucose", "PROBLEM", 321, 356], ["diabetic rats", "PROBLEM", 364, 377], ["L.", "OBSERVATION_MODIFIER", 112, 114], ["canadensis", "OBSERVATION_MODIFIER", 115, 125], ["L.", "OBSERVATION_MODIFIER", 126, 128], ["indica Linn", "OBSERVATION", 301, 312], ["moderate", "OBSERVATION_MODIFIER", 321, 329], ["lowering", "OBSERVATION_MODIFIER", 330, 338], ["plasma glucose", "OBSERVATION", 342, 356]]], ["Nevertheless, there are no evidences about the possible mechanism of action and no further research has been made about this compound.", [["no evidences", "UNCERTAINTY", 24, 36]]], ["As mentioned before, dimeric SLns could show an important activity in components of MetS derived from their double a,b-unsaturated g-lactone ring.", [["MetS", "DISEASE", 84, 88], ["b-unsaturated g-lactone", "CHEMICAL", 117, 140], ["b-unsaturated g-lactone", "CHEMICAL", 117, 140], ["SLns", "GENE_OR_GENE_PRODUCT", 29, 33], ["b-unsaturated g-lactone ring", "SIMPLE_CHEMICAL", 117, 145], ["dimeric SLns", "PROTEIN", 21, 33], ["dimeric SLns", "TEST", 21, 33], ["MetS", "PROBLEM", 84, 88], ["unsaturated g-lactone ring", "TREATMENT", 119, 145], ["MetS", "OBSERVATION", 84, 88]]], ["Because of its hypoglycemic properties and chemical structure, 16 is also a candidate to further studies that analyze deeply its effect in blood glucose levels and some other MetSs components.", [["blood", "ANATOMY", 139, 144], ["hypoglycemic", "DISEASE", 15, 27], ["glucose", "CHEMICAL", 145, 152], ["glucose", "CHEMICAL", 145, 152], ["blood", "ORGANISM_SUBSTANCE", 139, 144], ["glucose", "SIMPLE_CHEMICAL", 145, 152], ["MetSs", "GENE_OR_GENE_PRODUCT", 175, 180], ["its hypoglycemic properties", "PROBLEM", 11, 38], ["further studies", "TEST", 89, 104], ["blood glucose levels", "TEST", 139, 159], ["some other MetSs components", "PROBLEM", 164, 191], ["hypoglycemic properties", "OBSERVATION", 15, 38], ["chemical structure", "OBSERVATION", 43, 61]]], ["No in vivo toxicity studies on luctucain C (16) have been reported to date.Lactucain from Lactuca indica Linn6.10.", [["toxicity", "DISEASE", 11, 19], ["luctucain C", "CHEMICAL", 31, 42], ["Lactucain", "CHEMICAL", 75, 84], ["luctucain C", "CHEMICAL", 31, 42], ["luctucain C", "SIMPLE_CHEMICAL", 31, 42], ["Lactucain", "SIMPLE_CHEMICAL", 75, 84], ["Lactuca indica", "ORGANISM", 90, 104], ["Lactuca indica", "SPECIES", 90, 104], ["Lactuca indica", "SPECIES", 90, 104], ["Lactucain", "TREATMENT", 75, 84]]], ["8-Deoxylactucin from Cichorium intybus L Cichorium intybus, commonly known as chicory, was historically cultivated by the ancient Egyptians as a vegetable crop, a coffee substitute, and a medicinal plant.", [["8-Deoxylactucin", "CHEMICAL", 0, 15], ["8-Deoxylactucin", "CHEMICAL", 0, 15], ["8-Deoxylactucin", "SIMPLE_CHEMICAL", 0, 15], ["Cichorium intybus L Cichorium intybus", "ORGANISM", 21, 58], ["Egyptians", "ORGANISM", 130, 139], ["Cichorium intybus", "SPECIES", 21, 38], ["Cichorium intybus", "SPECIES", 41, 58], ["Cichorium intybus", "SPECIES", 21, 38], ["Cichorium intybus", "SPECIES", 41, 58], ["Deoxylactucin", "TREATMENT", 2, 15], ["Cichorium intybus L Cichorium intybus", "PROBLEM", 21, 58], ["a coffee substitute", "TREATMENT", 161, 180], ["a medicinal plant", "TREATMENT", 186, 203], ["Cichorium intybus", "OBSERVATION", 41, 58]]], ["Nowadays, it is appreciated for its bitter taste and widely used in India as a traditional treatment for diabetes mellitus (Al-Snafi, 2016; Pushparaj et al., 2007) .", [["diabetes mellitus", "DISEASE", 105, 122], ["a traditional treatment", "TREATMENT", 77, 100], ["diabetes mellitus", "PROBLEM", 105, 122]]], ["The antidiabetic, hypolipidemic, hepatoprotective, antioxidant and anti-inflammatory effects of C. intybus have been widely studied (Chandra and Sk, 2016) .", [["C. intybus", "ORGANISM", 96, 106], ["C. intybus", "SPECIES", 96, 106], ["C. intybus", "SPECIES", 96, 106], ["The antidiabetic", "TREATMENT", 0, 16], ["hypolipidemic", "TREATMENT", 18, 31], ["hepatoprotective", "TREATMENT", 33, 49], ["antioxidant", "TREATMENT", 51, 62], ["anti-inflammatory effects", "TREATMENT", 67, 92], ["C. intybus", "PROBLEM", 96, 106], ["antidiabetic", "OBSERVATION_MODIFIER", 4, 16], ["hypolipidemic", "OBSERVATION_MODIFIER", 18, 31]]], ["This broad spectrum of biological activities has been attributed to its high content of phytochemical constituents, being SLns the most abundant in roots and the responsible of the bitterness of leaves (Al-Snafi, 2016).Lactucain from Lactuca indica Linn8-deoxylactucin (17) (Fig. 2) is a guaianolide found as a major component of chicory root and it is also common in species of Lactuca.", [["roots", "ANATOMY", 148, 153], ["leaves", "ANATOMY", 195, 201], ["root", "ANATOMY", 338, 342], ["Lactucain", "CHEMICAL", 219, 228], ["Lactuca indica Linn8-deoxylactucin", "CHEMICAL", 234, 268], ["guaianolide", "CHEMICAL", 288, 299], ["Lactucain", "CHEMICAL", 219, 228], ["guaianolide", "CHEMICAL", 288, 299], ["SLns", "GENE_OR_GENE_PRODUCT", 122, 126], ["roots", "ORGAN", 148, 153], ["leaves", "ORGANISM_SUBDIVISION", 195, 201], ["Lactucain", "SIMPLE_CHEMICAL", 219, 228], ["Lactuca indica", "ORGANISM", 234, 248], ["Linn8-deoxylactucin (17)", "SIMPLE_CHEMICAL", 249, 273], ["Fig. 2", "SIMPLE_CHEMICAL", 275, 281], ["guaianolide", "SIMPLE_CHEMICAL", 288, 299], ["chicory root", "MULTI-TISSUE_STRUCTURE", 330, 342], ["Lactuca", "TISSUE", 379, 386], ["Lactuca indica", "SPECIES", 234, 248], ["Lactuca indica", "SPECIES", 234, 248], ["phytochemical constituents", "PROBLEM", 88, 114], ["SLns", "TREATMENT", 122, 126], ["Lactucain", "TREATMENT", 219, 228], ["Lactuca indica Linn8", "TREATMENT", 234, 254], ["deoxylactucin", "TREATMENT", 255, 268], ["a guaianolide", "TREATMENT", 286, 299], ["chicory root", "PROBLEM", 330, 342], ["high content", "OBSERVATION_MODIFIER", 72, 84], ["phytochemical constituents", "OBSERVATION", 88, 114], ["most abundant", "OBSERVATION_MODIFIER", 131, 144], ["chicory root", "OBSERVATION", 330, 342]]], ["It has been demonstrated that 17 possess anti-inflammatory activity by inhibiting the nuclear transcription factor NF-kB and as a selective inhibitor of COX-2 (Cavin et al., 2005 ).", [["nuclear", "ANATOMY", 86, 93], ["NF-kB", "GENE_OR_GENE_PRODUCT", 115, 120], ["COX-2", "GENE_OR_GENE_PRODUCT", 153, 158], ["nuclear transcription factor NF-kB", "PROTEIN", 86, 120], ["COX", "PROTEIN", 153, 156], ["a selective inhibitor of COX", "TREATMENT", 128, 156], ["17 possess", "OBSERVATION_MODIFIER", 30, 40], ["anti-inflammatory activity", "OBSERVATION", 41, 67]]], ["An important structural characteristic of 17 is the presence of a-methylene-g-lactone group and a,b-unsaturated cyclopentenone.", [["a-methylene-g-lactone", "CHEMICAL", 64, 85], ["cyclopentenone", "CHEMICAL", 112, 126], ["a-methylene-g-lactone", "CHEMICAL", 64, 85], ["b-unsaturated cyclopentenone", "CHEMICAL", 98, 126], ["a-methylene-g-lactone", "SIMPLE_CHEMICAL", 64, 85], ["b-unsaturated cyclopentenone", "SIMPLE_CHEMICAL", 98, 126], ["a-methylene-g-lactone group", "TREATMENT", 64, 91], ["unsaturated cyclopentenone", "TREATMENT", 100, 126]]], ["Compounds that possess these structures, such as Helenalin, can react with sulfhydryl group of Cys38 in NF-kB and prevent DNA binding (Ly\u00df et al., 1998; Widen et al., 2017) .", [["Helenalin", "CHEMICAL", 49, 58], ["sulfhydryl", "CHEMICAL", 75, 85], ["Helenalin", "CHEMICAL", 49, 58], ["sulfhydryl", "CHEMICAL", 75, 85], ["Cys38", "CHEMICAL", 95, 100], ["Helenalin", "SIMPLE_CHEMICAL", 49, 58], ["sulfhydryl", "SIMPLE_CHEMICAL", 75, 85], ["Cys38", "SIMPLE_CHEMICAL", 95, 100], ["NF-kB", "GENE_OR_GENE_PRODUCT", 104, 109], ["DNA", "CELLULAR_COMPONENT", 122, 125], ["NF-kB", "PROTEIN", 104, 109], ["DNA binding", "PROBLEM", 122, 133]]], ["Thus, 8-deoxylactucin (17) could interact with NF-kB by a similar mechanism.", [["8-deoxylactucin", "CHEMICAL", 6, 21], ["8-deoxylactucin", "CHEMICAL", 6, 21], ["8-deoxylactucin (17)", "SIMPLE_CHEMICAL", 6, 26], ["NF-kB", "GENE_OR_GENE_PRODUCT", 47, 52], ["NF-kB", "PROTEIN", 47, 52], ["deoxylactucin", "TREATMENT", 8, 21]]], ["No in vivo toxicity studies on 8-deoxylactucin (17) have been reported to date.Lactucain from Lactuca indica Linn6.11.", [["toxicity", "DISEASE", 11, 19], ["8-deoxylactucin", "CHEMICAL", 31, 46], ["Lactucain", "CHEMICAL", 79, 88], ["8-deoxylactucin", "CHEMICAL", 31, 46], ["Lactucain", "CHEMICAL", 79, 88], ["8-deoxylactucin", "SIMPLE_CHEMICAL", 31, 46], ["Lactucain", "SIMPLE_CHEMICAL", 79, 88], ["Lactuca indica", "ORGANISM", 94, 108], ["Linn6", "ORGANISM", 109, 114], ["Lactuca indica", "SPECIES", 94, 108], ["Lactuca indica", "SPECIES", 94, 108], ["vivo toxicity studies", "TEST", 6, 27], ["Lactucain", "TREATMENT", 79, 88]]], ["Artemisinin from Artemisia spp Artemisinin (18) (Fig. 2) is a cadinanolide endoperoxide sesquiterpene lactone originally isolated from Artemisa annua Linn in 1972 (Tu, 2016) .", [["Artemisinin", "CHEMICAL", 0, 11], ["Artemisia spp Artemisinin (18) (Fig. 2)", "CHEMICAL", 17, 56], ["cadinanolide endoperoxide sesquiterpene lactone", "CHEMICAL", 62, 109], ["Artemisinin", "CHEMICAL", 0, 11], ["Artemisinin", "CHEMICAL", 31, 42], ["cadinanolide endoperoxide", "CHEMICAL", 62, 87], ["sesquiterpene lactone", "CHEMICAL", 88, 109], ["Artemisinin", "SIMPLE_CHEMICAL", 0, 11], ["Artemisia spp", "ORGANISM", 17, 30], ["Artemisinin (18)", "SIMPLE_CHEMICAL", 31, 47], ["Fig. 2)", "SIMPLE_CHEMICAL", 49, 56], ["cadinanolide endoperoxide sesquiterpene lactone", "SIMPLE_CHEMICAL", 62, 109], ["Artemisa annua", "ORGANISM", 135, 149], ["Linn", "ORGANISM", 150, 154], ["Artemisa annua", "SPECIES", 135, 149], ["Artemisa annua", "SPECIES", 135, 149], ["Artemisinin", "TREATMENT", 0, 11], ["Artemisia spp Artemisinin", "TEST", 17, 42], ["a cadinanolide endoperoxide sesquiterpene lactone", "TREATMENT", 60, 109], ["Artemisia", "OBSERVATION_MODIFIER", 17, 26]]], ["Nowadays, 18 and their derivatives are part of the protocols for malaria treatment (Bridgford et al., 2018) .", [["malaria", "DISEASE", 65, 72], ["the protocols", "TREATMENT", 47, 60], ["malaria treatment", "TREATMENT", 65, 82]]], ["Experimental studies have also established their effectiveness as an anti-inflammatory, antioxidant, anti-tumor, and vascular protection agent Jiang et al., 2016; Efferth, 2017) .", [["vascular", "ANATOMY", 117, 125], ["anti-tumor", "CANCER", 101, 111], ["vascular", "MULTI-TISSUE_STRUCTURE", 117, 125], ["Experimental studies", "TEST", 0, 20], ["anti-tumor", "TREATMENT", 101, 111], ["vascular", "ANATOMY", 117, 125]]], ["Regarding to vascular protection, Cao et al. (2020) demonstrated that oral administration of artemisinin (18) effectively alleviated inflammatory response (MCP-1, IFN-g, IL-6 and TNF-a), elevated macrophage autophagy, suppressed foamy macrophage transformation, and thereby inhibiting atherosclerotic plaque formation in high-fat diet treated ApoE \u00c0/\u00c0 mice.", [["vascular", "ANATOMY", 13, 21], ["oral", "ANATOMY", 70, 74], ["macrophage", "ANATOMY", 196, 206], ["foamy macrophage", "ANATOMY", 229, 245], ["atherosclerotic plaque", "ANATOMY", 285, 307], ["artemisinin", "CHEMICAL", 93, 104], ["atherosclerotic plaque", "DISEASE", 285, 307], ["artemisinin", "CHEMICAL", 93, 104], ["vascular", "MULTI-TISSUE_STRUCTURE", 13, 21], ["oral", "ORGANISM_SUBDIVISION", 70, 74], ["artemisinin", "SIMPLE_CHEMICAL", 93, 104], ["MCP-1", "GENE_OR_GENE_PRODUCT", 156, 161], ["IFN-g", "GENE_OR_GENE_PRODUCT", 163, 168], ["IL-6", "GENE_OR_GENE_PRODUCT", 170, 174], ["TNF-a", "GENE_OR_GENE_PRODUCT", 179, 184], ["macrophage", "CELL", 196, 206], ["foamy macrophage", "CELL", 229, 245], ["atherosclerotic plaque", "PATHOLOGICAL_FORMATION", 285, 307], ["ApoE", "GENE_OR_GENE_PRODUCT", 343, 347], ["MCP", "PROTEIN", 156, 159], ["IFN", "PROTEIN", 163, 166], ["TNF", "PROTEIN", 179, 182], ["ApoE", "PROTEIN", 343, 347], ["mice", "SPECIES", 352, 356], ["mice", "SPECIES", 352, 356], ["oral administration of artemisinin", "TREATMENT", 70, 104], ["effectively alleviated inflammatory response", "PROBLEM", 110, 154], ["MCP", "TEST", 156, 159], ["IFN", "TEST", 163, 166], ["IL", "TEST", 170, 172], ["TNF", "TEST", 179, 182], ["elevated macrophage autophagy", "PROBLEM", 187, 216], ["suppressed foamy macrophage transformation", "PROBLEM", 218, 260], ["thereby inhibiting atherosclerotic plaque formation", "PROBLEM", 266, 317], ["vascular", "ANATOMY", 13, 21], ["inflammatory", "OBSERVATION_MODIFIER", 133, 145], ["macrophage autophagy", "OBSERVATION", 196, 216], ["foamy macrophage transformation", "OBSERVATION", 229, 260], ["atherosclerotic", "OBSERVATION_MODIFIER", 285, 300], ["plaque", "OBSERVATION", 301, 307]]], ["In addition, 18 has been discovered to be a potential therapeutic agent for ameliorating type 1 diabetes because of its ability to promote the conversion of pancreatic glucagon-producing a cells to insulinsecreting b cells in rats .", [["pancreatic", "ANATOMY", 157, 167], ["cells", "ANATOMY", 189, 194], ["insulinsecreting b cells", "ANATOMY", 198, 222], ["type 1 diabetes", "DISEASE", 89, 104], ["glucagon", "CHEMICAL", 168, 176], ["pancreatic", "ORGAN", 157, 167], ["glucagon", "GENE_OR_GENE_PRODUCT", 168, 176], ["cells", "CELL", 189, 194], ["insulinsecreting b cells", "CELL", 198, 222], ["rats", "ORGANISM", 226, 230], ["pancreatic glucagon-producing a cells", "CELL_TYPE", 157, 194], ["insulinsecreting b cells", "CELL_TYPE", 198, 222], ["rats", "SPECIES", 226, 230], ["ameliorating type 1 diabetes", "PROBLEM", 76, 104], ["pancreatic glucagon", "TREATMENT", 157, 176], ["a cells", "PROBLEM", 187, 194], ["diabetes", "OBSERVATION", 96, 104], ["pancreatic", "ANATOMY", 157, 167]]], ["Nevertheless, the widespread application of artemisinin as an anti-malarial drug could contributed to the selection of resistant strains of the etiologic agent Plasmodium, thus its use to combating non-communicable human diseases would raise the risk for this selection and lead to an important drug resistance development.", [["artemisinin", "CHEMICAL", 44, 55], ["non-communicable human diseases", "DISEASE", 198, 229], ["artemisinin", "CHEMICAL", 44, 55], ["artemisinin", "SIMPLE_CHEMICAL", 44, 55], ["Plasmodium", "ORGANISM", 160, 170], ["human", "ORGANISM", 215, 220], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 215, 220], ["artemisinin", "TREATMENT", 44, 55], ["an anti-malarial drug", "TREATMENT", 59, 80], ["resistant strains", "PROBLEM", 119, 136], ["the etiologic agent Plasmodium", "PROBLEM", 140, 170], ["non-communicable human diseases", "PROBLEM", 198, 229], ["this selection", "TREATMENT", 255, 269], ["an important drug resistance development", "PROBLEM", 282, 322], ["widespread", "OBSERVATION_MODIFIER", 18, 28], ["drug resistance", "OBSERVATION", 295, 310]]], ["Some authors have suggested that unless necessary, artemisinin (18) should be replaced by other therapeutic agents for the treatment of versatile types of human diseases (Dong-Sheng et al., 2017) .Lactucain from Lactuca indica LinnIt is important to note that some species of Artemisia have been traditionally used in treatment of diabetes such as A. dracunulus L., A. minor Jacq. ex Besser, A. pallens Wall. ex D.C., A. sphaerocephala Krasch and A. herba-alba Asso, (Mohamed et al., 2010; Subramoniam, 2016) .", [["artemisinin", "CHEMICAL", 51, 62], ["Lactucain", "CHEMICAL", 197, 206], ["diabetes", "DISEASE", 331, 339], ["artemisinin", "CHEMICAL", 51, 62], ["Lactucain", "CHEMICAL", 197, 206], ["artemisinin", "SIMPLE_CHEMICAL", 51, 62], ["human", "ORGANISM", 155, 160], ["Lactucain", "SIMPLE_CHEMICAL", 197, 206], ["Lactuca indica", "ORGANISM", 212, 226], ["LinnIt", "ORGANISM", 227, 233], ["Artemisia", "ORGANISM", 276, 285], ["A. dracunulus L.", "ORGANISM", 348, 364], ["A. pallens", "ORGANISM", 392, 402], ["A. sphaerocephala Krasch", "ORGANISM", 418, 442], ["A. herba-alba", "ORGANISM", 447, 460], ["human", "SPECIES", 155, 160], ["Lactuca indica", "SPECIES", 212, 226], ["A. dracunulus", "SPECIES", 348, 361], ["A. pallens", "SPECIES", 392, 402], ["A. sphaerocephala", "SPECIES", 418, 435], ["A. herba-alba", "SPECIES", 447, 460], ["human", "SPECIES", 155, 160], ["Lactuca indica", "SPECIES", 212, 226], ["A. dracunulus L.", "SPECIES", 348, 364], ["A. pallens", "SPECIES", 392, 402], ["A. sphaerocephala", "SPECIES", 418, 435], ["A. herba-alba", "SPECIES", 447, 460], ["artemisinin", "TREATMENT", 51, 62], ["therapeutic agents", "TREATMENT", 96, 114], ["human diseases", "PROBLEM", 155, 169], ["Lactucain", "TREATMENT", 197, 206], ["some species of Artemisia", "PROBLEM", 260, 285], ["diabetes", "PROBLEM", 331, 339], ["Artemisia", "OBSERVATION", 276, 285], ["diabetes", "OBSERVATION", 331, 339], ["pallens Wall", "OBSERVATION", 395, 407], ["sphaerocephala Krasch", "OBSERVATION", 421, 442]]], ["Several eudesmanolides and guaianolides have been isolated from A.Lactucain from Lactuca indica Linnherba-alba, all of them having in common the absence of the a-methylene in the g-lactone ring as in artemisinin (18) structure.", [["eudesmanolides", "CHEMICAL", 8, 22], ["guaianolides", "CHEMICAL", 27, 39], ["A.Lactucain", "CHEMICAL", 64, 75], ["a-methylene", "CHEMICAL", 160, 171], ["artemisinin", "CHEMICAL", 200, 211], ["eudesmanolides", "CHEMICAL", 8, 22], ["guaianolides", "CHEMICAL", 27, 39], ["a-methylene", "CHEMICAL", 160, 171], ["g-lactone", "CHEMICAL", 179, 188], ["artemisinin", "CHEMICAL", 200, 211], ["eudesmanolides", "SIMPLE_CHEMICAL", 8, 22], ["guaianolides", "SIMPLE_CHEMICAL", 27, 39], ["A.Lactucain", "SIMPLE_CHEMICAL", 64, 75], ["Lactuca indica", "ORGANISM", 81, 95], ["Linnherba-alba", "ORGANISM", 96, 110], ["a-methylene", "SIMPLE_CHEMICAL", 160, 171], ["g-lactone ring", "SIMPLE_CHEMICAL", 179, 193], ["artemisinin", "SIMPLE_CHEMICAL", 200, 211], ["Lactuca indica", "SPECIES", 81, 95], ["Linnherba-alba", "SPECIES", 96, 110], ["Lactuca indica Linnherba-alba", "SPECIES", 81, 110], ["Several eudesmanolides", "TREATMENT", 0, 22], ["guaianolides", "TREATMENT", 27, 39], ["the a-methylene in the g-lactone ring", "TREATMENT", 156, 193]]], ["Indeed the ethanol, chloroform and water extracts of this plant have showed important hypoglycemic activity (Mohamed et al., 2010) .Lactucain from Lactuca indica LinnAnimal experiments show considerable toxicity after the application of artemisinin family (neurotoxicity, embryotoxicity, genotoxicity, hemato-and immunotoxicity, cardiotoxicity, nephrotoxicity, and allergic reactions), but large clinical studies and meta-analyzes did not show serious human side effects, although proper monitoring of adverse effects in developing countries may not be a trivial task.", [["extracts", "ANATOMY", 41, 49], ["ethanol", "CHEMICAL", 11, 18], ["chloroform", "CHEMICAL", 20, 30], ["Lactucain", "CHEMICAL", 132, 141], ["toxicity", "DISEASE", 203, 211], ["artemisinin", "CHEMICAL", 237, 248], ["neurotoxicity", "DISEASE", 257, 270], ["embryotoxicity", "DISEASE", 272, 286], ["genotoxicity", "DISEASE", 288, 300], ["hemato-and immunotoxicity", "DISEASE", 302, 327], ["cardiotoxicity", "DISEASE", 329, 343], ["nephrotoxicity", "DISEASE", 345, 359], ["allergic reactions", "DISEASE", 365, 383], ["ethanol", "CHEMICAL", 11, 18], ["chloroform", "CHEMICAL", 20, 30], ["Lactucain", "CHEMICAL", 132, 141], ["artemisinin", "CHEMICAL", 237, 248], ["ethanol", "SIMPLE_CHEMICAL", 11, 18], ["chloroform", "SIMPLE_CHEMICAL", 20, 30], ["water extracts", "ORGANISM_SUBSTANCE", 35, 49], ["Lactucain", "SIMPLE_CHEMICAL", 132, 141], ["Lactuca indica", "ORGANISM", 147, 161], ["artemisinin", "SIMPLE_CHEMICAL", 237, 248], ["human", "ORGANISM", 452, 457], ["Lactuca indica", "SPECIES", 147, 161], ["human", "SPECIES", 452, 457], ["Lactuca indica", "SPECIES", 147, 161], ["human", "SPECIES", 452, 457], ["chloroform", "TREATMENT", 20, 30], ["water extracts", "TREATMENT", 35, 49], ["Lactucain", "TREATMENT", 132, 141], ["considerable toxicity", "PROBLEM", 190, 211], ["artemisinin family", "TREATMENT", 237, 255], ["neurotoxicity", "PROBLEM", 257, 270], ["embryotoxicity", "PROBLEM", 272, 286], ["genotoxicity", "PROBLEM", 288, 300], ["hemato", "PROBLEM", 302, 308], ["immunotoxicity", "PROBLEM", 313, 327], ["cardiotoxicity", "PROBLEM", 329, 343], ["nephrotoxicity", "PROBLEM", 345, 359], ["allergic reactions", "PROBLEM", 365, 383], ["large clinical studies", "TEST", 390, 412], ["serious human side effects", "PROBLEM", 444, 470], ["considerable", "OBSERVATION_MODIFIER", 190, 202], ["toxicity", "OBSERVATION", 203, 211]]], ["There is a paucity of large-scale clinical trials adequate to detect rare but significant toxicity.", [["toxicity", "DISEASE", 90, 98], ["significant toxicity", "PROBLEM", 78, 98], ["paucity", "OBSERVATION_MODIFIER", 11, 18], ["large", "OBSERVATION_MODIFIER", 22, 27], ["significant", "OBSERVATION_MODIFIER", 78, 89], ["toxicity", "OBSERVATION", 90, 98]]], ["The lesson learned from animal and human studies is that long-term availability rather than short-term peak concentrations of artemisinin cause toxicity (Efferth and Kaina, 2010) .", [["artemisinin", "CHEMICAL", 126, 137], ["toxicity", "DISEASE", 144, 152], ["artemisinin", "CHEMICAL", 126, 137], ["human", "ORGANISM", 35, 40], ["artemisinin", "SIMPLE_CHEMICAL", 126, 137], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["animal and human studies", "TEST", 24, 48], ["artemisinin cause toxicity", "PROBLEM", 126, 152]]], ["Thus, the observation of the toxicity of artemisinin derivatives in animals, but not in humans, is most likely due to different pharmacokinetic profiles after different routes of administrations.Lactucain from Lactuca indica Linn6.12.", [["toxicity", "DISEASE", 29, 37], ["artemisinin", "CHEMICAL", 41, 52], ["Lactucain", "CHEMICAL", 195, 204], ["artemisinin", "CHEMICAL", 41, 52], ["Lactucain", "CHEMICAL", 195, 204], ["artemisinin derivatives", "SIMPLE_CHEMICAL", 41, 64], ["humans", "ORGANISM", 88, 94], ["Lactucain", "SIMPLE_CHEMICAL", 195, 204], ["Lactuca indica", "ORGANISM", 210, 224], ["Linn6", "ORGANISM", 225, 230], ["humans", "SPECIES", 88, 94], ["Lactuca indica", "SPECIES", 210, 224], ["humans", "SPECIES", 88, 94], ["Lactuca indica", "SPECIES", 210, 224], ["artemisinin derivatives", "TREATMENT", 41, 64], ["different pharmacokinetic profiles", "PROBLEM", 118, 152], ["Lactucain", "TREATMENT", 195, 204], ["most likely", "UNCERTAINTY", 99, 110]]], ["Scoporanolide and estafiatin from Artemisia scoparia Waldst. & Kit Artemisia scoparia Waldst. & Kit. (redstem wormwood) is widely distributed in Southwest Asia and central Europe.", [["Scoporanolide", "CHEMICAL", 0, 13], ["estafiatin", "CHEMICAL", 18, 28], ["Scoporanolide", "CHEMICAL", 0, 13], ["estafiatin", "CHEMICAL", 18, 28], ["Scoporanolide", "SIMPLE_CHEMICAL", 0, 13], ["estafiatin", "SIMPLE_CHEMICAL", 18, 28], ["redstem wormwood", "ORGANISM", 102, 118], ["Artemisia scoparia", "SPECIES", 34, 52], ["Artemisia scoparia", "SPECIES", 34, 52], ["Artemisia scoparia", "SPECIES", 67, 85], ["Scoporanolide", "TREATMENT", 0, 13], ["estafiatin", "TREATMENT", 18, 28], ["Artemisia", "OBSERVATION", 34, 43], ["scoparia Waldst", "OBSERVATION", 44, 59], ["scoparia Waldst", "OBSERVATION", 77, 92], ["widely", "OBSERVATION_MODIFIER", 123, 129], ["distributed", "OBSERVATION_MODIFIER", 130, 141]]], ["This species has been reported to possess anti-obesity (Richard et al., 2014) and hypolipidemic (Boudreau et al., 2018) properties.", [["hypolipidemic", "PROBLEM", 82, 95]]], ["A. scoparia ethanolic extract reduces non-alcoholic fatty liver disease by enhancing hepatic insulin and AMP-AMPK signaling in diet-induced obese mice .", [["extract", "ANATOMY", 22, 29], ["non-alcoholic fatty liver", "ANATOMY", 38, 63], ["hepatic", "ANATOMY", 85, 92], ["scoparia ethanolic extract", "CHEMICAL", 3, 29], ["non-alcoholic fatty liver disease", "DISEASE", 38, 71], ["AMP", "CHEMICAL", 105, 108], ["AMP", "CHEMICAL", 105, 108], ["A. scoparia", "ORGANISM", 0, 11], ["liver", "ORGAN", 58, 63], ["hepatic", "MULTI-TISSUE_STRUCTURE", 85, 92], ["insulin", "GENE_OR_GENE_PRODUCT", 93, 100], ["AMP-AMPK", "GENE_OR_GENE_PRODUCT", 105, 113], ["mice", "ORGANISM", 146, 150], ["AMPK", "PROTEIN", 109, 113], ["A. scoparia", "SPECIES", 0, 11], ["mice", "SPECIES", 146, 150], ["A. scoparia", "SPECIES", 0, 11], ["mice", "SPECIES", 146, 150], ["non-alcoholic fatty liver disease", "PROBLEM", 38, 71], ["enhancing hepatic insulin", "TREATMENT", 75, 100], ["AMP", "TREATMENT", 105, 108], ["AMPK signaling in diet", "TREATMENT", 109, 131], ["scoparia", "OBSERVATION_MODIFIER", 3, 11], ["ethanolic extract", "OBSERVATION_MODIFIER", 12, 29], ["reduces", "OBSERVATION_MODIFIER", 30, 37], ["non-alcoholic", "OBSERVATION_MODIFIER", 38, 51], ["fatty liver disease", "OBSERVATION", 52, 71], ["hepatic", "ANATOMY", 85, 92], ["insulin", "OBSERVATION", 93, 100]]], ["A. scoparia hot water extract reduces blood pressure in spontaneously hypertensive rats via the inhibition of plasma angiotensin I-converting enzyme (ACE) activity (Cho et al., 2015) .", [["blood", "ANATOMY", 38, 43], ["plasma", "ANATOMY", 110, 116], ["hypertensive", "DISEASE", 70, 82], ["angiotensin", "CHEMICAL", 117, 128], ["A. scoparia", "ORGANISM", 0, 11], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["rats", "ORGANISM", 83, 87], ["plasma", "ORGANISM_SUBSTANCE", 110, 116], ["angiotensin I-converting enzyme", "GENE_OR_GENE_PRODUCT", 117, 148], ["ACE", "GENE_OR_GENE_PRODUCT", 150, 153], ["plasma angiotensin I-converting enzyme", "PROTEIN", 110, 148], ["ACE", "PROTEIN", 150, 153], ["A. scoparia", "SPECIES", 0, 11], ["rats", "SPECIES", 83, 87], ["A. scoparia", "SPECIES", 0, 11], ["blood pressure", "TEST", 38, 52], ["spontaneously hypertensive rats", "TREATMENT", 56, 87], ["plasma angiotensin I", "TREATMENT", 110, 130], ["scoparia hot", "OBSERVATION", 3, 15], ["pressure", "OBSERVATION_MODIFIER", 44, 52]]], ["The phytochemical analysis of this extract revealed that seven SLns contribute to the antihypertensive effect inhibition of ACE activity, highlighting the activity of scoporanolide (19) and estafiatin (20) (Fig. 2) (Cho et al., 2016) showing significantly higher ACE inhibitory activities than the other isolated SLns.", [["SLns", "CHEMICAL", 63, 67], ["scoporanolide", "CHEMICAL", 167, 180], ["estafiatin", "CHEMICAL", 190, 200], ["scoporanolide", "CHEMICAL", 167, 180], ["estafiatin", "CHEMICAL", 190, 200], ["SLns", "SIMPLE_CHEMICAL", 63, 67], ["ACE", "GENE_OR_GENE_PRODUCT", 124, 127], ["scoporanolide", "SIMPLE_CHEMICAL", 167, 180], ["estafiatin (20)", "SIMPLE_CHEMICAL", 190, 205], ["ACE", "GENE_OR_GENE_PRODUCT", 263, 266], ["SLns", "SIMPLE_CHEMICAL", 313, 317], ["ACE", "PROTEIN", 124, 127], ["ACE", "PROTEIN", 263, 266], ["The phytochemical analysis", "TEST", 0, 26], ["this extract", "TEST", 30, 42], ["seven SLns", "PROBLEM", 57, 67], ["the antihypertensive effect", "TREATMENT", 82, 109], ["ACE activity", "TREATMENT", 124, 136], ["the activity of scoporanolide", "TREATMENT", 151, 180], ["significantly higher ACE inhibitory activities", "PROBLEM", 242, 288], ["SLns", "OBSERVATION", 313, 317]]], ["No in vivo toxicity studies on scoporanolide (19) and estafiatin (20) have been reported to date.Cumambrin A from Chrysanthemum boreale (Makino) MakinoThe guaianolide cumambrin A (21) (Fig. 2) , isolated from Chrysanthemum boreale (Makino) Makino, has shown a pharmacological effect on the normalization of blood pressure in spontaneously hypertensive rats (Hong et al., 1999) .", [["blood", "ANATOMY", 307, 312], ["toxicity", "DISEASE", 11, 19], ["scoporanolide", "CHEMICAL", 31, 44], ["estafiatin", "CHEMICAL", 54, 64], ["Cumambrin A", "CHEMICAL", 97, 108], ["guaianolide", "CHEMICAL", 155, 166], ["cumambrin A (21)", "CHEMICAL", 167, 183], ["hypertensive", "DISEASE", 339, 351], ["scoporanolide", "CHEMICAL", 31, 44], ["estafiatin", "CHEMICAL", 54, 64], ["Cumambrin A", "CHEMICAL", 97, 108], ["cumambrin A", "CHEMICAL", 167, 178], ["scoporanolide (19)", "SIMPLE_CHEMICAL", 31, 49], ["estafiatin", "SIMPLE_CHEMICAL", 54, 64], ["Chrysanthemum boreale", "ORGANISM", 114, 135], ["guaianolide cumambrin A (21)", "SIMPLE_CHEMICAL", 155, 183], ["Fig. 2)", "SIMPLE_CHEMICAL", 185, 192], ["Chrysanthemum boreale", "ORGANISM", 209, 230], ["Makino) Makino", "ORGANISM", 232, 246], ["blood", "ORGANISM_SUBSTANCE", 307, 312], ["rats", "ORGANISM", 352, 356], ["Chrysanthemum boreale", "SPECIES", 114, 135], ["Chrysanthemum boreale", "SPECIES", 209, 230], ["rats", "SPECIES", 352, 356], ["Chrysanthemum boreale (Makino) Makino", "SPECIES", 114, 151], ["Chrysanthemum boreale", "SPECIES", 209, 230], ["scoporanolide", "TEST", 31, 44], ["Cumambrin A from Chrysanthemum boreale (Makino", "TREATMENT", 97, 143], ["The guaianolide cumambrin A", "TREATMENT", 151, 178], ["blood pressure", "TEST", 307, 321], ["spontaneously hypertensive rats", "PROBLEM", 325, 356], ["pharmacological effect", "OBSERVATION", 260, 282]]], ["Ex vivo study demonstrate that this compound is a potent relaxant of aortic smooth muscle at a concentration of 5 \u00a3 10 \u00c05 M (Hong et al., 2005) .", [["aortic smooth muscle", "ANATOMY", 69, 89], ["aortic smooth muscle", "TISSUE", 69, 89], ["Ex vivo study", "TEST", 0, 13], ["this compound", "PROBLEM", 31, 44], ["potent", "OBSERVATION_MODIFIER", 50, 56], ["aortic", "ANATOMY", 69, 75], ["smooth muscle", "ANATOMY", 76, 89]]], ["No in vivo toxicity studies on cumambrin A (21) have been reported to date.Concluding remarksThe potential beneficial effects of SLns on MetSs risk factors discussed in this review clearly demonstrate that these substances represent remarkable compounds with a diversity of molecular structure and biological activity.", [["toxicity", "DISEASE", 11, 19], ["cumambrin A", "CHEMICAL", 31, 42], ["SLns", "CHEMICAL", 129, 133], ["cumambrin A", "CHEMICAL", 31, 42], ["cumambrin A", "SIMPLE_CHEMICAL", 31, 42], ["SLns", "SIMPLE_CHEMICAL", 129, 133], ["SLns", "TREATMENT", 129, 133], ["remarkable compounds", "PROBLEM", 233, 253], ["molecular structure", "OBSERVATION", 274, 293], ["activity", "OBSERVATION_MODIFIER", 309, 317]]], ["These beneficial effects include normalization of blood glucose levels, improvement of blood lipid profiles, anti-inflammatory activity, improvement of insulin sensitivity and normalization of blood pressure.", [["blood", "ANATOMY", 50, 55], ["blood", "ANATOMY", 87, 92], ["blood", "ANATOMY", 193, 198], ["glucose", "CHEMICAL", 56, 63], ["glucose", "CHEMICAL", 56, 63], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["glucose", "SIMPLE_CHEMICAL", 56, 63], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["insulin", "GENE_OR_GENE_PRODUCT", 152, 159], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["blood glucose levels", "TEST", 50, 70], ["blood lipid profiles", "TEST", 87, 107], ["anti-inflammatory activity", "TREATMENT", 109, 135], ["insulin sensitivity", "TEST", 152, 171], ["blood pressure", "TEST", 193, 207], ["anti-inflammatory activity", "OBSERVATION", 109, 135]]], ["The underlying molecular targets mediating these effects have not been completely understood.", [["molecular targets", "OBSERVATION", 15, 32]]], ["Regardless of that, it can be noticed that at least six molecular targets or pathways could explain the effect of SLns on components of MetS: Furthermore, the evidence from published literature demonstrates that some SLns belonging to guaianolides like eremanthin (4) and germacranolides such as costunolide (5) and guaianolide dimers byrsonines A and B (14, 15), show multifunctional benefits due to their action on many MetSs risk factors.", [["SLns", "CHEMICAL", 114, 118], ["MetS", "DISEASE", 136, 140], ["SLns", "CHEMICAL", 217, 221], ["guaianolides", "CHEMICAL", 235, 247], ["eremanthin", "CHEMICAL", 253, 263], ["germacranolides", "CHEMICAL", 272, 287], ["costunolide", "CHEMICAL", 296, 307], ["guaianolide", "CHEMICAL", 316, 327], ["guaianolides", "CHEMICAL", 235, 247], ["eremanthin", "CHEMICAL", 253, 263], ["germacranolides", "CHEMICAL", 272, 287], ["costunolide", "CHEMICAL", 296, 307], ["guaianolide", "CHEMICAL", 316, 327], ["byrsonines A and B", "CHEMICAL", 335, 353], ["SLns", "SIMPLE_CHEMICAL", 114, 118], ["SLns", "GENE_OR_GENE_PRODUCT", 217, 221], ["guaianolides", "SIMPLE_CHEMICAL", 235, 247], ["eremanthin (4)", "SIMPLE_CHEMICAL", 253, 267], ["germacranolides", "SIMPLE_CHEMICAL", 272, 287], ["costunolide (5)", "SIMPLE_CHEMICAL", 296, 311], ["guaianolide dimers byrsonines A", "SIMPLE_CHEMICAL", 316, 347], ["B", "SIMPLE_CHEMICAL", 352, 353], ["MetSs", "GENE_OR_GENE_PRODUCT", 422, 427], ["MetSs risk factors", "PROTEIN", 422, 440], ["SLns", "TREATMENT", 114, 118], ["MetS", "PROBLEM", 136, 140], ["some SLns", "PROBLEM", 212, 221], ["guaianolides", "TREATMENT", 235, 247], ["germacranolides", "TREATMENT", 272, 287], ["costunolide", "TREATMENT", 296, 307], ["guaianolide dimers byrsonines", "TREATMENT", 316, 345], ["MetS", "OBSERVATION", 136, 140]]], ["These observations suggest that structural specificity may be a key for understanding the mechanisms of action of SLns.", [["SLns", "GENE_OR_GENE_PRODUCT", 114, 118], ["SLns", "PROTEIN", 114, 118], ["SLns", "TEST", 114, 118]]], ["Looking forward, the effects of SLns on MetS should be explained based on the molecular targets and should be related to biochemical mechanisms.", [["SLns", "CHEMICAL", 32, 36], ["MetS", "DISEASE", 40, 44], ["SLns", "SIMPLE_CHEMICAL", 32, 36], ["SLns", "TREATMENT", 32, 36], ["MetS", "TREATMENT", 40, 44], ["SLns", "OBSERVATION", 32, 36]]], ["MetS has become a major public health problem worldwide and represents a common clinical condition in countries with a high incidence of obesity and western dietary patterns.", [["MetS", "DISEASE", 0, 4], ["obesity", "DISEASE", 137, 144], ["MetS", "PROBLEM", 0, 4], ["obesity", "PROBLEM", 137, 144], ["obesity", "OBSERVATION", 137, 144]]], ["Natural products, such as SLns, are attractive drug candidates and more attention must be paid to their potential use in the treatment and prevention of MetS.Declaration of Competing InterestThe authors declare no conflict of interest.", [["SLns", "CHEMICAL", 26, 30], ["MetS", "DISEASE", 153, 157], ["SLns", "CHEMICAL", 26, 30], ["SLns", "SIMPLE_CHEMICAL", 26, 30], ["Natural products", "TREATMENT", 0, 16], ["SLns", "TREATMENT", 26, 30], ["the treatment", "TREATMENT", 121, 134], ["MetS", "PROBLEM", 153, 157], ["MetS", "OBSERVATION", 153, 157]]]], "PMC7120812": [["IntroductionDespite the advances in medical sciences, the threat posed by viruses has remained a serious problem, particularly outside industrialized countries.", [["a serious problem", "PROBLEM", 95, 112], ["viruses", "OBSERVATION", 74, 81]]], ["While the human immunodeficiency virus (HIV) and the hepatitis B and C viruses (HBV, HCV) continue to claim millions of lives every year, viruses like the SARS coronavirus appear as human pathogens and novel variants of well-known viruses, like the H1N1/09 influenza virus, cause pandemics of global dimensions.", [["human immunodeficiency virus (HIV)", "DISEASE", 10, 44], ["hepatitis B", "DISEASE", 53, 64], ["SARS coronavirus", "DISEASE", 155, 171], ["influenza virus", "DISEASE", 257, 272], ["human immunodeficiency virus", "ORGANISM", 10, 38], ["HIV", "ORGANISM", 40, 43], ["hepatitis B and C viruses", "ORGANISM", 53, 78], ["HBV", "ORGANISM", 80, 83], ["HCV", "ORGANISM", 85, 88], ["SARS coronavirus", "ORGANISM", 155, 171], ["human", "ORGANISM", 182, 187], ["H1N1/09 influenza virus", "ORGANISM", 249, 272], ["human", "SPECIES", 10, 15], ["immunodeficiency virus (HIV", "SPECIES", 16, 43], ["hepatitis B and C viruses", "SPECIES", 53, 78], ["SARS coronavirus", "SPECIES", 155, 171], ["human", "SPECIES", 182, 187], ["H1N1/09 influenza virus", "SPECIES", 249, 272], ["human immunodeficiency virus", "SPECIES", 10, 38], ["HIV", "SPECIES", 40, 43], ["hepatitis B and C viruses", "SPECIES", 53, 78], ["HBV", "SPECIES", 80, 83], ["HCV", "SPECIES", 85, 88], ["SARS coronavirus", "SPECIES", 155, 171], ["human", "SPECIES", 182, 187], ["H1N1/09 influenza virus", "SPECIES", 249, 272], ["the human immunodeficiency virus", "PROBLEM", 6, 38], ["HIV", "PROBLEM", 40, 43], ["the hepatitis B", "PROBLEM", 49, 64], ["C viruses", "PROBLEM", 69, 78], ["HBV", "PROBLEM", 80, 83], ["HCV", "PROBLEM", 85, 88], ["viruses", "PROBLEM", 138, 145], ["the SARS coronavirus", "PROBLEM", 151, 171], ["human pathogens", "PROBLEM", 182, 197], ["novel variants of well-known viruses", "PROBLEM", 202, 238], ["the H1N1/09 influenza virus", "PROBLEM", 245, 272]]], ["Thus, there is a pressing unmet medical need to develop new antiviral drugs.", [["new antiviral drugs", "TREATMENT", 56, 75], ["antiviral drugs", "OBSERVATION", 60, 75]]], ["While small molecules have dominated antivirals for decades, biologics like monoclonal antibodies and nucleic acids therapies have more recently been considered promising alternatives (1).IntroductionAmong the various oligonucleotide-based strategies, RNA interference (RNAi) is widely regarded as a particularly powerful technology (2\u20134).", [["nucleic acids", "CHEMICAL", 102, 115], ["nucleic acids", "SIMPLE_CHEMICAL", 102, 115], ["monoclonal antibodies", "PROTEIN", 76, 97], ["dominated antivirals", "TREATMENT", 27, 47], ["biologics", "TREATMENT", 61, 70], ["monoclonal antibodies", "TREATMENT", 76, 97], ["nucleic acids therapies", "TREATMENT", 102, 125], ["the various oligonucleotide-based strategies", "TREATMENT", 206, 250], ["small", "OBSERVATION_MODIFIER", 6, 11], ["molecules", "OBSERVATION", 12, 21]]], ["RNAi is a posttranscriptional gene silencing mechanism that is triggered by double-stranded RNA.", [["double-stranded RNA", "RNA", 76, 95], ["a posttranscriptional gene silencing mechanism", "PROBLEM", 8, 54], ["posttranscriptional gene silencing", "OBSERVATION", 10, 44], ["stranded RNA", "OBSERVATION", 83, 95]]], ["For applications in mammalian cells, small interfering RNAs (siRNA) of approximately 19 base pairs with two nucleotide overhangs at the 3\u2032 ends of both strands become incorporated into the RNA-induced silencing complex (RISC) and induce cleavage of a complementary target RNA.", [["mammalian cells", "ANATOMY", 20, 35], ["nucleotide", "CHEMICAL", 108, 118], ["nucleotide", "CHEMICAL", 108, 118], ["mammalian cells", "CELL", 20, 35], ["small interfering RNAs", "GENE_OR_GENE_PRODUCT", 37, 59], ["RNA-induced silencing complex", "GENE_OR_GENE_PRODUCT", 189, 218], ["RISC", "GENE_OR_GENE_PRODUCT", 220, 224], ["mammalian cells", "CELL_TYPE", 20, 35], ["small interfering RNAs", "RNA", 37, 59], ["3\u2032 ends", "DNA", 136, 143], ["RNA-induced silencing complex", "PROTEIN", 189, 218], ["RISC", "PROTEIN", 220, 224], ["complementary target RNA", "RNA", 251, 275], ["applications in mammalian cells", "TREATMENT", 4, 35], ["small interfering RNAs (siRNA)", "PROBLEM", 37, 67], ["two nucleotide overhangs", "TREATMENT", 104, 128], ["a complementary target RNA", "PROBLEM", 249, 275], ["mammalian cells", "OBSERVATION", 20, 35], ["small", "OBSERVATION_MODIFIER", 37, 42], ["interfering RNAs", "OBSERVATION", 43, 59]]], ["Moreover, the technology has been developed into a new therapeutic approach and approximately a dozen clinical trials based on RNAi are currently underway.", [["a new therapeutic approach", "TREATMENT", 49, 75], ["RNAi", "TREATMENT", 127, 131]]], ["Among these trials are various applications of RNAi to treat infections with the respiratory syncytial virus, HBV and HIV (5).IntroductionSilencing of endogenously expressed genes has become a routine procedure and predesigned or validated siRNAs with silencing guarantee against virtually any human or murine gene are commercially available.", [["infections", "DISEASE", 61, 71], ["respiratory syncytial virus", "DISEASE", 81, 108], ["respiratory syncytial virus", "ORGANISM", 81, 108], ["HBV", "ORGANISM", 110, 113], ["human", "ORGANISM", 294, 299], ["murine", "ORGANISM", 303, 309], ["human or murine gene", "DNA", 294, 314], ["respiratory syncytial virus", "SPECIES", 81, 108], ["HIV", "SPECIES", 118, 121], ["human", "SPECIES", 294, 299], ["murine", "SPECIES", 303, 309], ["respiratory syncytial virus", "SPECIES", 81, 108], ["HBV", "SPECIES", 110, 113], ["HIV", "SPECIES", 118, 121], ["human", "SPECIES", 294, 299], ["various applications", "TREATMENT", 23, 43], ["RNAi", "TREATMENT", 47, 51], ["infections", "PROBLEM", 61, 71], ["the respiratory syncytial virus", "PROBLEM", 77, 108], ["HBV", "PROBLEM", 110, 113], ["HIV", "PROBLEM", 118, 121], ["a routine procedure", "TREATMENT", 191, 210], ["silencing guarantee", "TREATMENT", 252, 271], ["respiratory syncytial", "ANATOMY", 81, 102]]], ["In contrast, the design of siRNAs with high antiviral activity still remains a challenging task.", [["siRNAs", "PROBLEM", 27, 33], ["high antiviral activity", "PROBLEM", 39, 62], ["siRNAs", "OBSERVATION", 27, 33], ["high", "OBSERVATION_MODIFIER", 39, 43], ["antiviral activity", "OBSERVATION", 44, 62]]], ["Several features have been described that influence the success of an RNAi approach (6):Thermodynamic design of the siRNA.Structure of the siRNA antisense strand.Structure of the target RNA.", [["siRNA antisense strand", "DNA", 139, 161], ["target RNA", "RNA", 179, 189], ["an RNAi approach", "TREATMENT", 67, 83], ["the siRNA", "PROBLEM", 112, 121], ["siRNA", "ANATOMY", 116, 121], ["siRNA antisense strand", "OBSERVATION", 139, 161], ["target RNA", "OBSERVATION", 179, 189]]]], "89c7f9299a9396d3a5e2023c8199da57c33fd4e9": [["Plain English summaryCoronavirus disease 2019 (COVID-19) is a global public health emergency and a novel, highly contagious pneumonia caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["Coronavirus disease", "DISEASE", 21, 40], ["COVID-19", "CHEMICAL", 47, 55], ["pneumonia", "DISEASE", 124, 133], ["acute respiratory syndrome coronavirus", "DISEASE", 155, 193], ["SARS-CoV-2", "ORGANISM", 197, 207], ["Coronavirus disease 2019 (COVID-19", "SPECIES", 21, 55], ["severe acute respiratory syndrome coronavirus", "SPECIES", 148, 193], ["SARS-CoV-2", "SPECIES", 197, 207], ["Coronavirus disease", "PROBLEM", 21, 40], ["COVID", "TEST", 47, 52], ["highly contagious pneumonia", "PROBLEM", 106, 133], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 144, 193], ["CoV", "TEST", 202, 205], ["contagious", "OBSERVATION_MODIFIER", 113, 123], ["pneumonia", "OBSERVATION", 124, 133], ["severe", "OBSERVATION_MODIFIER", 148, 154], ["acute", "OBSERVATION_MODIFIER", 155, 160], ["respiratory syndrome coronavirus", "OBSERVATION", 161, 193]]], ["Pregnant women are more susceptible to viral infection due to pregnancy alterations.", [["viral infection", "DISEASE", 39, 54], ["pregnancy alterations", "DISEASE", 62, 83], ["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14], ["viral infection", "PROBLEM", 39, 54], ["pregnancy alterations", "PROBLEM", 62, 83], ["viral", "OBSERVATION_MODIFIER", 39, 44], ["infection", "OBSERVATION", 45, 54]]], ["Social distancing program and fear of getting the sick lead to the reduction of prenatal care referrals, additionally pregnant women are also more willing to reduce the frequency of prenatal care.", [["women", "ORGANISM", 127, 132], ["women", "SPECIES", 127, 132], ["prenatal care", "TREATMENT", 182, 195]]], ["The lack of PNC during pregnancy might be drastically harmful.", [["PNC during pregnancy", "PROBLEM", 12, 32], ["drastically harmful", "PROBLEM", 42, 61]]], ["Prenatal care services institutes should identify the fears and demands of pregnant women during the COVID-19 pandemic by optimizing the means of PNC services and providing a service for the safety and well-being of pregnant women.", [["women", "ORGANISM", 84, 89], ["women", "ORGANISM", 225, 230], ["women", "SPECIES", 84, 89], ["women", "SPECIES", 225, 230], ["the COVID", "TEST", 97, 106], ["PNC services", "TREATMENT", 146, 158]]], ["The current study provides precise information about the prenatal care experiences of pregnant women, and the factors influencing it.", [["women", "ORGANISM", 95, 100], ["women", "SPECIES", 95, 100], ["The current study", "TEST", 0, 17]]], ["This study will be used in the mixed methods approach with the sequential explanatory design and is comprised of three phases.", [["This study", "TEST", 0, 10]]], ["The first phase is qualitative and will be exploring the experiences of pregnant women.", [["women", "ORGANISM", 81, 86], ["women", "SPECIES", 81, 86]]], ["The second phase is quantitative and will be used as a cross-sectional approach to assess the factors affecting self-care in pregnant women in Tabriz.", [["women", "ORGANISM", 134, 139], ["women", "SPECIES", 134, 139], ["a cross-sectional approach", "TREATMENT", 53, 79]]], ["The findings of the qualitative and quantitative phases, the literature review, and the nominal group technique will be used to establish some strategies to improve and may promote prenatal care.IntroductionThe COVID-19 disease is an emerging infection and also a re-emerging viral respiratory disease that has affected most countries in the world and its prevalence is increasing [1] [2] [3] .", [["respiratory", "ANATOMY", 282, 293], ["COVID-19 disease", "DISEASE", 211, 227], ["infection", "DISEASE", 243, 252], ["viral respiratory disease", "DISEASE", 276, 301], ["COVID-19", "SPECIES", 211, 219], ["the literature review", "TEST", 57, 78], ["the nominal group technique", "TREATMENT", 84, 111], ["The COVID-19 disease", "PROBLEM", 207, 227], ["an emerging infection", "PROBLEM", 231, 252], ["a re-emerging viral respiratory disease", "PROBLEM", 262, 301], ["infection", "OBSERVATION", 243, 252], ["viral", "OBSERVATION_MODIFIER", 276, 281], ["respiratory disease", "OBSERVATION", 282, 301]]], ["The virus is rapidly spreading around the world and due to the rapid spread of the virus, the World Health Organization (WHO) has identified it as a contagious pandemic disease [4] .", [["pandemic", "DISEASE", 160, 168], ["The virus", "PROBLEM", 0, 9], ["the rapid spread of the virus", "PROBLEM", 59, 88], ["a contagious pandemic disease", "PROBLEM", 147, 176], ["virus", "OBSERVATION", 4, 9], ["rapidly", "OBSERVATION_MODIFIER", 13, 20], ["spreading", "OBSERVATION_MODIFIER", 21, 30], ["rapid", "OBSERVATION_MODIFIER", 63, 68], ["spread", "OBSERVATION_MODIFIER", 69, 75], ["virus", "OBSERVATION", 83, 88], ["contagious", "OBSERVATION_MODIFIER", 149, 159]]], ["Despite the strong efforts taken to control the epidemic, Nearly 5 million people worldwide are reported to have contracted the infection [5, 6] .", [["infection", "DISEASE", 128, 137], ["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81], ["the infection", "PROBLEM", 124, 137], ["infection", "OBSERVATION", 128, 137]]], ["People over the age of 60 and those with weakened immune systems are at higher risk for the disease [9] , and because the immune system is partially suppressed during pregnancy; pregnant women are more vulnerable to viral infections and their complications; thus COVID-19 pandemic might have serious consequences for pregnant women [1, 10] .", [["immune system", "ANATOMY", 122, 135], ["viral infections", "DISEASE", 216, 232], ["People", "ORGANISM", 0, 6], ["women", "ORGANISM", 187, 192], ["COVID-19", "ORGANISM", 263, 271], ["women", "ORGANISM", 326, 331], ["People", "SPECIES", 0, 6], ["women", "SPECIES", 187, 192], ["women", "SPECIES", 326, 331], ["weakened immune systems", "PROBLEM", 41, 64], ["the disease", "PROBLEM", 88, 99], ["viral infections", "PROBLEM", 216, 232], ["their complications", "PROBLEM", 237, 256], ["COVID", "TEST", 263, 268]]], ["The available data about effects of COVID-19 on pregnancy and its probable complications seems to be insufficient [9, 11] .", [["COVID-19", "CHEMICAL", 36, 44], ["COVID-19", "CHEMICAL", 36, 44], ["COVID", "TEST", 36, 41], ["complications", "PROBLEM", 75, 88]]], ["However, due to the physiological changes in maternal immune and cardiopulmonary systems, pregnant women are more likely to develop severe illness after infection with respiratory viruses [2, 10] .", [["illness", "DISEASE", 139, 146], ["infection", "DISEASE", 153, 162], ["respiratory viruses", "DISEASE", 168, 187], ["women", "ORGANISM", 99, 104], ["women", "SPECIES", 99, 104], ["the physiological changes", "PROBLEM", 16, 41], ["maternal immune and cardiopulmonary systems", "PROBLEM", 45, 88], ["severe illness", "PROBLEM", 132, 146], ["infection", "PROBLEM", 153, 162], ["respiratory viruses", "PROBLEM", 168, 187], ["severe", "OBSERVATION_MODIFIER", 132, 138], ["illness", "OBSERVATION", 139, 146], ["respiratory viruses", "OBSERVATION", 168, 187]]], ["In 2009, pregnant women accounted for 1% of patients infected with influenza A subtype H1N1 virus, but they accounted for 5% of all H1N1-related deaths [12] .", [["influenza A subtype H1N1 virus", "DISEASE", 67, 97], ["H1N1", "DISEASE", 132, 136], ["deaths", "DISEASE", 145, 151], ["women", "ORGANISM", 18, 23], ["patients", "ORGANISM", 44, 52], ["influenza A subtype H1N1 virus", "ORGANISM", 67, 97], ["women", "SPECIES", 18, 23], ["patients", "SPECIES", 44, 52], ["influenza A subtype H1N1 virus", "SPECIES", 67, 97], ["influenza A subtype H1N1 virus", "SPECIES", 67, 97], ["influenza A subtype H1N1 virus", "PROBLEM", 67, 97], ["all H1N1", "PROBLEM", 128, 136]]], ["Severe complications have also been reported in SARS and MERS viruses epidemic, including tracheal intubation, hospitalization in the intensive care unit, renal failure, and death during pregnancy [13] .", [["tracheal", "ANATOMY", 90, 98], ["renal", "ANATOMY", 155, 160], ["SARS", "DISEASE", 48, 52], ["renal failure", "DISEASE", 155, 168], ["death", "DISEASE", 174, 179], ["tracheal", "ORGAN", 90, 98], ["renal", "ORGAN", 155, 160], ["Severe complications", "PROBLEM", 0, 20], ["SARS", "PROBLEM", 48, 52], ["MERS viruses epidemic", "PROBLEM", 57, 78], ["tracheal intubation", "TREATMENT", 90, 109], ["renal failure", "PROBLEM", 155, 168], ["death", "PROBLEM", 174, 179], ["complications", "OBSERVATION", 7, 20], ["tracheal", "ANATOMY", 90, 98], ["intubation", "OBSERVATION", 99, 109], ["renal", "ANATOMY", 155, 160], ["failure", "OBSERVATION", 161, 168]]], ["Reviews of studies have shown that clinical signs, laboratory results, and radiographic criteria in pregnant women with COVID-19 are similar to other affected adults, but the risk of developing COVID-19 disease in pregnant women is high for the reasons stated above and there is the possibility of complications in pregnancy and newborn infection [14] .", [["COVID-19 disease", "DISEASE", 194, 210], ["newborn infection", "DISEASE", 329, 346], ["women", "ORGANISM", 109, 114], ["COVID-19", "ORGANISM", 194, 202], ["women", "ORGANISM", 223, 228], ["women", "SPECIES", 109, 114], ["women", "SPECIES", 223, 228], ["Reviews of studies", "TEST", 0, 18], ["clinical signs", "TEST", 35, 49], ["radiographic criteria", "TEST", 75, 96], ["COVID", "TEST", 120, 125], ["developing COVID-19 disease", "PROBLEM", 183, 210], ["complications in pregnancy", "PROBLEM", 298, 324], ["newborn infection", "PROBLEM", 329, 346]]], ["These factors have led to anxiety and stress in pregnant women and their families [1, 15] .", [["anxiety", "DISEASE", 26, 33], ["women", "ORGANISM", 57, 62], ["women", "SPECIES", 57, 62], ["anxiety", "PROBLEM", 26, 33]]], ["On the other hand, with the rapid spread of the disease in different countries, including Iran, taking special precautions like physical distancing and quarantining are recommended to protect and prevent the disease [16] .", [["the disease", "PROBLEM", 44, 55], ["special precautions", "TREATMENT", 103, 122], ["physical distancing and quarantining", "TREATMENT", 128, 164], ["the disease", "PROBLEM", 204, 215], ["rapid", "OBSERVATION_MODIFIER", 28, 33], ["spread", "OBSERVATION_MODIFIER", 34, 40], ["disease", "OBSERVATION", 48, 55]]], ["However, social isolation and disconnection can cause sadness, concerns, fear, anger, irritation and frustration [17] .", [["anger", "DISEASE", 79, 84], ["irritation", "DISEASE", 86, 96], ["social isolation", "TREATMENT", 9, 25], ["sadness", "PROBLEM", 54, 61], ["irritation", "PROBLEM", 86, 96]]], ["Such behaviors are performed by individuals to maintain and promote health level and disease prevention [18] .", [["disease prevention", "TREATMENT", 85, 103]]], ["However, pregnant women have concerns about how to take care of their pregnancies and how to carry out their plans for childbirth during the outbreak of the novel corona virus [1] .", [["women", "ORGANISM", 18, 23], ["corona virus", "ORGANISM", 163, 175], ["women", "SPECIES", 18, 23]]], ["Social distancing program and fear of getting the sick lead to the reduction of prenatal care referrals, additionally pregnant women are also more willing to reduce the frequency of prenatal care visits [8, 19] .", [["women", "ORGANISM", 127, 132], ["women", "SPECIES", 127, 132]]], ["The lack of PNC during pregnancy might be drastically harmful [8] .", [["PNC during pregnancy", "PROBLEM", 12, 32], ["drastically harmful", "PROBLEM", 42, 61]]], ["Since qualitative studies can be helpful for a deep understanding of a particular phenomenon, and also, due to insufficient studies regarding prenatal care and its barriers or facilitators during COVID-19 pandemics, present study was designed to explore factors affecting prenatal care.", [["qualitative studies", "TEST", 6, 25], ["prenatal care", "TREATMENT", 142, 155], ["present study", "TEST", 216, 229]]], ["So appropriate interventions and guidelines can be developed in this regard.ObjectivesThe objectives of each phase are as follows:ObjectivesObjectives of the first phase: qualitative study 1) To explore prenatal care experiences among pregnant women during the COVID-19 pandemic.", [["women", "ORGANISM", 244, 249], ["women", "SPECIES", 244, 249], ["appropriate interventions", "TREATMENT", 3, 28], ["qualitative study", "TEST", 171, 188], ["the COVID", "TEST", 257, 266], ["pandemic", "PROBLEM", 270, 278]]], ["2) To explore views about barriers and facilitators of prenatal care among pregnant women during the COVID-19 pandemic.ObjectivesObjectives of the second phase: quantitative study 1) To determine self-care behaviors among pregnant women during the COVID-19 pandemic.", [["women", "ORGANISM", 84, 89], ["women", "ORGANISM", 231, 236], ["women", "SPECIES", 84, 89], ["women", "SPECIES", 231, 236], ["prenatal care", "TREATMENT", 55, 68], ["the COVID", "TEST", 97, 106], ["pandemic", "PROBLEM", 110, 118], ["quantitative study", "TEST", 161, 179], ["the COVID", "TEST", 244, 253], ["pandemic", "PROBLEM", 257, 265]]], ["2) To determine fear of COVID-19 among pregnant women during the COVID-19 pandemic.", [["women", "ORGANISM", 48, 53], ["women", "SPECIES", 48, 53], ["COVID", "TEST", 24, 29], ["the COVID", "TEST", 61, 70], ["pandemic", "PROBLEM", 74, 82]]], ["3) To determine anxiety of COVID-19 among pregnant women during the COVID-19 pandemic.", [["anxiety", "DISEASE", 16, 23], ["women", "ORGANISM", 51, 56], ["women", "SPECIES", 51, 56], ["anxiety of COVID", "PROBLEM", 16, 32], ["the COVID", "TEST", 64, 73], ["pandemic", "PROBLEM", 77, 85]]], ["4) To determine perceived stress among pregnant women during the COVID-19 pandemic.", [["women", "ORGANISM", 48, 53], ["women", "SPECIES", 48, 53], ["the COVID", "TEST", 61, 70], ["pandemic", "PROBLEM", 74, 82]]], ["5) To determine the association between fear of COVID-19 with self-care behaviors.", [["COVID", "TEST", 48, 53]]], ["6) To determine the association between anxiety of COVID-19 with self-care behaviors.", [["anxiety", "DISEASE", 40, 47], ["anxiety of COVID", "PROBLEM", 40, 56]]], ["7) To determine the association between perceived stress with self-care behaviors.ObjectivesObjectives of the third phase 1) To develop a prenatal care guideline and Strategies to improve the PNC and increase the self-care skills during the COVID-19 pandemic.Study designA mixed methods sequential explanatory design will be used to conduct this study by collecting, analyzing, and integrating the qualitative and quantitative data.", [["a prenatal care guideline", "TREATMENT", 136, 161], ["Strategies", "TREATMENT", 166, 176], ["the PNC", "TREATMENT", 188, 195], ["the COVID", "TEST", 237, 246], ["pandemic", "PROBLEM", 250, 258], ["this study", "TEST", 341, 351]]], ["The mixed-methods paradigm is based on the principles and logic of pragmatism.", [["The mixed-methods paradigm", "TREATMENT", 0, 26], ["mixed", "OBSERVATION_MODIFIER", 4, 9], ["pragmatism", "OBSERVATION", 67, 77]]], ["This study will have three phases, and the qualitative and quantitative data will be collected in the first and second phases, respectively.", [["This study", "TEST", 0, 10], ["quantitative data", "TEST", 59, 76]]], ["Phase one is an exploratory qualitative study, which aims to explore prenatal care experiences among pregnant women during the COVID-19 pandemic.", [["women", "ORGANISM", 110, 115], ["women", "SPECIES", 110, 115], ["an exploratory qualitative study", "TEST", 13, 45], ["the COVID", "TEST", 123, 132], ["pandemic", "PROBLEM", 136, 144]]], ["Phase two is a cross-sectional study, which aims to assess the factors affecting the self-care behaviors among pregnant women during the COVID-19 pandemic.", [["women", "ORGANISM", 120, 125], ["women", "SPECIES", 120, 125], ["a cross-sectional study", "TEST", 13, 36], ["the COVID", "TEST", 133, 142], ["pandemic", "PROBLEM", 146, 154]]], ["Phase three is about developing an evidence based and a culturally sensitive guideline based on literature review, the results of phase one and two and experts' opinion using the nominal group technique (Fig. 1 ).First phase: qualitative studyThe first Phase is an exploratory qualitative study with a conventional content analysis approach to explore the prenatal care experiences and views about barriers and facilitators of prenatal care among pregnant women during the COVID-19 pandemic.Sampling methodThe research participants will be selected through purposive sampling among pregnant women.", [["women", "ORGANISM", 456, 461], ["women", "ORGANISM", 591, 596], ["women", "SPECIES", 456, 461], ["participants", "SPECIES", 519, 531], ["women", "SPECIES", 591, 596], ["the nominal group technique", "TREATMENT", 175, 202], ["qualitative study", "TEST", 226, 243], ["an exploratory qualitative study", "TEST", 262, 294], ["prenatal care", "TREATMENT", 427, 440], ["the COVID", "TEST", 469, 478], ["pandemic", "PROBLEM", 482, 490], ["Sampling method", "TEST", 491, 506]]], ["Inclusion criteria included: having Iranian nationality and residency in Tabriz, ability to understand and to convey concepts to the researcher, single pregnancy with the age range of 18-40 years, pregnancy over 10 weeks, having the tendency and ability to express and transfer concepts, considering the maximum variability in terms of factors such as education, age, socioeconomic status, having any disease or medical, obstetric risk factor identified on the basis of the family's health records or, as the pregnant woman claims, also requiring special care or relative or absolute rest for the mother, as well as the withdrawal and non-attendance of the pregnant women were considered as the exclusion criteria.Data collectionQualitative data will be collected using in-depth and semistructured interviews, containing open questions.", [["woman", "ORGANISM", 518, 523], ["women", "ORGANISM", 666, 671], ["woman", "SPECIES", 518, 523], ["women", "SPECIES", 666, 671], ["the tendency", "PROBLEM", 229, 241], ["any disease or medical, obstetric risk factor", "PROBLEM", 397, 442], ["special care", "TREATMENT", 547, 559], ["Data collection", "TEST", 714, 729], ["Qualitative data", "TEST", 729, 745]]], ["The interviewer will pilot the interview on with a subset of participants, and will use this information to further refine the guide with respect to culturally sensitive and appropriate questions.", [["participants", "SPECIES", 61, 73]]], ["Then, the interview will continue by presenting other questions, such as \"How do you cope with the difficulties of prenatal care during the covid-19 pandemic?\", \"What can you do to prevent the disease during pregnancy?\", \"What do you think about prenatal care support?\", \"Have you received support?\", \"In your opinion What factors can be helpful in prenatal care?\", and \"What factors do you think may hinder your prenatal care?\".", [["the disease during pregnancy", "PROBLEM", 189, 217]]], ["During the interview, as far as possible, the Note field will be used and non-verbal data such as tone of voice and behaviors will be recorded, too.", [["non-verbal data", "TEST", 74, 89]]], ["The sampling will continue until data are saturated.", [["The sampling", "TREATMENT", 0, 12]]], ["All interviews will be carried out in care centers in a quiet room and without someone other than the interviewees.Data analysisData analysis process will be conducted simultaneously with data collection using MAXQDA software version 10.", [["Data analysisData analysis", "TEST", 115, 141]]], ["Qualitative data analysis can be conducted through qualitative content analysis based on the Graneheim and Lundman method [20] .", [["Qualitative data analysis", "TEST", 0, 25], ["qualitative content analysis", "TEST", 51, 79], ["the Graneheim and Lundman method", "TREATMENT", 89, 121]]], ["In this approach, the data will be analyzed through repeated Reading strategy to obtain a full understanding of it.", [["the data", "TEST", 18, 26]]], ["The researcher continued digging the text by taking notes from the initial analysis until the major codes will be extracted.", [["the initial analysis", "TEST", 63, 83]]], ["Subcategories will be extracted based on differences and similarities.ValidationTo validate the results, at first efforts will be made to build a friendly relationship with the participants.", [["participants", "SPECIES", 177, 189]]], ["In order to increase the accuracy of the data and to verify accuracy of the data, after the registration, the interviews will be given to the participants to review and confirm their stated content and, necessary points will be any other content, it will be added to the data.", [["participants", "SPECIES", 142, 154], ["the registration", "TEST", 88, 104]]], ["External monitoring will be also used to increase the reliability.", [["External monitoring", "TREATMENT", 0, 19]]], ["Through providing the initial code derived from the analysis and examples of the extraction, as external observers, the concepts will be given to other researchers; who are not related to the study in order to determine whether they also will have a similar perception of the data or not.", [["the analysis", "TEST", 48, 60], ["the extraction", "TREATMENT", 77, 91], ["the study", "TEST", 188, 197]]], ["Second phase: quantitative study First, a cross-sectional descriptive analytical study will be conducted to evaluate association between psychological factors with self-care in pregnant women.Sample size and sampling methodConsidering an acceptable error of 0.1 around the mean (m = 2.14), 95% confidence coefficient, 90% statistical power, and the standard deviation of 1.11 related to fear of COVID-19 [21] , the necessary sample size was determined to be 103 pregnant women, and regarding 95% confidence coefficient, 90% statistical power, an acceptable error of 0.05 around the mean (m = 71.9), and the standard deviation of 11.48 related to self-care, also an acceptable error of 0.05 around the mean (m = 60.27), and the standard deviation of 13.12 related perceived stress [18] , the necessary sample size was determined to be 40 and 73 pregnant women, respectively.", [["sample", "ANATOMY", 801, 807], ["women", "ORGANISM", 186, 191], ["women", "ORGANISM", 471, 476], ["women", "ORGANISM", 853, 858], ["women", "SPECIES", 186, 191], ["women", "SPECIES", 471, 476], ["women", "SPECIES", 853, 858], ["quantitative study", "TEST", 14, 32], ["a cross-sectional descriptive analytical study", "TEST", 40, 86], ["Sample size", "TEST", 192, 203], ["sampling method", "TEST", 208, 223], ["the standard deviation", "TEST", 345, 367], ["COVID", "TEST", 395, 400], ["the standard deviation", "TEST", 603, 625], ["size", "OBSERVATION_MODIFIER", 199, 203], ["size", "OBSERVATION_MODIFIER", 808, 812]]], ["Also, Considering 57% anxiety with an acceptable error of 0.1 [22] , the necessary sample size was determined to be 130.", [["anxiety", "DISEASE", 22, 29], ["57% anxiety", "PROBLEM", 18, 29], ["the necessary sample size", "TEST", 69, 94]]], ["As the sample size based on anxiety was greater, this was the sample size sought.", [["anxiety", "DISEASE", 28, 35], ["the sample size", "TEST", 3, 18], ["anxiety", "PROBLEM", 28, 35], ["size", "OBSERVATION_MODIFIER", 14, 18], ["size", "OBSERVATION_MODIFIER", 69, 73]]], ["Regarding cluster sampling and design effect of 1.5, the final sample size was considered to be 215 pregnant women.Sample size and sampling methodSampling will be conducted in the healthcare centers in Tabriz.", [["women", "ORGANISM", 109, 114], ["women", "SPECIES", 109, 114], ["cluster sampling", "PROBLEM", 10, 26], ["the final sample size", "TEST", 53, 74], ["Sample size", "TEST", 115, 126], ["sampling methodSampling", "TREATMENT", 131, 154], ["size", "OBSERVATION_MODIFIER", 122, 126]]], ["Most of the pregnant women have health records in these healthcare centers and posts.", [["women", "ORGANISM", 21, 26], ["women", "SPECIES", 21, 26]]], ["A two-stage cluster sampling will be carried out so that 13 healthcare centers and 14 healthcare posts were selected using a randomizer software (www.random.org).", [["A two-stage cluster sampling", "PROBLEM", 0, 28]]], ["A list of all pregnant women at each center will be extracted from the health records and the samples will be randomly selected from the ordered numbers.", [["women", "ORGANISM", 23, 28], ["women", "SPECIES", 23, 28]]], ["Afterward, using the phone number registered in each record, the researcher will call the potential participants and will invite them to participate in the study and will visit them in their homes if needed.", [["participants", "SPECIES", 100, 112], ["the study", "TEST", 152, 161]]], ["Eligible participants will be provided with full explanations about the study objectives and procedures.", [["participants", "SPECIES", 9, 21], ["the study objectives", "TEST", 68, 88], ["procedures", "TREATMENT", 93, 103]]], ["A number of participants are likely to be illiterate, so the questionnaires will be completed by the researcher in order that the data collection method to be the same for all individuals.Inclusion criteriaThe inclusion criteria consisted of 1) Iranian nationality, 2) residency in Tabriz, 3) ability to read and write, 4) intention to participate in the study, 5) single pregnant women with the age range of 18-40 years, 6) pregnancy over 10 weeks, 7) no history of stressors in the last 6 months (e.g., divorce, death of a family member, and diagnosis of a family member with an incurable or lifethreatening disease), 8) Having any disease or medical, obstetric risk factor identified on the basis of the family's health records or, as the pregnant woman claims, also requiring special care or relative or absolute rest for the mother.Exclusion criteriaThe exclusion criteria were failure to complete the questionnaire completely and unwillingness to continue the study.Scales and data collectionQuantitative data will be collected using 5 questioners, including:1-Sociodemographic characteristics questionnaire:consisted of questions about the women and their husband's ages, women and their husband's education, number of pregnancies, number of deliveries, gestational age, weigh, height, Number of prenatal care.2-Fear of COVID-19 Scale (FCV-19S):This scale which is provided by Ahorsu and et al. [23] , includes seven items.", [["death", "DISEASE", 514, 519], ["participants", "ORGANISM", 12, 24], ["women", "ORGANISM", 381, 386], ["woman", "ORGANISM", 751, 756], ["women", "ORGANISM", 1147, 1152], ["women", "ORGANISM", 1179, 1184], ["participants", "SPECIES", 12, 24], ["women", "SPECIES", 381, 386], ["woman", "SPECIES", 751, 756], ["women", "SPECIES", 1147, 1152], ["women", "SPECIES", 1179, 1184], ["the data collection method", "TEST", 126, 152], ["the study", "TEST", 351, 360], ["an incurable or lifethreatening disease)", "PROBLEM", 578, 618], ["any disease or medical, obstetric risk factor", "PROBLEM", 630, 675], ["the study", "TEST", 962, 971], ["data collection", "TEST", 983, 998], ["COVID", "TEST", 1327, 1332], ["FCV", "TEST", 1343, 1346], ["This scale", "TREATMENT", 1352, 1362], ["likely to be", "UNCERTAINTY", 29, 41]]], ["The participants indicate their level of agreement with the statements using a fiveitem Likert type scale.", [["participants", "SPECIES", 4, 16], ["a fiveitem Likert type scale", "TREATMENT", 77, 105]]], ["A total score is calculated by adding up each item score (ranging from 7 to 35).", [["A total score", "TEST", 0, 13]]], ["The higher the score, the greater the fear of coronavirus-19.", [["coronavirus-19", "ORGANISM", 46, 60], ["coronavirus", "TEST", 46, 57], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["greater", "OBSERVATION_MODIFIER", 26, 33]]], ["More specifically, reliability values such as internal consistency (\u03b1 = .82) and test-retest reliability (ICC = .72) were acceptable.", [["reliability values", "TEST", 19, 37], ["internal consistency", "TEST", 46, 66], ["test", "TEST", 81, 85], ["retest reliability", "TEST", 86, 104], ["ICC", "TEST", 106, 109]]], ["3-Corona Disease Anxiety Scale (CDAS): This questionnaire has been developed by Alipour et al. in Iran [24] .", [["Corona Disease Anxiety Scale", "PROBLEM", 2, 30], ["Corona", "OBSERVATION_MODIFIER", 2, 8], ["Disease", "OBSERVATION", 9, 16]]], ["The final version of this scale has 18 items and 2 components.", [["this scale", "TEST", 21, 31]]], ["Items 2 to 8 measure psychological symptoms and items 9 to 18 measure physical symptoms.", [["psychological symptoms", "PROBLEM", 21, 43], ["physical symptoms", "PROBLEM", 70, 87]]], ["The instrument is rated on a 4degree Likert scale (never = 0, sometimes = 1, most of the time = 2, and always = 3); Therefore, the highest and lowest scores obtained by the respondents in this questionnaire are between 0 and 54.", [["a 4degree Likert scale", "TEST", 27, 49]]], ["Higher scores in this questionnaire indicate a higher levels of anxiety in individuals.", [["anxiety", "DISEASE", 64, 71], ["Higher scores", "PROBLEM", 0, 13], ["anxiety in individuals", "PROBLEM", 64, 86]]], ["The reliability of this tool was obtained using Cronbach's alpha method for the cause of psychological symptoms (0.879), for physical symptoms (0.861) of the first questionnaire (0.919).", [["Cronbach's alpha method", "TEST", 48, 71], ["psychological symptoms", "PROBLEM", 89, 111], ["physical symptoms", "PROBLEM", 125, 142]]], ["We chose to use version 14 in this study.", [["version", "TREATMENT", 16, 23], ["this study", "TEST", 30, 40]]], ["All items are based on the Likert scale (0 = never, 1 = low, 2 = moderate, 3 = much, 4 = very much) scoring.", [["the Likert scale", "TEST", 23, 39]]], ["Scores are ranged from 0 to 56 sets.", [["Scores", "TEST", 0, 6]]], ["Reliability of PSS test was 0.85 and internal consistency of this test was calculated of 0.84 to 0.86 (43, 42).", [["Reliability of PSS test", "TEST", 0, 23], ["this test", "TEST", 61, 70]]], ["The homogeneity coefficients of this questionnaire in the Iranian population were also confirmed by Harris and Mousavi with the Cronbach's alpha was 0.84 [26] .", [["Cronbach's alpha", "GENE_OR_GENE_PRODUCT", 128, 144], ["the Cronbach's alpha", "TEST", 124, 144], ["homogeneity", "OBSERVATION_MODIFIER", 4, 15], ["coefficients", "OBSERVATION_MODIFIER", 16, 28]]], ["5-Pregnancy Self-Care questionnaire: It consists of 13 questions that are rated on a 4-degree Likert scale (never = 1, sometimes =2, most of the time = 3, and always = 4).", [["Likert scale", "TEST", 94, 106]]], ["The reliability of the questionnaire in the internal consistency method, Cronbach's alpha is 0.85 [18] .Data analysisSPSS-22 software is used to analyze the quantitative data.", [["Cronbach's alpha", "TEST", 73, 89], ["Data analysisSPSS", "TEST", 104, 121]]], ["Sociodemographic, FCV-19S, PSS, CDAS and scoring of Pregnancy Self-Care questionnaires score will be described by frequency (percent), as well as mean (standard deviation) if the data are normally distributed.", [["FCV", "SPECIES", 18, 21], ["FCV", "TEST", 18, 21]]], ["The association between Sociodemographic, FCV-19S, PSS, CDAS with Pregnancy Self-Care will be determined using the independent test, ANOVA and Pearson correlation tests in the bivariate analysis, and logistic linear regression adjusting the confounding variables in the multivariate analysis.Data analysisThird phase: integration of quantitative and qualitative dataData analysisTo develop a prenatal care guideline and Strategies to improve the PNC and increase the self-care skills during the COVID-19 pandemic, a comprehensive literature review will be carried out with a supportive approach to improve such practices.", [["FCV", "TEST", 42, 45], ["the independent test", "TEST", 111, 131], ["Pearson correlation tests", "TEST", 143, 168], ["the bivariate analysis", "TEST", 172, 194], ["the multivariate analysis", "TEST", 266, 291], ["Data analysis", "TEST", 292, 305], ["qualitative dataData analysis", "TEST", 350, 379], ["a prenatal care guideline", "TREATMENT", 390, 415], ["Strategies", "TREATMENT", 420, 430], ["the PNC", "TREATMENT", 442, 449], ["the COVID", "TEST", 491, 500], ["a supportive approach", "TREATMENT", 573, 594]]], ["Following this, the results from qualitative and quantitative studies will be delivered to 10-12 experts.", [["quantitative studies", "TEST", 49, 69]]], ["Then, their feedback and comments will be taken into account, using the nominal group technique.DiscussionThe current epidemic of COVID-19 is severe and worrying all over the world [27] , and the number of pregnant women with the virus is on the rise because of pregnancy is a physiological state that predisposes women to viral infection [15, 27] .", [["COVID-19", "CHEMICAL", 130, 138], ["viral infection", "DISEASE", 323, 338], ["women", "ORGANISM", 215, 220], ["women", "ORGANISM", 314, 319], ["women", "SPECIES", 215, 220], ["women", "SPECIES", 314, 319], ["the nominal group technique", "TREATMENT", 68, 95], ["COVID", "TEST", 130, 135], ["the virus", "PROBLEM", 226, 235], ["viral infection", "PROBLEM", 323, 338], ["severe", "OBSERVATION_MODIFIER", 142, 148]]], ["With the rise in global attention, much has been done to better understand and control COVID-19 from various perspectives [4] .", [["COVID-19", "CHEMICAL", 87, 95], ["COVID", "TEST", 87, 92], ["rise", "OBSERVATION_MODIFIER", 9, 13]]], ["Nonetheless, little has been mentioned regarding maternal health and prenatal care management [28] .", [["prenatal care management", "TREATMENT", 69, 93]]], ["Regarding the needs for health knowledge on COVID-19, personal protection against 2019 novel coronavirus (2019-nCoV) is the most concerned for pregnant women [13, 15] .", [["coronavirus", "ORGANISM", 93, 104], ["women", "ORGANISM", 152, 157], ["women", "SPECIES", 152, 157], ["COVID", "TEST", 44, 49]]], ["Social distance program which are taken in the community as a result of efforts to control the disease, as well as the fear and panic of pregnant women from getting sick, lead to reduced referrals for prenatal care [1, 8] .", [["panic", "DISEASE", 128, 133], ["women", "ORGANISM", 146, 151], ["women", "SPECIES", 146, 151], ["the disease", "PROBLEM", 91, 102], ["prenatal care", "TREATMENT", 201, 214], ["disease", "OBSERVATION", 95, 102]]], ["Canceling hospital visits may reduce the probability of viral infection; the aftereffect could leave a bigger impact on pregnancy outcomes [13] .", [["viral infection", "DISEASE", 56, 71], ["viral infection", "PROBLEM", 56, 71], ["pregnancy outcomes", "PROBLEM", 120, 138], ["viral", "OBSERVATION_MODIFIER", 56, 61], ["infection", "OBSERVATION", 62, 71]]], ["Pregnant women critically concern about the risk of infections, and high demand knowledge and measures on prevention and protection from COVID-19 [10] .", [["infections", "DISEASE", 52, 62], ["COVID-19", "CHEMICAL", 137, 145], ["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14], ["infections", "PROBLEM", 52, 62], ["COVID", "TEST", 137, 142], ["infections", "OBSERVATION", 52, 62]]], ["A critical component in the management of any communicable disease threat is the care of vulnerable populations such as pregnant women [13] .", [["women", "ORGANISM", 129, 134], ["women", "SPECIES", 129, 134], ["A critical component", "PROBLEM", 0, 20], ["any communicable disease threat", "PROBLEM", 42, 73], ["critical", "OBSERVATION_MODIFIER", 2, 10], ["component", "OBSERVATION_MODIFIER", 11, 20]]], ["So, Maternal care institutes should understand the demands and needs of pregnant women, optimize the means of prenatal care service, and provide tailored and accessible health education and service for the safety of them [8] .", [["women", "ORGANISM", 81, 86], ["women", "SPECIES", 81, 86]]], ["Pregnant women have the rights to participate in decisions involving their well-beings and what may or may not be done to their care.", [["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14]]], ["Understanding pregnant woman's experiences and perspectives of prenatal care and factors affecting it's during the outbreak of disease is particularly critical for enhancing the effectiveness of services delivery and addressing women's needs and expectations.", [["women", "ORGANISM", 228, 233], ["woman", "SPECIES", 23, 28], ["women", "SPECIES", 228, 233], ["prenatal care", "TREATMENT", 63, 76], ["disease", "PROBLEM", 127, 134], ["services delivery", "TREATMENT", 195, 212]]], ["The mixed-method approach focuses on Epistemological Pluralism.", [["The mixed-method approach", "TREATMENT", 0, 25], ["mixed", "OBSERVATION_MODIFIER", 4, 9], ["Epistemological Pluralism", "OBSERVATION", 37, 62]]], ["The strategy proposed by this study may be helpful in weariness of health professionals and policy makers should be aware of factors influencing prenatal and self-care among pregnant women.", [["women", "ORGANISM", 183, 188], ["women", "SPECIES", 183, 188], ["this study", "TEST", 25, 35]]], ["So, it can improve prenatal care and is helpful in promoting health in pregnancy in critical duration of outbreak of disease.", [["disease", "PROBLEM", 117, 124], ["disease", "OBSERVATION", 117, 124]]], ["Therefore, it is hoped that the strategy proposed in the current study can lead to improve ability of accessible prenatal care.", [["the current study", "TEST", 53, 70], ["accessible prenatal care", "TREATMENT", 102, 126]]]], "PMC7500408": [["Routes of transmission ::: IntroductionStructural analysis reveals the atomic level-specific communications between spike protein receptor-binding domain of SARS-CoV2 and ACE2 receptor present in the host to regulates the transmission of cross-species and human to human (Fig. 1, Fig. 2).", [["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 157, 166], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 171, 184], ["human", "ORGANISM", 256, 261], ["human", "ORGANISM", 265, 270], ["spike protein receptor-binding domain", "PROTEIN", 116, 153], ["SARS-CoV2 and ACE2 receptor", "PROTEIN", 157, 184], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 265, 270], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 265, 270], ["IntroductionStructural analysis", "TEST", 27, 58], ["the atomic level", "TEST", 67, 83], ["spike protein receptor", "PROBLEM", 116, 138], ["SARS", "PROBLEM", 157, 161], ["CoV2", "TREATMENT", 162, 166], ["ACE2 receptor", "TREATMENT", 171, 184]]], ["SARS-CoV-2also uses ACE2 as its binding receptor, to transfer from human to human.", [["SARS", "DISEASE", 0, 4], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["human", "ORGANISM", 67, 72], ["human", "ORGANISM", 76, 81], ["SARS-CoV-2also", "DNA", 0, 14], ["ACE2", "PROTEIN", 20, 24], ["binding receptor", "PROTEIN", 32, 48], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 76, 81], ["ACE2", "TREATMENT", 20, 24]]], ["The transmission of the SARS-CoV-2virus is possible from asymptomatic, presymptomatic, symptomatic, and COVID-19-infected persons (Organization, 2020b).", [["SARS", "DISEASE", 24, 28], ["COVID-19-infected", "DISEASE", 104, 121], ["SARS-CoV-2virus", "ORGANISM", 24, 39], ["persons", "ORGANISM", 122, 129], ["persons", "SPECIES", 122, 129], ["SARS-CoV-2virus", "SPECIES", 24, 39], ["the SARS", "PROBLEM", 20, 28], ["CoV-2virus", "TEST", 29, 39], ["presymptomatic", "PROBLEM", 71, 85], ["symptomatic", "PROBLEM", 87, 98], ["COVID", "TEST", 104, 109], ["symptomatic", "OBSERVATION_MODIFIER", 87, 98]]], ["The virus transmission from the asymptomatic person that does not show symptoms is notable and needs attention.", [["person", "SPECIES", 45, 51], ["symptoms", "PROBLEM", 71, 79], ["virus", "OBSERVATION", 4, 9]]], ["Alternatively, information from a presymptomatic individual can also occur before the onset of symptoms (i.e., during the time of incubation).", [["symptoms", "PROBLEM", 95, 103]]], ["Droplets (coughing or sneezing) and close contact play a central role in COVID-19 infection and human to human transmission.", [["Droplets", "DISEASE", 0, 8], ["infection", "DISEASE", 82, 91], ["COVID-19", "CELL", 73, 81], ["human", "ORGANISM", 96, 101], ["human", "ORGANISM", 105, 110], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 105, 110], ["Droplets (coughing", "PROBLEM", 0, 18], ["sneezing", "PROBLEM", 22, 30], ["infection", "OBSERVATION", 82, 91]]], ["The probable asymptomatic incubation period of COVID-19 is varied from 2 to 14 days, and the mean incubation period is around five days (Lauer et al., 2020).", [["COVID-19", "CHEMICAL", 47, 55], ["COVID-19", "CHEMICAL", 47, 55], ["COVID", "TEST", 47, 52], ["probable", "UNCERTAINTY", 4, 12], ["asymptomatic", "OBSERVATION_MODIFIER", 13, 25], ["incubation", "OBSERVATION_MODIFIER", 26, 36]]], ["Hence, the symptoms may manifest in the individual from 2 days to 2 weeks after viral exposure.", [["the symptoms", "PROBLEM", 7, 19], ["viral exposure", "PROBLEM", 80, 94]]], ["The SARS-CoV-2 virus has spike protein receptor binding and may use ACE2 as a functional receptor in stage 1 (Fig. 2) for cellular entry ACE2 (Hoffmann et al., 2020) and leads to COVID-19 pathogenesis.Routes of transmission ::: IntroductionThe SARS-CoV-2 genome consists of nucleotides nearly more than 30000 and encodes four structural proteins includes, Membrane protein, Spike protein, Envelope protein and nucleocapsid protein with several non-structural proteins.", [["cellular", "ANATOMY", 122, 130], ["nucleotides", "CHEMICAL", 274, 285], ["SARS-CoV-2 virus", "ORGANISM", 4, 20], ["ACE2", "GENE_OR_GENE_PRODUCT", 68, 72], ["cellular", "CELL", 122, 130], ["ACE2", "GENE_OR_GENE_PRODUCT", 137, 141], ["SARS-CoV-2", "ORGANISM", 244, 254], ["Membrane protein", "GENE_OR_GENE_PRODUCT", 356, 372], ["Spike", "GENE_OR_GENE_PRODUCT", 374, 379], ["Envelope protein", "GENE_OR_GENE_PRODUCT", 389, 405], ["spike protein receptor", "PROTEIN", 25, 47], ["ACE2", "PROTEIN", 68, 72], ["ACE2", "PROTEIN", 137, 141], ["SARS-CoV-2 genome", "DNA", 244, 261], ["structural proteins", "PROTEIN", 326, 345], ["Membrane protein", "PROTEIN", 356, 372], ["Spike protein", "PROTEIN", 374, 387], ["Envelope protein", "PROTEIN", 389, 405], ["nucleocapsid protein", "PROTEIN", 410, 430], ["non-structural proteins", "PROTEIN", 444, 467], ["CoV-2 virus", "SPECIES", 9, 20], ["SARS-CoV-2 virus", "SPECIES", 4, 20], ["SARS-CoV", "SPECIES", 244, 252], ["The SARS", "TEST", 0, 8], ["CoV-2 virus", "PROBLEM", 9, 20], ["spike protein receptor binding", "PROBLEM", 25, 55], ["ACE2", "TREATMENT", 68, 72], ["COVID", "TEST", 179, 184], ["The SARS", "TEST", 240, 248], ["CoV", "TEST", 249, 252], ["nucleotides", "TEST", 274, 285], ["Membrane protein", "TEST", 356, 372], ["Spike protein", "TEST", 374, 387], ["Envelope protein", "TEST", 389, 405], ["nucleocapsid protein", "TEST", 410, 430], ["several non-structural proteins", "PROBLEM", 436, 467], ["nucleocapsid protein", "OBSERVATION", 410, 430], ["non-structural proteins", "OBSERVATION", 444, 467]]], ["The capsid contains N-protein or nuclear capsid that binds to the single positive strand viral RNA that permits the virus to take over the human cells and convert them into viral factories.", [["nuclear", "ANATOMY", 33, 40], ["cells", "ANATOMY", 145, 150], ["nuclear", "CELLULAR_COMPONENT", 33, 40], ["human", "ORGANISM", 139, 144], ["cells", "CELL", 145, 150], ["N-protein", "PROTEIN", 20, 29], ["nuclear capsid", "PROTEIN", 33, 47], ["single positive strand viral RNA", "RNA", 66, 98], ["human cells", "CELL_TYPE", 139, 150], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 139, 144], ["nuclear capsid", "PROBLEM", 33, 47], ["the single positive strand viral RNA", "PROBLEM", 62, 98], ["the virus", "PROBLEM", 112, 121], ["the human cells", "TREATMENT", 135, 150], ["viral RNA", "OBSERVATION", 89, 98], ["viral factories", "OBSERVATION", 173, 188]]], ["Additionally the N protein that coats the viral RNA genome plays a major role in transcription and replication.", [["N protein", "PROTEIN", 17, 26], ["viral RNA genome", "DNA", 42, 58], ["the N protein", "TREATMENT", 13, 26], ["viral RNA genome", "OBSERVATION", 42, 58]]], ["The spike protein on SARS-CoV-2 binds with ACE2 receptors on the surface of various cells mainly via the lungs causing the viral entry, where E protein's ion channel activity is found on the transmembrane region of the protein.", [["surface", "ANATOMY", 65, 72], ["cells", "ANATOMY", 84, 89], ["lungs", "ANATOMY", 105, 110], ["transmembrane", "ANATOMY", 191, 204], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 21, 31], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["surface", "CELLULAR_COMPONENT", 65, 72], ["cells", "CELL", 84, 89], ["lungs", "ORGAN", 105, 110], ["E protein", "GENE_OR_GENE_PRODUCT", 142, 151], ["transmembrane", "CELLULAR_COMPONENT", 191, 204], ["spike protein", "PROTEIN", 4, 17], ["ACE2 receptors", "PROTEIN", 43, 57], ["E protein", "PROTEIN", 142, 151], ["transmembrane region", "PROTEIN", 191, 211], ["SARS-CoV", "SPECIES", 21, 29], ["The spike protein", "TEST", 0, 17], ["SARS", "TEST", 21, 25], ["CoV", "TEST", 26, 29], ["ACE2 receptors", "PROBLEM", 43, 57], ["various cells", "PROBLEM", 76, 89], ["the viral entry", "PROBLEM", 119, 134], ["E protein's ion channel activity", "TEST", 142, 174], ["various cells", "OBSERVATION", 76, 89], ["lungs", "ANATOMY", 105, 110], ["viral entry", "OBSERVATION", 123, 134]]], ["E protein found to have a vital role in regulation and control of ion influx and efflux and thus the intracellular and extracellular environment.", [["intracellular", "ANATOMY", 101, 114], ["extracellular", "ANATOMY", 119, 132], ["ion", "SIMPLE_CHEMICAL", 66, 69], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 101, 114], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 119, 132], ["E protein", "PROTEIN", 0, 9], ["E protein", "TEST", 0, 9], ["ion influx", "PROBLEM", 66, 76], ["efflux", "PROBLEM", 81, 87]]], ["Hence, the ion conductivity triggered by E-protein via the manipulation of SARS-CoV-2genome may seem to be a novel route involved in pathogenesis of virus.Receptor mediated mechanism of action ::: IntroductionIronically, ACE2, a gene mainly found in vascular endothelium in all structures such as type I and type II pneumocytes, smooth muscle cells in the pulmonary vasculature, bronchial epithelium, epithelial cells in the lungs, heart, intestine, blood vessels, testes and kidneys (Hamming et al., 2004; Imai et al., 2020).", [["vascular endothelium", "ANATOMY", 250, 270], ["structures", "ANATOMY", 278, 288], ["type II pneumocytes", "ANATOMY", 308, 327], ["smooth muscle cells", "ANATOMY", 329, 348], ["pulmonary vasculature", "ANATOMY", 356, 377], ["bronchial epithelium", "ANATOMY", 379, 399], ["epithelial cells", "ANATOMY", 401, 417], ["lungs", "ANATOMY", 425, 430], ["heart", "ANATOMY", 432, 437], ["intestine", "ANATOMY", 439, 448], ["blood vessels", "ANATOMY", 450, 463], ["testes", "ANATOMY", 465, 471], ["kidneys", "ANATOMY", 476, 483], ["E-protein", "CHEMICAL", 41, 50], ["E-protein", "GENE_OR_GENE_PRODUCT", 41, 50], ["ACE2", "GENE_OR_GENE_PRODUCT", 221, 225], ["vascular endothelium", "TISSUE", 250, 270], ["type II pneumocytes", "CELL", 308, 327], ["smooth muscle cells", "CELL", 329, 348], ["pulmonary vasculature", "MULTI-TISSUE_STRUCTURE", 356, 377], ["bronchial epithelium", "TISSUE", 379, 399], ["epithelial cells", "CELL", 401, 417], ["lungs", "ORGAN", 425, 430], ["heart", "ORGAN", 432, 437], ["intestine", "ORGAN", 439, 448], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 450, 463], ["testes", "ORGAN", 465, 471], ["kidneys", "ORGAN", 476, 483], ["E-protein", "PROTEIN", 41, 50], ["SARS-CoV-2genome", "DNA", 75, 91], ["ACE2", "PROTEIN", 221, 225], ["type I and type II pneumocytes", "CELL_TYPE", 297, 327], ["smooth muscle cells", "CELL_TYPE", 329, 348], ["epithelial cells", "CELL_TYPE", 401, 417], ["SARS-CoV", "SPECIES", 75, 83], ["the ion conductivity", "PROBLEM", 7, 27], ["SARS", "PROBLEM", 75, 79], ["pathogenesis of virus", "PROBLEM", 133, 154], ["type I and type II pneumocytes", "PROBLEM", 297, 327], ["bronchial epithelium, epithelial cells in the lungs", "PROBLEM", 379, 430], ["ion conductivity", "OBSERVATION_MODIFIER", 11, 27], ["virus", "OBSERVATION", 149, 154], ["vascular endothelium", "ANATOMY", 250, 270], ["pneumocytes", "OBSERVATION", 316, 327], ["smooth muscle cells", "OBSERVATION", 329, 348], ["pulmonary vasculature", "ANATOMY", 356, 377], ["bronchial", "ANATOMY", 379, 388], ["epithelium", "ANATOMY_MODIFIER", 389, 399], ["epithelial cells", "OBSERVATION", 401, 417], ["lungs", "ANATOMY", 425, 430], ["heart", "ANATOMY", 432, 437], ["intestine", "ANATOMY", 439, 448], ["blood vessels", "ANATOMY", 450, 463], ["testes", "ANATOMY", 465, 471], ["kidneys", "ANATOMY", 476, 483]]], ["SARS-CoV-2 (S protein) and ACE2 complex cleave S1 from S2 directly binds to the ACE2 RNA binding domain (RBD) (Fig. 3).", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["S protein", "GENE_OR_GENE_PRODUCT", 12, 21], ["ACE2 complex cleave S1", "GENE_OR_GENE_PRODUCT", 27, 49], ["S2", "GENE_OR_GENE_PRODUCT", 55, 57], ["ACE2", "GENE_OR_GENE_PRODUCT", 80, 84], ["SARS-CoV-2 (S protein", "PROTEIN", 0, 21], ["ACE2 complex", "PROTEIN", 27, 39], ["S1", "PROTEIN", 47, 49], ["S2", "PROTEIN", 55, 57], ["ACE2 RNA binding domain", "PROTEIN", 80, 103], ["RBD", "PROTEIN", 105, 108], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["S protein", "TEST", 12, 21], ["ACE2 complex cleave S1", "PROBLEM", 27, 49]]], ["The ACE2 extracellular peptidase domain recognizes RBD via polar residues and facilitates viral entry through the direct plasma membrane and viral membrane fusion (Belouzard et al., 2009).", [["extracellular", "ANATOMY", 9, 22], ["plasma membrane", "ANATOMY", 121, 136], ["membrane", "ANATOMY", 147, 155], ["ACE2", "GENE_OR_GENE_PRODUCT", 4, 8], ["RBD", "GENE_OR_GENE_PRODUCT", 51, 54], ["plasma membrane", "CELLULAR_COMPONENT", 121, 136], ["viral membrane", "CELLULAR_COMPONENT", 141, 155], ["ACE2 extracellular peptidase domain", "PROTEIN", 4, 39], ["RBD", "PROTEIN", 51, 54], ["The ACE2 extracellular peptidase domain", "TREATMENT", 0, 39], ["polar residues", "PROBLEM", 59, 73], ["the direct plasma membrane", "TREATMENT", 110, 136], ["viral membrane fusion", "TREATMENT", 141, 162], ["RBD", "OBSERVATION", 51, 54], ["polar residues", "OBSERVATION", 59, 73], ["viral entry", "OBSERVATION", 90, 101], ["viral membrane fusion", "OBSERVATION", 141, 162]]], ["Once entered into the host cells, Viral RNA genome translation occurs in the cytoplasm to form two structural proteins and polyproteins, that further assists the virus progeny assembly and eventually forms enveloped glycoproteins and genomic RNA within the protein machinery (Li et al., 2020a,b; Perlman & Netland, 2009).", [["cells", "ANATOMY", 27, 32], ["cytoplasm", "ANATOMY", 77, 86], ["cells", "CELL", 27, 32], ["cytoplasm", "ORGANISM_SUBSTANCE", 77, 86], ["host cells", "CELL_TYPE", 22, 32], ["structural proteins", "PROTEIN", 99, 118], ["polyproteins", "PROTEIN", 123, 135], ["enveloped glycoproteins", "PROTEIN", 206, 229], ["genomic RNA", "RNA", 234, 245], ["Viral RNA genome translation", "PROBLEM", 34, 62], ["two structural proteins and polyproteins", "PROBLEM", 95, 135], ["Viral", "OBSERVATION", 34, 39], ["RNA genome", "OBSERVATION", 40, 50]]], ["In the cytoplasm, structured protein nucleocapsids were combined with accessory proteins, genomic RNA, and R protein in the endoplasmic reticulum, eventually release the virions through exocytosis from the infected cell (Shereen et al., 2020).", [["cytoplasm", "ANATOMY", 7, 16], ["endoplasmic reticulum", "ANATOMY", 124, 145], ["virions", "ANATOMY", 170, 177], ["cell", "ANATOMY", 215, 219], ["cytoplasm", "ORGANISM_SUBSTANCE", 7, 16], ["R protein", "GENE_OR_GENE_PRODUCT", 107, 116], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 124, 145], ["virions", "CELLULAR_COMPONENT", 170, 177], ["cell", "CELL", 215, 219], ["accessory proteins", "PROTEIN", 70, 88], ["genomic RNA", "RNA", 90, 101], ["R protein", "PROTEIN", 107, 116], ["structured protein nucleocapsids", "PROBLEM", 18, 50], ["accessory proteins", "PROBLEM", 70, 88], ["genomic RNA", "TEST", 90, 101], ["R protein in the endoplasmic reticulum", "PROBLEM", 107, 145], ["protein nucleocapsids", "OBSERVATION", 29, 50], ["genomic RNA", "OBSERVATION", 90, 101], ["endoplasmic reticulum", "ANATOMY", 124, 145], ["infected cell", "OBSERVATION", 206, 219]]], ["The released infected viral particle readily binds with ACE2 receptors elsewhere (Z. Wu & McGoogan, 2020) and the process continues.COVID-19 with oxidative burst systemic inflammation ::: IntroductionIn response to viral and bacterial infections, the immune system develops both proinflammatory and anti-inflammatory cytokines.", [["immune system", "ANATOMY", 251, 264], ["systemic inflammation", "DISEASE", 162, 183], ["viral and bacterial infections", "DISEASE", 215, 245], ["ACE2", "GENE_OR_GENE_PRODUCT", 56, 60], ["ACE2 receptors", "PROTEIN", 56, 70], ["proinflammatory and anti-inflammatory cytokines", "PROTEIN", 279, 326], ["The released infected viral particle", "PROBLEM", 0, 36], ["COVID", "TEST", 132, 137], ["oxidative burst systemic inflammation", "PROBLEM", 146, 183], ["viral and bacterial infections", "PROBLEM", 215, 245], ["the immune system", "PROBLEM", 247, 264], ["anti-inflammatory cytokines", "TREATMENT", 299, 326], ["infected", "OBSERVATION_MODIFIER", 13, 21], ["viral particle", "OBSERVATION", 22, 36], ["burst", "OBSERVATION_MODIFIER", 156, 161], ["systemic inflammation", "OBSERVATION", 162, 183], ["viral", "OBSERVATION_MODIFIER", 215, 220], ["bacterial infections", "OBSERVATION", 225, 245], ["proinflammatory", "OBSERVATION_MODIFIER", 279, 294], ["anti-inflammatory cytokines", "OBSERVATION", 299, 326]]], ["Following exposure to antigen-presenting cells (APCs) by SARS-CoV-2antigen, T cells release cytokines in various T cell subsets.", [["antigen-presenting cells", "ANATOMY", 22, 46], ["APCs", "ANATOMY", 48, 52], ["T cells", "ANATOMY", 76, 83], ["T cell", "ANATOMY", 113, 119], ["antigen-presenting cells", "CELL", 22, 46], ["APCs", "CELL", 48, 52], ["SARS-CoV-2antigen", "GENE_OR_GENE_PRODUCT", 57, 74], ["T cells", "CELL", 76, 83], ["T cell subsets", "CELL", 113, 127], ["antigen-presenting cells", "CELL_TYPE", 22, 46], ["APCs", "CELL_TYPE", 48, 52], ["SARS-CoV-2antigen", "PROTEIN", 57, 74], ["T cells", "CELL_TYPE", 76, 83], ["cytokines", "PROTEIN", 92, 101], ["T cell subsets", "CELL_TYPE", 113, 127], ["antigen", "TEST", 22, 29], ["APCs", "TEST", 48, 52], ["SARS", "TEST", 57, 61], ["CoV", "TEST", 62, 65], ["T cells release cytokines", "PROBLEM", 76, 101], ["various T cell subsets", "OBSERVATION", 105, 127]]], ["They may further amplify the release of cytokine (cytokine storm) (Fig. 4) implies positive feedback between immune cells and cytokines (Kouhpayeh et al., 2020).", [["immune cells", "ANATOMY", 109, 121], ["immune cells", "CELL", 109, 121], ["cytokine", "PROTEIN", 40, 48], ["cytokine", "PROTEIN", 50, 58], ["immune cells", "CELL_TYPE", 109, 121], ["cytokines", "PROTEIN", 126, 135], ["cytokine (cytokine storm", "TREATMENT", 40, 64], ["positive feedback between immune cells", "PROBLEM", 83, 121]]], ["Alternatively, the genomic dsRNA virus may activate interferon regulatory factors and the NF\u2010\u03baB pathway, which releases enormous type I interferons and proinflammatory cytokines (Li et al., 2020c,d).", [["interferon regulatory factors", "GENE_OR_GENE_PRODUCT", 52, 81], ["NF\u2010\u03baB", "GENE_OR_GENE_PRODUCT", 90, 95], ["type I interferons", "GENE_OR_GENE_PRODUCT", 129, 147], ["interferon regulatory factors", "PROTEIN", 52, 81], ["NF\u2010\u03baB", "PROTEIN", 90, 95], ["type I interferons", "PROTEIN", 129, 147], ["proinflammatory cytokines", "PROTEIN", 152, 177], ["the genomic dsRNA virus", "PROBLEM", 15, 38], ["interferon regulatory factors", "TREATMENT", 52, 81], ["proinflammatory cytokines", "TREATMENT", 152, 177], ["dsRNA virus", "OBSERVATION", 27, 38]]], ["The increased serum IL-6, C-reactive protein, and TNF\u03b1 (Zhou et al., 2020a,b).", [["serum", "ANATOMY", 14, 19], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["IL-6", "GENE_OR_GENE_PRODUCT", 20, 24], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 26, 44], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 50, 54], ["serum IL-6", "PROTEIN", 14, 24], ["C-reactive protein", "PROTEIN", 26, 44], ["TNF", "PROTEIN", 50, 53], ["The increased serum IL", "TEST", 0, 22], ["C-reactive protein", "TEST", 26, 44], ["TNF", "TEST", 50, 53], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["serum IL", "OBSERVATION_MODIFIER", 14, 22], ["reactive protein", "OBSERVATION", 28, 44]]], ["TNF\u03b1 (Huang et al., 2020) are likely to involve the proinflammatory condition in COVID-19 disease.", [["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 0, 4], ["COVID-19 disease", "CANCER", 81, 97], ["TNF\u03b1", "PROTEIN", 0, 4], ["the proinflammatory condition", "PROBLEM", 48, 77], ["disease", "PROBLEM", 90, 97], ["likely to involve", "UNCERTAINTY", 30, 47], ["proinflammatory", "OBSERVATION_MODIFIER", 52, 67]]], ["The disease severity indicates the alteration in proinflammatory cytokines such as IL-7, IL-, IL-10, G-CSF, TNF\u03b1, IP-10, MIP-1A, MCP-1, in patients with COVID-19 (Huang et al., 2020).", [["IL-7", "GENE_OR_GENE_PRODUCT", 83, 87], ["IL", "GENE_OR_GENE_PRODUCT", 89, 91], ["IL-10", "GENE_OR_GENE_PRODUCT", 94, 99], ["G-CSF", "GENE_OR_GENE_PRODUCT", 101, 106], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 108, 112], ["IP-10", "GENE_OR_GENE_PRODUCT", 114, 119], ["MIP-1A", "GENE_OR_GENE_PRODUCT", 121, 127], ["MCP-1", "GENE_OR_GENE_PRODUCT", 129, 134], ["patients", "ORGANISM", 139, 147], ["proinflammatory cytokines", "PROTEIN", 49, 74], ["CSF", "PROTEIN", 103, 106], ["TNF\u03b1", "PROTEIN", 108, 112], ["MIP-1A", "PROTEIN", 121, 127], ["MCP", "PROTEIN", 129, 132], ["patients", "SPECIES", 139, 147], ["The disease severity", "PROBLEM", 0, 20], ["proinflammatory cytokines", "TEST", 49, 74], ["IL", "TEST", 83, 85], ["IL", "TEST", 89, 91], ["IL", "TEST", 94, 96], ["TNF", "TEST", 108, 111], ["IP", "TEST", 114, 116], ["MIP", "TEST", 121, 124], ["MCP", "TEST", 129, 132], ["COVID", "TEST", 153, 158], ["disease", "OBSERVATION", 4, 11], ["proinflammatory cytokines", "OBSERVATION", 49, 74]]], ["Proinflammatory cytokines have been shown to encourage reactive oxygen species and the formation of free radicals that lead to oxidative stress and, ultimately, apoptosis and necrosis due to NAD + and ATP exhaustion (Kouhpayeh et al., 2020).", [["oxygen", "CHEMICAL", 64, 70], ["necrosis", "DISEASE", 175, 183], ["NAD", "CHEMICAL", 191, 194], ["ATP", "CHEMICAL", 201, 204], ["oxygen", "CHEMICAL", 64, 70], ["NAD +", "CHEMICAL", 191, 196], ["ATP", "CHEMICAL", 201, 204], ["reactive oxygen species", "SIMPLE_CHEMICAL", 55, 78], ["free radicals", "SIMPLE_CHEMICAL", 100, 113], ["NAD +", "SIMPLE_CHEMICAL", 191, 196], ["ATP", "SIMPLE_CHEMICAL", 201, 204], ["Proinflammatory cytokines", "PROTEIN", 0, 25], ["Proinflammatory cytokines", "TEST", 0, 25], ["reactive oxygen species", "PROBLEM", 55, 78], ["free radicals", "PROBLEM", 100, 113], ["oxidative stress", "PROBLEM", 127, 143], ["apoptosis", "PROBLEM", 161, 170], ["necrosis", "PROBLEM", 175, 183], ["NAD", "PROBLEM", 191, 194], ["ATP exhaustion", "PROBLEM", 201, 215], ["reactive", "OBSERVATION_MODIFIER", 55, 63], ["oxygen species", "OBSERVATION", 64, 78], ["free radicals", "OBSERVATION", 100, 113], ["necrosis", "OBSERVATION", 175, 183]]], ["Like neutrophils and macrophages, the activated phagocytes create vast quantities of reactive oxygen species and reactive nitrogen species to kill the invading agents during the inflammatory process.", [["neutrophils", "ANATOMY", 5, 16], ["macrophages", "ANATOMY", 21, 32], ["phagocytes", "ANATOMY", 48, 58], ["oxygen", "CHEMICAL", 94, 100], ["nitrogen", "CHEMICAL", 122, 130], ["neutrophils", "CELL", 5, 16], ["macrophages", "CELL", 21, 32], ["phagocytes", "CELL", 48, 58], ["reactive oxygen species", "SIMPLE_CHEMICAL", 85, 108], ["reactive nitrogen species", "SIMPLE_CHEMICAL", 113, 138], ["neutrophils", "CELL_TYPE", 5, 16], ["macrophages", "CELL_TYPE", 21, 32], ["activated phagocytes", "CELL_TYPE", 38, 58], ["neutrophils", "TEST", 5, 16], ["macrophages", "PROBLEM", 21, 32], ["the activated phagocytes", "PROBLEM", 34, 58], ["reactive oxygen species", "PROBLEM", 85, 108], ["reactive nitrogen species", "PROBLEM", 113, 138], ["the invading agents", "TREATMENT", 147, 166], ["the inflammatory process", "PROBLEM", 174, 198], ["neutrophils", "OBSERVATION", 5, 16], ["macrophages", "OBSERVATION", 21, 32], ["vast", "OBSERVATION_MODIFIER", 66, 70], ["quantities", "OBSERVATION_MODIFIER", 71, 81], ["reactive", "OBSERVATION_MODIFIER", 85, 93], ["oxygen species", "OBSERVATION", 94, 108], ["reactive", "OBSERVATION_MODIFIER", 113, 121], ["nitrogen species", "OBSERVATION", 122, 138], ["inflammatory", "OBSERVATION", 178, 190]]], ["These intracellular sources of free radical generation may be subject to oxidative stress-induced DNA damage during viral infection (Kryston et al., 2011).", [["intracellular", "ANATOMY", 6, 19], ["viral infection", "DISEASE", 116, 131], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 6, 19], ["free radical", "SIMPLE_CHEMICAL", 31, 43], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["free radical generation", "PROBLEM", 31, 54], ["oxidative stress", "PROBLEM", 73, 89], ["DNA damage", "PROBLEM", 98, 108], ["viral infection", "PROBLEM", 116, 131], ["free radical", "OBSERVATION", 31, 43], ["viral infection", "OBSERVATION", 116, 131]]], ["In COVID-19 patients, oxidative stress and proinflammatory cytokines cause tissue damage mediated by inflammation.", [["tissue", "ANATOMY", 75, 81], ["inflammation", "DISEASE", 101, 113], ["patients", "ORGANISM", 12, 20], ["tissue", "TISSUE", 75, 81], ["proinflammatory cytokines", "PROTEIN", 43, 68], ["patients", "SPECIES", 12, 20], ["oxidative stress", "PROBLEM", 22, 38], ["proinflammatory cytokines", "TREATMENT", 43, 68], ["tissue damage", "PROBLEM", 75, 88], ["inflammation", "PROBLEM", 101, 113], ["inflammation", "OBSERVATION", 101, 113]]], ["Therefore, oxidative stress and immune response deregulation result in cytokine storm, and pro-inflammation could lead to various organ dysfunctions in SARS-CoV-2 infection (Chen et al., 2020a) (Table 2).COVID-19 and immune cells ::: IntroductionThe immune system is the multi-stage network for protecting the body against harmful bacteria, viruses, and other organisms.", [["organ", "ANATOMY", 130, 135], ["immune cells", "ANATOMY", 217, 229], ["immune system", "ANATOMY", 250, 263], ["body", "ANATOMY", 310, 314], ["organ dysfunctions", "DISEASE", 130, 148], ["SARS-CoV-2 infection", "DISEASE", 152, 172], ["organ", "ORGAN", 130, 135], ["SARS-CoV-2", "ORGANISM", 152, 162], ["COVID-19", "CELL", 204, 212], ["immune cells", "CELL", 217, 229], ["body", "ORGANISM_SUBDIVISION", 310, 314], ["cytokine", "PROTEIN", 71, 79], ["COVID", "PROTEIN", 204, 209], ["immune cells", "CELL_TYPE", 217, 229], ["SARS-CoV-2", "SPECIES", 152, 162], ["oxidative stress", "PROBLEM", 11, 27], ["immune response deregulation", "PROBLEM", 32, 60], ["cytokine storm", "PROBLEM", 71, 85], ["pro-inflammation", "PROBLEM", 91, 107], ["various organ dysfunctions", "PROBLEM", 122, 148], ["SARS", "PROBLEM", 152, 156], ["CoV-2 infection", "PROBLEM", 157, 172], ["COVID", "TEST", 204, 209], ["harmful bacteria", "PROBLEM", 323, 339], ["viruses", "PROBLEM", 341, 348], ["other organisms", "PROBLEM", 354, 369], ["cytokine storm", "OBSERVATION", 71, 85], ["organ", "ANATOMY", 130, 135], ["dysfunctions", "OBSERVATION", 136, 148]]], ["COVID-19's occurrence and development are mediated by viruses and the individual's immune system (Abdulamir & Hafidh, 2020).", [["COVID-19's", "CHEMICAL", 0, 10], ["COVID", "PROTEIN", 0, 5], ["COVID", "TEST", 0, 5], ["viruses", "PROBLEM", 54, 61], ["viruses", "OBSERVATION", 54, 61]]], ["The human self-immune system is the earliest tool to combat COVID-19.", [["COVID-19", "CHEMICAL", 60, 68], ["human", "ORGANISM", 4, 9], ["COVID-19", "DNA", 60, 68], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["COVID", "TEST", 60, 65]]], ["There has been little work on the relationship between SARS-CoV-2 and damage to immune cells (Table 1).", [["immune cells", "ANATOMY", 80, 92], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 55, 65], ["immune cells", "CELL", 80, 92], ["immune cells", "CELL_TYPE", 80, 92], ["SARS", "TEST", 55, 59], ["CoV", "TEST", 60, 63], ["damage to immune cells", "PROBLEM", 70, 92], ["little", "OBSERVATION_MODIFIER", 15, 21], ["immune cells", "OBSERVATION", 80, 92]]], ["This review curiously focused on understanding the interaction between the host immune system and the COVID-19 outbreak based on accumulated data.", [["the COVID", "TEST", 98, 107]]], ["The genetics of the immune system, e.g., HLA genes, can determine the individual infection, duration, severity, relapse, and reinfection (Li et al., 2020a,b).", [["immune system", "ANATOMY", 20, 33], ["infection", "DISEASE", 81, 90], ["HLA", "GENE_OR_GENE_PRODUCT", 41, 44], ["HLA genes", "DNA", 41, 50], ["the immune system", "TEST", 16, 33], ["the individual infection", "PROBLEM", 66, 90], ["relapse", "PROBLEM", 112, 119], ["reinfection", "PROBLEM", 125, 136], ["infection", "OBSERVATION", 81, 90]]], ["Also, the age factor is positively correlated with the SARS-CoV-2 viral load and clarifies the disease's severity in older patients (Huang et al., 2020; Xu et al., 2020a,b,c,d,e,f,).", [["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["SARS-CoV", "SPECIES", 55, 63], ["the SARS", "TEST", 51, 59], ["CoV", "TEST", 60, 63], ["the disease's severity", "PROBLEM", 91, 113]]], ["Ironically, by resting at home (self-quarantine), the infected individuals or patients can cure themselves with acute COVID-19 infection (Cascella et al., 2020).", [["infection", "DISEASE", 127, 136], ["individuals", "ORGANISM", 63, 74], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["the infected individuals", "PROBLEM", 50, 74], ["acute COVID-19 infection", "PROBLEM", 112, 136]]], ["It helps our immune cells to combat disease with COVID-19 and prevents transmission.", [["immune cells", "ANATOMY", 13, 25], ["COVID-19", "CHEMICAL", 49, 57], ["immune cells", "CELL", 13, 25], ["immune cells", "CELL_TYPE", 13, 25], ["combat disease", "PROBLEM", 29, 43], ["COVID", "TEST", 49, 54], ["immune cells", "OBSERVATION", 13, 25]]], ["The self-immune cells serve as a barrier, delay the virus's replication, and produce defensive antibodies and avoid further infections.", [["immune cells", "ANATOMY", 9, 21], ["infections", "DISEASE", 124, 134], ["immune cells", "CELL", 9, 21], ["self-immune cells", "CELL_TYPE", 4, 21], ["defensive antibodies", "PROTEIN", 85, 105], ["The self-immune cells", "TREATMENT", 0, 21], ["a barrier", "TREATMENT", 31, 40], ["the virus's replication", "TREATMENT", 48, 71], ["defensive antibodies", "PROBLEM", 85, 105], ["further infections", "PROBLEM", 116, 134], ["infections", "OBSERVATION", 124, 134]]], ["In response to infection, the proliferation of T-cells may take a week to boost their condition.", [["T-cells", "ANATOMY", 47, 54], ["infection", "DISEASE", 15, 24], ["T-cells", "CELL", 47, 54], ["T-cells", "CELL_TYPE", 47, 54], ["infection", "PROBLEM", 15, 24], ["infection", "OBSERVATION", 15, 24]]], ["However, patients may rapidly worsen as the infected cell proliferates beyond the point where T-cells' efforts become helpless.", [["cell", "ANATOMY", 53, 57], ["T-cells", "ANATOMY", 94, 101], ["patients", "ORGANISM", 9, 17], ["cell", "CELL", 53, 57], ["T-cells", "CELL", 94, 101], ["T-cells", "CELL_TYPE", 94, 101], ["patients", "SPECIES", 9, 17], ["the infected cell proliferates", "PROBLEM", 40, 70], ["helpless", "PROBLEM", 118, 126], ["infected cell proliferates", "OBSERVATION", 44, 70]]], ["Approximately 80% of COVID-19 patients experience a transition from mild to moderate with symptoms or no symptoms at all during this week.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["COVID", "TEST", 21, 26], ["a transition from mild to moderate with symptoms", "PROBLEM", 50, 98], ["symptoms", "PROBLEM", 105, 113], ["mild", "OBSERVATION_MODIFIER", 68, 72], ["moderate", "OBSERVATION_MODIFIER", 76, 84]]], ["Endothelium, one of the first line of the body defence system, plays a part in controlling the immune system through various receptors and cytosolic proteins (Takeuchi & Akira, 2010).", [["Endothelium", "ANATOMY", 0, 11], ["body", "ANATOMY", 42, 46], ["immune system", "ANATOMY", 95, 108], ["cytosolic", "ANATOMY", 139, 148], ["Endothelium", "TISSUE", 0, 11], ["body", "ORGANISM_SUBDIVISION", 42, 46], ["cytosolic proteins", "PROTEIN", 139, 157], ["body", "ANATOMY_MODIFIER", 42, 46]]], ["Endothelium secretes cytokines to regulate innate and adaptive immune responses, and at the site of action, it recruits immune cells (Marelli-Berg & Jarmin, 2004).", [["Endothelium", "ANATOMY", 0, 11], ["immune cells", "ANATOMY", 120, 132], ["Endothelium", "CELL", 0, 11], ["immune cells", "CELL", 120, 132], ["cytokines", "PROTEIN", 21, 30], ["immune cells", "CELL_TYPE", 120, 132], ["Endothelium secretes cytokines", "TREATMENT", 0, 30], ["immune cells", "OBSERVATION", 120, 132]]], ["SARS-CoV-2 targets the endothelial host cell by binding its spike glycoprotein to the ACE2 receptor (Marelli-Berg & Jarmin, 2004).", [["endothelial host cell", "ANATOMY", 23, 44], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["endothelial host cell", "CELL", 23, 44], ["ACE2", "GENE_OR_GENE_PRODUCT", 86, 90], ["endothelial host cell", "CELL_TYPE", 23, 44], ["spike glycoprotein", "PROTEIN", 60, 78], ["ACE2 receptor", "PROTEIN", 86, 99], ["SARS", "TEST", 0, 4], ["the endothelial host cell", "PROBLEM", 19, 44], ["endothelial", "ANATOMY", 23, 34], ["host cell", "OBSERVATION", 35, 44]]], ["SARS-CoV-2 targets the endothelial host cell by binding its spike glycoprotein to the ACE2 receptor (Lovren et al., 2008; Sardu et al., 2020), which is highly expressed in lungs (Hamming et al., 2004).", [["endothelial host cell", "ANATOMY", 23, 44], ["lungs", "ANATOMY", 172, 177], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["endothelial host cell", "CELL", 23, 44], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 86, 99], ["lungs", "ORGAN", 172, 177], ["endothelial host cell", "CELL_TYPE", 23, 44], ["spike glycoprotein", "PROTEIN", 60, 78], ["ACE2 receptor", "PROTEIN", 86, 99], ["SARS", "TEST", 0, 4], ["the endothelial host cell", "TREATMENT", 19, 44], ["endothelial", "ANATOMY", 23, 34], ["host cell", "OBSERVATION", 35, 44], ["lungs", "ANATOMY", 172, 177]]], ["Endothelial activation increases vascular permeability to plasma proteins, releases pro-inflammatory cytokines, tumour necrosis factor-1d6fc; (TNF-1d6fc;), chemokines, adhesion molecule (from activated leukocytes) and induces inflammation (Pober & Sessa, 2007).", [["Endothelial", "ANATOMY", 0, 11], ["vascular", "ANATOMY", 33, 41], ["plasma", "ANATOMY", 58, 64], ["leukocytes", "ANATOMY", 202, 212], ["necrosis", "DISEASE", 119, 127], ["inflammation", "DISEASE", 226, 238], ["Endothelial", "CELL", 0, 11], ["vascular", "MULTI-TISSUE_STRUCTURE", 33, 41], ["plasma", "ORGANISM_SUBSTANCE", 58, 64], ["tumour necrosis factor-1d6fc", "GENE_OR_GENE_PRODUCT", 112, 140], ["TNF-1d6fc", "GENE_OR_GENE_PRODUCT", 143, 152], ["leukocytes", "CELL", 202, 212], ["plasma proteins", "PROTEIN", 58, 73], ["pro-inflammatory cytokines", "PROTEIN", 84, 110], ["tumour necrosis factor", "PROTEIN", 112, 134], ["1d6fc", "PROTEIN", 135, 140], ["TNF", "PROTEIN", 143, 146], ["1d6fc", "PROTEIN", 147, 152], ["chemokines", "PROTEIN", 156, 166], ["adhesion molecule", "PROTEIN", 168, 185], ["activated leukocytes", "CELL_TYPE", 192, 212], ["Endothelial activation", "PROBLEM", 0, 22], ["plasma proteins", "TEST", 58, 73], ["pro-inflammatory cytokines", "TEST", 84, 110], ["tumour necrosis factor", "PROBLEM", 112, 134], ["TNF", "TEST", 143, 146], ["adhesion molecule", "PROBLEM", 168, 185], ["activated leukocytes", "PROBLEM", 192, 212], ["inflammation", "PROBLEM", 226, 238], ["vascular", "ANATOMY", 33, 41], ["tumour necrosis", "OBSERVATION", 112, 127], ["chemokines", "ANATOMY", 156, 166], ["adhesion molecule", "OBSERVATION", 168, 185], ["inflammation", "OBSERVATION", 226, 238]]], ["The endothelial dysfunction stimulates a sequence of signalling molecules releasing nuclear factor-kB (NF-kB) to control both the innate and adaptive immune response (Oeckinghaus & Ghosh, 2009).", [["endothelial", "ANATOMY", 4, 15], ["endothelial dysfunction", "DISEASE", 4, 27], ["endothelial", "CELL", 4, 15], ["nuclear factor-kB", "GENE_OR_GENE_PRODUCT", 84, 101], ["NF-kB", "GENE_OR_GENE_PRODUCT", 103, 108], ["signalling molecules", "PROTEIN", 53, 73], ["nuclear factor-kB (NF-kB", "PROTEIN", 84, 108], ["The endothelial dysfunction", "PROBLEM", 0, 27], ["signalling molecules", "PROBLEM", 53, 73], ["nuclear factor", "TEST", 84, 98], ["endothelial", "ANATOMY", 4, 15], ["dysfunction", "OBSERVATION", 16, 27]]], ["If an innate immunity effort fails to abolish threat, it activates adaptive immune reactions and converts the acute inflammation into chronic inflammation (Seledtsov et al., 2015).COVID-19 and immune cells ::: Introduction", [["immune cells", "ANATOMY", 193, 205], ["inflammation", "DISEASE", 116, 128], ["inflammation", "DISEASE", 142, 154], ["COVID-19", "CELL", 180, 188], ["immune cells", "CELL", 193, 205], ["COVID", "PROTEIN", 180, 185], ["immune cells", "CELL_TYPE", 193, 205], ["adaptive immune reactions", "PROBLEM", 67, 92], ["the acute inflammation into chronic inflammation", "PROBLEM", 106, 154], ["COVID", "TEST", 180, 185], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["inflammation", "OBSERVATION", 116, 128], ["chronic", "OBSERVATION_MODIFIER", 134, 141], ["inflammation", "OBSERVATION", 142, 154]]]], "045d35854a4f92e409d47b7fb5598dec1a877112": [["IntroductionBy June 8, 2020 , the COVID-19 pandemic had affected more than 6.9 million people worldwide, resulting in 401,970 deaths (1).", [["deaths", "DISEASE", 126, 132], ["people", "ORGANISM", 87, 93], ["people", "SPECIES", 87, 93], ["the COVID", "TEST", 30, 39]]], ["The most typical clinical presentation of COVID-19 is an acute febrile respiratory infection with dry cough, dyspnea, fatigue and myalgia.", [["respiratory", "ANATOMY", 71, 82], ["COVID", "DISEASE", 42, 47], ["respiratory infection", "DISEASE", 71, 92], ["dry cough", "DISEASE", 98, 107], ["dyspnea", "DISEASE", 109, 116], ["fatigue", "DISEASE", 118, 125], ["myalgia", "DISEASE", 130, 137], ["COVID", "TEST", 42, 47], ["an acute febrile respiratory infection", "PROBLEM", 54, 92], ["dry cough", "PROBLEM", 98, 107], ["dyspnea", "PROBLEM", 109, 116], ["fatigue", "PROBLEM", 118, 125], ["myalgia", "PROBLEM", 130, 137], ["most typical", "OBSERVATION_MODIFIER", 4, 16], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["febrile", "OBSERVATION_MODIFIER", 63, 70], ["respiratory", "ANATOMY", 71, 82], ["infection", "OBSERVATION", 83, 92], ["dry", "OBSERVATION_MODIFIER", 98, 101], ["cough", "OBSERVATION", 102, 107], ["myalgia", "OBSERVATION", 130, 137]]], ["Approximately 15-20% of patients have severe disease and the mortality is around 2-3% (2) (3) (4) .IntroductionIn the absence of vaccine or specific therapy available to date, it is essential to be able to diagnose this disease as early as possible in order to isolate infected subjects and thus limit the spread of the disease.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["severe disease", "PROBLEM", 38, 52], ["the mortality", "TEST", 57, 70], ["vaccine", "TREATMENT", 129, 136], ["specific therapy", "TREATMENT", 140, 156], ["this disease", "PROBLEM", 215, 227], ["the disease", "PROBLEM", 316, 327], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["disease", "OBSERVATION", 45, 52], ["infected", "OBSERVATION", 269, 277], ["disease", "OBSERVATION", 320, 327]]], ["The method of reference is laboratory testing of nasopharyngeal aspirates for identification of SARS-CoV-2 by reverse transcriptase -polymerase chain reaction (RT-PCR).", [["nasopharyngeal aspirates", "ANATOMY", 49, 73], ["SARS", "DISEASE", 96, 100], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 49, 73], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 96, 106], ["reverse transcriptase", "PROTEIN", 110, 131], ["SARS-CoV", "SPECIES", 96, 104], ["laboratory testing", "TEST", 27, 45], ["nasopharyngeal aspirates", "TEST", 49, 73], ["SARS", "PROBLEM", 96, 100], ["CoV", "TEST", 101, 104], ["reverse transcriptase -polymerase chain reaction", "PROBLEM", 110, 158], ["RT-PCR", "TEST", 160, 166], ["nasopharyngeal", "ANATOMY", 49, 63]]], ["However, it takes several hours to obtain the results, and the sensitivity of the test is only 60 to 70%, depending on the quality of the sample and the rate of viral replication in the upper respiratory tract (5, 6) .IntroductionChest computed tomography (CT) has rapidly emerged as a rapid and effective diagnostic tool, given the often quite characteristic presentation of COVID-19 pneumonia (7, 8) .", [["sample", "ANATOMY", 138, 144], ["upper respiratory tract", "ANATOMY", 186, 209], ["pneumonia", "DISEASE", 385, 394], ["upper respiratory", "ORGANISM_SUBDIVISION", 186, 203], ["tract", "ORGANISM_SUBDIVISION", 204, 209], ["the test", "TEST", 78, 86], ["the sample", "TEST", 134, 144], ["viral replication in the upper respiratory tract", "PROBLEM", 161, 209], ["IntroductionChest computed tomography (CT)", "TEST", 218, 260], ["COVID-19 pneumonia", "PROBLEM", 376, 394], ["viral replication", "OBSERVATION", 161, 178], ["upper", "ANATOMY_MODIFIER", 186, 191], ["respiratory tract", "ANATOMY", 192, 209], ["Chest", "ANATOMY", 230, 235], ["pneumonia", "OBSERVATION", 385, 394]]], ["Now that the J o u r n a l P r e -p r o o f 3 \"first wave\" has passed and the pandemic appears to be under control, we propose to review and update the current knowledge on COVID-19 pneumonia imaging.Role of chest CT in the management of suspected patientsThe massive arrival of patients suspected of having COVID-19 in emergency departments has prompted the setting up of \"COVID\" and \"non COVID\" pathways, making it necessary to triage patients as early as possible.", [["chest", "ANATOMY", 208, 213], ["pneumonia", "DISEASE", 182, 191], ["COVID-19", "CHEMICAL", 308, 316], ["chest", "ORGAN", 208, 213], ["patients", "ORGANISM", 248, 256], ["patients", "ORGANISM", 279, 287], ["patients", "ORGANISM", 437, 445], ["patients", "SPECIES", 248, 256], ["patients", "SPECIES", 279, 287], ["patients", "SPECIES", 437, 445], ["COVID", "TEST", 173, 178], ["pneumonia imaging", "TEST", 182, 199], ["chest CT", "TEST", 208, 216], ["COVID", "TEST", 308, 313], ["pneumonia", "OBSERVATION", 182, 191], ["chest", "ANATOMY", 208, 213], ["massive", "OBSERVATION_MODIFIER", 260, 267]]], ["According to the ESR/ESTI advice paper and recommendations of the French Society of Thoracic Imaging, unenhanced chest CT is currently indicated for patients presenting with dyspnea, polypnea or desaturation in order to refer them to \"COVID\" or \"non COVID\" wards, pending RT-PCR results (9) .", [["dyspnea", "DISEASE", 174, 181], ["polypnea", "DISEASE", 183, 191], ["desaturation", "DISEASE", 195, 207], ["chest", "ORGAN", 113, 118], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["Thoracic Imaging", "TEST", 84, 100], ["unenhanced chest CT", "TEST", 102, 121], ["dyspnea", "PROBLEM", 174, 181], ["polypnea", "PROBLEM", 183, 191], ["desaturation", "PROBLEM", 195, 207], ["RT-PCR", "TEST", 272, 278], ["Thoracic", "ANATOMY", 84, 92], ["chest", "ANATOMY", 113, 118], ["desaturation", "OBSERVATION", 195, 207]]], ["Chest CT sensitivity for the diagnosis of COVID-19 is greater than 90%, with false-negative findings mostly in patients who are symptomatic for less than 3 days (5, 10) .", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["Chest CT sensitivity", "TEST", 0, 20], ["COVID", "TEST", 42, 47], ["false-negative findings", "PROBLEM", 77, 100], ["symptomatic", "PROBLEM", 128, 139], ["negative", "OBSERVATION", 83, 91], ["symptomatic", "OBSERVATION_MODIFIER", 128, 139]]], ["CT specificity is more variable.", [["CT specificity", "TEST", 0, 14], ["more variable", "OBSERVATION_MODIFIER", 18, 31]]], ["A meta-analysis, including mainly Asian studies, reported pooled sensitivity and specificity of 94% and 37% respectively for the diagnosis of COVID-19 pneumonia (12) .", [["pneumonia", "DISEASE", 151, 160], ["A meta-analysis", "TEST", 0, 15], ["Asian studies", "TEST", 34, 47], ["pooled sensitivity", "TEST", 58, 76], ["specificity", "TEST", 81, 92], ["COVID", "TEST", 142, 147], ["pneumonia", "PROBLEM", 151, 160], ["pneumonia", "OBSERVATION", 151, 160]]], ["Furthermore, this meta-analysis reported a high degree of variability in positive predictive value of chest CT according to prevalence.Role of chest CT in the management of suspected patientsDepending on whether the prevalence is 1%, 10% or 39%, the positive predictive value would become 1.5%, 14.2% or 48.8%, respectively.", [["chest", "ANATOMY", 102, 107], ["chest", "ANATOMY", 143, 148], ["chest", "ORGANISM_SUBDIVISION", 102, 107], ["chest", "ORGAN", 143, 148], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["this meta-analysis", "TEST", 13, 31], ["chest CT", "TEST", 102, 110], ["chest CT", "TEST", 143, 151], ["the positive predictive value", "TEST", 246, 275], ["high degree", "OBSERVATION_MODIFIER", 43, 54], ["chest", "ANATOMY", 102, 107], ["chest", "ANATOMY", 143, 148]]], ["Thus, the use of CT as a screening tool in low prevalence areas would lead to a large number of false positives.", [["CT", "TEST", 17, 19], ["a screening tool", "TEST", 23, 39], ["low prevalence areas", "PROBLEM", 43, 63], ["false positives", "PROBLEM", 96, 111], ["large", "OBSERVATION_MODIFIER", 80, 85], ["false positives", "OBSERVATION", 96, 111]]], ["In addition, it should be noted that inter-reader agreement of chest CT for COVID-19 diagnosis is generally reported to be good or even excellent (13, 14) .Role of chest CT in the management of suspected patientsIn practice, chest CT results can lead to three scenarios: (i) when chest CT is very suggestive of COVID-19, the patient will be hospitalized in a COVID-19 isolation ward, and RT-PCR testing will generally confirm the diagnosis; (ii) when chest CT shows an obvious alternate diagnosis (e.g. bacterial lobar pneumonia or left ventricular failure), the patient will be hospitalized in a \"non COVID-19\" ward; (iii) when chest CT scan is indeterminate, RT-PCR testing along with clinical symptoms will be essential for referral to the most appropriate ward.Role of chest CT in the management of suspected patientsChest CT scans should not be performed for screening purpose in asymptomatic patients.Role of chest CT in the management of suspected patientsNeither chest X-ray nor ultrasonography is recommended for the diagnosis of COVID-19, as their performance appears to be significantly inferior to that of CT.Typical CT presentationThe most typical CT features of COVID-19 pneumonia are bilateral and multifocal groundglass opacities.", [["chest", "ANATOMY", 63, 68], ["chest", "ANATOMY", 164, 169], ["chest", "ANATOMY", 225, 230], ["chest", "ANATOMY", 280, 285], ["lobar", "ANATOMY", 513, 518], ["left ventricular", "ANATOMY", 532, 548], ["chest", "ANATOMY", 629, 634], ["chest", "ANATOMY", 773, 778], ["chest", "ANATOMY", 915, 920], ["pneumonia", "DISEASE", 519, 528], ["left ventricular failure", "DISEASE", 532, 556], ["pneumonia", "DISEASE", 1185, 1194], ["opacities", "DISEASE", 1236, 1245], ["chest", "ORGAN", 63, 68], ["chest", "ORGAN", 164, 169], ["patients", "ORGANISM", 204, 212], ["patient", "ORGANISM", 325, 332], ["ventricular", "ORGAN", 537, 548], ["patient", "ORGANISM", 563, 570], ["chest", "ORGAN", 629, 634], ["chest", "ORGAN", 773, 778], ["patients", "ORGANISM", 813, 821], ["patients", "ORGANISM", 898, 906], ["chest", "ORGAN", 915, 920], ["patients", "ORGANISM", 955, 963], ["patients", "SPECIES", 204, 212], ["patient", "SPECIES", 325, 332], ["patient", "SPECIES", 563, 570], ["patients", "SPECIES", 813, 821], ["patients", "SPECIES", 898, 906], ["patients", "SPECIES", 955, 963], ["chest CT", "TEST", 63, 71], ["COVID", "TEST", 76, 81], ["chest CT", "TEST", 164, 172], ["chest CT", "TEST", 225, 233], ["chest CT", "TEST", 280, 288], ["COVID", "TEST", 311, 316], ["RT-PCR testing", "TEST", 388, 402], ["chest CT", "TEST", 451, 459], ["bacterial lobar pneumonia", "PROBLEM", 503, 528], ["left ventricular failure", "PROBLEM", 532, 556], ["chest CT scan", "TEST", 629, 642], ["RT-PCR testing", "TEST", 661, 675], ["clinical symptoms", "PROBLEM", 687, 704], ["chest CT", "TEST", 773, 781], ["Chest CT scans", "TEST", 821, 835], ["screening purpose", "TEST", 864, 881], ["chest CT", "TEST", 915, 923], ["Neither chest X-ray", "TEST", 963, 982], ["ultrasonography", "TEST", 987, 1002], ["COVID", "TEST", 1039, 1044], ["CT", "TEST", 1118, 1120], ["Typical CT presentation", "TEST", 1121, 1144], ["COVID-19 pneumonia", "PROBLEM", 1176, 1194], ["bilateral and multifocal groundglass opacities", "PROBLEM", 1199, 1245], ["chest", "ANATOMY", 63, 68], ["chest", "ANATOMY", 164, 169], ["chest", "ANATOMY", 225, 230], ["chest", "ANATOMY", 280, 285], ["chest", "ANATOMY", 451, 456], ["lobar", "OBSERVATION_MODIFIER", 513, 518], ["pneumonia", "OBSERVATION", 519, 528], ["left ventricular", "ANATOMY", 532, 548], ["failure", "OBSERVATION", 549, 556], ["chest", "ANATOMY", 629, 634], ["indeterminate", "OBSERVATION_MODIFIER", 646, 659], ["chest", "ANATOMY", 773, 778], ["chest", "ANATOMY", 915, 920], ["chest", "ANATOMY", 971, 976], ["most typical", "OBSERVATION_MODIFIER", 1148, 1160], ["pneumonia", "OBSERVATION", 1185, 1194], ["bilateral", "ANATOMY_MODIFIER", 1199, 1208], ["multifocal", "OBSERVATION_MODIFIER", 1213, 1223], ["groundglass opacities", "OBSERVATION", 1224, 1245]]], ["Lesions classically predominate in the peripheral, posterior and basal part of the lungs (Figure 1 ) (10) .", [["peripheral", "ANATOMY", 39, 49], ["basal part", "ANATOMY", 65, 75], ["lungs", "ANATOMY", 83, 88], ["peripheral", "TISSUE", 39, 49], ["posterior", "MULTI-TISSUE_STRUCTURE", 51, 60], ["basal part", "MULTI-TISSUE_STRUCTURE", 65, 75], ["lungs", "ORGAN", 83, 88], ["Lesions", "PROBLEM", 0, 7], ["peripheral", "ANATOMY_MODIFIER", 39, 49], ["posterior", "ANATOMY_MODIFIER", 51, 60], ["basal", "ANATOMY_MODIFIER", 65, 70], ["lungs", "ANATOMY", 83, 88]]], ["Other signs have been reported such as the presence of fine reticulations, peribronchovascular thickening, vascular dilatations within pneumonia areas, or architectural distortion (15) .", [["peribronchovascular", "ANATOMY", 75, 94], ["vascular", "ANATOMY", 107, 115], ["pneumonia", "DISEASE", 135, 144], ["vascular", "MULTI-TISSUE_STRUCTURE", 107, 115], ["Other signs", "PROBLEM", 0, 11], ["fine reticulations", "PROBLEM", 55, 73], ["peribronchovascular thickening", "PROBLEM", 75, 105], ["vascular dilatations within pneumonia areas", "PROBLEM", 107, 150], ["architectural distortion", "PROBLEM", 155, 179], ["fine", "OBSERVATION_MODIFIER", 55, 59], ["reticulations", "OBSERVATION", 60, 73], ["peribronchovascular", "ANATOMY_MODIFIER", 75, 94], ["thickening", "OBSERVATION", 95, 105], ["vascular", "ANATOMY", 107, 115], ["dilatations", "OBSERVATION", 116, 127], ["pneumonia", "OBSERVATION", 135, 144], ["architectural distortion", "OBSERVATION", 155, 179]]], ["Usually, there are no micronodules, excavations, septal lines, mediastinal lymph node enlargement or pleural effusions.", [["micronodules", "ANATOMY", 22, 34], ["septal lines", "ANATOMY", 49, 61], ["mediastinal lymph node", "ANATOMY", 63, 85], ["pleural effusions", "ANATOMY", 101, 118], ["mediastinal lymph node enlargement", "DISEASE", 63, 97], ["pleural effusions", "DISEASE", 101, 118], ["septal lines", "CELL", 49, 61], ["lymph node", "MULTI-TISSUE_STRUCTURE", 75, 85], ["pleural effusions", "PATHOLOGICAL_FORMATION", 101, 118], ["micronodules", "PROBLEM", 22, 34], ["excavations", "PROBLEM", 36, 47], ["septal lines", "PROBLEM", 49, 61], ["mediastinal lymph node enlargement", "PROBLEM", 63, 97], ["pleural effusions", "PROBLEM", 101, 118], ["no", "UNCERTAINTY", 19, 21], ["micronodules", "OBSERVATION", 22, 34], ["excavations", "OBSERVATION_MODIFIER", 36, 47], ["septal lines", "OBSERVATION", 49, 61], ["mediastinal", "ANATOMY", 63, 74], ["lymph node", "OBSERVATION", 75, 85], ["enlargement", "OBSERVATION_MODIFIER", 86, 97], ["pleural", "ANATOMY", 101, 108], ["effusions", "OBSERVATION", 109, 118]]], ["Some infected but asymptomatic patients may have slight ground-glass opacities but these are generally not extensive (16) .Chest CT appearance of COVID-19 may be quite similar to that of other viral pneumonitis.However, the peripheral location of the lesions, involvement of the five lobes, the presence of thin reticulations and peribronchovascular thickening would be more frequently found in COVID-19 pneumonitis (17, 18) .", [["lesions", "ANATOMY", 251, 258], ["lobes", "ANATOMY", 284, 289], ["peribronchovascular", "ANATOMY", 330, 349], ["COVID-19", "CHEMICAL", 146, 154], ["pneumonitis", "DISEASE", 199, 210], ["pneumonitis", "DISEASE", 404, 415], ["patients", "ORGANISM", 31, 39], ["lesions", "PATHOLOGICAL_FORMATION", 251, 258], ["lobes", "CANCER", 284, 289], ["patients", "SPECIES", 31, 39], ["Some infected", "PROBLEM", 0, 13], ["slight ground-glass opacities", "PROBLEM", 49, 78], ["Chest CT", "TEST", 123, 131], ["COVID", "TEST", 146, 151], ["other viral pneumonitis", "PROBLEM", 187, 210], ["the lesions", "PROBLEM", 247, 258], ["involvement of the five lobes", "PROBLEM", 260, 289], ["thin reticulations", "PROBLEM", 307, 325], ["peribronchovascular thickening", "PROBLEM", 330, 360], ["COVID", "TEST", 395, 400], ["pneumonitis", "PROBLEM", 404, 415], ["infected", "OBSERVATION", 5, 13], ["asymptomatic", "OBSERVATION_MODIFIER", 18, 30], ["slight", "OBSERVATION_MODIFIER", 49, 55], ["ground-glass opacities", "OBSERVATION", 56, 78], ["extensive", "OBSERVATION_MODIFIER", 107, 116], ["viral", "OBSERVATION_MODIFIER", 193, 198], ["pneumonitis", "OBSERVATION", 199, 210], ["peripheral", "OBSERVATION_MODIFIER", 224, 234], ["lesions", "OBSERVATION", 251, 258], ["five lobes", "ANATOMY_MODIFIER", 279, 289], ["thin", "OBSERVATION_MODIFIER", 307, 311], ["reticulations", "OBSERVATION", 312, 325], ["peribronchovascular", "ANATOMY_MODIFIER", 330, 349], ["thickening", "OBSERVATION", 350, 360], ["pneumonitis", "OBSERVATION", 404, 415]]], ["In influenza pneumonia, nodular or micronodular tree-in-bud pattern may be more common, as may pleural effusions (19) .Atypical CT presentationIn approximately 10% of patients, lung involvement of COVID-19 may present as arciform or pseudonodular consolidation suggesting a pattern of organizing pneumonia (20) , sometimes with a \"reverse halo sign\" similar to the one observed in other infectious diseases (21) .Atypical CT presentationUnilateral presentation is possible in about 20-30% of patients, usually at an early stage before bilateralization of the lesions (5, 22) .", [["nodular", "ANATOMY", 24, 31], ["bud", "ANATOMY", 56, 59], ["pleural effusions", "ANATOMY", 95, 112], ["lung", "ANATOMY", 177, 181], ["arciform", "ANATOMY", 221, 229], ["pseudonodular", "ANATOMY", 233, 246], ["lesions", "ANATOMY", 559, 566], ["influenza pneumonia", "DISEASE", 3, 22], ["pleural effusions", "DISEASE", 95, 112], ["pneumonia", "DISEASE", 296, 305], ["infectious diseases", "DISEASE", 387, 406], ["pleural effusions", "PATHOLOGICAL_FORMATION", 95, 112], ["patients", "ORGANISM", 167, 175], ["lung", "ORGAN", 177, 181], ["patients", "ORGANISM", 492, 500], ["lesions", "PATHOLOGICAL_FORMATION", 559, 566], ["patients", "SPECIES", 167, 175], ["patients", "SPECIES", 492, 500], ["influenza pneumonia", "PROBLEM", 3, 22], ["nodular or micronodular tree", "PROBLEM", 24, 52], ["pleural effusions", "PROBLEM", 95, 112], ["Atypical CT presentationIn", "TEST", 119, 145], ["COVID", "TEST", 197, 202], ["pseudonodular consolidation", "PROBLEM", 233, 260], ["organizing pneumonia", "PROBLEM", 285, 305], ["a \"reverse halo sign", "PROBLEM", 328, 348], ["Atypical CT presentation", "TEST", 413, 437], ["the lesions", "PROBLEM", 555, 566], ["influenza", "OBSERVATION_MODIFIER", 3, 12], ["pneumonia", "OBSERVATION", 13, 22], ["nodular", "OBSERVATION_MODIFIER", 24, 31], ["micronodular", "OBSERVATION_MODIFIER", 35, 47], ["tree", "OBSERVATION_MODIFIER", 48, 52], ["bud", "ANATOMY_MODIFIER", 56, 59], ["may be", "UNCERTAINTY", 68, 74], ["more common", "OBSERVATION_MODIFIER", 75, 86], ["pleural", "ANATOMY", 95, 102], ["effusions", "OBSERVATION", 103, 112], ["lung", "ANATOMY", 177, 181], ["involvement", "OBSERVATION", 182, 193], ["pseudonodular", "OBSERVATION_MODIFIER", 233, 246], ["consolidation", "OBSERVATION", 247, 260], ["pattern", "OBSERVATION_MODIFIER", 274, 281], ["organizing", "OBSERVATION_MODIFIER", 285, 295], ["pneumonia", "OBSERVATION", 296, 305], ["infectious", "OBSERVATION", 387, 397], ["Unilateral", "OBSERVATION_MODIFIER", 437, 447], ["lesions", "OBSERVATION", 559, 566]]], ["Peribronchovascular or apical predominance is also described ( Figure 3 ) (23) .", [["Peribronchovascular", "ANATOMY", 0, 19], ["Peribronchovascular or apical predominance", "PROBLEM", 0, 42], ["apical", "ANATOMY_MODIFIER", 23, 29], ["predominance", "OBSERVATION", 30, 42]]], ["When COVID-19 pneumonia occurs in a previously abnormal lung (e.g., with underlying emphysema or fibrosis), CT presentation becomes less specific, making a careful comparison with previous CT examinations, when available, mandatory ( Figure 4) (24).Evolution of CT findingsGround-glass opacities tend to progress over time, both in extent and attenuation value, and evolve either towards crazy paving areas (i.e. superimposition of ground-glass and intralobular reticulations), or towards linear and retractile consolidation areas ( Figure 2 ) (10, (25) (26) (27) .", [["lung", "ANATOMY", 56, 60], ["intralobular reticulations", "ANATOMY", 449, 475], ["pneumonia", "DISEASE", 14, 23], ["emphysema", "DISEASE", 84, 93], ["fibrosis", "DISEASE", 97, 105], ["lung", "ORGAN", 56, 60], ["COVID", "TEST", 5, 10], ["pneumonia", "PROBLEM", 14, 23], ["a previously abnormal lung", "PROBLEM", 34, 60], ["underlying emphysema", "PROBLEM", 73, 93], ["fibrosis", "PROBLEM", 97, 105], ["CT presentation", "TEST", 108, 123], ["previous CT examinations", "TEST", 180, 204], ["CT findings", "TEST", 262, 273], ["Ground-glass opacities", "PROBLEM", 273, 295], ["ground-glass and intralobular reticulations", "PROBLEM", 432, 475], ["linear and retractile consolidation areas", "PROBLEM", 489, 530], ["pneumonia", "OBSERVATION", 14, 23], ["abnormal", "OBSERVATION_MODIFIER", 47, 55], ["lung", "ANATOMY", 56, 60], ["emphysema", "OBSERVATION", 84, 93], ["fibrosis", "OBSERVATION", 97, 105], ["-glass opacities", "OBSERVATION", 279, 295], ["both", "OBSERVATION_MODIFIER", 324, 328], ["extent", "OBSERVATION_MODIFIER", 332, 338], ["attenuation", "OBSERVATION_MODIFIER", 343, 354], ["value", "OBSERVATION_MODIFIER", 355, 360], ["crazy", "OBSERVATION_MODIFIER", 388, 393], ["superimposition", "OBSERVATION_MODIFIER", 413, 428], ["ground-glass", "OBSERVATION", 432, 444], ["intralobular", "ANATOMY_MODIFIER", 449, 461], ["reticulations", "OBSERVATION", 462, 475], ["linear", "OBSERVATION_MODIFIER", 489, 495], ["retractile", "OBSERVATION_MODIFIER", 500, 510], ["consolidation", "OBSERVATION", 511, 524], ["areas", "OBSERVATION_MODIFIER", 525, 530]]], ["Lung damage is maximal around day 10 and then generally decreases progressively in size and attenuation value (28).", [["Lung", "ANATOMY", 0, 4], ["Lung damage", "DISEASE", 0, 11], ["Lung", "ORGAN", 0, 4], ["Lung damage", "PROBLEM", 0, 11], ["attenuation value", "TEST", 92, 109], ["damage", "OBSERVATION", 5, 11], ["maximal", "OBSERVATION_MODIFIER", 15, 22], ["decreases", "OBSERVATION_MODIFIER", 56, 65], ["progressively", "OBSERVATION_MODIFIER", 66, 79], ["size", "OBSERVATION_MODIFIER", 83, 87], ["attenuation", "OBSERVATION_MODIFIER", 92, 103], ["value", "OBSERVATION_MODIFIER", 104, 109]]], ["However, early available data on the late appearance of lung parenchyma are still scarce.", [["lung parenchyma", "ANATOMY", 56, 71], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 56, 71], ["lung", "ANATOMY", 56, 60], ["parenchyma", "ANATOMY_MODIFIER", 61, 71]]], ["While complete resolution seems to be common in patients with mild pneumonia, it seems that many patients, especially those with initial severe disease, still present reticular pattern of fibrotic streaks after more than one month of evolution ( Figure 2 ).Evolution of CT findingsAccording to a recent study, lung abnormalities could persist beyond one month in 98% of patients (29).", [["reticular", "ANATOMY", 167, 176], ["lung", "ANATOMY", 310, 314], ["pneumonia", "DISEASE", 67, 76], ["lung abnormalities", "DISEASE", 310, 328], ["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 97, 105], ["fibrotic streaks", "PATHOLOGICAL_FORMATION", 188, 204], ["lung", "ORGAN", 310, 314], ["patients", "ORGANISM", 370, 378], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 370, 378], ["mild pneumonia", "PROBLEM", 62, 76], ["initial severe disease", "PROBLEM", 129, 151], ["fibrotic streaks", "PROBLEM", 188, 204], ["CT findings", "TEST", 270, 281], ["a recent study", "TEST", 294, 308], ["lung abnormalities", "PROBLEM", 310, 328], ["mild", "OBSERVATION_MODIFIER", 62, 66], ["pneumonia", "OBSERVATION", 67, 76], ["severe", "OBSERVATION_MODIFIER", 137, 143], ["disease", "OBSERVATION", 144, 151], ["reticular", "OBSERVATION_MODIFIER", 167, 176], ["pattern", "OBSERVATION_MODIFIER", 177, 184], ["fibrotic", "OBSERVATION_MODIFIER", 188, 196], ["streaks", "OBSERVATION", 197, 204], ["lung", "ANATOMY", 310, 314], ["abnormalities", "OBSERVATION", 315, 328]]], ["There is therefore some concern about a significant number of pulmonary fibrotic sequelae, although the proportion is not yet known (15, 26) .Severity signsThe total extent of lung involvement on the first CT examination is correlated with clinical severity (13, 25, 30) .", [["pulmonary", "ANATOMY", 62, 71], ["lung", "ANATOMY", 176, 180], ["pulmonary fibrotic sequelae", "DISEASE", 62, 89], ["pulmonary fibrotic", "PATHOLOGICAL_FORMATION", 62, 80], ["lung", "ORGAN", 176, 180], ["pulmonary fibrotic sequelae", "PROBLEM", 62, 89], ["Severity signs", "PROBLEM", 142, 156], ["lung involvement", "PROBLEM", 176, 192], ["the first CT examination", "TEST", 196, 220], ["clinical severity", "TEST", 240, 257], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["number", "OBSERVATION_MODIFIER", 52, 58], ["pulmonary", "ANATOMY", 62, 71], ["fibrotic", "OBSERVATION_MODIFIER", 72, 80], ["sequelae", "OBSERVATION", 81, 89], ["total", "OBSERVATION_MODIFIER", 160, 165], ["extent", "OBSERVATION_MODIFIER", 166, 172], ["lung", "ANATOMY", 176, 180], ["involvement", "OBSERVATION", 181, 192]]], ["The French Society of Thoracic Imaging (SIT) recommends grading lung involvement as absent or minimal (<10%), moderate (10-25%), extensive (25-50%), severe (50-75%) or critical (>75%) ( Figure 5 ).", [["lung", "ANATOMY", 64, 68], ["lung", "ORGAN", 64, 68], ["Thoracic Imaging", "TEST", 22, 38], ["grading lung involvement", "PROBLEM", 56, 80], ["Thoracic", "ANATOMY", 22, 30], ["lung", "ANATOMY", 64, 68], ["involvement", "OBSERVATION", 69, 80], ["minimal", "OBSERVATION_MODIFIER", 94, 101], ["moderate", "OBSERVATION_MODIFIER", 110, 118], ["extensive", "OBSERVATION_MODIFIER", 129, 138], ["severe", "OBSERVATION_MODIFIER", 149, 155]]], ["The density of pulmonary lesions is also a marker of severity, since lung consolidation areas appear more extensive than ground-glass opacities in critically ill patients (30).", [["pulmonary lesions", "ANATOMY", 15, 32], ["lung", "ANATOMY", 69, 73], ["pulmonary lesions", "DISEASE", 15, 32], ["critically ill", "DISEASE", 147, 161], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 15, 32], ["lung", "ORGAN", 69, 73], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["pulmonary lesions", "PROBLEM", 15, 32], ["lung consolidation areas", "PROBLEM", 69, 93], ["ground-glass opacities", "PROBLEM", 121, 143], ["density", "OBSERVATION_MODIFIER", 4, 11], ["pulmonary", "ANATOMY", 15, 24], ["lesions", "OBSERVATION", 25, 32], ["severity", "OBSERVATION_MODIFIER", 53, 61], ["lung", "ANATOMY", 69, 73], ["consolidation", "OBSERVATION", 74, 87], ["more", "OBSERVATION_MODIFIER", 101, 105], ["extensive", "OBSERVATION_MODIFIER", 106, 115], ["ground-glass opacities", "OBSERVATION", 121, 143], ["critically", "OBSERVATION_MODIFIER", 147, 157], ["ill patients", "OBSERVATION_MODIFIER", 158, 170]]], ["Pleural effusion and early architectural distortion with traction bronchiectasis on initial chest CT would also indicate a poor prognosis (15) .", [["Pleural", "ANATOMY", 0, 7], ["chest", "ANATOMY", 92, 97], ["Pleural effusion", "DISEASE", 0, 16], ["bronchiectasis", "DISEASE", 66, 80], ["Pleural", "PATHOLOGICAL_FORMATION", 0, 7], ["Pleural effusion", "PROBLEM", 0, 16], ["early architectural distortion", "PROBLEM", 21, 51], ["traction bronchiectasis", "PROBLEM", 57, 80], ["initial chest CT", "TEST", 84, 100], ["effusion", "OBSERVATION", 8, 16], ["early", "OBSERVATION_MODIFIER", 21, 26], ["architectural distortion", "OBSERVATION", 27, 51], ["traction", "OBSERVATION_MODIFIER", 57, 65], ["bronchiectasis", "OBSERVATION", 66, 80], ["chest", "ANATOMY", 92, 97]]], ["A Chinese series suggests that consolidation in upper lobes on initial CT is also associated with poor outcomes (31).ComplicationsBetween 15 and 30% of hospitalized patients progress to acute respiratory distress syndrome (ARDS), which is the main cause of mortality in COVID-19.", [["upper lobes", "ANATOMY", 48, 59], ["respiratory", "ANATOMY", 192, 203], ["acute respiratory distress syndrome", "DISEASE", 186, 221], ["ARDS", "DISEASE", 223, 227], ["upper lobes", "MULTI-TISSUE_STRUCTURE", 48, 59], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["A Chinese series", "TEST", 0, 16], ["consolidation in upper lobes", "PROBLEM", 31, 59], ["initial CT", "TEST", 63, 73], ["acute respiratory distress syndrome", "PROBLEM", 186, 221], ["ARDS", "PROBLEM", 223, 227], ["COVID", "TEST", 270, 275], ["consolidation", "OBSERVATION", 31, 44], ["upper lobes", "ANATOMY", 48, 59], ["acute", "OBSERVATION_MODIFIER", 186, 191], ["respiratory distress", "OBSERVATION", 192, 212], ["ARDS", "OBSERVATION", 223, 227], ["main", "OBSERVATION_MODIFIER", 243, 247]]], ["ARDS is characterized in CT by extensive bilateral lung consolidation with a predominance in dependent areas ( Figure 5 ) (4, 32) .", [["lung", "ANATOMY", 51, 55], ["ARDS", "DISEASE", 0, 4], ["lung", "ORGAN", 51, 55], ["ARDS", "PROBLEM", 0, 4], ["CT", "TEST", 25, 27], ["extensive bilateral lung consolidation", "PROBLEM", 31, 69], ["extensive", "OBSERVATION_MODIFIER", 31, 40], ["bilateral", "ANATOMY_MODIFIER", 41, 50], ["lung", "ANATOMY", 51, 55], ["consolidation", "OBSERVATION", 56, 69], ["predominance", "OBSERVATION_MODIFIER", 77, 89], ["dependent", "OBSERVATION_MODIFIER", 93, 102], ["areas", "OBSERVATION_MODIFIER", 103, 108]]], ["In addition, several complications can occur in the clinical course of these patients.ComplicationsPulmonary bacterial superinfection will be suspected in case of additional alveolar consolidation areas with pleural effusion and/or enlarged lymph nodes (15) .", [["alveolar", "ANATOMY", 174, 182], ["pleural", "ANATOMY", 208, 215], ["lymph nodes", "ANATOMY", 241, 252], ["Pulmonary bacterial superinfection", "DISEASE", 99, 133], ["pleural effusion", "DISEASE", 208, 224], ["patients", "ORGANISM", 77, 85], ["alveolar", "PATHOLOGICAL_FORMATION", 174, 182], ["pleural effusion", "CANCER", 208, 224], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 241, 252], ["patients", "SPECIES", 77, 85], ["several complications", "PROBLEM", 13, 34], ["Complications", "PROBLEM", 86, 99], ["Pulmonary bacterial superinfection", "PROBLEM", 99, 133], ["additional alveolar consolidation areas", "PROBLEM", 163, 202], ["pleural effusion", "PROBLEM", 208, 224], ["enlarged lymph nodes", "PROBLEM", 232, 252], ["several", "OBSERVATION_MODIFIER", 13, 20], ["complications", "OBSERVATION", 21, 34], ["Pulmonary", "ANATOMY", 99, 108], ["bacterial", "OBSERVATION_MODIFIER", 109, 118], ["superinfection", "OBSERVATION", 119, 133], ["additional", "OBSERVATION_MODIFIER", 163, 173], ["alveolar", "ANATOMY_MODIFIER", 174, 182], ["consolidation", "OBSERVATION", 183, 196], ["pleural", "ANATOMY", 208, 215], ["effusion", "OBSERVATION", 216, 224], ["enlarged", "OBSERVATION_MODIFIER", 232, 240], ["lymph nodes", "OBSERVATION", 241, 252]]], ["In a recent study, COVID-19 associated pulmonary aspergillosis was reported in 5 of 19 consecutive patients with ARDS( Figure 6 ) (33) .", [["pulmonary", "ANATOMY", 39, 48], ["COVID-19", "CHEMICAL", 19, 27], ["pulmonary aspergillosis", "DISEASE", 39, 62], ["ARDS", "DISEASE", 113, 117], ["COVID-19", "CELL", 19, 27], ["pulmonary", "ORGAN", 39, 48], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["COVID-19", "SPECIES", 19, 27], ["a recent study", "TEST", 3, 17], ["COVID", "TEST", 19, 24], ["pulmonary aspergillosis", "PROBLEM", 39, 62], ["ARDS", "PROBLEM", 113, 117], ["pulmonary", "ANATOMY", 39, 48], ["aspergillosis", "OBSERVATION", 49, 62], ["ARDS", "OBSERVATION", 113, 117]]], ["However, distinction between COVID-19 and pulmonary aspergillosis lesions with CT remains difficult (34) .ComplicationsPulmonary embolism has been reported in COVID-19 patients (Figure 7 ) (35) (36) (37) (38) .", [["pulmonary aspergillosis lesions", "ANATOMY", 42, 73], ["Pulmonary", "ANATOMY", 119, 128], ["pulmonary aspergillosis", "DISEASE", 42, 65], ["Pulmonary embolism", "DISEASE", 119, 137], ["COVID-19", "CANCER", 29, 37], ["pulmonary aspergillosis lesions", "PATHOLOGICAL_FORMATION", 42, 73], ["Pulmonary", "ORGAN", 119, 128], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["COVID", "TEST", 29, 34], ["pulmonary aspergillosis lesions", "PROBLEM", 42, 73], ["CT", "TEST", 79, 81], ["ComplicationsPulmonary embolism", "PROBLEM", 106, 137], ["COVID", "TEST", 159, 164], ["pulmonary", "ANATOMY", 42, 51], ["aspergillosis", "OBSERVATION", 52, 65], ["Pulmonary", "ANATOMY", 119, 128], ["embolism", "OBSERVATION", 129, 137]]], ["In critically ill patients, there is an exacerbated systemic inflammatory response leading to an hypercoagulability state, reflected by the marked increase of D-dimer serum level in these patients (39) .", [["serum", "ANATOMY", 167, 172], ["critically ill", "DISEASE", 3, 17], ["hypercoagulability", "DISEASE", 97, 115], ["patients", "ORGANISM", 18, 26], ["D-dimer", "GENE_OR_GENE_PRODUCT", 159, 166], ["serum", "ORGANISM_SUBSTANCE", 167, 172], ["patients", "ORGANISM", 188, 196], ["D-dimer", "PROTEIN", 159, 166], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 188, 196], ["an exacerbated systemic inflammatory response", "PROBLEM", 37, 82], ["an hypercoagulability state", "PROBLEM", 94, 121], ["the marked increase of D-dimer serum level", "PROBLEM", 136, 178], ["exacerbated", "OBSERVATION_MODIFIER", 40, 51], ["systemic", "OBSERVATION_MODIFIER", 52, 60], ["inflammatory", "OBSERVATION", 61, 73], ["hypercoagulability", "OBSERVATION", 97, 115], ["marked", "OBSERVATION_MODIFIER", 140, 146], ["increase", "OBSERVATION_MODIFIER", 147, 155]]], ["The occurrence of pulmonary embolism is mainly reported in intensive care unit patients, based on retrospective studies.", [["pulmonary", "ANATOMY", 18, 27], ["pulmonary embolism", "DISEASE", 18, 36], ["pulmonary", "ORGAN", 18, 27], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["pulmonary embolism", "PROBLEM", 18, 36], ["retrospective studies", "TEST", 98, 119], ["pulmonary", "ANATOMY", 18, 27], ["embolism", "OBSERVATION", 28, 36]]], ["The exact prevalence of pulmonary embolism in COVID19 remains unknown, and would require a prospective evaluation, with systematic assessment of clinical symptoms, CT features and D-dimers.", [["pulmonary", "ANATOMY", 24, 33], ["pulmonary embolism", "DISEASE", 24, 42], ["pulmonary", "ORGAN", 24, 33], ["D-dimers", "SIMPLE_CHEMICAL", 180, 188], ["pulmonary embolism", "PROBLEM", 24, 42], ["a prospective evaluation", "TEST", 89, 113], ["systematic assessment", "TEST", 120, 141], ["clinical symptoms", "PROBLEM", 145, 162], ["CT features", "TEST", 164, 175], ["pulmonary", "ANATOMY", 24, 33], ["embolism", "OBSERVATION", 34, 42]]], ["Routine CT pulmonary angiography to check for pulmonary embolism is so far not indicated as a first-line diagnostic tool.", [["pulmonary", "ANATOMY", 11, 20], ["pulmonary", "ANATOMY", 46, 55], ["pulmonary embolism", "DISEASE", 46, 64], ["pulmonary", "ORGAN", 11, 20], ["pulmonary", "ORGAN", 46, 55], ["Routine CT pulmonary angiography", "TEST", 0, 32], ["pulmonary embolism", "PROBLEM", 46, 64], ["pulmonary", "ANATOMY", 11, 20], ["pulmonary", "ANATOMY", 46, 55], ["embolism", "OBSERVATION", 56, 64]]], ["However, a clinical-radiological discordance (dyspnea and hypoxemia without lung abnormality) or respiratory worsening in a known COVID-19 patient should prompt the use of contrast medium injection.", [["lung", "ANATOMY", 76, 80], ["respiratory", "ANATOMY", 97, 108], ["dyspnea", "DISEASE", 46, 53], ["hypoxemia", "DISEASE", 58, 67], ["lung abnormality", "DISEASE", 76, 92], ["contrast medium", "CHEMICAL", 172, 187], ["lung", "ORGAN", 76, 80], ["patient", "ORGANISM", 139, 146], ["patient", "SPECIES", 139, 146], ["dyspnea", "PROBLEM", 46, 53], ["hypoxemia", "PROBLEM", 58, 67], ["lung abnormality", "PROBLEM", 76, 92], ["respiratory worsening", "PROBLEM", 97, 118], ["a known COVID", "TEST", 122, 135], ["contrast medium injection", "TREATMENT", 172, 197], ["hypoxemia", "OBSERVATION", 58, 67], ["without", "UNCERTAINTY", 68, 75], ["lung", "ANATOMY", 76, 80], ["abnormality", "OBSERVATION", 81, 92], ["respiratory", "OBSERVATION_MODIFIER", 97, 108], ["worsening", "OBSERVATION_MODIFIER", 109, 118]]], ["It would be worth assessing the value of routine CT pulmonary angiography in patients with highly elevated D-dimer levels.", [["pulmonary", "ANATOMY", 52, 61], ["pulmonary", "ORGAN", 52, 61], ["patients", "ORGANISM", 77, 85], ["D-dimer", "GENE_OR_GENE_PRODUCT", 107, 114], ["patients", "SPECIES", 77, 85], ["routine CT pulmonary angiography", "TEST", 41, 73], ["highly elevated D-dimer levels", "PROBLEM", 91, 121], ["pulmonary", "ANATOMY", 52, 61], ["elevated", "OBSERVATION", 98, 106]]], ["Finally, radiologists should be aware that pulmonary infarction secondary to pulmonary embolism may be quite similar in appearance to COVID-19 pneumonia (Figure 8 ).Specificities in children and pregnant womenIn the pediatric population, pulmonary CT involvement is often less extensive than in adults.Specificities in children and pregnant womenThere are often no CT abnormalities (40) .", [["pulmonary", "ANATOMY", 43, 52], ["pulmonary", "ANATOMY", 77, 86], ["pulmonary", "ANATOMY", 238, 247], ["pulmonary infarction", "DISEASE", 43, 63], ["pulmonary embolism", "DISEASE", 77, 95], ["pneumonia", "DISEASE", 143, 152], ["pulmonary", "ORGAN", 43, 52], ["pulmonary", "ORGAN", 77, 86], ["children", "ORGANISM", 182, 190], ["women", "ORGANISM", 204, 209], ["pulmonary", "ORGAN", 238, 247], ["children", "ORGANISM", 319, 327], ["women", "ORGANISM", 341, 346], ["children", "SPECIES", 182, 190], ["women", "SPECIES", 204, 209], ["children", "SPECIES", 319, 327], ["women", "SPECIES", 341, 346], ["pulmonary infarction", "PROBLEM", 43, 63], ["pulmonary embolism", "PROBLEM", 77, 95], ["COVID", "TEST", 134, 139], ["pneumonia", "PROBLEM", 143, 152], ["pulmonary CT involvement", "TEST", 238, 262], ["CT abnormalities", "PROBLEM", 365, 381], ["pulmonary", "ANATOMY", 43, 52], ["infarction", "OBSERVATION", 53, 63], ["pulmonary", "ANATOMY", 77, 86], ["embolism", "OBSERVATION", 87, 95], ["pneumonia", "OBSERVATION", 143, 152], ["pulmonary", "ANATOMY", 238, 247], ["no", "UNCERTAINTY", 362, 364], ["abnormalities", "OBSERVATION", 368, 381]]], ["In case of lung involvement, ground-glass is the predominant sign (40, 41) .", [["lung", "ANATOMY", 11, 15], ["lung", "ORGAN", 11, 15], ["lung involvement", "PROBLEM", 11, 27], ["lung", "ANATOMY", 11, 15], ["involvement", "OBSERVATION", 16, 27], ["ground-glass", "OBSERVATION_MODIFIER", 29, 41], ["predominant", "OBSERVATION_MODIFIER", 49, 60]]], ["The \"halo sign\" is found more frequently than in adults (39, 41) .Specificities in children and pregnant womenCoinfections, especially viral, are also more frequent (42) .In pregnant women, there is no evidence of maternal-fetal transmission of SARS-CoV-2 and nospecific per or post-partum complications (43) .", [["fetal", "ANATOMY", 223, 228], ["womenCoinfections", "DISEASE", 105, 122], ["SARS", "DISEASE", 245, 249], ["children", "ORGANISM", 83, 91], ["women", "ORGANISM", 183, 188], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 223, 228], ["SARS-CoV-2", "ORGANISM", 245, 255], ["children", "SPECIES", 83, 91], ["women", "SPECIES", 183, 188], ["SARS-CoV", "SPECIES", 245, 253], ["pregnant womenCoinfections", "PROBLEM", 96, 122], ["viral", "PROBLEM", 135, 140], ["SARS", "PROBLEM", 245, 249], ["CoV", "TEST", 250, 253], ["post-partum complications", "PROBLEM", 278, 303], ["no evidence of", "UNCERTAINTY", 199, 213]]], ["Consolidation might be more common than in the general population (44) .", [["Consolidation", "PROBLEM", 0, 13], ["more common", "OBSERVATION_MODIFIER", 23, 34]]], ["There appears to be no excess mortality related to COVID-19 in pregnant women (45) .Artificial intelligence (AI) in imaging of COVID-19Machine learning techniques have the potential to dramatically transform medical imaging (46) (47) (48) (50) .AI certainly has an important role to play in assessing the prognosis of COVID-19 andidentifying biomarkers predictive of patient outcomes.", [["COVID-19", "CHEMICAL", 51, 59], ["women", "ORGANISM", 72, 77], ["patient", "ORGANISM", 367, 374], ["women", "SPECIES", 72, 77], ["patient", "SPECIES", 367, 374], ["excess mortality", "PROBLEM", 23, 39], ["COVID", "TEST", 51, 56], ["imaging", "TEST", 116, 123], ["COVID", "TEST", 127, 132], ["medical imaging", "TEST", 208, 223], ["COVID", "TEST", 318, 323], ["appears to be", "UNCERTAINTY", 6, 19], ["no", "UNCERTAINTY", 20, 22], ["excess", "OBSERVATION_MODIFIER", 23, 29], ["mortality", "OBSERVATION", 30, 39]]], ["For this purpose, several national and international databases are currently being deployed to enable AI models to be trained on massive data.", [["massive data", "TEST", 129, 141]]]], "d6fb56628d628ba833829da107b8b31f0cb1d993": [["proteases are regulated by serpins found in plasma and by non-serpin secreted inhibitors.", [["plasma", "ANATOMY", 44, 50], ["serpins", "GENE_OR_GENE_PRODUCT", 27, 34], ["plasma", "ORGANISM_SUBSTANCE", 44, 50], ["proteases", "PROTEIN", 0, 9], ["serpins", "PROTEIN", 27, 34], ["proteases", "TREATMENT", 0, 9], ["plasma", "TEST", 44, 50], ["non-serpin secreted inhibitors", "TREATMENT", 58, 88]]], ["Distinct mechanisms leading to neutrophil cell death have been described for the granule serine proteases, neutrophil elastase, cathepsin G, and proteinase-3.", [["neutrophil cell", "ANATOMY", 31, 46], ["death", "DISEASE", 47, 52], ["serine", "CHEMICAL", 89, 95], ["neutrophil cell", "CELL", 31, 46], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 107, 126], ["cathepsin G", "GENE_OR_GENE_PRODUCT", 128, 139], ["proteinase-3", "GENE_OR_GENE_PRODUCT", 145, 157], ["granule serine proteases", "PROTEIN", 81, 105], ["neutrophil elastase", "PROTEIN", 107, 126], ["cathepsin G", "PROTEIN", 128, 139], ["proteinase-3", "PROTEIN", 145, 157], ["Distinct mechanisms", "PROBLEM", 0, 19], ["neutrophil cell death", "PROBLEM", 31, 52], ["the granule serine proteases", "TEST", 77, 105], ["neutrophil elastase", "TEST", 107, 126], ["cathepsin G", "TEST", 128, 139], ["proteinase", "TEST", 145, 155], ["leading to", "UNCERTAINTY", 20, 30], ["neutrophil cell death", "OBSERVATION", 31, 52], ["neutrophil elastase", "OBSERVATION", 107, 126]]], ["Granule leakage in neutrophils triggers death pathways mediated by cathepsin G and proteinase-3, and both proteases are tightly regulated by their inhibitor SERPINB1 in a cell intrinsic manner.", [["Granule", "ANATOMY", 0, 7], ["neutrophils", "ANATOMY", 19, 30], ["cell", "ANATOMY", 171, 175], ["death", "DISEASE", 40, 45], ["neutrophils", "CELL", 19, 30], ["cathepsin G", "GENE_OR_GENE_PRODUCT", 67, 78], ["proteinase-3", "GENE_OR_GENE_PRODUCT", 83, 95], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 157, 165], ["cell", "CELL", 171, 175], ["neutrophils", "CELL_TYPE", 19, 30], ["cathepsin G", "PROTEIN", 67, 78], ["proteinase-3", "PROTEIN", 83, 95], ["proteases", "PROTEIN", 106, 115], ["SERPINB1", "PROTEIN", 157, 165], ["Granule leakage in neutrophils triggers death pathways", "PROBLEM", 0, 54], ["cathepsin G and proteinase", "TEST", 67, 93], ["both proteases", "TREATMENT", 101, 115], ["leakage", "OBSERVATION_MODIFIER", 8, 15], ["neutrophils", "OBSERVATION", 19, 30]]], ["Although stored in the same types of granules, neutrophil elastase does not significantly contribute to cell death following intracellular release from granules into the cytoplasm.", [["granules", "ANATOMY", 37, 45], ["neutrophil", "ANATOMY", 47, 57], ["cell", "ANATOMY", 104, 108], ["intracellular", "ANATOMY", 125, 138], ["granules", "ANATOMY", 152, 160], ["cytoplasm", "ANATOMY", 170, 179], ["death", "DISEASE", 109, 114], ["granules", "ORGANISM_SUBSTANCE", 37, 45], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 47, 66], ["cell", "CELL", 104, 108], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 125, 138], ["granules", "CELLULAR_COMPONENT", 152, 160], ["cytoplasm", "ORGANISM_SUBSTANCE", 170, 179], ["neutrophil elastase", "PROTEIN", 47, 66], ["neutrophil elastase", "PROBLEM", 47, 66], ["cell death", "PROBLEM", 104, 114], ["granules", "OBSERVATION", 37, 45], ["neutrophil elastase", "OBSERVATION", 47, 66], ["cytoplasm", "OBSERVATION_MODIFIER", 170, 179]]], ["However, heterozygous mutations in ELANE, the gene encoding elastase, are the cause of severe congenital neutropenia, a life-threatening condition characterized by the death of neutrophils at an early precursor stage in the bone marrow.", [["neutrophils", "ANATOMY", 177, 188], ["bone marrow", "ANATOMY", 224, 235], ["congenital neutropenia", "DISEASE", 94, 116], ["death", "DISEASE", 168, 173], ["ELANE", "GENE_OR_GENE_PRODUCT", 35, 40], ["elastase", "GENE_OR_GENE_PRODUCT", 60, 68], ["neutrophils", "CELL", 177, 188], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 224, 235], ["ELANE", "DNA", 35, 40], ["elastase", "PROTEIN", 60, 68], ["neutrophils", "CELL_TYPE", 177, 188], ["heterozygous mutations in ELANE", "PROBLEM", 9, 40], ["severe congenital neutropenia", "PROBLEM", 87, 116], ["a life-threatening condition", "PROBLEM", 118, 146], ["the death of neutrophils", "PROBLEM", 164, 188], ["an early precursor stage in the bone marrow", "PROBLEM", 192, 235], ["heterozygous mutations", "OBSERVATION", 9, 31], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["congenital", "OBSERVATION_MODIFIER", 94, 104], ["neutropenia", "OBSERVATION", 105, 116], ["early", "OBSERVATION_MODIFIER", 195, 200], ["precursor stage", "OBSERVATION", 201, 216], ["bone marrow", "ANATOMY", 224, 235]]], ["This chapter focuses on recent work exploring the biology of clade B intracellular serpins that inhibit neutrophil serine proteases and their functions in neutrophil homeostasis and serine protease control at sites of inflammation.5.1Neutrophil Granules and Their ProteasesNeutrophil Biology and Neutrophil Serine ProteasesNeutrophils are white blood cells with a prominent function in the control of microbes at mucosal surfaces and in tissues.", [["intracellular", "ANATOMY", 69, 82], ["neutrophil", "ANATOMY", 155, 165], ["Neutrophils", "ANATOMY", 323, 334], ["white blood cells", "ANATOMY", 339, 356], ["mucosal surfaces", "ANATOMY", 413, 429], ["tissues", "ANATOMY", 437, 444], ["inflammation", "DISEASE", 218, 230], ["serine", "CHEMICAL", 115, 121], ["serine", "CHEMICAL", 182, 188], ["clade B intracellular serpins", "GENE_OR_GENE_PRODUCT", 61, 90], ["neutrophil", "CELL", 104, 114], ["neutrophil", "CELL", 155, 165], ["serine protease", "GENE_OR_GENE_PRODUCT", 182, 197], ["Neutrophil", "CELL", 273, 283], ["Neutrophils", "CELL", 323, 334], ["white blood cells", "CELL", 339, 356], ["mucosal surfaces", "TISSUE", 413, 429], ["tissues", "TISSUE", 437, 444], ["clade B intracellular serpins", "PROTEIN", 61, 90], ["neutrophil serine proteases", "PROTEIN", 104, 131], ["neutrophil", "CELL_TYPE", 155, 165], ["serine protease", "PROTEIN", 182, 197], ["Neutrophils", "CELL_TYPE", 323, 334], ["white blood cells", "CELL_TYPE", 339, 356], ["clade B intracellular serpins", "TREATMENT", 61, 90], ["neutrophil serine proteases", "TREATMENT", 104, 131], ["neutrophil homeostasis", "TREATMENT", 155, 177], ["serine protease control", "TREATMENT", 182, 205], ["inflammation", "PROBLEM", 218, 230], ["Neutrophil Granules", "TEST", 234, 253], ["Their Proteases", "TEST", 258, 273], ["Neutrophil Biology", "TEST", 273, 291], ["Neutrophil Serine Proteases", "TEST", 296, 323], ["Neutrophils", "TEST", 323, 334], ["white blood cells", "TEST", 339, 356], ["neutrophil homeostasis", "OBSERVATION", 155, 177], ["inflammation", "OBSERVATION", 218, 230], ["Neutrophil Granules", "OBSERVATION", 234, 253], ["prominent", "OBSERVATION_MODIFIER", 364, 373], ["function", "OBSERVATION_MODIFIER", 374, 382], ["mucosal surfaces", "ANATOMY", 413, 429], ["tissues", "ANATOMY", 437, 444]]], ["The containment and elimination of bacteria and fungi can be severely affected if too few neutrophils are available or if there is a defect in their ability to reach the infection site.", [["neutrophils", "ANATOMY", 90, 101], ["infection", "DISEASE", 170, 179], ["neutrophils", "CELL", 90, 101], ["neutrophils", "CELL_TYPE", 90, 101], ["The containment", "TREATMENT", 0, 15], ["bacteria", "PROBLEM", 35, 43], ["fungi", "PROBLEM", 48, 53], ["a defect", "PROBLEM", 131, 139], ["the infection site", "PROBLEM", 166, 184], ["containment", "OBSERVATION_MODIFIER", 4, 15], ["bacteria", "OBSERVATION", 35, 43], ["defect", "OBSERVATION", 133, 139], ["infection", "OBSERVATION", 170, 179]]], ["Neutrophils carry a vast repertoire of antimicrobial molecules and enzymes that directly contribute to killing pathogens.", [["Neutrophils", "ANATOMY", 0, 11], ["Neutrophils", "CELL", 0, 11], ["Neutrophils", "CELL_TYPE", 0, 11], ["antimicrobial molecules", "PROTEIN", 39, 62], ["enzymes", "PROTEIN", 67, 74], ["Neutrophils", "TEST", 0, 11], ["antimicrobial molecules", "TEST", 39, 62], ["enzymes", "TEST", 67, 74], ["killing pathogens", "PROBLEM", 103, 120]]], ["While neutrophils are essential to fight bacterial and fungal infections, the presence and death of neutrophils at inflammatory sites has been associated with delayed healing, tissue damage, and pathogenesis of chronic diseases.", [["neutrophils", "ANATOMY", 6, 17], ["neutrophils", "ANATOMY", 100, 111], ["tissue", "ANATOMY", 176, 182], ["bacterial and fungal infections", "DISEASE", 41, 72], ["death", "DISEASE", 91, 96], ["tissue damage", "DISEASE", 176, 189], ["chronic diseases", "DISEASE", 211, 227], ["neutrophils", "CELL", 6, 17], ["neutrophils", "CELL", 100, 111], ["tissue", "TISSUE", 176, 182], ["neutrophils", "CELL_TYPE", 6, 17], ["neutrophils", "CELL_TYPE", 100, 111], ["bacterial and fungal infections", "PROBLEM", 41, 72], ["neutrophils at inflammatory sites", "PROBLEM", 100, 133], ["delayed healing", "PROBLEM", 159, 174], ["tissue damage", "PROBLEM", 176, 189], ["chronic diseases", "PROBLEM", 211, 227], ["fungal", "OBSERVATION_MODIFIER", 55, 61], ["infections", "OBSERVATION", 62, 72], ["neutrophils", "OBSERVATION_MODIFIER", 100, 111], ["inflammatory", "OBSERVATION_MODIFIER", 115, 127], ["associated with", "UNCERTAINTY", 143, 158], ["delayed", "OBSERVATION_MODIFIER", 159, 166], ["healing", "OBSERVATION_MODIFIER", 167, 174], [", tissue", "OBSERVATION_MODIFIER", 174, 182], ["damage", "OBSERVATION", 183, 189], ["chronic", "OBSERVATION_MODIFIER", 211, 218], ["diseases", "OBSERVATION", 219, 227]]], ["For these reasons, neutrophils and their potentially harmful granule cargo have been considered a double-edged sword in inflammatory diseases.", [["neutrophils", "ANATOMY", 19, 30], ["granule cargo", "ANATOMY", 61, 74], ["inflammatory diseases", "DISEASE", 120, 141], ["neutrophils", "CELL", 19, 30], ["granule cargo", "CELLULAR_COMPONENT", 61, 74], ["neutrophils", "CELL_TYPE", 19, 30], ["neutrophils", "TEST", 19, 30], ["inflammatory diseases", "PROBLEM", 120, 141], ["inflammatory diseases", "OBSERVATION", 120, 141]]], ["Neutrophils are now emerging as a central orchestrator of inflammatory responses and their resolution through continuous interactions with components of the innate and adaptive responses (Nathan 2006; Kruger et al. 2015) .", [["Neutrophils", "ANATOMY", 0, 11], ["Neutrophils", "CELL", 0, 11], ["Neutrophils", "CELL_TYPE", 0, 11], ["Neutrophils", "TEST", 0, 11], ["inflammatory responses", "PROBLEM", 58, 80], ["inflammatory", "OBSERVATION", 58, 70]]], ["In this chapter, the function of the neutrophil granule serine proteases in neutrophil life cycle and their function in host defense and in inflammatory diseases will be reviewed with a special focus on their regulation by intracellular serpins.", [["neutrophil granule", "ANATOMY", 37, 55], ["neutrophil", "ANATOMY", 76, 86], ["intracellular", "ANATOMY", 223, 236], ["serine", "CHEMICAL", 56, 62], ["neutrophil", "CELL", 37, 47], ["neutrophil", "CELL", 76, 86], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 223, 236], ["neutrophil granule serine proteases", "PROTEIN", 37, 72], ["intracellular serpins", "PROTEIN", 223, 244], ["the neutrophil granule serine proteases", "PROBLEM", 33, 72], ["neutrophil life cycle", "TREATMENT", 76, 97], ["inflammatory diseases", "PROBLEM", 140, 161], ["neutrophil granule", "OBSERVATION", 37, 55], ["neutrophil life", "OBSERVATION", 76, 91], ["host defense", "OBSERVATION_MODIFIER", 120, 132], ["inflammatory", "OBSERVATION_MODIFIER", 140, 152]]], ["Neutrophils develop in the bone marrow from hematopoietic stem cells and differentiate progressively through progenitors with more restricted lineage potential known as the common myeloid progenitors and the granulocyte-macrophage progenitors (GMPs).", [["Neutrophils", "ANATOMY", 0, 11], ["bone marrow", "ANATOMY", 27, 38], ["hematopoietic stem cells", "ANATOMY", 44, 68], ["progenitors", "ANATOMY", 109, 120], ["myeloid progenitors", "ANATOMY", 180, 199], ["granulocyte-macrophage progenitors", "ANATOMY", 208, 242], ["GMPs", "ANATOMY", 244, 248], ["Neutrophils", "CELL", 0, 11], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 27, 38], ["hematopoietic stem cells", "CELL", 44, 68], ["progenitors", "CELL", 109, 120], ["myeloid progenitors", "CELL", 180, 199], ["granulocyte-macrophage progenitors", "CELL", 208, 242], ["GMPs", "CELL", 244, 248], ["Neutrophils", "CELL_TYPE", 0, 11], ["hematopoietic stem cells", "CELL_TYPE", 44, 68], ["common myeloid progenitors", "CELL_TYPE", 173, 199], ["granulocyte-macrophage progenitors", "CELL_TYPE", 208, 242], ["GMPs", "CELL_TYPE", 244, 248], ["Neutrophils", "TEST", 0, 11], ["the bone marrow", "TEST", 23, 38], ["hematopoietic stem cells", "PROBLEM", 44, 68], ["the common myeloid progenitors", "PROBLEM", 169, 199], ["the granulocyte", "TEST", 204, 219], ["bone marrow", "ANATOMY", 27, 38], ["hematopoietic stem cells", "OBSERVATION", 44, 68], ["common", "ANATOMY", 173, 179], ["myeloid progenitors", "OBSERVATION", 180, 199], ["granulocyte", "ANATOMY", 208, 219], ["macrophage progenitors", "OBSERVATION", 220, 242]]], ["The transcription factor PU.1 is essential for the generation of GMPs.", [["PU.1", "GENE_OR_GENE_PRODUCT", 25, 29], ["GMPs", "GENE_OR_GENE_PRODUCT", 65, 69], ["transcription factor", "PROTEIN", 4, 24], ["PU.1", "PROTEIN", 25, 29], ["GMPs", "PROTEIN", 65, 69], ["The transcription factor PU.1", "TEST", 0, 29], ["the generation of GMPs", "PROBLEM", 47, 69]]], ["At the GMP stage, the expression of the transcription factors, CCAAT/ enhancer-binding protein-\u03b1 (C/EBP\u03b1) and growth factor independent-1 (GFI-1), appears essential for commitment toward the neutrophil lineage, whereas PU.1 promotes monocyte differentiation (Cheng et al. 1996; Zhang et al. 1997; Dahl et al. 2003) .", [["neutrophil lineage", "ANATOMY", 191, 209], ["monocyte", "ANATOMY", 233, 241], ["GMP", "CHEMICAL", 7, 10], ["CCAAT/ enhancer-binding protein-\u03b1", "GENE_OR_GENE_PRODUCT", 63, 96], ["C/EBP\u03b1", "GENE_OR_GENE_PRODUCT", 98, 104], ["growth factor independent-1", "GENE_OR_GENE_PRODUCT", 110, 137], ["GFI-1", "GENE_OR_GENE_PRODUCT", 139, 144], ["neutrophil lineage", "CELL", 191, 209], ["PU.1", "GENE_OR_GENE_PRODUCT", 219, 223], ["monocyte", "CELL", 233, 241], ["transcription factors", "PROTEIN", 40, 61], ["CCAAT/ enhancer-binding protein", "PROTEIN", 63, 94], ["\u03b1", "PROTEIN", 95, 96], ["C", "PROTEIN", 98, 99], ["EBP\u03b1", "PROTEIN", 100, 104], ["growth factor independent-1 (GFI-1", "PROTEIN", 110, 144], ["neutrophil lineage", "CELL_TYPE", 191, 209], ["PU.1", "PROTEIN", 219, 223], ["the transcription factors", "PROBLEM", 36, 61], ["CCAAT/ enhancer", "TEST", 63, 78], ["binding protein", "TEST", 79, 94], ["C/EBP\u03b1", "TEST", 98, 104], ["growth factor independent", "TEST", 110, 135], ["GFI", "TEST", 139, 142], ["GMP stage", "OBSERVATION_MODIFIER", 7, 16], ["neutrophil lineage", "OBSERVATION", 191, 209]]], ["C/EBP-\u03b1 and GFI-1 promote proliferation of neutrophil precursors from myeloblasts, promyelocytes, and myelocytes, known as the mitotic pool of neutrophils in the bone marrow.", [["neutrophil precursors", "ANATOMY", 43, 64], ["myeloblasts", "ANATOMY", 70, 81], ["promyelocytes", "ANATOMY", 83, 96], ["myelocytes", "ANATOMY", 102, 112], ["neutrophils", "ANATOMY", 143, 154], ["bone marrow", "ANATOMY", 162, 173], ["C/EBP-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 7], ["GFI-1", "GENE_OR_GENE_PRODUCT", 12, 17], ["neutrophil precursors", "CELL", 43, 64], ["myeloblasts", "CELL", 70, 81], ["promyelocytes", "CELL", 83, 96], ["myelocytes", "CELL", 102, 112], ["neutrophils", "CELL", 143, 154], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 162, 173], ["C/EBP-\u03b1", "PROTEIN", 0, 7], ["GFI-1", "DNA", 12, 17], ["neutrophil precursors", "CELL_TYPE", 43, 64], ["myeloblasts", "CELL_TYPE", 70, 81], ["promyelocytes", "CELL_TYPE", 83, 96], ["myelocytes", "CELL_TYPE", 102, 112], ["neutrophils", "CELL_TYPE", 143, 154], ["C/EBP", "TEST", 0, 5], ["GFI", "TEST", 12, 15], ["neutrophil precursors", "PROBLEM", 43, 64], ["myeloblasts", "PROBLEM", 70, 81], ["promyelocytes", "TEST", 83, 96], ["myelocytes", "TEST", 102, 112], ["proliferation", "OBSERVATION_MODIFIER", 26, 39], ["neutrophil precursors", "OBSERVATION", 43, 64], ["myeloblasts", "OBSERVATION", 70, 81], ["myelocytes", "ANATOMY", 102, 112], ["mitotic pool of neutrophils", "OBSERVATION", 127, 154], ["bone marrow", "ANATOMY", 162, 173]]], ["These transcription factors are also key for the expression of neutrophil serine proteases and other primary granule proteins such as myeloperoxidase and defensins at the promyelocyte stage.", [["primary granule", "ANATOMY", 101, 116], ["promyelocyte", "ANATOMY", 171, 183], ["serine", "CHEMICAL", 74, 80], ["neutrophil serine proteases", "GENE_OR_GENE_PRODUCT", 63, 90], ["myeloperoxidase", "GENE_OR_GENE_PRODUCT", 134, 149], ["defensins", "GENE_OR_GENE_PRODUCT", 154, 163], ["transcription factors", "PROTEIN", 6, 27], ["neutrophil serine proteases", "PROTEIN", 63, 90], ["primary granule proteins", "PROTEIN", 101, 125], ["myeloperoxidase", "PROTEIN", 134, 149], ["defensins", "PROTEIN", 154, 163], ["neutrophil serine proteases", "PROBLEM", 63, 90], ["other primary granule proteins", "PROBLEM", 95, 125], ["myeloperoxidase and defensins", "TREATMENT", 134, 163]]], ["As C/EPB-\u03b1 and GFI-1 levels diminish, terminal granulocytic differentiation to mature neutrophils is under the transcriptional regulation of C/EBP-\u03b5, which controls the expression of secondary and tertiary granule proteins.", [["granulocytic", "ANATOMY", 47, 59], ["neutrophils", "ANATOMY", 86, 97], ["granule", "ANATOMY", 206, 213], ["C/EPB-\u03b1", "GENE_OR_GENE_PRODUCT", 3, 10], ["GFI-1", "GENE_OR_GENE_PRODUCT", 15, 20], ["granulocytic", "CELL", 47, 59], ["neutrophils", "CELL", 86, 97], ["C/EBP-\u03b5", "GENE_OR_GENE_PRODUCT", 141, 148], ["EPB", "PROTEIN", 5, 8], ["\u03b1", "PROTEIN", 9, 10], ["GFI", "PROTEIN", 15, 18], ["mature neutrophils", "CELL_TYPE", 79, 97], ["EBP", "PROTEIN", 143, 146], ["\u03b5", "PROTEIN", 147, 148], ["secondary and tertiary granule proteins", "PROTEIN", 183, 222], ["C/EPB", "TEST", 3, 8], ["GFI", "TEST", 15, 18], ["terminal granulocytic differentiation", "PROBLEM", 38, 75], ["mature neutrophils", "PROBLEM", 79, 97], ["C/EBP", "TEST", 141, 146], ["secondary and tertiary granule proteins", "PROBLEM", 183, 222], ["terminal", "OBSERVATION_MODIFIER", 38, 46], ["granulocytic differentiation", "OBSERVATION", 47, 75], ["mature neutrophils", "OBSERVATION", 79, 97], ["tertiary granule proteins", "OBSERVATION", 197, 222]]], ["These stages are also known as the postmitotic pool of neutrophils.", [["neutrophils", "ANATOMY", 55, 66], ["neutrophils", "CELL", 55, 66], ["neutrophils", "CELL_TYPE", 55, 66], ["postmitotic pool of neutrophils", "OBSERVATION", 35, 66]]], ["Mature neutrophils accumulate in the bone marrow as a large reserve pool that can be rapidly released to the circulation.", [["neutrophils", "ANATOMY", 7, 18], ["bone marrow", "ANATOMY", 37, 48], ["neutrophils", "CELL", 7, 18], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 37, 48], ["neutrophils", "CELL_TYPE", 7, 18], ["Mature neutrophils accumulate in the bone marrow", "PROBLEM", 0, 48], ["neutrophils", "OBSERVATION", 7, 18], ["bone marrow", "ANATOMY", 37, 48], ["large", "OBSERVATION_MODIFIER", 54, 59], ["reserve", "OBSERVATION", 60, 67], ["circulation", "OBSERVATION_MODIFIER", 109, 120]]], ["During the last phase of differentiation, neutrophils start expressing receptors to transduce signals for mobilization to the blood and for effector functions.", [["neutrophils", "ANATOMY", 42, 53], ["blood", "ANATOMY", 126, 131], ["neutrophils", "CELL", 42, 53], ["blood", "ORGANISM_SUBSTANCE", 126, 131], ["neutrophils", "CELL_TYPE", 42, 53], ["neutrophils", "TREATMENT", 42, 53], ["mobilization", "TREATMENT", 106, 118], ["the blood", "TEST", 122, 131]]], ["Once in the blood circulation, neutrophils have a relatively short life span of a few hours.", [["blood", "ANATOMY", 12, 17], ["neutrophils", "ANATOMY", 31, 42], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["neutrophils", "CELL", 31, 42], ["neutrophils", "CELL_TYPE", 31, 42], ["neutrophils", "TEST", 31, 42]]], ["They can sense tissue injury through cytokines, peptides, and lipid mediators secreted and/or presented by endothelial cells.", [["tissue", "ANATOMY", 15, 21], ["endothelial cells", "ANATOMY", 107, 124], ["tissue", "TISSUE", 15, 21], ["endothelial cells", "CELL", 107, 124], ["cytokines", "PROTEIN", 37, 46], ["lipid mediators", "PROTEIN", 62, 77], ["endothelial cells", "CELL_TYPE", 107, 124], ["sense tissue injury through cytokines, peptides", "PROBLEM", 9, 56], ["lipid mediators secreted", "PROBLEM", 62, 86], ["sense tissue", "OBSERVATION_MODIFIER", 9, 21], ["injury", "OBSERVATION", 22, 28], ["endothelial cells", "OBSERVATION", 107, 124]]], ["Once firmly arrested on the vascular endothelium, neutrophils migrate into the tissue in a highly directional manner toward the injury site.", [["vascular endothelium", "ANATOMY", 28, 48], ["neutrophils", "ANATOMY", 50, 61], ["tissue", "ANATOMY", 79, 85], ["vascular endothelium", "TISSUE", 28, 48], ["neutrophils", "CELL", 50, 61], ["tissue", "TISSUE", 79, 85], ["neutrophils", "CELL_TYPE", 50, 61], ["neutrophils", "TREATMENT", 50, 61], ["the injury site", "PROBLEM", 124, 139], ["arrested", "OBSERVATION", 12, 20], ["vascular endothelium", "ANATOMY", 28, 48], ["highly directional", "OBSERVATION_MODIFIER", 91, 109], ["injury", "OBSERVATION", 128, 134]]], ["Recruited neutrophils are highly efficient phagocytes and kill microbes using a broad range of antimicrobial peptides and enzymes.", [["neutrophils", "ANATOMY", 10, 21], ["phagocytes", "ANATOMY", 43, 53], ["neutrophils", "CELL", 10, 21], ["phagocytes", "CELL", 43, 53], ["neutrophils", "CELL_TYPE", 10, 21], ["phagocytes", "CELL_TYPE", 43, 53], ["enzymes", "PROTEIN", 122, 129], ["antimicrobial peptides", "TREATMENT", 95, 117], ["enzymes", "TEST", 122, 129]]], ["In the absence of inflammation, the neutrophil life cycle ends by efferocytosis, where neutrophils undergo apoptosis and are phagocytosed.", [["neutrophil", "ANATOMY", 36, 46], ["neutrophils", "ANATOMY", 87, 98], ["inflammation", "DISEASE", 18, 30], ["neutrophil", "CELL", 36, 46], ["neutrophils", "CELL", 87, 98], ["neutrophils", "CELL_TYPE", 87, 98], ["inflammation", "PROBLEM", 18, 30], ["efferocytosis", "PROBLEM", 66, 79], ["apoptosis", "PROBLEM", 107, 116], ["phagocytosed", "PROBLEM", 125, 137], ["inflammation", "OBSERVATION", 18, 30], ["neutrophil life", "OBSERVATION", 36, 51], ["efferocytosis", "OBSERVATION", 66, 79]]], ["Efferocytosis of neutrophils occurs in all tissues but, in steady-state conditions, it occurs principally in the spleen, the liver, and the bone marrow.", [["neutrophils", "ANATOMY", 17, 28], ["tissues", "ANATOMY", 43, 50], ["spleen", "ANATOMY", 113, 119], ["liver", "ANATOMY", 125, 130], ["bone marrow", "ANATOMY", 140, 151], ["neutrophils", "CELL", 17, 28], ["tissues", "TISSUE", 43, 50], ["spleen", "ORGAN", 113, 119], ["liver", "ORGAN", 125, 130], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 140, 151], ["neutrophils", "CELL_TYPE", 17, 28], ["Efferocytosis of neutrophils", "PROBLEM", 0, 28], ["neutrophils", "OBSERVATION", 17, 28], ["all tissues", "OBSERVATION_MODIFIER", 39, 50], ["spleen", "ANATOMY", 113, 119], ["liver", "ANATOMY", 125, 130], ["bone marrow", "ANATOMY", 140, 151]]], ["This form of cell death is important for several reasons (Vandivier et al. 2006) .", [["cell", "ANATOMY", 13, 17], ["death", "DISEASE", 18, 23], ["cell", "CELL", 13, 17], ["cell death", "PROBLEM", 13, 23], ["cell death", "OBSERVATION", 13, 23]]], ["First, it dampens the production of inflammatory mediators through the production of TGF-\u03b2, for example.", [["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 85, 90], ["inflammatory mediators", "PROTEIN", 36, 58], ["TGF-\u03b2", "PROTEIN", 85, 90], ["inflammatory mediators", "PROBLEM", 36, 58], ["inflammatory", "OBSERVATION_MODIFIER", 36, 48]]], ["Second, and in contrast to necrotic neutrophils, apoptotic neutrophils do not release their highly reactive contents, thus preventing damage to neighboring cells and extracellular matrix proteins.", [["necrotic neutrophils", "ANATOMY", 27, 47], ["neutrophils", "ANATOMY", 59, 70], ["cells", "ANATOMY", 156, 161], ["extracellular matrix", "ANATOMY", 166, 186], ["necrotic", "DISEASE", 27, 35], ["necrotic neutrophils", "CELL", 27, 47], ["neutrophils", "CELL", 59, 70], ["cells", "CELL", 156, 161], ["extracellular matrix", "CELLULAR_COMPONENT", 166, 186], ["necrotic neutrophils", "CELL_TYPE", 27, 47], ["apoptotic neutrophils", "CELL_TYPE", 49, 70], ["neighboring cells", "CELL_TYPE", 144, 161], ["extracellular matrix proteins", "PROTEIN", 166, 195], ["necrotic neutrophils", "TEST", 27, 47], ["apoptotic neutrophils", "TEST", 49, 70], ["damage to neighboring cells", "PROBLEM", 134, 161], ["extracellular matrix proteins", "TREATMENT", 166, 195], ["necrotic", "OBSERVATION_MODIFIER", 27, 35], ["neutrophils", "OBSERVATION", 36, 47], ["apoptotic neutrophils", "OBSERVATION", 49, 70], ["highly", "OBSERVATION_MODIFIER", 92, 98], ["reactive contents", "OBSERVATION", 99, 116], ["neighboring cells", "OBSERVATION", 144, 161], ["extracellular matrix proteins", "OBSERVATION", 166, 195]]], ["Third, impaired removal of apoptotic cells is associated with autoimmune disease.", [["cells", "ANATOMY", 37, 42], ["autoimmune disease", "DISEASE", 62, 80], ["cells", "CELL", 37, 42], ["apoptotic cells", "CELL_TYPE", 27, 42], ["impaired removal of apoptotic cells", "TREATMENT", 7, 42], ["autoimmune disease", "PROBLEM", 62, 80], ["impaired", "OBSERVATION_MODIFIER", 7, 15], ["removal", "OBSERVATION_MODIFIER", 16, 23], ["apoptotic cells", "OBSERVATION", 27, 42], ["associated with", "UNCERTAINTY", 46, 61], ["autoimmune disease", "OBSERVATION", 62, 80]]], ["Last but not least, phagocytosis of apoptotic neutrophils reduces the production of IL-23 by the macrophages.", [["neutrophils", "ANATOMY", 46, 57], ["macrophages", "ANATOMY", 97, 108], ["neutrophils", "CELL", 46, 57], ["IL-23", "GENE_OR_GENE_PRODUCT", 84, 89], ["macrophages", "CELL", 97, 108], ["apoptotic neutrophils", "CELL_TYPE", 36, 57], ["IL-23", "PROTEIN", 84, 89], ["macrophages", "CELL_TYPE", 97, 108], ["apoptotic neutrophils", "TEST", 36, 57], ["IL", "TEST", 84, 86], ["not least", "UNCERTAINTY", 9, 18], ["apoptotic neutrophils", "OBSERVATION", 36, 57], ["macrophages", "ANATOMY", 97, 108]]], ["IL-23 induces the production of IL-17 by \u03b1\u03b2 and \u03b3\u03b4 T cells.", [["\u03b3\u03b4 T cells", "ANATOMY", 48, 58], ["IL-23", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-17", "GENE_OR_GENE_PRODUCT", 32, 37], ["\u03b1\u03b2", "GENE_OR_GENE_PRODUCT", 41, 43], ["\u03b3\u03b4 T cells", "CELL", 48, 58], ["IL-23", "PROTEIN", 0, 5], ["IL-17", "PROTEIN", 32, 37], ["\u03b1\u03b2 and \u03b3\u03b4 T cells", "CELL_TYPE", 41, 58], ["IL", "TEST", 0, 2], ["IL", "TEST", 32, 34]]], ["IL-17, in turn, upregulates G-CSF production by stromal cells leading to increased granulopoiesis (Stark et al. 2005) .", [["stromal cells", "ANATOMY", 48, 61], ["IL-17", "GENE_OR_GENE_PRODUCT", 0, 5], ["G-CSF", "GENE_OR_GENE_PRODUCT", 28, 33], ["stromal cells", "CELL", 48, 61], ["IL-17", "PROTEIN", 0, 5], ["CSF", "PROTEIN", 30, 33], ["stromal cells", "CELL_TYPE", 48, 61], ["IL", "TEST", 0, 2], ["stromal cells", "PROBLEM", 48, 61], ["increased granulopoiesis", "PROBLEM", 73, 97], ["stromal cells", "OBSERVATION", 48, 61], ["increased", "OBSERVATION_MODIFIER", 73, 82], ["granulopoiesis", "OBSERVATION", 83, 97]]], ["Therefore, the removal of apoptotic cells in the periphery sends a negative feedback loop that ultimately regulates neutrophil production in the bone marrow.Granule Subsets and Protease PackagingNeutrophil serine proteases (NSPs) contribute to many aspects of neutrophil biology in host defense and diseases associated with neutrophilic inflammation (Pham 2006) .", [["cells", "ANATOMY", 36, 41], ["neutrophil", "ANATOMY", 116, 126], ["bone marrow", "ANATOMY", 145, 156], ["Granule", "ANATOMY", 157, 164], ["neutrophil", "ANATOMY", 260, 270], ["neutrophilic", "ANATOMY", 324, 336], ["neutrophilic inflammation", "DISEASE", 324, 349], ["serine", "CHEMICAL", 206, 212], ["cells", "CELL", 36, 41], ["neutrophil", "CELL", 116, 126], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 145, 156], ["Protease PackagingNeutrophil serine proteases", "GENE_OR_GENE_PRODUCT", 177, 222], ["NSPs", "GENE_OR_GENE_PRODUCT", 224, 228], ["neutrophil", "CELL", 260, 270], ["apoptotic cells", "CELL_TYPE", 26, 41], ["neutrophil", "CELL_TYPE", 116, 126], ["Protease PackagingNeutrophil serine proteases", "PROTEIN", 177, 222], ["NSPs", "PROTEIN", 224, 228], ["the removal of apoptotic cells", "TREATMENT", 11, 41], ["a negative feedback loop", "PROBLEM", 65, 89], ["neutrophil production in the bone marrow", "PROBLEM", 116, 156], ["Granule Subsets", "TREATMENT", 157, 172], ["Protease PackagingNeutrophil serine proteases", "TREATMENT", 177, 222], ["diseases", "PROBLEM", 299, 307], ["neutrophilic inflammation", "PROBLEM", 324, 349], ["apoptotic cells", "OBSERVATION", 26, 41], ["periphery", "ANATOMY_MODIFIER", 49, 58], ["negative", "OBSERVATION", 67, 75], ["feedback loop", "OBSERVATION", 76, 89], ["neutrophil production", "OBSERVATION", 116, 137], ["bone marrow", "ANATOMY", 145, 156], ["host defense", "OBSERVATION_MODIFIER", 282, 294], ["neutrophilic", "OBSERVATION_MODIFIER", 324, 336], ["inflammation", "OBSERVATION", 337, 349]]], ["Human neutrophils contain four NSPs with an active catalytic triad: neutrophil elastase (NE), proteinase-3 (PR3), cathepsin G (CG), and the recently characterized neutrophil serine protease-4 (NSP4).", [["neutrophils", "ANATOMY", 6, 17], ["serine", "CHEMICAL", 174, 180], ["Human", "ORGANISM", 0, 5], ["neutrophils", "CELL", 6, 17], ["NSPs", "GENE_OR_GENE_PRODUCT", 31, 35], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 68, 87], ["NE", "GENE_OR_GENE_PRODUCT", 89, 91], ["proteinase-3", "GENE_OR_GENE_PRODUCT", 94, 106], ["PR3", "GENE_OR_GENE_PRODUCT", 108, 111], ["cathepsin G", "GENE_OR_GENE_PRODUCT", 114, 125], ["CG", "GENE_OR_GENE_PRODUCT", 127, 129], ["neutrophil serine protease-4", "GENE_OR_GENE_PRODUCT", 163, 191], ["NSP4", "GENE_OR_GENE_PRODUCT", 193, 197], ["Human neutrophils", "CELL_TYPE", 0, 17], ["NSPs", "PROTEIN", 31, 35], ["catalytic triad", "PROTEIN", 51, 66], ["neutrophil elastase", "PROTEIN", 68, 87], ["NE", "PROTEIN", 89, 91], ["proteinase-3", "PROTEIN", 94, 106], ["PR3", "PROTEIN", 108, 111], ["cathepsin G", "PROTEIN", 114, 125], ["CG", "PROTEIN", 127, 129], ["neutrophil serine protease-4", "PROTEIN", 163, 191], ["NSP4", "PROTEIN", 193, 197], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human neutrophils", "TEST", 0, 17], ["neutrophil elastase", "TEST", 68, 87], ["proteinase", "TEST", 94, 104], ["cathepsin G (CG)", "TEST", 114, 130], ["neutrophil serine protease", "TEST", 163, 189], ["neutrophil elastase", "OBSERVATION", 68, 87]]], ["NE and PR3 are elastinolytic proteases, and CG has chymotrypsin-like activity, whereas NSP4 is a trypsin-like protease.", [["NE", "CHEMICAL", 0, 2], ["NE", "SIMPLE_CHEMICAL", 0, 2], ["PR3", "GENE_OR_GENE_PRODUCT", 7, 10], ["CG", "SIMPLE_CHEMICAL", 44, 46], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 51, 63], ["NSP4", "GENE_OR_GENE_PRODUCT", 87, 91], ["trypsin", "GENE_OR_GENE_PRODUCT", 97, 104], ["NE", "PROTEIN", 0, 2], ["PR3", "PROTEIN", 7, 10], ["elastinolytic proteases", "PROTEIN", 15, 38], ["CG", "PROTEIN", 44, 46], ["chymotrypsin", "PROTEIN", 51, 63], ["NSP4", "PROTEIN", 87, 91], ["trypsin", "PROTEIN", 97, 104], ["protease", "PROTEIN", 110, 118], ["elastinolytic proteases", "TREATMENT", 15, 38], ["chymotrypsin", "PROBLEM", 51, 63], ["NSP4", "PROBLEM", 87, 91], ["a trypsin-like protease", "PROBLEM", 95, 118]]], ["Azurocidin is encoded by a phylogenetically related serine protease gene, but its catalytic domain is mutated rendering the protease inactive.", [["Azurocidin", "CHEMICAL", 0, 10], ["Azurocidin", "CHEMICAL", 0, 10], ["serine", "CHEMICAL", 52, 58], ["Azurocidin", "GENE_OR_GENE_PRODUCT", 0, 10], ["Azurocidin", "PROTEIN", 0, 10], ["serine protease gene", "DNA", 52, 72], ["catalytic domain", "PROTEIN", 82, 98], ["protease inactive", "PROTEIN", 124, 141], ["Azurocidin", "TREATMENT", 0, 10], ["serine protease gene", "TREATMENT", 52, 72], ["its catalytic domain", "PROBLEM", 78, 98]]], ["NSPs evolved from a common ancestor and are phylogenetically related to other serine proteases found in innate immune cells including granzymes and mast cell proteases (Ahmad et al. 2014) .", [["immune cells", "ANATOMY", 111, 123], ["mast cell", "ANATOMY", 148, 157], ["NSPs", "CHEMICAL", 0, 4], ["serine", "CHEMICAL", 78, 84], ["NSPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["innate immune cells", "CELL", 104, 123], ["granzymes", "GENE_OR_GENE_PRODUCT", 134, 143], ["mast cell", "CELL", 148, 157], ["NSPs", "PROTEIN", 0, 4], ["serine proteases", "PROTEIN", 78, 94], ["innate immune cells", "CELL_TYPE", 104, 123], ["granzymes", "PROTEIN", 134, 143], ["mast cell proteases", "PROTEIN", 148, 167], ["NSPs", "PROBLEM", 0, 4], ["other serine proteases", "PROBLEM", 72, 94], ["innate immune cells", "PROBLEM", 104, 123], ["granzymes", "TEST", 134, 143], ["mast cell proteases", "PROBLEM", 148, 167], ["immune cells", "OBSERVATION", 111, 123], ["mast cell proteases", "OBSERVATION", 148, 167]]], ["NSPs are conserved in mice, and in contrast to granzymes and mast cell proteases, there is a single mouse homolog for each of the human NSP genes.Granule Subsets and Protease PackagingNeutrophils contain three types of granules (primary, secondary, and tertiary) and secretory vesicles.", [["mast cell", "ANATOMY", 61, 70], ["Granule", "ANATOMY", 146, 153], ["Neutrophils", "ANATOMY", 184, 195], ["granules", "ANATOMY", 219, 227], ["primary", "ANATOMY", 229, 236], ["secretory vesicles", "ANATOMY", 267, 285], ["NSPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 22, 26], ["granzymes", "GENE_OR_GENE_PRODUCT", 47, 56], ["mast cell", "CELL", 61, 70], ["mouse", "ORGANISM", 100, 105], ["human", "ORGANISM", 130, 135], ["NSP", "GENE_OR_GENE_PRODUCT", 136, 139], ["Granule Subsets", "CELL", 146, 161], ["Neutrophils", "CELL", 184, 195], ["granules", "CELLULAR_COMPONENT", 219, 227], ["secretory vesicles", "CELLULAR_COMPONENT", 267, 285], ["NSPs", "PROTEIN", 0, 4], ["granzymes", "PROTEIN", 47, 56], ["mast cell proteases", "PROTEIN", 61, 80], ["human NSP genes", "DNA", 130, 145], ["Neutrophils", "CELL_TYPE", 184, 195], ["mice", "SPECIES", 22, 26], ["mouse", "SPECIES", 100, 105], ["human", "SPECIES", 130, 135], ["mice", "SPECIES", 22, 26], ["mouse", "SPECIES", 100, 105], ["human", "SPECIES", 130, 135], ["mast cell proteases", "PROBLEM", 61, 80], ["a single mouse homolog", "TREATMENT", 91, 113], ["Protease PackagingNeutrophils", "TEST", 166, 195], ["granules (primary, secondary, and tertiary) and secretory vesicles", "PROBLEM", 219, 285], ["mast cell proteases", "OBSERVATION", 61, 80], ["NSP genes", "OBSERVATION", 136, 145], ["PackagingNeutrophils", "OBSERVATION", 175, 195], ["three types", "OBSERVATION_MODIFIER", 204, 215], ["granules", "OBSERVATION_MODIFIER", 219, 227], ["secretory vesicles", "ANATOMY", 267, 285]]], ["NSPs are principally stored in primary, also termed azurophil, granules.", [["azurophil", "ANATOMY", 52, 61], ["granules", "ANATOMY", 63, 71], ["NSPs", "SIMPLE_CHEMICAL", 0, 4], ["azurophil", "CELL", 52, 61], ["granules", "CELLULAR_COMPONENT", 63, 71], ["azurophil", "OBSERVATION", 52, 61], ["granules", "OBSERVATION", 63, 71]]], ["However, PR3 was also reported in other types of granules and secretory vesicles.", [["granules", "ANATOMY", 49, 57], ["secretory vesicles", "ANATOMY", 62, 80], ["PR3", "GENE_OR_GENE_PRODUCT", 9, 12], ["granules", "ORGANISM_SUBSTANCE", 49, 57], ["secretory vesicles", "CELLULAR_COMPONENT", 62, 80], ["PR3", "PROTEIN", 9, 12], ["PR3", "TEST", 9, 12], ["granules", "OBSERVATION", 49, 57], ["secretory vesicles", "OBSERVATION", 62, 80]]], ["Together with NSPs, primary granules carry myeloperoxidase, lysozyme, and antimicrobial peptides such as \u03b1-defensins and cathelicidin.", [["primary granules", "ANATOMY", 20, 36], ["NSPs", "SIMPLE_CHEMICAL", 14, 18], ["granules", "ORGANISM_SUBSTANCE", 28, 36], ["myeloperoxidase", "GENE_OR_GENE_PRODUCT", 43, 58], ["lysozyme", "GENE_OR_GENE_PRODUCT", 60, 68], ["\u03b1-defensins", "GENE_OR_GENE_PRODUCT", 105, 116], ["cathelicidin", "GENE_OR_GENE_PRODUCT", 121, 133], ["NSPs", "PROTEIN", 14, 18], ["myeloperoxidase", "PROTEIN", 43, 58], ["lysozyme", "PROTEIN", 60, 68], ["\u03b1-defensins", "PROTEIN", 105, 116], ["cathelicidin", "PROTEIN", 121, 133], ["NSPs", "PROBLEM", 14, 18], ["myeloperoxidase", "TEST", 43, 58], ["lysozyme", "TREATMENT", 60, 68], ["antimicrobial peptides", "TREATMENT", 74, 96], ["\u03b1-defensins", "TREATMENT", 105, 116], ["cathelicidin", "TREATMENT", 121, 133]]], ["How each cargo protein ends up in the correct granule appears largely controlled by transcriptional timing (Cowland and Borregaard 1999; Theilgaard-M\u20ac onch et al. 2005 ).", [["granule", "ANATOMY", 46, 53], ["granule", "CELLULAR_COMPONENT", 46, 53], ["largely", "OBSERVATION_MODIFIER", 62, 69], ["controlled", "OBSERVATION", 70, 80]]], ["As described above, different transcription factors dominate at different phases of neutrophil differentiation and mRNA expression of NSPs is highest in promyelocytes, which is the time where primary granules are formed.Granule Subsets and Protease PackagingNSPs are synthesized as pre-pro-enzymes and require posttranslational cleavage at the N-terminus and C-terminus to gain their fully mature active form.", [["neutrophil", "ANATOMY", 84, 94], ["promyelocytes", "ANATOMY", 153, 166], ["primary granules", "ANATOMY", 192, 208], ["Granule", "ANATOMY", 220, 227], ["C", "CHEMICAL", 359, 360], ["neutrophil", "CELL", 84, 94], ["NSPs", "GENE_OR_GENE_PRODUCT", 134, 138], ["promyelocytes", "CELL", 153, 166], ["granules", "ORGANISM_SUBSTANCE", 200, 208], ["Protease PackagingNSPs", "GENE_OR_GENE_PRODUCT", 240, 262], ["transcription factors", "PROTEIN", 30, 51], ["NSPs", "PROTEIN", 134, 138], ["promyelocytes", "CELL_TYPE", 153, 166], ["Protease PackagingNSPs", "PROTEIN", 240, 262], ["N-terminus and C-terminus", "PROTEIN", 344, 369], ["different transcription factors", "PROBLEM", 20, 51], ["neutrophil differentiation", "TEST", 84, 110], ["mRNA expression of NSPs", "PROBLEM", 115, 138], ["promyelocytes", "PROBLEM", 153, 166], ["Protease PackagingNSPs", "TREATMENT", 240, 262], ["posttranslational cleavage at the N-terminus", "TREATMENT", 310, 354], ["neutrophil differentiation", "OBSERVATION", 84, 110], ["NSPs", "OBSERVATION_MODIFIER", 134, 138], ["highest", "OBSERVATION_MODIFIER", 142, 149], ["active", "OBSERVATION", 397, 403]]], ["First, the signal peptide is cleaved by a signal peptidase.", [["signal peptidase", "PROTEIN", 42, 58], ["a signal peptidase", "TEST", 40, 58]]], ["The resulting pro-enzymes are then further processed by dipeptidyl peptidase I (DPPI), also known as cathepsin C, which cleaves the N-terminal dipeptide in the endoplasmic reticulum (ER) and Golgi apparatus before packaging into granules.", [["endoplasmic reticulum", "ANATOMY", 160, 181], ["ER", "ANATOMY", 183, 185], ["Golgi apparatus", "ANATOMY", 191, 206], ["granules", "ANATOMY", 229, 237], ["N", "CHEMICAL", 132, 133], ["dipeptide", "CHEMICAL", 143, 152], ["dipeptidyl peptidase I", "GENE_OR_GENE_PRODUCT", 56, 78], ["DPPI", "GENE_OR_GENE_PRODUCT", 80, 84], ["cathepsin C", "GENE_OR_GENE_PRODUCT", 101, 112], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 160, 181], ["ER", "GENE_OR_GENE_PRODUCT", 183, 185], ["Golgi apparatus", "CELLULAR_COMPONENT", 191, 206], ["granules", "CELLULAR_COMPONENT", 229, 237], ["pro-enzymes", "PROTEIN", 14, 25], ["dipeptidyl peptidase I", "PROTEIN", 56, 78], ["DPPI", "PROTEIN", 80, 84], ["cathepsin C", "PROTEIN", 101, 112], ["N-terminal dipeptide", "PROTEIN", 132, 152], ["ER", "PROTEIN", 183, 185], ["The resulting pro-enzymes", "TEST", 0, 25], ["dipeptidyl peptidase I (DPPI)", "TREATMENT", 56, 85], ["cathepsin C", "PROBLEM", 101, 112], ["endoplasmic reticulum", "ANATOMY", 160, 181]]], ["Cleavage of the pro-dipeptide by DPPI is essential for the enzymatic activity of the NSPs.", [["DPPI", "CHEMICAL", 33, 37], ["pro-dipeptide", "CHEMICAL", 16, 29], ["pro-dipeptide", "GENE_OR_GENE_PRODUCT", 16, 29], ["DPPI", "GENE_OR_GENE_PRODUCT", 33, 37], ["NSPs", "GENE_OR_GENE_PRODUCT", 85, 89], ["pro-dipeptide", "PROTEIN", 16, 29], ["DPPI", "PROTEIN", 33, 37], ["NSPs", "PROTEIN", 85, 89], ["the pro-dipeptide", "TREATMENT", 12, 29]]], ["Neutrophils of dppi \u00c0/\u00c0 mice have no detectable NSP activity, and CG protein is not detectable in neutrophil lysates (Adkison et al. 2002) .", [["Neutrophils", "ANATOMY", 0, 11], ["neutrophil lysates", "ANATOMY", 98, 116], ["Neutrophils", "CELL", 0, 11], ["dppi", "GENE_OR_GENE_PRODUCT", 15, 19], ["\u00c0", "GENE_OR_GENE_PRODUCT", 22, 23], ["NSP", "GENE_OR_GENE_PRODUCT", 48, 51], ["neutrophil lysates", "ORGANISM_SUBSTANCE", 98, 116], ["Neutrophils", "CELL_TYPE", 0, 11], ["NSP", "PROTEIN", 48, 51], ["CG protein", "PROTEIN", 66, 76], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 24, 28], ["Neutrophils", "TEST", 0, 11], ["dppi", "TEST", 15, 19], ["detectable NSP activity", "PROBLEM", 37, 60], ["CG protein", "TEST", 66, 76], ["neutrophil lysates", "TEST", 98, 116], ["no", "UNCERTAINTY", 34, 36], ["detectable", "OBSERVATION_MODIFIER", 37, 47], ["NSP activity", "OBSERVATION", 48, 60], ["not detectable", "UNCERTAINTY", 80, 94]]], ["The C-terminus of the pro-enzymes is also cleaved before packaging into granules, but the protease responsible for this process has not yet been identified.", [["granules", "ANATOMY", 72, 80], ["C-terminus", "GENE_OR_GENE_PRODUCT", 4, 14], ["granules", "ORGANISM_SUBSTANCE", 72, 80], ["C-terminus", "PROTEIN", 4, 14], ["pro-enzymes", "PROTEIN", 22, 33], ["protease", "PROTEIN", 90, 98], ["the protease", "TREATMENT", 86, 98]]], ["Mutants of NE and CG lacking the C-terminal peptide and expressed in RBL cell line are correctly routed to granules and are enzymatically active indicating that the C-terminal domain is not required for these functions (Gullberg et al. 1995) .Granule Subsets and Protease PackagingThe mechanisms of targeting and retention of NSPs in primary granules are not fully elucidated.", [["RBL cell line", "ANATOMY", 69, 82], ["granules", "ANATOMY", 107, 115], ["Granule", "ANATOMY", 243, 250], ["primary granules", "ANATOMY", 334, 350], ["NE", "CHEMICAL", 11, 13], ["C", "CHEMICAL", 33, 34], ["C", "CHEMICAL", 165, 166], ["NE", "GENE_OR_GENE_PRODUCT", 11, 13], ["RBL cell line", "CELL", 69, 82], ["granules", "CELLULAR_COMPONENT", 107, 115], ["Protease", "GENE_OR_GENE_PRODUCT", 263, 271], ["NSPs", "GENE_OR_GENE_PRODUCT", 326, 330], ["granules", "ORGANISM_SUBSTANCE", 342, 350], ["NE", "PROTEIN", 11, 13], ["CG", "DNA", 18, 20], ["RBL cell line", "CELL_LINE", 69, 82], ["C-terminal domain", "PROTEIN", 165, 182], ["NSPs", "PROTEIN", 326, 330], ["NE", "TREATMENT", 11, 13], ["CG", "TREATMENT", 18, 20], ["the C-terminal peptide", "TREATMENT", 29, 51], ["RBL cell line", "TREATMENT", 69, 82], ["the C-terminal domain", "PROBLEM", 161, 182], ["Granule Subsets", "TREATMENT", 243, 258], ["Protease Packaging", "TREATMENT", 263, 281], ["retention of NSPs in primary granules", "PROBLEM", 313, 350], ["NE", "OBSERVATION", 11, 13], ["RBL cell line", "OBSERVATION", 69, 82], ["retention", "OBSERVATION_MODIFIER", 313, 322], ["NSPs", "OBSERVATION_MODIFIER", 326, 330], ["primary granules", "OBSERVATION", 334, 350], ["not fully", "UNCERTAINTY", 355, 364]]], ["Cleavage of the C-terminus of NE appears to promote the routing of NE to granules by two mechanisms: first, the C-terminus contains a putative transmembrane domain that leads to membrane anchoring and leads to targeting to the plasma membrane; second, the cleavage of the C-terminus leads to the uncovering of a binding domain for adaptor protein complex 3 (AP3), which may favor protein distribution to granules (Benson et al. 2003) .", [["granules", "ANATOMY", 73, 81], ["transmembrane", "ANATOMY", 143, 156], ["membrane", "ANATOMY", 178, 186], ["plasma membrane", "ANATOMY", 227, 242], ["granules", "ANATOMY", 404, 412], ["NE", "CHEMICAL", 30, 32], ["NE", "CHEMICAL", 67, 69], ["C", "CHEMICAL", 112, 113], ["C", "CHEMICAL", 272, 273], ["C-terminus", "GENE_OR_GENE_PRODUCT", 16, 26], ["NE", "GENE_OR_GENE_PRODUCT", 30, 32], ["NE", "GENE_OR_GENE_PRODUCT", 67, 69], ["granules", "CELLULAR_COMPONENT", 73, 81], ["transmembrane", "CELLULAR_COMPONENT", 143, 156], ["membrane", "CELLULAR_COMPONENT", 178, 186], ["plasma membrane", "CELLULAR_COMPONENT", 227, 242], ["adaptor protein complex 3", "GENE_OR_GENE_PRODUCT", 331, 356], ["AP3", "GENE_OR_GENE_PRODUCT", 358, 361], ["granules", "CELLULAR_COMPONENT", 404, 412], ["C-terminus", "PROTEIN", 16, 26], ["NE", "PROTEIN", 30, 32], ["NE", "PROTEIN", 67, 69], ["C-terminus", "PROTEIN", 112, 122], ["putative transmembrane domain", "PROTEIN", 134, 163], ["C-terminus", "PROTEIN", 272, 282], ["binding domain", "PROTEIN", 312, 326], ["adaptor protein complex 3", "PROTEIN", 331, 356], ["AP3", "PROTEIN", 358, 361], ["the C-terminus of NE", "TREATMENT", 12, 32], ["a putative transmembrane domain", "PROBLEM", 132, 163], ["membrane anchoring", "TREATMENT", 178, 196], ["protein distribution to granules", "PROBLEM", 380, 412], ["plasma membrane", "OBSERVATION", 227, 242], ["may favor", "UNCERTAINTY", 370, 379], ["protein distribution", "OBSERVATION", 380, 400]]], ["The proteoglycan serglycin contributes to the retention of proteases and inflammatory mediators in leukocytes and endothelial cells (Kolset and Tveit 2008) .", [["leukocytes", "ANATOMY", 99, 109], ["endothelial cells", "ANATOMY", 114, 131], ["serglycin", "CHEMICAL", 17, 26], ["proteoglycan serglycin", "GENE_OR_GENE_PRODUCT", 4, 26], ["leukocytes", "CELL", 99, 109], ["endothelial cells", "CELL", 114, 131], ["Kolset", "CELL", 133, 139], ["proteoglycan serglycin", "PROTEIN", 4, 26], ["proteases", "PROTEIN", 59, 68], ["inflammatory mediators", "PROTEIN", 73, 95], ["leukocytes", "CELL_TYPE", 99, 109], ["endothelial cells", "CELL_TYPE", 114, 131], ["The proteoglycan serglycin", "TREATMENT", 0, 26], ["proteases", "PROBLEM", 59, 68], ["inflammatory mediators", "PROBLEM", 73, 95], ["endothelial cells", "TEST", 114, 131], ["proteoglycan serglycin", "OBSERVATION", 4, 26], ["inflammatory", "OBSERVATION_MODIFIER", 73, 85], ["endothelial cells", "OBSERVATION", 114, 131]]], ["In neutrophils of serglycin-deficient mice, only NE appeared to require serglycin for proper localization into granules, whereas sorting of CG and PR3 was not affected (Niemann et al. 2007 ).", [["neutrophils", "ANATOMY", 3, 14], ["granules", "ANATOMY", 111, 119], ["NE", "CHEMICAL", 49, 51], ["serglycin", "CHEMICAL", 72, 81], ["serglycin", "CHEMICAL", 72, 81], ["neutrophils", "CELL", 3, 14], ["serglycin", "GENE_OR_GENE_PRODUCT", 18, 27], ["mice", "ORGANISM", 38, 42], ["NE", "GENE_OR_GENE_PRODUCT", 49, 51], ["serglycin", "GENE_OR_GENE_PRODUCT", 72, 81], ["granules", "CELLULAR_COMPONENT", 111, 119], ["CG", "GENE_OR_GENE_PRODUCT", 140, 142], ["PR3", "GENE_OR_GENE_PRODUCT", 147, 150], ["neutrophils", "CELL_TYPE", 3, 14], ["serglycin", "PROTEIN", 18, 27], ["NE", "PROTEIN", 49, 51], ["serglycin", "PROTEIN", 72, 81], ["CG", "PROTEIN", 140, 142], ["PR3", "PROTEIN", 147, 150], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["serglycin-deficient mice", "TREATMENT", 18, 42], ["serglycin", "TREATMENT", 72, 81]]], ["While early studies showed that PR3 localized principally in primary granules (Borregaard and Cowland 1997) , PR3 has also been reported in secretory vesicles and other types of granules, which may explain the more rapid mobilization of PR3 to the plasma membrane (Witko-Sarsat et al. 1999; Loison et al. 2014 ).Secreted Clade A SerpinsSeveral inhibitors of the clade A and the clade B serpins, as well as non-serpin inhibitors of the macroglobulin and chelonianin families, contribute to the regulation of the activity of NSPs in different compartments of the cell, tissues, and the whole organism.Secreted Clade A SerpinsThe clade A serpins \u03b11-antitrypsin (AAT, SERPINA1) and \u03b11-antichymotrypsin (ACT, SERPINA3) are the two principal serpins found in plasma that inhibit NSPs.", [["primary granules", "ANATOMY", 61, 77], ["secretory vesicles", "ANATOMY", 140, 158], ["granules", "ANATOMY", 178, 186], ["plasma membrane", "ANATOMY", 248, 263], ["compartments", "ANATOMY", 541, 553], ["cell", "ANATOMY", 561, 565], ["tissues", "ANATOMY", 567, 574], ["plasma", "ANATOMY", 753, 759], ["PR3", "GENE_OR_GENE_PRODUCT", 32, 35], ["granules", "ORGANISM_SUBSTANCE", 69, 77], ["PR3", "GENE_OR_GENE_PRODUCT", 110, 113], ["secretory vesicles", "CELLULAR_COMPONENT", 140, 158], ["granules", "CELLULAR_COMPONENT", 178, 186], ["PR3", "GENE_OR_GENE_PRODUCT", 237, 240], ["plasma membrane", "CELLULAR_COMPONENT", 248, 263], ["clade B serpins", "GENE_OR_GENE_PRODUCT", 378, 393], ["macroglobulin", "GENE_OR_GENE_PRODUCT", 435, 448], ["chelonianin", "GENE_OR_GENE_PRODUCT", 453, 464], ["NSPs", "GENE_OR_GENE_PRODUCT", 523, 527], ["cell", "CELL", 561, 565], ["tissues", "TISSUE", 567, 574], ["\u03b11-antitrypsin", "GENE_OR_GENE_PRODUCT", 643, 657], ["AAT", "GENE_OR_GENE_PRODUCT", 659, 662], ["SERPINA1", "GENE_OR_GENE_PRODUCT", 664, 672], ["\u03b11-antichymotrypsin", "GENE_OR_GENE_PRODUCT", 678, 697], ["ACT", "GENE_OR_GENE_PRODUCT", 699, 702], ["SERPINA3", "GENE_OR_GENE_PRODUCT", 704, 712], ["serpins", "GENE_OR_GENE_PRODUCT", 736, 743], ["plasma", "ORGANISM_SUBSTANCE", 753, 759], ["NSPs", "GENE_OR_GENE_PRODUCT", 773, 777], ["PR3", "PROTEIN", 32, 35], ["PR3", "PROTEIN", 110, 113], ["PR3", "PROTEIN", 237, 240], ["clade B serpins", "PROTEIN", 378, 393], ["macroglobulin and chelonianin families", "PROTEIN", 435, 473], ["NSPs", "PROTEIN", 523, 527], ["\u03b11", "PROTEIN", 643, 645], ["antitrypsin", "PROTEIN", 646, 657], ["AAT", "PROTEIN", 659, 662], ["SERPINA1", "PROTEIN", 664, 672], ["\u03b11", "PROTEIN", 678, 680], ["antichymotrypsin", "PROTEIN", 681, 697], ["ACT", "PROTEIN", 699, 702], ["SERPINA3", "PROTEIN", 704, 712], ["serpins", "PROTEIN", 736, 743], ["NSPs", "PROTEIN", 773, 777], ["early studies", "TEST", 6, 19], ["PR3", "PROBLEM", 32, 35], ["PR3", "TREATMENT", 110, 113], ["A SerpinsSeveral inhibitors", "TREATMENT", 327, 354], ["the clade A", "TREATMENT", 358, 369], ["the clade B serpins", "TREATMENT", 374, 393], ["non-serpin inhibitors", "TREATMENT", 406, 427], ["the macroglobulin", "TREATMENT", 431, 448], ["the whole organism", "PROBLEM", 580, 598], ["The clade A serpins", "TEST", 623, 642], ["AAT", "TEST", 659, 662], ["SERPINA1", "TEST", 664, 672], ["\u03b11-antichymotrypsin (ACT", "TREATMENT", 678, 702], ["SERPINA3", "TREATMENT", 704, 712], ["secretory vesicles", "OBSERVATION", 140, 158], ["granules", "OBSERVATION", 178, 186], ["cell", "OBSERVATION", 561, 565]]], ["AAT inhibits NE, CG, and PR3 by the classical suicide-substrate mechanism of serpins (Huntington et al. 2000) .", [["NE", "CHEMICAL", 13, 15], ["AAT", "GENE_OR_GENE_PRODUCT", 0, 3], ["NE", "SIMPLE_CHEMICAL", 13, 15], ["CG", "SIMPLE_CHEMICAL", 17, 19], ["PR3", "GENE_OR_GENE_PRODUCT", 25, 28], ["serpins", "GENE_OR_GENE_PRODUCT", 77, 84], ["AAT", "PROTEIN", 0, 3], ["NE", "PROTEIN", 13, 15], ["CG", "PROTEIN", 17, 19], ["PR3", "PROTEIN", 25, 28], ["serpins", "PROTEIN", 77, 84]]], ["The three NSPs cleave the reactive center loop (RCL) of AAT at the same P1 site Met-358.", [["Met-358", "CHEMICAL", 80, 87], ["Met-358", "CHEMICAL", 80, 87], ["NSPs", "GENE_OR_GENE_PRODUCT", 10, 14], ["AAT", "GENE_OR_GENE_PRODUCT", 56, 59], ["Met-358", "AMINO_ACID", 80, 87], ["NSPs", "PROTEIN", 10, 14], ["RCL", "PROTEIN", 48, 51], ["AAT", "PROTEIN", 56, 59], ["P1 site", "DNA", 72, 79], ["reactive", "OBSERVATION_MODIFIER", 26, 34], ["center", "OBSERVATION_MODIFIER", 35, 41], ["loop", "OBSERVATION_MODIFIER", 42, 46], ["RCL", "OBSERVATION_MODIFIER", 48, 51]]], ["AAT and ACT are produced by the liver and respiratory airway epithelial cells and function by regulating NSPs in blood and extracellular compartments when NSPs are released from neutrophils following degranulation or necrosis.Secreted Clade A SerpinsAAT is also expressed in neutrophils during the late stages of granulopoiesis in the bone marrow and is found at relatively higher levels in mature differentiated cells (Missen et al. 2006 ).", [["liver", "ANATOMY", 32, 37], ["respiratory airway epithelial cells", "ANATOMY", 42, 77], ["NSPs", "ANATOMY", 105, 109], ["blood", "ANATOMY", 113, 118], ["extracellular compartments", "ANATOMY", 123, 149], ["NSPs", "ANATOMY", 155, 159], ["neutrophils", "ANATOMY", 178, 189], ["neutrophils", "ANATOMY", 275, 286], ["bone marrow", "ANATOMY", 335, 346], ["cells", "ANATOMY", 413, 418], ["necrosis", "DISEASE", 217, 225], ["AAT", "GENE_OR_GENE_PRODUCT", 0, 3], ["ACT", "GENE_OR_GENE_PRODUCT", 8, 11], ["liver", "ORGAN", 32, 37], ["respiratory airway epithelial cells", "CELL", 42, 77], ["NSPs", "GENE_OR_GENE_PRODUCT", 105, 109], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["extracellular compartments", "CELLULAR_COMPONENT", 123, 149], ["NSPs", "SIMPLE_CHEMICAL", 155, 159], ["neutrophils", "CELL", 178, 189], ["Clade A SerpinsAAT", "GENE_OR_GENE_PRODUCT", 235, 253], ["neutrophils", "CELL", 275, 286], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 335, 346], ["cells", "CELL", 413, 418], ["AAT", "PROTEIN", 0, 3], ["ACT", "PROTEIN", 8, 11], ["respiratory airway epithelial cells", "CELL_TYPE", 42, 77], ["NSPs", "PROTEIN", 105, 109], ["NSPs", "PROTEIN", 155, 159], ["neutrophils", "CELL_TYPE", 178, 189], ["Secreted Clade A SerpinsAAT", "PROTEIN", 226, 253], ["neutrophils", "CELL_TYPE", 275, 286], ["mature differentiated cells", "CELL_TYPE", 391, 418], ["degranulation", "PROBLEM", 200, 213], ["necrosis", "PROBLEM", 217, 225], ["granulopoiesis in the bone marrow", "PROBLEM", 313, 346], ["liver", "ANATOMY", 32, 37], ["respiratory airway", "ANATOMY", 42, 60], ["epithelial cells", "OBSERVATION", 61, 77], ["NSPs", "OBSERVATION_MODIFIER", 105, 109], ["blood", "ANATOMY", 113, 118], ["degranulation", "OBSERVATION", 200, 213], ["necrosis", "OBSERVATION", 217, 225], ["neutrophils", "OBSERVATION", 275, 286], ["late stages", "OBSERVATION_MODIFIER", 298, 309], ["granulopoiesis", "OBSERVATION", 313, 327], ["bone marrow", "ANATOMY", 335, 346], ["mature", "OBSERVATION_MODIFIER", 391, 397], ["differentiated cells", "OBSERVATION", 398, 418]]], ["AAT protein is found within neutrophil granules and can be secreted upon stimulation (Mason et al. 1991; Clemmensen et al. 2011) .", [["neutrophil granules", "ANATOMY", 28, 47], ["AAT", "GENE_OR_GENE_PRODUCT", 0, 3], ["neutrophil granules", "CELLULAR_COMPONENT", 28, 47], ["AAT protein", "PROTEIN", 0, 11], ["AAT protein", "TEST", 0, 11], ["neutrophil granules", "PROBLEM", 28, 47], ["neutrophil granules", "OBSERVATION", 28, 47]]], ["In circulating neutrophils, AAT levels in neutrophils are increased as the secretory vesicles are formed by engulfing plasma proteins that can later be released in response to inflammatory stimuli (Borregaard et al. 1992 ).", [["neutrophils", "ANATOMY", 15, 26], ["neutrophils", "ANATOMY", 42, 53], ["secretory vesicles", "ANATOMY", 75, 93], ["plasma", "ANATOMY", 118, 124], ["neutrophils", "CELL", 15, 26], ["AAT", "GENE_OR_GENE_PRODUCT", 28, 31], ["neutrophils", "CELL", 42, 53], ["secretory vesicles", "CELLULAR_COMPONENT", 75, 93], ["plasma", "ORGANISM_SUBSTANCE", 118, 124], ["circulating neutrophils", "CELL_TYPE", 3, 26], ["AAT", "PROTEIN", 28, 31], ["neutrophils", "CELL_TYPE", 42, 53], ["plasma proteins", "PROTEIN", 118, 133], ["circulating neutrophils", "TEST", 3, 26], ["AAT levels", "TEST", 28, 38], ["neutrophils", "TEST", 42, 53], ["inflammatory stimuli", "TEST", 176, 196], ["circulating", "OBSERVATION_MODIFIER", 3, 14], ["neutrophils", "OBSERVATION", 15, 26], ["increased", "OBSERVATION_MODIFIER", 58, 67], ["secretory vesicles", "OBSERVATION", 75, 93], ["engulfing plasma proteins", "OBSERVATION", 108, 133], ["inflammatory", "OBSERVATION_MODIFIER", 176, 188]]], ["The relative importance and function of AAT within the different granules of neutrophils in homeostatic and inflammatory conditions remain to be defined.", [["granules", "ANATOMY", 65, 73], ["neutrophils", "ANATOMY", 77, 88], ["AAT", "GENE_OR_GENE_PRODUCT", 40, 43], ["granules", "CELLULAR_COMPONENT", 65, 73], ["neutrophils", "CELL", 77, 88], ["AAT", "PROTEIN", 40, 43], ["neutrophils", "CELL_TYPE", 77, 88], ["inflammatory conditions", "PROBLEM", 108, 131], ["neutrophils", "ANATOMY", 77, 88], ["inflammatory", "OBSERVATION_MODIFIER", 108, 120]]], ["There is also growing evidence that AAT functions as an anti-inflammatory mediator independently of NSP inhibition (Jonigk et al. 2013) .", [["AAT", "GENE_OR_GENE_PRODUCT", 36, 39], ["NSP", "GENE_OR_GENE_PRODUCT", 100, 103], ["AAT", "PROTEIN", 36, 39], ["AAT functions", "PROBLEM", 36, 49]]], ["One mechanism may be through interference with TNF-\u03b1 signaling pathways (Bergin et al. 2014) .Secreted Clade A SerpinsIn mice and rats, AAT and ACT genes have been duplicated multiple times.", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 47, 52], ["mice", "ORGANISM", 121, 125], ["rats", "ORGANISM", 130, 134], ["AAT", "GENE_OR_GENE_PRODUCT", 136, 139], ["ACT", "GENE_OR_GENE_PRODUCT", 144, 147], ["TNF", "PROTEIN", 47, 50], ["Secreted Clade A SerpinsIn mice and rats, AAT and ACT genes", "DNA", 94, 153], ["mice", "SPECIES", 121, 125], ["rats", "SPECIES", 130, 134], ["mice", "SPECIES", 121, 125], ["TNF", "TEST", 47, 50], ["A SerpinsIn mice", "TREATMENT", 109, 125], ["may be", "UNCERTAINTY", 14, 20]]], ["The number of AAT genes and plasma concentrations appear to vary between different laboratory mouse strains.", [["plasma", "ANATOMY", 28, 34], ["AAT", "GENE_OR_GENE_PRODUCT", 14, 17], ["plasma", "ORGANISM_SUBSTANCE", 28, 34], ["mouse", "ORGANISM", 94, 99], ["AAT genes", "DNA", 14, 23], ["mouse", "SPECIES", 94, 99], ["mouse", "SPECIES", 94, 99], ["plasma concentrations", "TEST", 28, 49], ["mouse strains", "OBSERVATION", 94, 107]]], ["Modeling AAT deficiency by deleting the mouse genes has proved to be even more challenging because of embryonic lethality (Wang et al. 2011 ).Intracellular Clade B SerpinsClade B serpins regroup phylogenetically related proteins with nuclear and/or cytoplasmic localization.", [["embryonic", "ANATOMY", 102, 111], ["Intracellular", "ANATOMY", 142, 155], ["nuclear", "ANATOMY", 234, 241], ["cytoplasmic", "ANATOMY", 249, 260], ["AAT", "GENE_OR_GENE_PRODUCT", 9, 12], ["mouse", "ORGANISM", 40, 45], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 102, 111], ["Clade B SerpinsClade B serpins", "GENE_OR_GENE_PRODUCT", 156, 186], ["nuclear", "CELLULAR_COMPONENT", 234, 241], ["cytoplasmic", "ORGANISM_SUBSTANCE", 249, 260], ["AAT", "PROTEIN", 9, 12], ["mouse genes", "DNA", 40, 51], ["Intracellular Clade B SerpinsClade B serpins", "PROTEIN", 142, 186], ["mouse", "SPECIES", 40, 45], ["mouse", "SPECIES", 40, 45], ["Modeling AAT deficiency", "PROBLEM", 0, 23], ["embryonic lethality", "PROBLEM", 102, 121], ["Intracellular Clade", "TREATMENT", 142, 161], ["cytoplasmic localization", "TEST", 249, 273], ["AAT deficiency", "OBSERVATION", 9, 23]]], ["Vertebrate clade B serpins evolved from a single serpinB1-like gene that has remained conserved in fish, birds, and mammals (Kaiserman and Bird 2005; Benarafa and Remold-O'Donnell 2005) .", [["clade B serpins", "GENE_OR_GENE_PRODUCT", 11, 26], ["serpinB1", "GENE_OR_GENE_PRODUCT", 49, 57], ["fish", "ORGANISM_SUBDIVISION", 99, 103], ["Remold-O'Donnell 2005", "CELL", 163, 184], ["Vertebrate clade B serpins", "PROTEIN", 0, 26], ["serpinB1-like gene", "DNA", 49, 67], ["Vertebrate clade B serpins", "PROBLEM", 0, 26]]], ["In man, there are 13 clade B serpins found on two loci.", [["man", "ORGANISM", 3, 6], ["B serpins", "GENE_OR_GENE_PRODUCT", 27, 36], ["clade B serpins", "PROTEIN", 21, 36], ["man", "SPECIES", 3, 6], ["clade B serpins", "TREATMENT", 21, 36]]], ["SERPINB1, SERPINB6, and SERPINB9 genes are found on chromosome 6p25, and the ten other clade B serpin genes are clustered on chromosome 18q21.", [["chromosome 6p25", "ANATOMY", 52, 67], ["chromosome 18q21", "ANATOMY", 125, 141], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 0, 8], ["SERPINB6", "GENE_OR_GENE_PRODUCT", 10, 18], ["SERPINB9", "GENE_OR_GENE_PRODUCT", 24, 32], ["chromosome 6p25", "CELLULAR_COMPONENT", 52, 67], ["clade B serpin", "GENE_OR_GENE_PRODUCT", 87, 101], ["chromosome 18q21", "CELLULAR_COMPONENT", 125, 141], ["SERPINB1, SERPINB6, and SERPINB9 genes", "DNA", 0, 38], ["chromosome 6p25", "DNA", 52, 67], ["clade B serpin genes", "DNA", 87, 107], ["chromosome 18q21", "DNA", 125, 141], ["SERPINB1", "TEST", 0, 8], ["SERPINB6", "TREATMENT", 10, 18]]], ["Serpins encoded in the 6p25 cluster inhibit granule serine proteases of leukocytes, and high expression of these serpins is found in cells that also carry target proteases.Intracellular Clade B SerpinsSERPINB1 was the first cytoplasmic inhibitor of elastase to be identified in neutrophils and monocytes/macrophages (Remold-O'Donnell 1985 , 1989 Potempa et al. 1988) .", [["granule", "ANATOMY", 44, 51], ["leukocytes", "ANATOMY", 72, 82], ["cells", "ANATOMY", 133, 138], ["cytoplasmic", "ANATOMY", 224, 235], ["neutrophils", "ANATOMY", 278, 289], ["monocytes", "ANATOMY", 294, 303], ["macrophages", "ANATOMY", 304, 315], ["serine", "CHEMICAL", 52, 58], ["Serpins", "GENE_OR_GENE_PRODUCT", 0, 7], ["6p25", "GENE_OR_GENE_PRODUCT", 23, 27], ["granule serine proteases", "GENE_OR_GENE_PRODUCT", 44, 68], ["leukocytes", "CELL", 72, 82], ["serpins", "GENE_OR_GENE_PRODUCT", 113, 120], ["cells", "CELL", 133, 138], ["Clade B SerpinsSERPINB1", "GENE_OR_GENE_PRODUCT", 186, 209], ["cytoplasmic", "ORGANISM_SUBSTANCE", 224, 235], ["elastase", "GENE_OR_GENE_PRODUCT", 249, 257], ["neutrophils", "CELL", 278, 289], ["monocytes", "CELL", 294, 303], ["macrophages", "CELL", 304, 315], ["6p25 cluster", "DNA", 23, 35], ["granule serine proteases", "PROTEIN", 44, 68], ["leukocytes", "CELL_TYPE", 72, 82], ["serpins", "PROTEIN", 113, 120], ["proteases", "PROTEIN", 162, 171], ["Clade B SerpinsSERPINB1", "PROTEIN", 186, 209], ["elastase", "PROTEIN", 249, 257], ["neutrophils", "CELL_TYPE", 278, 289], ["monocytes", "CELL_TYPE", 294, 303], ["macrophages", "CELL_TYPE", 304, 315], ["granule serine proteases of leukocytes", "PROBLEM", 44, 82], ["these serpins", "PROBLEM", 107, 120], ["Intracellular Clade B SerpinsSERPINB1", "TREATMENT", 172, 209], ["elastase", "PROBLEM", 249, 257], ["neutrophils", "TEST", 278, 289], ["monocytes", "TEST", 294, 303], ["leukocytes", "ANATOMY", 72, 82], ["Clade", "OBSERVATION", 186, 191], ["elastase", "OBSERVATION", 249, 257], ["neutrophils", "ANATOMY", 278, 289], ["monocytes", "ANATOMY", 294, 303], ["macrophages", "ANATOMY", 304, 315]]], ["It was thus named monocyte/neutrophil elastase inhibitor (MNEI) and leukocyte elastase inhibitor (LEI).", [["monocyte", "ANATOMY", 18, 26], ["leukocyte", "ANATOMY", 68, 77], ["monocyte", "CELL", 18, 26], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 27, 46], ["MNEI", "SIMPLE_CHEMICAL", 58, 62], ["leukocyte elastase", "GENE_OR_GENE_PRODUCT", 68, 86], ["LEI", "SIMPLE_CHEMICAL", 98, 101], ["neutrophil elastase inhibitor", "PROTEIN", 27, 56], ["leukocyte elastase inhibitor", "PROTEIN", 68, 96], ["monocyte/neutrophil elastase inhibitor", "TREATMENT", 18, 56], ["MNEI", "TEST", 58, 62], ["leukocyte elastase inhibitor", "TREATMENT", 68, 96], ["neutrophil elastase", "OBSERVATION", 27, 46]]], ["SERPINB1 also inhibits CG and PR3 through the classical serpin complex inhibition mechanism.", [["SERPINB1", "GENE_OR_GENE_PRODUCT", 0, 8], ["CG", "MULTI-TISSUE_STRUCTURE", 23, 25], ["PR3", "GENE_OR_GENE_PRODUCT", 30, 33], ["serpin", "GENE_OR_GENE_PRODUCT", 56, 62], ["SERPINB1", "PROTEIN", 0, 8], ["PR3", "PROTEIN", 30, 33], ["serpin complex", "PROTEIN", 56, 70], ["SERPINB1", "TEST", 0, 8], ["CG", "TEST", 23, 25], ["PR3", "TEST", 30, 33]]], ["NE and PR3 target the RCL of SERPINB1 at Cys-344 at the classical P1 position, corresponding to Met-358 of AAT.", [["NE", "CHEMICAL", 0, 2], ["Cys-344", "CHEMICAL", 41, 48], ["Met-358", "CHEMICAL", 96, 103], ["Cys", "CHEMICAL", 41, 44], ["NE", "SIMPLE_CHEMICAL", 0, 2], ["PR3", "GENE_OR_GENE_PRODUCT", 7, 10], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 29, 37], ["Cys-344", "AMINO_ACID", 41, 48], ["Met-358", "GENE_OR_GENE_PRODUCT", 96, 103], ["AAT", "GENE_OR_GENE_PRODUCT", 107, 110], ["NE", "PROTEIN", 0, 2], ["PR3", "PROTEIN", 7, 10], ["RCL", "PROTEIN", 22, 25], ["SERPINB1", "PROTEIN", 29, 37], ["P1 position", "DNA", 66, 77], ["Met", "PROTEIN", 96, 99], ["AAT", "PROTEIN", 107, 110], ["Cys", "TEST", 41, 44], ["Met", "TEST", 96, 99], ["AAT", "TEST", 107, 110]]], ["In contrast, CG and other chymotrypsin-like proteases cleave the reactive center loop (RCL) of SERPINB1 at Phe-343 (Cooley et al. 2001) .", [["Phe", "CHEMICAL", 107, 110], ["Phe", "CHEMICAL", 107, 110], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 26, 38], ["chymotrypsin-like proteases", "PROTEIN", 26, 53], ["RCL", "PROTEIN", 87, 90], ["SERPINB1", "PROTEIN", 95, 103], ["CG", "TEST", 13, 15], ["other chymotrypsin", "TREATMENT", 20, 38], ["proteases", "TREATMENT", 44, 53], ["reactive", "OBSERVATION_MODIFIER", 65, 73]]], ["SERPINB1 is expressed in most tissues with higher levels in lymphoid organs such as the bone marrow and the spleen as well as in the pancreas and the lungs.", [["tissues", "ANATOMY", 30, 37], ["lymphoid organs", "ANATOMY", 60, 75], ["bone marrow", "ANATOMY", 88, 99], ["spleen", "ANATOMY", 108, 114], ["pancreas", "ANATOMY", 133, 141], ["lungs", "ANATOMY", 150, 155], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 0, 8], ["tissues", "TISSUE", 30, 37], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 60, 75], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 88, 99], ["spleen", "ORGAN", 108, 114], ["pancreas", "ORGAN", 133, 141], ["lungs", "ORGAN", 150, 155], ["SERPINB1", "PROTEIN", 0, 8], ["most tissues", "OBSERVATION_MODIFIER", 25, 37], ["higher levels", "OBSERVATION", 43, 56], ["lymphoid organs", "OBSERVATION", 60, 75], ["bone marrow", "ANATOMY", 88, 99], ["spleen", "ANATOMY", 108, 114], ["pancreas", "ANATOMY", 133, 141], ["lungs", "ANATOMY", 150, 155]]], ["In hematopoietic cells, SERPINB1 is expressed in stem cells, all leukocyte lineages, and platelets.", [["hematopoietic cells", "ANATOMY", 3, 22], ["stem cells", "ANATOMY", 49, 59], ["leukocyte", "ANATOMY", 65, 74], ["platelets", "ANATOMY", 89, 98], ["hematopoietic cells", "CELL", 3, 22], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 24, 32], ["stem cells", "CELL", 49, 59], ["leukocyte", "CELL", 65, 74], ["platelets", "CELL", 89, 98], ["hematopoietic cells", "CELL_TYPE", 3, 22], ["SERPINB1", "PROTEIN", 24, 32], ["stem cells", "CELL_TYPE", 49, 59], ["leukocyte lineages", "CELL_TYPE", 65, 83], ["platelets", "CELL_TYPE", 89, 98], ["SERPINB1", "TEST", 24, 32], ["all leukocyte lineages", "TEST", 61, 83], ["platelets", "TEST", 89, 98], ["hematopoietic cells", "OBSERVATION", 3, 22], ["stem cells", "OBSERVATION", 49, 59], ["leukocyte lineages", "OBSERVATION", 65, 83]]], ["SERPINB1 levels are the highest in the neutrophil lineage, where highest mRNA expression is found in the early stages of granulopoiesis and protein levels remain high in bone marrow and blood neutrophils (Benarafa et al. 2002; Missen et al. 2006) .", [["neutrophil lineage", "ANATOMY", 39, 57], ["bone marrow", "ANATOMY", 170, 181], ["blood neutrophils", "ANATOMY", 186, 203], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 0, 8], ["neutrophil lineage", "CELL", 39, 57], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 170, 181], ["blood neutrophils", "ORGANISM_SUBSTANCE", 186, 203], ["SERPINB1", "PROTEIN", 0, 8], ["neutrophil lineage", "CELL_TYPE", 39, 57], ["blood neutrophils", "CELL_TYPE", 186, 203], ["SERPINB1 levels", "TEST", 0, 15], ["the neutrophil lineage", "TEST", 35, 57], ["highest mRNA expression", "PROBLEM", 65, 88], ["granulopoiesis", "PROBLEM", 121, 135], ["protein levels", "TEST", 140, 154], ["bone marrow", "TEST", 170, 181], ["blood neutrophils", "TEST", 186, 203], ["highest", "OBSERVATION_MODIFIER", 24, 31], ["neutrophil lineage", "OBSERVATION", 39, 57], ["early stages", "OBSERVATION_MODIFIER", 105, 117], ["granulopoiesis", "OBSERVATION", 121, 135], ["high", "OBSERVATION_MODIFIER", 162, 166], ["bone marrow", "ANATOMY", 170, 181]]], ["Its role in neutrophil homeostasis is further described below.Intracellular Clade B SerpinsSERPINB6, previously described as proteinase inhibitor-6 (PI-6), inhibits CG but not NE and PR3 (Scott et al. 1999) .", [["neutrophil", "ANATOMY", 12, 22], ["PI-6", "CHEMICAL", 149, 153], ["neutrophil", "CELL", 12, 22], ["Clade B SerpinsSERPINB6", "GENE_OR_GENE_PRODUCT", 76, 99], ["proteinase inhibitor-6", "GENE_OR_GENE_PRODUCT", 125, 147], ["PI-6", "GENE_OR_GENE_PRODUCT", 149, 153], ["CG", "SIMPLE_CHEMICAL", 165, 167], ["NE", "SIMPLE_CHEMICAL", 176, 178], ["PR3", "GENE_OR_GENE_PRODUCT", 183, 186], ["neutrophil", "CELL_TYPE", 12, 22], ["Clade B SerpinsSERPINB6", "PROTEIN", 76, 99], ["NE", "PROTEIN", 176, 178], ["PR3", "PROTEIN", 183, 186], ["Intracellular Clade B SerpinsSERPINB6", "TREATMENT", 62, 99], ["proteinase inhibitor", "TEST", 125, 145], ["PI", "TEST", 149, 151], ["neutrophil homeostasis", "OBSERVATION", 12, 34], ["Clade", "OBSERVATION", 76, 81]]], ["SERPINB6 is also broadly expressed in various tissues and cells with high levels in all myeloid cells with relatively higher levels in monocytic/dendritic cells (Scarff et al. 2003; Missen et al. 2006) .Intracellular Clade B SerpinsFirst identified as squamous cell carcinoma antigen (SCCA), SERPINB4 (SCCA2) is also an inhibitor of CG but with slower association rate constants than SERPINB6 and SERPINB1 (Schick et al. 1997 ).", [["tissues", "ANATOMY", 46, 53], ["cells", "ANATOMY", 58, 63], ["myeloid cells", "ANATOMY", 88, 101], ["monocytic/dendritic cells", "ANATOMY", 135, 160], ["squamous cell carcinoma", "ANATOMY", 252, 275], ["squamous cell carcinoma", "DISEASE", 252, 275], ["SERPINB6", "GENE_OR_GENE_PRODUCT", 0, 8], ["tissues", "TISSUE", 46, 53], ["cells", "CELL", 58, 63], ["myeloid cells", "CELL", 88, 101], ["monocytic", "CELL", 135, 144], ["dendritic cells", "CELL", 145, 160], ["squamous cell carcinoma", "CANCER", 252, 275], ["antigen", "GENE_OR_GENE_PRODUCT", 276, 283], ["SCCA", "GENE_OR_GENE_PRODUCT", 285, 289], ["SERPINB4", "GENE_OR_GENE_PRODUCT", 292, 300], ["SCCA2", "GENE_OR_GENE_PRODUCT", 302, 307], ["SERPINB6", "PROTEIN", 0, 8], ["myeloid cells", "CELL_TYPE", 88, 101], ["monocytic/dendritic cells", "CELL_TYPE", 135, 160], ["Clade B SerpinsFirst", "PROTEIN", 217, 237], ["squamous cell carcinoma antigen", "PROTEIN", 252, 283], ["SCCA", "PROTEIN", 285, 289], ["SERPINB4", "PROTEIN", 292, 300], ["SCCA2", "PROTEIN", 302, 307], ["high levels in all myeloid cells", "PROBLEM", 69, 101], ["monocytic/dendritic cells", "PROBLEM", 135, 160], ["Intracellular Clade B SerpinsFirst", "TEST", 203, 237], ["squamous cell carcinoma antigen (SCCA)", "PROBLEM", 252, 290], ["an inhibitor of CG", "PROBLEM", 317, 335], ["slower association rate constants", "PROBLEM", 345, 378], ["SERPINB6", "TREATMENT", 384, 392], ["various tissues", "ANATOMY", 38, 53], ["high", "OBSERVATION_MODIFIER", 69, 73], ["myeloid cells", "OBSERVATION", 88, 101], ["higher", "OBSERVATION_MODIFIER", 118, 124], ["monocytic", "OBSERVATION_MODIFIER", 135, 144], ["dendritic cells", "OBSERVATION", 145, 160], ["Clade", "OBSERVATION", 217, 222], ["squamous cell carcinoma", "OBSERVATION", 252, 275]]], ["Its closest homolog in mice, serpinb3a, also inhibits CG but is not expressed in hematopoietic cells (Al-Khunaizi et al. 2002; Askew et al. 2004 ).Non-serpin Inhibitors of NSPs\u03b12-Macroglobulin (\u03b12M) is a very large (725 kDa) protease inhibitor found in plasma.", [["hematopoietic cells", "ANATOMY", 81, 100], ["plasma", "ANATOMY", 253, 259], ["NSPs\u03b12-Macroglobulin", "CHEMICAL", 172, 192], ["mice", "ORGANISM", 23, 27], ["serpinb3a", "GENE_OR_GENE_PRODUCT", 29, 38], ["CG", "GENE_OR_GENE_PRODUCT", 54, 56], ["hematopoietic cells", "CELL", 81, 100], ["NSPs\u03b12-Macroglobulin", "GENE_OR_GENE_PRODUCT", 172, 192], ["\u03b12M", "GENE_OR_GENE_PRODUCT", 194, 197], ["plasma", "ORGANISM_SUBSTANCE", 253, 259], ["serpinb3a", "PROTEIN", 29, 38], ["CG", "DNA", 54, 56], ["hematopoietic cells", "CELL_TYPE", 81, 100], ["Macroglobulin", "PROTEIN", 179, 192], ["\u03b12M", "PROTEIN", 194, 197], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["NSPs", "TEST", 172, 176], ["Macroglobulin", "TEST", 179, 192], ["protease inhibitor", "TREATMENT", 225, 243], ["hematopoietic cells", "OBSERVATION", 81, 100]]], ["It inhibits NSPs as well as many other serine proteases by a cleavageinduced conformational change that traps the proteases into a cavity within \u03b12M (Barrett and Starkey 1973) .", [["serine", "CHEMICAL", 39, 45], ["NSPs", "GENE_OR_GENE_PRODUCT", 12, 16], ["\u03b12M", "GENE_OR_GENE_PRODUCT", 145, 148], ["NSPs", "PROTEIN", 12, 16], ["serine proteases", "PROTEIN", 39, 55], ["proteases", "PROTEIN", 114, 123], ["\u03b12M", "PROTEIN", 145, 148], ["NSPs", "PROBLEM", 12, 16], ["many other serine proteases", "PROBLEM", 28, 55], ["a cleavageinduced conformational change", "TREATMENT", 59, 98], ["NSPs", "OBSERVATION", 12, 16], ["cavity", "ANATOMY", 131, 137]]], ["In contrast to serpin-protease complexes, proteases trapped by \u03b12M can still cleave small molecular weight substrates that can reach the proteolytic domain of the protease.", [["serpin-protease", "GENE_OR_GENE_PRODUCT", 15, 30], ["\u03b12M", "GENE_OR_GENE_PRODUCT", 63, 66], ["serpin", "PROTEIN", 15, 21], ["protease complexes", "PROTEIN", 22, 40], ["proteases", "PROTEIN", 42, 51], ["\u03b12M", "PROTEIN", 63, 66], ["proteolytic domain", "PROTEIN", 137, 155], ["protease", "PROTEIN", 163, 171], ["serpin-protease complexes", "TREATMENT", 15, 40], ["proteases", "TREATMENT", 42, 51], ["small molecular weight substrates", "PROBLEM", 84, 117], ["the protease", "TREATMENT", 159, 171]]], ["Because of its large size, the diffusion of \u03b12M into tissues during inflammation was considered to be limited and its realm of activity is thus likely limited to the blood circulation, where it regulates fibrinolysis, coagulation, complement, and NSPs (de Boer et al. 1993) .", [["tissues", "ANATOMY", 53, 60], ["blood", "ANATOMY", 166, 171], ["\u03b12M", "CHEMICAL", 44, 47], ["inflammation", "DISEASE", 68, 80], ["\u03b12M", "GENE_OR_GENE_PRODUCT", 44, 47], ["tissues", "TISSUE", 53, 60], ["blood", "ORGANISM_SUBSTANCE", 166, 171], ["\u03b12M", "PROTEIN", 44, 47], ["inflammation", "PROBLEM", 68, 80], ["large", "OBSERVATION_MODIFIER", 15, 20], ["size", "OBSERVATION_MODIFIER", 21, 25], ["inflammation", "OBSERVATION", 68, 80], ["fibrinolysis", "OBSERVATION", 204, 216]]], ["However, \u03b12M is found in the lung epithelial lining fluid in adult respiratory distress syndrome (ARDS), where it traps elastase and prevents cleavage of large substrates (Wewers et al. 1988) .Non-serpin Inhibitors of NSPsSecretory leukocyte protease inhibitor (SLPI) and elafin are two chelonianins that are secreted by epithelial cells and contribute to inhibition of extracellular NSPs at mucosal surfaces and in tissues (Sallenave 2010) .", [["lung epithelial lining fluid", "ANATOMY", 29, 57], ["epithelial cells", "ANATOMY", 321, 337], ["extracellular", "ANATOMY", 370, 383], ["mucosal surfaces", "ANATOMY", 392, 408], ["tissues", "ANATOMY", 416, 423], ["respiratory distress syndrome", "DISEASE", 67, 96], ["ARDS", "DISEASE", 98, 102], ["elafin", "CHEMICAL", 272, 278], ["elafin", "CHEMICAL", 272, 278], ["\u03b12M", "GENE_OR_GENE_PRODUCT", 9, 12], ["lung epithelial lining fluid", "TISSUE", 29, 57], ["elastase", "GENE_OR_GENE_PRODUCT", 120, 128], ["NSPsSecretory leukocyte protease inhibitor", "GENE_OR_GENE_PRODUCT", 218, 260], ["SLPI", "GENE_OR_GENE_PRODUCT", 262, 266], ["elafin", "SIMPLE_CHEMICAL", 272, 278], ["chelonianins", "GENE_OR_GENE_PRODUCT", 287, 299], ["epithelial cells", "CELL", 321, 337], ["extracellular NSPs", "CELLULAR_COMPONENT", 370, 388], ["mucosal surfaces", "TISSUE", 392, 408], ["tissues", "TISSUE", 416, 423], ["\u03b12M", "PROTEIN", 9, 12], ["elastase", "PROTEIN", 120, 128], ["NSPsSecretory leukocyte protease inhibitor", "PROTEIN", 218, 260], ["SLPI", "PROTEIN", 262, 266], ["epithelial cells", "CELL_TYPE", 321, 337], ["extracellular NSPs", "PROTEIN", 370, 388], ["the lung epithelial lining fluid", "PROBLEM", 25, 57], ["adult respiratory distress syndrome", "PROBLEM", 61, 96], ["ARDS", "PROBLEM", 98, 102], ["it traps elastase", "PROBLEM", 111, 128], ["large substrates", "PROBLEM", 154, 170], ["Non-serpin Inhibitors", "TREATMENT", 193, 214], ["NSPsSecretory leukocyte protease inhibitor", "TREATMENT", 218, 260], ["elafin", "TREATMENT", 272, 278], ["two chelonianins", "TREATMENT", 283, 299], ["epithelial cells", "PROBLEM", 321, 337], ["extracellular NSPs", "PROBLEM", 370, 388], ["lung", "ANATOMY", 29, 33], ["epithelial", "ANATOMY_MODIFIER", 34, 44], ["lining", "OBSERVATION_MODIFIER", 45, 51], ["fluid", "OBSERVATION", 52, 57], ["adult", "OBSERVATION_MODIFIER", 61, 66], ["respiratory distress syndrome", "OBSERVATION", 67, 96], ["ARDS", "OBSERVATION", 98, 102], ["large", "OBSERVATION_MODIFIER", 154, 159], ["epithelial cells", "OBSERVATION", 321, 337], ["extracellular NSPs", "OBSERVATION", 370, 388], ["mucosal surfaces", "ANATOMY", 392, 408], ["tissues", "ANATOMY", 416, 423]]], ["They use a reversible keyhole type of inhibition, where the small approximately 10 kDa inhibitors bind the catalytic pocket of the protease with high affinity.", [["catalytic pocket", "PROTEIN", 107, 123], ["protease", "PROTEIN", 131, 139], ["a reversible keyhole type of inhibition", "TREATMENT", 9, 48], ["the small approximately 10 kDa inhibitors", "TREATMENT", 56, 97], ["the protease", "TREATMENT", 127, 139], ["high affinity", "PROBLEM", 145, 158], ["small", "OBSERVATION_MODIFIER", 60, 65], ["catalytic pocket", "OBSERVATION", 107, 123], ["high affinity", "OBSERVATION", 145, 158]]], ["SLPI inhibits both NE and CG, while elafin inhibits NE and PR3.Non-serpin Inhibitors of NSPsThe relative importance of each inhibitor depends on expression levels, compartmentalization, and posttranslational modifications.", [["NE", "CHEMICAL", 19, 21], ["elafin", "CHEMICAL", 36, 42], ["NE", "CHEMICAL", 52, 54], ["elafin", "CHEMICAL", 36, 42], ["SLPI", "GENE_OR_GENE_PRODUCT", 0, 4], ["NE", "SIMPLE_CHEMICAL", 19, 21], ["CG", "SIMPLE_CHEMICAL", 26, 28], ["elafin", "SIMPLE_CHEMICAL", 36, 42], ["NE", "GENE_OR_GENE_PRODUCT", 52, 54], ["PR3", "GENE_OR_GENE_PRODUCT", 59, 62], ["NSPs", "GENE_OR_GENE_PRODUCT", 88, 92], ["SLPI", "PROTEIN", 0, 4], ["NE", "PROTEIN", 19, 21], ["NE", "PROTEIN", 52, 54], ["PR3", "PROTEIN", 59, 62], ["SLPI", "TEST", 0, 4], ["CG", "TEST", 26, 28], ["Non-serpin Inhibitors", "TREATMENT", 63, 84], ["NSPs", "TREATMENT", 88, 92], ["each inhibitor", "TREATMENT", 119, 133], ["expression levels", "TEST", 145, 162], ["posttranslational modifications", "OBSERVATION", 190, 221]]], ["In addition, because NSPs are usually released together, inhibitors that are inactivated by proteolysis by one NSP may be disarmed before inhibiting their target.", [["NSPs", "GENE_OR_GENE_PRODUCT", 21, 25], ["NSP", "GENE_OR_GENE_PRODUCT", 111, 114], ["NSPs", "PROTEIN", 21, 25], ["NSP", "PROTEIN", 111, 114], ["inhibitors", "TREATMENT", 57, 67]]], ["While redundancy and compensatory mechanisms are expected and observed between the different inhibitors, essential physiological functions have also been attributed to individual NSP inhibitors.5.3Neutrophil Death in Steady-State Conditions SERPINB1 has emerged as an important regulator of neutrophil survival.", [["neutrophil", "ANATOMY", 291, 301], ["NSP", "GENE_OR_GENE_PRODUCT", 179, 182], ["Neutrophil", "CELL", 197, 207], ["neutrophil", "CELL", 291, 301], ["SERPINB1", "PROTEIN", 241, 249], ["compensatory mechanisms", "PROBLEM", 21, 44], ["the different inhibitors", "TREATMENT", 79, 103], ["individual NSP inhibitors", "TREATMENT", 168, 193], ["Neutrophil Death", "PROBLEM", 197, 213], ["neutrophil survival", "TREATMENT", 291, 310], ["compensatory mechanisms", "OBSERVATION", 21, 44], ["Neutrophil Death", "OBSERVATION", 197, 213], ["neutrophil survival", "OBSERVATION", 291, 310]]], ["A cytoprotective function for intracellular serpins was postulated based on the presence of these inhibitors in cells carrying cell death-inducing granule proteases, such as granzymes (Bird 1999) .", [["intracellular", "ANATOMY", 30, 43], ["cells", "ANATOMY", 112, 117], ["cell", "ANATOMY", 127, 131], ["granule", "ANATOMY", 147, 154], ["death", "DISEASE", 132, 137], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 30, 43], ["cells", "CELL", 112, 117], ["cell", "CELL", 127, 131], ["granzymes", "GENE_OR_GENE_PRODUCT", 174, 183], ["intracellular serpins", "PROTEIN", 30, 51], ["cell death-inducing granule proteases", "PROTEIN", 127, 164], ["granzymes", "PROTEIN", 174, 183], ["A cytoprotective function", "TEST", 0, 25], ["intracellular serpins", "PROBLEM", 30, 51], ["these inhibitors", "TREATMENT", 92, 108], ["cell death", "PROBLEM", 127, 137], ["granule proteases", "PROBLEM", 147, 164], ["granule proteases", "OBSERVATION", 147, 164]]], ["In the case of SERPINB1, expression profiling during granulopoiesis supported this hypothesis since mRNA and protein levels of SERPINB1 peaked in promyelocyte and myelocyte stages, which coincided with the high but transient transcription of NSPs and other primary granule proteins (Theilgaard-M\u20ac onch et al. 2005; Benarafa et al. 2011) .", [["promyelocyte", "ANATOMY", 146, 158], ["myelocyte", "ANATOMY", 163, 172], ["primary granule", "ANATOMY", 257, 272], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 15, 23], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 127, 135], ["promyelocyte", "CELL", 146, 158], ["NSPs", "GENE_OR_GENE_PRODUCT", 242, 246], ["SERPINB1", "PROTEIN", 15, 23], ["SERPINB1", "PROTEIN", 127, 135], ["NSPs", "PROTEIN", 242, 246], ["primary granule proteins", "PROTEIN", 257, 281], ["SERPINB1", "TREATMENT", 15, 23], ["expression profiling during granulopoiesis", "PROBLEM", 25, 67], ["this hypothesis", "PROBLEM", 78, 93], ["mRNA and protein levels", "TEST", 100, 123], ["SERPINB1", "TEST", 127, 135], ["promyelocyte", "TEST", 146, 158], ["myelocyte stages", "PROBLEM", 163, 179], ["transient transcription of NSPs", "PROBLEM", 215, 246], ["granule proteins", "OBSERVATION", 265, 281]]], ["The evidence that SERPINB1 is cytoprotective for neutrophil has been elucidated in a series of studies of mice with a targeted deletion of serpinb1a (Benarafa et al. 2007) , the mouse ortholog of the human gene (Benarafa et al. 2002) .", [["neutrophil", "ANATOMY", 49, 59], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 18, 26], ["neutrophil", "CELL", 49, 59], ["mice", "ORGANISM", 106, 110], ["serpinb1a", "GENE_OR_GENE_PRODUCT", 139, 148], ["mouse", "ORGANISM", 178, 183], ["human", "ORGANISM", 200, 205], ["SERPINB1", "PROTEIN", 18, 26], ["neutrophil", "CELL_TYPE", 49, 59], ["mouse ortholog", "DNA", 178, 192], ["human gene", "DNA", 200, 210], ["mice", "SPECIES", 106, 110], ["mouse", "SPECIES", 178, 183], ["human", "SPECIES", 200, 205], ["mice", "SPECIES", 106, 110], ["mouse", "SPECIES", 178, 183], ["human", "SPECIES", 200, 205], ["neutrophil", "PROBLEM", 49, 59]]], ["In these mice, neutrophil numbers in the bone marrow are approximately 50 % of the levels of wild-type mice.", [["neutrophil", "ANATOMY", 15, 25], ["bone marrow", "ANATOMY", 41, 52], ["mice", "ORGANISM", 9, 13], ["neutrophil", "CELL", 15, 25], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 41, 52], ["mice", "ORGANISM", 103, 107], ["neutrophil", "CELL_TYPE", 15, 25], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 103, 107], ["neutrophil numbers", "TEST", 15, 33], ["neutrophil numbers", "OBSERVATION", 15, 33], ["bone marrow", "ANATOMY", 41, 52], ["approximately", "OBSERVATION_MODIFIER", 57, 70], ["50 %", "OBSERVATION_MODIFIER", 71, 75]]], ["The phenotype is highly penetrant as it is observed in 129S6 and C57BL/6J backgrounds.", [["C57BL/6J", "ORGANISM", 65, 73], ["highly", "OBSERVATION_MODIFIER", 17, 23], ["penetrant", "OBSERVATION", 24, 33]]], ["Circulating blood neutrophil numbers in serpinb1a \u00c0/\u00c0 mice are only marginally lower than in wild-type mice in normal conditions, but a faster decline in circulating neutrophils is observed after myeloablation with cyclophosphamide (Benarafa et al. 2011) .", [["blood neutrophil", "ANATOMY", 12, 28], ["neutrophils", "ANATOMY", 166, 177], ["cyclophosphamide", "CHEMICAL", 215, 231], ["cyclophosphamide", "CHEMICAL", 215, 231], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["neutrophil", "CELL", 18, 28], ["serpinb1a", "GENE_OR_GENE_PRODUCT", 40, 49], ["mice", "ORGANISM", 103, 107], ["neutrophils", "CELL", 166, 177], ["cyclophosphamide", "SIMPLE_CHEMICAL", 215, 231], ["circulating neutrophils", "CELL_TYPE", 154, 177], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 54, 58], ["Circulating blood neutrophil numbers", "TEST", 0, 36], ["serpinb1a", "TEST", 40, 49], ["a faster decline in circulating neutrophils", "PROBLEM", 134, 177], ["cyclophosphamide", "TREATMENT", 215, 231], ["neutrophil numbers", "OBSERVATION", 18, 36], ["marginally", "OBSERVATION_MODIFIER", 68, 78], ["lower", "OBSERVATION_MODIFIER", 79, 84], ["normal conditions", "OBSERVATION_MODIFIER", 111, 128], ["circulating neutrophils", "OBSERVATION", 154, 177]]], ["In mice, reduction of neutrophil numbers in the bone marrow is physiologically relevant as it holds over 90 % of mature neutrophils.", [["neutrophil", "ANATOMY", 22, 32], ["bone marrow", "ANATOMY", 48, 59], ["neutrophils", "ANATOMY", 120, 131], ["mice", "ORGANISM", 3, 7], ["neutrophil", "CELL", 22, 32], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 48, 59], ["neutrophils", "CELL", 120, 131], ["neutrophil", "CELL_TYPE", 22, 32], ["mature neutrophils", "CELL_TYPE", 113, 131], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["neutrophil numbers", "TEST", 22, 40], ["reduction", "OBSERVATION_MODIFIER", 9, 18], ["neutrophil numbers", "OBSERVATION", 22, 40], ["bone marrow", "ANATOMY", 48, 59], ["neutrophils", "OBSERVATION", 120, 131]]], ["Indeed, laboratory strains of mice have on average 1 \u00c2 10 6 neutrophils/ml of blood with a total volume of 2 ml; and a mouse femur represents approximately 6 % of the total bone marrow and contains 4-6 \u00c2 10 6 neutrophils depending on the mouse strain.", [["neutrophils", "ANATOMY", 60, 71], ["blood", "ANATOMY", 78, 83], ["femur", "ANATOMY", 125, 130], ["bone marrow", "ANATOMY", 173, 184], ["neutrophils", "ANATOMY", 209, 220], ["mice", "ORGANISM", 30, 34], ["neutrophils", "CELL", 60, 71], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["mouse", "ORGANISM", 119, 124], ["femur", "ORGAN", 125, 130], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 173, 184], ["neutrophils", "CELL", 209, 220], ["mouse", "ORGANISM", 238, 243], ["neutrophils", "CELL_TYPE", 209, 220], ["mice", "SPECIES", 30, 34], ["mouse", "SPECIES", 119, 124], ["mouse", "SPECIES", 238, 243], ["mice", "SPECIES", 30, 34], ["mouse", "SPECIES", 119, 124], ["mouse", "SPECIES", 238, 243], ["neutrophils", "TEST", 60, 71], ["blood", "TEST", 78, 83], ["a total volume", "TEST", 89, 103], ["the total bone marrow", "TEST", 163, 184], ["the mouse strain", "PROBLEM", 234, 250], ["femur", "ANATOMY", 125, 130], ["bone marrow", "ANATOMY", 173, 184]]], ["Neutropenia in serpinb1a \u00c0/\u00c0 mice is due to a cell intrinsic survival defect affecting differentiated neutrophils, while the development of mitotic neutrophil precursors is normal (Benarafa et al. 2011) .", [["cell", "ANATOMY", 46, 50], ["neutrophils", "ANATOMY", 102, 113], ["mitotic neutrophil precursors", "ANATOMY", 140, 169], ["Neutropenia", "DISEASE", 0, 11], ["serpinb1a", "GENE_OR_GENE_PRODUCT", 15, 24], ["\u00c0/\u00c0 mice", "ORGANISM", 25, 33], ["cell", "CELL", 46, 50], ["neutrophils", "CELL", 102, 113], ["neutrophil", "CELL", 148, 158], ["differentiated neutrophils", "CELL_TYPE", 87, 113], ["mitotic neutrophil precursors", "CELL_TYPE", 140, 169], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["Neutropenia", "PROBLEM", 0, 11], ["a cell intrinsic survival defect", "PROBLEM", 44, 76], ["differentiated neutrophils", "PROBLEM", 87, 113], ["mitotic neutrophil precursors", "TEST", 140, 169], ["survival defect", "OBSERVATION", 61, 76], ["differentiated neutrophils", "OBSERVATION", 87, 113], ["mitotic neutrophil precursors", "OBSERVATION", 140, 169]]], ["The mechanism of cell death in the absence of serpinb1a is dependent on CG in steady state in vivo.", [["cell", "ANATOMY", 17, 21], ["death", "DISEASE", 22, 27], ["cell", "CELL", 17, 21], ["serpinb1a", "GENE_OR_GENE_PRODUCT", 46, 55], ["CG", "SIMPLE_CHEMICAL", 72, 74], ["serpinb1a", "PROTEIN", 46, 55], ["cell death", "PROBLEM", 17, 27], ["cell death", "OBSERVATION", 17, 27]]], ["Indeed, neutropenia in serpinb1a \u00c0/\u00c0 mice was fully rescued by deficiency in CG (Ctsg \u00c0/\u00c0 ).", [["neutropenia", "DISEASE", 8, 19], ["serpinb1a \u00c0/\u00c0 mice", "ORGANISM", 23, 41], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["neutropenia", "PROBLEM", 8, 19], ["deficiency in CG", "PROBLEM", 63, 79], ["neutropenia", "OBSERVATION", 8, 19]]], ["In contrast, NE deficiency had no effect on neutrophil survival in serpinb1a \u00c0/\u00c0 mice (Baumann et al. 2013 ).", [["neutrophil", "ANATOMY", 44, 54], ["NE", "CHEMICAL", 13, 15], ["NE", "SIMPLE_CHEMICAL", 13, 15], ["neutrophil", "CELL", 44, 54], ["serpinb1a", "ORGANISM", 67, 76], ["NE", "PROTEIN", 13, 15], ["neutrophil", "CELL_TYPE", 44, 54], ["mice", "SPECIES", 81, 85], ["NE deficiency", "PROBLEM", 13, 26], ["neutrophil survival", "TREATMENT", 44, 63], ["NE deficiency", "OBSERVATION", 13, 26], ["no", "UNCERTAINTY", 31, 33], ["effect", "OBSERVATION_MODIFIER", 34, 40]]], ["Competitive stem cell transplantation of irradiated mice showed a survival advantage of wild-type neutrophils over serpinb1a \u00c0/\u00c0 neutrophils but not over Ctsg \u00c0/\u00c0 .serpinb1a \u00c0/\u00c0 double-deficient neutrophils.", [["stem cell", "ANATOMY", 12, 21], ["neutrophils", "ANATOMY", 98, 109], ["serpinb1a \u00c0/\u00c0 neutrophils", "ANATOMY", 115, 140], ["neutrophils", "ANATOMY", 195, 206], ["stem cell", "CELL", 12, 21], ["mice", "ORGANISM", 52, 56], ["neutrophils", "CELL", 98, 109], ["serpinb1a \u00c0/\u00c0 neutrophils", "CELL", 115, 140], ["Ctsg", "GENE_OR_GENE_PRODUCT", 154, 158], ["\u00c0", "GENE_OR_GENE_PRODUCT", 161, 162], ["\u00c0", "GENE_OR_GENE_PRODUCT", 176, 177], ["neutrophils", "CELL", 195, 206], ["wild-type neutrophils", "CELL_TYPE", 88, 109], ["serpinb1a \u00c0/\u00c0 neutrophils", "CELL_LINE", 115, 140], ["Ctsg \u00c0/\u00c0 .serpinb1a \u00c0/\u00c0 double-deficient neutrophils", "CELL_LINE", 154, 206], ["mice", "SPECIES", 52, 56], ["mice", "SPECIES", 52, 56], ["Competitive stem cell transplantation", "TREATMENT", 0, 37], ["type neutrophils", "PROBLEM", 93, 109], ["serpinb1a", "TEST", 115, 124], ["neutrophils", "TEST", 129, 140], ["Ctsg", "TEST", 154, 158], [".serpinb1a", "TEST", 163, 173], ["stem cell transplantation", "OBSERVATION", 12, 37]]], ["These mixed bone marrow chimera experiments demonstrated that neutrophil death was cell intrinsic in vivo and support intracellular leakage of granule proteins in mature neutrophils as a mechanism of cell death in the absence of SERPINB1.", [["bone marrow", "ANATOMY", 12, 23], ["neutrophil", "ANATOMY", 62, 72], ["cell", "ANATOMY", 83, 87], ["intracellular", "ANATOMY", 118, 131], ["granule", "ANATOMY", 143, 150], ["neutrophils", "ANATOMY", 170, 181], ["cell", "ANATOMY", 200, 204], ["death", "DISEASE", 73, 78], ["death", "DISEASE", 205, 210], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 12, 23], ["neutrophil", "CELL", 62, 72], ["cell", "CELL", 83, 87], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 118, 131], ["neutrophils", "CELL", 170, 181], ["cell", "CELL", 200, 204], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 229, 237], ["granule proteins", "PROTEIN", 143, 159], ["mature neutrophils", "CELL_TYPE", 163, 181], ["SERPINB1", "PROTEIN", 229, 237], ["These mixed bone marrow chimera experiments", "PROBLEM", 0, 43], ["neutrophil death", "PROBLEM", 62, 78], ["cell intrinsic in vivo", "PROBLEM", 83, 105], ["intracellular leakage of granule proteins", "PROBLEM", 118, 159], ["mature neutrophils", "PROBLEM", 163, 181], ["cell death", "PROBLEM", 200, 210], ["mixed", "OBSERVATION_MODIFIER", 6, 11], ["bone marrow chimera", "OBSERVATION", 12, 31], ["neutrophil death", "OBSERVATION", 62, 78], ["leakage", "OBSERVATION_MODIFIER", 132, 139], ["granule proteins", "OBSERVATION", 143, 159], ["mature neutrophils", "OBSERVATION", 163, 181], ["cell death", "OBSERVATION", 200, 210]]], ["Importantly, mice lacking one or all three NSPs, as in dppi \u00c0/\u00c0 mice, do not present increased neutrophil numbers in bone marrow and blood.", [["neutrophil", "ANATOMY", 95, 105], ["bone marrow", "ANATOMY", 117, 128], ["blood", "ANATOMY", 133, 138], ["mice", "ORGANISM", 13, 17], ["NSPs", "GENE_OR_GENE_PRODUCT", 43, 47], ["dppi", "GENE_OR_GENE_PRODUCT", 55, 59], ["neutrophil", "CELL", 95, 105], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 117, 128], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["NSPs", "PROTEIN", 43, 47], ["neutrophil", "CELL_TYPE", 95, 105], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 13, 17], ["increased neutrophil numbers in bone marrow", "PROBLEM", 85, 128], ["increased", "OBSERVATION_MODIFIER", 85, 94], ["neutrophil numbers", "OBSERVATION", 95, 113], ["bone marrow", "ANATOMY", 117, 128]]], ["These findings indicate that in homeostatic conditions, neutrophil homeostasis is not critically regulated by NSPs unless the intracellular anti-protease shield is deficient.5.3SERPINB6 may also contribute to neutrophil homeostasis in steady state as it is expressed in the cytoplasm of neutrophils and inhibits CG.", [["neutrophil", "ANATOMY", 56, 66], ["intracellular", "ANATOMY", 126, 139], ["neutrophil", "ANATOMY", 209, 219], ["cytoplasm", "ANATOMY", 274, 283], ["neutrophils", "ANATOMY", 287, 298], ["neutrophil", "CELL", 56, 66], ["NSPs", "GENE_OR_GENE_PRODUCT", 110, 114], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 126, 139], ["SERPINB6", "GENE_OR_GENE_PRODUCT", 177, 185], ["neutrophil", "CELL", 209, 219], ["cytoplasm", "ORGANISM_SUBSTANCE", 274, 283], ["neutrophils", "CELL", 287, 298], ["NSPs", "PROTEIN", 110, 114], ["SERPINB6", "PROTEIN", 177, 185], ["neutrophils", "CELL_TYPE", 287, 298], ["neutrophil homeostasis", "TEST", 56, 78], ["the intracellular anti-protease shield", "TREATMENT", 122, 160], ["neutrophil homeostasis", "PROBLEM", 209, 231], ["homeostatic conditions", "OBSERVATION", 32, 54], ["neutrophil homeostasis", "OBSERVATION", 56, 78], ["may also contribute to", "UNCERTAINTY", 186, 208], ["neutrophil homeostasis", "OBSERVATION", 209, 231]]], ["However, mice deficient in serpinb6a, the ortholog of the human gene (Kaiserman et al. 2002) , do not present an obvious defect in neutrophil numbers in vivo (Scarff et al. 2004) .", [["neutrophil", "ANATOMY", 131, 141], ["mice", "ORGANISM", 9, 13], ["serpinb6a", "GENE_OR_GENE_PRODUCT", 27, 36], ["human", "ORGANISM", 58, 63], ["neutrophil", "CELL", 131, 141], ["serpinb6a", "PROTEIN", 27, 36], ["human gene", "DNA", 58, 68], ["neutrophil", "CELL_TYPE", 131, 141], ["mice", "SPECIES", 9, 13], ["human", "SPECIES", 58, 63], ["mice", "SPECIES", 9, 13], ["human", "SPECIES", 58, 63], ["mice deficient in serpinb6a", "PROBLEM", 9, 36], ["an obvious defect in neutrophil numbers", "PROBLEM", 110, 149], ["obvious", "OBSERVATION_MODIFIER", 113, 120], ["defect", "OBSERVATION", 121, 127], ["neutrophil numbers", "OBSERVATION", 131, 149]]], ["This somewhat surprising result may be explained by a compensatory increase in serpinb1a expression in bone marrow cells of serpinb6a \u00c0/\u00c0 mice.", [["bone marrow cells", "ANATOMY", 103, 120], ["serpinb1a", "GENE_OR_GENE_PRODUCT", 79, 88], ["bone marrow cells", "CELL", 103, 120], ["serpinb6a \u00c0/\u00c0 mice", "ORGANISM", 124, 142], ["serpinb1a", "PROTEIN", 79, 88], ["bone marrow cells", "CELL_TYPE", 103, 120], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 138, 142], ["a compensatory increase in serpinb1a expression in bone marrow cells", "PROBLEM", 52, 120], ["may be explained", "UNCERTAINTY", 32, 48], ["compensatory", "OBSERVATION_MODIFIER", 54, 66], ["increase", "OBSERVATION_MODIFIER", 67, 75], ["serpinb1a expression", "OBSERVATION", 79, 99], ["bone", "ANATOMY", 103, 107], ["marrow cells", "OBSERVATION", 108, 120]]], ["The characterization of mice deficient in the two serpins may reveal complementary functions.Spontaneous Neutrophil Death In VitroMechanisms regulating neutrophil cell death are often investigated in vitro, where isolated neutrophils rapidly die by caspase-dependent apoptosis.", [["Neutrophil", "ANATOMY", 105, 115], ["neutrophil cell", "ANATOMY", 152, 167], ["neutrophils", "ANATOMY", 222, 233], ["death", "DISEASE", 168, 173], ["mice", "ORGANISM", 24, 28], ["serpins", "GENE_OR_GENE_PRODUCT", 50, 57], ["Neutrophil", "CELL", 105, 115], ["neutrophil cell", "CELL", 152, 167], ["neutrophils", "CELL", 222, 233], ["caspase", "GENE_OR_GENE_PRODUCT", 249, 256], ["serpins", "PROTEIN", 50, 57], ["neutrophils", "CELL_TYPE", 222, 233], ["caspase", "PROTEIN", 249, 256], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 24, 28], ["mice deficient", "PROBLEM", 24, 38], ["Spontaneous Neutrophil Death", "PROBLEM", 93, 121], ["neutrophil cell death", "PROBLEM", 152, 173], ["isolated neutrophils", "PROBLEM", 213, 233], ["caspase", "TEST", 249, 256], ["dependent apoptosis", "PROBLEM", 257, 276], ["Neutrophil Death", "OBSERVATION", 105, 121], ["neutrophil cell death", "OBSERVATION", 152, 173], ["dependent", "OBSERVATION_MODIFIER", 257, 266], ["apoptosis", "OBSERVATION", 267, 276]]], ["This process is often referred to as spontaneous apoptosis.", [["spontaneous apoptosis", "PROBLEM", 37, 58], ["apoptosis", "OBSERVATION", 49, 58]]], ["The survival of isolated neutrophils can be extended by addition of synthetic caspase inhibitors or by acting on upstream survival pathways.", [["neutrophils", "ANATOMY", 25, 36], ["neutrophils", "CELL", 25, 36], ["caspase", "GENE_OR_GENE_PRODUCT", 78, 85], ["isolated neutrophils", "CELL_TYPE", 16, 36], ["isolated neutrophils", "PROBLEM", 16, 36], ["synthetic caspase inhibitors", "TREATMENT", 68, 96], ["isolated neutrophils", "OBSERVATION", 16, 36]]], ["Serpinb1a \u00c0/\u00c0 neutrophils also demonstrate reduced survival in vitro that is only partly inhibited by caspase inhibitors.", [["neutrophils", "ANATOMY", 14, 25], ["Serpinb1a", "GENE_OR_GENE_PRODUCT", 0, 9], ["caspase", "GENE_OR_GENE_PRODUCT", 102, 109], ["Serpinb1a \u00c0/\u00c0 neutrophils", "CELL_LINE", 0, 25], ["Serpinb1a \u00c0/\u00c0 neutrophils", "TEST", 0, 25], ["caspase inhibitors", "TREATMENT", 102, 120], ["reduced", "OBSERVATION_MODIFIER", 43, 50], ["survival", "OBSERVATION", 51, 59]]], ["In contrast, the survival defect is fully rescued if neutrophils are concomitantly deficient in CG, indicating that in the absence of serpinb1, CG induce neutrophil death through both caspasedependent and caspase-independent pathways.", [["neutrophils", "ANATOMY", 53, 64], ["neutrophil", "ANATOMY", 154, 164], ["death", "DISEASE", 165, 170], ["neutrophils", "CELL", 53, 64], ["CG", "PATHOLOGICAL_FORMATION", 96, 98], ["serpinb1", "GENE_OR_GENE_PRODUCT", 134, 142], ["CG", "SIMPLE_CHEMICAL", 144, 146], ["neutrophil", "CELL", 154, 164], ["caspase", "GENE_OR_GENE_PRODUCT", 205, 212], ["neutrophils", "CELL_TYPE", 53, 64], ["serpinb1", "PROTEIN", 134, 142], ["caspase", "PROTEIN", 205, 212], ["the survival defect", "PROBLEM", 13, 32], ["neutrophils", "PROBLEM", 53, 64], ["serpinb1", "TREATMENT", 134, 142], ["neutrophil death", "PROBLEM", 154, 170], ["survival defect", "OBSERVATION", 17, 32], ["neutrophil death", "OBSERVATION", 154, 170]]], ["While CG has been shown to activate caspase-7 (Zhou and Salvesen 1997) , the targets of CG leading to caspaseindependent cell death are not yet know.", [["cell", "ANATOMY", 121, 125], ["CG", "CHEMICAL", 6, 8], ["death", "DISEASE", 126, 131], ["caspase-7", "GENE_OR_GENE_PRODUCT", 36, 45], ["CG", "GENE_OR_GENE_PRODUCT", 88, 90], ["cell", "CELL", 121, 125], ["caspase-7", "PROTEIN", 36, 45], ["caspase", "TEST", 36, 43], ["caspaseindependent cell death", "PROBLEM", 102, 131]]], ["Interestingly, isolated neutrophils of mice deficient in PR3 (prtn3 \u00c0/\u00c0 ) show improved survival in vitro compared to WT neutrophils and PR3 is found in the cytoplasm of aging neutrophils in vitro.", [["neutrophils", "ANATOMY", 24, 35], ["neutrophils", "ANATOMY", 121, 132], ["cytoplasm", "ANATOMY", 157, 166], ["neutrophils", "ANATOMY", 176, 187], ["neutrophils", "CELL", 24, 35], ["mice", "ORGANISM", 39, 43], ["PR3", "GENE_OR_GENE_PRODUCT", 57, 60], ["prtn3", "GENE_OR_GENE_PRODUCT", 62, 67], ["\u00c0", "GENE_OR_GENE_PRODUCT", 70, 71], ["neutrophils", "CELL", 121, 132], ["PR3", "GENE_OR_GENE_PRODUCT", 137, 140], ["cytoplasm", "ORGANISM_SUBSTANCE", 157, 166], ["neutrophils", "CELL", 176, 187], ["isolated neutrophils", "CELL_TYPE", 15, 35], ["PR3", "PROTEIN", 57, 60], ["prtn3 \u00c0", "PROTEIN", 62, 69], ["\u00c0", "PROTEIN", 70, 71], ["WT neutrophils", "CELL_TYPE", 118, 132], ["PR3", "PROTEIN", 137, 140], ["aging neutrophils", "CELL_TYPE", 170, 187], ["mice", "SPECIES", 39, 43], ["mice", "SPECIES", 39, 43], ["mice deficient", "PROBLEM", 39, 53], ["PR3", "TEST", 57, 60], ["WT neutrophils", "TEST", 118, 132], ["PR3", "TEST", 137, 140], ["neutrophils", "OBSERVATION_MODIFIER", 24, 35], ["improved", "OBSERVATION_MODIFIER", 79, 87], ["survival", "OBSERVATION_MODIFIER", 88, 96], ["aging neutrophils", "OBSERVATION", 170, 187]]], ["Inhibitory complexes between PR3 and serpinb1 are found in the cytoplasm of aging neutrophils, supporting the notion that granule leakage promotes cell death.", [["cytoplasm", "ANATOMY", 63, 72], ["neutrophils", "ANATOMY", 82, 93], ["granule", "ANATOMY", 122, 129], ["cell", "ANATOMY", 147, 151], ["death", "DISEASE", 152, 157], ["PR3", "GENE_OR_GENE_PRODUCT", 29, 32], ["serpinb1", "GENE_OR_GENE_PRODUCT", 37, 45], ["cytoplasm", "ORGANISM_SUBSTANCE", 63, 72], ["neutrophils", "CELL", 82, 93], ["granule", "CELLULAR_COMPONENT", 122, 129], ["cell", "CELL", 147, 151], ["PR3", "PROTEIN", 29, 32], ["serpinb1", "PROTEIN", 37, 45], ["aging neutrophils", "CELL_TYPE", 76, 93], ["Inhibitory complexes between PR3", "PROBLEM", 0, 32], ["serpinb1", "TREATMENT", 37, 45], ["granule leakage promotes cell death", "PROBLEM", 122, 157], ["aging neutrophils", "OBSERVATION", 76, 93], ["granule", "OBSERVATION", 122, 129], ["leakage promotes cell death", "OBSERVATION", 130, 157]]], ["In contrast to CG or NE, PR3 directly activates pro-caspase-3 leading to apoptosis (Loison et al. 2014) .", [["NE", "CHEMICAL", 21, 23], ["NE", "SIMPLE_CHEMICAL", 21, 23], ["PR3", "GENE_OR_GENE_PRODUCT", 25, 28], ["pro-caspase-3", "GENE_OR_GENE_PRODUCT", 48, 61], ["NE", "PROTEIN", 21, 23], ["PR3", "PROTEIN", 25, 28], ["pro-caspase-3", "PROTEIN", 48, 61], ["apoptosis", "PROBLEM", 73, 82]]], ["Therefore, serpinb1 appears to act at the intersection of death pathways mediated by CG and PR3.", [["serpinb1", "CHEMICAL", 11, 19], ["death", "DISEASE", 58, 63], ["serpinb1", "GENE_OR_GENE_PRODUCT", 11, 19], ["PR3", "GENE_OR_GENE_PRODUCT", 92, 95], ["serpinb1", "PROTEIN", 11, 19], ["PR3", "PROTEIN", 92, 95]]], ["It is conceivable that the two proteases function in a cascade because CG deletion alone rescues the cell intrinsic death pathway in serpinb1a \u00c0/\u00c0 mice in vitro and in steady-state conditions in vivo.", [["cell", "ANATOMY", 101, 105], ["death", "DISEASE", 116, 121], ["CG", "SIMPLE_CHEMICAL", 71, 73], ["cell", "CELL", 101, 105], ["serpinb1a \u00c0/\u00c0 mice", "ORGANISM", 133, 151], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 147, 151], ["the two proteases function", "PROBLEM", 23, 49], ["a cascade", "TREATMENT", 53, 62], ["CG deletion", "PROBLEM", 71, 82]]], ["This hypothesis could be tested in prtn3 \u00c0/\u00c0 . serpinb1a \u00c0/\u00c0 double knockout mice.", [["prtn3", "GENE_OR_GENE_PRODUCT", 35, 40], ["serpinb1a", "GENE_OR_GENE_PRODUCT", 47, 56], ["\u00c0", "GENE_OR_GENE_PRODUCT", 59, 60], ["prtn3 \u00c0/\u00c0", "CELL_LINE", 35, 44], ["serpinb1a", "PROTEIN", 47, 56], ["\u00c0", "PROTEIN", 59, 60], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81]]], ["Alternatively, CG and PR3 could induce neutrophil death through parallel pathways that would enhance each other by depletion of the serpin shield.5.5Neutrophil Elastase and Severe Congenital NeutropeniaGenetic Causes of Severe Congenital NeutropeniaSevere congenital neutropenia (SCN) is a rare inherited disease characterized by persistently low neutrophil counts (<500/\u03bcl) in blood and a maturation arrest of neutrophil precursors in the bone marrow.", [["neutrophil", "ANATOMY", 39, 49], ["neutrophil", "ANATOMY", 347, 357], ["blood", "ANATOMY", 378, 383], ["neutrophil precursors", "ANATOMY", 411, 432], ["bone marrow", "ANATOMY", 440, 451], ["death", "DISEASE", 50, 55], ["Congenital NeutropeniaSevere congenital neutropenia", "DISEASE", 227, 278], ["SCN", "DISEASE", 280, 283], ["PR3", "GENE_OR_GENE_PRODUCT", 22, 25], ["neutrophil", "CELL", 39, 49], ["serpin", "GENE_OR_GENE_PRODUCT", 132, 138], ["Neutrophil Elastase", "GENE_OR_GENE_PRODUCT", 149, 168], ["neutrophil", "CELL", 347, 357], ["blood", "ORGANISM_SUBSTANCE", 378, 383], ["neutrophil", "CELL", 411, 421], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 440, 451], ["PR3", "PROTEIN", 22, 25], ["serpin", "PROTEIN", 132, 138], ["neutrophil precursors", "CELL_TYPE", 411, 432], ["CG", "TEST", 15, 17], ["neutrophil death through parallel pathways", "PROBLEM", 39, 81], ["the serpin shield", "TREATMENT", 128, 145], ["Neutrophil Elastase", "TEST", 149, 168], ["Severe Congenital NeutropeniaGenetic Causes", "PROBLEM", 173, 216], ["Severe Congenital NeutropeniaSevere congenital neutropenia", "PROBLEM", 220, 278], ["a rare inherited disease", "PROBLEM", 288, 312], ["persistently low neutrophil counts", "PROBLEM", 330, 364], ["blood", "TEST", 378, 383], ["a maturation arrest", "PROBLEM", 388, 407], ["neutrophil precursors in the bone marrow", "PROBLEM", 411, 451], ["neutrophil death", "OBSERVATION", 39, 55], ["serpin shield", "OBSERVATION", 132, 145], ["Neutrophil Elastase", "OBSERVATION", 149, 168], ["Severe", "OBSERVATION_MODIFIER", 173, 179], ["Congenital", "OBSERVATION_MODIFIER", 180, 190], ["Severe", "OBSERVATION_MODIFIER", 220, 226], ["Congenital", "OBSERVATION_MODIFIER", 227, 237], ["NeutropeniaSevere", "OBSERVATION_MODIFIER", 238, 255], ["congenital neutropenia", "OBSERVATION", 256, 278], ["rare", "OBSERVATION_MODIFIER", 290, 294], ["inherited", "OBSERVATION_MODIFIER", 295, 304], ["disease", "OBSERVATION", 305, 312], ["persistently", "OBSERVATION_MODIFIER", 330, 342], ["low neutrophil counts", "OBSERVATION", 343, 364], ["blood", "ANATOMY", 378, 383], ["maturation arrest", "OBSERVATION", 390, 407], ["neutrophil precursors", "OBSERVATION", 411, 432], ["bone marrow", "ANATOMY", 440, 451]]], ["Infants with SCN consequently develop mouth ulcers and pneumonia that can be fatal.", [["mouth ulcers", "ANATOMY", 38, 50], ["mouth ulcers", "DISEASE", 38, 50], ["pneumonia", "DISEASE", 55, 64], ["Infants", "ORGANISM", 0, 7], ["mouth", "ORGANISM_SUBDIVISION", 38, 43], ["ulcers", "PATHOLOGICAL_FORMATION", 44, 50], ["Infants", "SPECIES", 0, 7], ["mouth ulcers", "PROBLEM", 38, 50], ["pneumonia", "PROBLEM", 55, 64], ["mouth", "ANATOMY", 38, 43], ["ulcers", "OBSERVATION", 44, 50], ["pneumonia", "OBSERVATION", 55, 64], ["fatal", "OBSERVATION_MODIFIER", 77, 82]]], ["Mutations in the neutrophil elastase gene (ELANE or ELA2) are the cause of most cases of SCN and of all cases of cyclic neutropenia (CyN) (Dale et al. 2000; Dale and Link 2009) .", [["cyclic neutropenia", "DISEASE", 113, 131], ["CyN", "DISEASE", 133, 136], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 17, 36], ["ELANE", "GENE_OR_GENE_PRODUCT", 43, 48], ["ELA2", "GENE_OR_GENE_PRODUCT", 52, 56], ["neutrophil elastase gene", "DNA", 17, 41], ["ELANE", "DNA", 43, 48], ["ELA2", "DNA", 52, 56], ["Mutations", "PROBLEM", 0, 9], ["the neutrophil elastase gene", "TEST", 13, 41], ["cyclic neutropenia", "PROBLEM", 113, 131], ["neutrophil", "ANATOMY", 17, 27], ["cyclic neutropenia", "OBSERVATION", 113, 131]]], ["CyN is a milder form of SCN where blood neutrophil counts oscillate between normal and very low counts with a cyclic period of 21 days (Horwitz et al. 1999) .Genetic Causes of Severe Congenital NeutropeniaSCN was first described in the 1950s by Dr. Rolf Kostmann in a family in northern Sweden.", [["blood neutrophil", "ANATOMY", 34, 50], ["CyN", "CHEMICAL", 0, 3], ["Congenital NeutropeniaSCN", "DISEASE", 183, 208], ["CyN", "GENE_OR_GENE_PRODUCT", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["neutrophil", "CELL", 40, 50], ["a milder form of SCN", "PROBLEM", 7, 27], ["blood neutrophil counts oscillate", "TEST", 34, 67], ["very low counts", "PROBLEM", 87, 102], ["Severe Congenital NeutropeniaSCN", "PROBLEM", 176, 208], ["SCN", "ANATOMY", 24, 27], ["neutrophil counts", "OBSERVATION", 40, 57], ["very", "OBSERVATION_MODIFIER", 87, 91], ["low counts", "OBSERVATION_MODIFIER", 92, 102], ["Severe", "OBSERVATION_MODIFIER", 176, 182], ["Congenital", "OBSERVATION", 183, 193]]], ["The genetic cause of the original cases of Kostmann's syndrome has recently been attributed to a homozygous mutation in the HAX1 (HCLS1associated protein X-1) gene (Klein et al. 2007) .", [["Kostmann's syndrome", "DISEASE", 43, 62], ["HAX1 (HCLS1associated protein X-1", "GENE_OR_GENE_PRODUCT", 124, 157], ["HAX1 (HCLS1associated protein X-1) gene", "DNA", 124, 163], ["Kostmann's syndrome", "PROBLEM", 43, 62], ["a homozygous mutation", "PROBLEM", 95, 116], ["homozygous mutation", "OBSERVATION", 97, 116]]], ["Other infrequent causes of SCN include mutations in adenylate kinase 2 (AK2), the transcriptional repressor (GFI1), and the glucose-6-phosphatase G6PC3 genes (Klein 2011 ).", [["glucose", "CHEMICAL", 124, 131], ["adenylate", "CHEMICAL", 52, 61], ["glucose", "CHEMICAL", 124, 131], ["adenylate kinase 2", "GENE_OR_GENE_PRODUCT", 52, 70], ["AK2", "GENE_OR_GENE_PRODUCT", 72, 75], ["GFI1", "GENE_OR_GENE_PRODUCT", 109, 113], ["glucose-6-phosphatase", "GENE_OR_GENE_PRODUCT", 124, 145], ["G6PC3", "GENE_OR_GENE_PRODUCT", 146, 151], ["adenylate kinase 2", "PROTEIN", 52, 70], ["AK2", "PROTEIN", 72, 75], ["transcriptional repressor", "PROTEIN", 82, 107], ["GFI1", "PROTEIN", 109, 113], ["glucose-6-phosphatase G6PC3 genes", "DNA", 124, 157], ["Klein 2011", "DNA", 159, 169], ["SCN", "PROBLEM", 27, 30], ["mutations in adenylate kinase", "TEST", 39, 68], ["the glucose", "TEST", 120, 131]]], ["X-linked neutropenia has also been described in a subset of patients with Wiskott-Aldrich syndrome (WAS) carrying activating mutations in the WAS gene (Albert et al. 2011 ).", [["neutropenia", "DISEASE", 9, 20], ["Wiskott-Aldrich syndrome", "DISEASE", 74, 98], ["WAS", "DISEASE", 100, 103], ["patients", "ORGANISM", 60, 68], ["Wiskott-Aldrich syndrome", "ORGANISM", 74, 98], ["WAS", "GENE_OR_GENE_PRODUCT", 142, 145], ["WAS gene", "DNA", 142, 150], ["patients", "SPECIES", 60, 68], ["linked neutropenia", "PROBLEM", 2, 20], ["Aldrich syndrome", "PROBLEM", 82, 98], ["carrying activating mutations", "PROBLEM", 105, 134], ["neutropenia", "OBSERVATION", 9, 20]]], ["Finally, a significant proportion of SCN cases remain genetically undefined, and with the advances in sequencing technology, new genetic defects leading to SCN will certainly be discovered (Boztug and Klein 2011) .", [["sequencing technology", "TEST", 102, 123], ["new genetic defects", "PROBLEM", 125, 144], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["SCN", "ANATOMY", 37, 40], ["defects", "OBSERVATION", 137, 144]]], ["Because it is genetically heterogeneous, several molecular pathways are likely leading to SCN.ELANE Mutations in SCN and CyNClose to two hundred distinct mutations in ELANE have been identified in patients with SCN and CyN (Germeshausen et al. 2013; Makaryan et al. 2015) .", [["CyNClose", "GENE_OR_GENE_PRODUCT", 121, 129], ["ELANE", "CANCER", 167, 172], ["patients", "ORGANISM", 197, 205], ["SCN.ELANE", "DNA", 90, 99], ["ELANE", "DNA", 167, 172], ["patients", "SPECIES", 197, 205], ["SCN.ELANE Mutations in SCN", "PROBLEM", 90, 116], ["genetically", "OBSERVATION_MODIFIER", 14, 25], ["heterogeneous", "OBSERVATION_MODIFIER", 26, 39], ["likely leading to", "UNCERTAINTY", 72, 89], ["SCN.ELANE Mutations", "OBSERVATION", 90, 109], ["SCN", "ANATOMY", 113, 116], ["distinct", "OBSERVATION_MODIFIER", 145, 153], ["mutations", "OBSERVATION", 154, 163]]], ["How mutant elastase leads to neutropenia is not completely elucidated, but the current working paradigm is that the mutated NE protein induces apoptosis in developing neutrophils in the bone marrow via the initiation of the unfolded protein response (UPR) (K\u20ac ollner et al. 2006; Grenda et al. 2007) .", [["neutrophils", "ANATOMY", 167, 178], ["bone marrow", "ANATOMY", 186, 197], ["neutropenia", "DISEASE", 29, 40], ["NE", "CHEMICAL", 124, 126], ["elastase", "GENE_OR_GENE_PRODUCT", 11, 19], ["NE", "GENE_OR_GENE_PRODUCT", 124, 126], ["neutrophils", "CELL", 167, 178], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 186, 197], ["mutant elastase", "PROTEIN", 4, 19], ["NE protein", "PROTEIN", 124, 134], ["developing neutrophils", "CELL_TYPE", 156, 178], ["How mutant elastase", "PROBLEM", 0, 19], ["neutropenia", "PROBLEM", 29, 40], ["the mutated NE protein", "PROBLEM", 112, 134], ["apoptosis", "PROBLEM", 143, 152], ["developing neutrophils in the bone marrow", "PROBLEM", 156, 197], ["the unfolded protein response", "TEST", 220, 249], ["UPR", "TEST", 251, 254], ["K", "TEST", 257, 258], ["elastase", "OBSERVATION", 11, 19], ["neutrophils", "OBSERVATION", 167, 178], ["bone marrow", "ANATOMY", 186, 197]]], ["NE mutants are predicted to have defective folding as the protein is synthesized in the ER.", [["ER", "ANATOMY", 88, 90], ["NE", "CHEMICAL", 0, 2], ["NE", "GENE_OR_GENE_PRODUCT", 0, 2], ["ER", "GENE_OR_GENE_PRODUCT", 88, 90], ["NE mutants", "PROTEIN", 0, 10], ["ER", "PROTEIN", 88, 90], ["defective folding", "PROBLEM", 33, 50]]], ["Misfolded proteins are detected by ER sensors, which trigger the UPR that can ultimately lead to apoptosis.", [["ER", "GENE_OR_GENE_PRODUCT", 35, 37], ["Misfolded proteins", "PROTEIN", 0, 18], ["ER", "PROTEIN", 35, 37], ["UPR", "PROTEIN", 65, 68], ["Misfolded proteins", "PROBLEM", 0, 18], ["apoptosis", "PROBLEM", 97, 106], ["proteins", "OBSERVATION", 10, 18]]], ["As very large amounts of mutant misfolded NE are produced at the promyelocyte stage, the UPR triggers apoptosis resulting in the absence of differentiated neutrophils in the bone marrow and blood.", [["neutrophils", "ANATOMY", 155, 166], ["bone marrow", "ANATOMY", 174, 185], ["blood", "ANATOMY", 190, 195], ["NE", "CHEMICAL", 42, 44], ["NE", "GENE_OR_GENE_PRODUCT", 42, 44], ["UPR", "GENE_OR_GENE_PRODUCT", 89, 92], ["neutrophils", "CELL", 155, 166], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 174, 185], ["blood", "ORGANISM_SUBSTANCE", 190, 195], ["mutant misfolded NE", "PROTEIN", 25, 44], ["UPR", "PROTEIN", 89, 92], ["differentiated neutrophils", "CELL_TYPE", 140, 166], ["mutant misfolded NE", "PROBLEM", 25, 44], ["the UPR triggers apoptosis", "PROBLEM", 85, 111], ["differentiated neutrophils in the bone marrow", "PROBLEM", 140, 185], ["large", "OBSERVATION_MODIFIER", 8, 13], ["amounts", "OBSERVATION_MODIFIER", 14, 21], ["misfolded NE", "OBSERVATION", 32, 44], ["differentiated", "OBSERVATION_MODIFIER", 140, 154], ["neutrophils", "OBSERVATION", 155, 166], ["bone marrow", "ANATOMY", 174, 185]]], ["Genotype-phenotype analysis studies suggest that the pattern of mutations in ELANE is different in patients that develop SCN or CyN (Makaryan et al. 2015) .", [["ELANE", "GENE_OR_GENE_PRODUCT", 77, 82], ["patients", "ORGANISM", 99, 107], ["ELANE", "DNA", 77, 82], ["patients", "SPECIES", 99, 107], ["Genotype", "TEST", 0, 8], ["phenotype analysis studies", "TEST", 9, 35], ["mutations in ELANE", "PROBLEM", 64, 82]]], ["However, some mutations can lead to both SCN and CyN suggesting that additional disease modifiers may affect the severity of the phenotype (Germeshausen et al. 2013) .", [["CyN", "GENE_OR_GENE_PRODUCT", 49, 52], ["some mutations", "PROBLEM", 9, 23], ["additional disease modifiers", "PROBLEM", 69, 97], ["the phenotype", "PROBLEM", 125, 138]]], ["Furthermore, about 25 % of mutations leading to SCN, but none to CyN, are associated with the development of myelodysplasia (MDS) and acute myeloid leukemia (AML).", [["acute myeloid leukemia", "ANATOMY", 134, 156], ["AML", "ANATOMY", 158, 161], ["myelodysplasia", "DISEASE", 109, 123], ["MDS", "DISEASE", 125, 128], ["acute myeloid leukemia", "DISEASE", 134, 156], ["AML", "DISEASE", 158, 161], ["CyN", "GENE_OR_GENE_PRODUCT", 65, 68], ["myelodysplasia", "CANCER", 109, 123], ["acute myeloid leukemia", "CANCER", 134, 156], ["AML", "CANCER", 158, 161], ["CyN", "DNA", 65, 68], ["mutations", "PROBLEM", 27, 36], ["SCN", "PROBLEM", 48, 51], ["myelodysplasia (MDS)", "PROBLEM", 109, 129], ["acute myeloid leukemia", "PROBLEM", 134, 156], ["AML", "PROBLEM", 158, 161], ["SCN", "ANATOMY", 48, 51], ["myelodysplasia", "OBSERVATION", 109, 123], ["acute", "OBSERVATION_MODIFIER", 134, 139], ["myeloid leukemia", "OBSERVATION", 140, 156]]], ["However, only a fraction of the patients with these mutations also develop MDS/AML, indicating again that other genetic, epigenetic, and environmental factors contribute to disease initiation and progression.A Role for Serpins in SCN?Whether mutations in intracellular serpin genes contribute to the severity of SCN or to the subsequent development of MDS/AML has yet to be demonstrated in humans.", [["AML", "ANATOMY", 79, 82], ["intracellular", "ANATOMY", 255, 268], ["AML", "ANATOMY", 356, 359], ["MDS", "DISEASE", 75, 78], ["AML", "DISEASE", 79, 82], ["MDS", "DISEASE", 352, 355], ["AML", "DISEASE", 356, 359], ["patients", "ORGANISM", 32, 40], ["AML", "CANCER", 79, 82], ["Serpins", "GENE_OR_GENE_PRODUCT", 219, 226], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 255, 268], ["serpin", "GENE_OR_GENE_PRODUCT", 269, 275], ["AML", "CANCER", 356, 359], ["humans", "ORGANISM", 390, 396], ["Serpins", "PROTEIN", 219, 226], ["intracellular serpin genes", "DNA", 255, 281], ["patients", "SPECIES", 32, 40], ["humans", "SPECIES", 390, 396], ["humans", "SPECIES", 390, 396], ["these mutations", "PROBLEM", 46, 61], ["MDS", "PROBLEM", 75, 78], ["AML", "PROBLEM", 79, 82], ["disease initiation", "PROBLEM", 173, 191], ["progression", "PROBLEM", 196, 207], ["mutations in intracellular serpin genes", "PROBLEM", 242, 281], ["the severity of SCN", "PROBLEM", 296, 315], ["MDS", "PROBLEM", 352, 355], ["AML", "PROBLEM", 356, 359], ["AML", "OBSERVATION", 79, 82], ["progression", "OBSERVATION_MODIFIER", 196, 207], ["MDS", "OBSERVATION", 352, 355], ["AML", "OBSERVATION", 356, 359]]], ["Studies presented above suggest that CG and PR3 can contribute to neutrophil death if the serpin shield is deficient as in serpinb1a \u00c0/\u00c0 mice.", [["neutrophil", "ANATOMY", 66, 76], ["death", "DISEASE", 77, 82], ["PR3", "GENE_OR_GENE_PRODUCT", 44, 47], ["neutrophil", "CELL", 66, 76], ["serpin", "GENE_OR_GENE_PRODUCT", 90, 96], ["serpinb1a", "GENE_OR_GENE_PRODUCT", 123, 132], ["PR3", "PROTEIN", 44, 47], ["neutrophil", "CELL_TYPE", 66, 76], ["serpin", "PROTEIN", 90, 96], ["mice", "SPECIES", 137, 141], ["Studies", "TEST", 0, 7], ["CG and PR3", "PROBLEM", 37, 47], ["neutrophil death", "PROBLEM", 66, 82]]], ["In addition, serpinb1a \u00c0/\u00c0 mice are more susceptible and succumb to lung infections with Pseudomonas aeruginosa (Benarafa et al. 2007) .", [["lung", "ANATOMY", 68, 72], ["lung infections", "DISEASE", 68, 83], ["serpinb1a \u00c0/\u00c0 mice", "ORGANISM", 13, 31], ["lung", "ORGAN", 68, 72], ["Pseudomonas aeruginosa", "ORGANISM", 89, 111], ["serpinb1a", "PROTEIN", 13, 22], ["mice", "SPECIES", 27, 31], ["Pseudomonas aeruginosa", "SPECIES", 89, 111], ["mice", "SPECIES", 27, 31], ["Pseudomonas aeruginosa", "SPECIES", 89, 111], ["lung infections", "PROBLEM", 68, 83], ["Pseudomonas aeruginosa", "PROBLEM", 89, 111], ["lung", "ANATOMY", 68, 72], ["infections", "OBSERVATION", 73, 83]]], ["However, the level of neutropenia observed in serpinb1a \u00c0/\u00c0 mice is milder than that observed in SCN and no maturation arrest is observed in the bone marrow (Benarafa et al. 2011) .A Role for Serpins in SCN?Several studies have investigated NE activity in the context of ELANE mutations, and the combined evidence does not support a role for altered NE activity as the direct cause of neutrophil precursor death in the bone marrow.", [["bone marrow", "ANATOMY", 145, 156], ["neutrophil", "ANATOMY", 385, 395], ["bone marrow", "ANATOMY", 419, 430], ["neutropenia", "DISEASE", 22, 33], ["NE", "CHEMICAL", 241, 243], ["NE", "CHEMICAL", 350, 352], ["death", "DISEASE", 406, 411], ["serpinb1a \u00c0/\u00c0 mice", "ORGANISM", 46, 64], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 145, 156], ["Serpins", "GENE_OR_GENE_PRODUCT", 192, 199], ["NE", "GENE_OR_GENE_PRODUCT", 241, 243], ["ELANE", "GENE_OR_GENE_PRODUCT", 271, 276], ["NE", "GENE_OR_GENE_PRODUCT", 350, 352], ["neutrophil", "CELL", 385, 395], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 419, 430], ["NE", "PROTEIN", 241, 243], ["NE", "PROTEIN", 350, 352], ["mice", "SPECIES", 60, 64], ["neutropenia", "PROBLEM", 22, 33], ["maturation arrest", "PROBLEM", 108, 125], ["Several studies", "TEST", 207, 222], ["ELANE mutations", "PROBLEM", 271, 286], ["altered NE activity", "PROBLEM", 342, 361], ["neutrophil precursor death in the bone marrow", "PROBLEM", 385, 430], ["neutropenia", "OBSERVATION", 22, 33], ["milder", "OBSERVATION_MODIFIER", 68, 74], ["no", "UNCERTAINTY", 105, 107], ["maturation arrest", "OBSERVATION", 108, 125], ["bone marrow", "ANATOMY", 145, 156], ["activity", "OBSERVATION_MODIFIER", 244, 252], ["neutrophil precursor death", "OBSERVATION", 385, 411], ["bone marrow", "ANATOMY", 419, 430]]], ["In transfection studies, recombinant NE mutants showed variable activity on peptide substrates ranging from the absence of activity, reduction in activity, to a higher activity than wild-type NE.", [["NE", "CHEMICAL", 37, 39], ["NE", "GENE_OR_GENE_PRODUCT", 37, 39], ["NE", "CELL", 192, 194], ["recombinant NE mutants", "PROTEIN", 25, 47], ["wild-type NE", "PROTEIN", 182, 194], ["transfection studies", "TEST", 3, 23], ["recombinant NE mutants", "TEST", 25, 47], ["variable activity on peptide substrates", "PROBLEM", 55, 94], ["variable activity", "OBSERVATION", 55, 72], ["activity", "OBSERVATION_MODIFIER", 123, 131], ["reduction", "OBSERVATION_MODIFIER", 133, 142], ["activity", "OBSERVATION_MODIFIER", 146, 154]]], ["In addition, AAT inhibited all active mutants in vitro (Li and Horwitz 2001) .", [["AAT", "CHEMICAL", 13, 16], ["AAT", "GENE_OR_GENE_PRODUCT", 13, 16], ["AAT", "PROTEIN", 13, 16]]], ["Because SCN patients have heterozygous mutations in ELANE, it was hypothesized that mutant NE might interfere with wild-type NE.", [["NE", "CHEMICAL", 91, 93], ["patients", "ORGANISM", 12, 20], ["NE", "GENE_OR_GENE_PRODUCT", 91, 93], ["NE", "GENE_OR_GENE_PRODUCT", 125, 127], ["ELANE", "PROTEIN", 52, 57], ["mutant NE", "PROTEIN", 84, 93], ["wild-type NE", "PROTEIN", 115, 127], ["patients", "SPECIES", 12, 20], ["heterozygous mutations", "PROBLEM", 26, 48], ["mutant NE", "PROBLEM", 84, 93]]], ["The overall NE activity was tested in blood neutrophils of SCN patients with or without ELANE mutations.", [["blood neutrophils", "ANATOMY", 38, 55], ["NE", "SIMPLE_CHEMICAL", 12, 14], ["blood neutrophils", "ORGANISM_SUBSTANCE", 38, 55], ["patients", "ORGANISM", 63, 71], ["NE", "PROTEIN", 12, 14], ["blood neutrophils", "CELL_TYPE", 38, 55], ["patients", "SPECIES", 63, 71], ["ELANE mutations", "PROBLEM", 88, 103], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["NE activity", "OBSERVATION", 12, 23]]], ["In single cell assays by flow cytometry, which are associated with technical caveats such as dye loading standardization, average NE activity was similar in neutrophils of SCN patients and those of normal subjects, but the variation between individuals was greater in the SCN patient group (Germeshausen et al. 2013 ).", [["cell", "ANATOMY", 10, 14], ["neutrophils", "ANATOMY", 157, 168], ["cell", "CELL", 10, 14], ["NE", "GENE_OR_GENE_PRODUCT", 130, 132], ["neutrophils", "CELL", 157, 168], ["patients", "ORGANISM", 176, 184], ["patient", "ORGANISM", 276, 283], ["NE", "PROTEIN", 130, 132], ["neutrophils", "CELL_TYPE", 157, 168], ["patients", "SPECIES", 176, 184], ["patient", "SPECIES", 276, 283], ["single cell assays", "TEST", 3, 21], ["flow cytometry", "TEST", 25, 39], ["dye loading standardization", "TEST", 93, 120], ["average NE activity", "PROBLEM", 122, 141], ["the variation between individuals", "PROBLEM", 219, 252], ["flow cytometry", "OBSERVATION", 25, 39], ["activity", "OBSERVATION_MODIFIER", 133, 141], ["normal", "OBSERVATION", 198, 204]]], ["In the same study, NE activity in lysates of blood neutrophils of a small subset of SCN patients with mutated NE was significantly lower than the activity of neutrophil lysates of SCN patients without ELANE mutation and than that of normal donors.", [["lysates", "ANATOMY", 34, 41], ["blood neutrophils", "ANATOMY", 45, 62], ["neutrophil lysates", "ANATOMY", 158, 176], ["NE", "CHEMICAL", 19, 21], ["NE", "SIMPLE_CHEMICAL", 19, 21], ["lysates", "ORGANISM_SUBSTANCE", 34, 41], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["neutrophils", "CELL", 51, 62], ["patients", "ORGANISM", 88, 96], ["neutrophil lysates", "ORGANISM_SUBSTANCE", 158, 176], ["patients", "ORGANISM", 184, 192], ["donors", "ORGANISM", 240, 246], ["NE", "PROTEIN", 19, 21], ["blood neutrophils", "CELL_TYPE", 45, 62], ["mutated NE", "PROTEIN", 102, 112], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 184, 192], ["the same study", "TEST", 3, 17], ["blood neutrophils", "TEST", 45, 62], ["mutated NE", "PROBLEM", 102, 112], ["neutrophil lysates", "TREATMENT", 158, 176], ["ELANE mutation", "PROBLEM", 201, 215], ["activity", "OBSERVATION_MODIFIER", 22, 30], ["small", "OBSERVATION_MODIFIER", 68, 73], ["subset", "OBSERVATION_MODIFIER", 74, 80]]], ["Therefore, ELANE mutations do not appear to be linked with consistently lower or higher NE activity.", [["NE", "CHEMICAL", 88, 90], ["ELANE", "GENE_OR_GENE_PRODUCT", 11, 16], ["NE", "SIMPLE_CHEMICAL", 88, 90], ["ELANE", "PROTEIN", 11, 16], ["NE", "PROTEIN", 88, 90], ["NE activity", "OBSERVATION", 88, 99]]], ["In addition, elane \u00c0/\u00c0 mice have normal granulopoiesis and neutrophil counts (Belaaouaj et al. 1998) , further indicating that reduced or absent NE activity is not required for neutrophil survival and differentiation.", [["neutrophil", "ANATOMY", 59, 69], ["neutrophil", "ANATOMY", 177, 187], ["NE", "CHEMICAL", 145, 147], ["elane \u00c0/\u00c0 mice", "ORGANISM", 13, 27], ["neutrophil", "CELL", 59, 69], ["NE", "GENE_OR_GENE_PRODUCT", 145, 147], ["neutrophil", "CELL", 177, 187], ["NE", "PROTEIN", 145, 147], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["neutrophil counts", "TEST", 59, 76], ["absent NE activity", "PROBLEM", 138, 156], ["neutrophil survival", "PROBLEM", 177, 196], ["granulopoiesis", "OBSERVATION", 40, 54], ["neutrophil counts", "OBSERVATION", 59, 76], ["reduced", "OBSERVATION_MODIFIER", 127, 134], ["NE activity", "OBSERVATION", 145, 156]]], ["Measurements of CG and PR3 activity and levels of SERPINB1 and SERPINB6 in neutrophils of SCN patients with or without ELANE mutations have not been investigated and may provide additional mechanistic clues on pathways leading to neutropenia.Therapy and Mouse Models for SCNG-CSF therapy is the standard treatment for almost all types of neutropenia, whether congenital or induced by chemotherapy.", [["neutrophils", "ANATOMY", 75, 86], ["neutropenia", "DISEASE", 230, 241], ["neutropenia", "DISEASE", 338, 349], ["CG", "MULTI-TISSUE_STRUCTURE", 16, 18], ["PR3", "GENE_OR_GENE_PRODUCT", 23, 26], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 50, 58], ["SERPINB6", "GENE_OR_GENE_PRODUCT", 63, 71], ["neutrophils", "CELL", 75, 86], ["patients", "ORGANISM", 94, 102], ["Mouse", "ORGANISM", 254, 259], ["SCNG-CSF", "GENE_OR_GENE_PRODUCT", 271, 279], ["PR3", "PROTEIN", 23, 26], ["SERPINB1", "PROTEIN", 50, 58], ["SERPINB6", "PROTEIN", 63, 71], ["neutrophils", "CELL_TYPE", 75, 86], ["patients", "SPECIES", 94, 102], ["Mouse", "SPECIES", 254, 259], ["CG", "TEST", 16, 18], ["PR3 activity", "TEST", 23, 35], ["levels", "TEST", 40, 46], ["SERPINB1", "TEST", 50, 58], ["SERPINB6", "TEST", 63, 71], ["ELANE mutations", "PROBLEM", 119, 134], ["neutropenia", "PROBLEM", 230, 241], ["Therapy", "TREATMENT", 242, 249], ["Mouse Models", "TREATMENT", 254, 266], ["SCNG", "TREATMENT", 271, 275], ["CSF therapy", "TREATMENT", 276, 287], ["the standard treatment", "TREATMENT", 291, 313], ["neutropenia", "PROBLEM", 338, 349], ["chemotherapy", "TREATMENT", 384, 396], ["neutropenia", "OBSERVATION", 338, 349]]], ["Long-term G-CSF therapy has considerably improved the quality of life and reduced mortality from infections in SCN patients (Rosenberg et al. 2008 ).", [["infections", "DISEASE", 97, 107], ["G-CSF", "GENE_OR_GENE_PRODUCT", 10, 15], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["Long-term G-CSF therapy", "TREATMENT", 0, 23], ["reduced mortality", "PROBLEM", 74, 91], ["infections", "PROBLEM", 97, 107], ["CSF therapy", "OBSERVATION", 12, 23], ["improved", "OBSERVATION_MODIFIER", 41, 49], ["infections", "OBSERVATION", 97, 107]]], ["Yet, as in other severe inherited diseases with defects in hematopoiesis, there is a high long-term risk of developing malignancy.", [["inherited diseases", "DISEASE", 24, 42], ["malignancy", "DISEASE", 119, 129], ["malignancy", "CANCER", 119, 129], ["other severe inherited diseases", "PROBLEM", 11, 42], ["defects in hematopoiesis", "PROBLEM", 48, 72], ["developing malignancy", "PROBLEM", 108, 129], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["inherited", "OBSERVATION_MODIFIER", 24, 33], ["diseases", "OBSERVATION", 34, 42], ["defects", "OBSERVATION", 48, 55], ["hematopoiesis", "OBSERVATION", 59, 72], ["high long-term", "OBSERVATION_MODIFIER", 85, 99], ["developing", "OBSERVATION_MODIFIER", 108, 118], ["malignancy", "OBSERVATION", 119, 129]]], ["Therefore, better understanding of disease mechanisms may help design better targeted therapies for SCN.", [["disease mechanisms", "PROBLEM", 35, 53], ["SCN", "PROBLEM", 100, 103]]], ["In serpinb1a \u00c0/\u00c0 mice, G-CSF treatment increased precursor proliferation and accumulation of mature neutrophils in the bone marrow to levels comparable to those of untreated wild-type mice.", [["neutrophils", "ANATOMY", 100, 111], ["bone marrow", "ANATOMY", 119, 130], ["serpinb1a", "GENE_OR_GENE_PRODUCT", 3, 12], ["G-CSF", "GENE_OR_GENE_PRODUCT", 23, 28], ["neutrophils", "CELL", 100, 111], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 119, 130], ["mice", "ORGANISM", 184, 188], ["mature neutrophils", "CELL_TYPE", 93, 111], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 184, 188], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 184, 188], ["G", "TEST", 23, 24], ["CSF treatment", "TREATMENT", 25, 38], ["precursor proliferation", "PROBLEM", 49, 72], ["mature neutrophils in the bone marrow", "PROBLEM", 93, 130], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["precursor proliferation", "OBSERVATION", 49, 72], ["accumulation", "OBSERVATION_MODIFIER", 77, 89], ["mature", "OBSERVATION_MODIFIER", 93, 99], ["neutrophils", "OBSERVATION", 100, 111], ["bone marrow", "ANATOMY", 119, 130]]], ["However, G-CSF treatment failed to accumulate neutrophils in blood of serpinb1a \u00c0/\u00c0 mice indicating that G-CSF therapy does not fully block NSP-mediated death in circulating cells (Baumann et al. 2013) .Therapy and Mouse Models for SCNAttempts at modeling SCN in mice expressing ELANE mutants found in SCN patients unfortunately did not live up to expectations.", [["neutrophils", "ANATOMY", 46, 57], ["blood", "ANATOMY", 61, 66], ["cells", "ANATOMY", 174, 179], ["G-CSF", "CHEMICAL", 9, 14], ["death", "DISEASE", 153, 158], ["G-CSF", "GENE_OR_GENE_PRODUCT", 9, 14], ["neutrophils", "CELL", 46, 57], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["serpinb1a \u00c0/\u00c0 mice", "ORGANISM", 70, 88], ["G-CSF", "GENE_OR_GENE_PRODUCT", 105, 110], ["NSP", "GENE_OR_GENE_PRODUCT", 140, 143], ["cells", "CELL", 174, 179], ["Mouse", "ORGANISM", 215, 220], ["mice", "ORGANISM", 263, 267], ["ELANE", "GENE_OR_GENE_PRODUCT", 279, 284], ["patients", "ORGANISM", 306, 314], ["G-CSF", "PROTEIN", 9, 14], ["neutrophils", "CELL_TYPE", 46, 57], ["NSP", "PROTEIN", 140, 143], ["circulating cells", "CELL_TYPE", 162, 179], ["ELANE mutants", "PROTEIN", 279, 292], ["mice", "SPECIES", 84, 88], ["Mouse", "SPECIES", 215, 220], ["mice", "SPECIES", 263, 267], ["patients", "SPECIES", 306, 314], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 263, 267], ["G-CSF treatment", "TREATMENT", 9, 24], ["neutrophils", "TEST", 46, 57], ["blood", "TEST", 61, 66], ["serpinb1a", "TEST", 70, 79], ["G-CSF therapy", "TREATMENT", 105, 118], ["mediated death in circulating cells", "PROBLEM", 144, 179], ["Therapy", "TREATMENT", 203, 210], ["Mouse Models", "TREATMENT", 215, 227], ["SCNAttempts", "TREATMENT", 232, 243]]], ["Knock-in mice expressing the human V72M mutant of NE instead of mouse NE did not develop SCN and had normal granulopoiesis in steady-state and in stress conditions (Grenda et al. 2002) .", [["NE", "CHEMICAL", 50, 52], ["NE", "CHEMICAL", 70, 72], ["mice", "ORGANISM", 9, 13], ["human", "ORGANISM", 29, 34], ["V72M mutant", "ORGANISM", 35, 46], ["NE", "GENE_OR_GENE_PRODUCT", 50, 52], ["mouse", "ORGANISM", 64, 69], ["NE", "CELL", 70, 72], ["human V72M mutant", "PROTEIN", 29, 46], ["NE", "PROTEIN", 50, 52], ["mouse NE", "PROTEIN", 64, 72], ["mice", "SPECIES", 9, 13], ["human", "SPECIES", 29, 34], ["mouse", "SPECIES", 64, 69], ["mice", "SPECIES", 9, 13], ["human", "SPECIES", 29, 34], ["mouse", "SPECIES", 64, 69], ["SCN", "PROBLEM", 89, 92], ["stress conditions", "PROBLEM", 146, 163], ["granulopoiesis", "OBSERVATION", 108, 122]]], ["Another knock-in mouse expressing the G193X mutation that leads to the truncation of the carboxy-terminal 27 amino acids of the mature NE protein was also generated but similarly showed normal granulopoiesis in steady-state conditions (Nanua et al. 2011) .", [["amino acids", "CHEMICAL", 109, 120], ["carboxy", "CHEMICAL", 89, 96], ["amino acids", "CHEMICAL", 109, 120], ["mouse", "ORGANISM", 17, 22], ["G193X", "GENE_OR_GENE_PRODUCT", 38, 43], ["amino acids", "AMINO_ACID", 109, 120], ["NE", "GENE_OR_GENE_PRODUCT", 135, 137], ["G193X", "PROTEIN", 38, 43], ["carboxy-terminal 27 amino acids", "PROTEIN", 89, 120], ["mature NE protein", "PROTEIN", 128, 145], ["mouse", "SPECIES", 17, 22], ["mouse", "SPECIES", 17, 22], ["the G193X mutation", "PROBLEM", 34, 52], ["the carboxy", "TEST", 85, 96], ["amino acids", "TEST", 109, 120], ["the mature NE protein", "TEST", 124, 145], ["knock", "OBSERVATION", 8, 13], ["normal granulopoiesis", "OBSERVATION", 186, 207]]], ["However, neutrophil precursors of mice carrying the G193X mutation showed reduced proliferation and survival after tunicamycin and bortezomib treatment, which block N-linked glycosylation and proteasome activity, respectively.", [["neutrophil precursors", "ANATOMY", 9, 30], ["tunicamycin", "CHEMICAL", 115, 126], ["bortezomib", "CHEMICAL", 131, 141], ["tunicamycin", "CHEMICAL", 115, 126], ["bortezomib", "CHEMICAL", 131, 141], ["N", "CHEMICAL", 165, 166], ["neutrophil", "CELL", 9, 19], ["mice", "ORGANISM", 34, 38], ["G193X", "GENE_OR_GENE_PRODUCT", 52, 57], ["tunicamycin", "SIMPLE_CHEMICAL", 115, 126], ["bortezomib", "SIMPLE_CHEMICAL", 131, 141], ["neutrophil precursors", "CELL_TYPE", 9, 30], ["proteasome", "PROTEIN", 192, 202], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 34, 38], ["neutrophil precursors", "TEST", 9, 30], ["the G193X mutation", "TEST", 48, 66], ["reduced proliferation", "PROBLEM", 74, 95], ["tunicamycin", "TREATMENT", 115, 126], ["bortezomib treatment", "TREATMENT", 131, 151], ["proteasome activity", "TREATMENT", 192, 211], ["reduced", "OBSERVATION_MODIFIER", 74, 81], ["proliferation", "OBSERVATION_MODIFIER", 82, 95]]], ["These effects were associated with endoplasmic reticulum stress and markers of unfolded protein responses suggesting that modulating the unfolded protein response may be of therapeutic benefit.", [["endoplasmic reticulum", "ANATOMY", 35, 56], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 35, 56], ["endoplasmic reticulum stress", "PROBLEM", 35, 63], ["unfolded protein responses", "PROBLEM", 79, 105], ["the unfolded protein response", "PROBLEM", 133, 162], ["reticulum stress", "OBSERVATION", 47, 63], ["unfolded", "OBSERVATION_MODIFIER", 137, 145], ["protein response", "OBSERVATION", 146, 162], ["may be of", "UNCERTAINTY", 163, 172]]], ["Finally, the overall lack of effect of these mutants may be due to the significantly lower expression levels of NE in mice compared to human neutrophils (Nanua et al. 2011) .", [["neutrophils", "ANATOMY", 141, 152], ["NE", "CHEMICAL", 112, 114], ["NE", "GENE_OR_GENE_PRODUCT", 112, 114], ["mice", "ORGANISM", 118, 122], ["human", "ORGANISM", 135, 140], ["neutrophils", "CELL", 141, 152], ["NE", "PROTEIN", 112, 114], ["human neutrophils", "CELL_TYPE", 135, 152], ["mice", "SPECIES", 118, 122], ["human", "SPECIES", 135, 140], ["mice", "SPECIES", 118, 122], ["human", "SPECIES", 135, 140], ["these mutants", "PROBLEM", 39, 52], ["the significantly lower expression levels of NE", "PROBLEM", 67, 114]]], ["Expressing ELANE mutants under the control of a stronger promoter may provide a model.5.6NSPs and Intracellular Serpins Beyond Neutrophils 5.6.1 Inflammatory Lung Disease AAT, SLPI, and elafin have been long established as part of the antiprotease shield against NSPs in the lungs (Greene and McElvaney 2009) .", [["Lung", "ANATOMY", 158, 162], ["lungs", "ANATOMY", 275, 280], ["elafin", "CHEMICAL", 186, 192], ["ELANE", "GENE_OR_GENE_PRODUCT", 11, 16], ["Lung", "ORGAN", 158, 162], ["SLPI", "GENE_OR_GENE_PRODUCT", 176, 180], ["elafin", "SIMPLE_CHEMICAL", 186, 192], ["NSPs", "SIMPLE_CHEMICAL", 263, 267], ["lungs", "ORGAN", 275, 280], ["ELANE mutants", "PROTEIN", 11, 24], ["SLPI", "PROTEIN", 176, 180], ["Intracellular Serpins", "TEST", 98, 119], ["Neutrophils", "TEST", 127, 138], ["Inflammatory Lung Disease AAT", "PROBLEM", 145, 174], ["SLPI", "TEST", 176, 180], ["elafin", "TREATMENT", 186, 192], ["the antiprotease shield", "TREATMENT", 231, 254], ["Intracellular Serpins", "OBSERVATION", 98, 119], ["Inflammatory", "OBSERVATION_MODIFIER", 145, 157], ["Lung", "ANATOMY", 158, 162], ["Disease", "OBSERVATION", 163, 170], ["lungs", "ANATOMY", 275, 280]]], ["Most prominently, patients with AAT deficiency develop lung emphysema at a young age (Laurell and Eriksson 1963) .", [["lung", "ANATOMY", 55, 59], ["AAT deficiency", "DISEASE", 32, 46], ["lung emphysema", "DISEASE", 55, 69], ["patients", "ORGANISM", 18, 26], ["AAT", "GENE_OR_GENE_PRODUCT", 32, 35], ["lung", "ORGAN", 55, 59], ["AAT", "PROTEIN", 32, 35], ["patients", "SPECIES", 18, 26], ["AAT deficiency", "PROBLEM", 32, 46], ["lung emphysema", "PROBLEM", 55, 69], ["lung", "ANATOMY", 55, 59], ["emphysema", "OBSERVATION", 60, 69]]], ["This finding is one of the pillars of protease-antiprotease paradigm of chronic lung disease, where NSPs destroy the lung elastin fibers and other matrix proteins leading to emphysema.", [["lung", "ANATOMY", 80, 84], ["lung elastin fibers", "ANATOMY", 117, 136], ["matrix", "ANATOMY", 147, 153], ["chronic lung disease", "DISEASE", 72, 92], ["emphysema", "DISEASE", 174, 183], ["lung", "ORGAN", 80, 84], ["NSPs", "SIMPLE_CHEMICAL", 100, 104], ["lung", "ORGAN", 117, 121], ["elastin fibers", "CELLULAR_COMPONENT", 122, 136], ["matrix", "CELLULAR_COMPONENT", 147, 153], ["emphysema", "PATHOLOGICAL_FORMATION", 174, 183], ["protease", "PROTEIN", 38, 46], ["matrix proteins", "PROTEIN", 147, 162], ["protease-antiprotease paradigm", "TREATMENT", 38, 68], ["chronic lung disease", "PROBLEM", 72, 92], ["other matrix proteins", "PROBLEM", 141, 162], ["emphysema", "PROBLEM", 174, 183], ["one", "OBSERVATION_MODIFIER", 16, 19], ["pillars", "OBSERVATION_MODIFIER", 27, 34], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["lung", "ANATOMY", 80, 84], ["disease", "OBSERVATION", 85, 92], ["lung", "ANATOMY", 117, 121], ["elastin fibers", "OBSERVATION", 122, 136], ["emphysema", "OBSERVATION", 174, 183]]], ["Single nucleotide polymorphism that alters the protein sequence of ACT has also been associated with chronic obstructive pulmonary disease (Lomas and Silverman 2001) , suggesting that CG may contribute to pathogenesis.", [["pulmonary", "ANATOMY", 121, 130], ["nucleotide", "CHEMICAL", 7, 17], ["chronic obstructive pulmonary disease", "DISEASE", 101, 138], ["ACT", "GENE_OR_GENE_PRODUCT", 67, 70], ["pulmonary", "ORGAN", 121, 130], ["ACT", "PROTEIN", 67, 70], ["Single nucleotide polymorphism", "PROBLEM", 0, 30], ["the protein sequence", "TEST", 43, 63], ["chronic obstructive pulmonary disease", "PROBLEM", 101, 138], ["CG", "PROBLEM", 184, 186], ["pathogenesis", "PROBLEM", 205, 217], ["polymorphism", "OBSERVATION", 18, 30], ["associated with", "UNCERTAINTY", 85, 100], ["chronic", "OBSERVATION_MODIFIER", 101, 108], ["obstructive", "OBSERVATION_MODIFIER", 109, 120], ["pulmonary", "ANATOMY", 121, 130], ["disease", "OBSERVATION", 131, 138], ["may contribute to", "UNCERTAINTY", 187, 204]]], ["SERPINB1 is also found in airway fluids during lung inflammatory disease (Cooley et al. 2011; Davies et al. 2010; Yasumatsu et al. 2006) .", [["airway fluids", "ANATOMY", 26, 39], ["lung", "ANATOMY", 47, 51], ["lung inflammatory disease", "DISEASE", 47, 72], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 0, 8], ["airway fluids", "TISSUE", 26, 39], ["lung", "ORGAN", 47, 51], ["SERPINB1", "PROTEIN", 0, 8], ["lung inflammatory disease", "PROBLEM", 47, 72], ["airway", "ANATOMY", 26, 32], ["fluids", "OBSERVATION", 33, 39], ["lung", "ANATOMY", 47, 51], ["inflammatory", "OBSERVATION", 52, 64]]], ["Indeed, SERPINB1 can be secreted by an alternative mechanism used by other leaderless cytoplasmic proteins such as IL-1 family members (Keller et al. 2008 ).", [["cytoplasmic", "ANATOMY", 86, 97], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 8, 16], ["cytoplasmic", "ORGANISM_SUBSTANCE", 86, 97], ["IL-1", "GENE_OR_GENE_PRODUCT", 115, 119], ["SERPINB1", "PROTEIN", 8, 16], ["leaderless cytoplasmic proteins", "PROTEIN", 75, 106], ["IL-1 family members", "PROTEIN", 115, 134]]], ["However, the relative importance of this secreting pathway and the release of SERPINB1 in the extracellular milieu after cell death remain to be established.", [["extracellular milieu", "ANATOMY", 94, 114], ["cell", "ANATOMY", 121, 125], ["death", "DISEASE", 126, 131], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 78, 86], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 94, 107], ["cell", "CELL", 121, 125], ["SERPINB1", "PROTEIN", 78, 86], ["this secreting pathway", "TREATMENT", 36, 58], ["SERPINB1", "TREATMENT", 78, 86], ["cell death", "PROBLEM", 121, 131]]], ["Because AAT and SERPINB1 are both fast inhibitors of all three NSPs, a role for SERPINB1 in preventing the development and the severity of pulmonary emphysema in aging mice and following cigarette smoke exposure was tested in serpinb1a \u00c0/\u00c0 mice.", [["pulmonary", "ANATOMY", 139, 148], ["pulmonary emphysema", "DISEASE", 139, 158], ["smoke", "CHEMICAL", 197, 202], ["AAT", "GENE_OR_GENE_PRODUCT", 8, 11], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 16, 24], ["NSPs", "GENE_OR_GENE_PRODUCT", 63, 67], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 80, 88], ["pulmonary", "ORGAN", 139, 148], ["emphysema", "PATHOLOGICAL_FORMATION", 149, 158], ["mice", "ORGANISM", 168, 172], ["cigarette", "ORGANISM", 187, 196], ["serpinb1a \u00c0/\u00c0 mice", "ORGANISM", 226, 244], ["AAT", "PROTEIN", 8, 11], ["SERPINB1", "PROTEIN", 16, 24], ["NSPs", "PROTEIN", 63, 67], ["SERPINB1", "PROTEIN", 80, 88], ["mice", "SPECIES", 168, 172], ["mice", "SPECIES", 240, 244], ["mice", "SPECIES", 168, 172], ["AAT", "TEST", 8, 11], ["SERPINB1", "TREATMENT", 16, 24], ["SERPINB1", "TREATMENT", 80, 88], ["pulmonary emphysema", "PROBLEM", 139, 158], ["pulmonary", "ANATOMY", 139, 148], ["emphysema", "OBSERVATION", 149, 158]]], ["Serpinb1a was expressed in the lungs of control mice and expression was higher after cigarette smoke exposure.", [["lungs", "ANATOMY", 31, 36], ["smoke", "CHEMICAL", 95, 100], ["Serpinb1a", "GENE_OR_GENE_PRODUCT", 0, 9], ["lungs", "ORGAN", 31, 36], ["mice", "ORGANISM", 48, 52], ["Serpinb1a", "PROTEIN", 0, 9], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["Serpinb1a", "TREATMENT", 0, 9], ["lungs", "ANATOMY", 31, 36]]], ["However, stereological analysis of the lungs and lung function tests revealed that serpinb1a \u00c0/\u00c0 mice did not develop early onset emphysema as they aged.", [["lungs", "ANATOMY", 39, 44], ["lung", "ANATOMY", 49, 53], ["emphysema", "DISEASE", 130, 139], ["lungs", "ORGAN", 39, 44], ["lung", "ORGAN", 49, 53], ["serpinb1a", "GENE_OR_GENE_PRODUCT", 83, 92], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 97, 101], ["stereological analysis", "TEST", 9, 31], ["the lungs", "TEST", 35, 44], ["lung function tests", "TEST", 49, 68], ["early onset emphysema", "PROBLEM", 118, 139], ["lungs", "ANATOMY", 39, 44], ["lung", "ANATOMY", 49, 53], ["onset", "OBSERVATION_MODIFIER", 124, 129], ["emphysema", "OBSERVATION", 130, 139]]], ["In addition, they developed cigarette smoke-induced emphysema to a comparable extent as wild-type mice after 6-month exposure (Cremona et al. 2013 ).", [["smoke", "CHEMICAL", 38, 43], ["emphysema", "DISEASE", 52, 61], ["cigarette", "ORGANISM", 28, 37], ["emphysema", "PATHOLOGICAL_FORMATION", 52, 61], ["mice", "ORGANISM", 98, 102], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 98, 102], ["emphysema", "PROBLEM", 52, 61], ["cigarette smoke", "OBSERVATION", 28, 43], ["emphysema", "OBSERVATION", 52, 61]]], ["These findings suggest distinct functions for the intracellular and extracellular serpins in emphysema development.Lung Infection ModelsExcessive inflammatory host response increases morbidity and mortality associated with seasonal respiratory influenza, and highly pathogenic virus strains are characterized by massive infiltration of leukocytes that produce a storm of injurious cytokines.", [["intracellular", "ANATOMY", 50, 63], ["extracellular", "ANATOMY", 68, 81], ["emphysema", "ANATOMY", 93, 102], ["Lung", "ANATOMY", 115, 119], ["leukocytes", "ANATOMY", 336, 346], ["emphysema", "DISEASE", 93, 102], ["respiratory influenza", "DISEASE", 232, 253], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 63], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 68, 81], ["serpins", "GENE_OR_GENE_PRODUCT", 82, 89], ["emphysema", "PATHOLOGICAL_FORMATION", 93, 102], ["Lung", "ORGAN", 115, 119], ["leukocytes", "CELL", 336, 346], ["intracellular and extracellular serpins", "PROTEIN", 50, 89], ["leukocytes", "CELL_TYPE", 336, 346], ["cytokines", "PROTEIN", 381, 390], ["the intracellular and extracellular serpins in emphysema development", "PROBLEM", 46, 114], ["Lung Infection", "PROBLEM", 115, 129], ["inflammatory host response", "PROBLEM", 146, 172], ["morbidity", "PROBLEM", 183, 192], ["seasonal respiratory influenza", "PROBLEM", 223, 253], ["highly pathogenic virus strains", "PROBLEM", 259, 290], ["massive infiltration of leukocytes", "PROBLEM", 312, 346], ["injurious cytokines", "PROBLEM", 371, 390], ["distinct", "OBSERVATION_MODIFIER", 23, 31], ["intracellular", "OBSERVATION_MODIFIER", 50, 63], ["extracellular", "OBSERVATION_MODIFIER", 68, 81], ["serpins", "OBSERVATION", 82, 89], ["emphysema", "OBSERVATION", 93, 102], ["Infection", "OBSERVATION", 120, 129], ["inflammatory", "OBSERVATION_MODIFIER", 146, 158], ["increases", "OBSERVATION_MODIFIER", 173, 182], ["morbidity", "OBSERVATION", 183, 192], ["seasonal", "OBSERVATION_MODIFIER", 223, 231], ["respiratory influenza", "OBSERVATION", 232, 253], ["pathogenic", "OBSERVATION_MODIFIER", 266, 276], ["virus strains", "OBSERVATION", 277, 290], ["massive", "OBSERVATION_MODIFIER", 312, 319], ["infiltration", "OBSERVATION", 320, 332], ["leukocytes", "OBSERVATION", 336, 346], ["injurious cytokines", "OBSERVATION", 371, 390]]], ["Following up on studies showing increased production of inflammatory cytokines in P. aeruginosa infection of serpinb1a \u00c0/\u00c0 mice (Benarafa et al. 2007 ), a role for SERPINB1 in influenza A virus infection was investigated.", [["P. aeruginosa infection", "DISEASE", 82, 105], ["influenza A virus infection", "DISEASE", 176, 203], ["P. aeruginosa", "ORGANISM", 82, 95], ["serpinb1a \u00c0/\u00c0 mice", "ORGANISM", 109, 127], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 164, 172], ["influenza A virus", "ORGANISM", 176, 193], ["inflammatory cytokines", "PROTEIN", 56, 78], ["SERPINB1", "PROTEIN", 164, 172], ["P. aeruginosa", "SPECIES", 82, 95], ["mice", "SPECIES", 123, 127], ["influenza A virus", "SPECIES", 176, 193], ["P. aeruginosa", "SPECIES", 82, 95], ["mice", "SPECIES", 123, 127], ["influenza A virus", "SPECIES", 176, 193], ["studies", "TEST", 16, 23], ["inflammatory cytokines", "PROBLEM", 56, 78], ["P. aeruginosa infection", "PROBLEM", 82, 105], ["SERPINB1", "TREATMENT", 164, 172], ["influenza", "PROBLEM", 176, 185], ["A virus infection", "PROBLEM", 186, 203], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["production", "OBSERVATION_MODIFIER", 42, 52], ["inflammatory cytokines", "OBSERVATION", 56, 78], ["aeruginosa", "OBSERVATION_MODIFIER", 85, 95]]], ["After challenge with a high-dose influenza A/Philadelphia/82 (H3N2), the survival of serpinb1a \u00c0/\u00c0 mice was significantly reduced.", [["Philadelphia/82 (H3N2)", "ORGANISM", 45, 67], ["serpinb1a \u00c0/\u00c0 mice", "ORGANISM", 85, 103], ["mice", "SPECIES", 99, 103], ["A/Philadelphia/82 (H3N2)", "SPECIES", 43, 67], ["mice", "SPECIES", 99, 103], ["Philadelphia/", "TEST", 45, 58], ["H3N2", "PROBLEM", 62, 66], ["serpinb1a", "TEST", 85, 94], ["reduced", "OBSERVATION_MODIFIER", 122, 129]]], ["Sublethally infected animals suffered increased morbidity, delayed resolution of lung injury, and increased immune cell death (Gong et al. 2011) .", [["lung", "ANATOMY", 81, 85], ["immune cell", "ANATOMY", 108, 119], ["lung injury", "DISEASE", 81, 92], ["immune cell death", "DISEASE", 108, 125], ["animals", "ORGANISM", 21, 28], ["lung", "ORGAN", 81, 85], ["immune cell", "CELL", 108, 119], ["increased morbidity", "PROBLEM", 38, 57], ["lung injury", "PROBLEM", 81, 92], ["increased immune cell death", "PROBLEM", 98, 125], ["infected", "OBSERVATION", 12, 20], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["morbidity", "OBSERVATION", 48, 57], ["delayed", "OBSERVATION_MODIFIER", 59, 66], ["resolution", "OBSERVATION_MODIFIER", 67, 77], ["lung", "ANATOMY", 81, 85], ["injury", "OBSERVATION", 86, 92], ["increased", "OBSERVATION_MODIFIER", 98, 107], ["immune cell death", "OBSERVATION", 108, 125]]], ["Importantly, early virus-induced cytokine and chemokine burst and influx of PMNs and monocytes were also normal, and these responses were associated with normal viral clearance in serpinb1a \u00c0/\u00c0 mice compared to wild-type.", [["PMNs", "ANATOMY", 76, 80], ["monocytes", "ANATOMY", 85, 94], ["PMNs", "CELL", 76, 80], ["monocytes", "CELL", 85, 94], ["serpinb1a \u00c0/\u00c0 mice", "ORGANISM", 180, 198], ["cytokine", "PROTEIN", 33, 41], ["chemokine", "PROTEIN", 46, 55], ["PMNs", "CELL_TYPE", 76, 80], ["monocytes", "CELL_TYPE", 85, 94], ["mice", "SPECIES", 194, 198], ["mice", "SPECIES", 194, 198], ["early virus", "PROBLEM", 13, 24], ["chemokine burst", "TEST", 46, 61], ["influx of PMNs", "TEST", 66, 80], ["monocytes", "TEST", 85, 94], ["virus", "OBSERVATION", 19, 24], ["chemokine burst", "OBSERVATION", 46, 61], ["monocytes", "ANATOMY", 85, 94], ["viral clearance", "OBSERVATION", 161, 176]]], ["Whereas initial cytokines and chemokines rapidly decreased in WT mice, TNF-\u03b1, IL-6, KC/CXCL1, G-CSF, IL-17A, and MCP-1/CCL2 remained elevated in serpinb1a \u00c0/\u00c0 mice.", [["WT mice", "ORGANISM", 62, 69], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 71, 76], ["IL-6", "GENE_OR_GENE_PRODUCT", 78, 82], ["KC", "GENE_OR_GENE_PRODUCT", 84, 86], ["CXCL1", "GENE_OR_GENE_PRODUCT", 87, 92], ["G-CSF", "GENE_OR_GENE_PRODUCT", 94, 99], ["IL-17A", "GENE_OR_GENE_PRODUCT", 101, 107], ["MCP-1", "GENE_OR_GENE_PRODUCT", 113, 118], ["CCL2", "GENE_OR_GENE_PRODUCT", 119, 123], ["serpinb1a \u00c0/\u00c0 mice", "ORGANISM", 145, 163], ["cytokines", "PROTEIN", 16, 25], ["chemokines", "PROTEIN", 30, 40], ["TNF", "PROTEIN", 71, 74], ["KC", "PROTEIN", 84, 86], ["CXCL1", "PROTEIN", 87, 92], ["CSF", "PROTEIN", 96, 99], ["MCP-1", "PROTEIN", 113, 118], ["CCL2", "PROTEIN", 119, 123], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 159, 163], ["mice", "SPECIES", 65, 69], ["initial cytokines", "TEST", 8, 25], ["chemokines", "TEST", 30, 40], ["TNF", "TEST", 71, 74], ["IL", "TEST", 78, 80], ["KC", "TEST", 84, 86], ["CXCL1", "TEST", 87, 92], ["G", "TEST", 94, 95], ["CSF", "TEST", 96, 99], ["IL", "TEST", 101, 103], ["MCP", "TEST", 113, 116], ["CCL2", "TEST", 119, 123], ["elevated", "PROBLEM", 133, 141], ["decreased", "OBSERVATION_MODIFIER", 49, 58], ["CXCL1", "ANATOMY", 87, 92]]], ["Monocyte-derived cells were the dominant immune cells in influenza-infected lungs, and those from serpinb1a \u00c0/\u00c0 mice produced more IL-6 and TNF-\u03b1 when tested ex vivo (Gong et al. 2011) .", [["Monocyte", "ANATOMY", 0, 8], ["cells", "ANATOMY", 17, 22], ["immune cells", "ANATOMY", 41, 53], ["lungs", "ANATOMY", 76, 81], ["influenza-infected", "DISEASE", 57, 75], ["Monocyte-derived cells", "CELL", 0, 22], ["immune cells", "CELL", 41, 53], ["influenza", "ORGANISM", 57, 66], ["lungs", "ORGAN", 76, 81], ["serpinb1a \u00c0/\u00c0 mice", "ORGANISM", 98, 116], ["IL-6", "GENE_OR_GENE_PRODUCT", 131, 135], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 140, 145], ["Monocyte-derived cells", "CELL_TYPE", 0, 22], ["dominant immune cells", "CELL_TYPE", 32, 53], ["IL-6", "PROTEIN", 131, 135], ["TNF", "PROTEIN", 140, 143], ["mice", "SPECIES", 112, 116], ["mice", "SPECIES", 112, 116], ["Monocyte", "TEST", 0, 8], ["derived cells", "PROBLEM", 9, 22], ["influenza", "PROBLEM", 57, 66], ["infected lungs", "PROBLEM", 67, 81], ["serpinb1a", "TEST", 98, 107], ["IL", "TEST", 131, 133], ["TNF", "TEST", 140, 143], ["dominant", "OBSERVATION_MODIFIER", 32, 40], ["immune cells", "OBSERVATION", 41, 53], ["infected", "OBSERVATION_MODIFIER", 67, 75], ["lungs", "ANATOMY", 76, 81]]], ["Because viral clearance was unimpaired, the study highlights the critical role of serpinB1 in mitigating tissue injury, restricting inflammatory cytokine production, and reducing morbidity.Lung Infection ModelsIn lung infection models, serpinb1a \u00c0/\u00c0 deficiency is characterized by defective microbial clearance and increased production of inflammatory cytokines (Benarafa et al. 2007; Gong et al. 2011) .", [["tissue", "ANATOMY", 105, 111], ["Lung", "ANATOMY", 189, 193], ["lung", "ANATOMY", 213, 217], ["serpinB1", "CHEMICAL", 82, 90], ["tissue injury", "DISEASE", 105, 118], ["lung infection", "DISEASE", 213, 227], ["serpinB1", "GENE_OR_GENE_PRODUCT", 82, 90], ["tissue", "TISSUE", 105, 111], ["Lung", "ORGAN", 189, 193], ["lung", "ORGAN", 213, 217], ["serpinb1a \u00c0", "GENE_OR_GENE_PRODUCT", 236, 247], ["\u00c0", "GENE_OR_GENE_PRODUCT", 248, 249], ["serpinB1", "PROTEIN", 82, 90], ["inflammatory cytokine", "PROTEIN", 132, 153], ["inflammatory cytokines", "PROTEIN", 339, 361], ["viral clearance", "TEST", 8, 23], ["the study", "TEST", 40, 49], ["mitigating tissue injury", "PROBLEM", 94, 118], ["inflammatory cytokine production", "PROBLEM", 132, 164], ["reducing morbidity", "PROBLEM", 170, 188], ["Lung Infection ModelsIn lung infection models", "PROBLEM", 189, 234], ["serpinb1a \u00c0/\u00c0 deficiency", "PROBLEM", 236, 260], ["defective microbial clearance", "PROBLEM", 281, 310], ["inflammatory cytokines", "PROBLEM", 339, 361], ["mitigating tissue", "OBSERVATION_MODIFIER", 94, 111], ["injury", "OBSERVATION", 112, 118], ["inflammatory", "OBSERVATION_MODIFIER", 132, 144], ["cytokine production", "OBSERVATION", 145, 164], ["Infection", "OBSERVATION", 194, 203], ["lung", "ANATOMY", 213, 217], ["infection", "OBSERVATION", 218, 227], ["defective", "OBSERVATION_MODIFIER", 281, 290], ["microbial clearance", "OBSERVATION", 291, 310], ["increased", "OBSERVATION_MODIFIER", 315, 324], ["production", "OBSERVATION_MODIFIER", 325, 335], ["inflammatory", "OBSERVATION_MODIFIER", 339, 351]]], ["Neutrophil extracellular traps (NETs) are web of nuclear DNA, histones, and antimicrobial molecules released by neutrophils following stimulation by endogenous and pathogen-associated inflammatory mediators.", [["Neutrophil extracellular", "ANATOMY", 0, 24], ["nuclear", "ANATOMY", 49, 56], ["neutrophils", "ANATOMY", 112, 123], ["Neutrophil extracellular traps", "GENE_OR_GENE_PRODUCT", 0, 30], ["nuclear", "CELLULAR_COMPONENT", 49, 56], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["histones", "CELLULAR_COMPONENT", 62, 70], ["neutrophils", "CELL", 112, 123], ["histones", "PROTEIN", 62, 70], ["antimicrobial molecules", "PROTEIN", 76, 99], ["neutrophils", "CELL_TYPE", 112, 123], ["endogenous and pathogen-associated inflammatory mediators", "PROTEIN", 149, 206], ["Neutrophil extracellular traps", "TREATMENT", 0, 30], ["nuclear DNA", "TEST", 49, 60], ["histones", "PROBLEM", 62, 70], ["antimicrobial molecules", "PROBLEM", 76, 99], ["antimicrobial molecules", "OBSERVATION", 76, 99], ["inflammatory", "OBSERVATION_MODIFIER", 184, 196]]], ["The generation of NETs, or NETosis, was initially described as the ultimate effort by neutrophils to contain microbes and prevent their dissemination by executing this form of programmed cell death (Brinkmann et al. 2004; Fuchs et al. 2007 ).", [["NETs", "ANATOMY", 18, 22], ["neutrophils", "ANATOMY", 86, 97], ["cell", "ANATOMY", 187, 191], ["programmed cell death", "DISEASE", 176, 197], ["NETs", "GENE_OR_GENE_PRODUCT", 18, 22], ["neutrophils", "CELL", 86, 97], ["cell", "CELL", 187, 191], ["neutrophils", "CELL_TYPE", 86, 97], ["NETosis", "PROBLEM", 27, 34], ["programmed cell death", "PROBLEM", 176, 197]]], ["However, some agonists, such as Staphylococcus aureus, may not require neutrophil death for NET release (Pilsczek et al. 2010) ; and GM-CSF-primed neutrophils release NETs composed of mitochondrial DNA following stimulation with complement C5a (Yousefi et al. 2009 ).", [["neutrophil", "ANATOMY", 71, 81], ["neutrophils", "ANATOMY", 147, 158], ["NETs", "ANATOMY", 167, 171], ["mitochondrial", "ANATOMY", 184, 197], ["Staphylococcus aureus", "DISEASE", 32, 53], ["death", "DISEASE", 82, 87], ["GM", "CHEMICAL", 133, 135], ["Staphylococcus aureus", "ORGANISM", 32, 53], ["neutrophil", "CELL", 71, 81], ["NET", "SIMPLE_CHEMICAL", 92, 95], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 133, 139], ["neutrophils", "CELL", 147, 158], ["NETs", "GENE_OR_GENE_PRODUCT", 167, 171], ["mitochondrial", "CELLULAR_COMPONENT", 184, 197], ["DNA", "CELLULAR_COMPONENT", 198, 201], ["complement C5a", "GENE_OR_GENE_PRODUCT", 229, 243], ["GM-CSF-primed neutrophils", "CELL_LINE", 133, 158], ["mitochondrial DNA", "DNA", 184, 201], ["complement C5a", "PROTEIN", 229, 243], ["Staphylococcus aureus", "SPECIES", 32, 53], ["Staphylococcus aureus", "SPECIES", 32, 53], ["some agonists", "PROBLEM", 9, 22], ["Staphylococcus aureus", "PROBLEM", 32, 53], ["neutrophil death", "PROBLEM", 71, 87], ["NET release", "TREATMENT", 92, 103], ["GM", "TEST", 133, 135], ["CSF", "TEST", 136, 139], ["mitochondrial DNA", "PROBLEM", 184, 201], ["mitochondrial DNA", "OBSERVATION", 184, 201]]], ["In vitro, serpinb1a \u00c0/\u00c0 neutrophils release more NETs than wild-type neutrophils in response to agonists that induce NETs via reactive oxygen species-dependent and species-independent routes (Farley et al. 2012) .", [["serpinb1a \u00c0/\u00c0 neutrophils", "ANATOMY", 10, 35], ["NETs", "ANATOMY", 49, 53], ["neutrophils", "ANATOMY", 69, 80], ["NETs", "ANATOMY", 117, 121], ["oxygen", "CHEMICAL", 135, 141], ["oxygen", "CHEMICAL", 135, 141], ["serpinb1a", "GENE_OR_GENE_PRODUCT", 10, 19], ["\u00c0 neutrophils", "CELL", 22, 35], ["neutrophils", "CELL", 69, 80], ["NETs", "GENE_OR_GENE_PRODUCT", 117, 121], ["reactive oxygen species", "SIMPLE_CHEMICAL", 126, 149], ["serpinb1a \u00c0/\u00c0 neutrophils", "CELL_LINE", 10, 35], ["wild-type neutrophils", "CELL_TYPE", 59, 80], ["serpinb1a", "TEST", 10, 19], ["neutrophils release", "PROBLEM", 24, 43], ["type neutrophils", "PROBLEM", 64, 80], ["agonists", "TREATMENT", 96, 104], ["NETs via reactive oxygen species", "PROBLEM", 117, 149], ["reactive oxygen species", "OBSERVATION", 126, 149]]], ["These findings suggest that SERPINB1 regulates a conserved portion of the NET release pathway.", [["SERPINB1", "GENE_OR_GENE_PRODUCT", 28, 36], ["NET", "GENE_OR_GENE_PRODUCT", 74, 77], ["SERPINB1", "PROTEIN", 28, 36], ["NET", "PROTEIN", 74, 77], ["the NET release pathway", "TREATMENT", 70, 93]]], ["SERPINB1 was also shown to regulate DNA release from activated neutrophils in vivo following Pseudomonas infection.", [["neutrophils", "ANATOMY", 63, 74], ["Pseudomonas infection", "DISEASE", 93, 114], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 0, 8], ["DNA", "CELLULAR_COMPONENT", 36, 39], ["neutrophils", "CELL", 63, 74], ["SERPINB1", "PROTEIN", 0, 8], ["activated neutrophils", "CELL_TYPE", 53, 74], ["DNA release", "PROBLEM", 36, 47], ["activated neutrophils", "TREATMENT", 53, 74], ["Pseudomonas infection", "PROBLEM", 93, 114], ["activated neutrophils", "OBSERVATION", 53, 74], ["Pseudomonas", "OBSERVATION_MODIFIER", 93, 104], ["infection", "OBSERVATION", 105, 114]]], ["Yet, despite producing more NETs, neutropenic serpinb1a \u00c0/\u00c0 mice fail to control Pseudomonas infection in the lung and cannot prevent systemic bacterial spreading (Benarafa et al. 2007; Farley et al. 2012 ).", [["NETs", "ANATOMY", 28, 32], ["lung", "ANATOMY", 110, 114], ["NETs", "DISEASE", 28, 32], ["Pseudomonas infection", "DISEASE", 81, 102], ["NETs", "CANCER", 28, 32], ["serpinb1a \u00c0/\u00c0 mice", "ORGANISM", 46, 64], ["lung", "ORGAN", 110, 114], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 60, 64], ["neutropenic serpinb1a", "TREATMENT", 34, 55], ["Pseudomonas infection in the lung", "PROBLEM", 81, 114], ["systemic bacterial spreading", "PROBLEM", 134, 162], ["Pseudomonas", "OBSERVATION_MODIFIER", 81, 92], ["infection", "OBSERVATION", 93, 102], ["lung", "ANATOMY", 110, 114], ["cannot prevent", "UNCERTAINTY", 119, 133], ["systemic", "OBSERVATION_MODIFIER", 134, 142], ["bacterial", "OBSERVATION_MODIFIER", 143, 152], ["spreading", "OBSERVATION_MODIFIER", 153, 162]]], ["On the contrary, increased NET generation in these mice may contribute to increased inflammation and tissue injury as observed during influenza infection (Gong et al. 2011) .Lung Infection ModelsSeveral questions thus remain on the potential molecular partners of SERPINB1 in DNA release and associated inflammation.", [["tissue", "ANATOMY", 101, 107], ["Lung", "ANATOMY", 174, 178], ["inflammation", "DISEASE", 84, 96], ["tissue injury", "DISEASE", 101, 114], ["influenza infection", "DISEASE", 134, 153], ["Lung Infection", "DISEASE", 174, 188], ["inflammation", "DISEASE", 303, 315], ["NET", "GENE_OR_GENE_PRODUCT", 27, 30], ["mice", "ORGANISM", 51, 55], ["tissue", "TISSUE", 101, 107], ["Lung", "ORGAN", 174, 178], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 264, 272], ["DNA", "CELLULAR_COMPONENT", 276, 279], ["SERPINB1", "PROTEIN", 264, 272], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["increased NET generation", "TREATMENT", 17, 41], ["increased inflammation", "PROBLEM", 74, 96], ["tissue injury", "PROBLEM", 101, 114], ["influenza infection", "PROBLEM", 134, 153], ["Lung Infection", "PROBLEM", 174, 188], ["associated inflammation", "PROBLEM", 292, 315], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["NET generation", "OBSERVATION", 27, 41], ["may contribute to", "UNCERTAINTY", 56, 73], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["inflammation", "OBSERVATION", 84, 96], ["tissue injury", "OBSERVATION", 101, 114], ["Lung", "ANATOMY", 174, 178], ["Infection", "OBSERVATION", 179, 188], ["inflammation", "OBSERVATION", 303, 315]]], ["Potential mechanistic pathways include inhibition of NE activity, which is required for NET generation (Papayannopoulos et al. 2010) .", [["NE", "CHEMICAL", 53, 55], ["NE", "GENE_OR_GENE_PRODUCT", 53, 55], ["NET", "GENE_OR_GENE_PRODUCT", 88, 91], ["NE", "PROTEIN", 53, 55], ["inhibition of NE activity", "TREATMENT", 39, 64]]], ["Moreover, prtn3 \u00c0/\u00c0 mice show reduced inflammation and increased survival in a peritonitis model (Loison et al. 2014) .", [["inflammation", "DISEASE", 38, 50], ["peritonitis", "DISEASE", 79, 90], ["prtn3", "GENE_OR_GENE_PRODUCT", 10, 15], ["prtn3", "PROTEIN", 10, 15], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["prtn3", "TEST", 10, 15], ["reduced inflammation", "PROBLEM", 30, 50], ["increased survival", "PROBLEM", 55, 73], ["a peritonitis model", "PROBLEM", 77, 96], ["reduced", "OBSERVATION_MODIFIER", 30, 37], ["inflammation", "OBSERVATION", 38, 50], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["survival", "OBSERVATION_MODIFIER", 65, 73], ["peritonitis", "OBSERVATION", 79, 90]]], ["Because SERPINB1 translocates to the nucleus during NET generation and is associated with chromatin, it was also hypothesized that SERPINB1 is involved in chromatin decondensation (Popova et al. 2006; Farley et al. 2012 ).SERPINB6 and DeafnessA homozygous truncating mutation in SERPINB6 is associated with non-syndromic sensorineural hearing loss in humans (Sirmaci et al. 2010) .", [["nucleus", "ANATOMY", 37, 44], ["chromatin", "ANATOMY", 90, 99], ["chromatin", "ANATOMY", 155, 164], ["sensorineural hearing loss", "DISEASE", 321, 347], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 8, 16], ["nucleus", "CELLULAR_COMPONENT", 37, 44], ["NET", "GENE_OR_GENE_PRODUCT", 52, 55], ["chromatin", "CELLULAR_COMPONENT", 90, 99], ["SERPINB1", "GENE_OR_GENE_PRODUCT", 131, 139], ["chromatin", "CELLULAR_COMPONENT", 155, 164], ["SERPINB6", "GENE_OR_GENE_PRODUCT", 222, 230], ["DeafnessA", "GENE_OR_GENE_PRODUCT", 235, 244], ["SERPINB6", "GENE_OR_GENE_PRODUCT", 279, 287], ["humans", "ORGANISM", 351, 357], ["SERPINB1", "PROTEIN", 8, 16], ["chromatin", "DNA", 90, 99], ["SERPINB1", "PROTEIN", 131, 139], ["chromatin", "DNA", 155, 164], ["SERPINB6", "DNA", 222, 230], ["SERPINB6", "DNA", 279, 287], ["humans", "SPECIES", 351, 357], ["humans", "SPECIES", 351, 357], ["chromatin decondensation", "PROBLEM", 155, 179], ["SERPINB6", "TREATMENT", 222, 230], ["DeafnessA homozygous truncating mutation", "PROBLEM", 235, 275], ["non-syndromic sensorineural hearing loss in humans", "PROBLEM", 307, 357], ["nucleus", "ANATOMY_MODIFIER", 37, 44], ["NET generation", "OBSERVATION", 52, 66], ["chromatin decondensation", "OBSERVATION", 155, 179], ["truncating mutation", "OBSERVATION", 256, 275], ["sensorineural hearing loss", "OBSERVATION", 321, 347]]], ["Most strikingly, progressive age-related hearing loss is also observed in serpinb6a \u00c0/\u00c0 mice (Tan et al. 2013) .", [["hearing loss", "DISEASE", 41, 53], ["mice", "SPECIES", 88, 92], ["hearing loss", "PROBLEM", 41, 53], ["progressive", "OBSERVATION_MODIFIER", 17, 28], ["hearing loss", "OBSERVATION", 41, 53]]], ["Serpinb6a is expressed in cells of the cochlea and its absence leads to degeneration of the organ of Corti, which is composed of hair cells required for transmitting auditory signals.", [["cells", "ANATOMY", 26, 31], ["cochlea", "ANATOMY", 39, 46], ["organ", "ANATOMY", 92, 97], ["Corti", "ANATOMY", 101, 106], ["hair cells", "ANATOMY", 129, 139], ["Serpinb6a", "GENE_OR_GENE_PRODUCT", 0, 9], ["cells", "CELL", 26, 31], ["cochlea", "ORGAN", 39, 46], ["organ", "ORGAN", 92, 97], ["Corti", "ORGAN", 101, 106], ["hair cells", "CELL", 129, 139], ["Serpinb6a", "PROTEIN", 0, 9], ["hair cells", "CELL_TYPE", 129, 139], ["Serpinb6a", "TREATMENT", 0, 9], ["degeneration of the organ of Corti", "PROBLEM", 72, 106], ["hair cells", "PROBLEM", 129, 139], ["transmitting auditory signals", "PROBLEM", 153, 182], ["cochlea", "ANATOMY", 39, 46], ["degeneration", "OBSERVATION", 72, 84], ["organ", "ANATOMY", 92, 97], ["Corti", "ANATOMY", 101, 106], ["hair cells", "OBSERVATION", 129, 139]]], ["Whether inhibition of proteases, and CG in particular, is involved in this process remains to be determined.", [["proteases", "PROTEIN", 22, 31], ["CG", "PROTEIN", 37, 39], ["inhibition of proteases", "PROBLEM", 8, 31]]]], "424d6c622643d36a7f8d9a1d2714f4cef49387ed": [["IntroductionCancer is the second leading cause of death worldwide.", [["IntroductionCancer", "DISEASE", 0, 18], ["death", "DISEASE", 50, 55], ["death", "PROBLEM", 50, 55]]], ["While major advances have been made in design of chemotherapy agents, radiation, and surgical procedures, mortality rates remain high.", [["chemotherapy agents", "TREATMENT", 49, 68], ["radiation", "TREATMENT", 70, 79], ["surgical procedures", "TREATMENT", 85, 104], ["mortality rates", "TEST", 106, 121]]], ["Terminal cancer requires innovative therapeutic approaches, which are currently limited.", [["Terminal cancer", "ANATOMY", 0, 15], ["Terminal cancer", "DISEASE", 0, 15], ["Terminal cancer", "CANCER", 0, 15], ["Terminal cancer", "PROBLEM", 0, 15], ["innovative therapeutic approaches", "TREATMENT", 25, 58], ["cancer", "OBSERVATION", 9, 15]]], ["Traditional use of herbs to treat diverse human illnesses dates back to thousands of years, but in today's society the use of natural product remedies is defined amongst others under the classification of \"complementary and alternative medicines\" (CAMs) [1] [2] [3] .", [["human illnesses", "DISEASE", 42, 57], ["human", "ORGANISM", 42, 47], ["[1] [2] [3]", "SIMPLE_CHEMICAL", 254, 265], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["herbs", "TREATMENT", 19, 24], ["diverse human illnesses", "PROBLEM", 34, 57], ["natural product remedies", "TREATMENT", 126, 150], ["alternative medicines", "TREATMENT", 224, 245]]], ["The field of CAM is of global interest, in particular to augment traditional chemotherapies, prevent cancer remission, or serve as basic chemopreventive strategies [4] [5] [6] [7] .IntroductionRhus chinensis (Mill.) belongs to the genus Rhus and the family Anacardiaceae.", [["CAM", "ANATOMY", 13, 16], ["cancer", "ANATOMY", 101, 107], ["cancer", "DISEASE", 101, 107], ["CAM", "MULTI-TISSUE_STRUCTURE", 13, 16], ["cancer", "CANCER", 101, 107], ["[4] [5] [6] [7]", "SIMPLE_CHEMICAL", 164, 179], ["Rhus chinensis", "ORGANISM", 193, 207], ["Mill.", "ORGANISM", 209, 214], ["Rhus chinensis", "SPECIES", 193, 207], ["Rhus chinensis", "SPECIES", 193, 207], ["augment traditional chemotherapies", "TREATMENT", 57, 91], ["cancer remission", "PROBLEM", 101, 117], ["genus", "ANATOMY", 231, 236]]], ["Rhus chinensis gall (RCG) is the abnormal growth of Rhus chinensis leaves caused by Chinese aphid Schlechtendalia chinensis [8, 9] , also used for decades by indigenous people in the treatment of diarrhea, hemorrhage, and inflammation [10] [11] [12] [13] [14] [15] [16] [17] .", [["RCG", "CHEMICAL", 21, 24], ["Chinese aphid Schlechtendalia chinensis [8, 9]", "CHEMICAL", 84, 130], ["diarrhea", "DISEASE", 196, 204], ["hemorrhage", "DISEASE", 206, 216], ["inflammation", "DISEASE", 222, 234], ["Rhus chinensis", "ORGANISM", 0, 14], ["gall", "ORGAN", 15, 19], ["RCG", "CANCER", 21, 24], ["Rhus chinensis", "ORGANISM", 52, 66], ["leaves", "ORGANISM", 67, 73], ["Schlechtendalia chinensis", "ORGANISM", 98, 123], ["people", "ORGANISM", 169, 175], ["[10] [11] [12] [13] [14] [15] [16] [17]", "SIMPLE_CHEMICAL", 235, 274], ["Rhus chinensis", "SPECIES", 0, 14], ["Rhus chinensis", "SPECIES", 52, 66], ["Schlechtendalia chinensis", "SPECIES", 98, 123], ["people", "SPECIES", 169, 175], ["Rhus chinensis", "SPECIES", 0, 14], ["Rhus chinensis", "SPECIES", 52, 66], ["Chinese aphid", "SPECIES", 84, 97], ["Schlechtendalia chinensis", "SPECIES", 98, 123], ["the abnormal growth", "PROBLEM", 29, 48], ["diarrhea", "PROBLEM", 196, 204], ["hemorrhage", "PROBLEM", 206, 216], ["inflammation", "PROBLEM", 222, 234], ["gall", "ANATOMY", 15, 19], ["abnormal", "OBSERVATION_MODIFIER", 33, 41], ["growth", "OBSERVATION_MODIFIER", 42, 48], ["diarrhea", "OBSERVATION", 196, 204], ["hemorrhage", "OBSERVATION", 206, 216]]], ["In a recent study conducted in our laboratory, a high-throughput screening of natural products revealed the extract of RGC to halt the proliferation of human breast cancer cells [7] and inhibit hLDH-A [18] , an enzyme which plays a significant role in driving aggressive malignancies [2, [19] [20] [21] , chemo-and radiotherapy resistance [22, 23] , tumorigenic potential [24] [25] [26] , and metastatic processes [22] .", [["extract", "ANATOMY", 108, 115], ["RGC", "ANATOMY", 119, 122], ["breast cancer cells", "ANATOMY", 158, 177], ["malignancies", "ANATOMY", 271, 283], ["RGC", "CHEMICAL", 119, 122], ["breast cancer", "DISEASE", 158, 171], ["aggressive malignancies", "DISEASE", 260, 283], ["RGC", "SIMPLE_CHEMICAL", 119, 122], ["human", "ORGANISM", 152, 157], ["breast cancer cells", "CELL", 158, 177], ["hLDH-A [18]", "GENE_OR_GENE_PRODUCT", 194, 205], ["malignancies", "CANCER", 271, 283], ["[19] [20", "SIMPLE_CHEMICAL", 288, 296], ["human breast cancer cells", "CELL_TYPE", 152, 177], ["hLDH", "PROTEIN", 194, 198], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 152, 157], ["a recent study", "TEST", 3, 17], ["natural products", "TREATMENT", 78, 94], ["RGC", "PROBLEM", 119, 122], ["human breast cancer cells", "PROBLEM", 152, 177], ["hLDH", "TEST", 194, 198], ["an enzyme", "TEST", 208, 217], ["aggressive malignancies", "PROBLEM", 260, 283], ["chemo", "TREATMENT", 305, 310], ["radiotherapy resistance", "TEST", 315, 338], ["tumorigenic potential", "TEST", 350, 371], ["metastatic processes", "PROBLEM", 393, 413], ["proliferation", "OBSERVATION_MODIFIER", 135, 148], ["breast", "ANATOMY", 158, 164], ["cancer", "OBSERVATION", 165, 171], ["significant", "OBSERVATION_MODIFIER", 232, 243], ["metastatic", "OBSERVATION", 393, 403]]], ["It is believed that the abundance of lactic acid produced and released by tumor cells assists in invasion and motility [27] where a low pH weakens the extracellular stroma which helps tumor cells to dislodge and burrow in the blood and lymphatic systems [28] .IntroductionGiven the potential value in the identification of novel hLDH-A inhibitors to augment targeted cancer therapies [16, 29] , we further investigate the constituent properties of Rhus chinensis gallnut so as to isolate the chemical responsible for hLDH-A inhibition.", [["tumor cells", "ANATOMY", 74, 85], ["extracellular stroma", "ANATOMY", 151, 171], ["tumor cells", "ANATOMY", 184, 195], ["blood", "ANATOMY", 226, 231], ["lymphatic systems", "ANATOMY", 236, 253], ["cancer", "ANATOMY", 367, 373], ["lactic acid", "CHEMICAL", 37, 48], ["tumor", "DISEASE", 74, 79], ["tumor", "DISEASE", 184, 189], ["cancer", "DISEASE", 367, 373], ["hLDH-A", "CHEMICAL", 517, 523], ["lactic acid", "CHEMICAL", 37, 48], ["lactic acid", "SIMPLE_CHEMICAL", 37, 48], ["tumor cells", "CELL", 74, 85], ["extracellular stroma", "CELLULAR_COMPONENT", 151, 171], ["tumor cells", "CELL", 184, 195], ["blood", "ORGANISM_SUBSTANCE", 226, 231], ["lymphatic systems", "MULTI-TISSUE_STRUCTURE", 236, 253], ["hLDH-A", "SIMPLE_CHEMICAL", 329, 335], ["cancer", "CANCER", 367, 373], ["Rhus chinensis", "ORGANISM", 448, 462], ["gallnut", "ORGANISM", 463, 470], ["hLDH-A", "SIMPLE_CHEMICAL", 517, 523], ["tumor cells", "CELL_TYPE", 74, 85], ["tumor cells", "CELL_TYPE", 184, 195], ["Rhus chinensis", "SPECIES", 448, 462], ["Rhus chinensis gallnut", "SPECIES", 448, 470], ["lactic acid", "PROBLEM", 37, 48], ["a low pH weakens the extracellular stroma", "PROBLEM", 130, 171], ["tumor cells", "PROBLEM", 184, 195], ["burrow in the blood and lymphatic systems", "TEST", 212, 253], ["novel hLDH", "TREATMENT", 323, 333], ["A inhibitors", "TREATMENT", 334, 346], ["augment targeted cancer therapies", "TREATMENT", 350, 383], ["Rhus chinensis gallnut", "TREATMENT", 448, 470], ["lactic acid", "OBSERVATION", 37, 48], ["tumor cells", "OBSERVATION", 74, 85], ["invasion", "OBSERVATION_MODIFIER", 97, 105], ["extracellular stroma", "OBSERVATION", 151, 171], ["tumor cells", "OBSERVATION", 184, 195], ["blood", "ANATOMY", 226, 231], ["lymphatic", "ANATOMY", 236, 245], ["cancer", "OBSERVATION", 367, 373], ["Rhus chinensis", "OBSERVATION", 448, 462]]], ["This was achieved through bioactivity 2 Evidence-Based Complementary and Alternative Medicine guided fractionation, theoretical molecular docking, and functional enzyme studies, followed by in vitro evaluation in a human breast cancer cell line with dominant protein expression of hLDH-A.Materials and MethodsMaterials used were Hanks Balanced Salt Solution, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), ethanol, 96-well plates, general reagents and supplies, and hLDH-A from Abcam (Cambridge, MA, USA).", [["breast cancer cell line", "ANATOMY", 221, 244], ["breast cancer", "DISEASE", 221, 234], ["4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid", "CHEMICAL", 359, 409], ["HEPES", "CHEMICAL", 411, 416], ["ethanol", "CHEMICAL", 419, 426], ["hLDH-A", "CHEMICAL", 479, 485], ["4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid", "CHEMICAL", 359, 409], ["HEPES", "CHEMICAL", 411, 416], ["ethanol", "CHEMICAL", 419, 426], ["human", "ORGANISM", 215, 220], ["breast cancer cell line", "CELL", 221, 244], ["hLDH-A.", "GENE_OR_GENE_PRODUCT", 281, 288], ["4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid", "SIMPLE_CHEMICAL", 359, 409], ["HEPES", "SIMPLE_CHEMICAL", 411, 416], ["ethanol", "SIMPLE_CHEMICAL", 419, 426], ["hLDH-A", "SIMPLE_CHEMICAL", 479, 485], ["human breast cancer cell line", "CELL_LINE", 215, 244], ["hLDH", "PROTEIN", 281, 285], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 215, 220], ["Alternative Medicine guided fractionation", "TREATMENT", 73, 114], ["theoretical molecular docking", "TEST", 116, 145], ["functional enzyme studies", "TEST", 151, 176], ["vitro evaluation", "TEST", 193, 209], ["a human breast cancer cell line", "TREATMENT", 213, 244], ["dominant protein expression of hLDH", "PROBLEM", 250, 285], ["MethodsMaterials", "TREATMENT", 302, 318], ["Hanks Balanced Salt Solution", "TREATMENT", 329, 357], ["hydroxyethyl)", "TREATMENT", 364, 377], ["piperazineethanesulfonic acid (HEPES", "TREATMENT", 380, 416], ["ethanol", "TREATMENT", 419, 426], ["general reagents", "TREATMENT", 444, 460], ["breast", "ANATOMY", 221, 227], ["cancer", "OBSERVATION", 228, 234], ["cell line", "OBSERVATION", 235, 244]]], ["Rhus chinensis gallnut was purchased from Kalyx Natural Marketplace (Camden, NY), cell lines were purchased from ATCC (Manassas, VA, USA), and penta-1,2,3,4,6-O-galloyl--d-glucose, chemical reagents, and HPLC supplies and columns were purchased from Sigma Aldrich (St. Louis, MO, USA) and VWR International (Suwanee, GA, USA).Herbal Extract.Dry RCG (500 g) was ground, homogenized, and then extracted in 90% ethanol three times for 24 h and the solutions were then combined and evaporated to obtain the crude extract.", [["cell lines", "ANATOMY", 82, 92], ["extract", "ANATOMY", 509, 516], ["penta-1,2,3,4,6-O-galloyl--d-glucose", "CHEMICAL", 143, 179], ["RCG", "CHEMICAL", 345, 348], ["ethanol", "CHEMICAL", 408, 415], ["penta-1,2,3,4,6-O-galloyl--d-glucose", "CHEMICAL", 143, 179], ["ethanol", "CHEMICAL", 408, 415], ["Rhus chinensis", "ORGANISM", 0, 14], ["gallnut", "ORGANISM", 15, 22], ["cell lines", "CELL", 82, 92], ["penta-1,2,3,4,6-O-galloyl--d-glucose", "SIMPLE_CHEMICAL", 143, 179], ["St. Louis", "ORGANISM", 265, 274], ["ethanol", "SIMPLE_CHEMICAL", 408, 415], ["cell lines", "CELL_LINE", 82, 92], ["Rhus chinensis", "SPECIES", 0, 14], ["Rhus chinensis gallnut", "SPECIES", 0, 22], ["ATCC", "SPECIES", 113, 117], ["Manassas", "SPECIES", 119, 127], ["cell lines", "TREATMENT", 82, 92], ["penta", "TEST", 143, 148], ["galloyl", "TEST", 161, 168], ["chemical reagents", "TREATMENT", 181, 198], ["Herbal Extract", "TREATMENT", 326, 340], ["the solutions", "TREATMENT", 441, 454], ["chinensis gallnut", "OBSERVATION", 5, 22], ["cell lines", "OBSERVATION", 82, 92], ["Extract", "OBSERVATION", 333, 340]]], ["Extract was then dissolved in water and successively fractionated by liquid-liquid partitioning between petroleum ether (three times, 200 mL), ethyl acetate (six times, 300 mL each), and n-butanol (three times, 200 mL each) to yield a petroleum ether soluble portion 3.5 g, ethyl acetate soluble portion 86 g, n-butanol soluble portion 7 g, and water-soluble portion 12 g.", [["petroleum ether", "CHEMICAL", 104, 119], ["ethyl acetate", "CHEMICAL", 143, 156], ["n-butanol", "CHEMICAL", 187, 196], ["petroleum ether", "CHEMICAL", 235, 250], ["ethyl acetate", "CHEMICAL", 274, 287], ["n-butanol", "CHEMICAL", 310, 319], ["petroleum ether", "CHEMICAL", 104, 119], ["ethyl acetate", "CHEMICAL", 143, 156], ["n-butanol", "CHEMICAL", 187, 196], ["petroleum ether", "CHEMICAL", 235, 250], ["ethyl acetate", "CHEMICAL", 274, 287], ["n-butanol", "CHEMICAL", 310, 319], ["Extract", "ORGANISM_SUBSTANCE", 0, 7], ["petroleum ether", "SIMPLE_CHEMICAL", 104, 119], ["ethyl acetate", "SIMPLE_CHEMICAL", 143, 156], ["n-butanol", "SIMPLE_CHEMICAL", 187, 196], ["ethyl acetate", "SIMPLE_CHEMICAL", 274, 287], ["n-butanol", "SIMPLE_CHEMICAL", 310, 319], ["Extract", "TREATMENT", 0, 7], ["liquid-liquid partitioning between petroleum ether", "TREATMENT", 69, 119], ["ethyl acetate", "TREATMENT", 143, 156], ["n-butanol", "TREATMENT", 187, 196], ["a petroleum ether soluble portion", "TREATMENT", 233, 266], ["ethyl acetate soluble portion", "TREATMENT", 274, 303], ["n-butanol soluble portion", "TREATMENT", 310, 335], ["water-soluble portion", "TREATMENT", 345, 366]]], ["The different fractions were tested against hLDH-A (0.02 units/mL) activity at concentrations ranging from 0.7 to 0.0007 mg/mL (all serial dilutions were made using diluents consisting of HBSS with 10-mM HEPES adjusted to a pH 7.4).", [["hLDH-A", "CHEMICAL", 44, 50], ["HEPES", "CHEMICAL", 204, 209], ["hLDH-A", "SIMPLE_CHEMICAL", 44, 50], ["The different fractions", "TREATMENT", 0, 23], ["hLDH", "TEST", 44, 48], ["all serial dilutions", "TREATMENT", 128, 148], ["HBSS", "TREATMENT", 188, 192], ["mM HEPES", "TREATMENT", 201, 209], ["a pH", "TEST", 222, 226]]], ["The dried ethyl acetate fraction showed hLDH-A inhibitory activity at a concentration of 0.0007 mg/mL.Bioactivity-Guided Isolation and Identification.The ethyl acetate fraction (20 g) was flash chromatographed over silica gel (200-400 mesh) and eluted at 10 mL/min with chloroform: methanol gradient (100 : 0, 10 : 90) solvent system.", [["ethyl acetate", "CHEMICAL", 10, 23], ["hLDH-A", "CHEMICAL", 40, 46], ["ethyl acetate", "CHEMICAL", 154, 167], ["silica gel", "CHEMICAL", 215, 225], ["ethyl acetate", "CHEMICAL", 10, 23], ["ethyl acetate", "CHEMICAL", 154, 167], ["silica gel", "CHEMICAL", 215, 225], ["chloroform", "CHEMICAL", 270, 280], ["methanol", "CHEMICAL", 282, 290], ["ethyl acetate", "SIMPLE_CHEMICAL", 10, 23], ["hLDH-A", "SIMPLE_CHEMICAL", 40, 46], ["ethyl acetate", "SIMPLE_CHEMICAL", 154, 167], ["silica", "SIMPLE_CHEMICAL", 215, 221], ["chloroform", "SIMPLE_CHEMICAL", 270, 280], ["methanol", "SIMPLE_CHEMICAL", 282, 290], ["The dried ethyl acetate fraction", "TEST", 0, 32], ["Identification", "TEST", 135, 149], ["The ethyl acetate fraction", "TREATMENT", 150, 176], ["flash chromatographed over silica gel", "TREATMENT", 188, 225], ["methanol gradient", "TEST", 282, 299]]], ["Fractions were pooled according to their value on TLC and then combined to give 5 distinct fractions which were then evaporated to yield 0.5 g (1-166), 11.5 g (167-215), 4.2 g (216-267), 2.1 g (268-350), and 1.2 g (351-500).", [["TLC", "TEST", 50, 53]]], ["The resulting fractions were tested for activity at 0.7-0.0007 mg/mL.", [["The resulting fractions", "TEST", 0, 23]]], ["Fractions (167-215) showed significant hLDH-A inhibitory activity relative to other fractions.", [["167-215", "CHEMICAL", 11, 18], ["hLDH-A", "SIMPLE_CHEMICAL", 39, 45], ["Fractions", "TEST", 0, 9], ["significant hLDH", "PROBLEM", 27, 43], ["significant", "OBSERVATION_MODIFIER", 27, 38]]], ["1.5 g of the active fraction, 167-215, was further analyzed and separated into four major fractions by RP-HPLC with UV detection at 214 nm on PRP-15 um 15 \u00d7 2.1 mm column and eluted with a gradient system of acetonitrile: water consisting of 0.2% TFA.Bioactivity-Guided Isolation and Identification.Fraction 1 (0.8 g) showed significant activity compared to the other three fractions and was further separated over RPcolumn chromatography on a C18-125\u00c5 55-105 um column and eluted with 30% acetonitrile to yield three fractions.", [["acetonitrile", "CHEMICAL", 208, 220], ["TFA", "CHEMICAL", 247, 250], ["acetonitrile", "CHEMICAL", 490, 502], ["acetonitrile", "CHEMICAL", 208, 220], ["TFA", "CHEMICAL", 247, 250], ["acetonitrile", "CHEMICAL", 490, 502], ["acetonitrile", "SIMPLE_CHEMICAL", 208, 220], ["TFA", "SIMPLE_CHEMICAL", 247, 250], ["acetonitrile", "SIMPLE_CHEMICAL", 490, 502], ["the active fraction", "TEST", 9, 28], ["RP", "TEST", 103, 105], ["UV detection", "TEST", 116, 128], ["PRP", "TEST", 142, 145], ["mm column", "TEST", 161, 170], ["Identification", "TEST", 284, 298], ["Fraction", "TEST", 299, 307], ["significant activity", "PROBLEM", 325, 345], ["RPcolumn chromatography", "TEST", 415, 438], ["a C18", "TEST", 442, 447], ["30% acetonitrile", "TREATMENT", 486, 502], ["significant", "OBSERVATION_MODIFIER", 325, 336], ["activity", "OBSERVATION", 337, 345]]], ["Fractions 2 (0.2 g) and 3 (0.15 g) showed similar activity and then were identified by 1H-NMR and 13C-NMR to be the same and then later combined.", [["1H", "CHEMICAL", 87, 89], ["13C", "CHEMICAL", 98, 101], ["1H", "SIMPLE_CHEMICAL", 87, 89], ["13C", "SIMPLE_CHEMICAL", 98, 101], ["Fractions", "TEST", 0, 9], ["NMR", "TEST", 90, 93], ["NMR", "TEST", 102, 105]]], ["The substance extracted was identified as PGG ( , supplemented with 10% FBS and penicillin/streptomycin (100 U/ 0.1 mg/mL).", [["PGG", "CHEMICAL", 42, 45], ["penicillin", "CHEMICAL", 80, 90], ["streptomycin", "CHEMICAL", 91, 103], ["PGG", "CHEMICAL", 42, 45], ["penicillin", "CHEMICAL", 80, 90], ["streptomycin", "CHEMICAL", 91, 103], ["PGG", "SIMPLE_CHEMICAL", 42, 45], ["FBS", "ORGANISM_SUBSTANCE", 72, 75], ["penicillin", "SIMPLE_CHEMICAL", 80, 90], ["streptomycin", "SIMPLE_CHEMICAL", 91, 103], ["10% FBS", "TREATMENT", 68, 75], ["penicillin", "TREATMENT", 80, 90], ["streptomycin", "TREATMENT", 91, 103]]], ["After confluence, the cells were subcultured and grown in DMEM containing phenol red, 10% FBS, 4 mM L-glutamine, 20 M sodium pyruvate, and penicillin/streptomycin (100 U/0.1 mg/mL).", [["cells", "ANATOMY", 22, 27], ["phenol", "CHEMICAL", 74, 80], ["L-glutamine", "CHEMICAL", 100, 111], ["sodium pyruvate", "CHEMICAL", 118, 133], ["penicillin", "CHEMICAL", 139, 149], ["streptomycin", "CHEMICAL", 150, 162], ["phenol red", "CHEMICAL", 74, 84], ["L-glutamine", "CHEMICAL", 100, 111], ["sodium pyruvate", "CHEMICAL", 118, 133], ["penicillin", "CHEMICAL", 139, 149], ["streptomycin", "CHEMICAL", 150, 162], ["cells", "CELL", 22, 27], ["phenol red", "SIMPLE_CHEMICAL", 74, 84], ["FBS", "ORGANISM_SUBSTANCE", 90, 93], ["L-glutamine", "SIMPLE_CHEMICAL", 100, 111], ["sodium pyruvate", "SIMPLE_CHEMICAL", 118, 133], ["penicillin", "SIMPLE_CHEMICAL", 139, 149], ["streptomycin", "SIMPLE_CHEMICAL", 150, 162], ["the cells", "PROBLEM", 18, 27], ["phenol red", "TREATMENT", 74, 84], ["FBS", "TEST", 90, 93], ["4 mM L-glutamine", "TREATMENT", 95, 111], ["20 M sodium pyruvate", "TREATMENT", 113, 133], ["penicillin", "TREATMENT", 139, 149], ["streptomycin", "TREATMENT", 150, 162], ["confluence", "OBSERVATION_MODIFIER", 6, 16]]], ["Culture conditions were maintained [37 \u2218 C-5% CO 2 /atmosphere] and every 2-5 days, the media were replaced and cells subcultured.", [["cells", "ANATOMY", 112, 117], ["CO", "CHEMICAL", 46, 48], ["cells", "CELL", 112, 117], ["Culture conditions", "TEST", 0, 18], ["C", "TEST", 41, 42], ["the media", "TREATMENT", 84, 93]]], ["For experiments, plating media consisted of DMEM, 1% FBS (24-hour toxicity studies), or 5% FBS (72-hour proliferation studies) + penicillin/streptomycin (100 U/0.1 mg/mL), 25 mM glucose, 2 mM sodium pyruvate, and 3 mM L-glutamine.Cell Count.Viable cell count was quantified using resazurin (Alamar Blue) indicator dye [30] .", [["FBS", "ANATOMY", 91, 94], ["Cell", "ANATOMY", 230, 234], ["cell", "ANATOMY", 248, 252], ["toxicity", "DISEASE", 66, 74], ["penicillin", "CHEMICAL", 129, 139], ["streptomycin", "CHEMICAL", 140, 152], ["glucose", "CHEMICAL", 178, 185], ["sodium pyruvate", "CHEMICAL", 192, 207], ["L-glutamine", "CHEMICAL", 218, 229], ["resazurin", "CHEMICAL", 280, 289], ["penicillin", "CHEMICAL", 129, 139], ["streptomycin", "CHEMICAL", 140, 152], ["glucose", "CHEMICAL", 178, 185], ["sodium pyruvate", "CHEMICAL", 192, 207], ["L-glutamine", "CHEMICAL", 218, 229], ["resazurin", "CHEMICAL", 280, 289], ["Alamar Blue", "CHEMICAL", 291, 302], ["FBS", "ORGANISM_SUBSTANCE", 53, 56], ["FBS", "ORGANISM_SUBSTANCE", 91, 94], ["penicillin", "SIMPLE_CHEMICAL", 129, 139], ["streptomycin", "SIMPLE_CHEMICAL", 140, 152], ["glucose", "SIMPLE_CHEMICAL", 178, 185], ["sodium pyruvate", "SIMPLE_CHEMICAL", 192, 207], ["L-glutamine", "SIMPLE_CHEMICAL", 218, 229], ["Cell", "CELL", 230, 234], ["Viable cell", "CELL", 241, 252], ["resazurin", "SIMPLE_CHEMICAL", 280, 289], ["Alamar Blue", "SIMPLE_CHEMICAL", 291, 302], ["DMEM", "PROBLEM", 44, 48], ["FBS", "TEST", 53, 56], ["toxicity studies", "TEST", 66, 82], ["FBS", "TEST", 91, 94], ["proliferation studies", "TEST", 104, 125], ["penicillin", "TREATMENT", 129, 139], ["streptomycin", "TREATMENT", 140, 152], ["25 mM glucose", "TREATMENT", 172, 185], ["2 mM sodium pyruvate", "TREATMENT", 187, 207], ["3 mM L-glutamine", "TREATMENT", 213, 229], ["Cell Count", "TEST", 230, 240], ["Viable cell count", "TEST", 241, 258], ["resazurin (Alamar Blue", "TREATMENT", 280, 302], ["cell count", "OBSERVATION", 248, 258]]], ["A working solution of resazurin was prepared in sterile PBS, phenol red (0.5 mg/mL), and added (15% v/v) to each sample.", [["sample", "ANATOMY", 113, 119], ["resazurin", "CHEMICAL", 22, 31], ["phenol", "CHEMICAL", 61, 67], ["resazurin", "CHEMICAL", 22, 31], ["phenol red", "CHEMICAL", 61, 71], ["resazurin", "SIMPLE_CHEMICAL", 22, 31], ["phenol red", "SIMPLE_CHEMICAL", 61, 71], ["A working solution of resazurin", "TREATMENT", 0, 31], ["phenol red", "TREATMENT", 61, 71]]], ["Samples were returned to the incubator for 6-8 hr, and reduction of the dye by viable cells (to resorufin, a fluorescent compound) was quantitatively analyzed using a microplate fluorometer, Model 7620, version 5 using matrix assisted laser desorption ionisation (MALDI) mass spectrometry and analysis by Mascot ID [18] .", [["Samples", "ANATOMY", 0, 7], ["cells", "ANATOMY", 86, 91], ["resorufin", "CHEMICAL", 96, 105], ["resorufin", "CHEMICAL", 96, 105], ["cells", "CELL", 86, 91], ["resorufin", "SIMPLE_CHEMICAL", 96, 105], ["Samples", "TEST", 0, 7], ["the dye", "TREATMENT", 68, 75], ["a microplate fluorometer", "TREATMENT", 165, 189], ["matrix assisted laser desorption ionisation (MALDI) mass spectrometry", "TREATMENT", 219, 288]]], ["Briefly, the enzyme assay buffer consisted of HBSS + calcium and Mg, pH adjusted to 7.0.", [["calcium", "CHEMICAL", 53, 60], ["Mg", "CHEMICAL", 65, 67], ["HBSS", "CHEMICAL", 46, 50], ["calcium", "CHEMICAL", 53, 60], ["Mg", "CHEMICAL", 65, 67], ["HBSS + calcium", "SIMPLE_CHEMICAL", 46, 60], ["Mg", "SIMPLE_CHEMICAL", 65, 67], ["the enzyme assay buffer", "TEST", 9, 32], ["HBSS", "TEST", 46, 50], ["calcium", "TEST", 53, 60], ["Mg", "TEST", 65, 67], ["pH", "TEST", 69, 71]]], ["PGG was added at various concentrations to hLDH-A enzyme (final concentration .02 units/mL) and -nicotinamide adenine dinucleotide, reduced form solution ( -NADH) (final working concentration of 500 M), and a prereading at 340 nm was established to eliminate background.", [["PGG", "CHEMICAL", 0, 3], ["hLDH-A", "CHEMICAL", 43, 49], ["nicotinamide", "CHEMICAL", 97, 109], ["adenine", "CHEMICAL", 110, 117], ["NADH", "CHEMICAL", 157, 161], ["PGG", "CHEMICAL", 0, 3], ["nicotinamide adenine dinucleotide", "CHEMICAL", 97, 130], ["NADH", "CHEMICAL", 157, 161], ["PGG", "SIMPLE_CHEMICAL", 0, 3], ["hLDH-A", "SIMPLE_CHEMICAL", 43, 49], ["-nicotinamide adenine dinucleotide", "SIMPLE_CHEMICAL", 96, 130], ["NADH", "SIMPLE_CHEMICAL", 157, 161], ["PGG", "TREATMENT", 0, 3], ["hLDH", "TEST", 43, 47], ["A enzyme", "TEST", 48, 56], ["nicotinamide adenine dinucleotide", "TREATMENT", 97, 130], ["reduced form solution", "TREATMENT", 132, 153]]], ["The reaction was started with a solution containing the substrate pyruvate (final concentration = 3 mM) and a reading was taken intermittently over 60 minutes at 340 nm using a 96-well microplate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA).Western Blot: hLDH-A Protein Expression.The presence of hLDH-A in MDA-MB-231 cells was determined using recombinant hLDH-A as the standard.", [["MDA-MB-231 cells", "ANATOMY", 316, 332], ["pyruvate", "CHEMICAL", 66, 74], ["hLDH-A", "CHEMICAL", 306, 312], ["MDA-MB-231", "CHEMICAL", 316, 326], ["pyruvate", "CHEMICAL", 66, 74], ["pyruvate", "SIMPLE_CHEMICAL", 66, 74], ["hLDH-A", "GENE_OR_GENE_PRODUCT", 264, 270], ["hLDH-A", "SIMPLE_CHEMICAL", 306, 312], ["MDA-MB-231 cells", "CELL", 316, 332], ["hLDH-A", "GENE_OR_GENE_PRODUCT", 366, 372], ["hLDH", "PROTEIN", 264, 268], ["hLDH", "PROTEIN", 306, 310], ["MDA-MB-231 cells", "CELL_LINE", 316, 332], ["hLDH", "PROTEIN", 366, 370], ["The reaction", "PROBLEM", 0, 12], ["a solution", "TREATMENT", 30, 40], ["the substrate pyruvate", "TREATMENT", 52, 74], ["Bio-Tek Instruments", "TREATMENT", 204, 223], ["hLDH", "TEST", 306, 310], ["A in MDA-MB", "TEST", 311, 322]]], ["Cells were washed and centrifuged and the supernatant was discarded using ice-cold sterile PBS at 4 \u2218 C. The pellet was resuspended and homogenized/sonicated in RIPA lysis buffer containing protease inhibitors.", [["Cells", "ANATOMY", 0, 5], ["supernatant", "ANATOMY", 42, 53], ["Cells", "CELL", 0, 5], ["ice-cold sterile PBS", "TREATMENT", 74, 94], ["RIPA lysis buffer", "TREATMENT", 161, 178], ["protease inhibitors", "TREATMENT", 190, 209]]], ["Samples were placed on ice for 30 min and centrifuged at 10,000 \u00d7g for 10 minutes at 4 \u2218 C. The supernatant was added at 1 : 1 of Laemmli sample buffer (Biorad number 161-0737) + fresh -ME and boiled for 5 minutes.", [["Samples", "ANATOMY", 0, 7], ["supernatant", "ANATOMY", 96, 107], ["Biorad number 161-0737", "CHEMICAL", 153, 175], ["Samples", "TEST", 0, 7], ["ice", "TREATMENT", 23, 26]]], ["Approximately 50 g of protein was loaded/lane and separated using 5%-15% SDS-PAGE gels, running buffer, 25 mM Tris, 192 mM glycine, and pH 8.3 (Biorad #161-0734) and applying 200 constant V constant \u223c35 min.", [["glycine", "CHEMICAL", 123, 130], ["Tris", "CHEMICAL", 110, 114], ["glycine", "CHEMICAL", 123, 130], ["glycine", "SIMPLE_CHEMICAL", 123, 130], ["mM glycine", "TEST", 120, 130], ["pH", "TEST", 136, 138], ["Biorad", "TEST", 144, 150]]], ["The proteins were transferred to polyvinylidene fluoride membranes (100 V for 30-60 minutes) in ice-cold transfer buffer containing 25 mM Tris, 192 mM glycine, and 20% methanol.", [["polyvinylidene fluoride", "CHEMICAL", 33, 56], ["glycine", "CHEMICAL", 151, 158], ["methanol", "CHEMICAL", 168, 176], ["polyvinylidene fluoride", "CHEMICAL", 33, 56], ["Tris", "CHEMICAL", 138, 142], ["glycine", "CHEMICAL", 151, 158], ["methanol", "CHEMICAL", 168, 176], ["polyvinylidene fluoride membranes", "SIMPLE_CHEMICAL", 33, 66], ["glycine", "SIMPLE_CHEMICAL", 151, 158], ["methanol", "SIMPLE_CHEMICAL", 168, 176], ["polyvinylidene fluoride membranes", "TREATMENT", 33, 66], ["mM glycine", "TREATMENT", 148, 158], ["20% methanol", "TREATMENT", 164, 176]]], ["The membranes were placed in a blocking buffer consisting of 5% bovine serum albumin fraction V (BSA) w/v in TBS + 0.05% Tween-20, pH 7.4.", [["membranes", "ANATOMY", 4, 13], ["serum", "ANATOMY", 71, 76], ["Tween-20", "CHEMICAL", 121, 129], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["bovine", "ORGANISM", 64, 70], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["albumin", "SIMPLE_CHEMICAL", 77, 84], ["BSA", "SIMPLE_CHEMICAL", 97, 100], ["Tween-20", "SIMPLE_CHEMICAL", 121, 129], ["bovine", "SPECIES", 64, 70], ["a blocking buffer", "TREATMENT", 29, 46], ["5% bovine serum albumin fraction", "TREATMENT", 61, 93], ["BSA", "TEST", 97, 100], ["TBS", "TEST", 109, 112], ["pH", "TEST", 131, 133]]], ["The membranes were washed and placed in 1 \u2218 rabbit antihuman LDH-A antibody (1 : 500) containing 1% BSA in TTBS at RT for 2 Hr. The membranes were washed in TTBS and incubated in 2 \u2218 goat anti-rabbit IgG (Fc specific) peroxidase conjugate (1 : 4000) in 2% nonfat dried milk in PBS for 1.5 Hr at RT.", [["membranes", "ANATOMY", 4, 13], ["membranes", "ANATOMY", 132, 141], ["milk", "ANATOMY", 269, 273], ["BSA", "CHEMICAL", 100, 103], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["rabbit", "ORGANISM", 44, 50], ["BSA", "SIMPLE_CHEMICAL", 100, 103], ["membranes", "CELLULAR_COMPONENT", 132, 141], ["goat", "ORGANISM", 183, 187], ["peroxidase conjugate", "SIMPLE_CHEMICAL", 218, 238], ["milk", "ORGANISM_SUBSTANCE", 269, 273], ["antihuman LDH-A antibody", "PROTEIN", 51, 75], ["anti-rabbit IgG", "PROTEIN", 188, 203], ["Fc specific) peroxidase", "PROTEIN", 205, 228], ["rabbit", "SPECIES", 44, 50], ["goat", "SPECIES", 183, 187], ["anti-rabbit", "SPECIES", 188, 199], ["rabbit", "SPECIES", 44, 50], ["goat", "SPECIES", 183, 187], ["rabbit antihuman LDH", "TEST", 44, 64], ["A antibody", "TEST", 65, 75]]], ["After a final wash, peroxidase was detected with Sigma FAST DAB (3,3 -diaminobenzidine tetrahydrochloride) with a metal enhancer cobalt chloride.", [["3,3 -diaminobenzidine tetrahydrochloride", "CHEMICAL", 65, 105], ["cobalt chloride", "CHEMICAL", 129, 144], ["DAB", "CHEMICAL", 60, 63], ["3,3 -diaminobenzidine tetrahydrochloride", "CHEMICAL", 65, 105], ["cobalt chloride", "CHEMICAL", 129, 144], ["peroxidase", "GENE_OR_GENE_PRODUCT", 20, 30], ["Sigma FAST DAB", "SIMPLE_CHEMICAL", 49, 63], ["3,3 -diaminobenzidine tetrahydrochloride", "SIMPLE_CHEMICAL", 65, 105], ["cobalt chloride", "SIMPLE_CHEMICAL", 129, 144], ["peroxidase", "PROTEIN", 20, 30], ["Sigma FAST DAB", "TEST", 49, 63], ["diaminobenzidine tetrahydrochloride", "TREATMENT", 70, 105], ["a metal enhancer cobalt chloride", "TREATMENT", 112, 144]]], ["Images were scanned using an Epson Stylus CX-8400.", [["CX-8400", "CHEMICAL", 42, 49], ["Images", "TEST", 0, 6], ["an Epson Stylus CX", "TEST", 26, 44]]], ["Intensity analysis was performed using ImageJ software provided from the National Institutes of Health [31] .Lactic AcidDetermination.", [["Intensity analysis", "TEST", 0, 18], ["ImageJ software", "TEST", 39, 54], ["Lactic AcidDetermination", "PROBLEM", 109, 133]]], ["Cellular production of lactic acid was determined in 96-well plates using a colorimetric enzymatic assay (procedure number 735, Sigma Diagnostics, St. Louis, MO).", [["Cellular", "ANATOMY", 0, 8], ["lactic acid", "CHEMICAL", 23, 34], ["lactic acid", "CHEMICAL", 23, 34], ["Cellular", "CELL", 0, 8], ["lactic acid", "SIMPLE_CHEMICAL", 23, 34], ["Cellular production", "TEST", 0, 19], ["lactic acid", "TEST", 23, 34], ["a colorimetric enzymatic assay", "TEST", 74, 104], ["lactic acid", "OBSERVATION", 23, 34]]], ["Briefly, lactate was quantified by conversion to pyruvate and H 2 O 2 using a base lactate reagent containing lactate oxidase (400 U/L) and horseradish peroxidase 2400 U/L (Trinity Biotech Jamestown, NY, USA).", [["lactate", "CHEMICAL", 9, 16], ["pyruvate", "CHEMICAL", 49, 57], ["H 2 O", "CHEMICAL", 62, 67], ["lactate", "CHEMICAL", 83, 90], ["lactate", "CHEMICAL", 110, 117], ["lactate", "CHEMICAL", 9, 16], ["pyruvate", "CHEMICAL", 49, 57], ["H 2 O 2", "CHEMICAL", 62, 69], ["lactate", "CHEMICAL", 83, 90], ["lactate", "CHEMICAL", 110, 117], ["lactate", "SIMPLE_CHEMICAL", 9, 16], ["pyruvate", "SIMPLE_CHEMICAL", 49, 57], ["H 2 O 2", "SIMPLE_CHEMICAL", 62, 69], ["lactate", "SIMPLE_CHEMICAL", 83, 90], ["lactate oxidase", "GENE_OR_GENE_PRODUCT", 110, 125], ["horseradish peroxidase", "GENE_OR_GENE_PRODUCT", 140, 162], ["lactate oxidase", "PROTEIN", 110, 125], ["horseradish peroxidase", "PROTEIN", 140, 162], ["horseradish", "SPECIES", 140, 151], ["lactate", "TEST", 9, 16], ["a base lactate reagent", "TEST", 76, 98], ["lactate oxidase", "TEST", 110, 125], ["horseradish peroxidase", "TREATMENT", 140, 162]]], ["The reagent was added to a chromogen and samples were incubated for 10 minutes at 37 \u2218 C. Lactate was quantified at 490 nm on a UV microplate spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA).", [["samples", "ANATOMY", 41, 48], ["Lactate", "CHEMICAL", 90, 97], ["chromogen", "CHEMICAL", 27, 36], ["Lactate", "CHEMICAL", 90, 97], ["chromogen", "SIMPLE_CHEMICAL", 27, 36], ["Lactate", "SIMPLE_CHEMICAL", 90, 97], ["a chromogen", "TEST", 25, 36], ["Lactate", "TEST", 90, 97], ["a UV microplate spectrophotometer (BioTek Instruments", "TREATMENT", 126, 179]]], ["Human LDH-A activity (% control)Lactic AcidRhus chinensis gallnut (mg/mL) IC 50 < 1 g/mL * * * * * * * * * Figure 1 : Potent hLDH-A enzyme inhibition by RCG extract.", [["hLDH-A", "CHEMICAL", 125, 131], ["RCG extract", "CHEMICAL", 153, 164], ["Human", "ORGANISM", 0, 5], ["LDH-A", "SIMPLE_CHEMICAL", 6, 11], ["hLDH-A", "SIMPLE_CHEMICAL", 125, 131], ["RCG", "SIMPLE_CHEMICAL", 153, 156], ["Human", "SPECIES", 0, 5], ["AcidRhus chinensis", "SPECIES", 39, 57], ["AcidRhus chinensis", "SPECIES", 39, 57], ["Human LDH", "TEST", 0, 9], ["A activity (% control", "TREATMENT", 10, 31], ["Lactic AcidRhus chinensis gallnut", "TREATMENT", 32, 65], ["A enzyme inhibition", "TREATMENT", 130, 149]]], ["The data represent hLDH-A activity as % control (NADH oxidation) at 60 minutes and are expressed as the mean \u00b1 SEM, = 4, with significance from controls using a one-way ANOVA followed by a Bonferroni's multiple comparison test; * = < 0.05, IC 50 < 1 g/mL.MolecularDocking.", [["NADH", "CHEMICAL", 49, 53], ["NADH", "CHEMICAL", 49, 53], ["hLDH-A", "SIMPLE_CHEMICAL", 19, 25], ["NADH", "SIMPLE_CHEMICAL", 49, 53], ["The data", "TEST", 0, 8], ["hLDH", "TEST", 19, 23], ["NADH oxidation", "TEST", 49, 63], ["the mean \u00b1 SEM", "TEST", 100, 114], ["a Bonferroni's multiple comparison test", "TEST", 187, 226], ["IC", "TEST", 240, 242]]], ["The X-ray crystal structure of human LDH (M form), predominantly found in human muscle, was downloaded from the RCSB protein data bank (PDB: 1I10).", [["muscle", "ANATOMY", 80, 86], ["human", "ORGANISM", 31, 36], ["LDH", "GENE_OR_GENE_PRODUCT", 37, 40], ["human", "ORGANISM", 74, 79], ["muscle", "ORGAN", 80, 86], ["human LDH", "PROTEIN", 31, 40], ["RCSB protein", "PROTEIN", 112, 124], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 74, 79], ["The X-ray crystal structure", "TEST", 0, 27], ["human LDH", "TEST", 31, 40], ["human LDH", "OBSERVATION", 31, 40], ["human muscle", "ANATOMY", 74, 86]]], ["Chain A was extracted and selected for the docking studies.", [["Chain A", "SIMPLE_CHEMICAL", 0, 7], ["the docking studies", "TEST", 39, 58]]], ["The chain A of the protein was then refined using the structure preparation tool of the biopolymer module offered by Sybyl-X 1.3 suite [26] .", [["chain A", "PROTEIN", 4, 11], ["the biopolymer module", "TREATMENT", 84, 105]]], ["In this process, mislabeled atom types from the pdb file were corrected, backbone and side chains repaired, side-chain bumps fixed, side chain amides checked to maximize potential hydrogen bonding, and all hydrogen atoms added to the protein.", [["amides", "CHEMICAL", 143, 149], ["hydrogen", "CHEMICAL", 180, 188], ["hydrogen", "CHEMICAL", 206, 214], ["side chain amides", "SIMPLE_CHEMICAL", 132, 149], ["hydrogen atoms", "SIMPLE_CHEMICAL", 206, 220], ["pdb file", "PROTEIN", 48, 56], ["the pdb file", "TEST", 44, 56], ["backbone and side chains repaired", "TREATMENT", 73, 106], ["side-chain bumps", "TREATMENT", 108, 124], ["side chain amides", "TEST", 132, 149], ["potential hydrogen bonding", "TREATMENT", 170, 196], ["all hydrogen atoms", "TREATMENT", 202, 220], ["pdb", "ANATOMY", 48, 51]]], ["The protein was then subjected to energy minimization following the gradient termination of the Powell method for 10,000 iterations using MMFF94s force field incorporating MMFF94 charges with nonbonding cut-off set at 8.0 and dielectric constant set at 1.0.", [["energy minimization", "TREATMENT", 34, 53], ["the gradient termination", "TREATMENT", 64, 88], ["the Powell method", "TREATMENT", 92, 109], ["MMFF94s force field", "TREATMENT", 138, 157], ["nonbonding cut", "TEST", 192, 206]]], ["The resulting refined protein was used for docking purposes.MolecularThe 3D conformer of the compound in present study, PGG structure, was download from the PubChem database and subjected to minimization following the gradient termination of the conjugate gradient method for 5000 iterations using Tripos force field incorporating Gasteiger-Huckel charges with the nonbonding cut-off set at 8.0 and dielectric constant set at 1.0.", [["PGG", "SIMPLE_CHEMICAL", 120, 123], ["docking purposes", "TEST", 43, 59], ["present study", "TEST", 105, 118], ["the PubChem database", "TEST", 153, 173], ["the gradient termination", "TREATMENT", 214, 238], ["the conjugate gradient method", "TREATMENT", 242, 271], ["Tripos force field", "TREATMENT", 298, 316], ["the nonbonding cut", "TREATMENT", 361, 379], ["Huckel charges", "OBSERVATION", 341, 355]]], ["Thus optimized compound PGG was docked in the catalytic active site of the chain A of the LDH protein complex (PDB: 1I10) using high precision Surlex-Dock GeomX program as implemented in Sybyl software by incremental construction approach of building the structure in the active site so as to favor the binding affinity.", [["PGG", "CHEMICAL", 24, 27], ["PGG", "CHEMICAL", 24, 27], ["PGG", "SIMPLE_CHEMICAL", 24, 27], ["LDH", "GENE_OR_GENE_PRODUCT", 90, 93], ["catalytic active site", "PROTEIN", 46, 67], ["chain A", "PROTEIN", 75, 82], ["LDH protein complex", "PROTEIN", 90, 109], ["PDB: 1I10", "PROTEIN", 111, 120], ["optimized compound PGG", "TREATMENT", 5, 27], ["the LDH protein complex", "TEST", 86, 109], ["incremental construction approach", "TREATMENT", 205, 238], ["the binding affinity", "PROBLEM", 299, 319], ["compound PGG", "OBSERVATION", 15, 27], ["active site", "OBSERVATION", 272, 283]]], ["In this process, initially, protomol was generated using the bound ligand 1,4-dihydronicotinamide adenine dinucleotide (NAI), allowing us to map the active site for docking the test ligand PGG.", [["protomol", "CHEMICAL", 28, 36], ["1,4-dihydronicotinamide adenine", "CHEMICAL", 74, 105], ["NAI", "CHEMICAL", 120, 123], ["protomol", "CHEMICAL", 28, 36], ["1,4-dihydronicotinamide adenine dinucleotide", "CHEMICAL", 74, 118], ["NAI", "CHEMICAL", 120, 123], ["protomol", "SIMPLE_CHEMICAL", 28, 36], ["1,4-dihydronicotinamide adenine dinucleotide", "SIMPLE_CHEMICAL", 74, 118], ["NAI", "SIMPLE_CHEMICAL", 120, 123], ["PGG", "GENE_OR_GENE_PRODUCT", 189, 192], ["PGG", "PROTEIN", 189, 192], ["protomol", "TREATMENT", 28, 36], ["the bound ligand", "TREATMENT", 57, 73], ["dihydronicotinamide adenine dinucleotide", "TREATMENT", 78, 118], ["docking the test ligand PGG", "TEST", 165, 192]]], ["During the entire docking process, ring flexibility of the ligand was considered.", [["ligand", "ANATOMY", 59, 65]]], ["Predock and postdock minimizations were performed and a self-scoring term was included for optimum results. .", [["postdock minimizations", "TEST", 12, 34]]], ["Significance of difference between multiple groups was assessed using a one-way ANOVA, followed by Bonferroni's multiple comparison test or Student's t-test.ResultsHigh-throughput screening has identified Rhus chinensis gallnut ethanol extract with inhibitory activity on human recombinant hLDH-A.", [["ethanol", "CHEMICAL", 228, 235], ["ethanol", "CHEMICAL", 228, 235], ["Rhus chinensis", "ORGANISM", 205, 219], ["gallnut", "ORGANISM", 220, 227], ["ethanol", "SIMPLE_CHEMICAL", 228, 235], ["human", "ORGANISM", 272, 277], ["hLDH", "PROTEIN", 290, 294], ["Rhus chinensis", "SPECIES", 205, 219], ["human", "SPECIES", 272, 277], ["Rhus chinensis", "SPECIES", 205, 219], ["human", "SPECIES", 272, 277], ["Student's t-test", "TEST", 140, 156], ["throughput screening", "TEST", 169, 189], ["difference", "OBSERVATION_MODIFIER", 16, 26]]], ["As previously reported, this was one of the most potent natural products elucidated with an IC 50 < 1 g/mL [18] .", [["an IC", "TREATMENT", 89, 94]]], ["In order to elucidate the active constituents within the RCG extract responsible for hLDH-A inhibition, bioactivity guided fractionation (Figure 2(a) ) was conducted to where hLDH-A activity was inhibited by the ethyl acetate fraction (167-215) (Figures 2(b) , and 2(c)), which further yielded two active fractions within (Figure 2(d) ).ResultsFractions 2 (0.2 g) and 3 (0.15 g) showed similar activity and then were identified by 1H-NMR and 13C-NMR to be the same and then later combined.", [["extract", "ANATOMY", 61, 68], ["RCG extract", "CHEMICAL", 57, 68], ["hLDH-A", "CHEMICAL", 85, 91], ["hLDH-A", "CHEMICAL", 175, 181], ["ethyl acetate", "CHEMICAL", 212, 225], ["167-215", "CHEMICAL", 236, 243], ["ethyl acetate", "CHEMICAL", 212, 225], ["1H", "CHEMICAL", 431, 433], ["13C", "CHEMICAL", 442, 445], ["RCG", "SIMPLE_CHEMICAL", 57, 60], ["hLDH-A", "SIMPLE_CHEMICAL", 85, 91], ["hLDH-A", "SIMPLE_CHEMICAL", 175, 181], ["ethyl acetate", "SIMPLE_CHEMICAL", 212, 225], ["2(c)", "SIMPLE_CHEMICAL", 265, 269], ["1H", "SIMPLE_CHEMICAL", 431, 433], ["13C", "SIMPLE_CHEMICAL", 442, 445], ["hLDH", "PROBLEM", 85, 89], ["A inhibition", "TREATMENT", 90, 102], ["bioactivity guided fractionation", "TREATMENT", 104, 136], ["the ethyl acetate fraction", "TEST", 208, 234], ["Figures", "TEST", 246, 253], ["ResultsFractions", "TEST", 337, 353], ["NMR", "TEST", 434, 437], ["NMR", "TEST", 446, 449]]], ["The molecule is identified as PGG (1,2,3,4,6-pentagalloylglucose) which is a solid and an off-white substance.", [["PGG", "CHEMICAL", 30, 33], ["1,2,3,4,6-pentagalloylglucose", "CHEMICAL", 35, 64], ["PGG", "CHEMICAL", 30, 33], ["1,2,3,4,6-pentagalloylglucose", "CHEMICAL", 35, 64], ["PGG", "SIMPLE_CHEMICAL", 30, 33], ["1,2,3,4,6-pentagalloylglucose", "SIMPLE_CHEMICAL", 35, 64], ["PGG", "TEST", 30, 33], ["molecule", "OBSERVATION", 4, 12]]], ["The melting point was determined on a Mel-Temp II apparatus (Laboratory Devices) and found to be 337 \u2218 C. MW Figure 3) where an external standard (b) versus extract (a) indicating PGG was present at 24.8 \u00b1 .85 g/mL, which is equivalent to 9.95 \u00b1 .34 of crude extract.ResultsTo assess if PGG could theoretically inhibit hLDH-A, molecular docking studies were conducted and the data show predicted competitive binding of PGG (Figure 4(a) ) within the NADH binding cofactor site of the hLDH-A enzyme (Figures 4(b) and 4(c) ).", [["extract", "ANATOMY", 259, 266], ["PGG", "CHEMICAL", 180, 183], ["PGG", "CHEMICAL", 287, 290], ["PGG", "CHEMICAL", 419, 422], ["NADH", "CHEMICAL", 449, 453], ["PGG", "CHEMICAL", 287, 290], ["PGG", "CHEMICAL", 419, 422], ["NADH", "CHEMICAL", 449, 453], ["PGG", "SIMPLE_CHEMICAL", 180, 183], ["PGG", "SIMPLE_CHEMICAL", 287, 290], ["hLDH-A", "GENE_OR_GENE_PRODUCT", 319, 325], ["PGG", "SIMPLE_CHEMICAL", 419, 422], ["NADH", "SIMPLE_CHEMICAL", 449, 453], ["hLDH-A", "GENE_OR_GENE_PRODUCT", 483, 489], ["PGG", "PROTEIN", 287, 290], ["hLDH", "PROTEIN", 319, 323], ["PGG", "PROTEIN", 419, 422], ["NADH binding cofactor site", "PROTEIN", 449, 475], ["hLDH-A enzyme", "PROTEIN", 483, 496], ["an external standard (b) versus extract", "TREATMENT", 125, 164], ["PGG", "TEST", 180, 183], ["PGG", "TEST", 287, 290], ["molecular docking studies", "TEST", 327, 352], ["the data", "TEST", 372, 380], ["the NADH binding cofactor site", "PROBLEM", 445, 475], ["the hLDH", "TEST", 479, 487], ["A enzyme", "TEST", 488, 496], ["Figures", "TEST", 498, 505], ["PGG", "OBSERVATION", 180, 183]]], ["Docking studies showed H bond interactions between the docked ligand PGG and the protein in the cofactor site (Figures 5(a) (Figures 1 and 2) .", [["H", "CHEMICAL", 23, 24], ["H", "CHEMICAL", 23, 24], ["H bond", "SIMPLE_CHEMICAL", 23, 29], ["PGG", "SIMPLE_CHEMICAL", 69, 72], ["PGG", "PROTEIN", 69, 72], ["cofactor site", "PROTEIN", 96, 109], ["Docking studies", "TEST", 0, 15], ["H bond interactions", "PROBLEM", 23, 42], ["cofactor site", "OBSERVATION", 96, 109]]], ["When compound PGG was docked alongside the bound ligand 1,4-dihydronicotinamide adenine dinucleotide (NAI), the total scores which are expressed aslog( ) obtained were 5.86 and 12.61, respectively, for PGG and the bound ligand NIA, respectively.", [["PGG", "CHEMICAL", 14, 17], ["1,4-dihydronicotinamide adenine", "CHEMICAL", 56, 87], ["NAI", "CHEMICAL", 102, 105], ["PGG", "CHEMICAL", 14, 17], ["1,4-dihydronicotinamide adenine dinucleotide", "CHEMICAL", 56, 100], ["NAI", "CHEMICAL", 102, 105], ["PGG", "CHEMICAL", 202, 205], ["PGG", "SIMPLE_CHEMICAL", 14, 17], ["1,4-dihydronicotinamide adenine dinucleotide", "SIMPLE_CHEMICAL", 56, 100], ["NAI", "SIMPLE_CHEMICAL", 102, 105], ["PGG", "SIMPLE_CHEMICAL", 202, 205], ["PGG", "PROTEIN", 202, 205], ["compound PGG", "PROBLEM", 5, 17], ["the bound ligand", "TEST", 39, 55], ["dihydronicotinamide adenine dinucleotide", "TREATMENT", 60, 100], ["the total scores", "TEST", 108, 124], ["PGG", "TEST", 202, 205]]], ["These effects were also confirmed by functional studies (Figure 5(a) ), where PGG was found to be an extremely potent hLDH-A inhibitor within the therapeutic range IC 50 = 27.17 nM compared to a known hLDH-A inhibitor oxalic acid ( Figure 5(b) ) demonstrating a relative weak potency reflected by an IC 50 > 6 mM.", [["PGG", "CHEMICAL", 78, 81], ["oxalic acid", "CHEMICAL", 218, 229], ["PGG", "CHEMICAL", 78, 81], ["oxalic acid", "CHEMICAL", 218, 229], ["PGG", "SIMPLE_CHEMICAL", 78, 81], ["hLDH-A", "SIMPLE_CHEMICAL", 118, 124], ["hLDH-A", "SIMPLE_CHEMICAL", 201, 207], ["oxalic acid", "SIMPLE_CHEMICAL", 218, 229], ["functional studies", "TEST", 37, 55], ["PGG", "TEST", 78, 81], ["A inhibitor", "TREATMENT", 123, 134], ["a known hLDH-A inhibitor oxalic acid", "TREATMENT", 193, 229], ["a relative weak potency", "PROBLEM", 260, 283], ["weak potency", "OBSERVATION_MODIFIER", 271, 283]]], ["Competitive binding of PGG versus NADH clearly shows that the site has greater affinity for PGG than NADH ( Figure 6 ).ResultsIn order to determine the effects of PGG in vitro, a human breast cancer cell line (MDA-MB-231) lysate was evaluated for the baseline expression of hLDH-A by Western blot (Figure 7) .", [["breast cancer cell line", "ANATOMY", 185, 208], ["MDA-MB-231) lysate", "ANATOMY", 210, 228], ["PGG", "CHEMICAL", 23, 26], ["NADH", "CHEMICAL", 34, 38], ["NADH", "CHEMICAL", 101, 105], ["PGG", "CHEMICAL", 163, 166], ["breast cancer", "DISEASE", 185, 198], ["MDA-MB-231", "CHEMICAL", 210, 220], ["PGG", "CHEMICAL", 23, 26], ["NADH", "CHEMICAL", 34, 38], ["PGG", "CHEMICAL", 92, 95], ["NADH", "CHEMICAL", 101, 105], ["PGG", "SIMPLE_CHEMICAL", 23, 26], ["NADH", "SIMPLE_CHEMICAL", 34, 38], ["PGG", "SIMPLE_CHEMICAL", 92, 95], ["NADH", "SIMPLE_CHEMICAL", 101, 105], ["PGG", "SIMPLE_CHEMICAL", 163, 166], ["human", "ORGANISM", 179, 184], ["breast cancer cell line", "CELL", 185, 208], ["MDA-MB-231) lysate", "CELL", 210, 228], ["hLDH-A", "GENE_OR_GENE_PRODUCT", 274, 280], ["PGG", "PROTEIN", 23, 26], ["NADH", "PROTEIN", 34, 38], ["PGG", "PROTEIN", 92, 95], ["PGG", "PROTEIN", 163, 166], ["human breast cancer cell line", "CELL_LINE", 179, 208], ["MDA-MB-231", "CELL_LINE", 210, 220], ["hLDH", "PROTEIN", 274, 278], ["human", "SPECIES", 179, 184], ["human", "SPECIES", 179, 184], ["Competitive binding of PGG versus NADH", "PROBLEM", 0, 38], ["the site", "PROBLEM", 58, 66], ["PGG in vitro", "TREATMENT", 163, 175], ["a human breast cancer cell line", "TREATMENT", 177, 208], ["MDA-MB", "TEST", 210, 216], ["lysate", "TEST", 222, 228], ["PGG", "OBSERVATION", 23, 26], ["breast", "ANATOMY", 185, 191], ["cancer", "OBSERVATION", 192, 198]]], ["These findings validate the identity of the recombinant protein used in this study, as well as demonstrating dominant expression level in MDA-MB-231 cells, further subject to in vitro effects incurred by PGG.ResultsIn vitro analyses on the lethality of PGG versus reduction in lactic acid accumulated in the supernatant were near identical (Figures 8(a) and 8(b) ).", [["MDA-MB-231 cells", "ANATOMY", 138, 154], ["supernatant", "ANATOMY", 308, 319], ["PGG", "CHEMICAL", 204, 207], ["PGG", "CHEMICAL", 253, 256], ["lactic acid", "CHEMICAL", 277, 288], ["PGG", "CHEMICAL", 253, 256], ["lactic acid", "CHEMICAL", 277, 288], ["MDA-MB-231 cells", "CELL", 138, 154], ["PGG", "SIMPLE_CHEMICAL", 204, 207], ["PGG", "SIMPLE_CHEMICAL", 253, 256], ["lactic acid", "SIMPLE_CHEMICAL", 277, 288], ["recombinant protein", "PROTEIN", 44, 63], ["MDA-MB-231 cells", "CELL_LINE", 138, 154], ["PGG", "PROTEIN", 204, 207], ["the recombinant protein", "PROBLEM", 40, 63], ["this study", "TEST", 72, 82], ["dominant expression level", "PROBLEM", 109, 134], ["MDA-MB", "TEST", 138, 144], ["PGG versus reduction", "TREATMENT", 253, 273], ["lactic acid", "PROBLEM", 277, 288], ["dominant", "OBSERVATION_MODIFIER", 109, 117], ["expression", "OBSERVATION", 118, 128], ["lactic acid", "OBSERVATION", 277, 288]]], ["However, given that all toxic compounds regardless of mechanism of action will reduce lactic acid as a process of cell death in tumor cells, there is no conclusion drawn from this data.", [["cell", "ANATOMY", 114, 118], ["tumor cells", "ANATOMY", 128, 139], ["lactic acid", "CHEMICAL", 86, 97], ["death", "DISEASE", 119, 124], ["tumor", "DISEASE", 128, 133], ["lactic acid", "CHEMICAL", 86, 97], ["lactic acid", "SIMPLE_CHEMICAL", 86, 97], ["cell", "CELL", 114, 118], ["tumor cells", "CELL", 128, 139], ["tumor cells", "CELL_TYPE", 128, 139], ["all toxic compounds", "PROBLEM", 20, 39], ["lactic acid", "PROBLEM", 86, 97], ["cell death in tumor cells", "PROBLEM", 114, 139], ["this data", "TEST", 175, 184], ["tumor cells", "OBSERVATION", 128, 139], ["no", "UNCERTAINTY", 150, 152]]], ["If loss of lactate significantly preceded cell death, one could say there was a correlation, but further analysis will be required.", [["cell", "ANATOMY", 42, 46], ["lactate", "CHEMICAL", 11, 18], ["death", "DISEASE", 47, 52], ["lactate", "CHEMICAL", 11, 18], ["lactate", "SIMPLE_CHEMICAL", 11, 18], ["cell", "CELL", 42, 46], ["loss of lactate significantly preceded cell death", "PROBLEM", 3, 52], ["further analysis", "TEST", 97, 113]]], ["The antiproliferative effects of PGG relative to paclitaxel were evaluated over a three-day growth period (Figure 9 ).", [["PGG", "CHEMICAL", 33, 36], ["paclitaxel", "CHEMICAL", 49, 59], ["PGG", "CHEMICAL", 33, 36], ["paclitaxel", "CHEMICAL", 49, 59], ["PGG", "SIMPLE_CHEMICAL", 33, 36], ["paclitaxel", "SIMPLE_CHEMICAL", 49, 59], ["PGG", "TREATMENT", 33, 36], ["paclitaxel", "TREATMENT", 49, 59], ["antiproliferative", "OBSERVATION_MODIFIER", 4, 21]]], ["In this study, we provide data toDiscussionThe data in this study confirm penta-1,2,3,4,6-O-galloyl--dglucose (PGG)-a component in RCG-as a newly identified hLDH-A inhibitor with potential application as a CAM for use in cancer treatment.", [["cancer", "ANATOMY", 221, 227], ["penta-1,2,3,4,6-O-galloyl--dglucose", "CHEMICAL", 74, 109], ["PGG", "CHEMICAL", 111, 114], ["RCG", "CHEMICAL", 131, 134], ["cancer", "DISEASE", 221, 227], ["penta-1,2,3,4,6-O-galloyl--dglucose", "CHEMICAL", 74, 109], ["PGG", "CHEMICAL", 111, 114], ["penta-1,2,3,4,6-O-galloyl--dglucose", "SIMPLE_CHEMICAL", 74, 109], ["PGG", "SIMPLE_CHEMICAL", 111, 114], ["RCG", "SIMPLE_CHEMICAL", 131, 134], ["hLDH-A", "SIMPLE_CHEMICAL", 157, 163], ["CAM", "MULTI-TISSUE_STRUCTURE", 206, 209], ["cancer", "CANCER", 221, 227], ["this study", "TEST", 3, 13], ["this study", "TEST", 55, 65], ["penta", "TEST", 74, 79], ["galloyl", "TEST", 92, 99], ["A inhibitor", "TREATMENT", 162, 173], ["a CAM", "TREATMENT", 204, 209], ["cancer treatment", "TREATMENT", 221, 237], ["cancer", "OBSERVATION", 221, 227]]], ["Our work supports/builds on the findings of others in describing therapeutic value of this molecule as an anticancer agent, now having been established in the suppression of prostate cancer metastasis [32] , angiogenesis, with capacity to initiate apoptosis [33] [34] [35] [36] , and halt cell cycle at the G1 phase [37, 38] at the DNA replication Sphase [39] , corresponding to the primary basis of proposed therapeutic use in treatment of cancers [40] .", [["anticancer", "ANATOMY", 106, 116], ["prostate cancer", "ANATOMY", 174, 189], ["cell", "ANATOMY", 289, 293], ["cancers", "ANATOMY", 441, 448], ["prostate cancer", "DISEASE", 174, 189], ["cancers", "DISEASE", 441, 448], ["anticancer", "CANCER", 106, 116], ["prostate cancer", "CANCER", 174, 189], ["cell", "CELL", 289, 293], ["DNA", "CELLULAR_COMPONENT", 332, 335], ["cancers", "CANCER", 441, 448], ["an anticancer agent", "TREATMENT", 103, 122], ["prostate cancer metastasis", "PROBLEM", 174, 200], ["angiogenesis", "PROBLEM", 208, 220], ["apoptosis", "TEST", 248, 257], ["halt cell cycle", "TEST", 284, 299], ["cancers", "PROBLEM", 441, 448], ["prostate", "ANATOMY", 174, 182], ["cancer", "OBSERVATION", 183, 189], ["cancers", "OBSERVATION", 441, 448]]], ["At the same time, the RGC extract as a whole is equally capable of inhibiting angiogenesis, inducing apoptosis in cancer cells [34] and as a cytostatic agent [7] .", [["RGC extract", "ANATOMY", 22, 33], ["cancer cells", "ANATOMY", 114, 126], ["cancer", "DISEASE", 114, 120], ["cancer cells", "CELL", 114, 126], ["cancer cells", "CELL_TYPE", 114, 126], ["inhibiting angiogenesis", "PROBLEM", 67, 90], ["apoptosis in cancer cells", "PROBLEM", 101, 126], ["a cytostatic agent", "TREATMENT", 139, 157]]], ["Moreover, its medicinal value has been described in the scientific literature for its multidimensional therapeutic value, also effective against harmful intestinal and periodontal bacteria [9, 41] , hepatitis carcinoma virus [15] , severe acute respiratory syndrome corona [42] and as an anti-inflammatory [11, [43] [44] [45] .DiscussionThe data in this study also confirm the ability of PGG to inhibit hLDH-A which is a therapeutic target in particular given its role in tumor initiation, progression, and metastasis [46, 47] and in aggressive malignancies such as pheochromocytomas, paragangliomas [48] , or breast cancer [49] .", [["intestinal", "ANATOMY", 153, 163], ["tumor", "ANATOMY", 472, 477], ["malignancies", "ANATOMY", 545, 557], ["pheochromocytomas", "ANATOMY", 566, 583], ["paragangliomas", "ANATOMY", 585, 599], ["breast cancer", "ANATOMY", 610, 623], ["hepatitis carcinoma", "DISEASE", 199, 218], ["acute respiratory syndrome corona", "DISEASE", 239, 272], ["PGG", "CHEMICAL", 388, 391], ["hLDH-A", "CHEMICAL", 403, 409], ["tumor", "DISEASE", 472, 477], ["malignancies", "DISEASE", 545, 557], ["pheochromocytomas", "DISEASE", 566, 583], ["paragangliomas", "DISEASE", 585, 599], ["breast cancer", "DISEASE", 610, 623], ["PGG", "CHEMICAL", 388, 391], ["intestinal", "ORGAN", 153, 163], ["hepatitis carcinoma virus", "ORGANISM", 199, 224], ["[43] [44] [45]", "SIMPLE_CHEMICAL", 311, 325], ["PGG", "SIMPLE_CHEMICAL", 388, 391], ["hLDH-A", "GENE_OR_GENE_PRODUCT", 403, 409], ["tumor", "CANCER", 472, 477], ["malignancies", "CANCER", 545, 557], ["pheochromocytomas", "CANCER", 566, 583], ["paragangliomas", "CANCER", 585, 599], ["breast cancer", "CANCER", 610, 623], ["PGG", "PROTEIN", 388, 391], ["hLDH", "PROTEIN", 403, 407], ["hepatitis carcinoma virus", "SPECIES", 199, 224], ["harmful intestinal and periodontal bacteria", "PROBLEM", 145, 188], ["hepatitis carcinoma virus", "PROBLEM", 199, 224], ["severe acute respiratory syndrome corona", "PROBLEM", 232, 272], ["an anti-inflammatory", "TEST", 285, 305], ["this study", "TEST", 349, 359], ["PGG", "PROBLEM", 388, 391], ["tumor initiation", "TREATMENT", 472, 488], ["metastasis", "PROBLEM", 507, 517], ["aggressive malignancies", "PROBLEM", 534, 557], ["pheochromocytomas", "PROBLEM", 566, 583], ["paragangliomas", "PROBLEM", 585, 599], ["breast cancer", "PROBLEM", 610, 623], ["periodontal", "ANATOMY", 168, 179], ["hepatitis carcinoma", "OBSERVATION", 199, 218], ["severe", "OBSERVATION_MODIFIER", 232, 238], ["acute", "OBSERVATION_MODIFIER", 239, 244], ["respiratory syndrome", "OBSERVATION", 245, 265], ["tumor", "OBSERVATION", 472, 477], ["progression", "OBSERVATION_MODIFIER", 490, 501], ["metastasis", "OBSERVATION", 507, 517], ["aggressive", "OBSERVATION_MODIFIER", 534, 544], ["malignancies", "OBSERVATION", 545, 557], ["pheochromocytomas", "OBSERVATION", 566, 583], ["paragangliomas", "OBSERVATION", 585, 599], ["breast", "ANATOMY", 610, 616], ["cancer", "OBSERVATION", 617, 623]]], ["Interestingly, while LDH is a specific therapeutic target in tumor cells, its exact mechanism of action to exert anticancer effects remains unknown.DiscussionIt is believe that elevated hLDH-A protein expression in tumor cells, and subsequent over production of lactic acid contributes to development of radiation and chemotherapy resistance [27, 28] .", [["tumor cells", "ANATOMY", 61, 72], ["anticancer", "ANATOMY", 113, 123], ["tumor cells", "ANATOMY", 215, 226], ["tumor", "DISEASE", 61, 66], ["tumor", "DISEASE", 215, 220], ["lactic acid", "CHEMICAL", 262, 273], ["lactic acid", "CHEMICAL", 262, 273], ["LDH", "GENE_OR_GENE_PRODUCT", 21, 24], ["tumor cells", "CELL", 61, 72], ["anticancer", "CANCER", 113, 123], ["hLDH-A", "GENE_OR_GENE_PRODUCT", 186, 192], ["tumor cells", "CELL", 215, 226], ["lactic acid", "SIMPLE_CHEMICAL", 262, 273], ["LDH", "PROTEIN", 21, 24], ["tumor cells", "CELL_TYPE", 61, 72], ["hLDH", "PROTEIN", 186, 190], ["tumor cells", "CELL_TYPE", 215, 226], ["LDH", "TEST", 21, 24], ["tumor cells", "PROBLEM", 61, 72], ["anticancer effects", "TREATMENT", 113, 131], ["elevated hLDH", "PROBLEM", 177, 190], ["A protein expression in tumor cells", "PROBLEM", 191, 226], ["lactic acid", "PROBLEM", 262, 273], ["radiation and chemotherapy resistance", "TREATMENT", 304, 341], ["tumor cells", "OBSERVATION", 61, 72], ["tumor cells", "OBSERVATION", 215, 226], ["radiation", "OBSERVATION", 304, 313]]], ["Tumor cell overproduction of lactic acid (in the absence or presence of O 2 ) was described almost a century ago by Otto Warburg, having been termed \"the Warburg effect. \"", [["Tumor cell", "ANATOMY", 0, 10], ["lactic acid", "CHEMICAL", 29, 40], ["lactic acid", "CHEMICAL", 29, 40], ["O 2", "CHEMICAL", 72, 75], ["Tumor cell", "CELL", 0, 10], ["lactic acid", "SIMPLE_CHEMICAL", 29, 40], ["Tumor cell overproduction", "PROBLEM", 0, 25], ["lactic acid", "PROBLEM", 29, 40], ["lactic acid", "OBSERVATION", 29, 40], ["Warburg effect", "OBSERVATION", 154, 168]]], ["While many scientists theorize that this aberration is a function of altered metabolism, studies in our laboratory exploring this phenomenon using current technologies such as whole-genomic, proteomic MALDI-TOF-MS and metabolite analysis show that the Warburg effect has a functional role not in metabolism, but in regulating acidic pericellular pH (pHe).", [["pericellular", "ANATOMY", 333, 345], ["altered metabolism", "PROBLEM", 69, 87], ["this phenomenon", "PROBLEM", 125, 140], ["current technologies", "TREATMENT", 147, 167], ["proteomic MALDI", "TEST", 191, 206], ["TOF", "TEST", 207, 210], ["MS", "PROBLEM", 211, 213], ["metabolite analysis", "TEST", 218, 237], ["the Warburg effect", "PROBLEM", 248, 266]]], ["For some unknown reason, cancer cells inherently thrive in slightly acidic pH, are extremely vulnerable to necrosis as the pH shifts toward alkaline, and will sustain a steady state pH through metabolic inversion or fluctuating dominance between glycolytic-rate substrate level phosphorylation (SLP) and mitochondrial (mt) oxidative phosphorylation to control lactic acid production [50] .", [["cancer cells", "ANATOMY", 25, 37], ["mitochondrial", "ANATOMY", 304, 317], ["cancer", "DISEASE", 25, 31], ["necrosis", "DISEASE", 107, 115], ["lactic acid", "CHEMICAL", 360, 371], ["lactic acid", "CHEMICAL", 360, 371], ["cancer cells", "CELL", 25, 37], ["mitochondrial", "CELLULAR_COMPONENT", 304, 317], ["lactic acid", "SIMPLE_CHEMICAL", 360, 371], ["cancer cells", "CELL_TYPE", 25, 37], ["SLP", "PROTEIN", 295, 298], ["cancer cells", "PROBLEM", 25, 37], ["slightly acidic pH", "PROBLEM", 59, 77], ["necrosis", "PROBLEM", 107, 115], ["the pH shifts", "TEST", 119, 132], ["alkaline", "TEST", 140, 148], ["metabolic inversion", "PROBLEM", 193, 212], ["fluctuating dominance", "PROBLEM", 216, 237], ["glycolytic-rate substrate level phosphorylation", "TREATMENT", 246, 293], ["mitochondrial (mt) oxidative phosphorylation", "TREATMENT", 304, 348], ["lactic acid production", "PROBLEM", 360, 382], ["cancer", "OBSERVATION", 25, 31], ["slightly", "OBSERVATION_MODIFIER", 59, 67], ["acidic pH", "OBSERVATION_MODIFIER", 68, 77], ["necrosis", "OBSERVATION", 107, 115]]], ["If this is the case, then hLDH-A would comprise a vehicle to maintain acidic pH where tumor cells thrive, but the question after much work still remains as to why tumor cells require ample concentrations of acid.DiscussionAcidity alone, can trigger aggressive forms of malignancy, augment metastases, and initiate chemoresistance all of which correlate to low survival rates [51, 52] .", [["tumor cells", "ANATOMY", 86, 97], ["tumor cells", "ANATOMY", 163, 174], ["malignancy", "ANATOMY", 269, 279], ["metastases", "ANATOMY", 289, 299], ["hLDH-A", "CHEMICAL", 26, 32], ["tumor", "DISEASE", 86, 91], ["tumor", "DISEASE", 163, 168], ["malignancy", "DISEASE", 269, 279], ["metastases", "DISEASE", 289, 299], ["hLDH-A", "SIMPLE_CHEMICAL", 26, 32], ["tumor cells", "CELL", 86, 97], ["tumor cells", "CELL", 163, 174], ["malignancy", "CANCER", 269, 279], ["tumor cells", "CELL_TYPE", 86, 97], ["tumor cells", "CELL_TYPE", 163, 174], ["acidic pH", "PROBLEM", 70, 79], ["tumor cells thrive", "PROBLEM", 86, 104], ["tumor cells", "PROBLEM", 163, 174], ["ample concentrations of acid", "TREATMENT", 183, 211], ["malignancy", "PROBLEM", 269, 279], ["augment metastases", "PROBLEM", 281, 299], ["chemoresistance", "PROBLEM", 314, 329], ["low survival rates", "PROBLEM", 356, 374], ["malignancy", "OBSERVATION", 269, 279], ["metastases", "OBSERVATION", 289, 299]]], ["Data collected from our lab and by others seems to indicate that acid can Figure 9 : Inhibitory growth properties of PGG on MDA-MB-231 human breast carcinoma cells relative to 1 M paclitaxel.", [["MDA-MB-231 human breast carcinoma cells", "ANATOMY", 124, 163], ["PGG", "CHEMICAL", 117, 120], ["MDA-MB-231", "CHEMICAL", 124, 134], ["breast carcinoma", "DISEASE", 141, 157], ["paclitaxel", "CHEMICAL", 180, 190], ["PGG", "CHEMICAL", 117, 120], ["paclitaxel", "CHEMICAL", 180, 190], ["PGG", "SIMPLE_CHEMICAL", 117, 120], ["MDA-MB-231 human breast carcinoma cells", "CELL", 124, 163], ["paclitaxel", "SIMPLE_CHEMICAL", 180, 190], ["MDA-MB-231 human breast carcinoma cells", "CELL_LINE", 124, 163], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 135, 140], ["PGG", "TEST", 117, 120], ["MDA", "TEST", 124, 127], ["MB", "TEST", 128, 130], ["human breast carcinoma cells", "PROBLEM", 135, 163], ["1 M paclitaxel", "TREATMENT", 176, 190], ["breast", "ANATOMY", 141, 147], ["carcinoma cells", "OBSERVATION", 148, 163]]], ["The data represent growth from an initial plating density of 4,000 cells/well in 96-well plates over a 72-hour period as proliferation (% untreated controls) established with resazurin (Alamar Blue) fluorometric analysis.", [["cells", "ANATOMY", 67, 72], ["resazurin", "CHEMICAL", 175, 184], ["resazurin", "CHEMICAL", 175, 184], ["Alamar Blue", "CHEMICAL", 186, 197], ["cells", "CELL", 67, 72], ["resazurin", "SIMPLE_CHEMICAL", 175, 184], ["4,000 cells", "CELL_LINE", 61, 72], ["an initial plating density", "TEST", 31, 57], ["proliferation (% untreated controls", "TREATMENT", 121, 156], ["resazurin", "TREATMENT", 175, 184], ["fluorometric analysis", "TEST", 199, 220], ["growth", "OBSERVATION_MODIFIER", 19, 25]]], ["The data represents cell proliferation as % control and is presented as the mean \u00b1 SEM, = 4, with significance from controls determined using a one-way ANOVA followed by Bonferroni's multiple comparison test; * = < 0.05.DiscussionEvidence-Based Complementary and Alternative Medicine 9 turn on anabolic processes in tumor cells, due to energy efficiency with elevated protein expression for nutrient sensor G L (G protein, beta protein subunit-like), a component of mTOR (mammalian target of rapamycin), PI3K/Akt signaling, and its downstream eIF4E tumor promoting target [53] .", [["cell", "ANATOMY", 20, 24], ["tumor cells", "ANATOMY", 316, 327], ["tumor", "ANATOMY", 549, 554], ["tumor", "DISEASE", 316, 321], ["rapamycin", "CHEMICAL", 492, 501], ["tumor", "DISEASE", 549, 554], ["rapamycin", "CHEMICAL", 492, 501], ["cell", "CELL", 20, 24], ["tumor cells", "CELL", 316, 327], ["nutrient sensor G L", "GENE_OR_GENE_PRODUCT", 391, 410], ["G protein", "GENE_OR_GENE_PRODUCT", 412, 421], ["beta protein subunit", "GENE_OR_GENE_PRODUCT", 423, 443], ["mTOR", "GENE_OR_GENE_PRODUCT", 466, 470], ["mammalian target of rapamycin", "GENE_OR_GENE_PRODUCT", 472, 501], ["PI3K", "GENE_OR_GENE_PRODUCT", 504, 508], ["Akt", "GENE_OR_GENE_PRODUCT", 509, 512], ["eIF4E", "GENE_OR_GENE_PRODUCT", 543, 548], ["tumor", "CANCER", 549, 554], ["tumor cells", "CELL_TYPE", 316, 327], ["G L", "PROTEIN", 407, 410], ["G protein", "PROTEIN", 412, 421], ["beta protein subunit", "PROTEIN", 423, 443], ["mTOR", "PROTEIN", 466, 470], ["mammalian target of rapamycin", "PROTEIN", 472, 501], ["PI3K", "PROTEIN", 504, 508], ["Akt", "PROTEIN", 509, 512], ["eIF4E", "PROTEIN", 543, 548], ["cell proliferation", "TREATMENT", 20, 38], ["the mean \u00b1 SEM", "TEST", 72, 86], ["Bonferroni's multiple comparison test", "TEST", 170, 207], ["Alternative Medicine", "TREATMENT", 263, 283], ["anabolic processes", "TREATMENT", 294, 312], ["tumor cells", "PROBLEM", 316, 327], ["energy efficiency", "PROBLEM", 336, 353], ["elevated protein expression", "PROBLEM", 359, 386], ["nutrient sensor G L (G protein", "TEST", 391, 421], ["beta protein subunit", "TEST", 423, 443], ["rapamycin", "TREATMENT", 492, 501], ["PI3K/Akt signaling", "PROBLEM", 504, 522], ["cell proliferation", "OBSERVATION", 20, 38], ["tumor cells", "OBSERVATION", 316, 327]]], ["These changes are indicative that feedback sensors (such as acid) could switch the metabolic state of tumor cells from anabolic to catabolic [54] .", [["tumor cells", "ANATOMY", 102, 113], ["tumor", "DISEASE", 102, 107], ["tumor cells", "CELL", 102, 113], ["tumor cells", "CELL_TYPE", 102, 113], ["feedback sensors", "PROBLEM", 34, 50], ["tumor cells", "PROBLEM", 102, 113]]], ["While the exact role of hLDH-A remains elusive, it is known that hLDH-A knockdown, or lowering the functional capacity of hLDH-A, can lead to suppressed tumor growth and metastasis indicating this enzyme as a novel targeted cancer therapy strategy.", [["tumor", "ANATOMY", 153, 158], ["cancer", "ANATOMY", 224, 230], ["hLDH-A", "CHEMICAL", 122, 128], ["tumor", "DISEASE", 153, 158], ["cancer", "DISEASE", 224, 230], ["hLDH-A", "GENE_OR_GENE_PRODUCT", 24, 30], ["hLDH-A", "GENE_OR_GENE_PRODUCT", 65, 71], ["hLDH-A", "GENE_OR_GENE_PRODUCT", 122, 128], ["tumor", "CANCER", 153, 158], ["cancer", "CANCER", 224, 230], ["hLDH", "PROTEIN", 24, 28], ["hLDH", "PROTEIN", 122, 126], ["A knockdown", "PROBLEM", 70, 81], ["suppressed tumor growth", "PROBLEM", 142, 165], ["metastasis", "PROBLEM", 170, 180], ["this enzyme", "PROBLEM", 192, 203], ["a novel targeted cancer therapy strategy", "TREATMENT", 207, 247], ["tumor", "OBSERVATION", 153, 158], ["metastasis", "OBSERVATION", 170, 180], ["cancer", "OBSERVATION", 224, 230]]], ["In this study, we provide data to support therapeutic efficacy of PGG, a component of RGC extract, to inhibit human LDH-A and halt proliferation of a human tumor cell line MDA-MB-231, which highly expresses the hLDH-A protein.ConclusionPentagalloylglucose, PGG, a component of RGC, shows a remarkable competitive inhibitory activity against hLDH-A at the NADH cofactor docking site.", [["RGC extract", "ANATOMY", 86, 97], ["tumor cell line MDA-MB-231", "ANATOMY", 156, 182], ["PGG", "CHEMICAL", 66, 69], ["tumor", "DISEASE", 156, 161], ["MDA-MB-231", "CHEMICAL", 172, 182], ["Pentagalloylglucose", "CHEMICAL", 236, 255], ["PGG", "CHEMICAL", 257, 260], ["hLDH-A", "CHEMICAL", 341, 347], ["NADH", "CHEMICAL", 355, 359], ["PGG", "CHEMICAL", 66, 69], ["Pentagalloylglucose", "CHEMICAL", 236, 255], ["PGG", "CHEMICAL", 257, 260], ["NADH", "CHEMICAL", 355, 359], ["PGG", "SIMPLE_CHEMICAL", 66, 69], ["RGC", "SIMPLE_CHEMICAL", 86, 89], ["human", "ORGANISM", 110, 115], ["LDH-A", "GENE_OR_GENE_PRODUCT", 116, 121], ["human", "ORGANISM", 150, 155], ["tumor cell line MDA-MB-231", "CELL", 156, 182], ["hLDH-A", "GENE_OR_GENE_PRODUCT", 211, 217], ["Pentagalloylglucose", "SIMPLE_CHEMICAL", 236, 255], ["PGG", "SIMPLE_CHEMICAL", 257, 260], ["RGC", "SIMPLE_CHEMICAL", 277, 280], ["hLDH-A", "SIMPLE_CHEMICAL", 341, 347], ["NADH", "SIMPLE_CHEMICAL", 355, 359], ["human tumor cell line MDA-MB-231", "CELL_LINE", 150, 182], ["hLDH-A protein", "PROTEIN", 211, 225], ["hLDH", "PROTEIN", 341, 345], ["NADH cofactor docking site", "PROTEIN", 355, 381], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 150, 155], ["this study", "TEST", 3, 13], ["PGG", "TREATMENT", 66, 69], ["RGC extract", "PROBLEM", 86, 97], ["human LDH", "TEST", 110, 119], ["halt proliferation", "PROBLEM", 126, 144], ["a human tumor cell line MDA", "TEST", 148, 175], ["MB", "TEST", 176, 178], ["PGG", "TREATMENT", 257, 260], ["RGC", "PROBLEM", 277, 280], ["hLDH", "PROBLEM", 341, 345], ["tumor cell line", "OBSERVATION", 156, 171], ["docking site", "OBSERVATION", 369, 381]]], ["Its effect in tumor cells baring high expression of hLDH-A resulted in blocking proliferation.", [["tumor cells", "ANATOMY", 14, 25], ["tumor", "DISEASE", 14, 19], ["hLDH-A", "CHEMICAL", 52, 58], ["tumor cells", "CELL", 14, 25], ["hLDH-A", "GENE_OR_GENE_PRODUCT", 52, 58], ["tumor cells", "CELL_TYPE", 14, 25], ["hLDH-A", "PROTEIN", 52, 58], ["tumor cells", "PROBLEM", 14, 25], ["blocking proliferation", "PROBLEM", 71, 93], ["effect", "OBSERVATION_MODIFIER", 4, 10], ["tumor cells", "OBSERVATION", 14, 25], ["blocking proliferation", "OBSERVATION", 71, 93]]], ["Future research will be required to determine in detail cause-effect relationship between hLDH-A inhibition and biochemical metabolic or process related effects in tumor cells.", [["tumor cells", "ANATOMY", 164, 175], ["hLDH-A", "CHEMICAL", 90, 96], ["tumor", "DISEASE", 164, 169], ["hLDH-A", "SIMPLE_CHEMICAL", 90, 96], ["tumor cells", "CELL", 164, 175], ["tumor cells", "CELL_TYPE", 164, 175], ["A inhibition", "TREATMENT", 95, 107], ["tumor cells", "PROBLEM", 164, 175], ["tumor cells", "OBSERVATION", 164, 175]]]], "PMC7165285": [], "9da8749940131581ade4649db069a80b22394c8c": [["IntroductionThe emergence of shape and structure in animate and inanimate systems is among the most fascinating phenomena in our planet.", [["shape", "OBSERVATION_MODIFIER", 29, 34]]], ["Rivers carry water and sediment supplied by the hydrological cycle and erosional mechanisms, which play a major role in the shaping of the Earth's surface.", [["surface", "ANATOMY", 147, 154], ["surface", "CELLULAR_COMPONENT", 147, 154], ["erosional mechanisms", "PROBLEM", 71, 91], ["sediment", "OBSERVATION", 23, 31], ["hydrological cycle", "OBSERVATION", 48, 66]]], ["River basins result, for instance, from these naturally organized flow architectures (Bejan 1999; Reis 2006a) .", [["flow architectures", "OBSERVATION", 66, 84]]], ["Flow architectures also underline the phenomenon by which wet soil exposed to the sun and wind loses moisture, shrinks superficially, and develops a network of cracks (Bejan 2000) .", [["Flow architectures", "TEST", 0, 18], ["the phenomenon", "PROBLEM", 34, 48], ["shrinks", "OBSERVATION_MODIFIER", 111, 118], ["superficially", "OBSERVATION_MODIFIER", 119, 132], ["cracks", "OBSERVATION_MODIFIER", 160, 166]]], ["Similarly, in complex cellular systems such as the vertebrates, the requirement of large amount of oxygen for the metabolic needs of the cells constitutes the basis of the development of specialized and hierarchically organized flow systems, such as the respiratory tract and the circulatory system (Bejan et al. 2004; Reis et al. 2004; Bejan 2005; Reis and Miguel 2006) .IntroductionThe formation of dissimilar patterns inside similar systems under different environmental conditions is especially intriguing.", [["cellular systems", "ANATOMY", 22, 38], ["cells", "ANATOMY", 137, 142], ["respiratory tract", "ANATOMY", 254, 271], ["circulatory system", "ANATOMY", 280, 298], ["oxygen", "CHEMICAL", 99, 105], ["oxygen", "CHEMICAL", 99, 105], ["cellular", "CELL", 22, 30], ["oxygen", "SIMPLE_CHEMICAL", 99, 105], ["cells", "CELL", 137, 142], ["respiratory tract", "ORGANISM_SUBDIVISION", 254, 271], ["oxygen", "TREATMENT", 99, 105], ["complex", "OBSERVATION_MODIFIER", 14, 21], ["cellular systems", "OBSERVATION", 22, 38], ["large", "OBSERVATION_MODIFIER", 83, 88], ["amount", "OBSERVATION_MODIFIER", 89, 95], ["oxygen", "OBSERVATION_MODIFIER", 99, 105], ["hierarchically", "OBSERVATION_MODIFIER", 203, 217], ["organized", "OBSERVATION_MODIFIER", 218, 227], ["flow systems", "OBSERVATION", 228, 240], ["respiratory tract", "ANATOMY", 254, 271], ["circulatory system", "ANATOMY", 280, 298], ["environmental conditions", "OBSERVATION", 460, 484]]], ["Examples of these phenomena can be found in almost every field, ranging from physics to the behavior of social groups.", [["these phenomena", "PROBLEM", 12, 27], ["phenomena", "OBSERVATION", 18, 27]]], ["For instance, in a horizontal fluid layer that is confined between two plates, and which is heated from below to produce a fixed temperature difference, there is a critical Rayleigh number for which the fluid breaks off from its macroscopically motionless form and starts to present a roll configurationthe Rayleigh-B\u00e9nard convection (Gettling 1998; Bejan 2000) .", [["fluid layer", "ANATOMY", 30, 41], ["fluid", "ANATOMY", 203, 208], ["a horizontal fluid layer", "PROBLEM", 17, 41], ["a fixed temperature difference", "PROBLEM", 121, 151], ["the fluid breaks", "PROBLEM", 199, 215], ["horizontal", "OBSERVATION_MODIFIER", 19, 29], ["fluid layer", "OBSERVATION", 30, 41], ["plates", "OBSERVATION_MODIFIER", 71, 77], ["critical", "OBSERVATION_MODIFIER", 164, 172], ["Rayleigh", "OBSERVATION_MODIFIER", 173, 181], ["number", "OBSERVATION_MODIFIER", 182, 188], ["fluid breaks", "OBSERVATION", 203, 215]]], ["It is equally well known that stony corals collected from exposed growth sites, where higher water currents are found, present more spherical and compact shape than corals of the same species growing in sheltered sites, which display a thin-branched morphology (Kaandorp and Sloot 2001; Merks et al. 2003) .", [["sites", "ANATOMY", 213, 218], ["stony corals", "PROBLEM", 30, 42], ["exposed growth sites", "PROBLEM", 58, 78], ["growth", "OBSERVATION_MODIFIER", 66, 72], ["sites", "OBSERVATION_MODIFIER", 73, 78], ["more spherical", "OBSERVATION_MODIFIER", 127, 141], ["compact", "OBSERVATION_MODIFIER", 146, 153], ["shape", "OBSERVATION_MODIFIER", 154, 159], ["species", "OBSERVATION_MODIFIER", 184, 191], ["growing", "OBSERVATION_MODIFIER", 192, 199], ["sheltered sites", "OBSERVATION", 203, 218], ["thin", "OBSERVATION_MODIFIER", 236, 240], ["branched morphology", "OBSERVATION_MODIFIER", 241, 260]]], ["Furthermore, bacterial colonies that have to cope with hostile environmental conditions have more branched growth forms than colonies of the same species from nutrientrich environments (Ben-Jacob et al. 1995; Thar and K\u00fchl 2005) .", [["colonies", "ANATOMY", 23, 31], ["colonies", "ANATOMY", 125, 133], ["bacterial colonies", "CELL_LINE", 13, 31], ["bacterial colonies", "PROBLEM", 13, 31], ["hostile environmental conditions", "PROBLEM", 55, 87], ["bacterial colonies", "OBSERVATION", 13, 31], ["more branched", "OBSERVATION_MODIFIER", 93, 106]]], ["In a similar manner, plant roots seem to be able to respond to localized regions of high nutrient supply by proliferating or elongating root branches into the nutrient-rich patches (Robinson 1994; Hodge et al. 1999) .", [["roots", "ANATOMY", 27, 32], ["root branches", "ANATOMY", 136, 149], ["roots", "ORGAN", 27, 32], ["root branches", "MULTI-TISSUE_STRUCTURE", 136, 149], ["plant roots", "OBSERVATION", 21, 32], ["high nutrient", "OBSERVATION", 84, 97], ["elongating", "OBSERVATION_MODIFIER", 125, 135], ["root", "OBSERVATION_MODIFIER", 136, 140], ["branches", "OBSERVATION_MODIFIER", 141, 149], ["nutrient", "OBSERVATION_MODIFIER", 159, 167]]], ["Root systems in soil are more open and more thinly branched than roots which are growing in hydroponics regime.IntroductionPedestrian crowd motion also exhibits a variety of conjunction patterns, from more-or-less 'chaotic' appearance (Schweitzer 1997) to spontaneous organization in lanes of uniform walking direction looking like river-like streams (Navin and Wheeler 1969; Helbing et al. 2001) .", [["Root systems", "ANATOMY", 0, 12], ["roots", "ANATOMY", 65, 70], ["roots", "ORGAN", 65, 70], ["hydroponics regime", "TREATMENT", 92, 110], ["soil", "OBSERVATION", 16, 20], ["more", "OBSERVATION_MODIFIER", 25, 29], ["open", "OBSERVATION", 30, 34], ["more", "OBSERVATION_MODIFIER", 39, 43], ["thinly", "OBSERVATION_MODIFIER", 44, 50], ["branched", "OBSERVATION_MODIFIER", 51, 59], ["growing", "OBSERVATION_MODIFIER", 81, 88], ["hydroponics regime", "OBSERVATION", 92, 110], ["crowd motion", "OBSERVATION", 134, 146]]], ["Understanding crowd motion is essential on a wide range of applications including crowd safety (Donald and Canter 1990; Langston et al. 2006) .", [["crowd motion", "OBSERVATION", 14, 26]]], ["From what principle can pedestrian facilities be deduced?IntroductionThere has been a renewed impetus for the study of geotemporal spread of epidemics, following concerns over the increasing potential outbreak of infectious diseases (Koopmans et al. 2004; Hsu et al. 2006; Suwandono et al. 2006) .", [["infectious diseases", "DISEASE", 213, 232], ["the study", "TEST", 106, 115], ["epidemics", "PROBLEM", 141, 150], ["infectious diseases", "PROBLEM", 213, 232], ["infectious", "OBSERVATION_MODIFIER", 213, 223]]], ["Throughout history several pandemics have occurred in many areas of our planet, infecting and wiping out a large number of people.", [["people", "ORGANISM", 123, 129], ["people", "SPECIES", 123, 129], ["several", "OBSERVATION_MODIFIER", 19, 26], ["pandemics", "OBSERVATION", 27, 36], ["many", "OBSERVATION_MODIFIER", 54, 58], ["areas", "OBSERVATION_MODIFIER", 59, 64], ["large", "OBSERVATION_MODIFIER", 107, 112], ["number", "OBSERVATION_MODIFIER", 113, 119]]], ["One of the most catastrophic pandemics was the bubonic plague (Black Death) in the fourteenth century.", [["bubonic plague", "DISEASE", 47, 61], ["Death", "DISEASE", 69, 74], ["the bubonic plague", "PROBLEM", 43, 61], ["most", "OBSERVATION_MODIFIER", 11, 15], ["catastrophic", "OBSERVATION_MODIFIER", 16, 28], ["pandemics", "OBSERVATION", 29, 38], ["bubonic", "OBSERVATION_MODIFIER", 47, 54], ["plague", "OBSERVATION_MODIFIER", 55, 61], ["fourteenth century", "OBSERVATION", 83, 101]]], ["It is estimated that a third of the European population at the time died as a consequence of this outbreak.", [["this outbreak", "PROBLEM", 93, 106]]], ["Moreover, historic records of the progress of this outbreak suggest a wave-like propagation of the disease (Langer 1964) .", [["the disease", "PROBLEM", 95, 106], ["disease", "OBSERVATION", 99, 106]]], ["Based on this view, common features between systems in very different fields are evidenced, and the importance of an optimum balance of competing trends (flow regimes, resistances, etc.) on the generation of patterns (architecture) is stressed.", [["this view", "TEST", 9, 18], ["flow regimes", "TREATMENT", 154, 166]]], ["Consider, e.g., the drainage of fluid through a nonhomogeneous surface (e.g., a surface with a central strip having a low resistance to fluid flow and lateral strips with high resistances to fluid flow) depicted in Fig. 5 .1.", [["fluid", "ANATOMY", 32, 37], ["surface", "ANATOMY", 63, 70], ["surface", "ANATOMY", 80, 87], ["fluid", "ANATOMY", 136, 141], ["fluid", "ANATOMY", 191, 196], ["surface", "CELLULAR_COMPONENT", 63, 70], ["surface", "CELLULAR_COMPONENT", 80, 87], ["the drainage of fluid", "TREATMENT", 16, 37], ["a central strip", "TREATMENT", 93, 108], ["a low resistance to fluid flow", "TREATMENT", 116, 146], ["lateral strips", "TREATMENT", 151, 165], ["high resistances to fluid flow", "TREATMENT", 171, 201], ["drainage", "OBSERVATION", 20, 28], ["fluid", "OBSERVATION", 32, 37], ["nonhomogeneous", "OBSERVATION_MODIFIER", 48, 62], ["surface", "OBSERVATION_MODIFIER", 63, 70], ["low resistance", "OBSERVATION", 118, 132], ["fluid flow", "OBSERVATION", 136, 146], ["high resistances", "OBSERVATION", 171, 187], ["fluid flow", "OBSERVATION", 191, 201]]], ["According to the constructal law put forward by Bejan (1997 Bejan ( , 2000 , in order \"for a flow system to persist (to survive) it must morph over time (evolve) in such a way that it provides easier access to the imposed currents that flow through it.\"", [["a flow system", "TREATMENT", 91, 104]]], ["Thus, the shape and flow architecture of In fact, the constructal theory proposes that every flow system exists with a purpose and that flows are free to morph their configuration in search of the best architectural solution within a framework of existing constraints (area or volume allocated, material properties, etc.).", [["shape", "OBSERVATION_MODIFIER", 10, 15], ["flow architecture", "OBSERVATION", 20, 37]]], ["Therefore, the shape and flow architecture of the system are the result of the optimum balance between two competing trends-slow and fast (a surface with different flow resistances in this example, although it could be different flow regimes or other)-that ensures the maximization of fluid drainage.Constructal Law and the Generation of ConfigurationIn summary, the optimum balance between competing trends-slow (high resistivity) and fast (low resistivity)-is at the origin of shape and flow architecture.Formation of Dissimilar Patterns Inside Flow SystemsThe spreading of a tracer or a solute, and the transport of heat or fluid can be analyzed within the framework of diffusive-convective phenomena ( Fig. 5 .2).", [["surface", "ANATOMY", 141, 148], ["fluid", "ANATOMY", 285, 290], ["slow and fast", "PROBLEM", 124, 137], ["different flow resistances", "TREATMENT", 154, 180], ["different flow regimes", "TREATMENT", 219, 241], ["fluid drainage", "TREATMENT", 285, 299], ["slow (high resistivity) and fast (low resistivity)", "PROBLEM", 408, 458], ["fluid", "PROBLEM", 627, 632], ["diffusive-convective phenomena", "PROBLEM", 673, 703], ["shape", "OBSERVATION_MODIFIER", 15, 20], ["flow architecture", "OBSERVATION", 25, 42], ["flow resistances", "OBSERVATION", 164, 180], ["fluid drainage", "OBSERVATION", 285, 299], ["high resistivity", "OBSERVATION_MODIFIER", 414, 430], ["low resistivity", "OBSERVATION_MODIFIER", 442, 457], ["origin", "ANATOMY_MODIFIER", 469, 475], ["shape", "OBSERVATION_MODIFIER", 479, 484], ["flow architecture", "OBSERVATION", 489, 506], ["Dissimilar Patterns", "OBSERVATION", 520, 539], ["Flow Systems", "OBSERVATION", 547, 559], ["spreading", "OBSERVATION_MODIFIER", 563, 572], ["fluid", "OBSERVATION", 627, 632], ["convective phenomena", "OBSERVATION", 683, 703]]], ["For example, the one-dimensional tracer transport within a fluid is governed by the macroscopic equation:Formation of Dissimilar Patterns Inside Flow Systemswhere u is the average fluid velocity, D is the tracer diffusion coefficient, n is the tracer concentration, and t is the time.", [["fluid", "ANATOMY", 180, 185], ["D", "SIMPLE_CHEMICAL", 196, 197], ["the average fluid velocity", "TEST", 168, 194], ["the tracer diffusion coefficient", "PROBLEM", 201, 233], ["the tracer concentration", "TEST", 240, 264], ["fluid", "OBSERVATION", 59, 64], ["Flow Systemswhere", "OBSERVATION", 145, 162], ["average", "OBSERVATION_MODIFIER", 172, 179], ["fluid velocity", "OBSERVATION", 180, 194], ["tracer concentration", "OBSERVATION", 244, 264]]], ["The time scales can be obtained by applying scale analysis (Bejan 2000) to the above equation:Formation of Dissimilar Patterns Inside Flow SystemsTherefore, the characteristic times corresponding to the diffusive and convective driven transport areFormation of Dissimilar Patterns Inside Flow Systemswhere t dif and t cv are the characteristic times corresponding to diffusive and convective driven transport, and v dif and v cv are the velocities corresponding to diffusive and convective driven transport, respectively.", [["v cv", "GENE_OR_GENE_PRODUCT", 424, 428], ["The time scales", "TEST", 0, 15], ["the diffusive", "PROBLEM", 199, 212], ["diffusive and convective driven transport", "PROBLEM", 367, 408], ["the velocities", "TEST", 433, 447], ["diffusive", "OBSERVATION_MODIFIER", 465, 474]]], ["(5.3) and (5.4):Formation of Dissimilar Patterns Inside Flow SystemsIf t < t * diffusion overcomes convection.", [["Flow SystemsIf", "OBSERVATION", 56, 70]]], ["Diffusion coefficients are usually much smaller than 1 m 2 s \u22121 (e.g., the diffusion coefficient for oxygen in air is approximately 2 \u00d7 10 \u22125 m 2 s \u22121 ).", [["oxygen", "CHEMICAL", 101, 107], ["oxygen", "CHEMICAL", 101, 107], ["oxygen", "SIMPLE_CHEMICAL", 101, 107], ["Diffusion coefficients", "TEST", 0, 22], ["oxygen in air", "PROBLEM", 101, 114], ["air", "ANATOMY", 111, 114]]], ["When u << D (e.g., u is close to zero), the time of transition t * becomes very large (t * \u2192 ).", [["very", "OBSERVATION_MODIFIER", 75, 79], ["large", "OBSERVATION", 80, 85]]], ["In this situation, transition from diffusive to convective driven transport is not very likely to occur and the tracer transport is linked only to a diffusive phenomenon.", [["the tracer transport", "TEST", 108, 128], ["a diffusive phenomenon", "PROBLEM", 147, 169], ["not very likely", "UNCERTAINTY", 79, 94], ["diffusive phenomenon", "OBSERVATION", 149, 169]]], ["However, if fluid velocity is much larger than the tracer diffusivity, the transition time (Eq.", [["fluid", "ANATOMY", 12, 17], ["fluid velocity", "TEST", 12, 26], ["the tracer diffusivity", "TEST", 47, 69], ["fluid velocity", "OBSERVATION", 12, 26], ["much", "OBSERVATION_MODIFIER", 30, 34], ["larger", "OBSERVATION_MODIFIER", 35, 41]]], ["5.7) is very small.", [["very", "OBSERVATION_MODIFIER", 8, 12], ["small", "OBSERVATION_MODIFIER", 13, 18]]], ["The initial diffusive velocity (Eq.", [["The initial diffusive velocity", "TEST", 0, 30], ["diffusive velocity", "OBSERVATION", 12, 30]]], ["5.5) is larger than any convective velocity (Eq.", [["any convective velocity", "TEST", 20, 43], ["larger", "OBSERVATION_MODIFIER", 8, 14], ["convective velocity", "OBSERVATION", 24, 43]]], ["5.6), but decreases as t \u22121/2 .", [["decreases", "OBSERVATION_MODIFIER", 10, 19]]], ["Diffusion is the main driving mechanism at very beginning of the transport process but for times slightly greater than t * , convective transport takes its place as the main mechanism.", [["convective transport", "TREATMENT", 125, 145], ["main mechanism", "OBSERVATION", 169, 183]]], ["Similar results were obtained by B\u00e9gu\u00e9 and Lorente (2006) for the ionic transport through saturated porous media.Formation of Dissimilar Patterns Inside Flow SystemsIn summary, the architecture of the flow is the result of the trade-off between two competing trends-diffusion (slow or high resistivity) and convection or channeling (fast or low resistivity)-which ensure the maximization of the transport process.Formation of Dissimilar Patterns Inside Flow SystemsOther flow systems exhibit a similar tendency.", [["the ionic transport through saturated porous media", "TREATMENT", 62, 112], ["diffusion (slow or high resistivity)", "PROBLEM", 266, 302], ["channeling (fast or low resistivity)", "PROBLEM", 321, 357], ["a similar tendency", "PROBLEM", 492, 510], ["Dissimilar Patterns", "OBSERVATION", 126, 145], ["Flow Systems", "OBSERVATION", 153, 165], ["flow", "OBSERVATION", 201, 205], ["high resistivity", "OBSERVATION_MODIFIER", 285, 301], ["low resistivity", "OBSERVATION_MODIFIER", 341, 356], ["Dissimilar", "OBSERVATION_MODIFIER", 426, 436], ["Flow SystemsOther", "OBSERVATION", 453, 470], ["similar", "OBSERVATION_MODIFIER", 494, 501], ["tendency", "OBSERVATION", 502, 510]]], ["Bejan (2000) showed that the onset of a roll configuration in fluid layers heated from below (Rayleigh-B\u00e9nard convection) can be predicted based on the constructal theory.", [["fluid layers", "ANATOMY", 62, 74], ["a roll configuration in fluid layers", "TREATMENT", 38, 74], ["Rayleigh-B\u00e9nard convection", "TREATMENT", 94, 120], ["roll configuration", "OBSERVATION", 40, 58], ["fluid layers", "OBSERVATION", 62, 74]]], ["Conduction or thermal diffusion (high resistivity) prevails as the main mechanism, as long as it provides the shortest time in transporting heat across a surface layer.", [["surface layer", "ANATOMY", 154, 167], ["thermal diffusion (high resistivity)", "PROBLEM", 14, 50], ["thermal", "OBSERVATION_MODIFIER", 14, 21], ["diffusion", "OBSERVATION_MODIFIER", 22, 31], ["high resistivity", "OBSERVATION_MODIFIER", 33, 49], ["main", "OBSERVATION_MODIFIER", 67, 71], ["surface", "OBSERVATION_MODIFIER", 154, 161], ["layer", "OBSERVATION_MODIFIER", 162, 167]]], ["Conversely, rolls/channeling or convection cells (low resistivity) start to occur when the Rayleigh number reaches a critical value (>1700), so as to maximize the heat transport process (Fig. 5 .3).", [["cells", "ANATOMY", 43, 48], ["cells", "CELL", 43, 48], ["convection cells", "CELL_TYPE", 32, 48], ["convection cells", "PROBLEM", 32, 48], ["the heat transport process", "TREATMENT", 159, 185], ["low resistivity", "OBSERVATION_MODIFIER", 50, 65]]], ["Therefore, flow architecture is the result of the trade-off between two competing trends, and rolls are the optimized access for internal currents (e.g., the optimal architecture).", [["flow architecture", "TEST", 11, 28], ["internal currents", "TREATMENT", 129, 146], ["flow architecture", "OBSERVATION", 11, 28]]], ["Bejan (2000) also showed that a turbulent flow is a combination of the same two mechanisms-viscous diffusion (high resistivity) and eddies (low resistivity)-and can therefore be covered by the constructal law.The Shapes of Stony Coral Colonies and Plant RootsIn stony corals and other organisms, which have a relatively weakly developed transport system, the amount of nutrients arriving at a certain site in the tissue, as well as the local deposition velocity of the skeleton material, are limited both by the locally available suspended material and the local amount of contact with the environment (Sebens et al. 1997; Anthony 1999) .", [["tissue", "ANATOMY", 413, 419], ["tissue", "TISSUE", 413, 419], ["a turbulent flow", "PROBLEM", 30, 46], ["viscous diffusion (high resistivity)", "PROBLEM", 91, 127], ["eddies (low resistivity)", "PROBLEM", 132, 156], ["other organisms", "PROBLEM", 279, 294], ["turbulent", "OBSERVATION_MODIFIER", 32, 41], ["flow", "OBSERVATION", 42, 46], ["viscous", "OBSERVATION_MODIFIER", 91, 98], ["high resistivity", "OBSERVATION_MODIFIER", 110, 126], ["low resistivity", "OBSERVATION_MODIFIER", 140, 155], ["Shapes", "OBSERVATION_MODIFIER", 213, 219], ["Stony Coral Colonies", "OBSERVATION", 223, 243], ["Plant Roots", "OBSERVATION", 248, 259], ["stony corals", "OBSERVATION", 262, 274], ["amount", "OBSERVATION_MODIFIER", 359, 365], ["tissue", "ANATOMY", 413, 419], ["local", "OBSERVATION_MODIFIER", 436, 441], ["deposition", "OBSERVATION_MODIFIER", 442, 452], ["velocity", "OBSERVATION_MODIFIER", 453, 461], ["skeleton", "ANATOMY", 469, 477]]], ["In plants, the water and dissolved minerals necessary for their survival are provided by the root systems.", [["root systems", "ANATOMY", 93, 105], ["water", "SIMPLE_CHEMICAL", 15, 20], ["root systems", "MULTI-TISSUE_STRUCTURE", 93, 105], ["the water and dissolved minerals", "TREATMENT", 11, 43], ["their survival", "TREATMENT", 58, 72], ["root", "ANATOMY", 93, 97]]], ["Consequently, plants produce new roots to maximize nutrient absorption and continue to grow.The Shapes of Stony Coral Colonies and Plant RootsBoth coral colonies and plant roots show an intraspecific variability of the shape.", [["roots", "ANATOMY", 33, 38], ["colonies", "ANATOMY", 153, 161], ["roots", "ANATOMY", 172, 177], ["roots", "ORGAN", 33, 38], ["roots", "ORGAN", 172, 177], ["new roots", "PROBLEM", 29, 38], ["Stony Coral Colonies", "TEST", 106, 126], ["plant roots", "TEST", 166, 177], ["an intraspecific variability of the shape", "PROBLEM", 183, 224], ["Shapes", "OBSERVATION_MODIFIER", 96, 102], ["Stony Coral Colonies", "OBSERVATION", 106, 126], ["Plant Roots", "OBSERVATION", 131, 142], ["coral colonies", "OBSERVATION", 147, 161], ["plant roots", "OBSERVATION", 166, 177], ["intraspecific", "OBSERVATION_MODIFIER", 186, 199], ["variability", "OBSERVATION_MODIFIER", 200, 211], ["shape", "OBSERVATION_MODIFIER", 219, 224]]], ["They may develop a branched or a more round shape apparently in a differentiated response to the variability of environmental conditions (Thaler and Pages 1998; Merks et al. 2003) .", [["a more round shape", "PROBLEM", 31, 49], ["branched", "OBSERVATION_MODIFIER", 19, 27], ["more", "OBSERVATION_MODIFIER", 33, 37], ["round", "OBSERVATION_MODIFIER", 38, 43], ["shape", "OBSERVATION_MODIFIER", 44, 49]]], ["For example, it is known that stony corals collected from exposed growth sites, where higher water currents are found, present more spherical and compact shape, than corals of same species from sheltered sites, which display more thin-branched morphologies (Merks et al. 2003) .The Shapes of Stony Coral Colonies and Plant RootsBranched and circular (round) shapes are quite different regarding their ability to fill space ( Fig. 5.4) .", [["sites", "ANATOMY", 204, 209], ["stony corals", "PROBLEM", 30, 42], ["exposed growth sites", "PROBLEM", 58, 78], ["Plant RootsBranched and circular (round) shapes", "PROBLEM", 317, 364], ["Fig.", "TEST", 425, 429], ["stony corals", "OBSERVATION", 30, 42], ["growth", "OBSERVATION_MODIFIER", 66, 72], ["sites", "OBSERVATION_MODIFIER", 73, 78], ["higher", "OBSERVATION_MODIFIER", 86, 92], ["water currents", "OBSERVATION_MODIFIER", 93, 107], ["more spherical", "OBSERVATION_MODIFIER", 127, 141], ["compact", "OBSERVATION_MODIFIER", 146, 153], ["shape", "OBSERVATION_MODIFIER", 154, 159], ["sheltered sites", "OBSERVATION", 194, 209], ["branched morphologies", "OBSERVATION_MODIFIER", 235, 256], ["Stony", "OBSERVATION_MODIFIER", 292, 297], ["Coral Colonies", "OBSERVATION", 298, 312], ["Plant RootsBranched", "OBSERVATION", 317, 336], ["circular", "OBSERVATION_MODIFIER", 341, 349], ["round", "OBSERVATION_MODIFIER", 351, 356]]], ["Consider that l is the characteristic length/radius of the biological system and w is the width of the branch/needle (e.g., a very small quantity).", [["length", "OBSERVATION_MODIFIER", 38, 44], ["radius", "ANATOMY_MODIFIER", 45, 51], ["biological system", "ANATOMY", 59, 76], ["branch", "ANATOMY_MODIFIER", 103, 109], ["needle", "OBSERVATION", 110, 116]]], ["The surface area of the biological system is \u223c lw for branches/needles and \u223c l 2 for a circular shape.", [["surface area", "ANATOMY", 4, 16], ["branches/needles", "TREATMENT", 54, 70], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["area", "OBSERVATION_MODIFIER", 12, 16], ["biological system", "ANATOMY", 24, 41], ["branches", "OBSERVATION_MODIFIER", 54, 62], ["needles", "OBSERVATION", 63, 70], ["circular", "OBSERVATION_MODIFIER", 87, 95], ["shape", "OBSERVATION_MODIFIER", 96, 101]]], ["Undoubtedly, l 2 >> lw which means that the circular shape is the most effective arrangement for filling the space in the shortest time and thus, according to the constructal law, it constitutes the optimal architecture.", [["filling the space", "PROBLEM", 97, 114], ["circular", "OBSERVATION_MODIFIER", 44, 52], ["shape", "OBSERVATION_MODIFIER", 53, 58], ["most effective", "OBSERVATION_MODIFIER", 66, 80], ["filling", "OBSERVATION", 97, 104], ["space", "OBSERVATION_MODIFIER", 109, 114]]], ["But sometimes stony corals and roots develop a branched shape.", [["roots", "ANATOMY", 31, 36], ["roots", "ORGAN", 31, 36], ["stony", "OBSERVATION", 14, 19], ["roots", "ANATOMY_MODIFIER", 31, 36], ["branched", "OBSERVATION_MODIFIER", 47, 55], ["shape", "OBSERVATION_MODIFIER", 56, 61]]], ["How can one reconcile such an obvious contradiction with the maximization of flow access?The Shapes of Stony Coral Colonies and Plant RootsThe answer was provided by Miguel (2004 Miguel ( , 2006 , based on the constructal description made by Bejan (2000) of the structure of a dendritic crystal formed during rapid solidification.", [["dendritic crystal", "ANATOMY", 277, 294], ["flow access", "TREATMENT", 77, 88], ["a dendritic crystal", "TREATMENT", 275, 294], ["rapid solidification", "TREATMENT", 309, 329], ["Shapes", "OBSERVATION_MODIFIER", 93, 99], ["Stony", "OBSERVATION_MODIFIER", 103, 108], ["Coral Colonies", "OBSERVATION", 109, 123], ["Plant Roots", "OBSERVATION", 128, 139], ["dendritic crystal", "OBSERVATION", 277, 294], ["rapid solidification", "OBSERVATION", 309, 329]]], ["Consider, e.g., stony corals growing in exposed (open) sites.", [["stony corals", "PROBLEM", 16, 28], ["stony", "OBSERVATION_MODIFIER", 16, 21], ["corals", "OBSERVATION_MODIFIER", 22, 28], ["growing", "OBSERVATION_MODIFIER", 29, 36]]], ["In this case, nutrient transport is driven mainly by convection.", [["nutrient transport", "TREATMENT", 14, 32]]], ["The velocity of the nutrient-rich water which surrounds the coral colony is much larger than the growth velocity of corals (which for a specie named Porites spp. is, for instance, about 12 mm per year).", [["colony", "ANATOMY", 66, 72], ["Porites spp.", "ORGANISM", 149, 161], ["Porites spp.", "SPECIES", 149, 161], ["velocity", "OBSERVATION_MODIFIER", 4, 12], ["nutrient", "OBSERVATION_MODIFIER", 20, 28], ["rich", "OBSERVATION_MODIFIER", 29, 33], ["water", "OBSERVATION_MODIFIER", 34, 39], ["coral colony", "OBSERVATION", 60, 72], ["much", "OBSERVATION_MODIFIER", 76, 80], ["larger", "OBSERVATION_MODIFIER", 81, 87], ["growth", "OBSERVATION_MODIFIER", 97, 103], ["velocity", "OBSERVATION_MODIFIER", 104, 112]]], ["Consequently, it is able to spread (diffuse) in all directions and develop the most effective arrangement for filling the space in the shortest time-a round shape.", [["filling the space", "PROBLEM", 110, 127], ["diffuse", "OBSERVATION_MODIFIER", 36, 43], ["round", "OBSERVATION_MODIFIER", 151, 156], ["shape", "OBSERVATION_MODIFIER", 157, 162]]], ["Assume that the coral is growing in a sheltered site.", [["coral", "OBSERVATION_MODIFIER", 16, 21], ["growing", "OBSERVATION_MODIFIER", 25, 32], ["sheltered site", "OBSERVATION", 38, 52]]], ["When the velocity of the water containing nutrients becomes close to zero, the transport of nutrients is mainly due to diffusion and nutrients close to the coral colony are quickly depleted.", [["colony", "ANATOMY", 162, 168], ["diffusion and nutrients", "PROBLEM", 119, 142], ["coral colony", "ANATOMY", 156, 168]]], ["Thus, the decrease of nutrient concentration around the coral triggers a wave of nutrients with a velocity of propagation v dif = dL dif dt \u223c 1 2 D t 1/2 , Eq.", [["nutrient concentration", "TREATMENT", 22, 44], ["propagation v dif", "PROBLEM", 110, 127], ["dL dif dt", "TEST", 130, 139], ["decrease", "OBSERVATION_MODIFIER", 10, 18], ["nutrient concentration", "OBSERVATION", 22, 44]]], ["(5.5), and a characteristic length L dif \u223c 1 2 Dt 1/2 .", [["a characteristic length L dif", "TEST", 11, 40], ["length", "OBSERVATION_MODIFIER", 28, 34]]], ["The initial velocity of propagation v dif \u2192 is much larger than the growth velocity of corals (\u223c 12 mm per year), but decreases as t \u22121/2 .", [["propagation v dif", "TEST", 24, 41], ["velocity", "OBSERVATION_MODIFIER", 12, 20], ["propagation v", "OBSERVATION", 24, 37], ["much", "OBSERVATION_MODIFIER", 47, 51], ["larger", "OBSERVATION_MODIFIER", 52, 58], ["growth", "OBSERVATION_MODIFIER", 68, 74], ["velocity", "OBSERVATION_MODIFIER", 75, 83], ["corals", "OBSERVATION_MODIFIER", 87, 93], ["decreases", "OBSERVATION_MODIFIER", 118, 127]]], ["Thus, there is a moment when the growth speed of the biological system exceeds the speed of nutrient propagation.The Shapes of Stony Coral Colonies and Plant RootsThe temporal evolution of the characteristic length of the coral and nutrient propagation are presented in Fig. 5 .5.", [["nutrient propagation", "OBSERVATION", 92, 112], ["Shapes", "OBSERVATION_MODIFIER", 117, 123], ["Stony Coral Colonies", "OBSERVATION", 127, 147], ["Plant Roots", "OBSERVATION", 152, 163], ["temporal", "OBSERVATION_MODIFIER", 167, 175], ["characteristic", "OBSERVATION_MODIFIER", 193, 207], ["length", "OBSERVATION_MODIFIER", 208, 214], ["coral", "ANATOMY", 222, 227], ["nutrient propagation", "OBSERVATION", 232, 252]]], ["This plot shows that at the critical time, t ct , the characteristic length of the coral system overtakes the characteristic length corresponding to the diffusive transport.", [["This plot", "TEST", 0, 9], ["t ct", "TEST", 43, 47], ["the diffusive transport", "TEST", 149, 172], ["length", "OBSERVATION_MODIFIER", 69, 75], ["coral system", "ANATOMY", 83, 95], ["length", "OBSERVATION_MODIFIER", 125, 131], ["diffusive", "OBSERVATION_MODIFIER", 153, 162]]], ["From this moment on the circular shape is no longer the most effective arrangement to fill the space.", [["no longer", "UNCERTAINTY", 42, 51], ["most effective", "OBSERVATION_MODIFIER", 56, 70]]], ["At times slightly larger than t ct , the biological system starts to grow outside of the nutrient diffusion region.", [["t ct", "TEST", 30, 34], ["slightly", "OBSERVATION_MODIFIER", 9, 17], ["larger", "OBSERVATION_MODIFIER", 18, 24]]], ["Guaranteed survival, branches are then generated to promote the easiest possible access to nutrients.", [["branches", "OBSERVATION_MODIFIER", 21, 29]]], ["This \"biological channeling\" enables the system to experience again growth inside the nutrient diffusion region from t ct until 2t ct .", [["t ct", "TEST", 117, 121], ["2t ct", "TEST", 128, 133]]], ["At times slightly greater than 2t ct , the coral once again sticks out the nutrient diffusion region.", [["2t ct", "TEST", 31, 36], ["slightly", "OBSERVATION_MODIFIER", 9, 17], ["greater", "OBSERVATION_MODIFIER", 18, 25], ["coral", "ANATOMY", 43, 48]]], ["New branches are consequently sent forward in order to promote the growth inside the nutrient diffusion region until a new critical time is reached.", [["branches", "OBSERVATION_MODIFIER", 4, 12], ["nutrient diffusion", "OBSERVATION", 85, 103]]], ["This means that each branch generates a new group of branches, and the result of this process is a dendritic-shaped system.", [["dendritic", "ANATOMY", 99, 108], ["a dendritic-shaped system", "PROBLEM", 97, 122], ["branch", "OBSERVATION_MODIFIER", 21, 27], ["new", "OBSERVATION_MODIFIER", 40, 43], ["branches", "OBSERVATION_MODIFIER", 53, 61], ["dendritic", "OBSERVATION_MODIFIER", 99, 108], ["shaped", "OBSERVATION_MODIFIER", 109, 115]]], ["Thus, in these circumstances \"biological channeling\" clearly becomes the most competitive shape configuration.The Shapes of Stony Coral Colonies and Plant RootsTo conclude, the coral system, in its struggle for survival, must morph toward the configuration that provides an easier access to nutrients.", [["Stony Coral Colonies", "TREATMENT", 124, 144], ["survival", "TREATMENT", 211, 219], ["most competitive shape", "OBSERVATION_MODIFIER", 73, 95], ["configuration", "OBSERVATION_MODIFIER", 96, 109], ["Shapes", "OBSERVATION_MODIFIER", 114, 120], ["Stony", "OBSERVATION_MODIFIER", 124, 129], ["Coral Colonies", "OBSERVATION", 130, 144], ["Plant Roots", "OBSERVATION", 149, 160], ["coral system", "ANATOMY", 177, 189]]], ["The generation of branches is the response of the system when growth takes it out of the nutrient-rich region.", [["nutrient-rich region", "PROTEIN", 89, 109], ["branches", "OBSERVATION_MODIFIER", 18, 26], ["rich", "ANATOMY_MODIFIER", 98, 102], ["region", "ANATOMY_MODIFIER", 103, 109]]], ["These branches provide thus the paths that maximize the access to nutrients (e.g., the branches constitute the optimal shape under these circumstances).", [["branches", "ANATOMY_MODIFIER", 6, 14], ["branches", "ANATOMY_MODIFIER", 87, 95]]], ["It is interesting to note that the optimal architecture of the system composed by nutrients and coral colony once more results from two competing trends: a convective (or channeling) transport of nutrients (e.g., low resistivity) implies a round (diffusive) coral morphology (e.g., high resistivity), while a diffusive (round) transport of nutrients (e.g., high resistivity) implies a branched (channeling) coral morphology (e.g., low resistivity).", [["colony", "ANATOMY", 102, 108], ["a round (diffusive) coral morphology", "PROBLEM", 238, 274], ["high resistivity)", "PROBLEM", 282, 299], ["a diffusive (round) transport of nutrients", "PROBLEM", 307, 349], ["low resistivity", "OBSERVATION_MODIFIER", 213, 228], ["round", "OBSERVATION_MODIFIER", 240, 245], ["high resistivity", "OBSERVATION_MODIFIER", 282, 298], ["high resistivity", "OBSERVATION_MODIFIER", 357, 373], ["branched", "OBSERVATION_MODIFIER", 385, 393], ["low resistivity", "OBSERVATION_MODIFIER", 431, 446]]], ["Similar results are also achieved for plant roots (Miguel 2006 ).Pedestrian Dynamics: Observation and ModelsThe interest in the movement of crowds is not a recent one: it has existed ever since large events involving high number of people were organized.", [["roots", "ANATOMY", 44, 49], ["roots", "ORGAN", 44, 49], ["people", "ORGANISM", 232, 238], ["people", "SPECIES", 232, 238], ["large events", "PROBLEM", 194, 206], ["high number", "OBSERVATION_MODIFIER", 217, 228]]], ["The Coliseum in Rome, for instance, has 80 strategic walkways designed to facilitate access and exit.Pedestrian Dynamics: Observation and ModelsPedestrian dynamics has an important impact on a wide range of applications including transportation (Timmermans et al. 1992; Hankin and Wright 1958) , architecture and urban planning (Thompson and Marchant 1995), event organization (Smith and Dickie 1993) , emergency exit planning (Donald and Canter 1990, Langston et al. 2006) , and crowd control (Hunter et al. 2005) .Pedestrian Dynamics: Observation and ModelsOne is usually convinced that human behavior is unpredictable and the way that people move is chaotic or, at least, very irregular.", [["human", "ORGANISM", 589, 594], ["people", "ORGANISM", 638, 644], ["human", "SPECIES", 589, 594], ["people", "SPECIES", 638, 644], ["human", "SPECIES", 589, 594], ["Coliseum", "OBSERVATION", 4, 12], ["irregular", "OBSERVATION", 680, 689]]], ["This desired velocity is of about 1 34 ms \u22121 and a standard deviation of 0 26 ms \u22121 . (ii) Pedestrians can move freely only at low pedestrian densities.", [["This desired velocity", "TEST", 0, 21], ["a standard deviation", "TEST", 49, 69], ["velocity", "OBSERVATION_MODIFIER", 13, 21], ["low", "OBSERVATION_MODIFIER", 127, 130], ["pedestrian densities", "OBSERVATION", 131, 151]]], ["As the pedestrian density increases (e.g., interpersonal distances lessen), walking velocity decreases. (iii) A group of pedestrians (families, friends, colleagues) behave similarly to single pedestrians (group sizes are Poisson distributed). (iv) Pedestrians try to keep a certain distance between themselves or to borders (walls, objects, columns, etc.) .", [["pedestrian density", "OBSERVATION", 7, 25], ["increases", "OBSERVATION_MODIFIER", 26, 35], ["velocity", "OBSERVATION_MODIFIER", 84, 92], ["decreases", "OBSERVATION_MODIFIER", 93, 102]]], ["This behavior helps to avoid contact in case of sudden velocity change and maintain a private area around (territorial effect). (v) Pedestrians feel uncomfortable when they have to move in a direction opposite to the destination.", [["sudden velocity change", "PROBLEM", 48, 70], ["uncomfortable", "PROBLEM", 149, 162]]], ["It is interesting to note that the movement of pedestrians displays many of the attributes of fluid and granular * flows (Helbing et al. 2001 , Hughes 2003 ):Pedestrian Dynamics: Observation and Models(i) Footsteps in the sand and snow look similar to fluid streamlines ( Fig. 5.7) .Pedestrian Dynamics: Observation and Models(ii) Pedestrians organize themselves in the shape of river-like streams (channeling) when a stationary crowd needs to be crossed ( Fig. 5.8 ). (iii) When moving in crowded places, individuals organize themselves spontaneously in lanes of uniform walking direction (channeling) (Fig. 5.9 ). (iv) In dense crowds which push forward, one can observe a kind of shock-wave propagation. (v) At bottlenecks (e.g., doors, corridors) the pedestrian's passing direction oscillates with a frequency that increases with width and declines with the length of the bottleneck.", [["shock", "DISEASE", 683, 688], ["fluid streamlines", "TEST", 252, 269], ["shock-wave propagation", "TREATMENT", 683, 705], ["fluid", "OBSERVATION", 94, 99], ["dense", "OBSERVATION_MODIFIER", 624, 629], ["crowds", "OBSERVATION", 630, 636]]], ["This is similar to granular \"ticking hour glasses,\" in which grains alternate between flowing and not flowing at a constant rate.Pedestrian Dynamics: Observation and ModelsA number of empirical models based on observational data are available in published studies (e.g., see Predtechenskii and Milinski 1969; Sandahl and Percivall 1972; TRB 1985; Nelson and MacLennan 1995; Graat et al. 1999) .", [["grains", "ANATOMY", 61, 67], ["empirical models", "TEST", 184, 200], ["observational data", "TEST", 210, 228], ["granular", "OBSERVATION_MODIFIER", 19, 27], ["flowing", "OBSERVATION_MODIFIER", 102, 109]]], ["Some models considering the analogies between physical systems and pedestrian motion have also been proposed, a number of which represent crowds as an aggregate of individuals having a set of motivations and basic rules (Table 5 .1).", [["crowds", "OBSERVATION", 138, 144]]], ["It consists of self-driven people (particles) that interact through social rules-the \"social forces.\"", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33]]], ["These forces produce changes in the velocities and reflect in turn, a change in motivation rather than in the physical forces acting on the person.", [["person", "SPECIES", 140, 146], ["the velocities", "TEST", 32, 46], ["a change in motivation", "PROBLEM", 68, 90], ["velocities", "OBSERVATION_MODIFIER", 36, 46], ["change", "OBSERVATION_MODIFIER", 70, 76]]], ["The models presented by Hoogendoorn and Fukui and Ishibashi (1999) Cellular automata discrete model - Helbing (1992) Social force High and low densities Helbing and Moln\u00e1r (1995) Active walker low density Hoogendoorn and Bovy (2000) Extremal principle (generalization of the social force) Density less than five people per square meter Hoogendoorn et al. (2002) Hughes (2002) Thinking fluid High and low densities Langston et al. (2006) Discrete element discrete model High and low densities Muramatsu et al. (1999) Random walk -Bovy (2000) and Hoogendoorn et al. (2002) provide a generalization of the social force model.", [["people", "ORGANISM", 312, 318], ["people", "SPECIES", 312, 318], ["Thinking fluid High and low densities", "PROBLEM", 376, 413], ["Discrete element discrete model High and low densities Muramatsu et al", "PROBLEM", 437, 507], ["low densities", "OBSERVATION_MODIFIER", 139, 152], ["less", "OBSERVATION_MODIFIER", 297, 301], ["low densities", "OBSERVATION_MODIFIER", 400, 413], ["discrete", "OBSERVATION_MODIFIER", 454, 462], ["model", "OBSERVATION_MODIFIER", 463, 468], ["High", "OBSERVATION_MODIFIER", 469, 473], ["low densities", "OBSERVATION_MODIFIER", 478, 491]]], ["Early on, Reynolds (1987) presented a model to approach animal motion, like that of bird flocks and fish schools, that bears relevance to crowd dynamics.", [["fish", "ORGANISM_SUBDIVISION", 100, 104]]], ["This flocking model consisted of three simple steering behaviors which described how each individual flocking element (called boid) maneuvered based on the positions and velocities of its nearby flock mates.Pedestrian Dynamics: Observation and ModelsThe \"thinking fluid\" model (Hughes 2002 (Hughes , 2003 results from the combination of fluid dynamics with three hypotheses which are supposed to govern the motion of pedestrians.", [["flocking element", "DNA", 101, 117], ["This flocking model", "TREATMENT", 0, 19], ["fluid dynamics", "TREATMENT", 337, 351], ["velocities", "OBSERVATION_MODIFIER", 170, 180], ["nearby flock", "OBSERVATION", 188, 200]]], ["These hypotheses, together with those governing the motion of the boids, and the \"social forces\" are listed in Table 5 .2.Diffusion and Channeling in Pedestrian MotionThe constructal law states that if a system is free to morph in time (evolve), the best flow architecture is the one that maximizes the global flow access (e.g., minimizes the global flow resistances).", [["Pedestrian Motion", "OBSERVATION", 150, 167], ["global", "OBSERVATION_MODIFIER", 303, 309], ["flow", "OBSERVATION", 310, 314], ["global", "OBSERVATION_MODIFIER", 343, 349], ["flow resistances", "OBSERVATION", 350, 366]]], ["Thus, the shape and flow architecture of the system do not develop by chance, but result from the permanent struggle between slow and fast for better performance and must thus evolve in time (Bejan 2000) .Diffusion and Channeling in Pedestrian MotionHow and by which mechanism do then pedestrians evolve in space and time?", [["the permanent struggle between slow and fast", "PROBLEM", 94, 138], ["shape", "OBSERVATION_MODIFIER", 10, 15], ["flow architecture", "OBSERVATION", 20, 37]]], ["To answer this question, let us consider pedestrian groups that proceed from one point to every point of a finite-size area (territory).", [["size", "OBSERVATION_MODIFIER", 114, 118]]], ["As described earlier, there are two mechanisms for achieving this purpose: diffusion (slow or high resistivity) and channeling (fast or low resistivity).", [["diffusion (slow or high resistivity)", "PROBLEM", 75, 111], ["channeling (fast or low resistivity)", "PROBLEM", 116, 152], ["high resistivity", "OBSERVATION_MODIFIER", 94, 110], ["low resistivity", "OBSERVATION_MODIFIER", 136, 151]]], ["The access time for a diffusive process through a territory of length L is \u223c L 2 /D, Eq.", [["a diffusive process", "PROBLEM", 20, 39], ["territory", "OBSERVATION_MODIFIER", 50, 59], ["length", "OBSERVATION_MODIFIER", 63, 69]]], ["(5.3), and the access time for a channeling flow is \u223c L/u, Eq.", [["a channeling flow", "TREATMENT", 31, 48]]], ["In accordance with field surveys, it has been established that pedestrians prefer to move with a walking velocity around 1 34 ms \u22121 , which corresponds to the least energy-consuming velocity (Fruin 1971; Henderson 1971; Helbing et al. 2001) .", [["a walking velocity", "TEST", 95, 113]]], ["This walking velocity is only reachable if there are no other pedestrians and obstacles in the surroundings.", [["This walking velocity", "TEST", 0, 21]]], ["Furthermore, it was noticed that pedestrians in a shopping mall or busy city street (random and nondirectional crowd) exhibit a velocity reduction that is related with the free area available around each individual (Fig. 5.10) .", [["a velocity reduction", "PROBLEM", 126, 146], ["the free area", "PROBLEM", 168, 181], ["velocity", "OBSERVATION_MODIFIER", 128, 136], ["reduction", "OBSERVATION", 137, 146], ["free", "OBSERVATION_MODIFIER", 172, 176]]], ["Consequently, and as in physics, the pedestrian's diffusion coefficient may be defined as the product of walking (random) velocity, u crd , and the mean available interpersonal distance, .Diffusion and Channeling in Pedestrian MotionA pedestrian's diffusion coefficient-mean interpersonal distance relationship can be established with the help of the coefficient's definition and the data plotted in Fig. 5.10 .", [["the pedestrian's diffusion coefficient", "TEST", 33, 71], ["Diffusion", "TEST", 188, 197], ["the coefficient's definition", "TEST", 347, 375], ["the data", "TEST", 380, 388]]], ["The form of the curve-fitted equation, justified by the correlation coefficient, isDiffusion and Channeling in Pedestrian MotionHere a 1 and a 2 are the correlation coefficients, which have been listed in Table 5 .3.", [["the curve", "TEST", 12, 21]]], ["Consider, e.g., the curve-fitted equation obtained based on Fruin data (Fruin 1971) , that when combined with Eqs.", [["the curve", "TEST", 16, 25]]], ["Based on this, it is straightforward to conclude that channeling enables a better performance if L/ is larger than 1 2 \u2212 0 5 \u22121 (or in terms of the pedestrians' density, , larger than 1 2 \u2212 0 5 \u22121/2 .", [["larger", "OBSERVATION_MODIFIER", 103, 109]]], ["If the target is to promote the easiest access to pedestrians over a large territory where, for some reason, the velocity is lower than the desired walking velocity (\u223c1 34 ms \u22121 ), the placement of gates/lanes/columns/trees along walkways/corridors helps to stabilize the pedestrian flow and make it more fluid (Fig. 5.12 ).", [["the velocity", "TEST", 109, 121], ["the placement of gates/lanes/columns/trees along walkways/corridors", "TREATMENT", 181, 248], ["large", "OBSERVATION_MODIFIER", 69, 74], ["territory", "OBSERVATION", 75, 84], ["lower", "OBSERVATION_MODIFIER", 125, 130]]], ["The placement of gates/lanes/columns/trees (channeling) is especially important in case of pedestrians walking in opposite directions (Fig. 5.13 ).Diffusion and Channeling in Pedestrian MotionPedestrians have a preferred side to walk because they profit from it (e.g., moving against the stream is more difficult because it increases interaction and consequently the resistance).", [["The placement of gates/lanes/columns/trees", "TREATMENT", 0, 42]]], ["Therefore, a baffler along walkways/corridors helps to optimize the flow of pedestrians, as well as to save space that can be used for other purposes.Crowd Density and Pedestrian FlowEmpirical observations have also highlighted that pedestrians can move freely only at very small pedestrian densities.", [["a baffler along walkways/corridors", "TREATMENT", 11, 45], ["Crowd Density", "PROBLEM", 150, 163], ["Density", "OBSERVATION", 156, 163], ["Pedestrian FlowEmpirical", "OBSERVATION", 168, 192], ["small", "OBSERVATION_MODIFIER", 274, 279], ["pedestrian densities", "OBSERVATION", 280, 300]]], ["Fig. 5 .14 illustrates velocities of pedestrians in the crowds.", [["crowds", "OBSERVATION", 56, 62]]], ["Pedestrians in low-density crowds ( < 1 person m \u22122 ) are able to walk with an individual desired velocity that corresponds to the comfortable walking velocity (\u223c1 34 ms \u22121 ).", [["person", "SPECIES", 40, 46], ["the comfortable walking velocity", "TEST", 127, 159], ["low-density", "OBSERVATION_MODIFIER", 15, 26]]], ["In higher crowd densities, interpersonal distances are lessened and the walking velocity is reduced, in order to where u 0 is the desired velocity (e.g., \u223c1 34 ms \u22121 , ct is the critical density of pedestrians (e.g., \u223c1 person m \u22122 and max is the maximum density of pedestrians.", [["person", "SPECIES", 220, 226], ["the walking velocity", "TEST", 68, 88], ["ms", "TEST", 160, 162], ["ct", "TEST", 168, 170], ["higher", "OBSERVATION_MODIFIER", 3, 9], ["crowd densities", "OBSERVATION", 10, 25], ["interpersonal", "OBSERVATION_MODIFIER", 27, 40], ["lessened", "OBSERVATION_MODIFIER", 55, 63], ["walking", "OBSERVATION_MODIFIER", 72, 79], ["velocity", "OBSERVATION_MODIFIER", 80, 88], ["reduced", "OBSERVATION_MODIFIER", 92, 99], ["velocity", "OBSERVATION_MODIFIER", 138, 146], ["critical", "OBSERVATION_MODIFIER", 178, 186], ["density", "OBSERVATION", 187, 194], ["maximum", "OBSERVATION_MODIFIER", 247, 254], ["density", "OBSERVATION", 255, 262]]], ["Let us suppose that, above the critical pedestrian density, the temporal change of the pedestrian velocity is the result of \"repulsive\" forces due to a decrease of interpersonal distances (especially the relative distance to the front person).", [["person", "SPECIES", 235, 241], ["a decrease of interpersonal distances", "PROBLEM", 150, 187], ["density", "OBSERVATION", 51, 58], ["temporal", "OBSERVATION_MODIFIER", 64, 72], ["pedestrian velocity", "OBSERVATION", 87, 106], ["repulsive", "OBSERVATION", 125, 134], ["decrease", "OBSERVATION_MODIFIER", 152, 160]]], ["\"Repulsive\" forces decrease with the interpersonal distance, and as the area available for the next step is accounted, they are also dependent of the walking velocity (Helbing et al. 2001 ).", [["Repulsive", "OBSERVATION", 1, 10]]], ["According to the Newton's second law of motion d 2 r dt 2 = F r (5.13)Crowd Density and Pedestrian FlowHere r is the position of the pedestrian and F r is the \"repulsive\" force per mass affecting the behavior of the pedestrian which is given by (Fang et al. 2003 )Crowd Density and Pedestrian Flowwhere is a constant, and r \u2212 r o = ) and dr/dt \u2212 dr o /dt are the mean interpersonal distance and the mean relative velocity to the pedestrians situated around, respectively.", [["motion d 2 r dt", "TEST", 40, 55], ["Crowd Density", "PROBLEM", 70, 83], ["Density", "OBSERVATION", 76, 83], ["Pedestrian Flow", "OBSERVATION", 88, 103], ["repulsive", "OBSERVATION", 160, 169], ["mass", "OBSERVATION", 181, 185], ["Density", "OBSERVATION", 270, 277], ["mean", "OBSERVATION_MODIFIER", 399, 403], ["velocity", "OBSERVATION_MODIFIER", 413, 421], ["pedestrians", "OBSERVATION", 429, 440]]], ["Replacing of F r by Eq.", [["F r", "GENE_OR_GENE_PRODUCT", 13, 16]]], ["(5.13) and integrating the resulting equation, we find thatCrowd Density and Pedestrian Flowwhere c is an integration constant.", [["Crowd Density", "OBSERVATION", 59, 72]]], ["By definition, the interpersonal distance is minimum (e.g., crowd density maximum) when the walking velocity is zero.", [["the walking velocity", "TEST", 88, 108]]], ["(5.15) assumes the form u = ln min (5.16) and in terms of pedestrian density u = 1 2 ln max (5.17)Crowd Density and Pedestrian FlowIn summary, Eqs.", [["pedestrian density u", "TEST", 58, 78], ["pedestrian density", "OBSERVATION", 58, 76]]], ["(5.16) and (5.17) should hold when the pedestrian's density is between the critical and the maximum densities.", [["the pedestrian's density", "PROBLEM", 35, 59], ["density", "OBSERVATION", 52, 59], ["maximum", "OBSERVATION_MODIFIER", 92, 99], ["densities", "OBSERVATION", 100, 109]]], ["Note that experimental walking velocities in this density range show a good agreement with these equations (Fig. 5.15 ).", [["experimental walking velocities", "TEST", 10, 41], ["walking", "OBSERVATION_MODIFIER", 23, 30], ["velocities", "OBSERVATION_MODIFIER", 31, 41]]], ["The flow of pedestrians may be defined as the product of walking velocity and pedestrian density, Based on these equations a flow-density diagram can be drawn (Fig. 5.16 ).", [["pedestrian density", "PROBLEM", 78, 96], ["these equations", "TEST", 107, 122], ["a flow-density diagram", "TEST", 123, 145], ["flow", "OBSERVATION_MODIFIER", 4, 8], ["pedestrian density", "OBSERVATION", 78, 96]]], ["When \u2264 ct , the individual desired velocity is a constant and the maximum flow of pedestrians corresponds to ct u 0 .", [["\u2264 ct", "TEST", 5, 9], ["ct u 0", "TEST", 109, 115], ["constant", "OBSERVATION_MODIFIER", 49, 57]]], ["For densities above the critical density, there is also an optimal crowd density such that the flow of pedestrians is maximized.", [["densities", "PROBLEM", 4, 13], ["an optimal crowd density", "PROBLEM", 56, 80], ["densities", "OBSERVATION", 4, 13], ["critical", "OBSERVATION_MODIFIER", 24, 32], ["density", "OBSERVATION", 33, 40], ["optimal", "OBSERVATION_MODIFIER", 59, 66], ["crowd", "OBSERVATION_MODIFIER", 67, 72], ["density", "OBSERVATION", 73, 80], ["flow", "OBSERVATION_MODIFIER", 95, 99]]], ["(5.20), the flow has a maximum value of 0 5 max / exp 1 at = max /exp 1 .", [["the flow", "TEST", 8, 16], ["a maximum value", "TEST", 21, 36]]], ["It is useful to obtain also the relationship between flow and velocity.", [["flow", "OBSERVATION", 53, 57], ["velocity", "OBSERVATION_MODIFIER", 62, 70]]], ["For ct < \u2264 max it follows from Eqs.", [["ct", "TEST", 4, 6]]], ["(5.17) and (5.18) thatCrowd Density and Pedestrian FlowThe flow-velocity diagram is depicted in Fig. 5 .17.", [["Crowd Density", "TEST", 22, 35], ["Pedestrian Flow", "TEST", 40, 55], ["The flow-velocity diagram", "TEST", 55, 80], ["Crowd Density", "OBSERVATION", 22, 35], ["Pedestrian Flow", "OBSERVATION", 40, 55], ["flow", "OBSERVATION_MODIFIER", 59, 63], ["velocity diagram", "OBSERVATION", 64, 80]]], ["This diagram shows that there is also an optimal velocity such that the crowd flow is maximized.", [["This diagram", "TEST", 0, 12], ["the crowd flow", "TEST", 68, 82], ["optimal", "OBSERVATION_MODIFIER", 41, 48], ["velocity", "OBSERVATION_MODIFIER", 49, 57], ["crowd flow", "OBSERVATION", 72, 82]]], ["(5.21), the flow has a maximum value of 0 5 max / exp 1 at u = /2.", [["the flow", "TEST", 8, 16], ["a maximum value", "TEST", 21, 36]]], ["As expected, this maximum flow has the same value as that obtained with Eq.", [["this maximum flow", "TEST", 13, 30], ["maximum", "OBSERVATION_MODIFIER", 18, 25], ["flow", "OBSERVATION", 26, 30]]], ["(5.20).Crowd Density and Pedestrian FlowComparing the flow-density and flow-velocity diagrams (Figs.", [["Crowd Density", "TEST", 7, 20], ["Pedestrian FlowComparing", "TEST", 25, 49], ["Density", "OBSERVATION", 13, 20], ["Pedestrian FlowComparing", "OBSERVATION", 25, 49], ["flow", "OBSERVATION_MODIFIER", 54, 58], ["-density", "OBSERVATION_MODIFIER", 58, 66], ["flow", "OBSERVATION_MODIFIER", 71, 75], ["velocity", "OBSERVATION_MODIFIER", 76, 84]]], ["5.16 and 5.17, respectively), we note that each velocity/density corresponds to a single flow but, with the exception of maximum flow, the same flow may correspond to two different velocities/densities.", [["each velocity/density", "PROBLEM", 43, 64], ["two different velocities/densities", "PROBLEM", 167, 201], ["velocity", "OBSERVATION_MODIFIER", 48, 56], ["density", "OBSERVATION", 57, 64], ["single", "OBSERVATION_MODIFIER", 82, 88], ["flow", "OBSERVATION", 89, 93], ["maximum", "OBSERVATION_MODIFIER", 121, 128], ["flow", "OBSERVATION", 129, 133], ["flow", "OBSERVATION", 144, 148], ["two", "OBSERVATION_MODIFIER", 167, 170], ["different", "OBSERVATION_MODIFIER", 171, 180], ["velocities", "OBSERVATION_MODIFIER", 181, 191], ["densities", "OBSERVATION", 192, 201]]], ["As the flow progresses to the maximum, the increase of pedestrian velocity (or decrease of density) is offset by a decrease of pedestrian density (or increase of velocity).", [["pedestrian velocity", "PROBLEM", 55, 74], ["a decrease of pedestrian density", "PROBLEM", 113, 145], ["flow", "OBSERVATION", 7, 11], ["maximum", "OBSERVATION_MODIFIER", 30, 37], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["pedestrian velocity", "OBSERVATION", 55, 74], ["decrease", "OBSERVATION_MODIFIER", 79, 87], ["density", "OBSERVATION", 91, 98], ["offset", "OBSERVATION_MODIFIER", 103, 109], ["decrease", "OBSERVATION_MODIFIER", 115, 123], ["pedestrian density", "OBSERVATION", 127, 145], ["increase", "OBSERVATION_MODIFIER", 150, 158], ["velocity", "OBSERVATION_MODIFIER", 162, 170]]], ["After reaching the maximum flow, there is a decrease of the pedestrian flow because the growth in velocity (or decrease of density) does not compensate the reduction of pedestrian density (or increase of velocity).", [["the maximum flow", "TEST", 15, 31], ["a decrease of the pedestrian flow", "PROBLEM", 42, 75], ["pedestrian density", "PROBLEM", 169, 187], ["maximum", "OBSERVATION_MODIFIER", 19, 26], ["flow", "OBSERVATION", 27, 31], ["decrease", "OBSERVATION_MODIFIER", 44, 52], ["pedestrian flow", "OBSERVATION", 60, 75], ["growth", "OBSERVATION_MODIFIER", 88, 94], ["velocity", "OBSERVATION_MODIFIER", 98, 106], ["decrease", "OBSERVATION_MODIFIER", 111, 119], ["density", "OBSERVATION", 123, 130], ["reduction", "OBSERVATION_MODIFIER", 156, 165], ["pedestrian density", "OBSERVATION", 169, 187], ["increase", "OBSERVATION_MODIFIER", 192, 200], ["velocity", "OBSERVATION_MODIFIER", 204, 212]]], ["Consequently, the same flow may correspond to two different velocities/densities.The Optimal Gates GeometryAt high pedestrian densities, the walking velocity is drastically reduced and impatient pedestrians trying to use any gap to move on may lead in turn to a complete obstruction of walking paths.", [["two different velocities/densities", "PROBLEM", 46, 80], ["the walking velocity", "TEST", 137, 157], ["a complete obstruction of walking paths", "PROBLEM", 260, 299], ["flow", "OBSERVATION", 23, 27], ["may correspond to", "UNCERTAINTY", 28, 45], ["two", "OBSERVATION_MODIFIER", 46, 49], ["different", "OBSERVATION_MODIFIER", 50, 59], ["velocities", "OBSERVATION_MODIFIER", 60, 70], ["densities", "OBSERVATION", 71, 80], ["high", "OBSERVATION_MODIFIER", 110, 114], ["pedestrian densities", "OBSERVATION", 115, 135], ["drastically", "OBSERVATION_MODIFIER", 161, 172], ["reduced", "OBSERVATION_MODIFIER", 173, 180], ["obstruction", "OBSERVATION", 271, 282]]], ["Thus, at a high density there is risk of overcrowding and personal injury that should be avoided.The Optimal Gates GeometryGates are used at sport facilities, theaters, and so on, to reduce the interpersonal interactions and stabilize the pedestrian flow, by facilitating the access over the territory (Fig. 5.12) .", [["overcrowding", "PROBLEM", 41, 53], ["personal injury", "PROBLEM", 58, 73], ["high density", "OBSERVATION_MODIFIER", 11, 23], ["risk of", "UNCERTAINTY", 33, 40], ["overcrowding", "OBSERVATION", 41, 53], ["pedestrian flow", "OBSERVATION", 239, 254]]], ["Thus, pedestrians must be channeled optimally through gates since channeled flow is characterized by a much lower travel time (Section 5.4.2).", [["flow", "OBSERVATION", 76, 80]]], ["The question put forward by the constructal principle is, then, how can the gates be designed in order to ensure that pedestrians flow over the entire space in the shortest time possible?The Optimal Gates GeometryConsider a crowd approaching gates of the same size and uniformly distributed in space.", [["crowd", "OBSERVATION", 224, 229], ["same", "OBSERVATION_MODIFIER", 255, 259], ["size", "OBSERVATION_MODIFIER", 260, 264], ["uniformly", "OBSERVATION_MODIFIER", 269, 278], ["distributed", "OBSERVATION_MODIFIER", 279, 290], ["space", "OBSERVATION_MODIFIER", 294, 299]]], ["According to mass conservation equation,The Optimal Gates Geometrywhere n is the number of gates, W g is the total width allocated to the gates, w g is the width of each individual gate, u is the velocity of the crowd approaching the gates, u i is the pedestrians velocity within the gates, is the density of the crowd approaching the gates, and i is the density of the pedestrians within the gates.", [["mass", "OBSERVATION", 13, 17], ["pedestrians velocity", "OBSERVATION", 252, 272], ["density", "OBSERVATION_MODIFIER", 298, 305], ["crowd", "OBSERVATION", 313, 318], ["density", "OBSERVATION_MODIFIER", 355, 362]]], ["The goal is the optimal spacing of the gates, w g , in a fixed territory, W g , to minimize the travel time of pedestrians defined as t tr = 1 l g (5.23)The Optimal Gates GeometryLet us consider that the length of the gates, l g , is fixed.", [["fixed", "OBSERVATION", 234, 239]]], ["The time of travel is minimal when the flow of pedestrians is maximal.", [["minimal", "OBSERVATION_MODIFIER", 22, 29]]], ["It is not that difficult to show that the maximum flow of pedestrians corresponds to 0 5 max / exp 1 (Section 5.4.3) and that the minimum travel time is given by t tr = 2 exp 1 l g max (5.24) Given that max is a constant, the variation of nw g /W g is only dependent on the density of the crowd approaching the gates.", [["nw g /W g", "TREATMENT", 239, 248], ["maximum", "OBSERVATION_MODIFIER", 42, 49], ["flow", "OBSERVATION", 50, 54]]], ["Fig. 5 .18 shows how nw g /W g responds to changes of crowd density.", [["crowd density", "PROBLEM", 54, 67], ["crowd density", "OBSERVATION", 54, 67]]], ["It reveals that there is a maximum for nw g /W g that occurs when / max \u223c 0 37.", [["nw g /W g", "TREATMENT", 39, 48]]], ["Thus, the optimal number of gates n is W g /w g taking w g \u223c 0 75 m which corresponds to the square root of the free area available around each individual when the flow of pedestrians is maximum (Fig. 5.16 ).Optimal Architecture for Different Locomotion VelocitiesConstructal theory also predicts the architecture of flow paths that connect a finite territory to a single point when different locomotion velocities are available (Bejan and Ledezma 1998; Bejan 2000) .", [["W g /w g", "TREATMENT", 39, 47], ["different locomotion velocities", "TEST", 383, 414], ["Different", "OBSERVATION_MODIFIER", 233, 242], ["Locomotion Velocities", "OBSERVATION", 243, 264], ["flow paths", "OBSERVATION", 317, 327]]], ["Let us assume that the territory is covered in sequential steps of increasingly larger elements (A 1 < A 2 ).", [["territory", "OBSERVATION_MODIFIER", 23, 32], ["increasingly", "OBSERVATION_MODIFIER", 67, 79], ["larger", "OBSERVATION_MODIFIER", 80, 86]]], ["According to the constructal theory, the global system (territory) will perform best when all its elements (constructs, portions of territory) perform in an optimal way.", [["global system", "ANATOMY", 41, 54]]], ["Thus, both the shape of the area and the angle between each path and its branches are optimized at each stage.", [["shape", "OBSERVATION_MODIFIER", 15, 20], ["area", "OBSERVATION_MODIFIER", 28, 32], ["angle", "OBSERVATION_MODIFIER", 41, 46], ["path", "OBSERVATION_MODIFIER", 60, 64], ["branches", "ANATOMY_MODIFIER", 73, 81]]], ["The flow path is constructed starting with the smallest element (construct, portions of territory) and continuing with the larger areas (assemblies, constructs).Optimal Architecture for Different Locomotion VelocitiesConsider pedestrians walking in a rectangular domain with a fixed area H 1 L 1 = A 1 at two different velocities: at velocity u 1 in all directions (diffusion) and at velocity u 2 along a centred longitudinal path (u 1 < u 2 ).", [["The flow path", "TEST", 0, 13], ["Different Locomotion Velocities", "TEST", 186, 217], ["a fixed area H", "TEST", 275, 289], ["velocity u", "TEST", 334, 344], ["a centred longitudinal path", "TEST", 403, 430], ["flow path", "OBSERVATION", 4, 13], ["smallest", "OBSERVATION_MODIFIER", 47, 55], ["element", "OBSERVATION_MODIFIER", 56, 63], ["territory", "OBSERVATION_MODIFIER", 88, 97], ["larger", "OBSERVATION_MODIFIER", 123, 129], ["areas", "OBSERVATION_MODIFIER", 130, 135], ["Locomotion Velocities", "OBSERVATION", 196, 217], ["velocities", "OBSERVATION_MODIFIER", 319, 329]]], ["There are two degrees of freedom in this design: the shape H 1 /L 1 and the deviation from the normal for the angle between the slower and the faster paths A1 .", [["A1", "PROTEIN", 156, 158], ["two", "OBSERVATION_MODIFIER", 10, 13], ["degrees", "OBSERVATION_MODIFIER", 14, 21], ["freedom", "OBSERVATION_MODIFIER", 25, 32], ["shape", "OBSERVATION_MODIFIER", 53, 58], ["deviation", "OBSERVATION", 76, 85], ["normal", "OBSERVATION", 95, 101], ["slower", "OBSERVATION_MODIFIER", 128, 134], ["faster", "OBSERVATION_MODIFIER", 143, 149], ["paths", "OBSERVATION_MODIFIER", 150, 155]]], ["Consider now a larger fixed area A 2 = H 2 L 2 ) and a faster regime at velocity u 3 (e.g., the desired walking velocity) along a centred longitudinal path (u 3 > u 2 ).", [["a faster regime", "TREATMENT", 53, 68], ["larger", "OBSERVATION_MODIFIER", 15, 21]]], ["Once again one seeks to optimize the access from an arbitrary point of A 2 to a common exit point on its periphery.", [["periphery", "ANATOMY_MODIFIER", 105, 114]]], ["The number of elements A 1 assembled into A 2 is given by n A2A1 = 2 1 2 u 3 u 1 1 \u2212 u 2 2 4u 2 3 (5.31) and the optimal geometry is represented by H 2 L 2 optimal = 1 2 u 2 u 3 (5.32) A2 optimal = cos \u22121 2 (5.33) with 2 = 1 \u2212 u 2 2u 3 2 1/2 (5.34)Optimal Architecture for Different Locomotion VelocitiesThese results are very similar to those obtained by the optimization of A 1 apart of a constant factor.", [["elements A 1", "DNA", 14, 26], ["u", "TEST", 174, 175], ["cos", "TEST", 198, 201], ["u", "TEST", 227, 228], ["Different Locomotion Velocities", "TEST", 273, 304], ["Locomotion Velocities", "OBSERVATION", 283, 304]]], ["The final paths' geometry forms a tree network.", [["tree network", "MULTI-TISSUE_STRUCTURE", 34, 46]]], ["Figures 5.20 and 5.21 show how the shape H/L and the optimal angle A respond to changes of velocity ratios.", [["Figures", "TEST", 0, 7], ["velocity ratios", "TEST", 91, 106]]], ["When the two modes of locomotion have similar velocities, the optimal angles A1 and A2 are close to 90 and 30 , respectively, and the optimal lengths H/L are maximal.", [["A2", "GENE_OR_GENE_PRODUCT", 84, 86], ["A1", "PROTEIN", 77, 79], ["A2", "PROTEIN", 84, 86], ["similar", "OBSERVATION_MODIFIER", 38, 45], ["velocities", "OBSERVATION_MODIFIER", 46, 56], ["optimal", "OBSERVATION_MODIFIER", 62, 69], ["angles", "OBSERVATION_MODIFIER", 70, 76], ["A2", "OBSERVATION_MODIFIER", 84, 86], ["lengths", "OBSERVATION_MODIFIER", 142, 149], ["maximal", "OBSERVATION_MODIFIER", 158, 165]]], ["On the other hand, if the faster walking velocity is much larger than the slower walking velocity then paths are perpendicular and the centred longitudinal path L is the much larger than H. We also note that H = L when u 2 /u 1 \u223c 0 45 ( A1 \u223c 26 7 ) and u 3 /u 2 \u223c 0 9 A2 \u223c 26 7 ).The Optimal Queuing FlowAnother interesting collective effect of pedestrian dynamics is the formation of queues.", [["A2", "PROTEIN", 268, 270], ["H.", "SPECIES", 187, 189], ["the faster walking velocity", "TEST", 22, 49], ["u", "TEST", 219, 220], ["u", "TEST", 253, 254], ["u", "TEST", 258, 259], ["A2 \u223c", "TEST", 268, 272], ["much", "OBSERVATION_MODIFIER", 53, 57], ["larger", "OBSERVATION_MODIFIER", 58, 64], ["slower", "OBSERVATION_MODIFIER", 74, 80], ["walking velocity", "OBSERVATION", 81, 97], ["perpendicular", "OBSERVATION_MODIFIER", 113, 126], ["larger", "OBSERVATION_MODIFIER", 175, 181]]], ["Queuing is a common practice is our lives.", [["Queuing", "DISEASE", 0, 7]]], ["When q s \u2265 q a , all Empirical observations reveal that the higher the flow of individuals, the higher the queuing time.", [["higher", "OBSERVATION_MODIFIER", 60, 66]]], ["The velocity within the queue, v, is (Heidemann 1996; Vandaele et al. 2000 )The Optimal Queuing FlowHere is a coefficient that accounts for deviations from the expected service time (e.g., 2 = 1 means that pedestrians are served within the expected time).", [["The velocity", "TEST", 0, 12], ["velocity", "OBSERVATION_MODIFIER", 4, 12]]], ["The relation between velocity and flow in queues can be obtained by combining Eqs.", [["velocity", "OBSERVATION_MODIFIER", 21, 29], ["flow", "OBSERVATION", 34, 38]]], ["(5.18) and (5.35) intoThe Optimal Queuing FlowBased on this equation a flow-velocity diagram can be drawn (Fig. 5.22 ).", [["a flow-velocity diagram", "TEST", 69, 92]]], ["This diagram reveals one flow can correspond to two different velocities (with the exception of the maximum flow) in spite of each pedestrian velocity matching a single pedestrian flow.", [["This diagram", "TEST", 0, 12], ["one", "OBSERVATION_MODIFIER", 21, 24], ["flow", "OBSERVATION", 25, 29], ["two", "OBSERVATION_MODIFIER", 48, 51], ["different", "OBSERVATION_MODIFIER", 52, 61], ["velocities", "OBSERVATION_MODIFIER", 62, 72], ["maximum", "OBSERVATION_MODIFIER", 100, 107], ["flow", "OBSERVATION", 108, 112], ["pedestrian velocity", "OBSERVATION", 131, 150], ["pedestrian flow", "OBSERVATION", 169, 184]]], ["Figure 5 .22 also reveals that there is an optimal velocity such that the flow in the queue is maximized (or time of travel is minimized).", [["Figure", "TEST", 0, 6], ["optimal", "OBSERVATION_MODIFIER", 43, 50], ["velocity", "OBSERVATION_MODIFIER", 51, 59], ["flow", "OBSERVATION", 74, 78]]], ["We can also observe that an increase of 2 reduces the maximum value (the peak) of the flow and that this peak occurs at lower velocities.", [["the flow", "TEST", 82, 90], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["lower", "OBSERVATION_MODIFIER", 120, 125], ["velocities", "OBSERVATION_MODIFIER", 126, 136]]], ["When 2 < 1, the maximum flow occurs at higher velocities.", [["the maximum flow", "TEST", 12, 28], ["maximum", "OBSERVATION_MODIFIER", 16, 23], ["flow", "OBSERVATION", 24, 28], ["higher velocities", "OBSERVATION", 39, 56]]], ["After that the pedestrian flow drops very fast until it ceases totally.", [["the pedestrian flow", "TEST", 11, 30]]], ["Consequently, more pedestrians are allowed to enter in the queue, which can be by increasing the arrival velocity of pedestrians to the queue.Constructal View of Self-organized Pedestrian MovementOne of the more striking occurrences in pedestrian dynamics is the evidence of spontaneous, self-organized motion.", [["spontaneous, self-organized motion", "PROBLEM", 275, 309]]], ["Pedestrians in very crowded open spaces tend to organize in lanes of uniform walking velocity (Fig. 5.9 ).", [["Pedestrians in very crowded open spaces", "PROBLEM", 0, 39]]], ["Similarly, when facing a stationary crowd, pedestrians spontaneously self-organize in river-like streams (rivers of people) in order to cross it ( Fig. 5.8 ).", [["people", "ORGANISM", 116, 122], ["people", "SPECIES", 116, 122]]], ["How and by which mechanism do they evolve in space and time?Constructal View of Self-organized Pedestrian MovementThe constructal theory's answer to these questions is simple and direct.", [["Pedestrian Movement", "OBSERVATION", 95, 114]]], ["In line with the access-optimization principle, the optimal flow architecture will be the one that promotes the easiest flow of pedestrian.", [["the access-optimization principle", "TREATMENT", 13, 46], ["flow architecture", "OBSERVATION", 60, 77]]], ["As described before, there are two locomotion modes for achieving motion: diffusion (slow or high resistivity) and channeling (fast or low resistivity).", [["diffusion (slow or high resistivity)", "PROBLEM", 74, 110], ["channeling (fast or low resistivity)", "PROBLEM", 115, 151], ["high resistivity", "OBSERVATION_MODIFIER", 93, 109], ["low resistivity", "OBSERVATION_MODIFIER", 135, 150]]], ["Diffusion is the preferred locomotion mode as long as it provides the faster pedestrian transport across the territory (e.g., for L/ < 1 2 \u2212 0 5 \u22121 , i.e., for large inter-personal distances or low pedestrian densities).", [["large inter-personal distances or low pedestrian densities", "PROBLEM", 160, 218], ["territory", "ANATOMY_MODIFIER", 109, 118], ["large", "OBSERVATION_MODIFIER", 160, 165], ["low", "OBSERVATION_MODIFIER", 194, 197], ["pedestrian densities", "OBSERVATION", 198, 218]]], ["This explains why moving pedestrians form lanes of uniform velocity when the density is high enough.", [["uniform", "OBSERVATION_MODIFIER", 51, 58], ["velocity", "OBSERVATION_MODIFIER", 59, 67], ["density", "OBSERVATION", 77, 84], ["high", "OBSERVATION_MODIFIER", 88, 92]]], ["The answer to this is that a group of pedestrians is often composed of many pedestrians with different walking velocities (e.g., young people walk faster than older people).", [["people", "ORGANISM", 165, 171], ["people", "SPECIES", 135, 141], ["people", "SPECIES", 165, 171]]], ["These factors are then responsible for differences of velocity between lanes.Constructal View of Self-organized Pedestrian MovementThe movement of pedestrians across stationary crowds (rivers of people) can be deduced from the constructal principle in a way similar to river basin structures (Bejan 2000 (Bejan , 2002 .", [["people", "ORGANISM", 195, 201], ["people", "SPECIES", 195, 201], ["Pedestrian Movement", "OBSERVATION", 112, 131], ["movement", "OBSERVATION_MODIFIER", 135, 143]]], ["The crowd can be seen as the river basin and the space vacated by the crossing pedestrians as the eroded river bed (path of low resistance).", [["crowd", "OBSERVATION", 4, 9], ["eroded", "OBSERVATION_MODIFIER", 98, 104], ["river", "OBSERVATION_MODIFIER", 105, 110], ["low resistance", "OBSERVATION", 124, 138]]], ["The lines formed by coalescence of many such paths are the river branches.Constructal View of Self-organized Pedestrian MovementIn crowds that panic, the streams of people of uniform walking velocity are destroyed because individuals do not know which the right way to escape is.", [["panic", "DISEASE", 143, 148], ["lines", "CELL", 4, 9], ["river branches", "MULTI-TISSUE_STRUCTURE", 59, 73], ["people", "ORGANISM", 165, 171], ["people", "SPECIES", 165, 171], ["The lines", "TREATMENT", 0, 9], ["panic", "PROBLEM", 143, 148], ["lines", "OBSERVATION_MODIFIER", 4, 9], ["formed", "OBSERVATION_MODIFIER", 10, 16], ["coalescence", "OBSERVATION_MODIFIER", 20, 31], ["many", "OBSERVATION_MODIFIER", 35, 39], ["such paths", "OBSERVATION", 40, 50], ["river", "ANATOMY_MODIFIER", 59, 64], ["branches", "ANATOMY_MODIFIER", 65, 73], ["right", "ANATOMY_MODIFIER", 256, 261], ["escape", "OBSERVATION", 269, 275]]], ["They strive to go forward, thereby reducing interpersonal distances, inducing interpersonal contact (collision) or even loss of balance of other individuals.Population Motion and Spread of EpidemicsLarge-scale epidemic outbreaks have occurred through the centuries causing major surges in mortality (Anderson and May 1991; Cohn 2002; Suwandono et al. 2006) , the worst being the bubonic plague (or Black Death) in the fourteenth century.", [["bubonic", "DISEASE", 379, 386], ["Death", "DISEASE", 404, 409], ["Population Motion", "PROBLEM", 157, 174], ["EpidemicsLarge-scale epidemic outbreaks", "PROBLEM", 189, 228], ["the bubonic plague", "PROBLEM", 375, 393], ["Black Death", "PROBLEM", 398, 409], ["Motion", "OBSERVATION_MODIFIER", 168, 174], ["Spread", "OBSERVATION_MODIFIER", 179, 185], ["scale", "OBSERVATION_MODIFIER", 204, 209], ["epidemic", "OBSERVATION_MODIFIER", 210, 218], ["major", "OBSERVATION_MODIFIER", 273, 278], ["surges", "OBSERVATION_MODIFIER", 279, 285], ["bubonic", "OBSERVATION_MODIFIER", 379, 386], ["plague", "OBSERVATION", 387, 393]]], ["Historians estimated that the Black Death wiped out a third of the European population in less than four years, no such large-scale outbreak has been reported since (Langer 1964) .", [["Death", "DISEASE", 36, 41], ["the Black Death", "PROBLEM", 26, 41], ["such large-scale outbreak", "PROBLEM", 115, 140], ["large", "OBSERVATION_MODIFIER", 120, 125]]], ["The last large-scale outbreak was the socalled Spanish Influenza epidemic of 1918 -1919 (Oxford et al. 2005 .", [["Influenza", "DISEASE", 55, 64], ["large", "OBSERVATION_MODIFIER", 9, 14], ["-scale", "OBSERVATION_MODIFIER", 14, 20]]], ["It is estimated that about half of the people living worldwide became infected and 20 million died.", [["people", "ORGANISM", 39, 45], ["people", "SPECIES", 39, 45], ["infected", "OBSERVATION", 70, 78]]], ["An estimated 60,000 died in Portugal, 200,000 in the UK, more than 400,000 in France, and about 600,000 in the USA (Fig. 5.23) .Population Motion and Spread of EpidemicsEpidemic diseases still occur in many areas of our planet at a local scale (Barreto et al. 1994; Koopmans et al. 2004; Hsu et al. 2006 ).", [["EpidemicsEpidemic diseases", "DISEASE", 160, 186], ["Population Motion", "PROBLEM", 128, 145], ["EpidemicsEpidemic diseases", "PROBLEM", 160, 186], ["Spread", "OBSERVATION_MODIFIER", 150, 156], ["EpidemicsEpidemic diseases", "OBSERVATION", 160, 186], ["many", "OBSERVATION_MODIFIER", 202, 206], ["areas", "OBSERVATION_MODIFIER", 207, 212]]], ["There can be little doubt that the improvement of healthcare, a greater vaccine manufacturing capacity, a development of hygiene habits, and an expanded surveillance reduced greatly the impact of an epidemic disease since the second-half of the twentieth century.", [["a greater vaccine", "TREATMENT", 62, 79], ["an expanded surveillance", "TEST", 141, 165], ["an epidemic disease", "PROBLEM", 196, 215], ["improvement", "OBSERVATION_MODIFIER", 35, 46], ["epidemic", "OBSERVATION_MODIFIER", 199, 207], ["disease", "OBSERVATION", 208, 215]]], ["Nevertheless, the widespread avian influenza outbreaks occurring nowadays throughout Asia show us that a global epidemic is still a possibility (Hsu et al. 2006) .Population Motion and Spread of EpidemicsIn order to prevent epidemics and minimize disease transmission, it is essential that we are able to evaluate the epidemic spread mechanisms and capability.", [["influenza outbreaks", "DISEASE", 35, 54], ["the widespread avian influenza outbreaks", "PROBLEM", 14, 54], ["a global epidemic", "PROBLEM", 103, 120], ["Population Motion", "PROBLEM", 163, 180], ["Epidemics", "PROBLEM", 195, 204], ["epidemics", "PROBLEM", 224, 233], ["disease transmission", "PROBLEM", 247, 267], ["widespread", "OBSERVATION_MODIFIER", 18, 28], ["avian", "OBSERVATION_MODIFIER", 29, 34], ["influenza", "OBSERVATION", 35, 44], ["global", "OBSERVATION_MODIFIER", 105, 111], ["epidemic", "OBSERVATION", 112, 120], ["Spread", "OBSERVATION_MODIFIER", 185, 191], ["Epidemics", "OBSERVATION_MODIFIER", 195, 204]]], ["Models for spread of epidemics have existed since the early twentieth century.", [["epidemics", "PROBLEM", 21, 30]]], ["In microparasite .", [["microparasite", "ANATOMY", 3, 16]]], ["Susceptible individuals can catch the infection from contact with infected individuals, and the fraction of these individuals recovered is assumed to be immune to the disease.", [["infection", "DISEASE", 38, 47], ["individuals", "ORGANISM", 12, 23], ["Susceptible individuals", "PROBLEM", 0, 23], ["the infection", "PROBLEM", 34, 47], ["infected individuals", "PROBLEM", 66, 86], ["the disease", "PROBLEM", 163, 174], ["infection", "OBSERVATION", 38, 47], ["disease", "OBSERVATION", 167, 174]]], ["On the other hand, the Noble's model considers that the spatial dispersal of individuals can be well approximated by a diffusion process, with the spread of epidemics being modeled as a diffusivereactive phenomenon.", [["the Noble's model", "TEST", 19, 36], ["a diffusion process", "PROBLEM", 117, 136], ["epidemics", "PROBLEM", 157, 166], ["a diffusivereactive phenomenon", "PROBLEM", 184, 214], ["diffusivereactive phenomenon", "OBSERVATION", 186, 214]]], ["This model was applied to the dynamics of bubonic plague as described throughout Europe in the fourteenth century.", [["bubonic plague", "DISEASE", 42, 56], ["bubonic plague", "PROBLEM", 42, 56], ["bubonic plague", "OBSERVATION", 42, 56]]], ["Since then reactiondiffusion models have been used to describe, among others, the spatial dynamics of rabies in fox (Kallen et al. 1985) and the Lyme disease transmission (Caraco et al. 2002) .", [["rabies", "DISEASE", 102, 108], ["Lyme disease", "DISEASE", 145, 157], ["rabies", "ORGANISM", 102, 108], ["the Lyme disease transmission", "PROBLEM", 141, 170], ["Lyme disease", "OBSERVATION", 145, 157]]], ["In this section we explore two main issues: the mechanics of epidemics propagation and the effect of population motion on the spread of epidemics.Modeling the Spreading of an EpidemicConsider two interacting populations of individuals-susceptible and infective.", [["epidemics propagation", "PROBLEM", 61, 82], ["population motion", "PROBLEM", 101, 118], ["epidemics", "PROBLEM", 136, 145], ["an EpidemicConsider", "TREATMENT", 172, 191], ["infective", "PROBLEM", 251, 260], ["Spreading", "OBSERVATION_MODIFIER", 159, 168], ["interacting", "OBSERVATION_MODIFIER", 196, 207], ["populations", "OBSERVATION_MODIFIER", 208, 219], ["susceptible", "OBSERVATION_MODIFIER", 235, 246], ["infective", "OBSERVATION_MODIFIER", 251, 260]]], ["Transmission is the driving force due to which susceptible population becomes infective.", [["infective", "PROBLEM", 78, 87], ["infective", "OBSERVATION", 78, 87]]], ["The mass conservation of individuals S and I in a territory are governed by:Modeling the Spreading of an EpidemicHere S and I are the density of susceptible and infective populations, q S and q I are the flux of susceptible and infected, and S and I are the sources/sinks of susceptible and infected, respectively.", [["q I", "GENE_OR_GENE_PRODUCT", 192, 195], ["The mass conservation of individuals S", "PROBLEM", 0, 38], ["susceptible and infective populations", "PROBLEM", 145, 182], ["susceptible and infected", "PROBLEM", 212, 236], ["mass", "OBSERVATION", 4, 8], ["density", "OBSERVATION_MODIFIER", 134, 141], ["susceptible", "OBSERVATION_MODIFIER", 145, 156], ["infective", "OBSERVATION_MODIFIER", 161, 170], ["populations", "OBSERVATION_MODIFIER", 171, 182], ["susceptible", "OBSERVATION_MODIFIER", 212, 223], ["infected", "OBSERVATION", 228, 236], ["susceptible", "OBSERVATION_MODIFIER", 275, 286], ["infected", "OBSERVATION", 291, 299]]], ["(5.37) and (5.38) a representation of the fluxes q S and q I and sources/sinks S and I are required.", [["the fluxes", "PROBLEM", 38, 48]]], ["Today, different modes of transportation (cars, trains, airplanes) deliver people in business and holidays to the most distant parts of the world in only a few hours.", [["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81]]], ["In the preceding section we have shown that diffusion and convection (channeling) are the regimes to distribute individuals through a territory (area).", [["territory", "OBSERVATION_MODIFIER", 134, 143]]], ["Therefore, we can consider that the flux of individuals is a convective-diffusive process, described generically by The sources/sinks of susceptible and infective populations can be modeled based on the following assumptions: (i) natural births and deaths are proportional to the size of the susceptible population (Mena-Lorca and Hethcote 1992); (ii) the infective population has a disease-induced death that is proportional to its size (Nobel 1974) ; and (iii) the transmission from susceptible to infective is proportional to the size of the susceptible and infective populations (Nobel 1974 where t dif and t cv are the time scales associated with the diffusive and the convective populations motion (Section 5.3.1), t S is the time scale associated with the births and life expectancy of the susceptible population, t I is the life expectancy of an inflective, and t I is the contagious time of the disease.", [["deaths", "DISEASE", 249, 255], ["death", "DISEASE", 399, 404], ["the flux of individuals", "PROBLEM", 32, 55], ["a convective-diffusive process", "PROBLEM", 59, 89], ["susceptible and infective populations", "PROBLEM", 137, 174], ["the infective population", "PROBLEM", 352, 376], ["a disease-induced death", "PROBLEM", 381, 404], ["susceptible to infective", "PROBLEM", 485, 509], ["the susceptible and infective populations", "PROBLEM", 541, 582], ["t dif", "TEST", 601, 606], ["the diffusive", "PROBLEM", 652, 665], ["the disease", "PROBLEM", 900, 911], ["infective", "OBSERVATION", 153, 162], ["size", "OBSERVATION_MODIFIER", 280, 284], ["susceptible", "OBSERVATION_MODIFIER", 292, 303], ["population", "OBSERVATION", 304, 314], ["infective", "OBSERVATION_MODIFIER", 356, 365], ["size", "OBSERVATION_MODIFIER", 433, 437], ["infective", "OBSERVATION", 500, 509], ["size", "OBSERVATION_MODIFIER", 533, 537], ["susceptible", "OBSERVATION_MODIFIER", 545, 556], ["infective", "OBSERVATION_MODIFIER", 561, 570], ["disease", "OBSERVATION", 904, 911]]], ["Note that the diffusion and convective mechanisms only influence the spread of epidemic after it occurs but they do not play any role on whether the epidemic will occur.", [["the diffusion and convective mechanisms", "PROBLEM", 10, 49]]], ["The time scale corresponding to the diffusive mode of travel is only smaller than the time scale corresponding to the convective mode if the territory length to access is smaller than D/u.", [["The time scale", "TEST", 0, 14], ["smaller", "OBSERVATION_MODIFIER", 69, 76], ["territory", "OBSERVATION_MODIFIER", 141, 150], ["length", "OBSERVATION_MODIFIER", 151, 157], ["smaller", "OBSERVATION_MODIFIER", 171, 178]]], ["Therefore, diffusion is the optimal travel regime to provide access to all locations while convection is optimal for providing access at large distances.Modeling the Spreading of an EpidemicThe growth rate of the susceptible population is strongly associated to t S and t I .", [["t S and t I", "DNA", 262, 273], ["the susceptible population", "PROBLEM", 209, 235], ["Spreading", "OBSERVATION_MODIFIER", 166, 175], ["Epidemic", "OBSERVATION_MODIFIER", 182, 190], ["growth", "OBSERVATION_MODIFIER", 194, 200], ["susceptible", "OBSERVATION_MODIFIER", 213, 224], ["population", "OBSERVATION", 225, 235]]], ["There is a positive contribution to the growth of susceptibles since t S is positive and the absolute value is smaller than t I (e.g., the ratio between bdS and the density of infectives has to exceed the disease transmission coefficient).", [["bdS", "PROTEIN", 153, 156], ["t S", "TEST", 69, 72], ["the absolute value", "TEST", 89, 107], ["the ratio", "TEST", 135, 144], ["infectives", "PROBLEM", 176, 186], ["positive contribution to", "UNCERTAINTY", 11, 35], ["growth", "OBSERVATION_MODIFIER", 40, 46], ["absolute", "OBSERVATION_MODIFIER", 93, 101], ["smaller", "OBSERVATION_MODIFIER", 111, 118]]], ["Furthermore, the development of the epidemic is strongly associated to t I and t I .", [["t I and t I", "DNA", 71, 82], ["epidemic", "OBSERVATION", 36, 44]]], ["When the life expectancy of an infective is much smaller than the contagious time, the disease tends to disappear.", [["an infective", "PROBLEM", 28, 40], ["the disease", "PROBLEM", 83, 94], ["infective", "OBSERVATION", 31, 40], ["much smaller", "OBSERVATION_MODIFIER", 44, 56], ["disease", "OBSERVATION", 87, 94]]], ["This topic will be detailed further in the next section.Geotemporal Dynamics of EpidemicsThe pattern of propagation of the Black Death and other plagues suggest a wavelike mechanism of propagation (Noble 1974) .", [["Death", "DISEASE", 129, 134], ["Epidemics", "PROBLEM", 80, 89], ["the Black Death", "PROBLEM", 119, 134], ["Epidemics", "OBSERVATION", 80, 89], ["propagation", "OBSERVATION_MODIFIER", 104, 115]]], ["How do dI and affect the propagation of the wave?Geotemporal Dynamics of EpidemicsFor the sake of simplicity, consider a one-dimensional wave traveling in a positive direction with a velocity c.", [["dI", "PROTEIN", 7, 9], ["Epidemics", "PROBLEM", 73, 82], ["Epidemics", "OBSERVATION", 73, 82]]], ["Setting S x t = SGeotemporal Dynamics of Epidemicsand I x t = I with = \u2212 ct, and substituting them into Eqs.", [["ct", "TEST", 73, 75]]], ["(5.43) and (5.44) the following coupled differential equations are obtained: From these equations we note that the convective velocity is exclusively related to the damping factor while the diffusive process is related both with the damping and oscillatory factors.", [["damping factor", "PROTEIN", 165, 179], ["oscillatory factors", "PROTEIN", 245, 264], ["differential equations", "TEST", 40, 62], ["the convective velocity", "TEST", 111, 134], ["the damping factor", "PROBLEM", 161, 179], ["the diffusive process", "PROBLEM", 186, 207], ["the damping and oscillatory factors", "PROBLEM", 229, 264], ["convective velocity", "OBSERVATION", 115, 134], ["damping", "OBSERVATION", 165, 172], ["diffusive", "OBSERVATION_MODIFIER", 190, 199], ["process", "OBSERVATION", 200, 207], ["damping", "OBSERVATION", 233, 240], ["oscillatory factors", "OBSERVATION", 245, 264]]], ["When the damping factor equals zero, c \u2212 u I /D I = 0, the system composed by the infective populations reduces to the case of a simple harmonic oscillator: continuous oscillation at the natural frequency I .", [["damping factor", "PROTEIN", 9, 23], ["I", "PROTEIN", 43, 44], ["the damping factor", "TEST", 5, 23], ["c \u2212 u I /D I", "TEST", 37, 49], ["a simple harmonic oscillator", "TREATMENT", 127, 155], ["infective", "OBSERVATION", 82, 91]]], ["On the other hand, when c \u2212 u I /D I > 0, the system may or may not oscillate, depending on the relation between the damping factor and the natural frequency: If I > c \u2212 u I /2D I , the system is under damped conditions and exhibits transient behavior, oscillating at Id with an amplitude that decays exponentially.", [["Id", "GENE_OR_GENE_PRODUCT", 268, 270], ["damping factor", "PROTEIN", 117, 131], ["Id", "PROTEIN", 268, 270], ["transient behavior", "PROBLEM", 233, 251], ["damped", "OBSERVATION", 202, 208], ["transient", "OBSERVATION_MODIFIER", 233, 242], ["behavior", "OBSERVATION_MODIFIER", 243, 251]]], ["When c \u2212 u I /2D I \u2265 I , there is no oscillatory behavior and the system returns smoothly to its equilibrium position.", [["c \u2212 u I", "GENE_OR_GENE_PRODUCT", 5, 12], ["I \u2265 I", "PROTEIN", 17, 22], ["oscillatory behavior", "PROBLEM", 37, 57], ["no", "UNCERTAINTY", 34, 36], ["oscillatory behavior", "OBSERVATION", 37, 57], ["equilibrium position", "OBSERVATION", 97, 117]]], ["Thus, a wave-like solution can only exist when c \u2265 u I + 2 D I S \u2212 dI 1/2 \u2265 0 and S \u2265 dI (5.53)Geotemporal Dynamics of EpidemicsThis result has important implications that deserve to be analyzed.", [["a wave-like solution", "TREATMENT", 6, 26], ["I S", "TEST", 61, 64], ["dI", "TEST", 67, 69], ["dI", "TEST", 86, 88], ["Epidemics", "PROBLEM", 119, 128]]], ["In the case of a wave-like solution, an increase of the diffusion coefficient D I and velocity u I implies waves with higher velocities.", [["a wave-like solution", "PROBLEM", 15, 35], ["the diffusion coefficient D I", "PROBLEM", 52, 81], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["waves", "OBSERVATION_MODIFIER", 107, 112], ["higher velocities", "OBSERVATION", 118, 135]]], ["Besides these, the life expectancy of an inflective (1/ dI ) must be larger than the contagious time of the disease (1/ S).Geotemporal Dynamics of EpidemicsThe last result has two consequences: (i) a wave-like solution implies a minimum critical value of the susceptible population density of \u223c dI / , and (ii) there is a critical transmission coefficient from the infective to the susceptible population above which an epidemic wave occurs (\u223c dI /S).", [["dI", "PROTEIN", 295, 297], ["an inflective (1/ dI", "PROBLEM", 38, 58], ["a wave-like solution", "PROBLEM", 198, 218], ["a critical transmission coefficient", "PROBLEM", 320, 355], ["the infective", "PROBLEM", 361, 374], ["larger", "OBSERVATION_MODIFIER", 69, 75], ["susceptible", "OBSERVATION_MODIFIER", 259, 270], ["population", "OBSERVATION_MODIFIER", 271, 281], ["density", "OBSERVATION", 282, 289], ["infective", "OBSERVATION", 365, 374]]], ["Thus, low-populated territories and rapidly fatal diseases prevent the spread of infection.", [["infection", "DISEASE", 81, 90], ["low-populated territories", "PROBLEM", 6, 31], ["rapidly fatal diseases", "PROBLEM", 36, 58], ["infection", "PROBLEM", 81, 90], ["low", "OBSERVATION_MODIFIER", 6, 9], ["populated", "OBSERVATION_MODIFIER", 10, 19], ["territories", "OBSERVATION_MODIFIER", 20, 31], ["rapidly", "OBSERVATION_MODIFIER", 36, 43], ["fatal", "OBSERVATION_MODIFIER", 44, 49], ["diseases", "OBSERVATION", 50, 58], ["spread", "OBSERVATION_MODIFIER", 71, 77], ["infection", "OBSERVATION", 81, 90]]], ["This explains why very deathly diseases, such as the Ebola virus, do not spread around the world: up to now these diseases show up in poorly populated and remote areas (e.g., S is very small), and the life expectancy of the inflected population is very short.", [["Ebola virus", "DISEASE", 53, 64], ["Ebola virus", "ORGANISM", 53, 64], ["Ebola virus", "SPECIES", 53, 64], ["Ebola virus", "SPECIES", 53, 64], ["very deathly diseases", "PROBLEM", 18, 39], ["the Ebola virus", "PROBLEM", 49, 64], ["these diseases", "PROBLEM", 108, 122], ["diseases", "OBSERVATION", 114, 122], ["small", "OBSERVATION_MODIFIER", 185, 190], ["very", "OBSERVATION_MODIFIER", 248, 252], ["short", "OBSERVATION_MODIFIER", 253, 258]]], ["If we reduce travel and commerce (e.g., diffusion and convection mechanisms), we also prevent the spread of the epidemic (an increase of diffusive and convective fluxes of infective population induce traveling waves with higher velocities).", [["the epidemic", "PROBLEM", 108, 120], ["infective population", "PROBLEM", 172, 192], ["increase", "OBSERVATION_MODIFIER", 125, 133], ["convective fluxes", "OBSERVATION_MODIFIER", 151, 168], ["higher velocities", "OBSERVATION_MODIFIER", 221, 238]]], ["In territories having a susceptible population below the minimum critical density, a sudden influx of susceptible individuals may initiate an epidemic.", [["a susceptible population", "PROBLEM", 22, 46], ["a sudden influx of susceptible individuals", "PROBLEM", 83, 125], ["an epidemic", "PROBLEM", 139, 150], ["susceptible", "OBSERVATION_MODIFIER", 24, 35], ["population", "OBSERVATION", 36, 46], ["minimum", "OBSERVATION_MODIFIER", 57, 64], ["critical", "OBSERVATION_MODIFIER", 65, 73], ["density", "OBSERVATION", 74, 81], ["epidemic", "OBSERVATION_MODIFIER", 142, 150]]], ["On the other hand, when S > di / , a sudden outflow of susceptible (health) population or immunization of a part of individuals by medical intervention (vaccination, culling) reduces the density of susceptible population and may prevent the spread of disease.", [["a sudden outflow of susceptible (health) population", "PROBLEM", 35, 86], ["immunization", "TREATMENT", 90, 102], ["medical intervention", "TREATMENT", 131, 151], ["vaccination", "TREATMENT", 153, 164], ["susceptible population", "PROBLEM", 198, 220], ["disease", "PROBLEM", 251, 258], ["susceptible", "OBSERVATION_MODIFIER", 198, 209], ["population", "OBSERVATION", 210, 220], ["may prevent", "UNCERTAINTY", 225, 236], ["disease", "OBSERVATION", 251, 258]]], ["Finally, by isolation of the infective population we are able to reduce the transmission coefficient and, if the critical transmission coefficient is not exceeded, there is no epidemic outbreak.", [["the infective population", "PROBLEM", 25, 49], ["epidemic outbreak", "PROBLEM", 176, 193], ["infective", "OBSERVATION", 29, 38], ["no", "UNCERTAINTY", 173, 175], ["epidemic", "OBSERVATION_MODIFIER", 176, 184], ["outbreak", "OBSERVATION", 185, 193]]]]}